Crohn's, Primary Sclerosing Cholangitis Literature

Primary Sclerosing Cholangitis Literature

Home Page

FAQ

PSC Partners

www Resources

Scientific Literature

Scientific Literature, Crohn's

Aadland E, Schrumpf E, Fausa O, Elgjo K, Heilo A, Aakhus T, Gjone E. Primary sclerosing cholangitis: a long-term follow-up study. Scand. J. Gastroenterol. 22: 655-664 (1987).
Aamodt G, Bukholm G, Jahnsen J, Moum B, Vatn MH; the IBSEN Study Group. The association between water supply and inflammatory bowel disease based on a 1990-1993 cohort study in Southeastern Norway. Am. J. Epidemiol. 168: 1065-1072 (2008). *
Aamodt G, Jahnsen J, Bengtson MB, Moum B, Vatn MH; the IBSEN Study Group. Geographic distribution and ecological studies of inflammatory bowel disease in southeastern Norway in 1990-1993. Inflamm. Bowel Dis. 14: 984-991 (2008). *
Aase S, Koppang HS, Solheim T, Kjaerheim A, Axell T, Storhaug K, Refsum S. Crohn disease of the oral cavity, illustrated by some cases. Tidsskr. Nor. Laegeforen. 121: 2489-2491 (2001).
Abad C, Gomariz RP, Waschek JA. Neuropeptide mimetics and antagonists in the treatment of inflammatory disease: focus on VIP and PACAP. Curr. Top. Med. Chem. 6: 151-163 (2006).
Abad C, Juarranz Y, Martinez C, Arranz A, Rosignoli F, Garcia-Gomez M, Leceta J, Gomariz RP. cDNA array analysis of cytokines, chemokines, and receptors involved in the development of TNBS-induced colitis: homeostatic role of VIP. Inflamm. Bowel Dis. 11: 674-684 (2005). *
Abad E, Tural C, Mirapeix E, Cuxart A. Relationship between ANCA and clinical activity in inflammatory bowel disease: variation in prevalence of ANCA and evidence of heterogeneity. J. Autoimmun. 10: 175-180 (1997). *
Abadia-Molina AC, Ji H, Faubion WA, Julien A, Latchman Y, Yagita H, Sharpe A, Bhan AK, Terhorst C. CD48 controls T cell and antigen-presenting cell functions in experimental colitis. Gastroenterology 130: 424-434 (2006). *
Abakar-Mahamat A, Filippi J, Pradier C, Dozol A, Hebuterne X. Incidence of inflammatory bowel disease in Corsica from 2002 to 2003. Gastroenterol. Clin. Biol. 31: 1098-1103 (2007).
Abbas Z, Khan R, Abid S, Hamid S, Shah H, Jafri W. Is Crohn's disease in Pakistan less severe than in the West? Trop. Doct. 34: 39-41 (2004).
Abbott DW, Wilkins A, Asara JM, Cantley LC. The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr. Biol. 14: 2217-2227 (2004). *
Abbott DW, Yang Y, Hutti JE, Madhavarapu S, Kelliher MA, Cantley LC. Coordinate regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol. Cell. Biol. 27: 6012-6025 (2007). *
Abd El-Atti S, Wasicek K, Mark S, Hegazi R. Use of probiotics in the management of chemotherapy-induced diarrhea: a case study. JPEN J. Parenter. Enteral Nutr. 33: 569-570 (2009). *
Abdelli MN, Ben Abdallah H, Houissa F, Bouali MR, Khediri MF. Azathioprine for prevention of postoperative recurrence in Crohn's disease. Tunis. Med. 85: 569-572 (2007).
Abdelmalek MF, Liu C, Valentine JF. Successful treatment of chronic hepatitis C with pegylated interferon, ribavirin, and infliximab in a patient with Crohn's disease. Am. J. Gastroenterol. 102: 1333-1334 (2007).
Abdin AA, Saeid EM. An experimental study on ulcerative colitis as a potential target for probiotic therapy by Lactobacillus acidophilus with or without “olsalazine”. Journal of Crohn's and Colitis 2: 296-303 (2008).
Abdul-Baki H, Elhajj I, El-Zahabi LM, Azar C, Aoun E, Zantout H, Nasreddine W, Ayyach B, Mourad FH, Soweid A, Barada KA, Sharara AI. Clinical epidemiology of inflammatory bowel disease in Lebanon. Inflamm. Bowel Dis. 13: 475-480 (2007). *
Abdullgaffar B. Review article: granulomatous diseases and granulomas of the appendix. Int. J. Surg. Pathol. 18: 14-20 (2010).
Abe Y, Yoshikawa T, Kamada H, Shibata H, Nomura T, Minowa K, Kayamuro H, Katayama K, Miyoshi H, Mukai Y, Yoshioka Y, Nakagawa S, Tsunoda SI, Tsutsumi Y. Simple and highly sensitive assay system for TNFR2-mediated soluble- and transmembrane-TNF activity. J. Immunol. Methods 335: 71-78 (2008). *
Abedin M, Scheurich D, Reimold SC, Reimold AM. Acute coronary syndrome after infliximab infusion. Cardiol. Rev. 14: 50-52 (2006).
Aberra FN. Omega-3 fatty acids for maintenance of remission of Crohn's disease. Gastroenterology 135: 1005-1006 (2008). *
Aberra FN, Brensinger CM, Bilker WB, Lichtenstein GR, Lewis JD. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 3: 459-465 (2005). *
Aberra FN, Lichtenstein GR. Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment. Pharmacol. Ther. 21: 307-319 (2005). *
Aberra FN, Stettler N, Brensinger C, Lichtenstein GR, Lewis JD. Risk for active tuberculosis in inflammatory bowel disease patients. Clin. Gastroenterol. Hepatol. 5: 1070-1075 (2007).
Abitbol V, Roux C, Chaussade S, Guillemant S, Kolta S, Dougados M, Couturier D, Amor B. Metabolic bone assessment in patients with inflammatory bowel disease. Gastroenterology 108: 417-422 (1995). *
Ablassmaier B, Hartmann J. A case of severe gangrenous ischemic colitis following nonsteroidal anti-inflammatory drug intake. Zentralbl. Chir. 129: 510-512 (2004).
Abo T, Kawamura T, Kawamura H, Tomiyama-Miyaji C, Kanda Y. Relationship between diseases accompanied by tissue destruction and granulocytes with surface adrenergic receptors. Immunol. Res. 37: 201-210 (2007).
Abraham C, Cho J. Interleukin-23/Th17 pathways and inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1090-1100 (2009). *
Abraham C, Cho JH. Functional consequences of NOD2 (CARD15) mutations. Inflamm. Bowel Dis. 12: 641-650 (2006). *
Abraham C, Cho JH. IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease. Annu. Rev. Med. 60: 97-110 (2009). *
Abraham C, Cho JH. Inflammatory bowel disease. N. Engl. J. Med. 361: 2066-2078 (2009). *
Abreu MT. Immunologic regulation of Toll-like receptors in gut epithelium. Curr. Opin. Gastroenterol. 19: 559-564 (2003).
Abreu MT. Serologies in Crohn's disease: can we change the gray zone to black and white? Gastroenterology 131: 664-667 (2006). *
Abreu MT. Effectiveness of controlled-release budesonide in preserving bone mineral density in patients with Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 210-211 (2005). *
Abreu MT. Certolizumab pegol in Crohn's disease: a viewpoint by Maria T. Abreu. BioDrugs 21: 202-203 (2007).
Abreu MT. Crohn's disease in patients who fail infliximab therapy: what does the future hold? Rev. Gastroenterol. Disord. 7 Suppl. 1: S20-S26 (2007).
Abreu MT. Choosing therapy on the basis of disease classifications in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 7: 169-179 (2004).
Abreu MT. The pathogenesis of inflammatory bowel disease: translational implications for clinicians. Curr. Gastroenterol. Rep. 4: 481-489 (2002).
Abreu MT, Geller JL, Vasiliauskas EA, Kam LY, Vora P, Martyak LA, Yang H, Hu B, Lin YC, Keenan G, Price J, Landers CJ, Adams JS, Targan SR. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J. Clin. Gastroenterol. 40: 55-63 (2006).
Abreu MT, Kantorovich V, Vasiliauskas EA, Gruntmanis U, Matuk R, Daigle K, Chen S, Zehnder D, Lin YC, Yang H, Hewison M, Adams JS. Measurement of vitamin D levels in inflammatory bowel disease patients reveals a subset of Crohn's disease patients with elevated 1,25-dihydroxyvitamin D and low bone mineral density. Gut 53: 1129-1136 (2004). *
Abreu MT, Plevy S, Sands BE, Weinstein R. Selective leukocyte apheresis for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 874-888 (2007).
Abreu MT, Sparrow MP. The role of translational research in inflammatory bowel disease. Rev. Gastroenterol. Mex. 72: 146-153 (2007).
Abreu MT, Sparrow MP. Translational research in inflammatory bowel disease. Mt. Sinai J. Med. 73: 1067-1073 (2006). *
Abreu MT, Taylor KD, Lin YC, Hang T, Gaiennie J, Landers CJ, Vasiliauskas EA, Kam LY, Rojany M, Papadakis KA, Rotter JI, Targan SR, Yang H. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 123: 679-688 (2002). *
Abreu MT, von Tirpitz C, Hardi R, Kaatz M, Van Assche G, Rutgeerts P, Bisaccia E, Goerdt S, Hanauer S, Knobler R, Mannon P, Mayer L, Ochsenkuhn T, Sandborn WJ, Parenti D, Lee K, Reinisch W; Crohn's Disease Photopheresis Study Group. Extracorporeal photopheresis for the treatment of refractory Crohn's disease: results of an open-label pilot study. Inflamm. Bowel Dis. 15: 829-836 (2009). *
Abreu MT, Yang H. Is genetic testing in IBD ready for prime time? Am. J. Gastroenterol. 99: 316-318 (2004). *
Abu-Suboh Abadia M, Casellas F, Vilaseca J, Malagelada J. Response of first attack of inflammatory bowel disease requiring hospital admission to steroid therapy. Rev. Esp. Enferm. Dig. 96: 539-547 (2004).
Abubakar I, Myhill D, Aliyu SH, Hunter PR. Detection of Mycobacterium avium subspecies paratuberculosis from patients with Crohn's disease using nucleic acid-based techniques: a systematic review and meta-analysis. Inflamm. Bowel Dis. 14: 401-410 (2008). *
Abubakar I, Myhill DJ, Hart AR, Lake IR, Harvey I, Rhodes JM, Robinson R, Lobo AJ, Probert CS, Hunter PR. A case-control study of drinking water and dairy products in Crohn's disease - further investigation of the possible role of Mycobacterium avium paratuberculosis. Am. J. Epidemiol. 165: 776-783 (2007). *
Abuzakouk M, Feighery C, Jackson J. Tumour necrosis factor blocking agents: a new therapeutic modality for inflammatory disorders. Br. J. Biomed. Sci. 59: 173-179 (2002).
Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment. Pharmacol. Ther. 10: 321-326 (1996). *
Achkar JP, Dassopoulos T, Silverberg MS, Tuvlin JA, Duerr RH, Brant SR, Siminovitch K, Reddy D, Datta LW, Bayless TM, Zhang L, Barmada MM, Rioux JD, Steinhart AH, McLeod RS, Griffiths AM, Cohen Z, Yang H, Bromfield GP, Schumm P, Hanauer SB, Cho JH, et al. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am. J. Gastroenterol. 101: 572-580 (2006). *
Achkar JP, Duerr R. The expanding universe of inflammatory bowel disease genetics. Curr. Opin. Gastroenterol. 24: 429-434 (2008). *
Achkar JP, Fiocchi C. Gene-gene interactions in inflammatory bowel disease: biological and clinical implications. Am. J. Gastroenterol. 104: 1734-1736 (2009). *
Achneck HE, Pradhan SK, Kavic SM, Longo WE. Primary signet-ring cell carcinoma mimicking segmental Crohn's colitis. Dig. Liver Dis. 37: 537-541 (2005).
Achneck HE, Wong IY, Kim PJ, Fernandes MA, Walther Z, Seymour NE, Jain D. Ileostomy adenocarcinomas in the setting of ulcerative colitis. J. Clin. Gastroenterol. 39: 396-400 (2005).
Achord JL, Gunn CH Jr, Jackson JF. Regional enteritis and HLA concordance in multiple siblings. Dig. Dis. Sci. 27: 330-332 (1982).
Ackermann C, Kavanaugh A. Tumor necrosis factor as a therapeutic target of rheumatologic disease. Expert Opin. Ther. Targets 11: 1369-1384 (2007).
Actis GC, Pellicano R, Bugianesi E, Lagget M, Rizzetto M. Use of corticosteroids, immunomodulators, and infliximab at a third-level day-hospital service of gastro-hepatology. Minerva Gastroenterol. Dietol. 54: 239-242 (2008).
Adachi JD, Rostom A. Metabolic bone disease in adults with inflammatory bowel disease. Inflamm. Bowel Dis. 5: 200-211 (1999).
Adachi Y, Yoshio-Hoshino N, Nishimoto N. The blockade of IL-6 signaling in rational drug design. Curr. Pharm. Des. 14: 1217-1224 (2008).
Adam SJ, Counter CM. A method to generate genetically defined tumors in pigs. Methods Enzymol. 439: 39-51 (2008). *
Adamopoulos AB. Inflammatory bowel disease (IBD) and the liver. Annals of Gastroenterology 19: 146-151 (2006). *
Adams AE, Zwicker J, Curiel C, Kadin ME, Falchuk KR, Drews R, Kupper TS. Aggressive cutaneous T-cell lymphomas after TNFalpha blockade. J. Am. Acad. Dermatol. 51: 660-662 (2004).
Adams R, McGuckin M, Florin T. Dietary antigens in Crohn's disease. Am. J. Gastroenterol. 104: 526 (2009). *
Adams RJ, Heazlewood SP, Gilshenan KS, O'Brien M, McGuckin MA, Florin TH. IgG antibodies against common gut bacteria are more diagnostic for Crohn's disease than IgG against mannan or flagellin. Am. J. Gastroenterol. 103: 386-396 (2008). *
Adamska I, Czerwionka-Szaflarska M, Kulwas A, Mierzwa G, Bala G, Rosc D. Value of E-selectin and L-selectin determination in children and youth with inflammatory bowel disease. Med. Wieku. Rozwoj. 11: 413-418 (2007).
Adamska I, Czerwionka-Szaflarska M, Kulwas A, Mierzwa G, Bala G, Rosc D. Adhesion molecules of immunoglobin super family in children and youth with inflammatory bowel disease. Pol. Merkur. Lekarski. 26: 101-104 (2009).
Adani GL, Baccarani U, Risaliti A, Donini A, Aoki T, Avital I. Appendicectomy and Crohn's disease: clinical and genetic associations. Gastroenterology 125: 1562-1563 (2003). *
Addo A, Le J, Li W, Aksentijevich I, Balow J Jr, Lee A, Gregersen PK, Kastner DL, Remmers EF. Analysis of CARD15/NOD2 haplotypes fails to identify common variants associated with rheumatoid arthritis susceptibility. Scand. J. Rheumatol. 34: 198-203 (2005). *
Addolorato G, Capristo E, Stefanini GF, Gasbarrini G. Inflammatory bowel disease: a study of the association between anxiety and depression, physical morbidity, and nutritional status. Scand. J. Gastroenterol. 32: 1013-1021 (1997).
Adhiah AH, Jasim HA, Fadhil AM. HLA antigens and inflammatory bowel disease in a sample of Iraqi patients. East. Mediterr. Health J. 14: 1155-1163 (2008).
Adibi SA. Regulation of expression of the intestinal oligopeptide transporter (Pept-1) in health and disease. Am. J. Physiol. Gastrointest. Liver Physiol. 285: G779-G788 (2003). *
Adler J, Raju S, Beveridge AS, Wang S, Zhu J, Zimmermann EM. College adjustment in University of Michigan students with Crohn's and colitis. Inflamm. Bowel Dis. 14: 1281-1286 (2008). *
Afdhal NH, Long A, Lennon J, Crowe J, O'Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn's disease. Clofazimine versus placebo. Dig. Dis. Sci. 36: 449-453 (1991).
Afzal MA, Armitage E, Ghosh S, Williams LC, Minor PD. Further evidence of the absence of measles virus genome sequence in full thickness intestinal specimens from patients with Crohn's disease. J. Med. Virol. 62: 377-382 (2000). *
Afzal MA, Minor PD, Armitage E, Ghosh S. Measles virus and Crohn's disease. Gut 44: 896-897 (1999). *
Afzal MA, Minor PD, Schild GC. Clinical safety issues of measles, mumps and rubella vaccines. Bull. World Health Organ. 78: 199-204 (2000).
Afzal NA, Davies S, Paintin M, Arnaud-Battandier F, Walker-Smith JA, Murch S, Heuschkel R, Fell J. Colonic Crohn's disease in children does not respond well to treatment with enteral nutrition if the ileum is not involved. Dig. Dis. Sci. 50: 1471-1475 (2005). *
Afzal NA, Ozzard A, Keady S, Thomson M, Murch S, Heuschkel R. Infliximab delays but does not avoid the need for surgery in treatment-resistant pediatric Crohn' disease. Dig. Dis. Sci. 52: 3329-3333 (2007). *
Afzal NA, Van Der Zaag-Loonen HJ, Arnaud-Battandier F, Davies S, Murch S, Derkx B, Heuschkel R, Fell JM. Improvement in quality of life of children with acute Crohn's disease does not parallel mucosal healing after treatment with exclusive enteral nutrition. Aliment. Pharmacol. Ther. 20: 167-172 (2004). *
Aganna E, Hawkins PN, Ozen S, Pettersson T, Bybee A, McKee SA, Lachmann HJ, Karenko L, Ranki A, Bakkaloglu A, Besbas N, Topaloglu R, Hoffman HM, Hitman GA, Woo P, McDermott MF. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 5: 289-293 (2004). *
Agapov M. Balantidiasis in a patient with suspected Crohn's disease. Endoscopy 38: 655 (2006). *
Agarwal S, Mayer L. Gastrointestinal manifestations in primary immune disorders. Inflamm. Bowel Dis. Jul 27 [Epub ahead of print] (2009). *
Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann. N. Y. Acad. Sci. 1030: 434-441 (2004). *
Aggarwal BB, Shishodia S, Takada Y, Jackson-Bernitsas D, Ahn KS, Sethi G, Ichikawa H. TNF blockade: an inflammatory issue. Ernst Schering Res. Found. Workshop 56: 161-186 (2006).
Aghazadeh R, Zali MR, Bahari A, Amin K, Ghahghaie F, Firouzi F. Inflammatory bowel disease in Iran: a review of 457 cases. J. Gastroenterol. Hepatol. 20: 1691-1695 (2005). *
Aghdassi E, Wendland BE, Stapleton M, Raman M, Allard JP. Adequacy of nutritional intake in a Canadian population of patients with Crohn's disease. J. Am. Diet. Assoc. 107: 1575-1580 (2007). *
Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, Allard JP. Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. a randomized controlled trial. Am. J. Gastroenterol. 98: 348-353 (2003). *
Agius LM. A primary dysregulation in the immunoregulatory role of the intestinal mucosal epithelial cell in inflammatory bowel disease pathogenesis? Biology of inflammatory response as tissue pattern entities in Crohn's versus ulcerative colitis. J. Theor. Biol. 227: 219-228 (2004). *
Agnholt J. Biological therapy as treatment of inflammatory bowel diseases. Ugeskr. Laeger. 170: 2152-2156 (2008).
Agnholt J, Dahlerup JF, Buntzen S, Tottrup A, Nielsen SL, Lundorf E. Response, relapse and mucosal immune regulation after infliximab treatment in fistulating Crohn's disease. Aliment. Pharmacol. Ther. 17: 703-710 (2003). *
Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 23: 76-85 (2003). *
Agnholt J, Kaltoft K, Jakobsen NO, Dahlerup JF. T-cell vaccination in Crohn's disease: principles and presentation of the first two cases. Cytokines Cell Mol. Ther. 7: 117-123 (2002).
Agnholt J, Kelsen J, Brandsborg B, Jakobsen NO, Dahlerup JF. Increased production of granulocyte-macrophage colony-stimulating factor in Crohn's disease - a possible target for infliximab treatment. Eur. J. Gastroenterol. Hepatol. 16: 649-655 (2004).
Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES. Osteopontin, a protein with cytokine-like properties, is associated with inflammation in Crohn's disease. Scand. J. Immunol. 65: 453-460 (2007). *
Agrawal A, Durrani S, Leiper K, Ellis A, Morris AI, Rhodes JM. Effect of systemic corticosteroid therapy on risk for intra-abdominal or pelvic abscess in non-operated Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 1215-1220 (2005).
Agrawal D, Rukkannagari S, Kethu S. Pathogenesis and clinical approach to extraintestinal manifestations of inflammatory bowel disease. Minerva Gastroenterol. Dietol. 53: 233-248 (2007).
Agret F, Cosnes J, Hassani Z, Gornet JM, Gendre JP, Lemann M, Beaugerie L. Impact of pregnancy on the clinical activity of Crohn's disease. Aliment. Pharmacol. Ther. 21: 509-513 (2005). *
Aguas M, Bastida G, Nos P, Beltran B, Grueso JL, Ponce J. Septic thrombophlebitis of the superior mesenteric vein and multiple liver abscesses in a patient with Crohn's disease at onset. BMC Gastroenterol. 7: 22 (2007). *
Aguilera-Montilla N, Perez-Blas M, Valeri AP, Lopez-Santalla M, Rodriguez-Juan C, Mencia A, Castellano G, Manzano ML, Casis B, Sanchez F, Martin-Villa JM. Higher proliferative capacity of T lymphocytes from patients with Crohn disease than from ulcerative colitis is disclosed by use of Herpesvirus saimiri-transformed T-cell lines. Scand. J. Gastroenterol. 39: 1236-1242 (2004). *
Aguillon JC, Contreras J, Dotte A, Cruzat A, Catalan D, Salazar L, Molina MC, Guerrero J, Lopez M, Soto L, Salazar-Onfray F, Cuchacovich M. New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies. Rev. Med. Chil. 131: 1445-1453 (2003).
Aharoni R, Kayhan B, Arnon R. Therapeutic effect of the immunomodulator glatiramer acetate on trinitrobenzene sulfonic acid-induced experimental colitis. Inflamm. Bowel Dis. 11: 106-115 (2005). *
Ahern PP, Izcue A, Maloy KJ, Powrie F. The interleukin-23 axis in intestinal inflammation. Immunol. Rev. 226: 147-159 (2008). *
Ahmad K, Rogers S. Development of Crohn disease in a patient on etanercept for psoriasis. Br. J. Dermatol. 157: 396 (2007).
Ahmad NM, Ahmad KM, Younus F. Severe adenovirus pneumonia (AVP) following infliximab infusion for the treatment of Crohn's disease. J. Infect. 54: e29-e32 (2007).
Ahmad S, Tester RF, Corbett A, Karkalas J. Dextran and 5-aminosalicylic acid (5-ASA) conjugates: synthesis, characterisation and enzymic hydrolysis. Carbohydr. Res. 341: 2694-2701 (2006). *
Ahmad T. Phenotype-determining genes in inflammatory bowel disease. Novartis Found. Symp. 263: 17-29 (2004).
Ahmad T, Armuzzi A, Bunce M, Mulcahy-Hawes K, Marshall SE, Orchard TR, Crawshaw J, Large O, de Silva A, Cook JT, Barnardo M, Cullen S, Welsh KI, Jewell DP. The molecular classification of the clinical manifestations of Crohn's disease. Gastroenterology 122: 854-866 (2002). *
Ahmad T, Marshall S, Jewell D. Genotype-based phenotyping heralds a new taxonomy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 19: 327-335 (2003).
Ahmad T, Marshall SE, Jewell D. Genetics of inflammatory bowel disease: the role of the HLA complex. World J. Gastroenterol. 12: 3628-3635 (2006). *
Ahmad T, Marshall SE, Mulcahy-Hawes K, Orchard T, Crawshaw J, Armuzzi A, Neville M, van Heel D, Barnardo M, Welsh KI, Jewell DP, Bunce M. High resolution MIC genotyping: design and application to the investigation of inflammatory bowel disease susceptibility. Tissue Antigens 60: 164-179 (2002). *
Ahmad T, Pesi Tamboli C, Jewell D, Colombel JF. Clinical relevance of advances in genetics and pharmacogenetics of IBD. Gastroenterology 126: 1533-1549 (2004). *
Ahmad T, Satsangi J, McGovern D, Bunce M, Jewell DP. Review article: the genetics of inflammatory bowel disease. Aliment. Pharmacol. Ther. 15: 731-748 (2001). *
Ahmad T, Zhang L, Gogus F, Verity D, Wallace G, Madanat W, Fayyad F, James T, Neville M, Kanawati C, Fortune F, Celik A, Stanford M, Jewell DP, Marshall SE. CARD15 polymorphisms in Behcet's disease. Scand. J. Rheumatol. 34: 233-237 (2005).
Ahmadi A, Li Q, Muller K, Collins D, Valentine JF, Drane W, Polyak S. Diagnostic value of noninvasive combined fluorine-18 labeled fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography enterography in active Crohn's disease. Inflamm. Bowel Dis. Nov 2 [Epub ahead of print] (2009).
Ahmadi AA, Polyak S. Endoscopy/surveillance in inflammatory bowel disease. Surg. Clin. North Am. 87: 743-762 (2007).
Ahman T. Molecular classification of IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 27. May 7-8 (2004). *
Ahmed FE. Role of genes, the environment and their interactions in the etiology of inflammatory bowel diseases. Expert Rev. Mol. Diagn. 6: 345-363 (2006).
Ahmed I, Boulter MK, Lobo DN. The SLAPPA (significance of lower abdominal/periumbilical piercing as a predictor of acute appendicitis) audit. Sex Health 3: 195-196 (2006).
Ahmed KA, Thompson JW, Joyner RE, Stocks RM. Airway obstruction secondary to tracheobronchial involvement of asymptomatic undiagnosed Crohn's disease in a pediatric patient. Int. J. Pediatr. Otorhinolaryngol. 69: 1003-1005 (2005).
Ahmed M, Jenkins HR. Vitamin B-12 in Crohn's disease patients with small bowel surgery. Arch. Dis. Child. 89: 293 (2004). *
Ahmed M, Kosgallana A, Soon D, O'Donovan D, Chaudhuri A. Respiratory muscle weakness in a patient with quiescent Crohn's disease and pneumonia. QJM 101: 245-247 (2008).
Ahmed SF, Horrocks IA, Patterson T, Zaidi S, Ling SC, McGrogan P, Weaver LT. Bone mineral assessment by dual energy X-ray absorptiometry in children with inflammatory bowel disease: evaluation by age or bone area. J. Pediatr. Gastroenterol. Nutr. 38: 276-280 (2004). *
Ahn HS, Lee SK, Kim HJ, Jang JY, Joo KR, Dong SH, Kim BH, Lee JI, Chang YW, Chang R. Risk of postoperative infection in patients with inflammatory bowel disease. Korean J. Gastroenterol. 48: 306-312 (2006).
Ahn LB, Huang CS, Forse RA, Hess DT, Andrews C, Farraye FA. Crohn's disease after gastric bypass surgery for morbid obesity: is there an association? Inflamm. Bowel Dis. 11: 622-624 (2005). *
Ahn SH, Shah YM, Inoue J, Morimura K, Kim I, Yim S, Lambert G, Kurotani R, Nagashima K, Gonzalez FJ, Inoue Y. Hepatocyte nuclear factor 4 in the intestinal epithelial cells protects against inflammatory bowel disease. Inflamm. Bowel Dis. 14: 908-920 (2008). *
Ahrens R, Waddell A, Seidu L, Blanchard C, Carey R, Forbes E, Lampinen M, Wilson T, Cohen E, Stringer K, Ballard E, Munitz A, Xu H, Lee N, Lee JJ, Rothenberg ME, Denson L, Hogan SP. Intestinal macrophage/epithelial cell-derived CCL11/eotaxin-1 mediates eosinophil recruitment and function in pediatric ulcerative colitis. J. Immunol. 181: 7390-7399 (2008). *
Ahuja V. Crohn's disease and mycobacteria: 'the Thomson brothers' or 'back to the future'. Trop. Gastroenterol. 25: 151-155 (2004).
Aihara H, Hiwatashi N. Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis. Nippon Rinsho 57: 2476-2480 (1999).
Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am. J. Gastroenterol. 103: 944-948 (2008). *
Ainsworth MA, Brynskov J. Anti-TNF-alpha antibody treatment of patients with active ulcerative colitis. Ugeskr. Laeger. 169: 789-791 (2007).
Aisenberg J, Legnani PE, Nilubol N, Cobrin GM, Ellozy SH, Hegazi RAF, Yager J, Bodian C, Gorfine SR, Bauer JJ, Plevy SE, Sachar DB. Are pANCA, ASCA, or cytokine gene polymorphisms associated with pouchitis? Long-term follow-up in 102 ulcerative colitis patients. Am. J. Gastroenterol. 99: 432-441 (2004). *
Aisenberg J, Wagreich J, Shim J, Almer S, Peen E, Heimann T, Gelernt IM, Greenstein A, Rubin P, Harpaz N, et al. Perinuclear anti-neutrophil cytoplasmic antibody and refractory pouchitis. A case-control study. Dig. Dis. Sci. 40: 1866-1872 (1995).
Aithal GP, Craggs A, Day CP, Welfare M, Daly AK, Mansfield JC, Hudson M. Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Dig. Dis. Sci. 46: 1520-1525 (2001). *
Aithal GP, Day CP, Leathart J, Daly AK, Hudson M. Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohn's disease in a British population. Genes Immun. 2: 44-47 (2001). *
Aizawa Y, Sutoh S, Matsuoka M, Negishi M, Torii A, Miyakawa Y, Sugisaka H, Nakamura M, Toda G. Association of interleukin-18 gene single-nucleotide polymorphisms with susceptibility to inflammatory bowel disease. Tissue Antigens 65: 88-92 (2005). *
Ajaj W, Goyen M, Langhorst J, Ruehm SG, Gerken G, Lauenstein TC. MR colonography for the assessment of colonic anastomoses. J. Magn. Reson. Imaging 24: 101-107 (2006).
Ajaj W, Lauenstein TC, Langhorst J, Kuehle C, Goyen M, Zoepf T, Ruehm SG, Gerken G, Debatin JF, Goehde SC. Small bowel hydro-MR imaging for optimized ileocecal distension in Crohn's disease: should an additional rectal enema filling be performed? J. Magn. Reson. Imaging 22: 92-100 (2005).
Ajlouni Y, Iser JH, Gibson PR. Endoscopic balloon dilatation of intestinal strictures in Crohn's disease: safe alternative to surgery. J. Gastroenterol. Hepatol. 22: 486-490 (2007). *
Akagi S, Hiyama E, Imamura Y, Takesue Y, Matsuura Y, Yokoyama T. Interleukin-10 expression in intestine of Crohn disease. Int. J. Mol. Med. 5: 389-395 (2000).
Akahoshi M, Ishihara M, Namba K, Kitaichi N, Ando Y, Takenaka S, Ishida T, Ohno S, Mizuki N, Nakashima H, Shirakawa T. Mutation screening of the CARD15 gene in sarcoidosis. Tissue Antigens 71: 564-567 (2008). *
Akay N, Boyvat A, Heper AO, Soykan I, Arica IE, Bektas M, Ensari A, Cokca F. Behcet's disease-like presentation of bullous pyoderma gangrenosum associated with Crohn's disease. Clin. Exp. Dermatol. 31: 384-386 (2006). *
Akazawa A, Sakaida I, Higaki S, Kubo Y, Uchida K, Okita K. Increased expression of tumor necrosis factor-alpha messenger RNA in the intestinal mucosa of inflammatory bowel disease, particularly in patients with disease in the inactive phase. J. Gastroenterol. 37: 345-353 (2002). *
Akbayir N, Calis AB, Alkim C, Sokmen HM, Erdem L, Ozbal A, Bolukbas F, Akbayir N. Sensorineural hearing loss in patients with inflammatory bowel disease: a subclinical extraintestinal manifestation. Dig. Dis. Sci. 50: 1938-1945 (2005). *
Akbulut S, Yavuz B, Koseoglu T, Gokoz A, Saritas U. Crohn's disease with isolated esophagus and gastric involvement. Turk. J. Gastroenterol. 15: 196-200 (2004). *
Akcam M, Artan R, Yilmaz A, Cig H, Aksoy NH. Abdominal tuberculosis in adolescents. Difficulties in diagnosis. Saudi Med. J. 26: 122-126 (2005).
Akhavan A, Jackman SV, Costa G, Davies B, Wu T, Bond G, Abu-Elmagd K. Urogenital disorders associated with gut failure and intestinal transplantation. J. Urol. 178: 2067-2072 (2007).
Akhtar RY, Lewis BS, Ullman T. Mucosal healing of Crohn's disease demonstrated by capsule endoscopy in a woman with obscure gastrointestinal bleeding. Am. J. Gastroenterol. 104: 1065-1066 (2009).
Akiho H, Lovato P, Deng Y, Ceponis PJ, Blennerhassett P, Collins SM. Interleukin-4 and -13-induced hypercontractility of human intestinal muscle cells: implication for motility changes in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 288: G609-G615 (2005). *
Akman SA, Arikan C, Sozen G, Ozturk C, Yagci RV. Infliximab treatment of pediatric refractory Crohn's disease: a case report. Turk. J. Gastroenterol. 17: 133-136 (2006). *
Akobeng A, Thomas A. Enteral nutrition for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD005984 (2007). *
Akobeng A, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD003574 (2004). *
Akobeng AK. Review article: the evidence base for interventions used to maintain remission in Crohn's disease. Aliment. Pharmacol. Ther. 27: 11-18 (2008). *
Akobeng AK. Anti-mycobacterials and Crohn's disease: author's reply. Aliment. Pharmacol. Ther. 28: 374-375 (2008). *
Akobeng AK. Crohn's disease: current treatment options. Arch. Dis. Child. 93: 787-792 (2008).
Akobeng AK, Gardener E. Oral 5-aminosalicylic acid for maintenance of medically-induced remission in Crohn's disease Cochrane Database Syst. Rev. 1: CD003715 (2004). *
Akobeng AK, Richmond K, Miller V, Thomas AG. Effect of exclusive enteral nutritional treatment on plasma antioxidant concentrations in childhood Crohn's disease. Clin. Nutr. 26: 51-56 (2007).
Akobeng AK, Stokkers PC. Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD007351 (2009). *
Akolkar PN, Gulwani-Akolkar B, Heresbach D, Lin XY, Fisher S, Katz S, Silver J. Differences in risk of Crohn's disease in offspring of mothers and fathers with inflammatory bowel disease. Am. J. Gastroenterol. 92: 2241-224 (1997).
Akolkar PN, Gulwani-Akolkar B, Lin XY, Zhou Z, Daly M, Katz S, Levine J, Present D, Gelb B, Desnick R, Mayer L, Silver J. The IBD1 locus for susceptibility to Crohn's disease has a greater impact in Ashkenazi Jews with early onset disease. Am. J. Gastroenterol. 96: 1127-1132 (2001). *
Aktas H, Mensink PB. Therapeutic balloon-assisted enteroscopy. Dig. Dis. 26: 309-313 (2008).
Akyildiz HY, Akcan AC, Sozuer E, Kucuk C, Yilmaz N, Artis T. Unusual causes of intestinal perforation and their surgical treatment. Ulus. Travma. Acil. Cerrahi. Derg. 15: 579-583 (2009).
Al-Akeely MH. The impact of elective diagnostic laparoscopy in chronic abominal disorders. Saudi J. Gastroenterol. 12: 27-30 (2006). *
Al-Ghamdi AS, Al-Mofleh IA, Al-Rashed RS, Al-Amri SM, Aljebreen AM, Isnani AC, El-Badawi R. Epidemiology and outcome of Crohn's disease in a teaching hospital in Riyadh. World J. Gastroenterol. 10: 1341-1344 (2004). *
Al-Haddad S, Riddell RH. The role of eosinophils in inflammatory bowel disease. Gut 54: 1674-1675 (2005). *
Al-Jarallah A, Oriowo MA, Khan I. Mechanism of reduced colonic contractility in experimental colitis: role of sarcoplasmic reticulum pump isoform-2. Mol. Cell. Biochem. 298: 169-178 (2007). *
Al-Mofarreh MA, Al Mofleh IA, Al-Teimi IN, Al-Jebreen AM. Crohn's disease in a Saudi outpatient population: is it still rare? Saudi J. Gastroenterol. 15: 111-116 (2009). *
Al-Mubarak L, Al-Khenaizan S, Al Goufi T. Cutaneous presentation of kwashiorkor due to infantile Crohn's disease. Eur. J. Pediatr. 169: 117-119 (2010).
Al-Ratrout JT, Ansari NA. Epidermolysis bullosa acquisita and Crohn's disease. Saudi Med. J. 25: 1736-1738 (2004).
Al-Sadi R, Ye D, Dokladny K, Ma TY. Mechanism of IL-1beta-induced increase in intestinal epithelial tight junction permeability. J. Immunol. 180: 5653-5661 (2008). *
Al-Saeed A, Helmy A, Al-Ashgar H, Al-Kahtani K. Tender thigh in a patient with Crohn's disease. Saudi J. Gastroenterol. 14: 214-215 (2008). *
Al-Shamali M, Khan I, Al-Nakib B, Al-Hassan F, Mustafa AS. A multiplex polymerase chain reaction assay for the detection of Mycobacterium paratuberculosis DNA in Crohn's disease tissue. Scand. J. Gastroenterol. 32: 819-823 (1997).
Al-Toma A, Mulder CJ. Review article: stem cell transplantation for the treatment of gastrointestinal diseases - current applications and future perspectives. Aliment. Pharmacol. Ther. 26 Suppl. 2: 77-89 (2007). *
Al-Za'abi AM, Ghazarian D, Greenberg GR, Shaw JC. Eruptive tufted angiomas in a patient with Crohn's disease. J. Clin. Pathol. 58: 214-216 (2005). *
Alam I, Nolan N, Geoghegan J. Isolated Crohn's disease of the appendix. Ir. J. Med. Sci. 173: 114 (2004).
Alameel T, Maclean DA, Macdougall R. Colobronchial fistula presenting with persistent pneumonia in a patient with Crohn's disease: a case report. Cases J. 2: 9114 (2009). *
Alarcon de la Lastra C, Sanchez-Fidalgo S, Villegas I, Motilva V. New pharmacological perspectives and therapeutic potential of PPAR-gamma agonists. Curr. Pharm. Des. 10: 3505-3524 (2004).
Alaya WB, Sfar I, Aouadi H, Jendoubi S, Najjar T, Filali A, Gorgi Y, Abdallah TB, Mouelhi L, Matri S, Ayed K. Association between CTLA-4 gene promoter (49 A/G) in exon 1 polymorphisms and inflammatory bowel disease in the Tunisian population. Saudi J. Gastroenterol. 15: 29-34 (2009). *
Albert JG, Gittinger FS, Hainz M, Lubbert C, Spiller R. In disguise as an acute flare: an unusual differential diagnosis of Crohn's disease. Gut 58: 742 (2009).
Albert JG, Kotsch J, Kostler W, Behl S, Kaltz B, Bokemeyer B, Dollinger MM, Haerting J, Fleig WE. Course of Crohn's disease prior to establishment of the diagnosis. Z. Gastroenterol. 46: 187-192 (2008).
Albert JG, Martiny F, Krummenerl A, Stock K, Lesske J, Gobel CM, Lotterer E, Nietsch HH, Behrmann C, Fleig WE. Diagnosis of small bowel Crohn's disease: a prospective comparison of capsule endoscopy with magnetic resonance imaging and fluoroscopic enteroclysis. Gut 54: 1721-1727 (2005). *
Albert JG, Wiedbrauck F, Keuchel M. Small bowel endoscopy. Dtsch. Med. Wochenschr. 133: 1136-1141 (2008).
Albrecht K, Schumann R, Peitgen K, Walz MK. Laparoscopic therapy of appendicovesical fistula - two case reports. Zentralbl. Chir. 129: 396-398 (2004).
Alcala MJ, Casellas F, Fontanet G, Prieto L, Malagelada JR. Shortened questionnaire on quality of life for inflammatory bowel disease. Inflamm. Bowel Dis. 10: 383-391 (2004). *
Aldebert D, Masy E, Reumaux D, Lion G, Colombel JF, Duthilleul P. Immunoglobulin G subclass distribution of anti-endothelial cell antibodies (AECA) in patients with ulcerative colitis or Crohn's disease. Dig. Dis. Sci. 42: 2350-2355 (1997). *
Aldhous MC, Drummond HE, Anderson N, Smith LA, Arnott ID, Satsangi J. Does cigarette smoking influence the phenotype of Crohn's disease? Analysis using the Montreal classification. Am. J. Gastroenterol. 102: 577-588 (2007). *
Aldhous MC, Meister D, Ghosh S. Modification of enteral diets in inflammatory bowel disease. Proc. Nutr. Soc. 60: 457-461 (2001). *
Aldhous MC, Noble CL, Satsangi J. Dysregulation of human beta-defensin-2 protein in inflammatory bowel disease. PLoS One 4: e6285 (2009). *
Aldhous MC, Prescott RJ, Roberts S, Samuel K, Waterfall M, Satsangi J. Does nicotine influence cytokine profile and subsequent cell cycling/apoptotic responses in inflammatory bowel disease? Inflamm. Bowel Dis. 14: 1469-1482 (2008). *
Aleksandra Nielsen A, Nederby Nielsen J, Schmedes A, Brandslund I, Hey H. Saliva interleukin-6 in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1444-1448 (2005). *
Alexakis C, Caruelle JP, Sezeur A, Cosnes J, Gendre JP, Mosnier H, Beaugerie L, Gallot D, Malafosse M, Barritault D, Kern P. Reversal of abnormal collagen production in Crohn's disease intestinal biopsies treated with regenerating agents. Gut 53: 85-90 (2004). *
Alexander F. Complications of ileal pouch anal anastomosis. Semin. Pediatr. Surg. 16: 200-204 (2007).
Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identification of colon cancer with microsatellite instability. Am. J. Pathol. 158: 527-535 (2001). *
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF. Expression of growth factor receptor-encoded mRNA by colonic epithelial cells is altered in inflammatory bowel disease. Dig. Dis. Sci. 40: 485-494 (1995).
Alexander RJ, Panja A, Kaplan-Liss E, Mayer L, Raicht RF. Expression of protooncogene-encoded mRNA by colonic epithelial cells in inflammatory bowel disease. Dig. Dis. Sci. 41: 660-669 (1996).
Alexandridis E, Zisimopoulos A, Liratzopoulos N, Katsos I, Manolas K, Kouklakis G. Obestatin/ghrelin ratio: a new activity index in inflammatory bowel diseases. Inflamm. Bowel Dis. 15: 1557-1561 (2009).
Alexis AF, Strober BE. Off-label dermatologic uses of anti-TNF-a therapies. J. Cutan. Med. Surg. 9: 296-302 (2005). *
Alexopoulou E, Roma E, Loggitsi D, Economopoulos N, Papakonstantinou O, Panagiotou I, Pahoula I, Kelekis NL. Magnetic resonance imaging of the small bowel in children with idiopathic inflammatory bowel disease: evaluation of disease activity. Pediatr. Radiol. 39: 791-797 (2009).
Alfadhli A, McDonald J, Feagan B. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2005). *
Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst. Rev. 1: CD003459 (2003). *
Alhopuro P, Ahvenainen T, Mecklin JP, Juhola M, Jarvinen HJ, Karhu A, Aaltonen LA. NOD2 3020insC alone is not sufficient for colorectal cancer predisposition. Cancer Res. 64: 7245-7247 (2004). *
Alic M. Epidemiology supports oral contraceptives as a risk factor in Crohn's disease. Gut 46: 140 (2000). *
Alic M. Crohn's disease epidemiology at the turn of the century-solving the puzzle. Am. J. Gastroenterol. 95: 321-323 (2000). *
Alic M. Is exposure to a patient with Crohn's disease an environmental factor for developing the disease. Gut 45: 631-632 (1999). *
Alison M, Kheniche A, Azoulay R, Roche S, Sebag G, Belarbi N. Ultrasonography of Crohn disease in children. Pediatr. Radiol. 37: 1071-1082 (2007).
Alkhouri N, Hupertz V, Mahajan L. Adalimumab treatment for peristomal pyoderma gangrenosum associated with Crohn's disease. Inflamm. Bowel Dis. 15: 803-806 (2009).
Alkim C, Balci M, Alkim H, Dagli U, Parlak E, Tezel A, Ulker A. The importance of peripheral immune cells in inflammatory bowel disease. Turk. J. Gastroenterol. 18: 82-88 (2007). *
Alkim C, Savas B, Ensari A, Alkim H, Dagli U, Parlak E, Ulker A, Sahin B. Expression of p53, VEGF, microvessel density, and cyclin-D1 in noncancerous tissue of inflammatory bowel disease. Dig. Dis. Sci. 54: 1979-1984 (2009). *
Allen AS, Satten GA. Statistical models for haplotype sharing in case-parent trio data. Hum. Hered. 64: 35-44 (2007). *
Allen CA, Niesel DW, Torres AG. The effects of low-shear stress on adherent-invasive Escherichia coli. Environ. Microbiol. 10: 1512-1525 (2008). *
Allen PB, Lindsay H, Tham TC. How do patients with inflammatory bowel disease want their biological therapy administered? BMC Gastroenterol. 10: 1 (2010). *
Allez M, Modigliani R. Clinical features of inflammatory bowel disease. Curr. Opin. Gastroenterol. 16: 329-336 (2000).
Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, Caillat-Zucman S, Paul P, Gornet JM, Douay C, Ravet S, Tamouza R, Charron D, Lemann M, Mayer L, Toubert A. CD4(+)NKG2D(+) T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology 132: 2346-2358 (2007). *
Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hebuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, Vanassche G, Rutgeerts P, Lemann M, Colombel JF. The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF. Aliment. Pharmacol. Ther. 31: 92-101 (2010). *
Allgayer H. Sulfasalazine and 5-ASA compounds. Gastroenterol. Clin. North Am. 21: 643-658 (1992).
Allgayer H, Holtmeier W, Dietrich CF. Crohn's disease and cancer risk. Incidence/prevalence, clinical characteristics, and potential prevention strategies. Med. Klin. (Munich) 102: 727-733 (2007).
Allgayer H, Kruis W. Recent knowledge of the pathophysiology of inflammation in Crohn disease and ulcerative colitis: possible sequelae for future treatment concepts. Z. Gastroenterol. 28: 117-120 (1990).
Allgayer H, Roisch U, Zehnter E, Ziegenhagen DJ, Dienes HP, Kruis W. Colonic ornithine decarboxylase in inflammatory bowel disease: ileorectal activity gradient, guanosine triphosphate stimulation, and association with epithelial regeneration but not the degree of inflammation and clinical features. Dig. Dis. Sci. 52: 25-30 (2007). *
Allison MC, Poulter LW. Changes in phenotypically distinct mucosal macrophage populations may be a prerequisite for the development of inflammatory bowel disease. Clin. Exp. Immunol. 85: 504-509 (1991). *
Allison SP, Williams L, Sandhar B, Swaffield G, Newman GH, Bastow MD, Fox JE, Hardcastle JH. Supplementation of nutritional fluid and electrolyte balance by perfusion of an isolated small bowel loop in a patient with Crohn's disease. Clin. Nutr. 2: 107-111 (1983).
Allorge D, Hamdan R, Broly F, Libersa C, Colombel JF. ITPA genotyping test does not improve detection of Crohn's disease patients at risk of azathioprine/6-mercaptopurine induced myelosuppression. Gut 54: 565 (2005). *
Alluwaimi AM. The etiology of Mycobacterium avium subspecies paratuberculosis in Crohn's disease. Saudi Med. J. 28: 1479-1484 (2007).
Ally MR, Veerappan GR, Koff JM. Treatment of recurrent Crohn's uveitis with infliximab. Am. J. Gastroenterol. 103: 2150-2151 (2008). *
Almadi MA, Ghosh S, Aljebreen AM. Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am. J. Gastroenterol. 104: 1003-1012 (2009). *
Almeghaiseeb ES. Probiotics: an overview and their role in inflammatory bowel disease. Saudi J. Gastroenterol. 13: 150-152 (2007). *
Almeida N, Portela F, Oliveira P, Duarte A, Gregorio C, Gomes D, Gouveia H, Leitao MC. Meningitis in a patient with previously undiagnosed Crohn's disease. Inflamm. Bowel Dis. 15: 643-645 (2009).
Almer S, Granerus G, Strom M, Olaison G, Bonnet J, Lemann M, Smedh K, Franzen L, Bertheau P, Cattan P, Rain JD, Modigliani R. Leukocyte scintigraphy compared to intraoperative small bowel enteroscopy and laparotomy findings in Crohn's disease. Inflamm. Bowel Dis. 13: 164-174 (2007). *
Almer SH, Hjortswang H, Hindorf U. 6-Thioguanine therapy in Crohn's disease - observational data in Swedish patients. Dig. Liver Dis. 41: 194-200 (2009).
Aloi M, Cucchiara S. Extradigestive manifestations of IBD in pediatrics. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 23-32 (2009).
Alonso-Hearn M, Molina E, Geijo M, Vazquez P, Sevilla I, Garrido JM, Juste RA. Isolation of Mycobacterium avium subsp. paratuberculosis from muscle tissue of naturally infected cattle. Foodborne Pathog. Dis. 6: 513-518 (2009).
Alos R, Hinojosa J. Timing of surgery in Crohn's disease: a key issue in the management. World J. Gastroenterol. 14: 5532-5539 (2008). *
Alos R, Solana A. Inflammatory bowel disease. Is laparotomy an obsolete technique in the elective surgery of Crohn's disease? Should laparoscopy always be performed in these patients? Gastroenterol. Hepatol. 32: 122-123 (2009).
Alpers DH. The role of nutritional deficiency in the osteopenia and osteoporosis of gastrointestinal diseases. Curr. Opin. Gastroenterol. 18: 203-208 (2002).
Alqahtani S, Coffin CS, Burak K, Chen F, Macgregor J, Beck P. Hepatic portal venous gas: a report of two cases and a review of the epidemiology, pathogenesis, diagnosis and approach to management. Can. J. Gastroenterol. 21: 309-313 (2007). *
Alrefai WA, Saksena S, Tyagi S, Gill RK, Ramaswamy K, Dudeja PK. Taurodeoxycholate modulates apical Cl(-)/OH(-) exchange activity in Caco2 cells. Dig. Dis. Sci. 52: 1270-1278 (2007). *
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of oral implant failures, up to abutment connection. J. Clin. Periodontol. 34: 610-617 (2007).
Alsaadi G, Quirynen M, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of late oral implant loss. Clin. Oral Implants Res. 19: 670-676 (2008).
Alsaadi G, Quirynen M, Michiles K, Teughels W, Komarek A, van Steenberghe D. Impact of local and systemic factors on the incidence of failures up to abutment connection with modified surface oral implants. J. Clin. Periodontol. 35: 51-57 (2008).
Alstead EM. The pill: safe sex and Crohn's disease? Gut 45: 165-166 (1999). *
Alstead EM. Inflammatory bowel disease in pregnancy. Postgrad. Med. J. 78: 23-26 (2002). *
Altarescu G, Elstein D. Coexistence of Fabry disease and Crohn's disease: a case report. Inflamm. Bowel Dis. 11: 87-88 (2005). *
Altschuler EL. Mycophenolate mofetil, Crohn's disease, measles? Am. J. Gastroenterol. 95: 550-551 (2000). *
Altschuler EL, Kast RE. Bupropion for Blau syndrome. Med. Hypotheses 62: 297-298 (2004).
Alva E, Vasquez J, Frisancho O, Mantilla L, Yabar A, Morales D. Refractary corticosteroids colonic Crohn disease with successful remission with infliximab. Rev. Gastroenterol. Peru 29: 51-54 (2009).
Alvarez Beltran M, Infante Pina D, Tormo Carnice R, Segarra Canton O, Redecillas Ferreiro S. Optimising azathioprine treatment: determination of thiopurine methyltransferase activity and thiopurine metabolites. An. Pediatr. (Barc.) 70: 120-125 (2009).
Alvarez-Blanco M, Fernandez-Mere LA, Martinez-Rodriguez E. Crohns disease of the appendix. Cir. Esp. 78: 333-335 (2005).
Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Piu J, Reverter JC, Pique JM, Yague J, Panes J. Combined type-1 plasminogen activator inhibitor and NOD2/CARD15 genotyping predicts complicated Crohn's disease behaviour. Aliment. Pharmacol. Ther. 25: 429-440 (2007). *
Alvarez-Lobos M, Arostegui JI, Sans M, Tassies D, Plaza S, Delgado S, Lacy AM, Pique JM, Yague J, Panes J. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann. Surg. 242: 693-700 (2005). *
Alves A, Panis Y, Bouhnik Y, Marceau C, Rouach Y, Lavergne-Slove A, Vicaut E, Valleur P. Factors that predict conversion in 69 consecutive patients undergoing laparoscopic ileocecal resection for Crohn's disease: a prospective study. Dis. Colon Rectum 48: 2302-2308 (2005). *
Alves A, Panis Y, Joly F, Pocard M, Lavergne-Slove A, Bouhnik Y, Valleur P. Could immunosuppressive drugs reduce recurrence rate after second resection for Crohn disease? Inflamm. Bowel Dis. 10: 491-495 (2004). *
Alves C, Vieira N, Toralles MB, Lyra A. Human histocompatibility system association with gastrointestinal diseases. Acta Gastroenterol. Latinoam. 36: 86-93 (2006).
Alzoghaibi MA, Al Mofleh IA, Al-Jebreen AM. Lipid peroxides in patients with inflammatory bowel disease. Saudi J. Gastroenterol. 13: 187-190 (2007). *
Alzoghaibi MA, Al-Mofleh IA, Al-Jebreen AM. Neutrophil chemokines GCP-2 and GRO-alpha in patients with inflammatory bowel disease. J. Dig. Dis. 9: 144-148 (2008). *
Alzoghaibi MA, Walsh SW, Willey A, Fowler Iii AA, Graham MF. Linoleic acid, but not oleic acid, upregulates the production of interleukin-8 by human intestinal smooth muscle cells isolated from patients with Crohn's disease. Clin. Nutr. 22: 529-535 (2003). *
Alzoghaibi MA, Walsh SW, Willey A, Yager DR, Fowler AA 3rd, Graham MF. Linoleic acid induces interleukin-8 production by Crohn's human intestinal smooth muscle cells via arachidonic acid metabolites. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G528-G537 (2004). *
Amarapurkar DN, Patel ND, Amarapurkar AD, Agal S, Baigal R, Gupte P. Tissue polymerase chain reaction in diagnosis of intestinal tuberculosis and Crohn's disease. J. Assoc. Physicians India 52: 863-867 (2004).
Amarapurkar DN, Patel ND, Rane PS. Diagnosis of Crohn's disease in India where tuberculosis is widely prevalent. World J. Gastroenterol. 14: 741-746 (2008). *
Amati L, Caradonna L, Jirillo E, Caccavo D. Immunological disorders in inflammatory bowel disease and immunotherapeutic implications. Ital. J. Gastroenterol. Hepatol. 31: 313-325 (1999).
Amati L, Caradonna L, Leandro G, Magrone T, Minenna M, Faleo G, Pellegrino NM, Jirillo E, Caccavo D. Immune abnormalities and endotoxemia in patients with ulcerative colitis and in their first degree relatives: attempts at neutralizing endotoxin-mediated effects. Curr. Pharm. Design 9: 1937-1945 (2003).
Amati L, Passeri ME, Selicato F, Mastronardi ML, Penna A, Jirillo E, Covelli V. New insights into the biological and clinical significance of fecal calprotectin in inflammatory bowel disease. Immunopharmacol. Immunotoxicol. 28: 665-681 (2006).
Ambort D, Brellier F, Becker-Pauly C, Stocker W, Andrejevic-Blant S, Chiquet M, Sterchi EE. Specific processing of tenascin-C by the metalloprotease meprinbeta neutralizes its inhibition of cell spreading. Matrix Biol. Sep 10 [Epub ahead of print] (2009).
Ambrosini R, Barchiesi A, Di Mizio V, Di Terlizzi M, Leo L, Filippone A, Canalis L, Fossaceca R, Carriero A. Inflammatory chronic disease of the colon: how to image. Eur. J. Radiol. 61: 442-448 (2007).
Amemori S, Iwakiri R, Endo H, Ootani A, Ogata S, Noda T, Tsunada S, Sakata H, Matsunaga H, Mizuguchi M, Ikeda Y, Fujimoto K. Oral dimethyl sulfoxide for systemic amyloid A amyloidosis complication in chronic inflammatory disease: a retrospective patient chart review. J. Gastroenterol. 41: 444-449 (2006). *
Ament ME, Berquist W, Vargas J. Advances in ulcerative colitis. Pediatrician 15: 45-57 (1988).
American Gastroenterological Association Clinical Practice Committee. American Gastroenterological Association medical position statement: perianal Crohn's disease. Gastroenterology 125: 1503-1507 (2003). *
Amin J, Wong M. Measles-Mumps-Rubella immunisation, autism and inflammatory bowel disease: update. CDI: Current Issues in Immunisation 23: 222 [http://www.cda.gov.au/pubs/cdi/1999/cdi2308/pdf/cdi2308e.pdf] (1999). *
Amitai MM, Arazi-Kleinman T, Avidan B, Apter S, Konen E, Biegon A, Hertz M. Fat halo sign in the bowel wall of patients with Crohn's disease. Clin. Radiol. 62: 994-997 (2007).
Amitai MM, Arazi-Kleinman T, Hertz M, Apter S, Portnoy O, Guranda L, Chowers Y, Avidan B. Multislice CT compared to small bowel follow-through in the evaluation of patients with Crohn disease. Clin. Imaging 32: 355-361 (2008).
Ammon HP. Boswellic acids in chronic inflammatory diseases. Planta Med. 72: 1100-1116 (2006).
Amonkar SJ, Hughes T, Browell DA. Crohn's disease discovered by an obstructing chick pea. Br. J. Hosp. Med. (Lond.) 68: 445 (2007).
Amoudruz P, Holmlund U, Schollin J, Sverremark-Ekstrom E, Montgomery SM. Maternal country of birth and previous pregnancies are associated with breast milk characteristics. Pediatr. Allergy Immunol. 20: 19-29 (2009).
Amre DK. Going with the flow of autophagy in Crohn's disease: IRGM risk polymorphism found upstream. Inflamm. Bowel Dis. 16: 179-180 (2010). *
Amre DK, D'Souza S, Morgan K, Seidman G, Lambrette P, Grimard G, Israel D, Mack D, Ghadirian P, Deslandres C, Chotard V, Budai B, Law L, Levy E, Seidman EG. Imbalances in dietary consumption of fatty acids, vegetables, and fruits are associated with risk for Crohn's disease in children. Am. J. Gastroenterol. 102: 2016-2025 (2007). *
Amre DK, Lambrette P, Law L, Krupoves A, Chotard V, Costea F, Grimard G, Israel D, Mack D, Seidman EG. Investigating the hygiene hypothesis as a risk factor in pediatric onset Crohn's disease: a case-control study. Am. J. Gastroenterol. 101: 1005-1011 (2006). *
Amre DK, Lu SE, Costea F, Seidman EG. Utility of serological markers in predicting the early occurrence of complications and surgery in pediatric Crohn's disease patients. Am. J. Gastroenterol. 101: 645-652 (2006). *
Amre DK, Mack D, Israel D, Morgan K, Lambrette P, Law L, Grimard G, Deslandres C, Krupoves A, Bucionis V, Costea I, Bissonauth V, Feguery H, D'Souza S, Levy E, Seidman EG. Association between genetic variants in the IL-23R gene and early-onset Crohn's disease: results from a case-control and family-based study among Canadian children. Am. J. Gastroenterol. 103: 615-620 (2008). *
Amre DK, Mack DR, Israel D, Morgan K, Krupoves A, Costea I, Lambrette P, Grimard G, Deslandres C, Levy E, Seidman EG. Investigation of associations between the pregnane X receptor gene (NR1I2) and Crohn's disease in Canadian children using a gene-wide haplotype-based approach. Inflamm. Bowel Dis. 14: 1214-1218 (2008). *
Amre DK, Mack DR, Morgan K, Fujiwara M, Israel D, Deslandres C, Seidman EG, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Grimard G, Levy E. Investigation of reported associations between the 20q13 and 21q22 loci and pediatric-onset Crohn's disease in Canadian children. Am. J. Gastroenterol. 104: 2824-2828 (2009). *
Amre DK, Mack DR, Morgan K, Israel D, Lambrette P, Costea I, Krupoves A, Fegury H, Dong J, Grimard G, Deslandres C, Levy E, Seidman EG. Interleukin 10 (IL-10) gene variants and susceptibility for pediatric onset Crohn's disease. Aliment. Pharmacol. Ther. 29: 1025-1031 (2009). *
Amre DK, Mack DR, Morgan K, Krupoves A, Costea I, Lambrette P, Grimard G, Dong J, Feguery H, Bucionis V, Deslandres C, Levy E, Seidman EG. Autophagy gene ATG16L1 but not IRGM is associated with Crohn's disease in Canadian children. Inflamm. Bowel Dis. 15: 501-507 (2009). *
Amre DK, Seidman EG. DNA variants in cytokine and NOD2 genes, exposures to infections and risk for Crohn's disease. Paediatr. Perinat. Epidemiol. 17: 302-312 (2003).
Amu J, Phadnis S, Sanusi A. Bartholin's gland carcinoma from Crohn's disease. J. Obstet. Gynaecol. 27: 98-99 (2007).
Amundsen SS, Vatn M; the IBSEN study group; Wijmenga C, Sollid LM, Lie BA. Association analysis of MYO9B gene polymorphisms and inflammatory bowel disease in a Norwegian cohort. Tissue Antigens 68: 249-252 (2006). *
Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol. Pharm. 4: 807-818 (2007). *
Anand V, Russell AS, Tsuyuki R, Fedorak R. Perinuclear antineutrophil cytoplasmic autoantibodies and anti-Saccharomyces cerevisiae antibodies as serological markers are not specific in the identification of Crohn's disease and ulcerative colitis. Can. J. Gastroenterol. 22: 33-36 (2008). *
Anandasabapathy S. Endoscopic imaging: emerging optical techniques for the detection of colorectal neoplasia. Curr. Opin. Gastroenterol. 24: 64-69 (2008). *
Ananthakrishnan AN, Attila T, Otterson MF, Lipchik RJ, Massey BT, Komorowski RA, Binion DG. Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 41: 682-688 (2007).
Ananthakrishnan AN, Beaulieu DB, Ulitsky A, Zadvornova Y, Skaros S, Johnson K, Naik A, Perera L, Issa M, Binion DG, Saeian K. Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease? Inflamm. Bowel Dis. 16: 494-500 (2010). *
Ananthakrishnan AN, Binion DG. Treatment of ulcerative colitis in the elderly. Dig. Dis. 27: 327-334 (2009).
Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium difficile in patients with inflammatory bowel disease. Gut 57: 205-210 (2008).
Ananthakrishnan AN, McGinley EL, Binion DG. Inflammatory bowel disease in the elderly is associated with worse outcomes: a national study of hospitalizations. Inflamm. Bowel Dis. 15: 182-189 (2009). *
Ananthakrishnan AN, McGinley EL, Binion DG. Does it matter where you are hospitalized for inflammatory bowel disease? A nationwide analysis of hospital volume. Am. J. Gastroenterol. 103: 2789-2798 (2008). *
Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Trends in ambulatory and emergency room visits for inflammatory bowel diseases in the United States: 1994-2005. Am. J. Gastroenterol. Oct 6 [Epub ahead of print] (2009). *
Ananthakrishnan AN, Weber LR, Knox JF, Skaros S, Emmons J, Lundeen S, Issa M, Otterson MF, Binion DG. Permanent work disability in Crohn's disease. Am. J. Gastroenterol. 103: 154-161 (2008). *
Anastasopoulos G, Marinis A, Konstantinidis C, Theodosopoulos T, Fragulidis G, Vassiliou I. Adenocarcinoma of the third portion of the duodenum in a man with CREST syndrome. World J. Surg. Oncol. 6: 106 (2008). *
Andersen J, Kehlet H. Fast track open ileo-colic resections for Crohn's disease. Colorectal Dis. 7: 394-397 (2005). *
Andersen K, Vogt C, Blondin D, Beck A, Heinen W, Aurich V, Haussinger D, Modder U, Cohnen M. Multi-detector CT-colonography in inflammatory bowel disease: prospective analysis of CT-findings to high-resolution video colonoscopy. Eur. J. Radiol. 58: 140-146 (2006).
Andersen NN, Caspersen S, Jess T, Munkholm P. Occurrence of demyelinating diseases after anti-TNFa treatment of inflammatory bowel disease: a Danish Crohn colitis database study. Journal of Crohn's and Colitis 2: 304-309 (2008).
Andersohn F, Waring M, Garbe E. Risk of ischemic stroke in patients with Crohn's disease: a population-based nested case-control study. Inflamm. Bowel Dis. Dec 14 [Epub ahead of print] (2009).
Anderson CA, Massey DC, Barrett JC, Prescott NJ, Tremelling M, Fisher SA, Gwilliam R, Jacob J, Nimmo ER, Drummond H, Lees CW, Onnie CM, Hanson C, Blaszczyk K, Ravindrarajah R, Hunt S, Varma D, Hammond N, Lewis G, Attlesey H, Watkins N, et al. Investigation of Crohn’s disease risk loci in ulcerative colitis further defines their molecular relationship. Gastroenterology 136: 523-529.e3 (2009). *
Anderson DW. Cytokines as drug targets. IDrugs 4: 375-377 (2001).
Andersson P, Olaison G, Hallbook O, Boeryd B, Sjodahl R. Increased anal resting pressure and rectal sensitivity in Crohn's disease. Dis. Colon Rectum 46: 1685-1689 (2003).
Andersson RE, Olaison G, Tysk C, Ekbom A. Appendectomy is followed by increased risk of Crohn's disease. Gastroenterology 124: 40-46 (2003). *
Andersson UG, Tracey KJ. HMGB1, a pro-inflammatory cytokine of clinical interest: introduction. J. Intern. Med. 255: 318-319 (2004). *
Ando T, Nobata K, Watanabe O, Ina K, Kusugami K, Maeda O, Ishiguro K, Ohmiya N, Niwa Y, Goto H. Abnormalities in the upper gastrointestinal tract in inflammatory bowel disease. Inflammopharmacology 15: 101-104 (2007).
Ando T, Watanabe O, Ishiguro K, Maeda O, Ishikawa D, Minami M, Hasegawa M, Kondo S, Goto Y, Ohmiya N, Niwa Y, Goto H. Relationships between Helicobacter pylori infection status, endoscopic, histopathological findings, and cytokine production in the duodenum of Crohn's disease patients. J. Gastroenterol. Hepatol. 23 Suppl. 2: S193-S197 (2008). *
Ando T, Watanabe O, Nobata K, Ishiguro K, Maeda O, Ishikawa D, Hasegawa M, Kondo S, Kato T, Ohmiya N, Niwa Y, Goto H. Immunological status of the stomach in inflammatory bowel disease - comparison between ulcerative colitis and Crohn's disease. Digestion 77: 145-149 (2008). *
Ando Y, Matsushita M, Kawamata S, Shimatani M, Fujii T, Okazaki K. Infliximab for severe gastrointestinal bleeding in Crohn's disease. Inflamm. Bowel Dis. 15: 483-484 (2009).
Andoh A, Bamba T. Treatment of Crohn's disease by anti-cytokine monoclonal antibodies. Nippon Rinsho 60: 117-122 (2002).
Andoh A, Benno Y, Kanauchi O, Fujiyama Y. Recent advances in molecular approaches to gut microbiota in inflammatory bowel disease. Curr. Pharm. Des. 15: 2066-2073 (2009).
Andoh A, Deguchi Y, Inatomi O, Yagi Y, Bamba S, Tsujikawa T, Fujiyama Y. Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease. Oncol. Rep. 16: 103-107 (2006). *
Andoh A, Endo Y, Kushima R, Hata K, Tsujikawa T, Sasaki M, Mekata E, Tani T, Fujiyama Y. A case of Crohn's disease involving the gallbladder. World J. Gastroenterol. 12: 977-978 (2006). *
Andoh A, Fujino S, Hirai Y, Fujiyama Y. Epimorphin expression in human colonic myofibroblasts. Int. J. Mol. Med. 13: 57-61 (2004).
Andoh A, Fujino S, Okuno T, Fujiyama Y, Bamba T. Intestinal subepithelial myofibroblasts in inflammatory bowel diseases. J. Gastroenterol. 37 Suppl. 14: 33-37 (2002).
Andoh A, Fujiyama Y. Therapeutic approaches targeting intestinal microflora in inflammatory bowel disease. World J. Gastroenterol. 12: 4452-4460 (2006). *
Andoh A, Hirashima M, Maeda H, Hata K, Inatomi O, Tsujikawa T, Sasaki M, Takahashi K, Fujiyama Y. Serum selenoprotein-P levels in patients with inflammatory bowel disease. Nutrition 21: 574-579 (2005). *
Andoh A, Saotome T, Sato H, Tsujikawa T, Araki Y, Fujiyama Y, Bamba T. Epithelial expression of caveolin-2, but not caveolin-1, is enhanced in the inflamed mucosa of patients with ulcerative colitis. Inflamm. Bowel Dis. 7: 210-214 (2001). *
Andoh A, Shioya M, Nishida A, Bamba S, Tsujikawa T, Kim-Mitsuyama S, Fujiyama Y. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J. Immunol. 183: 687-695 (2009).
Andoh A, Tsujikawa T, Ban H, Hashimoto T, Bamba S, Ogawa A, Sasaki M, Saito Y, Fujiyama Y. Monitoring 6-thioguanine nucleotide concentrations in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 23: 1373-1377 (2008). *
Andoh A, Tsujikawa T, Hata K, Araki Y, Kitoh K, Sasaki M, Yoshida T, Fujiyama Y. Elevated circulating platelet-derived microparticles in patients with active inflammatory bowel disease. Am. J. Gastroenterol. 100: 2042-2048 (2005). *
Andoh A, Tsujikawa T, Sasaki M, Mitsuyama K, Suzuki Y, Matsui T, Matsumoto T, Benno Y, Fujiyama Y. Fecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. Aliment. Pharmacol. Ther. 29: 75-82 (2009). *
Andoh A, Yagi Y, Shioya M, Nishida A, Tsujikawa T, Fujiyama Y. Mucosal cytokine network in inflammatory bowel disease. World J. Gastroenterol. 14: 5154-5161 (2008). *
Andoh A, Yoshida T, Yagi Y, Bamba S, Hata K, Tsujikawa T, Kitoh K, Sasaki M, Fujiyama Y. Increased aggregation response of platelets in patients with inflammatory bowel disease. J. Gastroenterol. 41: 47-54 (2006). *
Andoh A, Zhang Z, Inatomi O, Fujino S, Deguchi Y, Araki Y, Tsujikawa T, Kitoh K, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y. Interleukin-22, a member of the IL-10 subfamily, induces inflammatory responses in colonic subepithelial myofibroblasts. Gastroenterology 129: 969-984 (2005). *
Andou A, Hisamatsu T, Okamoto S, Chinen H, Kamada N, Kobayashi T, Hashimoto M, Okutsu T, Shimbo K, Takeda T, Matsumoto H, Sato A, Ohtsu H, Suzuki M, Hibi T. Dietary histidine ameliorates murine colitis by inhibition of proinflammatory cytokine production from macrophages. Gastroenterology 136: 564-574.e2 (2009). *
Andrabi SI, Ahmad J, Rathore MA, El-Hakeem AA. Gallbladder perforation in a patient on steroid therapy. N. Z. Med. J. 120: U2686 (2007).
Andre MF, Aumaitre O, Grateau G, Chamaillard M, Costedoat-Chalumeau N, Cardoso MC, Henry-Berger J, Ramakrishna BS, Delpech M, Piette JC, Creveaux I. Longest form of CCTG microsatellite repeat in the promoter of the CD2BP1/PSTPIP1 gene is associated with aseptic abscesses and with Crohn disease in French patients. Dig. Dis. Sci. Sep 3 [Epub ahead of print] (2009). *
Andre MF, Aumaitre O, Piette JC, Grateau G, Cardoso MC, Ouchchane L, Kemeny JL, Dastugue B, Delpech M, Creveaux I. Analysis of the NOD2/CARD15 gene in patients affected with the aseptic abscesses syndrome with or without inflammatory bowel disease. Dig. Dis. Sci. 53: 490-499 (2008). *
Andre MF, Kemeny JL, Aumaitre O. Aseptic abscesses: entity already described in Crohn's disease: comment on the case report by Holstein et al. J. Gastroenterol. Hepatol. 22: 765 (2007). *
Andreakos E. Common and uncommon features of rheumatoid arthritis and chronic obstructive pulmonary disease: clues to a future therapy. Curr. Drug Targets Immune Endocr. Metabol. Disord. 4: 85-92 (2004).
Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol. Rev. 202: 250-265 (2004). *
Andreani ML, Frasca G, Brusco G, Borgnino L, Biagi F, Gasbarrini G, Corazza GR. Antineutrophil cytoplasmic antibodies in inflammatory bowel disease: diagnostic tool or research procedure?. Ann. Ital. Med. Int. 11: 254-257 (1996).
Andreani SM, Dang HH, Edwards DP, Baig MK, Khan M, Payne JG. Ovarian Crohn's disease: contiguous or metastatic? Inflamm. Bowel Dis. 12: 1091-1092 (2006). *
Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn's disease. Dis. Colon Rectum 50: 2215-2222 (2007). *
Andreassen H, Rix M, Brot C, Eskildsen P. Regulators of calcium homeostasis and bone mineral density in patients with Crohn's disease. Scand. J. Gastroenterol. 33: 1087-1093 (1998). *
Andreassen H, Rungby J, Dahlerup JF, Mosekilde L. Inflammatory bowel disease and osteoporosis. Scand. J. Gastroenterol. 32: 1247-1255 (1997).
Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol. Clin. North Am. 28: 255-281, vii (1999).
Andrews JM, Mountifield RE, Van Langenberg DR, Bampton PA, Holtmann GJ. Un-promoted issues in inflammatory bowel disease (IBD): opportunities to optimise care. Intern. Med. J. Oct 22 [Epub ahead of print] (2009). *
Andrews JM, Travis SP, Gibson PR, Gasche C. Does concurrent therapy with 5-ASA and immunomodulator(s) in inflammatory bowel disease improve outcomes? Aliment. Pharmacol. Ther. 29: 459-469 (2009). *
Andus T, Daig R, Vogl D, Aschenbrenner E, Lock G, Hollerbach S, Kollinger M, Scholmerich J, Gross V. Imbalance of the interleukin 1 system in colonic mucosa - association with intestinal inflammation and interleukin 1 receptor antagonist genotype 2. Gut 41: 651-657 (1997). *
Andus T, Gross V. Etiology and pathophysiology of inflammatory bowel disease - environmental factors. Hepatogastroenterology 47: 29-43 (2000).
Andus T, Gross V, Caesar I, Schulz HJ, Lochs H, Strohm WD, Gierend M, Weber A, Ewe K, Scholmerich J; German/Austrian Budesonide Study Group. Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial. Dig. Dis. Sci. 48: 373-378 (2003). *
Andus T, Klebl F, Rogler G, Bregenzer N, Scholmerich J, Straub RH. Patients with refractory Crohn's disease or ulcerative colitis respond to dehydroepiandrosterone: a pilot study. Aliment. Pharmacol. Ther. 17: 409-414 (2003). *
Andus T, Stange EF, Hoffler D, Keller-Stanislawski B. Suspected cases of severe side effects after infliximab (Remicade) in Germany. Med. Klin. (Munich) 98: 429-436 (2003).
Ang TL, Fock KM, Ng TM, Teo EK, Tan YL. Clinical utility, safety and tolerability of capsule endoscopy in urban Southeast Asian population. World J. Gastroenterol. 9: 2313-2316 (2003). *
Angelberger S, Fink KG, Schima W, Szlauer R, Vogelsang H, Reinisch W, Gangl A, Novacek G. Complications in Crohn's disease: right-sided ureteric stenosis and hydronephrosis. Inflamm. Bowel Dis. 13: 1056-1057 (2007). *
Angelberger S, Reinisch W, Dejaco C, Miehsler W, Waldhoer T, Wehkamp J, Lichtenberger C, Schaeffeler E, Vogelsang H, Schwab M, Teml A. NOD2/CARD15 gene variants are linked to failure of antibiotic treatment in perianal fistulating Crohn's disease. Am. J. Gastroenterol. 103: 1197-1202 (2008). *
Angelberger S, Vogelsang H, Novacek G, Miehsler W, Dejaco C, Gangl A, Reinisch W. Public awareness of Crohn's disease and ulcerative colitis: a national survey. Journal of Crohn's and Colitis 3: 157-161 (2009).
Angeloni G, Latteri M, Manna R, Rumi C, Gasbarrini G, Navarra P. Circulating levels of cyclosporin A in inflammatory bowel disease: relationships with lymphocyte inhibition and the age of patients. Eur. J. Clin. Pharmacol. 60: 161-164 (2004). *
Angelucci E, Cocco A, Cesarini M, Crudeli A, Necozione S, Caprilli R, Latella G. Monthly and seasonal birth patterns and the occurrence of Crohn's disease. Am. J. Gastroenterol. 104: 1608-1609 (2009). *
Angelucci E, Cocco A, Latella G, Caprilli R. Clinical course of late-onset Crohn's disease. Inflamm. Bowel Dis. 15: 1290-1292 (2009).
Angelucci E, Cocco A, Viscido A, Caprilli R. Safe use of infliximab for the treatment of fistulizing Crohn's disease during pregnancy within 3 months of conception. Inflamm. Bowel Dis. 14: 435-436 (2008). *
Angelucci E, Cocco A, Viscido A, Vernia P, Caprilli R. Another paradox in Crohn's disease: new onset of psoriasis in a patient receiving tumor necrosis factor-alpha antagonist. Inflamm. Bowel Dis. 13: 1059-1061 (2007). *
Angelucci E, Malesci A, Danese S. Budesonide: teaching an old dog new tricks for inflammatory bowel disease treatment. Curr. Med. Chem. 15: 2527-2535 (2008).
Angriman I, Scarpa M, D'Inca R, Basso D, Ruffolo C, Polese L, Sturniolo GC, D'Amico DF, Plebani M. Enzymes in feces: useful markers of chronic inflammatory bowel disease. Clin. Chim. Acta 381: 63-68 (2007). *
Angriman I, Scarpa M, Ruffolo C, Pomerri F, Filosa T, Polese L, Pagano D, Norberto L, D'Amico DF. Double contrast small-bowel radiography in the preoperative assessment of Crohn's disease: is it still useful? Surg. Today 38: 700-704 (2008).
Angulo P, Lindor KD. Primary biliary cirrhosis and primary sclerosing cholangitis. Clin. Liver Dis. 3: 529-570 (1999). *
Annese V. Digging out Crohn's disease genes. Inflamm. Bowel Dis. 15: 1436-1437 (2009). *
Annese V, Andreoli A, Andriulli A, Dinca R, Gionchetti P, Latiano A, Lombardi G, Piepoli A, Poulain D, Sendid B, Colombel JF. Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in Crohn's disease and ulcerative colitis: a GISC study. Am. J. Gastroenterol. 96: 2407-2412 (2001). *
Annese V, Andreoli A, Astegiano M, Campieri M, Caprilli R, Cucchiara S, D'Inca R, Giaccari S, Iaquinto G, Lombardi G, Napolitano G, Pera A, Riegler G, Valpiani D, Andriulli A; Italian Study Group for the Disease of Colon and Rectum. Clinical features in familial cases of Crohn's disease and ulcerative colitis in Italy: a GISC study. Italian Study Group for the Disease of Colon and Rectum. Am. J. Gastroenterol. 96: 2939-2945 (2001). *
Annese V, Latiano A, Andriulli A. Genetics of inflammatory bowel disease: the beginning of the end or the end of the beginning? Dig. Liver Dis. 35: 442-449 (2003).
Annese V, Latiano A, Bovio P, Forabosco P, Piepoli A, Lombardi G, Andreoli A, Astegiano M, Gionchetti P, Riegler G, Sturniolo GC, Clementi M, Rappaport E, Fortina P, Devoto M, Gasparini P, Andriulli A. Genetic analysis in Italian families with inflammatory bowel disease supports linkage to the IBD1 locus - a GISC study. Eur. J. Hum. Genet. 7: 567-573 (1999). *
Annese V, Latiano A, Palmieri O, Lombardi G, Andriulli A; Italian Group of Inflammatory Bowel Disease. NOD2/CARD15 in healthy relatives of IBD patients. Eur. Rev. Med. Pharmacol. Sci. 10: 33-36 (2006).
Annese V, Latiano A, Rossi L, Bossa F, Damonte G, Dallapiccola B, Serafini S, Pierige F, Andriulli A, Magnani M. The polymorphism of multi-drug resistance 1 gene (MDR1) does not influence the pharmacokinetics of dexamethasone loaded into autologous erythrocytes of patients with inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 27-31 (2006).
Annese V, Latiano A, Rossi L, Lombardi G, Dallapiccola B, Serafini S, Damonte G, Andriulli A, Magnani M. Erythrocytes-mediated delivery of dexamethasone in steroid-dependent IBD patients - a pilot uncontrolled study. Am. J. Gastroenterol. 100: 1370-1375 (2005). *
Annese V, Lombardi G, Perri F, D'Inca R, Ardizzone S, Riegler G, Giaccari S, Vecchi M, Castiglione F, Gionchetti P, Cocchiara E, Vigneri S, Latiano A, Palmieri O, Andriulli A. Variants of CARD15 are associated with an aggressive clinical course of Crohn's disease - an IG-IBD study. Am. J. Gastroenterol. 100: 84-92 (2005). *
Annese V, Palmieri O, Latiano A, Ardizzone S, Castiglione F, Cottone M, D'Inca R, Gionchetti P, Papi C, Riegler G, Vecchi M, Andriulli A; Italian Group for Inflammatory Bowel Disease. Frequency of NOD2/CARD15 variants in both sporadic and familial cases of Crohn's disease across Italy. An Italian Group for Inflammatory Bowel Disease Study. Dig. Liver Dis. 36: 121-124 (2004).
Annese V, Piepoli A, Andriulli A, Latiano A, Napolitano G, Li HH, Forabosco P, Devoto M. Association of Crohn's disease and ulcerative colitis with haplotypes of the MLH1 gene in Italian inflammatory bowel disease patients. J. Med. Genet. 39: 332-334 (2002). *
Annese V, Piepoli A, Andriulli A, Napolitano G, Bisceglia L, Zelante L, Gasparini P. Polymorphism of motilin gene in patients with Crohn's disease. Dig. Dis. Sci. 43: 715-719 (1998). *
Annese V, Piepoli A, Latiano A, Lombardi G, Napolitano G, Caruso N, Cocchiara E, Accadia L, Perri F, Andriulli A. HLA-DRB1 alleles may influence disease phenotype in patients with inflammatory bowel disease: a critical reappraisal with review of the literature. Dis. Colon Rectum 48: 57-64 (2005).
Annese V, Piepoli A, Perri F, Lombardi G, Latiano A, Napolitano G, Corritore G, Vandewalle P, Poulain D, Colombel JF, Andriulli A. Anti-Saccharomyces cerevisiae mannan antibodies in inflammatory bowel disease: comparison of different assays and correlation with clinical features. Aliment Pharmacol. Ther. 20: 1143-1152 (2004). *
Annibale B, Capurso G, Baccini F, Lahner E, D'Ambra G, Di Giulio E, Delle Fave G. Role of small bowel investigation in iron deficiency anaemia after negative endoscopic/histologic evaluation of the upper and lower gastrointestinal tract. Dig. Liver Dis. 35: 784-787 (2003).
Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, Parente E, Filì L, Ferri S, Frosali F, Giudici F, Romagnani P, Parronchi P, Tonelli F, Maggi E, Romagnani S. Phenotypic and functional features of human Th17 cells. J. Exp. Med. 204: 1849-1861 (2007). *
Ansaldo GL, Varaldo E, Assalino M, Borgonovo G. Artificial nutrition in inflammatory bowel disease. Ann. Ital. Chir. 75: 629-634 (2004).
Ansari A, Aslam Z, DE Sica A, Smith M, Gilshenan K, Fairbanks L, Marinaki A, Sanderson J, Duley J. The influence of xanthine oxidase on thiopurine metabolism in Crohn's disease. Aliment. Pharmacol. Ther. 28: 749-757 (2008). *
Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 734-741 (2008). *
Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 28: 734-741 (2008). *
Ansari A, Elliott T, Fong F, Arenas-Hernandez M, Rottenberg G, Portmann B, Lucas S, Marinaki A, Sanderson J. Further experience with the use of 6-thioguanine in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1399-1405 (2008). *
Ansari N, Abdulla J, Zayyani N, Brahmi U, Taha S, Abdel Satir A. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis? J. Clin. Pathol. 59: 1066-1072 (2006). *
Anthony A, Dhillon AP, Pounder RE, Wakefield AJ. The colonic mesenteric margin is most susceptible to injury in an experimental model of colonic ulceration. Aliment. Pharmacol. Ther. 13: 531-535 (1999). *
Anthony A, Dhillon AP, Pounder RE, Wakefield AJ. Ulceration of the ileum in Crohn's disease: correlation with vascular anatomy. J. Clin. Pathol. 50: 1013-1017 (1997). *
Anthony A, Pounder RE, Dhillon AP, Wakefield AJ. Similarities between ileal Crohn's disease and indomethacin experimental jejunal ulcers in the rat. Aliment. Pharmacol. Ther. 14: 241-245 (2000). *
Anthony MP, Zhang J, Khong PL. PET/CT appearance of intestinal Behcet disease. Clin. Nucl. Med. 34: 825-826 (2009).
Antoniu SA. Infliximab for chronic obstructive pulmonary disease: towards a more specific inflammation targeting? Expert Opin. Investig. Drugs 15: 181-184 (2006).
Antunes DM, da Costa JP, Campos SM, Paschoal PO, Garrido V, Siqueira M, Teixeira GA, Cardoso GP. The serum D-xylose test as a useful tool to identify malabsorption in rats with antigen specific gut inflammatory reaction. Int. J. Exp. Pathol. 90: 141-147 (2009).
Anumakonda V, Hayee B, Chung-Faye G. Remission and relapse of Crohn's disease following autologous haematopoietic stem cell transplantation for non-Hodgkin's lymphoma. Gut 56: 1325 (2007). *
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, de Bruin PA, Mieremet-Ooms MA, van der Zon JM, van Tol EA, Lamers CB. In vitro cellular cytotoxicity in Crohn's disease and ulcerative colitis: relation with disease activity and treatment, and the effect of recombinant gamma-interferon. J. Clin. Lab. Immunol. 29: 119-124 (1989).
Aparicio-Pages MN, Verspaget HW, Pena AS, Weterman IT, Mieremet-Ooms MA, van der Zon JM, de Bruin PA, Lamers CB. Natural, lectin- and phorbol ester-induced cellular cytotoxicity in Crohn's disease and ulcerative colitis. J. Clin. Lab. Immunol. 27: 109-113 (1988).
APDW2004 Chinese IBD Working Group. Retrospective analysis of 515 cases of Crohn's disease hospitalization in China: nationwide study from 1990 to 2003. J. Gastroenterol. Hepatol. 21: 1009-1015 (2006). *
Apgar JT. Newer aspects of inflammatory bowel disease and its cutaneous manifestations: a selective review. Semin. Dermatol. 10: 138-147 (1991).
Apostolaki M, Manoloukos M, Roulis M, Wurbel MA, Muller W, Papadakis KA, Kontoyiannis DL, Malissen B, Kollias G. Role of beta7 integrin and the chemokine/chemokine receptor pair CCL25/CCR9 in modeled TNF-dependent Crohn's disease. Gastroenterology 134: 2025-2035 (2008). *
Appau KA, Fazio VW, Shen B, Church JM, Lashner B, Remzi F, Brzezinski A, Strong SA, Hammel J, Kiran RP. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J. Gastrointest. Surg. 12: 1738-1744 (2008). *
Appenrodt B, Grunhage F, Gentemann MG, Thyssen L, Sauerbruch T, Lammert F. Nucleotide-binding oligomerization domain containing 2 (NOD2) variants are genetic risk factors for death and spontaneous bacterial peritonitis in liver cirrhosis. Hepatology Nov 20 [Epub ahead of print] (2009). *
Appleyard CB, Hernandez G, Rios-Bedoya CF. Basic epidemiology of inflammatory bowel disease in Puerto Rico. Inflamm. Bowel Dis. 10: 106-111 (2004). *
Aquilina P, Savage NW, Lynham A. Crohn's disease with oral presenting signs masquerading as chronic osteomyelitis. Aust. Dent. J. 48: 134-137 (2003).
Arai F, Takahashi T, Furukawa K, Matsushima K, Asakura H. Mucosal expression of interleukin-6 and interleukin-8 messenger RNA in ulcerative colitis and in Crohn's disease. Dig. Dis. Sci. 43: 2071-2079 (1998). *
Arai T, Esaki Y, Sawabe M, Honma N, Nakamura KI, Takubo K. Hypermethylation of the hMLH1 promoter with absent hMLH1 expression in medullary-type poorly differentiated colorectal adenocarcinoma in the elderly. Mod. Pathol. 17: 172-179 (2004). *
Araki Y, Sugihara H, Hattori T. The free radical scavengers edaravone and tempol suppress experimental dextran sulfate sodium-induced colitis in mice. Int. J. Mol. Med. 17: 331-334 (2006). *
Aranda R, Horgan K. Immunosuppressive drugs in the treatment of inflammatory bowel disease. Semin. Gastrointest. Dis. 9: 2-9 (1998).
Aratari A, Caprilli R. Seasonality in onset of symptoms in Crohn's disease. Dig. Liver Dis. 38: 356 (2006).
Aratari A, Papi C, Galletti B, Angelucci E, Viscido A, D'Ovidio V, Ciaco A, Abdullahi M, Caprilli R. Seasonal variations in onset of symptoms in Crohn's disease. Dig. Liver Dis. 38: 319-323 (2006).
Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn's disease. Aliment. Pharmacol. Ther. 26: 1303-1312 (2007). *
Arber N, Berliner S, Hallak A, Bujanover Y, Dotan I, Liberman E, Santo M, Moshkowitz M, Ratan J, Dotan G, et al. Increased leucocyte adhesiveness/aggregation is a most useful indicator of disease activity in patients with inflammatory bowel disease. Gut 37: 77-80 (1995). *
Ardite E, Panes J, Miranda M, Salas A, Elizalde JI, Sans M, Arce Y, Bordas JM, Fernandez-Checa JC, Pique JM. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br. J. Pharmacol. 124: 431-433 (1998). *
Ardizzone S. Ulcerative colitis. Orphanet encyclopedia [http://www.orpha.net/data/patho/GB/uk-UC.pdf] (2003). *
Ardizzone S, Bianchi Porro G. Biologic therapy for inflammatory bowel disease. Drugs 65: 2253-2286 (2005).
Ardizzone S, Bianchi Porro G. Perianal Crohn's disease: overview. Dig. Liver Dis. 39: 957-958 (2007).
Ardizzone S, Bollani S, Bettica P, Bevilacqua M, Molteni P, Bianchi Porro G. Altered bone metabolism in inflammatory bowel disease: there is a difference between Crohn's disease and ulcerative colitis. J. Intern. Med. 247: 63-70 (2000). *
Ardizzone S, Bollani S, Manzionna G, Colombo E, Maconi G, Imbesi V, Bianchi Porro G. Efficacy of medical therapy in preventing the post-surgical recurrence in Crohn's disease. Ann. Ital. Chir. 74: 621-625 (2003).
Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig. Liver Dis. 35: 619-627 (2003).
Ardizzone S, Cassinotti A, Trabattoni D, Manzionna G, Rainone V, Bevilacqua M, Massari A, Manes G, Maconi G, Clerici M, Bianchi Porro G. Immunomodulatory effects of 1,25-dihydroxyvitamin D3 on TH1/TH2 cytokines in inflammatory bowel disease: an in vitro study. Int. J. Immunopathol. Pharmacol. 22: 63-71 (2009).
Ardizzone S, Colombo E, Maconi G, Bollani S, Manzionna G, Petrone MC, Bianchi Porro G. Infliximab in treatment of Crohn's disease: the Milan experience. Dig. Liver Dis. 34: 411-418 (2002).
Ardizzone S, Maconi G, Bianchi V, Russo A, Colombo E, Cassinotti A, Penati C, Tenchini ML, Bianchi Porro G. Multidrug resistance 1 gene polymorphism and susceptibility to inflammatory bowel disease. Inflamm. Bowel Dis. 13: 516-523 (2007). *
Ardizzone S, Maconi G, Cassinotti A, Massari A, Bianchi Porro G. Imaging of perianal Crohn's disease. Dig. Liver Dis. 39: 970-978 (2007).
Ardizzone S, Maconi G, Colombo E, Manzionna G, Bollani S, Porro GB. Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm. Bowel Dis. 10: 91-96 (2004). *
Ardizzone S, Maconi G, Sampietro GM, Russo A, Radice E, Colombo E, Imbesi V, Molteni M, Danelli PG, Taschieri AM, Bianchi Porro G. Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn's disease. Gastroenterology 127: 730-740 (2004). *
Ardizzone S, Porro GB. Should azathioprine be withdrawn in patients with Crohn's disease who are in long-term remission? Nat. Clin. Pract. Gastroenterol. Hepatol. 2: 348-349 (2005). *
Ardizzone S, Porro GB. Is it possible to modify the clinical course of Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 428-429 (2008).
Ardizzone S, Puttini PS, Cassinotti A, Porro GB. Extraintestinal manifestations of inflammatory bowel disease. Dig. Liver Dis. 40 Suppl. 2: S253-S259 (2008).
Arend SM, Breedveld FC, van Dissel JT. TNF-alpha blockade and tuberculosis: better look before you leap. Neth. J. Med. 61: 111-119 (2003). *
Arend SM, Leyten EM, Franken WP, Huisman EM, van Dissel JT. A patient with de novo tuberculosis during anti-tumor necrosis factor- alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment. Clin. Infect. Dis. 45: 1470-1475 (2007). *
Arents NL, Thijs JC, Van Zwet AA, Kleibeuker JH. Does the declining prevalence of Helicobacter pylori unmask patients with idiopathic peptic ulcer disease? Trends over an 8 year period. Eur. J. Gastroenterol. Hepatol. 16: 779-783 (2004).
Arfaoui D, Elloumi H, Debbebi W, Bel Hadj Ali N, Ajmi S. Psychological disorder associated to inflammatory bowel disease. Tunis. Med. 85: 189-191 (2007).
Arfaoui D, Elloumi H, Salah A, Ajmi S. Predictive factors of recurrence in Crohn's disease. Tunis. Med. 83: 83-86 (2005).
Argov S, Sahu RK, Bernshtain E, Salman A, Shohat G, Zelig U, Mordechai S. Inflamatory bowel diseases as an intermediate stage between normal and cancer: a FTIR-microspectroscopy approach. Biopolymers 75: 384-392 (2004). *
Arguelles Arias F, Arguelles Martin F, Caunedo Alvarez A, Rodriguez-Tellez M, Herrerias Gutierrez JM. Utility of capsule endoscopy in pediatric gastroenterology. An. Pediatr. (Barc.) 59: 586-589 (2003).
Arguelles-Arias F, Arguelles Martin F, Caunedo Alvarez A, Sanchez Yague A, Romero Vazquez J, Garcia Montes MJ, Rodriguez-Tellez M, Pellicer Bautista FJ, Herrerias Gutierrez JM. Is capsule endoscopy useful in children with chronic abdominal pain? An. Pediatr. (Barc.) 67: 385-389 (2007).
Arguelles-Arias F, Caunedo A, Romero J, Sanchez A, Rodriguez-Tellez M, Pellicer FJ, Arguelles-Martin F, Herrerias JM. The value of capsule endoscopy in pediatric patients with a suspicion of Crohn's disease. Endoscopy 36: 869-873 (2004).
Arihiro S, Ohtani H, Suzuki M, Murata M, Ejima C, Oki M, Kinouchi Y, Fukushima K, Sasaki I, Nakamura S, Matsumoto T, Torii A, Toda G, Nagura H. Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohn's disease. Pathol. Int. 52: 367-374 (2002). *
Arijs I, De Hertogh G, Lemaire K, Quintens R, Van Lommel L, Van Steen K, Leemans P, Cleynen I, Van Assche G, Vermeire S, Geboes K, Schuit F, Rutgeerts P. Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment. PLoS One 4: e7984 (2009). *
Arin Letamendia A, Borda Celaya F, Burusco Paternain MJ, Prieto Martinez C, Martinez Echeverria A, Elizalde Apestegui I, Laiglesia Izquierdo M, Macias Mendizabal E, Tamburri Moso P, Sanchez Valverde F. High incidence rates of inflammatory bowel disease in Navarra (Spain). Results of a prospective, population-based study. Gastroenterol. Hepatol. 31: 111-116 (2008).
Arluk GM, Pickhardt PJ. Images in clinical medicine. Inflammatory pseudopolyposis in Crohn's disease. N. Engl. J. Med. 350: 923 (2004). *
Armaka M, Apostolaki M, Jacques P, Kontoyiannis DL, Elewaut D, Kollias G. Mesenchymal cell targeting by TNF as a common pathogenic principle in chronic inflammatory joint and intestinal diseases. J. Exp. Med. 205: 331-337 (2008). *
Armitage EL, Aldhous MC, Anderson N, Drummond HE, Riemersma RA, Ghosh S, Satsangi J. Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology 127: 1051-1057 (2004). *
Armuzzi A, Ahmad T, Ling KL, De Silva A, Cullen S, van Heel D, Orchard TR, Welsh KI, Marshall SE, Jewell DP. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 52: 1133-1139 (2003). *
Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Dig. Liver Dis. 40 Suppl. 2: S271-S279 (2008).
Arnett HA, Viney JL. Gatekeepers of intestinal inflammation. Inflamm. Res. 59: 1-14 (2010). *
Arnett HA, Viney JL. Gatekeepers of intestinal inflammation. Inflamm. Res. Sep 11 [Epub ahead of print] (2009). *
Arnold GL, Beaves MR, Pryjdun VO, Mook WJ. Preliminary study of ciprofloxacin in active Crohn's disease. Inflamm. Bowel Dis. 8: 10-15 (2002). *
Arnold J, Sangwaiya A, Bhatkal B, Geoghegan F, Busbridge M. Hepcidin and inflammatory bowel disease: dual role in host defence and iron homoeostasis. Eur. J. Gastroenterol. Hepatol. 21: 425-429 (2009).
Arnott ID, Drummond HE, Ghosh S. Frequency of continuing mucosal inflammation in clinically inactive Crohn's disease. Scott. Med. J. 46: 136-139 (2001).
Arnott ID, Drummond HE, Ghosh S. Gut luminal neutrophil migration is influenced by the anatomical site of Crohn's disease. Eur. J. Gastroenterol. Hepatol. 13: 239-243 (2001).
Arnott ID, Ho GT, Nimmo ER, Satsangi J, Franchimont D, Vermeire S, Deviere J, Rutgeerts PJ. Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe (Author's reply). Gut 54: 308-309 (2005). *
Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand. J. Gastroenterol. 35: 1163-1169 (2000). *
Arnott ID, Landers CJ, Nimmo EJ, Drummond HE, Smith BK, Targan SR, Satsangi J. Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype. Am. J. Gastroenterol. 99: 2376-2384 (2004). *
Arnott ID, McDonald D, Williams A, Ghosh S. Clinical use of infliximab in Crohn's disease: the Edinburgh experience. Aliment. Pharmacol. Ther. 15: 1639-1646 (2001). *
Arnott ID, McNeill G, Satsangi J. An analysis of factors influencing short-term and sustained response to infliximab treatment for Crohn's disease. Aliment. Pharmacol. Ther. 17: 1451-1457 (2003). *
Arnott ID, Nimmo ER, Drummond HE, Fennell J, Smith BR, MacKinlay E, Morecroft J, Anderson N, Kelleher D, O'Sullivan M, McManus R, Satsangi J. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: evidence for genetic heterogeneity within Europe? Genes Immun. 5: 417-425 (2004). *
Arnott ID, Satsangi J. Crohn's disease or Crohn's diseases? Gut 52: 460-461 (2003). *
Arnott ID, Shand A, Ghosh S. Administration of infliximab in Crohn's disease does not deplete complement components C3 and C4. Am. J. Gastroenterol. 95: 3326-3327 (2000). *
Arnott ID, Watts D, Satsangi J. Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety. Pharmacol. Res. 47: 1-10 (2003). *
Aronoff JS, Korelitz BI, Sohn N, Ky A, Rajapakse R, Weinstein MA, Cohen FS. Anorectal Crohn's disease: surgical and medical management. BioDrugs 13: 95-105 (2000).
Arranz A, Abad C, Juarranz Y, Leceta J, Martinez C, Gomariz RP. Vasoactive intestinal peptide as a healing mediator in Crohn's disease. Neuroimmunomodulation 15: 46-53 (2008).
Arranz A, Abad C, Juarranz Y, Torroba M, Rosignoli F, Leceta J, Gomariz RP, Martinez C. Effect of VIP on TLR2 and TLR4 expression in lymph node immune cells during TNBS-induced colitis. Ann. N. Y. Acad. Sci. 1070: 129-134 (2006). *
Arranz A, Juarranz Y, Leceta J, Gomariz RP, Martinez C. VIP balances innate and adaptive immune responses induced by specific stimulation of TLR2 and TLR4. Peptides 29: 948-956 (2008). *
Arseneau KO, Stukenborg GJ, Connors AF Jr, Cominelli F. The incidence of lymphoid and myeloid malignancies among hospitalized Crohn's disease patients. Inflamm. Bowel Dis. 7: 106-112 (2001). *
Arseneau KO, Tamagawa H, Pizarro TT, Cominelli F. Innate and adaptive immune responses related to IBD pathogenesis. Curr. Gastroenterol. Rep. 9: 508-512 (2007).
Arsenescu R, Bruno ME, Rogier EW, Stefka AT, McMahan AE, Wright TB, Nasser MS, de Villiers WJ, Kaetzel CS. Signature biomarkers in Crohn's disease: toward a molecular classification. Mucosal Immunol. 1: 399-411 (2008).
Arslan G, Brunborg LA, Froyland L, Brun JG, Valen M, Berstad A. Effects of duodenal seal oil administration in patients with inflammatory bowel disease. Lipids 37: 935-940 (2002).
Arslan S, Kav T, Besisik F, Kaymakoglu S, Pinarbasi B, Tozun N, Hamzaoglu HO, Duman D, Ulker A, Parlak E, Palabiyikoglu M, Dokmeci A. Clinical outcome of Crohn's disease treated with infliximab. Hepatogastroenterology 50: 952-956 (2003).
Artiko V, Petrovic M, Sobic-Saranovic D, Krajnovic-Jaksic E, Tulic C, Milovanovic J, Djukic V, Rankovic V, Matic S, Antic A, Radoman I, Lausevic Z, Stojkovic M, Pavlovic S, Obradovic V. Detection of gastrointestinal and abdominal infections by 99mTc-antigranulocyte antibodies. Hepatogastroenterology 56: 1053-1058 (2009).
Asakura H. Treatment of ulcerative colitis and Crohn's disease with monoclonal antibody. Nippon Rinsho 60: 531-538 (2002).
Asakura H, Sugimura K. Present states of development in new drugs and treatment of inflammatory bowel disease. Nippon Rinsho 57: 2490-2495 (1999).
Asakura H, Suzuki K, Kitahora T, Morizane T. Is there a link between food and intestinal microbes and the occurrence of Crohn's disease and ulcerative colitis? J. Gastroenterol. Hepatol. 23: 1794-1801 (2008). *
Asakura H, Yao T, Matsui T, Koganei K, Fukushima T, Takazoe M, Hobara R, Nakano H, Okamura S, Matsueda K, Kashida H, Makiyama K, Hiwatashi N, Kashiwagi K, Hibi T. Efficacy of treatment with chimeric monoclonal antibody (Infliximab) to tumor necrosis factor-alpha for Crohn's disease in Japan: evaluation by rapid turnover proteins, and radiologic and endoscopic findings. J. Gastroenterol. Hepatol. 16: 763-769 (2001). *
Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn's disease in Japan. J. Gastroenterol. 44: 659-665 (2009). *
Asami T, Koyama S, Watanabe Y, Miwa C, Ushimaru S, Nakashima Y, Nokubi M. Tracheobronchitis in a patient with Crohn's disease. Intern. Med. 48: 1475-1478 (2009). *
Aschoff AJ. MDCT of the abdomen. Eur. Radiol. 16 Suppl. 7: M54-M57 (2006).
Asheim P, Uggen PE, Aasarod K, Aadahl P. Intraperitoneal fluid therapy: an alternative to intravenous treatment in a patient with limited vascular access. Anaesthesia 61: 502-504 (2006). *
Ashley MJ. Smoking and diseases of the gastrointestinal system: an epidemiological review with special reference to sex differences. Can. J. Gastroenterol. 11: 345-352 (1997). *
Ashok D, Kiely P. Bowel associated dermatosis - arthritis syndrome: a case report. J. Med. Case Reports 1: 81 (2007). *
Ashorn S, Honkanen T, Kolho KL, Ashorn M, Valineva T, Wei B, Braun J, Rantala I, Luukkaala T, Iltanen S. Fecal calprotectin levels and serological responses to microbial antigens among children and adolescents with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 199-205 (2009). *
Ashorn S, Raukola H, Valineva T, Ashorn M, Wei B, Braun J, Rantala I, Kaukinen K, Luukkaala T, Collin P, Mäki M, Iltanen S. Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease. J. Clin. Immunol. 28: 486-494 (2008). *
Ashwood P, Anthony A, Torrente F, Wakefield AJ. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory interleukin-10. J. Clin. Immunol. 24: 664-673 (2004). *
Ashwood P, Wakefield AJ. Immune activation of peripheral blood and mucosal CD3(+) lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms. J. Neuroimmunol. 173: 126-134 (2006).
Asimakopoulos G. Pregnancy and inflammatory bowel disease. Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 46-50 (2004).
Askling J, Brandt L, Lapidus A, Karlen P, Bjorkholm M, Lofberg R, Ekbom A. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 54: 617-622 (2005). *
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Family history as a risk factor for colorectal cancer in inflammatory bowel disease. Gastroenterology 120: 1356-1362 (2001). *
Askling J, Dickman PW, Karlen P, Brostrom O, Lapidus A, Lofberg R, Ekbom A. Colorectal cancer rates among first-degree relatives of patients with inflammatory bowel disease: a population-based cohort study. Lancet 357: 262-266 (2001). *
Asma SD, Soumaya Y, Kahena J, Raouf DM, Nejib D. Perianal Crohn disease. Dermatol. Online J. 12: 18 (2006).
Aspberg S, Dahlquist G, Kahan T, Kallen B. Fetal and perinatal risk factors for inflammatory bowel disease. Acta Paediatr. 95: 1001-1004 (2006). *
Aspinall RJ. Are adherent Escherichia coli in Crohn's disease and colon cancer truly pathogenic? Gastroenterology 127: 1649-1650 (2004). *
Asplund S, Gramlich T, Fazio V, Petras R. Histologic changes in defunctioned rectums in patients with inflammatory bowel disease: a clinicopathologic study of 82 patients with long-term follow-up. Dis. Colon Rectum 45: 1206-1213 (2002).
Asquith DL, McInnes IB. Emerging cytokine targets in rheumatoid arthritis. Curr. Opin. Rheumatol. 19: 246-251 (2007). *
Asquith P, Thompson RA, Cooke WT. Oral manifestations of Crohn's disease. Gut 16: 1249-1254 (1975). *
Assche GV, Rutgeerts P. Medical management of postoperative recurrence in Crohn's disease. Gastroenterol. Clin. North Am. 33: 347-360 (2004).
Astegiano M, Bresso F, Demarchi B, Sapone N, Novero D, Palestro G, Resegotti A, Pellicano R, Rizzetto M. Association between Crohn's disease and Conn's syndrome. A report of two cases. Panminerva Med. 47: 61-64 (2005).
Astegiano M, Cammarota T, Bresso F, Sapone N, Demarchi B, Bertolusso L, Sarno A, Bruno M, Pellicano R, Rizzetto M. Abdominal pain and bowel dysfunction: diagnostic flow-chart could be semplified? Minerva Gastroenterol. Dietol. 47: 53-60 (2001).
Astegiano M, Pagano N, Sapone N, Simondi D, Bertolusso L, Bresso F, Demarchi B, Pellicano R, Bonardi R, Marconi S, Rizzetto M. Efficacy and safety of oral beclomethasone dipropionate for ileal or ileal-right colon Crohn's disease of mild-to-moderate activity or in remission: retrospective study. Biomed. Pharmacother. 61: 370-376 (2007).
Asteria CR, Ficari F, Bagnoli S, Milla M, Tonelli F. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Scand. J. Gastroenterol. 41: 1064-1072 (2006). *
Ataseven H, Ozturk ZA, Arhan M, Yuksel O, Koklu S, Ibis M, Basar O, Yilmaz FM, Yuksel I. Cancer antigen 125 levels in inflammatory bowel diseases. J. Clin. Lab. Anal. 23: 244-248 (2009). *
Atay O, Mahajan L, Kay M, Mohr F, Kaplan B, Wyllie R. Risk of capsule endoscope retention in pediatric patients: a large single-center experience and review of the literature. J. Pediatr. Gastroenterol. Nutr. 49: 196-201 (2009).
Ates Y, Degertekin B, Erdil A, Yaman H, Dagalp K. Serum ghrelin levels in inflammatory bowel disease with relation to disease activity and nutritional status. Dig. Dis. Sci. 53: 2215-2221 (2008). *
Athanasiadis S, Yazigi R, Kohler A, Helmes C. Recovery rates and functional results after repair for rectovaginal fistula in Crohn's disease: a comparison of different techniques. Int. J. Colorectal Dis. 22: 1051-1060 (2007). *
Atienza P. Refractory perineal fistulas in Crohn's disease. Gastroenterol. Clin. Biol. 31: 404-411 (2007).
Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J. Intern. Med. 263: 591-596 (2008). *
Atreya R, Atreya I, Neurath MF. Novel signal transduction pathways: analysis of STAT-3 and Rac-1 signaling in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1072: 98-113 (2006). *
Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, Schutz M, Bartsch B, Holtmann M, Becker C, Strand D, Czaja J, Schlaak JF, Lehr HA, Autschbach F, Schurmann G, Nishimoto N, Yoshizaki K, Ito H, Kishimoto T, Galle PR, Rose-John S, Neurath MF. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat. Med. 6: 583-588 (2000). *
Atreya R, Neurath MF. Involvement of IL-6 in the pathogenesis of inflammatory bowel disease and colon cancer. Clin. Rev. Allergy Immunol. 28: 187-196 (2005).
Atreya R, Neurath MF. Signaling molecules: the pathogenic role of the IL-6/STAT-3 trans signaling pathway in intestinal inflammation and in colonic cancer. Curr. Drug Targets 9: 369-374 (2008).
Attar A, Bon C, Sebbagh V, Bejou B, Benamouzig R. Endoscopic argon plasma coagulation for the treatment of hemorrhagic pseudopolyps in colonic Crohn's disease. Endoscopy 39: E249 (2007).
Attard TM, Horton KM, DeVito K, Darbari A, Oliva-Hemker M, Thompson R, Cuffari C. Pediatric jejunoileitis: a severe Crohn's disease phenotype that requires intensive nutritional management. Inflamm. Bowel Dis. 10: 357-360 (2004). *
Attvall E, Frigyesi A, Sternby B. What is the impact of resistance to activated protein C (Leiden mutation to factor V) in inflammatory bowel disease? Int. J. Colorectal Dis. 21: 705-710 (2006). *
Attwood SE, Lamb CA. Eosinophilic oesophagitis and other non-reflux inflammatory conditions of the oesophagus: Diagnostic imaging and management. Best Pract. Res. Clin. Gastroenterol. 22: 639-660 (2008).
Atug O, Hamzaoglu H, Tahan V, Alican I, Kurtkaya O, Elbuken E, Ozdogan O, Tozun N. Hyperbaric oxygen therapy is as effective as dexamethasone in the treatment of TNBS-E-induced experimental colitis. Dig. Dis. Sci. 53: 481-485 (2008). *
Atug O, Tahan V, Eren F, Tiftikci A, Imeryuz N, Hamzaoglu HO, Tozun N. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma (PPARgamma) gene in inflammatory bowel disease. J. Gastrointestin. Liver Dis. 17: 433-437 (2008). *
Atzeni F, Ardizzone S, Bertani L, Antivalle M, Batticciotto A, Sarzi-Puttini P. Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. World J. Gastroenterol. 15: 2469-2471 (2009). *
Atzeni F, Ardizzone S, Sarzi-Puttini P, Colombo E, Maconi G, DE Portu S, Carrabba M, Bianchi Porro G. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study. Aliment. Pharmacol. Ther. 22: 453-461 (2005). *
Atzeni F, Doria A, Carrabba M, Turiel M, Sarzi-Puttini P. Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun. Rev. 6: 529-536 (2007).
Atzeni F, Sarzi-Puttini P, Doria A, Iaccarino L, Capsoni F. Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun. Rev. 4: 144-152 (2005).
Atzeni F, Turiel M, Capsoni F, Doria A, Meroni P, Sarzi-Puttini P. Autoimmunity and anti-TNF-alpha agents. Ann. N. Y. Acad. Sci. 1051: 559-569 (2005). *
Audrain MA, Gourbil A, Muller JY, Esnault LM. Anti-lactoferrin autoantibodies: relation between epitopes and iron-binding domain. J. Autoimmun. 9: 569-574 (1996).
Auer IO. Immunologic aspects of chronic inflammatory intestinal diseases. Klin. Padiatr. 195: 337-341 (1983).
Auer IO, Buschmann C, Ziemer E. Immune status in Crohn's disease. 2. Originally unimpaired primary cell mediated immunity in vitro. Gut 19: 618-626 (1978). *
Auer IO, Gotz S, Ziemer E, Malchow H, Ehms H. Immune status in Crohn's disease. 3. Peripheral blood B lymphocytes, enumerated by means of F(ab)2-antibody fragments, Null and T lymphocytes. Gut 20: 261-268 (1979). *
Auer IO, Roder A, Wensinck F, van de Merwe JP, Schmidt H. Selected bacterial antibodies in Crohn's disease and ulcerative colitis. Scand. J. Gastroenterol. 18: 217-223 (1983).
Auer IO, Ziemer E, Sommer H. Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood. Clin. Exp. Immunol. 42: 41-49 (1980). *
Auernhammer CJ, Zitzmann K, Schnitzler F, Seiderer J, Lohse P, Vlotides G, Engelhardt D, Sackmann M, Goke B, Ochsenkuhn T. Role of the intracellular receptor domain of gp130 (exon 17) in human inflammatory bowel disease. World J. Gastroenterol. 11: 1196-1199 (2005). *
Augoustides JG, Pochettino A, Pyeritz RE. Successful surgical management of acute type A aortic dissection associated with Crohn disease. J. Thorac. Cardiovasc. Surg. 134: 1048-1049 (2007).
Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Schafer I. Epidemiology and comorbidity of psoriasis in children. Br. J. Dermatol. Nov 18 [Epub ahead of print] (2009). *
Aurello P, Dente M, D'Angelo F, Nigri G, Cescon M, Ramacciato G. Intestinal occlusion resulting from a small bowel adenocarcinoma as first onset of Crohn's disease in a healthy patient. Am. Surg. 75: 189-190 (2009).
Auslander JN, Lieberman DA, Sonnenberg A. Lack of seasonal variation in the endoscopic diagnoses of Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 100: 2233-2238 (2005). *
Austin GL, Shaheen NJ, Sandler RS. Positive and negative predictive values: use of inflammatory bowel disease serologic markers. Am. J. Gastroenterol. 101: 413-416 (2006). *
Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bera AP, Beau-Salinas F. Pharmacovigilance of vaccines. Arch. Pediatr. 13: 175-180 (2006).
Autret-Leca E, Jonville-Bera AP, Beau-Salinas F. Vaccines pharmacovigilance. Rev. Prat. 54: 526-531 (2004).
Autschbach F, Braunstein J, Helmke B, Zuna I, Schurmann G, Niemir ZI, Wallich R, Otto HF, Meuer SC. In situ expression of interleukin-10 in noninflamed human gut and in inflammatory bowel disease. Am. J. Pathol. 153: 121-130 (1998). *
Autschbach F, Eisold S, Hinz U, Zinser S, Linnebacher M, Giese T, Loffler T, Buchler MW, Schmidt J. High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut 54: 944-949 (2005). *
Autschbach F, Funke B, Katzenmeier M, Gassler N. Expression of chemokine receptors in normal and inflamed human intestine, tonsil, and liver - an immunohistochemical analysis with new monoclonal antibodies from the 8th international workshop and conference on human leucocyte differentiation antigens. Cell. Immunol. 236: 110-114 (2005). *
Autschbach F, Giese T, Gassler N, Sido B, Heuschen G, Heuschen U, Zuna I, Schulz P, Weckauf H, Berger I, Otto HF, Meuer SC. Cytokine/chemokine messenger-RNA expression profiles in ulcerative colitis and Crohn's disease. Virchows Arch. 441: 500-513 (2002). *
Auvin S, Molinie F, Gower-Rousseau C, Brazier F, Merle V, Grandbastien B, Marti R, Lerebours E, Dupas JL, Colombel JF, Salomez JL, Cortot A, Turck D. Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population-based study in Northern France (1988-1999). J. Pediatr. Gastroenterol. Nutr. 41: 49-55 (2005). *
Avidan B, Sakhnini E, Lahat A, Lang A, Koler M, Zmora O, Bar-Meir S, Chowers Y. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 72: 248-253 (2005).
Avila Alvarez A, García-Alonso L, Solar Boga A, Garcia-Silva J. Flexural psoriasis induced by infliximab and adalimumab in a patient with Crohn's disease. An. Pediatr. (Barc.) 70: 278-281 (2009).
Avinash B, Dutta AK, Chacko A. Pediatric inflammatory bowel disease in South India. Indian Pediatr. 46: 639-640 (2009). *
Avital S, Hermon H, Greenberg R, Karin E, Skornick Y. Learning curve in laparoscopic colorectal surgery: our first 100 patients. Isr. Med. Assoc. J. 8: 683-686 (2006). *
Awad J, Farah R, Reshef R, Cohen H, Horn I. Pyloric stenosis as a presenting symptom of Crohn's disease. J. Gastrointestin. Liver Dis. 15: 175-177 (2006). *
Awotesu O, Missotten T, Pitcher MC, Lynn WA, Lightman S. Uveitis in a patient receiving rifabutin for Crohn's disease. J. R. Soc. Med. 97: 440-441 (2004). *
Ayala F, Ayala F. Clinical aspects and comorbidities of psoriasis. J. Rheumatol. Suppl. 83: 19-20 (2009).
Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47: 142-144 (2008). *
Aylett P. Digestive Disease Week 2006. Therapies for Crohn's disease and ulcerative colitis. IDrugs 9: 452-454 (2006).
Ayrizono Mde L, Meirelles LR, Leal RF, Coy CS, Fagundes JJ, Goes JR. Long-term outcomes of ileal pouch after secondary diagnosis of Crohn's disease. Arq. Gastroenterol. 45: 204-207 (2008).
Ba'ath ME, Mahmalat M, Smith NP, Dalzell M, Casson DH, Lamont GL, Baillie CT. Surgical management of inflammatory bowel disease. Arch. Dis. Child. 92: 312-316 (2007).
Baars JE, Markus T, Kuipers EJ, van der Woude CJ. Patients' preferences regarding shared decision-making in the treatment of inflammatory bowel disease: results from a patient-empowerment study. Digestion 81: 113-119 (2010).
Baars JE, Siegel CA, Kuipers EJ, van der Woude CJ. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion 79: 30-35 (2009).
Baars JE, Zelinkova Z, Mensink PB, Markus T, Looman CW, Kuipers EJ, Van Der Woude CJ. High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patient organization: a patient empowerment study. Aliment. Pharmacol. Ther. 30: 864-872 (2009). *
Babb RR. The use of metronidazole (Flagyl) in Crohn's disease. J. Clin. Gastroenterol. 10: 479-481 (1988).
Babu TG, Boctor D, Davey A, Bond MC, Jacobson K. Cytomegalovirus-associated hemophagocytic syndrome in a child with Crohn disease receiving azathioprine. J. Pediatr. Gastroenterol. Nutr. 39: 418-421 (2004). *
Baburajan B, Parkes M. The genetics of inflammatory bowel disease. Hosp. Med. 64: 599-602 (2003).
Babusukumar U, Wang T, McGuire E, Broeckel U, Kugathasan S. Contribution of OCTN variants within the IBD5 locus to pediatric onset Crohn's disease. Am. J. Gastroenterol. 101: 1354-1361 (2006). *
Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 110: 975-984 (1996). *
Baca B, Hamzaoglu I, Karahasanoglu T, Hamzaoglu HO. Laparoscopic treatment of pyogenic liver abscess complicating Crohn's disease: a case report. Turk. J. Gastroenterol. 18: 58-61 (2007). *
Bacher S, Schmitz ML. The NF-kappa B pathway as a potential target for autoimmune disease therapy. Curr. Pharm. Des. 10: 2827-2837 (2004).
Bachmann C, Klibanov AL, Olson TS, Sonnenschein JR, Rivera-Nieves J, Cominelli F, Ley KF, Lindner JR, Pizarro TT. Targeting mucosal addressin cellular adhesion molecule (MAdCAM)-1 to noninvasively image experimental Crohn's disease. Gastroenterology 130: 8-16 (2006). *
Bachmann O, Baus S, Hoffmann MW, Manns MP, Gebel M. Incarcerated Spieghel-Hernie mimicking an acute exacerbation of Crohn's disease. Z. Gastroenterol. 43: 1309-1312 (2005).
Bachmeyer C, Leclerc-Landgraf N, Laurette F, Coutarel P, Cadranel JF, Medioni J, Dhote R, Mougeot-Martin M. Acute autoimmune sensorineural hearing loss associated with Crohn's disease. Am. J. Gastroenterol. 93: 2565-2567 (1998). *
Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. Gastroenterology 115: 1045-1048 (1998). *
Bachwich DR, Lichtenstein GR, Traber PG. Cancer in inflammatory bowel disease. Med. Clin. North Am. 78: 1399-1412 (1994).
Bacon PA. Vasculitic syndromes associated with other rheumatic conditions and unclassified systemic vasculitis. Curr. Opin. Rheumatol. 3: 56-61 (1991).
Badina L, Taddio A, Ventura A. Early combined immunosuppression in Crohn's disease. Lancet 371: 1995 (2008). *
Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top-down or step-up? Dig. Dis. 25: 260-266 (2007).
Baert F, De Vos M, Louis E, Vermeire S; Belgian IBD Research Group. Immunogenicity of infliximab: how to handle the problem? Acta Gastroenterol. Belg. 70: 163-170 (2007).
Baert F, Moortgat L, Van Assche G, Caenepeel P, Vergauwe P, De Vos M, Stokkers P, Hommes D, Rutgeerts P, Vermeire S, D'Haens G; Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease. Gastroenterology 138: 463-468 (2010). *
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N. Engl. J. Med. 348: 601-608 (2003). *
Baert F, Vermeire S, Noman M, Van Assche G, D'Haens G, Rutgeerts P. Management of ulcerative colitis and Crohn's disease. Acta Clin. Belg. 59: 304-314 (2004).
Baert FJ, D'Haens GR, Peeters M, Hiele MI, Schaible TF, Shealy D, Geboes K, Rutgeerts PJ. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 116: 22-28 (1999). *
Baert FJ, Rutgeerts PJ. Medical therapies for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 2: 446-450 (2000).
Baert FJ, Rutgeerts PR. Anti-TNF strategies in Crohn's disease: mechanisms, clinical effects, indications. Int. J. Colorectal Dis. 14: 47-51 (1999). *
Bagnoli S, Putignano AL, Melean G, Baglioni S, Sestini R, Milla M, d'Albasio G, Genuardi M, Pacini F, Trallori G, Papi L. Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm. Bowel Dis. 10: 705-708 (2004). *
Bahadursingh AM, Longo WE. Malignant transformation of chronic perianal Crohn's fistula. Am. J. Surg. 189: 61-62 (2005). *
Bahari A, Aarabi M, Aarabi M, Hedayati M, Jarollahi A, Firouzi F, Aghazadeh R, Zali MR, Hashemi M. Diagnostic value of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibody in Iranian patients with inflammatory bowel disease. Acta Gastroenterol. Belg. 72: 301-305 (2009).
Bai A, Hu P, Chen J, Song X, Chen W, Peng W, Zeng Z, Gao X. Blockade of STAT3 by antisense oligonucleotide in TNBS-induced murine colitis. Int. J. Colorectal Dis. 22: 625-635 (2007). *
Bai AP, Ouyang Q, Hu RW. Basic research on inflammatory bowel disease in China. J. Dig. Dis. 8: 194-197 (2007). *
Bai M, Katsanos KH, Economou M, Kamina S, Balli C, Briasoulis E, Kappas AM, Agnantis N, Tsianos EV. Rectal Epstein-Barr virus-positive Hodgkin's lymphoma in a patient with Crohn's disease: case report and review of the literature. Scand. J. Gastroenterol. 41: 866-869 (2006). *
Baichi MM, Arifuddin RM, Mantry PS. What we have learned from 5 cases of permanent capsule retention. Gastrointest. Endosc. 64: 283-287 (2006).
Baidoo L, Lichtenstein GR. What next after infliximab? Am. J. Gastroenterol. 100: 80-83 (2005). *
Baidoo L, Regueiro M. Radiologic testing in Crohn's disease. Inflamm. Bowel Dis. 14 Suppl. 2: S181-S182 (2008). *
Baier PK, Arampatzis G, Imdahl A, Hopt UT. The iliopsoas abscess: aetiology, therapy, and outcome. Langenbecks Arch. Surg. 391: 411-417 (2006). *
Bailen LS. Bones and Crohn's: should we treat Crohn's disease patients with alendronate? Inflamm. Bowel Dis. 7: 175-176 (2001). *
Bailon E, Camuesco D, Nieto A, Concha A, Arriba AF, Roman J, Ramis I, Merlos M, Zarzuelo A, Galvez J, Comalada M. The intestinal anti-inflammatory effects of the novel agent UR-1505 in the TNBS model of rat colitis are mediated by T-lymphocyte inhibition. Biochem. Pharmacol. 74: 1496-1506 (2007). *
Bairead E, Harmon DL, Curtis AM, Kelly Y, O'Leary C, Gardner M, Leahy DT, Vaughan P, Keegan D, O'Morain C, O'Donoghue D, Shanahan F, Parfrey NA, Quane KA. Association of NOD2 with Crohn's disease in a homogenous Irish population. Eur. J. Hum. Genet. 11: 237-244 (2003). *
Baisse B, Fontolliet C, Bian YS, Vuilleumier H, Benhattar J. Synchronous ileal and colonic adenocarcinomas associated with Crohn's disease: report of a case with a focus on genetic alterations and carcinogenesis. J. Clin. Pathol. 57: 885-887 (2004). *
Baixauli J, Delaney CP, Wu JS, Remzi FH, Lavery IC, Fazio VW. Functional outcome and quality of life after repeat ileal pouch-anal anastomosis for complications of ileoanal surgery. Dis. Colon Rectum 47: 2-11 (2004). *
Bajaj JS, Saeian K, Varma RR, Franco J, Knox J F, Podoll J, Emmons J, Levy M, Binion DG. Increased rates of early adverse reaction to azathioprine in patients with Crohn's disease compared to autoimmune hepatitis: a tertiary referral center experience. Am. J. Gastroenterol. 100: 1121-1125 (2005). *
Bajaj-Elliott M, Breese E, Poulsom R, Fairclough PD, MacDonald TT. Keratinocyte growth factor in inflammatory bowel disease. Increased mRNA transcripts in ulcerative colitis compared with Crohn's disease in biopsies and isolated mucosal myofibroblasts. Am. J. Pathol. 151: 1469-1476 (1997). *
Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev. Gastroenterol. Disord. 5: 19-30 (2005).
Baker DE. Adalimumab: human recombinant immunoglobulin g1 anti-tumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord. 4: 196-210 (2004). *
Baker DE. MMX Mesalamine. Rev. Gastroenterol. Disord. 6: 146-152 (2006).
Baker DE. Natalizumab: overview of its pharmacology and safety. Rev. Gastroenterol. Disord. 7: 38-46 (2007).
Baker DE. Certolizumab pegol: a polyethylene glycolated fab' fragment of humanized anti-tumor necrosis factor alpha monoclonal antibody for the treatment of Crohn's disease. Rev. Gastroenterol. Disord. 8: 240-253 (2008).
Baker K, Jewell DP. Cyclosporin for the treatment of severe inflammatory bowel disease. Aliment. Pharmacol. Ther. 3: 143-149 (1989).
Baker ME, Walter J, Obuchowski NA, Achkar JP, Einstein D, Veniero JC, Vogel J, Stocchi L. Mural attenuation in normal small bowel and active inflammatory Crohn's disease on CT enterography: location, absolute attenuation, relative attenuation, and the effect of wall thickness. AJR Am. J. Roentgenol. 192: 417-423 (2009). *
Baker PI, Love DR, Ferguson LR. Role of gut microbiota in Crohn's disease. Expert Rev. Gastroenterol. Hepatol. 3: 535-546 (2009).
Baker SJ, Jacob E, Bowden GH. Crohn disease arthropathy: antigens in synovial fluid share epitopes with strains of two species of Viridans streptococci. Scand. J. Gastroenterol. 35: 287-292 (2000). *
Bakhshai J, Bleu-Laine R, Jung M, Lim J, Reyes C, Sun L, Rochester C, Shaya FT. The cost effectiveness and budget impact of natalizumab for formulary inclusion. J. Med. Econ. Dec 22 [Epub ahead of print] (2009).
Bakker D, Willemsen PT, van Zijderveld FG. Paratuberculosis recognized as a problem at last: a review. Vet. Q. 22: 200-204 (2000).
Baksh FK, Finkelstein SD, Ariyanayagam-Baksh SM, Swalsky PA, Klein EC, Dunn JC. Absence of Mycobacterium avium subsp. paratuberculosis in the microdissected granulomas of Crohn's disease. Mod. Pathol. 17: 1289-1294 (2004). *
Bakshi E, Ashkenazi I, Katzenell U, Cohen O, Niv Y, Bar-Dayan Y. Wireless capsule endoscopy in Israeli Defense Force: two years of experience. Mil. Med. 174: 991-995 (2009).
Bala G, Swincow G, Rytarowska A, Czerwionka-Szaflarska M. Non-specific inflammatory bowel disease or allergic colitis in small children - what is the final diagnosis? Med. Wieku. Rozwoj. X: 475-482 (2006).
Balasa A, Gathungu G, Kisfali P, Smith EO, Cho JH, Melegh B, Kellermayer R. Assessment of DNA methylation at the interferon regulatory factor 5 (IRF5) promoter region in inflammatory bowel diseases. Int. J. Colorectal Dis. Feb 2 [Epub ahead of print] (2010). *
Balasubramanian K, Kumar S, Singh RR, Sharma U, Ahuja V, Makharia GK, Jagannathan NR. Metabolism of the colonic mucosa in patients with inflammatory bowel diseases: an in vitro proton magnetic resonance spectroscopy study. Magn. Reson. Imaging 27: 79-86 (2009). *
Baldassano R, Braegger CP, Escher JC, DeWoody K, Hendricks DF, Keenan GF, Winter HS. Infliximab (REMICADE) therapy in the treatment of pediatric Crohn's disease. Am. J. Gastroenterol. 98: 833-838 (2003). *
Baldassano RN. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: pro. Why use steroids if safer therapies are available? Inflamm. Bowel Dis. 7: 338-341 (2001). *
Baldassano RN, Bradfield JP, Monos DS, Kim CE, Glessner JT, Casalunovo T, Frackelton EC, Otieno FG, Kanterakis S, Shaner JL, Smith RM, Eckert AW, Robinson LJ, Onyiah CC, Abrams DJ, Chiavacci RM, Skraban R, Devoto M, Grant SF, Hakonarson H. Association of variants of the interleukin-23 receptor gene with susceptibility to pediatric Crohn's disease. Clin. Gastroenterol. Hepatol. 5: 972-976 (2007).
Baldassano RN, Bradfield JP, Monos DS, Kim CE, Glessner JT, Casalunovo T, Frackelton EC, Otieno FG, Kanterakis S, Shaner JL, Smith RM, Eckert AW, Robinson LJ, Onyiah CC, Abrams DJ, Chiavacci RM, Skraban R, Devoto M, Grant SF, Hakonarson H. Association of the T300A non-synonymous variant of the ATG16L1 gene with susceptibility to paediatric Crohn's disease. Gut 56: 1171-1173 (2007). *
Baldassano RN, Schreiber S, Johnston RB Jr, Fu RD, Muraki T, MacDermott RP. Crohn's disease monocytes are primed for accentuated release of toxic oxygen metabolites. Gastroenterology 105: 60-66 (1993).
Balding J, Livingstone WJ, Conroy J, Mynett-Johnson L, Weir DG, Mahmud N, Smith OP. Inflammatory bowel disease: the role of inflammatory cytokine gene polymorphisms. Mediators Inflamm.13: 181-187 (2004). *
Balfour Sartor R. Bacteria in Crohn's disease: mechanisms of inflammation and therapeutic implications. J. Clin. Gastroenterol. 41 Suppl. 1: S37-S43 (2007).
Ballinger A. Fundamental mechanisms of growth failure in inflammatory bowel disease. Horm. Res. 58 Suppl. 1: 7-10 (2002).
Balog A, Klausz G, Gal J, Molnar T, Nagy F, Ocsovszky I, Gyulai Z, Mandi Y. Investigation of the prognostic value of TNF-alpha gene polymorphism among patients treated with infliximab, and the effects of infliximab therapy on TNF-alpha production and apoptosis. Pathobiology 71: 274-280 (2004).
Balsara KP, Shah CR, Maru S, Sehgal R. Laparoscopic-assisted ileo-colectomy for tuberculosis. Surg. Endosc. 19: 986-989 (2005). *
Balzola FA, Khan K, Pera A, Bonino F, Pounder RE, Wakefield AJ. Measles IgM immunoreactivity in patients with inflammatory bowel disease. Ital. J. Gastroenterol. Hepatol. 30: 378-382 (1998).
Bamba S, Lee CY, Brittan M, Preston S, Direkze N, Poulsom R, Alison M, Wright N, Otto W. Bone marrow transplantation ameliorates pathology in interleukin-10 knockout colitic mice. J. Pathol. 209: 265-273 (2006). *
Bamias G, Cominelli F. Novel strategies to attenuate immune activation in Crohn's disease. Curr. Opin. Pharmacol. 6: 401-407 (2006).
Bamias G, Cominelli F. Immunopathogenesis of inflammatory bowel disease: current concepts. Curr. Opin. Gastroenterol. 23: 365-369 (2007).
Bamias G, Marini M, Moskaluk CA, Odashima M, Ross WG, Rivera-Nieves J, Cominelli F. Down-regulation of intestinal lymphocyte activation and Th1 cytokine production by antibiotic therapy in a murine model of Crohn's disease. J. Immunol. 169: 5308-5314 (2002). *
Bamias G, Martin C 3rd, Marini M, Hoang S, Mishina M, Ross WG, Sachedina MA, Friel CM, Mize J, Bickston SJ, Pizarro TT, Wei P, Cominelli F. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J. Immunol. 171: 4868-4874 (2003). *
Bamias G, Martin C, Mishina M, Ross WG, Rivera-Nieves J, Marini M, Cominelli F. Proinflammatory effects of TH2 cytokines in a murine model of chronic small intestinal inflammation. Gastroenterology 128: 654-666 (2005). *
Bamias G, Mishina M, Nyce M, Ross WG, Kollias G, Rivera-Nieves J, Pizarro TT, Cominelli F. Role of TL1A and its receptor DR3 in two models of chronic murine ileitis. Proc. Natl. Acad. Sci. U.S.A. 103: 8441-8446 (2006). *
Bamias G, Okazawa A, Rivera-Nieves J, Arseneau KO, De La Rue SA, Pizarro TT, Cominelli F. Commensal bacteria exacerbate intestinal inflammation but are not essential for the development of murine ileitis. J. Immunol. 178: 1809-1818 (2007). *
Bamias G, Sugawara K, Pagnini C, Cominelli F. The Th1 immune pathway as a therapeutic target in Crohn's disease. Curr. Opin. Investig. Drugs 4: 1279-1286 (2003).
Ban L, Zhang J, Wang L, Kuhtreiber W, Burger D, Faustman DL. Selective death of autoreactive T cells in human diabetes by TNF or TNF receptor 2 agonism. Proc. Natl. Acad. Sci. U.S.A. 105: 13644-13649 (2008). *
Ban Y, Tozaki T, Taniyama M, Nakano Y, Yoneyama KI, Ban Y, Hirano T. Association studies of the IL-23R gene in autoimmune thyroid disease in the Japanese population. Autoimmunity 42: 126-130 (2009).
Bandyopadhyay D, Sagar P, Mirnezami A, Lengyel J, Morrison C, Gatt M. Laparoscopic resection for recurrent Crohn's disease: safety, feasibility and short-term outcomes. Colorectal Dis. Nov 2 [Epub ahead of print] (2009). *
Banerjee R, Bhargav P, Reddy P, Gupta R, Lakhtakia S, Tandan M, Rao VG, Reddy ND. Safety and efficacy of the M2A patency capsule for diagnosis of critical intestinal patency: results of a prospective clinical trial. J. Gastroenterol. Hepatol. 22: 2060-2063 (2007). *
Banerjee S, Peppercorn MA. Inflammatory bowel disease. Medical therapy of specific clinical presentations. Gastroenterol. Clin. North Am. 31: 185-202, x (2002).
Bang UC, Nielsen AM. The use of adalimumab in severe fistulising Crohn's disease - three cases. Ugeskr. Laeger. 170: 2256 (2008).
Banic M, Babic Z, Kujundzic M, Petricusic L, Urek-Crncevic M, Grgurevic I, Kardum D, Bokun T. Video capsule endoscopy - preliminary experience in university hospital setting. Acta Med. Croatica 63: 159-164 (2009).
Bank I, Busari JO. Crohn's disease, autoimmune thyroiditis, and beta-thalassemia trait in an adolescent: an unusual combination of diseases. Eur. J. Pediatr. 167: 1343-1346 (2008). *
Banks C, Bateman A, Payne R, Johnson P, Sheron N. Chemokine expression in IBD. Mucosal chemokine expression is unselectively increased in both ulcerative colitis and Crohn's disease. J. Pathol. 199: 28-35 (2003). *
Bannantine JP, Barletta RG, Stabel JR, Paustian ML, Kapur V. Application of the genome sequence to address concerns that Mycobacterium avium subspecies paratuberculosis might be a foodborne pathogen. Foodborne Pathog. Dis. 1: 3-15 (2004).
Banner KH, Cattaneo C, Net JL, Popovic A, Collins D, Gale JD. Macroscopic, microscopic and biochemical characterisation of spontaneous colitis in a transgenic mouse, deficient in the multiple drug resistance 1a gene. Br. J. Pharmacol.143: 590-598 (2004). *
Bannerjee K, Camacho-Hubner C, Babinska K, Dryhurst KM, Edwards R, Savage MO, Sanderson IR, Croft NM. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn disease. J. Pediatr. Gastroenterol. Nutr. 38: 270-275 (2004). *
Banno T, Gazel A, Blumenberg M. Effects of tumor necrosis factor-alpha (TNFalpha) in epidermal keratinocytes revealed using global transcriptional profiling. J. Biol. Chem. 279: 32633-32642 (2004). *
Banos Madrid R, Salama Benerroch H, Moran Sanchez S, Gallardo Sanchez F, Albadalejo Merono A, Mercader Martinez J. Lactose malabsorption in patients with inflammatory bowel disease without activity: it would be necessary to exclude the lactose products in their diet to all the patients? An. Med. Interna 21: 212-214 (2004).
Banovic I, Gilibert D, Cosnes J. Perception of improved state of health and subjective quality of life in Crohn's disease patients treated with infliximab. Journal of Crohn's and Colitis 3: 25-31 (2009). *
Bansal P, Sonnenberg A. Risk factors of colorectal cancer in inflammatory bowel disease. Am. J. Gastroenterol. 91: 44-48 (1996).
Bansi DS, Chapman RW, Fleming KA. Prevalence and diagnostic role of antineutrophil cytoplasmic antibodies in inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 8: 881-885 (1996).
Banville N, Broderick A, Fitzgerald R, Drumm B, McDermott M. Giant inflammatory polyposis coli as a manifestation of Crohn's disease in patients with coexistent cystic fibrosis. Pediatr. Dev. Pathol. 9: 25-30 (2006).
Baptista ML, Amarante H, Picheth G, Sdepanian VL, Peterson N, Babasukumar U, Lima HC, Kugathasan S. CARD15 and IL23R influences Crohn's disease susceptibility but not disease phenotype in a Brazilian population. Inflamm. Bowel Dis. 14: 674-679 (2008). *
Baqir M, Usman MH, Adenwalla HN, Aziz S, Noor F, Islam TU, Ahmed M, Hotiana M. Takayasu's arteritis with skin manifestations in a patient with inflammatory bowel disease: coincidence or concurrence? Clin. Rheumatol. 26: 996-998 (2007). *
Bar-Meir S. Review article: capsule endoscopy - are all small intestinal lesions Crohn's disease? Aliment. Pharmacol. Ther. 24 Suppl. 3: 19-21 (2006). *
Bar-Meir S. Mild to moderate Crohn's disease: still room for step-up therapies? Dig. Dis. 27: 347-350 (2009).
Barahona-Garrido J, Sarti HM, Barahona-Garrido MK, Hernandez-Calleros J, Coss-Adame E, Garcia-Saenz SM, Yamamoto-Furusho JK. Serological markers in inflammatory bowel disease: a review of their clinical utility. Rev. Gastroenterol. Mex. 74: 230-237 (2009).
Barahona-Garrido J, Yamamoto-Furusho JK. New treatment options in the management of IBD - focus on colony stimulating factors. Biologics 2: 501-504 (2008). *
Baranzini SE. The genetics of autoimmune diseases: a networked perspective. Curr. Opin. Immunol. 21: 596-605 (2009). *
Baratti C, De Simone A, Grassi C, Righi I, Massara PP, Pizzi M, Ferla F, Sposato J, Ardizzone S, Trabucchi E. Inflammatory colitis: classification and surgical treatment. Ann. Ital. Chir. 77: 313-317 (2006).
Barbier M, Vidal H, Desreumaux P, Dubuquoy L, Bourreille A, Colombel JF, Cherbut C, Galmiche JP. Overexpression of leptin mRNA in mesenteric adipose tissue in inflammatory bowel diseases. Gastroenterol. Clin. Biol. 27: 987-991 (2003). *
Barbieri D. Inflammatory bowel diseases. J. Pediatr. (Rio. J.) 76: S173-S180 (2000). *
Barbuscia M, Pratico C, Di Pietro N, Rizzo AG, Melita G, De Luca M, Castriciano G, Vita F, Sano M, Gorgone S. Diagnosis and treatment of Crohn's disease. G. Chir. 24: 428-434 (2003).
Barclay AR, Keightley JM, Horrocks I, Garrick V, McGrogan P, Russell RK. Cerebral thromboembolic events in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. Oct 12 [Epub ahead of print] (2009).
Barclay AR, Russell RK, Wilson ML, Gilmour WH, Satsangi J, Wilson DC. Systematic review: the role of breastfeeding in the development of pediatric inflammatory bowel disease. J. Pediatr. 155: 421-426 (2009). *
Bardel C, Danjean V, Hugot JP, Darlu P, Genin E. On the use of haplotype phylogeny to detect disease susceptibility loci. BMC Genet. 6: 24 (2005). *
Bardella MT, Elli L, De Matteis S, Floriani I, Torri V, Piodi L. Autoimmune disorders in patients affected by celiac sprue and inflammatory bowel disease. Ann. Med. 41: 139-143 (2009).
Barden L, Lipson A, Pert P, Walker-Smith JA. Mesalazine in childhood inflammatory bowel disease. Aliment. Pharmacol. Ther. 3: 597-603 (1989).
Bardin N, Reumaux D, Geboes K, Colombel JF, Blot-Chabaud M, Sampol J, Duthilleul P, Dignat-George F. Increased expression of CD146, a new marker of the endothelial junction in active inflammatory bowel disease. Inflamm. Bowel Dis. 12: 16-21 (2006). *
Baretton GB, Aust DE. Intraepithelial neoplasia/dysplasia - histopathology in ulcerative colitis. Pathologe 29 Suppl. 2: 280-285 (2008).
Baricevic I, Jones DR, Nikolic JA, Nedic O. Gastrointestinal inflammation and the circulating IGF system in humans. Horm. Metab. Res. 38: 22-27 (2006).
Barish CF. Alicaforsen therapy in inflammatory bowel disease. Expert Opin. Biol. Ther. 5: 1387-1391 (2005).
Barisic GI, Krivokapic ZV, Adzic TN, Pavlovic AR, Popovic MA, Gojnic M. Fecopneumothorax and colopleural fistula - uncommon complications of Crohn's disease. BMC Gastroenterol. 6: 17 (2006). *
Barkay O, Moshkowitz M, Reif S. Crohn's disease diagnosed by wireless capsule endoscopy in adolescents with abdominal pain, protein-losing enteropathy, anemia and negative endoscopic and radiologic findings. Isr. Med. Assoc. J. 7: 216-218 (2005). *
Barkholt L, Lofberg R. Resetting the immune system in refractory Crohn's disease: is autologous hematopoietic stem cell transplantation the way forward? Gastroenterology 128: 786-799 (2005). *
Barksby HE, Lea SR, Preshaw PM, Taylor JJ. The expanding family of interleukin-1 cytokines and their role in destructive inflammatory disorders. Clin. Exp. Immunol. 149: 217-225 (2007). *
Barmada MM, Brant SR, Nicolae DL, Achkar JP, Panhuysen CI, Bayless TM, Cho JH, Duerr RH. A genome scan in 260 inflammatory bowel disease-affected relative pairs. Inflamm. Bowel Dis. 10: 513-520 (2004). *
Barnes BH, Borowitz SM, Saulsbury FT, Hellems M, Sutphen JL. Discordant erythrocyte sedimentation rate and C-reactive protein in children with inflammatory bowel disease taking azathioprine or 6-mercaptopurine. J. Pediatr. Gastroenterol. Nutr. 38: 509-512 (2004). *
Barnes DS. Intrahepatic cholestatic liver disease. http://www.clevelandclinicmeded.com/diseasemanagement/gastro/intrahepatic/intrahepatic1.htm (2002). *
Barnes SL, Vidrich A, Wang ML, Wu GD, Cominelli F, Rivera-Nieves J, Bamias G, Cohn SM. Resistin-like molecule beta (RELMbeta/FIZZ2) is highly expressed in the ileum of SAMP1/YitFc mice and is associated with initiation of ileitis. J. Immunol. 179: 7012-7020 (2007). *
Barnich N, Aguirre JE, Reinecker HC, Xavier R, Podolsky DK. Membrane recruitment of NOD2 in intestinal epithelial cells is essential for nuclear factor-kappaB activation in muramyl dipeptide recognition. J. Cell. Biol. 170: 21-26 (2005). *
Barnich N, Bringer MA, Claret L, Darfeuille-Michaud A. Involvement of lipoprotein NlpI in the virulence of adherent invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease. Infect. Immun. 72: 2484-2493 (2004). *
Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A. CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J. Clin. Invest. 117: 1566-1574 (2007). *
Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr. Opin. Gastroenterol. 23: 16-20 (2007).
Barnich N, Darfeuille-Michaud A. Role of bacteria in the etiopathogenesis of inflammatory bowel disease. World J. Gastroenterol. 13: 5571-5576 (2007). *
Barnich N, Hisamatsu T, Aguirre JE, Xavier R, Reinecker HC, Podolsky DK. GRIM-19 interacts with NOD2 and serves as down-stream effector of anti-bacterial function in intestinal epithelial cells. J. Biol. Chem. 280: 19021-19026 (2005). *
Baron FA, Hermanne JP, Dowlati A, Weber T, Thiry A, Fassotte MF, Fillet G, Beguin Y. Bronchiolitis obliterans organizing pneumonia and ulcerative colitis after allogeneic bone marrow transplantation. Bone Marrow Transplant. 21: 951-954 (1998).
Baron S, Turck D, Leplat C, Merle V, Gower-Rousseau C, Marti R, Yzet T, Lerebours E, Dupas JL, Debeugny S, Salomez JL, Cortot A, Colombel JF. Environmental risk factors in paediatric inflammatory bowel diseases: a population based case control study. Gut 54: 357-363 (2005). *
Baron TH, Truss CD, Elson CO. Low-dose oral methotrexate in refractory inflammatory bowel disease. Dig. Dis. Sci. 38: 1851-1856 (1993).
Barratt HS, Kalantzis C, Polymeros D, Forbes A. Functional symptoms in inflammatory bowel disease and their potential influence in misclassification of clinical status. Aliment. Pharmacol. Ther. 21: 141-147 (2005). *
Barrau V. What can be expected from digestive tract MRI? J. Chir. (Paris) 144: 398-402 (2007).
Barreau F, Madre C, Dusaillant M, Berrebi D, Merlin F, Sterkers G, Bonacorsi S, Lesuffleur T, Hugot JP. Nod2 regulates the host response towards microflora by modulating T-cell function and epithelial permeability in mouse Peyer’s patches. Gut Oct 15 [Epub ahead of print] (2009). *
Barreau F, Meinzer U, Chareyre F, Berrebi D, Niwa-Kawakita M, Dussaillant M, Foligne B, Ollendorff V, Heyman M, Bonacorsi S, Lesuffleur T, Sterkers G, Giovannini M, Hugot JP. CARD15/NOD2 is required for Peyer's patches homeostasis in mice. PLoS ONE 2: e523 (2007). *
Barreiro de Acosta M, Seijo Rios S, Dominguez Munoz J. Life-threatenig acute lower gastrointestinal bleeding in patients with Crohn's disease. Rev. Esp. Enferm. Dig. 99: 388-391 (2007).
Barreiro-de Acosta M, Enrique Dominguez-Munoz J, Concepcion Nunez-Pardo de Vera M, Lozano-Leon A, Lorenzo A, Pena S. Relationship between clinical features of Crohn's disease and the risk of developing extraintestinal manifestations. Eur. J. Gastroenterol. Hepatol. 19: 73-78 (2007).
Barreiro-de Acosta M, Pena AS. Clinical applications of NOD2/CARD15 mutations in Crohn's disease. Acta Gastroenterol. Latinoam. 37: 49-54 (2007).
Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40: 955-962 (2008). *
Barrett JS, Irving PM, Shepherd SJ, Muir JG, Gibson PR. Comparison of the prevalence of fructose and lactose malabsorption across chronic intestinal disorders. Aliment. Pharmacol. Ther. 30: 165-174 (2009). *
Barrie A, Regueiro M. Biologic therapy in the management of extraintestinal manifestations of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1424-1429 (2007). *
Barrie III AM, Plevy SE. The interleukin-12 family of cytokines: therapeutic targets for inflammatory disease mediation. Clin. Appl. Immunol. Rev. 5: 225-240 (2005). *
Barta Z, Csipo I, Antal-Szalmas P, Sipka S, Szabo G, Szegedi G. Anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Orv. Hetil. 142: 2303-2307 (2001).
Barta Z, Csipo I, Mekkel G, Zeher M, Majoros L, Bernstein CN, Collins MT. Seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease. J. Clin. Microbiol. 42: 5432-5433 (2004). *
Barta Z, Csipo I, Szabo GG, Szegedi G. Seroreactivity against Saccharomyces cerevisiae in patients with Crohn's disease and celiac disease. World J. Gastroenterol. 9: 2308-2312 (2003). *
Barta Z, Toth L, Szabo GG, Szegedi G, Zeher M. Intravenous pulse cyclophosphamide therapy in Crohn's disease and ulcerative colitis. Gut 53: 1058 (2004). *
Barta Z, Toth L, Zeher M. Pulse cyclophosphamide therapy for inflammatory bowel disease. World J. Gastroenterol. 12: 1278-1280 (2006). *
Bartel G, Weiss I, Turetschek K, Schima W, Puspok A, Waldhoer T, Gasche C. Ingested matter affects intestinal lesions in Crohn's disease. Inflamm. Bowel Dis. 14: 374-382 (2008). *
Bartels LE, Jorgensen SP, Agnholt J, Kelsen J, Hvas CL, Dahlerup JF. 1,25-Dihydroxyvitamin D3 and dexamethasone increase interleukin-10 production in CD4+ T cells from patients with Crohn's disease. Int. Immunopharmacol. 7: 1755-1764 (2007).
Barthel HR, Gille T, Halbsguth A, Kramer M. Successful treatment with adalimumab in infliximab-resistant Crohn's disease. J. Gastroenterol. Hepatol. 20: 1464-1465 (2005). *
Barthet M, Hastier P, Bernard JP, Bordes G, Frederick J, Allio S, Mambrini P, Saint-Paul MC, Delmont JP, Salducci J, Grimaud JC, Sahel J. Chronic pancreatitis and inflammatory bowel disease: true or coincidental association? Am. J. Gastroenterol. 94: 2141-2148 (1999). *
Barthet M, Juhan V, Gasmi M, Grimaud JC. Imaging of perianal Crohn's disease. Gastroenterol. Clin. Biol. 28: S52-S60 (2004).
Bartholo RM, Zaltman C, Elia C, Cardoso AP, Flores V, Lago P, Cassabian L, Carvalho Dorileo F, Lapa-E-Silva JR. Bronchial hyperresponsiveness and analysis of induced sputum cells in Crohn's disease. Braz. J. Med. Biol. Res. 38: 197-203 (2005). *
Bartnik W. Inflammatory bowel disease - Polish contribution. J. Physiol. Pharmacol. 54 Suppl. 3: 205-210 (2003). *
Barton A, Eyre S, Bowes J, Ho P, John S, Worthington J. Investigation of the SLC22A4 gene (associated with rheumatoid arthritis in a Japanese population) in a United Kingdom population of rheumatoid arthritis patients. Arthritis Rheum. 52: 752-758 (2005). *
Barton SG, Rampton DS, Winrow VR, Domizio P, Feakins RM. Expression of heat shock protein 32 (hemoxygenase-1) in the normal and inflamed human stomach and colon: an immunohistochemical study. Cell Stress Chaperones 8: 329-334 (2003). *
Bartram SA, Peaston RT, Rawlings DJ, Francis RM, Thompson NP. A randomized controlled trial of calcium with vitamin D, alone or in combination with intravenous pamidronate, for the treatment of low bone mineral density associated with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1121-1127 (2003). *
Bartram SA, Peaston RT, Rawlings DJ, Walshaw D, Francis RM, Thompson NP. Mutifactorial analysis of risk factors for reduced bone mineral density in patients with Crohn's disease. World J. Gastroenterol. 12: 5680-5686 (2006). *
Bartsch H, Nair J. Accumulation of lipid peroxidation-derived DNA lesions: potential lead markers for chemoprevention of inflammation-driven malignancies. Mutat. Res. 591: 34-44 (2005).
Bartsch H, Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 391: 499-510 (2006). *
Bartt RE. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 19: 341-349 (2006).
Bartunkova J, Kolarova I, Sediva A, Holzelova E. Antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, and specific IgE to food allergens in children with inflammatory bowel diseases. Clin. Immunol. 102: 162-168 (2002). *
Baryshnikov EN, Neiman KP. Pyoderma gangrenosum associated Crohn's disease. Eksp. Klin. Gastroenterol. 5: 92-94 (2008).
Basile G, Chiarenza S, Di Mari P, Leanza S, Boscarelli G, Buffone A. Crohn's disease in the elderly. Ann. Ital. Chir. 77: 247-251 (2006).
Basili G, Lorenzetti L, Celona G, Biondi G, Preziuso E, Angrisano C, Goletti O, Belcari C, Venturini G. Gallstone ileus in patient with Crohn's disease: report of a clinical observation. Surg. Endosc. 20: 703-704 (2006).
Basit AW. Advances in colonic drug delivery. Drugs 65: 1991-2007 (2005).
Basler T, Geffers R, Weiss S, Valentin-Weigand P, Goethe R. Mycobacterium avium subspecies induce differential expression of pro-inflammatory mediators in a murine macrophage model: Evidence for enhanced pathogenicity of Mycobacterium avium subspecies paratuberculosis. Immunobiology 213: 879-888 (2008).
Basler T, Holtmann H, Abel J, Eckstein T, Baumer W, Valentin-Weigand P, Goethe R. Reduced transcript stabilization restricts TNF-alpha expression in RAW264.7 macrophages infected with pathogenic mycobacteria: evidence for an involvement of lipomannan. J. Leukoc. Biol. Oct 22 [Epub ahead of print] (2009). *
Basler T, Jeckstadt S, Valentin-Weigand P, Goethe R. Mycobacterium paratuberculosis, Mycobacterium smegmatis, and lipopolysaccharide induce different transcriptional and post-transcriptional regulation of the IRG1 gene in murine macrophages. J. Leukoc. Biol. 79: 628-638 (2006). *
Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 53: 1471-1478 (2004). *
Bastida Pa G, Nos Mate P, Aguas Peri M, Beltran Niclas B, Rodriguez Sole M, Ponce Garcia J. Optimization of immunomodulatory treatment with azathioprine or 6-mercaptopurine in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 511-516 (2007).
Basturk T, Ozagari A, Ozturk T, Kusaslan R, Unsal A. Crohn's disease and secondary amyloidosis: early complication? A case report and review of the literature. J. Ren. Care 35: 147-150 (2009).
Basu D, Lopez I, Kulkarni A, Sellin JH. Impact of race and ethnicity on inflammatory bowel disease. Am. J. Gastroenterol. 100: 2254-2261 (2005). *
Basu SK, Govardhan CP, Jung CW, Margolin AL. Protein crystals for the delivery of biopharmaceuticals. Expert Opin. Biol. Ther. 4: 301-317 (2004).
Bat B, Lodowska J, Orchel A, Parfiniewicz B, Weglarz L, Dzierzewicz Z, Wilczok T. Evaluation of biotransformation of sulphasalazine in the colon epithelial Caco-2 cells. Acta Pol. Pharm. 61 Suppl.: 8-10 (2004).
Bataille F, Klebl F, Rummele P, Schroeder J, Farkas S, Wild PJ, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G. Morphological characterisation of Crohn's disease fistulae. Gut 53: 1314-1321 (2004). *
Bataille F, Rohrmeier C, Bates R, Weber A, Rieder F, Brenmoehl J, Strauch U, Farkas S, Furst A, Hofstadter F, Scholmerich J, Herfarth H, Rogler G. Evidence for a role of epithelial mesenchymal transition during pathogenesis of fistulae in Crohn's disease. Inflamm. Bowel Dis. 14: 1514-1527 (2008). *
Bateson MC. Advances in gastroenterology and hepatology. Postgrad. Med. J. 76: 328-332 (2000). *
Batra A, Zeitz M, Siegmund B. Adipokine signaling in inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1897-1905 (2009).
Batra AK, Levey JM, Trister J, Patwardhan R. Pyoderma gangrenosum in a patient with collagenous colitis. J. Am. Acad. Dermatol. 49: 277-279 (2003).
Batta AK, Tint GS, Xu G, Shefer S, Salen G. Synthesis and intestinal metabolism of ursodeoxycholic acid conjugate with an antiinflammatory agent, 5-aminosalicylic acid. J. Lipid Res. 39: 1641-1646 (1998). *
Battaglia E, Biancone L, Resegotti A, Emanuelli G, Fronda GR, Camussi G. Expression of CD40 and its ligand, CD40L, in intestinal lesions of Crohn's disease. Am. J. Gastroenterol. 94: 3279-3284 (1999). *
Bauditz J, Haemling J, Ortner M, Lochs H, Raedler A, Schreiber S. Treatment with tumour necrosis factor inhibitor oxpentifylline does not improve corticosteroid dependent chronic active Crohn's disease. Gut 40: 470-474 (1997). *
Bauditz J, Lochs H, Schreiber S. Chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. N. Engl. J. Med. 338: 334 (1998).
Bauditz J, Ruckert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet 345: 1445 (1995).
Bauditz J, Schachschal G, Wedel S, Lochs H. Thalidomide for treatment of severe intestinal bleeding. Gut 53: 609-612 (2004). *
Bauditz J, Wedel S, Lochs H. Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200 (2002). *
Bauerfeind P, Beglinger C, Beltinger J, Braegger C, Eigenmann F, Fried M, Guyot J, Hurlimann R, Michetti P, Seibold F, Straumann A. Infliximab - practical guidelines for the treatment of Crohn's disease. Rev. Med. Suisse. 2: 1807-1815 (2006).
Baughman RP, Bradley DA, Lower EE. Infliximab in chronic ocular inflammation. Int. J. Clin. Pharmacol. Ther. 43: 7-11 (2005).
Baughman RP, Iannuzzi M. Tumour necrosis factor in sarcoidosis and its potential for targeted therapy. BioDrugs 17: 425-431 (2003).
Baum CL, Selhub J, Rosenberg IH. Antifolate actions of sulfasalazine on intact lymphocytes. J. Lab. Clin. Med. 97: 779-784 (1981).
Baumgart DC. What's new in inflammatory bowel disease in 2008? World J. Gastroenterol. 14: 329-330 (2008). *
Baumgart DC. The diagnosis and treatment of Crohn's disease and ulcerative colitis. Dtsch. Arztebl. Int. 106: 123-133 (2009). *
Baumgart DC. Veto on vedolizumab (MLN0002) for Crohn's disease. Inflamm. Bowel Dis. 16: 537-538 (2010). *
Baumgart DC, Buning C, Geerdts L, Schmidt HH, Genschel J, Fiedler T, Gentz E, Molnar T, Nagy F, Lonovics J, Lochs H, Wiedenmann B, Nickel R, Witt H, Dignass A. The c.1-260C>T promoter variant of CD14 but not the c.896A>G (p.D299G) variant of Toll-like receptor 4 (TLR4) genes is associated with inflammatory bowel disease. Digestion 76: 196-202 (2007). *
Baumgart DC, Carding SR. Inflammatory bowel disease: cause and immunobiology. Lancet 369: 1627-1640 (2007). *
Baumgart DC, Lowder JN, Targan SR, Sandborn WJ, Frankel MB. Transient cytokine-Induced liver injury following administration of the humanized anti-CD3 antibody visilizumab (HuM291) in Crohn's disease. Am. J. Gastroenterol. 104: 868-876 (2009). *
Baumgart DC, Metzke D, Schmitz J, Scheffold A, Sturm A, Wiedenmann B, Dignass AU. Patients with active inflammatory bowel disease lack immature peripheral blood plasmacytoid and myeloid dendritic cells. Gut 54: 228-236 (2005). *
Baumgart DC, Pintoffl JP, Sturm A, Wiedenmann B, Dignass AU. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease - a long-term follow-up. Am. J. Gastroenterol. 101: 1048-1056 (2006). *
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369: 1641-1657 (2007). *
Baumgart DC, Thomas S, Przesdzing I, Metzke D, Bielecki C, Lehmann SM, Lehnardt S, Dorffel Y, Sturm A, Scheffold A, Schmitz J, Radbruch A. Exaggerated inflammatory response of primary human myeloid dendritic cells to lipopolysaccharide in patients with inflammatory bowel disease. Clin. Exp. Immunol. 157: 423-436 (2009). *
Baumgart M, Dogan B, Rishniw M, Weitzman G, Bosworth B, Yantiss R, Orsi RH, Wiedmann M, McDonough P, Kim SG, Berg D, Schukken Y, Scherl E, Simpson KW. Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum. ISME J. 1: 403-418 (2007). *
Baxter PS, Dickson JA, Variend S, Taylor CJ. Intestinal disease in cystic fibrosis. Arch. Dis. Child. 63: 1496-1497 (1988). *
Bayerdorffer E, Bock H. Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease. Leber. Magen. Darm. 18: 104-113 (1988).
Bayle FJ, Bouvard MP. Anorexia nervosa and Crohn's disease dual diagnosis: a case study. Eur. Psychiatry 18: 421-422 (2003).
Bayless TM, Picco MF, LaBuda MC. Genetic anticipation in Crohn's disease. Am. J. Gastroenterol. 93: 2322-2325 (1998). *
Bayraktar Y, Arslan S, Saglam F, Uzunalimoglu B, Kayhan B. What is the association of primary sclerosing cholangitis with sex and inflammatory bowel disease in Turkish patients? Hepatogastroenterology 45: 2064-2072 (1998).
Beattie RM. Enteral nutrition as primary therapy in childhood Crohn's disease: control of intestinal inflammation and anabolic response. JPEN J. Parenter. Enteral Nutr. 29: S151-S159 (2005). *
Beattie RM. Symposium 6: Young people, artificial nutrition and transitional care. Nutrition, growth and puberty in children and adolescents with Crohn's disease. Proc. Nutr. Soc. Dec 8 [Epub ahead of print] (2009). *
Beattie RM, Croft NM, Fell JM, Afzal NA, Heuschkel RB. Inflammatory bowel disease. Arch. Dis. Child. 91: 426-432 (2006). *
Beaugerie L. What is an inflammatory bowel disease? Rev. Prat. 55: 943-948 (2005).
Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lemann M, Cosnes J, Hebuterne X, Cortot A, Bouhnik Y, Gendre JP, Simon T, Maynadie M, Hermine O, Faivre J, Carrat F; for the CESAME Study Group. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374: 1617-1625 (2009). *
Beaugerie L, Lamy P, Ganne N, Carbonnel F, Le Quintrec Y, Cosnes J, Gendre JP. Morbid associations in Crohn's disease. Study of a series of 832 patients. Presse. Med. 26: 892-894 (1997).
Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of disabling Crohn’s disease. Gastroenterology 130: 650-656 (2006). *
Beaugerie L, Sokol H, Seksik P. Noncolorectal malignancies in inflammatory bowel disease: more than meets the eye. Dig. Dis. 27: 375-381 (2009).
Beaulieu DB, Ananthakrishnan AN, Issa M, Rosenbaum L, Skaros S, Newcomer JR, Kuhlmann RS, Otterson MF, Emmons J, Knox J, Binion DG. Budesonide induction and maintenance therapy for Crohn's disease during pregnancy. Inflamm. Bowel Dis. 15: 25-28 (2009). *
Beaven SW, Abreu MT. Biomarkers in inflammatory bowel disease. Curr. Opin. Gastroenterol. 20: 318-327 (2004).
Bebb JR, Scott BB. How effective are the usual treatments for Crohn's disease? Aliment. Pharmacol. Ther. 20: 151-159 (2004). *
Becheanu G, Manuc M, Dumbrava M, Herlea V, Hortopan M, Costache M. The evaluation of interstitial Cajal cells distribution in non-tumoral colon disorders. Rom. J. Morphol. Embryol. 49: 351-355 (2008).
Bechtold S, Alberer M, Arenz T, Putzker S, Filipiak-Pittroff B, Schwarz HP, Koletzko S. Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease. Inflamm. Bowel Dis. 16: 216-225 (2010).
Beck PL, Podolsky DK. Growth factors in inflammatory bowel disease. Inflamm. Bowel Dis. 5: 44-60 (1999). *
Beck PL, Wallace JL. Cytokines in inflammatory bowel disease. Mediators Inflamm. 6: 95-103 (1997). *
Beck PL, Xavier R, Wong J, Ezedi I, Mashimo H, Mizoguchi A, Mizoguchi E, Bhan AK, Podolsky DK. Paradoxical roles of different nitric oxide synthase isoforms in colonic injury. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G137-G147 (2004). *
Becker C, Wirtz S, Blessing M, Pirhonen J, Strand D, Bechthold O, Frick J, Galle PR, Autenrieth I, Neurath MF. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112: 693-706 (2003). *
Becker E, Horn S, Hussla B, Irle H, Knorr I, Korsukewitz C, Pottins I, Rohwetter M, Schuhknecht P, Timner K. Guidelines for the sociomedical assessment of performance in patients suffering from inflammatory bowel disease. Gesundheitswesen 67: 396-415 (2005).
Becker KG. Comparative genetics of type 1 diabetes and autoimmune disease: common loci, common pathways? Diabetes 48: 1353-1358 (1999). *
Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc. Natl. Acad. Sci. U.S.A. 95: 9979-9984 (1998). *
Becker ML, Rose CD. Blau syndrome and related genetic disorders causing childhood arthritis. Curr. Rheumatol. Rep. 7: 427-433 (2005).
Becker SA. Perianal Crohn's disease. Isr. Med. Assoc. J. 9: 495 (2007).
Beckler DR, Elwasila S, Ghobrial G, Valentine JF, Naser SA. Correlation between rpoB gene mutation in Mycobacterium avium subspecies paratuberculosis and clinical rifabutin and rifampicin resistance for treatment of Crohn's disease. World J. Gastroenterol. 14: 2723-2730 (2008). *
Beckly JB, Hancock L, Geremia A, Cummings JR, Morris A, Cooney R, Pathan S, Guo C, Jewell DP. Two-stage candidate gene study of chromosome 3p demonstrates an association between nonsynonymous variants in the MST1R gene and Crohn's disease. Inflamm. Bowel Dis. 14: 500-507 (2008). *
Beddy D, Mulsow J, Watson RW, Fitzpatrick JM, O'Connell PR. Expression and regulation of connective tissue growth factor by transforming growth factor beta and tumour necrosis factor alpha in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 93: 1290-1296 (2006). *
Beddy D, Watson RW, Fitzpatrick JM, O'Connell PR. Increased vascular endothelial growth factor production in fibroblasts isolated from strictures in patients with Crohn's disease. Br. J. Surg. 91: 72-77 (2004). *
Beddy DJ, Watson WR, Fitzpatrick JM, O'Connell PR. Critical involvement of stress-activated mitogen-activated protein kinases in the regulation of intracellular adhesion molecule-1 in serosal fibroblasts isolated from patients with Crohn's disease. J. Am. Coll. Surg. 199: 234-242 (2004). *
Bedford PA, Todorovic V, Westcott ED, Windsor AC, English NR, Al-Hassi HO, Raju KS, Mills S, Knight SC. Adipose tissue of human omentum is a major source of dendritic cells, which lose MHC class II and stimulatory function in Crohn's disease. J. Leukoc. Biol. 80: 546-554 (2006). *
Bedioui H, Jouini M, Ksantini R, Fteriche F, Chebbi F, Daghfous A, Ayadi S, Kacem M, Boubaker J, Filali A, Ben Safta Z. A previously unreported late complication of Finney strictureplasty. J. Chir. (Paris) 144: 69-71 (2007).
Bedioui H, Mouelhi L, Jouini M, Nouira K, Najjar T, Bensafta Z. Crohn colitis complicated by a gastrocolic and a colovesical fistula: diagnosis and therapeutic management. Presse. Med. 38: e11-e14 (2009).
Bedioui H, Nouira K, Chaker Y, Chebbi F, Ksantini R, Daghfous A, Rebai W, Fteriche F, Ammous A, Jouini M, Kacem MJ, Bensafta Z. Radiologic diagnosis of enterosalpingeal fistula complicating Crohn's disease. Gastroenterol. Clin. Biol. 32: 158-161 (2008).
Bednarz W, Czopnik P, Wojtczak B, Olewinski R, Domoslawski P, Spodzieja J. Analysis of results of surgical treatment in Crohn's disease. Hepatogastroenterology 55: 998-1001 (2008).
Beer TW, Edwards CW. Pulmonary nodules due to reactive systemic amyloidosis (AA) in Crohn's disease. Thorax 48: 1287-1288 (1993). *
Beesley H, Rhodes J, Salmon P. Anger and childhood sexual abuse are independently associated with irritable bowel syndrome. Br. J. Health Psychol. Aug 18 [Epub ahead of print] (2009).
Befeler AS, Lissoos TW, Schiano TD, Conjeevaram H, Dasgupta KA, Millis JM, Newell KA, Thistlethwaite JR, Baker AL. Clinical course and management of inflammatory bowel disease after liver transplantation. Transplantation 65: 393-396 (1998).
Beglinger Ch. Treatment of Crohn's disease. Ther. Umsch. 60: 159-163 (2003).
Beglinger Ch, Gyr N. Incapacity to work, occupational disability and disability in inflammatory bowel disease. Ther. Umsch. 64: 457-462 (2007).
Begue B, Dumant C, Bambou JC, Beaulieu JF, Chamaillard M, Hugot JP, Goulet O, Schmitz J, Philpott DJ, Cerf-Bensussan N, Ruemmele FM. Microbial induction of CARD15 expression in intestinal epithelial cells via Toll-like receptor 5 triggers an antibacterial response loop. J. Cell. Physiol. 209: 241-252 (2006). *
Behjati S, Frank MH. The effects of tamoxifen on immunity. Curr. Med. Chem. 16: 3076-3080 (2009).
Behm B, Bickston S. Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn's disease. Cochrane Database Syst. Rev. 1: CD006893 (2008). *
Behm BW, Bickston SJ. Efficacy of infliximab for luminal and fistulizing Crohn's disease and in ulcerative colitis. Curr. Treat. Options Gastroenterol. 10: 171-177 (2007).
Behr MA. The path to Crohn's disease: is mucosal pathology a secondary event? Inflamm. Bowel Dis. Nov 18 [Epub ahead of print] (2009). *
Behr MA, Bruere P, Oxlade O. Global rates of Crohn's disease. Inflamm. Bowel Dis. 14: 1170-1172 (2008). *
Behr MA, Hanley J. Antimycobacterial therapy for Crohn's disease: a reanalysis. Lancet Infect. Dis. 8: 344 (2008).
Behr MA, Kapur V. The evidence for Mycobacterium paratuberculosis in Crohn's disease. Curr. Opin. Gastroenterol. 24: 17-21 (2008). *
Behr MA, Schurr E. Mycobacteria in Crohn's disease: a persistent hypothesis. Inflamm. Bowel Dis. 12: 1000-1004 (2006). *
Behr MA, Semret M, Poon A, Schurr E. Crohn's disease, mycobacteria, and NOD2. Lancet Infect. Dis. 4: 136-137 (2004).
Behrens R, Segerer H, Bowing B, Bender SW. Crohn's disease in cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 9: 528-531 (1989).
Beigel F, Jurgens M, Filik L, Bader L, Luck C, Goke B, Ochsenkuhn T, Brand S, Seiderer J. Severe Legionella pneumophila pneumonia following infliximab therapy in a patient with Crohn's disease. Inflamm. Bowel Dis. 15: 1240-1244 (2009). *
Beigel F, Jurgens M, Tillack C, Subklewe M, Mayr D, Goke B, Brand S, Ochsenkuhn T. Hepatosplenic T-cell lymphoma in a patient with Crohn's disease. Nat. Rev. Gastroenterol. Hepatol. 6: 433-436 (2009).
Beil WJ, McEuen AR, Schulz M, Wefelmeyer U, Kraml G, Walls AF, Jensen-Jarolim E, Pabst R, Pammer J. Selective alterations in mast cell subsets and eosinophil infiltration in two complementary types of intestinal inflammation: ascariasis and Crohn's disease. Pathobiology 70: 303-313 (2003).
Beildeck ME, Islam M, Shah S, Welsh J, Byers SW. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines. PLoS One 4: e7872 (2009). *
Beitz JM. Continent diversions: the new gold standards of ileoanal reservoir and neobladder. Ostomy Wound Manage. 50: 26-35 (2004).
Bejarano Garcia A, Pallares Manrique H, Nunez Sousa C, Gata Cuadrado M, Garcia Esteban MC, Rojas Feria M, Ramos Lora M, Dominguez Macias A. Intermitent small bowel obstruction secondary to enterolithiasis in Crohn's disease. Rev. Esp. Enferm. Dig. 101: 738-740 (2009).
Beji S, Kaaroud H, Ben Moussa F, Goucha R, Abderrahim E, El Younsi F, Ben Maiz H. Renal amyloidosis complicating the outcome of chronic inflammatory colitis. Presse. Med. 33: 862-865 (2004).
Bekpen C, Marques-Bonet T, Alkan C, Antonacci F, Leogrande MB, Ventura M, Kidd JM, Siswara P, Howard JC, Eichler EE. Death and resurrection of the human IRGM gene. PLoS Genet. 5: e1000403 (2009). *
Belaiche J, Chapelier N, Wertz S, Louis E. Innovative therapies in inflammatory bowel disease at the CHU. Rev. Med. Liege. 62 Spec. No: 63-67 (2008).
Belaiche J, Louis E. Early obstructive colon after treatment of active refractory Crohn's disease with infliximab. Gastroenterol. Clin. Biol. 27: 1045 (2003).
Belaiche J, Louis E. Treatment of Crohn disease in adults with tumor necrosis factor-alpha (TNF-alpha) antibodies. Rev. Med. Liege. 55: 827-832 (2000).
Belazarian L. New insights and therapies for teenage psoriasis. Curr. Opin. Pediatr. 20: 419-424 (2008).
Belda A, Hinojosa J, Serra B, Garcia L, Merino C, Belda A, Moles JR. Systemic candidiasis and infliximab therapy. Gastroenterol. Hepatol. 27: 365-367 (2004).
Belizon A, Sardinha CT, Sher ME. Converted laparoscopic colectomy: what are the consequences? Surg. Endosc. 20: 947-951 (2006). *
Belkahla N, Maamouri N, Ouerghi H, Ben Ammar A. Role of intestinal flora in inflammatory bowel disease and probiotics place in their management. Tunis. Med. 83: 132-136 (2005).
Bell AJ, Price AB, Forbes A, Ciclitira PJ, Groves C, Nicholls RJ. Pre-pouch ileitis: a disease of the ileum in ulcerative colitis after restorative proctocolectomy. Colorectal Dis. 8: 402-410 (2006). *
Bell SJ, Chisholm SA, Owen RJ, Borriello SP, Kamm MA. Evaluation of Helicobacter species in inflammatory bowel disease. Aliment. Pharmacol. Ther. 18: 481-486 (2003). *
Bell SJ, Rigby R, English N, Mann SD, Knight SC, Kamm MA, Stagg AJ. Migration and maturation of human colonic dendritic cells. J. Immunol. 166: 4958-4967 (2001). *
Belling R, McLaren S, Woods L. Specialist nursing interventions for inflammatory bowel disease. Cochrane Database Syst. Rev. 4: CD006597 (2009).
Belling R, Woods L, McLaren S. Stakeholder perceptions of specialist inflammatory bowel disease nurses' role and personal attributes. Int. J. Nurs. Pract. 14: 67-73 (2008).
Bello C, Goldstein F, Thornton JJ. Alternate-day prednisone treatment and treatment maintenance in Crohn's disease. Am. J. Gastroenterol. 86: 460-466 (1991).
Bellolio R F, Zuniga A JM, Wagner H P, Pinedo M G, Duarte G I, Zuniga D A. Ileorectal anastomosis in the surgical treatment of ulcerative colitis: long-term results. Rev. Med. Chil. 136: 1121-1126 (2008).
Belloni Fortina A, Piaserico S, Zattra E, Alaibac M. Dermoscopic features of eruptive melanocytic naevi in an adult patient receiving immunosuppressive therapy for Crohn's disease. Melanoma Res. 15: 223-224 (2005).
Belluzzi A. n-3 Fatty acids for the treatment of inflammatory bowel diseases. Proc. Nutr. Soc. 61: 391-395 (2002). *
Belluzzi A. Polyunsaturated fatty acids (n-3 PUFAs) and inflammatory bowel disease (IBD): pathogenesis and treatment. Eur. Rev. Med. Pharmacol. Sci. 8: 225-229 (2004).
Belluzzi A, Boschi S, Brignola C, Munarini A, Cariani G, Miglio F. Polyunsaturated fatty acids and inflammatory bowel disease. Am. J. Clin. Nutr. 71: 339S-342S (2000). *
Belluzzi A, Roda G, Tonon F, Soleti A, Caponi A, Tuci A, Roda A, Roda E. A new iron free treatment with oral fish cartilage polysaccharide for iron deficiency chronic anemia in inflammatory bowel diseases: a pilot study. World J. Gastroenterol. 13: 1575-1578 (2007). *
Belmiro CL, Souza HS, Elia CC, Castelo-Branco MT, Silva FR, Machado RL, Pavao MS. Biochemical and immunohistochemical analysis of glycosaminoglycans in inflamed and non-inflamed intestinal mucosa of patients with Crohn's disease. Int. J. Colorectal Dis. 20: 295-304 (2005). *
Belniak E, Stelmasiak Z, Papuc E. Multiple sclerosis and other autoimmune diseases. Neurol. Neurochir. Pol. 41: 259-266 (2007).
Belousova E. Epidemiology of inflammatory bowel disease in Russia. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, p. 31 (2006). *
Beltinger J, Froehlich F. Patients with inflammatory bowel disease in specialist gastroenterology practice: a prospective survey. Schweiz. Rundsch. Med. Prax. 94: 459-465 (2005).
Beltran B, Nos P, Bastida G, Iborra M, Hoyos M, Ponce J. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn's disease. Gut 55: 1670-1671 (2006). *
Beltran B, Nos P, Dasi F, Iborra M, Bastida G, Martinez M, O'Connor JE, Saez G, Moret I, Ponce J. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in immune cells of naive and treated Crohn's disease. Inflamm. Bowel Dis. 16: 76-86 (2010).
Beltran CJ, Nunez LE, Díaz-Jimenez D, Farfan N, Candia E, Heine C, Lopez F, Gonzalez MJ, Quera R, Hermoso MA. Characterization of the novel ST2/IL-33 system in patients with inflammatory bowel disease. Inflamm. Bowel Dis. Dec 14 [Epub ahead of print] (2009). *
Ben AJ, Bouasker I, Dahmani A, Bedoui R, Guesmi F, Hani MA, Nouira R, Zoghlami A, Najah N. Entro-vesical fistula complicating Crohn's disease. Tunis. Med. 87: 365-366 (2009).
Ben Aleya W, Sfar I, Mouelhi L, Aouadi H, Makhlouf M, Ayed-Jendoubi S, Matri S, Filali A, Najjar T, Ben Abdallah T, Ayed K, Gorgi Y. Association of Fas/Apo1 gene promoter (-670 A/G) polymorphism in Tunisian patients with IBD. World J. Gastroenterol. 15: 3643-3648 (2009). *
Ben Hamida KS, Serghini M, Ksontini I, Kedadi H, Ben Yaghlene L, Bougassas W, Dougui MH. Bone loss owing to inflammatory bowel disease: prospective study about 50 cases. Tunis. Med. 87: 144-148 (2009).
Ben Said B, Kanitakis J, Graber I, Berard F, Nicolas JF, Saurin JC, Augey F. Severe sporotrichoid fishtank granuloma following infliximab therapy for Crohn's disease. Inflamm. Bowel Dis. 16: 375-376 (2010).
Ben Temime L, Gherib BS, Daldoul S, Bel Hadj Salah R, Abdesselem Mel M, Zaouche A. Adenocarcinoma at the site of ileo-anal anastomosis in Crohn's disease: report of a case. Tunis. Med. 83: 55-58 (2005).
Ben-Horin S, Avidan B, Yanai H, Lang A, Chowers Y, Bar-Meir S. Familial clustering of Crohn's disease in Israel: prevalence and association with disease severity. Inflamm. Bowel Dis. 15: 171-175 (2009). *
Ben-Horin S, Chowers Y. Neuroimmunology of the gut: physiology, pathology, and pharmacology. Curr. Opin. Pharmacol. 8: 490-495 (2008).
Ben-Horin S, Margalit M, Bossuyt P, Maul J, Shapira Y, Bojic D, Chermesh I, Al-Rifai A, Schoepfer A, Bosani M, Allez M, Lakatos PL, Bossa F, Eser A, Stefanelli T, Carbonnel F, Katsanos K, Checchin D, de Miera IS, Chowers Y, Moran GW. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and C. difficile infection. Clin. Gastroenterol. Hepatol. 7: 981-987 (2009).
Benchimol E, Seow Ch, Steinhart A, Griffiths A. Traditional corticosteroids for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 2: CD006792 (2008). *
Bendet N, Scapa E, Cohen O, Bloch O, Aharoni D, Ramot Y, Weiss M, Halevi A, Rapoport MJ. Enhanced glucose-dependent glucagon-like peptide-1 and insulin secretion in Crohn patients with terminal ileum disease is unrelated to disease activity or ileal resection. Scand. J. Gastroenterol. 39: 650-656 (2004). *
Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand. J. Gastroenterol. 44: 774-781 (2009). *
Bene J, Komlosi K, Magyari L, Talian G, Horvath K, Gasztonyi B, Miheller P, Figler M, Mozsik G, Tulassay Z, Melegh B. Plasma carnitine ester profiles in Crohn's disease patients characterized for SLC22A4 C1672T and SLC22A5 G-207C genotypes. Br. J. Nutr. 98: 345-350 (2007). *
Bene J, Magyari L, Talian G, Komlosi K, Gasztonyi B, Tari B, Varkonyi A, Mozsik G, Melegh B. Prevalence of SLC22A4, SLC22A5 and CARD15 gene mutations in Hungarian pediatric patients with Crohn's disease. World J. Gastroenterol. 12: 5550-5553 (2006). *
Bene L, Fust G, Huszti Z, Hernadi Z, Fekete B, Meszaros M, Veres A, Kovacs A, Miklos K, Singh M, Romics L, Prohaszka Z. Impaired humoral immune response against mycobacterial 65-kDa heat shock protein (HSP65) in patients with inflammatory bowel disease. Dig. Dis. Sci. 47: 1432-1437 (2002). *
Benes Z. Crohn's disease and infectious agents. Klin. Mikrobiol. Infekc. Lek. 11: 15-19 (2005).
Bengmark S, Mesa MD, Gil A. Plant-derived health: the effects of turmeric and curcuminoids. Nutr. Hosp. 24: 273-281 (2009). *
Bengtson MB, Aamodt G, Vatn MH, Harris JR. Concordance for IBD among twins compared to ordinary siblings - a Norwegian population-based study. Journal of Crohn's and Colitis [In Press] (2010).
Bengtson MB, Solberg C, Aamodt G, Jahnsen J, Moum B, Sauar J, Vatn MH; Ibsen Study Group. Clustering in time of familial IBD separates ulcerative colitis from Crohn's disease. Inflamm. Bowel Dis. 15: 1867-1874 (2009). *
Bengtson MB, Solberg C, Aamodt G, Sauar J, Jahnsen J, Moum B, Lygren I, Vatn MH; IBSEN study group. Familial aggregation in Crohn's disease and ulcerative colitis in a Norwegian population-based cohort followed for ten years. Journal of Crohn's and Colitis 3: 92-99 (2009).
Bengtson MB, Solberg IC, Aamodt G, Jahnsen J, Moum B, Vatn MH; and the IBSEN Study Group. Relationships between inflammatory bowel disease and perinatal factors: both maternal and paternal disease are related to preterm birth of offspring. Inflamm. Bowel Dis. Sep 30 [Epub ahead of print] (2009).
Beniada A, Benoist G, Maurel J, Dreyfus M. Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature. J. Gynecol. Obstet. Biol. Reprod. (Paris) 34: 581-588 (2005).
Benjamin J, Makharia GK, Ahuja V, Kalaivani M, Joshi YK. Intestinal permeability and its association with the patient and disease characteristics in Crohn's disease. World J. Gastroenterol. 14: 1399-1405 (2008). *
Benjamin J, Makharia GK, Joshi YK. Association between intestinal permeability and anti-Saccharomyces cerevisiae antibodies in patients with Crohn's disease. Inflamm. Bowel Dis. 14: 1610-1611 (2008). *
Benjamin J, Makharia GK, Kalaivani M, Joshi YK. Nutritional status of patients with Crohn's disease. Indian J. Gastroenterol. 27: 195-200 (2008). *
Benoni C, Nilsson A. Smoking habits in patients with inflammatory bowel disease. A case-control study. Scand. J. Gastroenterol. 22: 1130-1136 (1987).
Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 14: 7-12 (2008). *
Bensoussan M, Jovenin N, Garcia B, Vandromme L, Jolly D, Bouche O, Thiefin G, Cadiot G. Complementary and alternative medicine use by patients with inflammatory bowel disease. Gastroenterol. Clin. Biol. 30: 14-23 (2006). *
Bentley RW, Keenan JI, Gearry RB, Kennedy MA, Barclay ML, Roberts RL. Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn's disease and control subjects. Am. J. Gastroenterol. 103: 1168-1172 (2008). *
Bentley RW, Pearson J, Gearry RB, Barclay ML, McKinney C, Merriman TR, Roberts RL. Association of higher DEFB4 genomic copy number with Crohn's disease. Am. J. Gastroenterol. Oct 6 [Epub ahead of print] (2009). *
Bentsen BS, Moum B, Ekbom A. Incidence of inflammatory bowel disease in children in southeastern Norway: a prospective population-based study 1990-94. Scand. J. Gastroenterol. 37: 540-545 (2002). *
Bergamaschi G, Di Sabatino A, Albertini R, Ardizzone S, Biancheri P, Bonetti E, Cassinotti A, Cazzola P, Markopoulos K, Massari A, Rosti V, Bianchi Porro G, Corazza GR. Prevalence and pathogenesis of anemia in inflammatory bowel disease. Influence of anti-tumor necrosis factor-alpha treatment. Haematologica Oct 8 [Epub ahead of print] (2009). *
Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs. 1: 583-589 (2009).
Berger P, Wolf R, Flierman A, den Dunnen WF, Hoekstra HJ. Myositis as the first manifestation of an exacerbation of Crohn's disease. Ned. Tijdschr. Geneeskd. 151: 1295-1298 (2007).
Bergman L, Lindblom JB, Safwenberg J, Krause U. HL-A frequencies in Crohn's disease and ulcerative colitis. Tissue Antigens 7: 145-150 (1976).
Bergman R, Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment. Pharmacol. Ther. 23: 841-855 (2006). *
Bergman R, Sloots CE. Diagnostic image (246). A man with faecal production of the umbilicus. Ned. Tijdschr. Geneeskd. 149: 1940 (2005).
Bergquist A, Lindberg G, Saarinen S, Broome U. Increased prevalence of primary sclerosing cholangitis among first-degree relatives. J. Hepatol. 42: 252-256 (2005). *
Bergquist A, Montgomery SM, Bahmanyar S, Olsson R, Danielsson A, Lindgren S, Prytz H, Hultcrantz R, Loof LA, Sandberg-Gertzen H, Almer S, Askling J, Ehlin A, Ekbom A. Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin. Gastroenterol. Hepatol. 6: 939-943 (2008).
Berkelhammer C, Andrejic J, Mohammed A. Endocarditis in Crohn's disease. Inflamm. Bowel Dis. 15: 1293-1294 (2009).
Berkelhammer C, Debre M, Gutti P. Piriformis muscle abscess complicating Crohn's ileitis. Inflamm. Bowel Dis. 11: 1028-1029 (2005). *
Berkelhammer C, Mohammed A, Zalzaleh G, Grela J, Blumstein A, Stein R. Spontaneous multiperforation in lymphomatous colitis masquerading as Crohn's disease: 2 cases. Inflamm. Bowel Dis. 14: 1172-1173 (2008). *
Berlec A, Strukelj B. Novel applications of recombinant lactic acid bacteria in therapy and in metabolic engineering. Recent Pat. Biotechnol. 3: 77-87 (2009).
Bermejo F, Lopez-Sanroman A, Algaba A, Van-Domselaar M, Gisbert JP, Garcia-Garzon S, Garrido E, Piqueras B, De La Poza G, Guerra I. Mercaptopurine rescue after azathioprine-induced liver injury in inflammatory bowel disease. Aliment. Pharmacol. Ther. 31: 120-124 (2010). *
Bermejo F, Lopez-Sanroman A, Hinojosa J, Castro L, Jurado C, Gomez-Beldal AB. Infliximab induces clinical, endoscopic and histological responses in refractory ulcerative colitis. Rev. Esp. Enferm. Dig. 96: 94-101 (2004).
Bermejo F, Lopez-Sanroman A, Taxonera C, Gisbert JP, Perez-Calle JL, Vera I, Menchen L, Martin-Arranz MD, Opio V, Carneros JA, Van-Domselaar M, Mendoza JL, Luna M, Lopez P, Calvo M, Algaba A. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine-induced pancreatitis. Aliment. Pharmacol. Ther. 28: 623-628 (2008). *
Bermejo F, San Roman AL, Algaba A, Van Domselaar M, Carneros JA, Rivero M, Piqueras B, Paz Valer M. Efficacy of premedication with intravenous corticosteroids and antihistaminics in preventing infusion reactions to infliximab. Gastroenterol. Hepatol. 31: 629-632 (2008).
Bermejo PE, Burgos A. Neurological complications of inflammatory bowel disease. Med. Clin. (Barc.) 130: 666-675 (2008).
Bernal I, Domenech E, Garcia-Planella E, Marin L, Manosa M, Navarro M, Cabre E, Gassull MA. Medication-taking behavior in a cohort of patients with inflammatory bowel disease. Dig. Dis. Sci. 51: 2165-2169 (2006). *
Bernard A, Langille M, Hughes S, Rose C, Leddin D, Veldhuyzen van Zanten S. A systematic review of patient inflammatory bowel disease information resources on the world wide web. Am. J. Gastroenterol. 102: 2070-2077 (2007). *
Bernardes-Silva CF, Damiao AO, Sipahi AM, Laurindo FR, Iriya K, Lopasso FP, Buchpiguel CA, Lordello ML, Agostinho CL, Laudanna AA. Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress. Dig. Dis. Sci. 49: 1569-1574 (2004). *
Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM, Moretta A, Marconi M, Valli M, Novara F, Bonetti F, Zuffardi O, Maccario R, Corazza GR, Locatelli F. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy 11: 825-836 (2009).
Bernardo ME, Avanzini MA, Ciccocioppo R, Perotti C, Cometa AM, Moretta A, Marconi M, Valli M, Novara F, Bonetti F, Zuffardi O, Maccario R, Corazza GR, Locatelli F. Phenotypical/functional characterization of in vitro-expanded mesenchymal stromal cells from patients with Crohn's disease. Cytotherapy Aug 13 [Epub ahead of print] (2009).
Bernasconi E, Favre L, Maillard MH, Bachmann D, Pythoud C, Bouzourene H, Croze E, Velichko S, Parkinson J, Michetti P, Velin D. Granulocyte-macrophage colony-stimulating factor elicits bone marrow-derived cells that promote efficient colonic mucosal healing. Inflamm. Bowel Dis. 16: 428-441 (2010).
Berndt U, Bartsch S, Philipsen L, Danese S, Wiedenmann B, Dignass AU, Hammerle M, Sturm A. Proteomic analysis of the inflamed intestinal mucosa reveals distinctive immune response profiles in Crohn's disease and ulcerative colitis. J. Immunol. 179: 295-304 (2007). *
Bernhard H, Deutschmann A, Leschnik B, Novak M, Hauer A, Haidl H, Rosenkranz A, Muntean W. Calibrated automated thrombin generation in paediatric patients with inflammatory bowel disease. Hamostaseologie. 29 Suppl. 1: S90-S93 (2009).
Bernhardt WM, Schefold JC, Weichert W, Rudolph B, Frei U, Groneberg DA, Schindler R. Amelioration of anemia after kidney transplantation in severe secondary oxalosis. Clin. Nephrol. 65: 216-221 (2006).
Berni Canani R, Terrin G, Borrelli O, Romano MT, Manguso F, Coruzzo A, D'Armiento F, Romeo EF, Cucchiara S. Short- and long-term therapeutic efficacy of nutritional therapy and corticosteroids in paediatric Crohn's disease. Dig. Liver Dis. 38: 381-387 (2006).
Berni Canani R, Terrin G, Rapacciuolo L, Miele E, Siani MC, Puzone C, Cosenza L, Staiano A, Troncone R. Faecal calprotectin as reliable non-invasive marker to assess the severity of mucosal inflammation in children with inflammatory bowel disease. Dig. Liver Dis. 40: 547-553 (2008).
Bernklev T, Jahnsen J, Aadland E, Sauar J, Schulz T, Lygren I, Henriksen M, Stray N, Kjellevold O, Vatn M, Moum B; IBSEN Study Group. Health-related quality of life in patients with inflammatory bowel disease five years after the initial diagnosis. Scand. J. Gastroenterol. 39: 365-373 (2004). *
Bernklev T, Jahnsen J, Henriksen M, Lygren I, Aadland E, Sauar J, Schulz T, Stray N, Vatn M, Moum B. Relationship between sick leave, unemployment, disability, and health-related quality of life in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 12: 402-412 (2006). *
Bernklev T, Jahnsen J, Lygren I, Henriksen M, Vatn M, Moum B. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm. Bowel Dis. 11: 909-918 (2005). *
Bernklev T, Jahnsen J, Schulz T, Sauar J, Lygren I, Henriksen M, Stray N, Kjellevold O, Aadland E, Vatn M, Moum B. Course of disease, drug treatment and health-related quality of life in patients with inflammatory bowel disease 5 years after initial diagnosis. Eur. J. Gastroenterol. Hepatol. 17: 1037-1045 (2005).
Bernstein CN. Challenges in designing a randomized trial of surveillance colonoscopy in IBD. Inflamm. Bowel Dis. 4: 132-141 (1998). *
Bernstein CN. Limiting fracture risk in Crohn's disease: is there anything better than calcium and vitamin D? Clin. Gastroenterol. Hepatol. 3: 110-112 (2005). *
Bernstein CN. Osteoporosis and other complications of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 428-434 (2002).
Bernstein CN. Neoplasia in inflammatory bowel disease: surveillance and management strategies. Curr. Gastroenterol. Rep. 8: 513-518 (2006).
Bernstein CN. Inflammatory bowel diseases as secondary causes of osteoporosis. Curr. Osteoporos. Rep. 4: 116-123 (2006).
Bernstein CN. Section editor's commentary. Infliximab as first-line therapy for Crohn's disease. Inflamm. Bowel Dis. 8: 63-65 (2002). *
Bernstein CN. Is hyperhomocysteinemia associated with osteoporosis in patients with Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 550-551 (2007). *
Bernstein CN. Assessing environmental risk factors affecting the inflammatory bowel diseases: a joint workshop of the Crohn's & Colitis Foundations of Canada and the USA. Inflamm. Bowel Dis. 14: 1139-1146 (2008). *
Bernstein CN. Treatment of the extraintestinal manifestations of inflammatory bowel disease. Curr. Gastroenterol. Rep. 4: 513-516 (2002).
Bernstein CN, Blanchard JF. Viruses and inflammatory bowel disease: is there evidence for a causal association? Inflamm. Bowel Dis. 6: 34-39 (2000). *
Bernstein CN, Blanchard JF, Houston DS, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb. Haemost. 85: 430-434 (2001).
Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 91: 854-862 (2001). *
Bernstein CN, Blanchard JF, Rawsthorne P, Collins MT. Population-based case control study of seroprevalence of Mycobacterium paratuberculosis in patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 42: 1129-1135 (2004). *
Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study. Am. J. Gastroenterol. 96: 1116-1122 (2001). *
Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon PH. Cancer prevention in inflammatory bowel disease and the chemoprophylactic potential of 5-aminosalicylic acid. Inflamm. Bowel Dis. 8: 356-361 (2002). *
Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, Hamid S, Khan AG, Lemair AW; Malfertheiner, Ouyang Q, Rey JF, Sood A, Steinwurz F, Thomsen OO, Thomson A, Watermeyer G. World Gastroenterology Organisation practice guidelines for the diagnosis and management of IBD in 2010. Inflamm. Bowel Dis. 16: 112-124 (2010).
Bernstein CN, Greenberg H, Boult I, Chubey S, Leblanc C, Ryner L. A prospective comparison study of MRI versus small bowel follow-through in recurrent Crohn's disease. Am. J. Gastroenterol. 100: 2493-2502 (2005). *
Bernstein CN, Leslie WD. Osteoporosis and inflammatory bowel disease. Aliment. Pharmacol. Ther. 19: 941-952 (2004). *
Bernstein CN, Nabalamba A. Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am. J. Gastroenterol. 101: 110-118 (2006). *
Bernstein CN, Nabalamba A. Hospitalization-based major comorbidity of inflammatory bowel disease in Canada. Can. J. Gastroenterol. 21: 507-511 (2007). *
Bernstein CN, Nayar G, Hamel A, Blanchard JF. Study of animal-borne infections in the mucosas of patients with inflammatory bowel disease and population-based controls. J. Clin. Microbiol. 41: 4986-4990 (2003). *
Bernstein CN, Nugent Z, Longobardi T, Blanchard JF. Isotretinoin is not associated with inflammatory bowel disease: a population-based case-control study. Am. J. Gastroenterol. 104: 2774-2778 (2009). *
Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am. J. Gastroenterol. 95: 677-683 (2000). *
Bernstein CN, Pettigrew NM, el-Gabalawy HS, Sargent M, Meu Y, Wilkins J. The differential expression of a novel intestinal epithelial glycoprotein in various forms of inflammatory bowel disease. Am. J. Clin. Pathol. 106: 42-51 (1996).
Bernstein CN, Rawsthorne P, Blanchard JF. Population-based case-control study of measles, mumps, and rubella and inflammatory bowel disease. Inflamm. Bowel Dis. 13: 759-762 (2007). *
Bernstein CN, Rawsthorne P, Cheang M, Blanchard JF. A population-based case control study of potential risk factors for IBD. Am. J. Gastroenterol. 101: 993-1002 (2006). *
Bernstein CN, Sargent M, Gallatin WM. Beta2 integrin/ICAM expression in Crohn's disease. Clin. Immunol. Immunopathol. 86: 147-160 (1998).
Bernstein CN, Sargent M, Leslie WD. Serum osteoprotegerin is increased in Crohn's disease: a population-based case control study. Inflamm. Bowel Dis. 11: 325-330 (2005). *
Bernstein CN, Sargent M, Vos HL, Rosendaal FR. Mutations in clotting factors and inflammatory bowel disease. Am. J. Gastroenterol. 102: 338-343 (2007). *
Bernstein CN, Seeger LL, Sayre JW, Anton PA, Artinian L, Shanahan F. Decreased bone density in inflammatory bowel disease is related to corticosteroid use and not disease diagnosis. J. Bone Miner. Res. 10: 250-256 (1995).
Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in IBD: a population-based study. Gastroenterology 129: 827-836 (2005). *
Bernstein CN, Wajda A, Blanchard JF. The incidence of arterial thromboembolic diseases in inflammatory bowel disease: a population-based study. Clin. Gastroenterol. Hepatol. 6: 41-45 (2008).
Bernstein CN, Wajda A, Svenson LW, MacKenzie A, Koehoorn M, Jackson M, Fedorak R, Israel D, Blanchard JF. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol. 101: 1559-1568 (2006). *
Bernstein CN, Wang MH, Sargent M, Brant SR, Collins MT. Testing the interaction between NOD-2 status and serological response to Mycobacterium paratuberculosis in cases of inflammatory bowel disease. J. Clin. Microbiol. 45: 968-971 (2007). *
Bernstein D, Rogers A. Malignancy in Crohn's disease. Am. J. Gastroenterol. 91: 434-440 (1996).
Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am. J. Gastroenterol. 100: 2031-2035 (2005). *
Berrebi D, Maudinas R, Hugot JP, Chamaillard M, Chareyre F, De Lagausie P, Yang C, Desreumaux P, Giovannini M, Cezard JP, Zouali H, Emilie D, Peuchmaur M. Card15 gene overexpression in mononuclear and epithelial cells of the inflamed Crohn's disease colon. Gut 52: 840-846 (2003). *
Berstad AE, Brandtzaeg P. Expression of cell membrane complement regulatory glycoproteins along the normal and diseased human gastrointestinal tract. Gut 42: 522-529 (1998). *
Bertalot G, Villanacci V, Gramegna M, Orvieto E, Negrini R, Saleri A, Terraroli C, Ravelli P, Cestari R, Viale G. Evidence of Epstein-Barr virus infection in ulcerative colitis. Dig. Liver Dis. 33: 551-558 (2001).
Bertrand MJ, Doiron K, Labbe K, Korneluk RG, Barker PA, Saleh M. Cellular inhibitors of apoptosis cIAP1 and cIAP2 are required for innate immunity signaling by the pattern recognition receptors NOD1 and NOD2. Immunity 30: 789-801 (2009). *
Beslek A, Onen F, Birlik M, Akarsu M, Akar S, Sari I, Gurler O, Akpinar H, Manisali M, Akkoc N. Prevalence of spondyloarthritis in Turkish patients with inflammatory bowel disease. Rheumatol. Int. 29: 955-957 (2009). *
Best WR. Predicting the Crohn's disease activity index from the Harvey-Bradshaw index. Inflamm. Bowel Dis. 12: 304-310 (2006). *
Betis F, Brest P, Hofman V, Guignot J, Kansau I, Rossi B, Servin A, Hofman P. Afa/Dr diffusely adhering Escherichia coli infection in T84 cell monolayers induces increased neutrophil transepithelial migration, which in turn promotes cytokine-dependent upregulation of decay-accelerating factor (CD55), the receptor for Afa/Dr … Infect. Immun. 71: 1774-1783 (2003). *
Beutler B. Autoimmunity and apoptosis: the Crohn's connection. Immunity 15: 5-14 (2001). *
Beutler B, Bazzoni F. TNF, apoptosis and autoimmunity: a common thread? Blood Cells Mol. Dis. 24: 216-230 (1998). *
Beutler BA. The role of tumor necrosis factor in health and disease. J. Rheumatol. Suppl. 57: 16-21 (1999).
Bevins CL. The Paneth cell and the innate immune response. Curr. Opin. Gastroenterol. 20: 572-580 (2004).
Bevins CL. Defensins and other antibacterial mediators. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 45 (2005). *
Bevins CL. Events at the host-microbial interface of the gastrointestinal tract V. Paneth cell alpha-defensins in intestinal host defense. Am. J. Physiol. Gastrointest. Liver Physiol. 289: G173-G176 (2005). *
Bevins CL. Paneth cell defensins: key effector molecules of innate immunity. Biochem. Soc. Trans. 34: 263-266 (2006). *
Bevins CL. The role of gut flora and innate immunity in pathogenesis of inflammatory bowel disease. Falk Symposium 135. Immmunological diseases of liver and gut. Prague (Czech Republic). p. 58. September 12 - 13 (2003). *
Bevins CL, Stange EF, Wehkamp J. Decreased Paneth cell defensin expression in ileal Crohn's disease is independent of inflammation, but linked to the NOD2 1007fs genotype. Gut 58: 882-883 (2009).
Bewtra M, Lichtenstein GR. Infliximab use in Crohn's disease. Expert Opin. Biol. Ther. 5: 589-599 (2005).
Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin. Gastroenterol. Hepatol. 5: 597-601.e1 (2007).
Beynon V, Cotofana S, Brand S, Lohse P, Mair A, Wagner S, Mussack T, Ochsenkuhn T, Folwaczny M, Folwaczny C, Glas J, Torok HP. NOD2/CARD15 genotype influences MDP-induced cytokine release and basal IL-12p40 levels in primary isolated peripheral blood monocytes. Inflamm. Bowel Dis. 14: 1033-1040 (2008). *
Beyrouti MI, Beyrouti R, Kharrat M, Kchaou I, Abbes M, Affes N, Tafech I, Ghorbel A, Krichene MS, Boudawara T, Sellami A. Intestinal Crohn disease: surgical aspects and predictive factors of risk of relapse. About 26 cases. Tunis. Med. 82: 927-940 (2004).
Bezabeh T, Somorjai RL, Smith IC. MR metabolomics of fecal extracts: applications in the study of bowel diseases. Magn. Reson. Chem. 47 Suppl. 1: S54-S61 (2009).
Bezabeh T, Somorjai RL, Smith IC, Nikulin AE, Dolenko B, Bernstein CN. The use of 1H magnetic resonance spectroscopy in inflammatory bowel diseases: distinguishing ulcerative colitis from Crohn's disease. Am. J. Gastroenterol. 96: 442-448 (2001). *
Bhaduri S, Jenkinson S, Lewis F. Vulval Crohn's disease - a multi-specialty approach. Int. J. STD AIDS 16: 512-514 (2005).
Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum. Mol. Genet. 7: 1537-1545 (1998). *
Bhan AK, Mizoguchi E, Smith RN, Mizoguchi A. Colitis in transgenic and knockout animals as models of human inflammatory bowel disease. Immunol. Rev. 169: 195-207 (1999).
Bhat M, Dawson D. Wheezes, blisters, bumps and runs: multisystem manifestations of a Crohn's disease flare-up. CMAJ 177: 715-718 (2007). *
Bhat M, Nguyen GC, Pare P, Lahaie R, Deslandres C, Bernard EJ, Aumais G, Jobin G, Wild G, Cohen A, Langelier D, Brant S, Dassopoulos T, McGovern D, Torres E, Duerr R, Regueiro M, Silverberg MS, Steinhart H, Griffiths AM, Elkadri A, Cho J, et al. Phenotypic and genotypic characteristics of inflammatory bowel disease in French Canadians: comparison with a large North American repository. Am. J. Gastroenterol. 104: 2233-2240 (2009). *
Bhatia J, Bratcher J, Korelitz B, Vakher K, Mannor S, Shevchuk M, Panagopoulos G, Ofer A, Tamas E, Kotsali P, Vele O. Abnormalities of uterine cervix in women with inflammatory bowel disease. World J. Gastroenterol. 12: 6167-6171 (2006). *
Bhatia JK, Korelitz BI, Panagopoulos G, Lobel E, Mirsky F, Sultan K, Disanti W, Chun A, Keenan G, Mamun K. A prospective open-label trial of remicade(R) in patients with severe exacerbation of Crohn's disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J. Clin. Gastroenterol. 41: 677-681 (2007).
Bhatt J, Patil S, Joshi A, Abraham P, Desai D. Self-reported treatment adherence in inflammatory bowel disease in Indian patients. Indian J. Gastroenterol. Nov 24 [Epub ahead of print] (2009). *
Bhuket T, Takami M, Fisher L. The use of wireless capsule endoscopy in clinical diagnostic gastroenterology. Expert Rev. Med. Devices 2: 259-266 (2005).
Biagi F, Rondonotti E, Campanella J, Villa F, Bianchi PI, Klersy C, De Franchis R, Corazza GR. Video capsule endoscopy and histology for small-bowel mucosa evaluation: a comparison performed by blinded observers. Clin. Gastroenterol. Hepatol. 4: 998-1003 (2006).
Biagioni C, Favilli F, Catarzi S, Marcucci T, Fazi M, Tonelli F, Vincenzini MT, Iantomasi T. Redox state and O2*- production in neutrophils of Crohn's disease patients. Exp. Biol. Med. (Maywood) 231: 186-195 (2006). *
Bialecka M, Kurzawski M, Klodowska-Duda G, Opala G, Juzwiak S, Kurzawski G, Tan EK, Drozdzik M. CARD15 variants in patients with sporadic Parkinson's disease. Neurosci. Res. 57: 473-476 (2007). *
Bianchi V, Maconi G, Ardizzone S, Colombo E, Ferrara E, Russo A, Tenchini ML, Porro GB. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population. Eur. J. Gastroenterol. Hepatol. 19: 217-223 (2007).
Biancone L, Calabrese E, Palmieri G, Petruzziello C, Onali S, Sica GS, Cossignani M, Condino G, Das KM, Pallone F. Ileal lesions in patients with ulcerative colitis after ileo-rectal anastomosis: relationship with colonic metaplasia. World J. Gastroenterol. 14: 5290-5300 (2008). *
Biancone L, Calabrese E, Petruzziello C, Pallone F. Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 78-91 (2007). *
Biancone L, Cretella M, Tosti C, Palmieri G, Petruzziello C, Geremia A, Calabrese E, Pallone F. Local injection of infliximab in the postoperative recurrence of Crohn's disease. Gastrointest. Endosc. 63: 486-492 (2006).
Biancone L, De Nigris F, Del Vecchio Blanco G, Monteleone I, Vavassori P, Geremia A, Pallone F. Review article: monitoring the activity of Crohn's disease. Aliment. Pharmacol. Ther. 16 Suppl. 4: 29-33 (2002). *
Biancone L, Fiori R, Tosti C, Marinetti A, Catarinacci M, De Nigris F, Simonetti G, Pallone F. Virtual colonoscopy compared with conventional colonoscopy for stricturing postoperative recurrence in Crohn's disease. Inflamm. Bowel Dis. 9: 343-350 (2003). *
Biancone L, Geboes K, Spagnoli LG, Del Vecchio Blanco G, Monteleone I, Vavassori P, Palmieri G, Chimenti S, Pallone F. Metastatic Crohn's disease of the forehead. Inflamm. Bowel Dis. 8: 101-105 (2002). *
Biancone L, Mandal A, Yang H, Dasgupta T, Paoluzi AO, Marcheggiano A, Paoluzi P, Pallone F, Das KM. Production of immunoglobulin G and G1 antibodies to cytoskeletal protein by lamina propria cells in ulcerative colitis. Gastroenterology 109: 3-12 (1995). *
Biancone L, Michetti P, Travis S, Escher JC, Moser G, Forbes A, Hoffmann JC, Dignass A, Gionchetti P, Jantschek G, Kiesslich R, Kolacek S, Mitchell R, Panes J, Soderholm J, Vucelic B, Stange E, for the European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus on the management of ulcerative colitis: special situations. Journal of Crohn's and Colitis 2: 63-92 (2008). *
Biancone L, Monteleone G, Marasco R, Pallone F. Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives. Clin. Exp. Immunol. 113: 198-205 (1998). *
Biancone L, Onali S, Calabrese E, Petruzziello C, Zorzi F, Condino G, Sica GS, Pallone F. Non-invasive techniques for assessing postoperative recurrence in Crohn's disease. Dig. Liver Dis. 40 Suppl. 2: S265-S270 (2008).
Biancone L, Orlando A, Kohn A, Colombo E, Sostegni R, Angelucci E, Rizzello F, Castiglione F, Benezzato L, Papi C, Meucci G, Riegler G, Mocciaro F, Geremia A, Calabrese E, Cottone M, Pallone F. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched-pair study. Gut 55: 228-233 (2006). *
Biancone L, Pavia M, Del Vecchio Blanco G, D'Inca R, Castiglione F, De Nigris F, Doldo P, Cosco F, Vavassori P, Bresci GP, Arrigoni A, Cadau G, Monteleone I, Rispo A, Fries W, Mallardi B, Sturniolo GC, Pallone F. Hepatitis B and C virus infection in Crohn's disease. Inflamm. Bowel Dis. 7: 287-294 (2001). *
Biancone L, Schillaci O, Capoccetti F, Bozzi RM, Fina D, Petruzziello C, Geremia A, Simonetti G, Pallone F. Technetium-99m-HMPAO labeled leukocyte single photon emission computerized tomography (SPECT) for assessing Crohn's disease extent and intestinal infiltration. Am. J. Gastroenterol. 100: 344-354 (2005). *
Biancone L, Sica GS, Calabrese E, Onali S, Petruzziello C, Pallone F. Frequency and pattern of endoscopic recurrence in Crohn's disease patients with ileocolonic resection using a laparoscopic versus laparotomic approach: a prospective longitudinal study. Am. J. Gastroenterol. 103: 809-811 (2008). *
Biancone L, Tosti C, Fina D, Fantini M, De Nigris F, Geremia A, Pallone F. Review article: maintenance treatment of Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 31-37 (2003). *
Biancone L, Tosti C, Geremia A, Fina D, Petruzziello C, Emerenziani S, Pallone F. Rofecoxib and early relapse of inflammatory bowel disease: an open-label trial. Aliment. Pharmacol. Ther. 19: 755-764 (2004). *
Biancone L, Vernia P, Agostini D, Ferrieri A, Pallone F. Effect of rifaximin on intestinal bacterial overgrowth in Crohn's disease as assessed by the H2-glucose breath test. Curr. Med. Res. Opin. 16: 14-20 (2000).
Biank V, Broeckel U, Kugathasan S. Pediatric inflammatory bowel disease: clinical and molecular genetics. Inflamm. Bowel Dis. 13: 1430-1438 (2007). *
Biank V, Friedrichs F, Babusukumar U, Wang T, Stoll M, Broeckel U, Kugathasan S. DLG5 R30Q variant is a female-specific protective factor in pediatric onset Crohn's disease. Am. J. Gastroenterol. 102: 391-398 (2007). *
Biank VF, Kugathasan S. What are the risk factors for surgery and their implications for management of children with Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 660-661 (2006). *
Biasi F, Mascia C, Poli G. TGFbeta1 expression in colonic mucosa: modulation by dietary lipids. Genes Nutr. 2: 233-243 (2007). *
Bibiloni R, Mangold M, Madsen KL, Fedorak RN, Tannock GW. The bacteriology of biopsies differs between newly diagnosed, untreated, Crohn's disease and ulcerative colitis patients. J. Med. Microbiol. 55: 1141-1149 (2006). *
Bibiloni R, Tandon P, Vargas-Voracka F, Barreto-Zuniga R, Lupian-Sanchez A, Rico-Hinojosa MA, Guban J, Fedorak R, Tannock GW. Differential clustering of bowel biopsy-associated bacterial profiles of specimens collected in Mexico and Canada: what do these profiles represent? J. Med. Microbiol. 57: 111-117 (2008). *
Bickston SJ. Keeping the M in mind: recombinant human GMCSF and Crohn's disease. Inflamm. Bowel Dis. 9: 132 (2003). *
Bickston SJ, Comerford LW, Cominelli F. Future therapies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 518-523 (2003).
Bickston SJ, Foley E, Lawrence C, Rockoff T, Shaffer HA Jr, Yeaton P. Terminal ileal stricture in Crohn's disease: treatment using a metallic enteral endoprosthesis. Dis. Colon Rectum 48: 1081-1085 (2005). *
Bickston SJ, Lichtenstein GR, Arseneau KO, Cohen RB, Cominelli F. The relationship between infliximab treatment and lymphoma in Crohn's disease. Gastroenterology 117: 1433-1437 (1999). *
Biczysko M, Kosciniski T, Biczysko R. Unusual complication after caesarean section in a pregnant women with undiagnosed Crohn's disease. Ginekol. Pol. 79: 635-637 (2008).
Bielecki K, Baczuk L. Anorectal Lesniowski-Crohn's disease. Wiad. Lek. 61: 177-182 (2008).
Bielefeldt K, Davis B, Binion DG. Pain and inflammatory bowel disease. Inflamm. Bowel Dis. 15: 778-788 (2009). *
Biemond I, Burnham WR, D'Amaro J, Langman MJ. HLA-A and -B antigens in inflammatory bowel disease. Gut 27: 934-941 (1986). *
Biesalski HK, Hafner G, Gross M, Bassler KH. Vitamin A in the serum of healthy probands and clinical groups. Infusionsther. Klin. Ernahr. 12: 109-114 (1985).
Biet F, Boschiroli ML, Thorel MF, Guilloteau LA. Zoonotic aspects of Mycobacterium bovis and Mycobacterium avium-intracellulare complex (MAC). Vet. Res. 36: 411-436 (2005). *
Billich A. Drug evaluation: Apilimod, an oral IL-12/IL-23 inhibitor for the treatment of autoimmune diseases and common variable immunodeficiency. IDrugs 10: 53-59 (2007).
Bin C, Zhirong Z, Xiaoqin W, Minhu C, Mei L, Xiang G, Baili C, Pinjin H. Contribution of rs11465788 in IL23R gene to Crohn's disease susceptibility and phenotype in Chinese population. J. Genet. 88: 191-196 (2009). *
Binder B, Ahlgrimm-Siess V, Hofmann-Wellenhof R. Eruptive melanocytic nevi of the palms and soles in a patient with Crohn disease. J. Dtsch. Dermatol. Ges. 4: 486-488 (2006).
Binder HJ. Mechanisms of diarrhea in inflammatory bowel diseases. Ann. N. Y. Acad. Sci. 1165: 285-293 (2009). *
Binder V. Epidemiology of IBD during the twentieth century: an integrated view. Best Pract. Res. Clin. Gastroenterol. 18: 463-479 (2004).
Binder V. Genetic epidemiology in inflammatory bowel disease. Dig. Dis. 16: 351-355 (1998).
Binder V, Orholm M. Familial occurrence and inheritance studies in inflammatory bowel disease. Neth. J. Med. 48: 53-56 (1996).
Binion DG, Alemzadeh R. Growth of an IBD controversy: growth hormone and Crohn's disease. Inflamm. Bowel Dis. 7: 176-178 (2001). *
Binion DG, Kugathasan S, Dwinell MB. Molecular stratification of Crohn's disease by chemokine receptors: fractalkine receptor polymorphisms define a fibrostenosing ileal subgroup. Am. J. Gastroenterol. 101: 107-109 (2006). *
Binion DG, Theriot KR, Shidham S, Lundeen S, Hatoum O, Lim HJ, Otterson MF. Clinical factors contributing to rapid reoperation for Crohn's disease patients undergoing resection and/or strictureplasty. J. Gastrointest. Surg. 11: 1692-1698 (2007). *
Bioque G, Bouma G, Crusius JB, Koutroubakis I, Kostense PJ, Meuwissen SG, Pena AS. Evidence of genetic heterogeneity in IBD: 1. The interleukin-1 receptor antagonist in the predisposition to suffer from ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 8: 105-110 (1996).
Bioque G, Crusius JB, Koutroubakis I, Bouma G, Kostense PJ, Meuwissen SG, Pena AS. Allelic polymorphism in IL-1 beta and IL-1 receptor antagonist (IL-1Ra) genes in inflammatory bowel disease. Clin. Exp. Immunol. 102: 379-383 (1995). *
Birchard KR, Brown MA, Hyslop WB, Firat Z, Semelka RC. MRI of acute abdominal and pelvic pain in pregnant patients. AJR Am. J. Roentgenol. 184: 452-458 (2005). *
Birnie AJ, Perkins W. A case of linear IgA disease occurring in a patient with colonic Crohn's disease. Br. J. Dermatol. 153: 1050-1052 (2005). *
Birrenbach T, Bocker U. Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and therapeutic implications. Inflamm. Bowel Dis. 10: 848-859 (2004). *
Birtwistle J. The role of cigarettes and nicotine in the onset and treatment of ulcerative colitis. Postgrad. Med. J. 72: 714-718 (1996). *
Bisaccia E, Palangio M, Gonzalez J. Extracorporeal photochemotherapy for the treatment of refractory Crohn's disease. Transfus. Apher. Sci. 37: 171-174 (2007).
Bischoff SC, Herrmann A, Goke M, Manns MP, von zur Muhlen A, Brabant G. Altered bone metabolism in inflammatory bowel disease. Am. J. Gastroenterol. 92: 1157-1163 (1997).
Bischoff SC, Schwengberg S, Lorentz A, Manns MP, Bektas H, Sann H, Levi-Schaffer F, Shanahan F, Schemann M. Substance P and other neuropeptides do not induce mediator release in isolated human intestinal mast cells. Neurogastroenterol. Motil. 16: 185-193 (2004).
Bisping G, Lugering N, Lutke-Brintrup S, Pauels HG, Schurmann G, Domschke W, Kucharzik T. Patients with inflammatory bowel disease (IBD) reveal increased induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ lymphocytes co-cultured with intestinal epithelial cells. Clin. Exp. Immunol. 123: 15-22 (2001). *
Bissonnette R, Ho V, Langley RG. Safety of conventional systemic agents and biologic agents in the treatment of psoriasis. J. Cutan. Med. Surg. 13 Suppl. 2: S67-S76 (2009).
Bister VO, Salmela MT, Karjalainen-Lindsberg ML, Uria J, Lohi J, Puolakkainen P, Lopez-Otin C, Saarialho-Kere U. Differential expression of three matrix metalloproteinases, MMP-19, MMP-26, and MMP-28, in normal and inflamed intestine and colon cancer. Dig. Dis. Sci. 49: 653-661 (2004). *
Bitton A. Preventing postoperative recurrence in Crohn's disease with 6-mercaptopurine and azathioprine: approaching the cutting edge. Inflamm. Bowel Dis. 11: 513-514 (2005). *
Bitton A. Anti-tumor necrosis factor alpha: Crohn's disease guided missile. Inflamm. Bowel Dis. 4: 173-174 (1998). *
Bitton A, Dobkin P, Edwardes MD, Sewitch M, Meddings J, Rawal S, Cohen A, Vermeire S, Dufresne L, Franchimont D, Wild GE. Predicting relapse in Crohn's disease: a biopsychosocial model. Gut 57: 1386-1392 (2008).
Bizzaro N. The predictive significance of autoantibodies in organ-specific autoimmune diseases. Clin. Rev. Allergy Immunol. 34: 326-331 (2007).
Bjarnason I. Intestinal permeability. Gut 35: S18-S22 (1994). *
Bjarnason I, Macpherson A, Mackintosh C, Buxton-Thomas M, Forgacs I, Moniz C. Reduced bone density in patients with inflammatory bowel disease. Gut 40: 228-233 (1997). *
Bjorkkjaer T, Brunborg LA, Arslan G, Lind RA, Brun JG, Valen M, Klementsen B, Berstad A, Froyland L. Reduced joint pain after short-term duodenal administration of seal oil in patients with inflammatory bowel disease: comparison with soy oil. Scand. J. Gastroenterol. 39: 1088-1094 (2004). *
Bjornsson E, Angulo P. Cholangiocarcinoma in young individuals with and without primary sclerosing cholangitis. Am. J. Gastroenterol. 102: 1677-1682 (2007). *
Bjornsson E, Chapman RW. Sclerosing cholangitis. Curr. Opin. Gastroenterol. 19: 270-275 (2003).
Bjornsson S. Inflammatory bowel disease in Iceland during a 30-year period, 1950-1979. Scand. J. Gastroenterol. Suppl. 170: 47-49 (1989).
Bjornsson S, Johannsson JH, Oddsson E. Inflammatory bowel disease in Iceland, 1980-89. A retrospective nationwide epidemiologic study. Scand. J. Gastroenterol. 33: 71-77 (1998). *
Blackwell JM, Searle S. Genetic regulation of macrophage activation: understanding the function of Nramp1 (=Ity/Lsh/Bcg). Immunol. Lett. 65: 73-80 (1999).
Blakelock RT, Beasley SW. Infection and the gut. Semin. Pediatr. Surg. 12: 265-274 (2003).
Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am. J. Gastroenterol. 96: 1977-1997 (2001). *
Blanchard JF, Bernstein CN, Wajda A, Rawsthorne P. Small-area variations and sociodemographic correlates for the incidence of Crohn's disease and ulcerative colitis. Am. J. Epidemiol. 154: 328-335 (2001). *
Blanchet E, Beau P. Efficacy of hydrostatic balloon dilatation of anastomotic Crohn's disease strictures. Gastroenterol. Clin. Biol. 27: 1105-1109 (2003).
Blanchet E, Beau P, Frat JP. Bone marrow aplasia following dipyrone treatment in a patient with Crohn's disease receiving long-term methotrexate. Gastroenterol. Clin. Biol. 28: 502-503 (2004).
Bland RM, Evans TJ, Raine P, Weaver LT. Inflammatory bowel disease in Scottish children. Health Bull. (Edinb.) 57: 365-373 (1999).
Blaser MJ, Hoverson D, Ely IG, Duncan DJ, Wang WL, Brown WR. Studies of Campylobacter jejuni in patients with inflammatory bowel disease. Gastroenterology 86: 33-38 (1984).
Blaser MJ, Miller RA, Lacher J, Singleton JW. Patients with active Crohn's disease have elevated serum antibodies to antigens of seven enteric bacterial pathogens. Gastroenterology 87: 888-894 (1984).
Blazovics A. Gallstone disease: free radical reactions and the ambivalent role of bilirubin in the pathomechanism of gallstone formation. Orv. Hetil. 148: 589-596 (2007).
Bleday R, Lee E, Jessurun J, Heine J, Wong WD. Increased risk of early colorectal neoplasms after hepatic transplant in patients with inflammatory bowel disease. Dis. Colon Rectum 36: 908-912 (1993).
Bleich A, Hopf S, Hedrich HJ, van Lith HA, Li F, Sartor RB, Mahler M. Genetic dissection of granulomatous enterocolitis and arthritis in the intramural peptidoglycan-polysaccharide-treated rat model of IBD. Inflamm. Bowel Dis. 15: 1794-1802 (2009). *
Bleiziffer O, Dragu A, Kneser U, Horch RE. Solving acne inversa (hidradenitis suppurativa) in Crohn disease with buried chip skin grafts. J. Cutan. Med. Surg. 13: 164-168 (2009).
Blick SK, Curran MP. Certolizumab pegol in Crohn's disease. BioDrugs 21: 195-201 (2007).
Blokzijl H, van Steenpaal A, Vander Borght S, Bok LI, Libbrecht L, Tamminga M, Geuken M, Roskams TA, Dijkstra G, Moshage H, Jansen PL, Faber KN. Upregulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J. Biol. Chem. 283: 35630-35637 (2008). *
Blokzijl H, Vander Borght S, Bok LI, Libbrecht L, Geuken M, van den Heuvel FA, Dijkstra G, Roskams TA, Moshage H, Jansen PL, Faber KN. Decreased P-glycoprotein (P-gp/MDR1) expression in inflamed human intestinal epithelium is independent of PXR protein levels. Inflamm. Bowel Dis. 13: 710-720 (2007). *
Blonski W, Lichtenstein GR. Complications of biological therapy for inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 30-43 (2006).
Blonski W, Lichtenstein GR. Infliximab treatment of postoperative ulcers in Crohn's disease: to inject or not to inject-that is the question. Gastrointest. Endosc. 63: 493-496 (2006).
Blonski W, Lichtenstein GR. Safety of biologics in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 9: 221-233 (2006).
Blonski W, Lichtenstein GR. Safety of biologic therapy. Inflamm. Bowel Dis. 13: 769-796 (2007). *
Blonski WC, Katzka DA, Lichtenstein GR, Metz DC. Idiopathic gastric acid hypersecretion presenting as a diarrheal disorder and mimicking both Zollinger-Ellison syndrome and Crohn's disease. Eur. J. Gastroenterol. Hepatol. 17: 441-444 (2005).
Bloom S, Heryet A, Fleming K, Chapman RW. Inappropriate expression of blood group antigens on biliary and colonic epithelia in primary sclerosing cholangitis. Gut 34: 977-983 (1993). *
Blum E, Katz JA. Postoperative therapy for Crohn's disease. Inflamm. Bowel Dis. 15: 463-472 (2009).
Blumberg RS. Crohn disease. JAMA 300: 439-440 (2008). *
Blumberg RS, Strober W. Prospects for research in inflammatory bowel disease. JAMA 285: 643-647 (2001). *
BMJ Group. Crohn's disease or abdominal tuberculosis? Gut 56: 1757-1758 (2007). *
Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Santoro G, Balato N, Castiglione F, Scarpa R, Perna F, Signoriello G, Galati D, Ponticiello A, Sanduzzi A. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur. J. Clin. Microbiol. Infect. Dis. 27: 907-913 (2008). *
Bocker U, Damiao A, Holt L, Han DS, Jobin C, Panja A, Mayer L, Sartor RB. Differential expression of interleukin 1 receptor antagonist isoforms in human intestinal epithelial cells. Gastroenterology 115: 1426-1438 (1998).
Bocker U, Dinter D, Litterer C, Hummel F, Knebel P, Franke A, Weiss C, Singer MV, Lohr JM. Comparison of magnetic resonance imaging and video capsule enteroscopy in diagnosing small-bowel pathology: localization-dependent diagnostic yield. Scand. J. Gastroenterol. Feb 5 [Epub ahead of print] (2010). *
Bocker U, Lohr JM, Marx A. Twenty-six-year-old female with assumed Crohn's disease and a gastrointestinal stromal tumor: response. Inflamm. Bowel Dis. 15: 489-490 (2009).
Bodar E, Netea MG, Jong DJ, Kullberg BJ, Joosten LA, Meer JW. NOD2 engagement induces proinflammatory cytokine production, but not apoptosis, in leukocytes isolated from patients with Crohn's disease. Eur. Cytokine Netw. 19: 185-189 (2008).
Bode L, Freeze HH. Applied glycoproteomics-approaches to study genetic-environmental collisions causing protein-losing enteropathy. Biochim. Biophys. Acta 1760: 547-559 (2006). *
Bode M, Eder S, Schurmann G. Perianal fistulas in Crohn's disease - biologicals and surgery: is it worthwhile? Z. Gastroenterol. 46: 1376-1383 (2008).
Bodger K. Economic implications of biological therapies for Crohn's disease: review of infliximab. Pharmacoeconomics 23: 875-888 (2005).
Bodger K, Halfvarson J, Dodson A, Campbell F, Wilson S, Lee R, Lindberg E, Jarnerot G, Tysk C, Rhodes J. Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 55: 973-977 (2006). *
Bodger K, Kikuchi T, Hughes D. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment. Pharmacol. Ther. 30: 265-274 (2009). *
Bodily KD, Fletcher JG, Solem CA, Johnson CD, Fidler JL, Barlow JM, Bruesewitz MR, McCollough CH, Sandborn WJ, Loftus EV Jr, Harmsen WS, Crownhart BS. Crohn disease: mural attenuation and thickness at contrast-enhanced CT enterography - correlation with endoscopic and histologic findings of inflammation. Radiology 238: 505-516 (2006). *
Boedeker EC. Crohn's mucosa harbors adherent-invasive E. coli. Inflamm. Bowel Dis. 6: 155 (2000). *
Boehm D, Krzystek-Korpacka M, Neubauer K, Matusiewicz M, Berdowska I, Zielinski B, Paradowski L, Gamian A. Paraoxonase-1 status in Crohn's disease and ulcerative colitis. Inflamm. Bowel Dis. 15: 93-99 (2009). *
Boehncke WH, Buerger C, Boehncke S. Co-morbidities in psoriasis vulgaris. Hautarzt. 60: 116-121 (2009).
Bogaard HJ, Erkelens GW, Faber WR, de Vries PJ. Cutaneous nocardiosis as an opportunistic infection. Ned. Tijdschr. Geneeskd. 148: 533-536 (2004).
Bognar M, Blake W, Agudelo C. Chronic recurrent multifocal osteomyelitis associated with Crohn's disease. Am. J. Med. Sci. 315: 133-135 (1998).
Bohm SK, Kruis W. Probiotics: do they help to control intestinal inflammation? Ann. N. Y. Acad. Sci. 1072: 339-350 (2006). *
Bohr UR, Glasbrenner B, Primus A, Zagoura A, Wex T, Malfertheiner P. Identification of enterohepatic Helicobacter species in patients suffering from inflammatory bowel disease. J. Clin. Microbiol. 42: 2766-2768 (2004). *
Boirivant M, Marini M, Di Felice G, Pronio AM, Montesani C, Tersigni R, Strober W. Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis. Gastroenterology 116: 557-565 (1999).
Boisse L, Chisholm SP, Lukewich MK, Lomax AE. Clinical and experimental evidence of sympathetic neural dysfunction during inflammatory bowel disease. Clin. Exp. Pharmacol. Physiol. 36: 1026-1033 (2009).
Boivin MA, Ye D, Kennedy JC, Al-Sadi R, Shepela C, Ma TY. Mechanism of glucocorticoid regulation of the intestinal tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G590-G598 (2007). *
Bojarski C. Malignant transformation in inflammatory bowel disease: prevention, surveillance and treatment - new techniques in endoscopy. Dig. Dis. 27: 571-575 (2009).
Bokemeyer B. Asymptomatic elevation of serum lipase and amylase in conjunction with Crohn's disease and ulcerative colitis. Z. Gastroenterol. 40: 5-10 (2002).
Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M. Neutrophil gelatinase-associated lipocalin levels in patients with Crohn disease undergoing treatment with infliximab. J. Investig. Med. Jan 7 [Epub ahead of print] (2010).
Bolukbas FF, Bolukbas C, Horoz M, Baba F, Uzunkoy A. A case of previously undiagnosed Crohn's disease presenting with acute pancreatitis as an extraintestinal manifestation. Ann. Saudi Med. 25: 71-73 (2005).
Bona D, Incarbone R, Chella B, Vecchi M, Bonavina L. Heartburn and multiple-site foregut perforations as primary manifestation of Crohn's disease. Dis. Esophagus 18: 199-201 (2005). *
Bonaz B, Boitard J, Marteau P, Lemann M, Coffin B, Flourie B, Belaiche J, Cadiot G, Metman EH, Cortot A, Colombel JF; Getaid. Tioguanine in patients with Crohn's disease intolerant or resistant to azathioprine/mercaptopurine. Aliment. Pharmacol. Ther. 18: 401-408 (2003). *
Bondeson J, Maini RN. Tumour necrosis factor as a therapeutic target in rheumatoid arthritis and other chronic inflammatory diseases: the clinical experience with infliximab (REMICADE). Int. J. Clin. Pract. 55: 211-216 (2001).
Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology 124: 521-536 (2003). *
Bonen DK, Ogura Y, Nicolae DL, Inohara N, Saab L, Tanabe T, Chen FF, Foster SJ, Duerr RH, Brant SR, Cho JH, Nunez G. Crohn's disease-associated NOD2 variants share a signaling defect in response to lipopolysaccharide and peptidoglycan. Gastroenterology 124: 140-146 (2003). *
Boner AL, Peroni D, Bodini A, Delaini G, Piacentini G. Azithromycin may reduce cholestasis in primary sclerosing cholangitis: a case report and serendipitous observation. Int. J. Immunopathol. Pharmacol. 20: 847-849 (2007).
Bongiovanni M, Ranieri R, Ferrero S, Casanova F, Monforte AD. Crohn's disease onset in an HIV/hepatitis C virus co-infected woman taking pegylated interferon alpha-2b plus ribavirin. AIDS 20: 1989-1990 (2006).
Bonheur JL, Braunstein J, Korelitz BI, Panagopoulos G. Anal skin tags in inflammatory bowel disease: new observations and a clinical review. Inflamm. Bowel Dis. 14: 1236-1239 (2008). *
Bonnard A, Fouquet V, Berrebi D, Hugot JP, Belarbi N, Bruneau B, Aigrain Y, de Lagausie P. Crohn's disease in children. Preliminary experience with a laparoscopic approach. Eur. J. Pediatr. Surg. 16: 90-93 (2006).
Bonner GF, Fakhri A, Vennamaneni SR. A long-term cohort study of nonsteroidal anti-inflammatory drug use and disease activity in outpatients with inflammatory bowel disease. Inflamm. Bowel Dis. 10: 751-757 (2004). *
Bonner GF, Walczak M, Kitchen L, Bayona M. Tolerance of nonsteroidal antiinflammatory drugs in patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 1946-1948 (2000). *
Booth IW. The nutritional consequences of gastrointestinal disease in adolescence. Acta Paediatr. Scand. Suppl. 373: 91-102 (1991).
Booya F, Akram S, Fletcher JG, Huprich JE, Johnson CD, Fidler JL, Barlow JM, Solem CA, Sandborn WJ, Loftus EV Jr. CT enterography and fistulizing Crohn's disease: clinical benefit and radiographic findings. Abdom. Imaging 34: 467-475 (2009). *
Booya F, Fletcher JG, Huprich JE, Barlow JM, Johnson CD, Fidler JL, Solem CA, Sandborn WJ, Loftus EV Jr, Harmsen WS. Active Crohn disease: CT findings and interobserver agreement for enteric phase CT enterography. Radiology 241: 787-795 (2006). *
Bor MV, Nexo E, Hvas AM. Holo-transcobalamin concentrations and transcobalamin saturation reflect recent vitamin B12 absorption better than does serum vitamin B12. Clin. Chem. 50: 1043-1049 (2004). *
Boraschi P, Braccini G, Gigoni R, Cartei F, Perri G. MR enteroclysis using iron oxide particles (ferristene) as an endoluminal contrast agent: an open phase III trial. Magn. Reson. Imaging 22: 1085-1095 (2004). *
Boraska Jelavic T, Barisic M, Drmic Hofman I, Boraska V, Vrdoljak E, Peruzovic M, Hozo I, Puljiz Z, Terzic J. Microsatelite GT polymorphism in the Toll-like receptor 2 is associated with colorectal cancer. Clin. Genet. 70: 156-160 (2006). *
Boraz RA. Oral manifestations of Crohn disease: update of the literature and report of case. ASDC J. Dent. Child. 55: 72-74 (1988).
Borchardt JK. Focus on small molecule inhibitors for treatment of inflammatory and autoimmune diseases. Drug News Perspect. 17: 607-614 (2004).
Borcherding F, Nitschke M, Hundorfean G, Rupp J, von Smolinski D, Bieber K, van Kooten C, Lehnert H, Fellermann K, Buning J. The CD40-CD40L pathway contributes to the proinflammatory function of intestinal epithelial cells in inflammatory bowel disease. Am. J. Pathol. Feb 4 [Epub ahead of print] (2010). *
Borchers R, Heinzlmann M, Zahn R, Witter K, Martin K, Loeschke K, Folwaczny C. K-ras mutations in sera of patients with colorectal neoplasias and long-standing inflammatory bowel disease. Scand. J. Gastroenterol. 37: 715-718 (2002). *
Bordas JM, Llach J, Mata A. Utility of single- and double-balloon enteroscopy. Gastroenterol. Hepatol. 32: 424-430 (2009).
Bordeianou L, Dursun A. Current thinking on recurrence: does anastomotic surgical technique affect recurrence rates in Crohn's patients? Inflamm. Bowel Dis. 16: 539-540 (2010). *
Bordeianou L, Kunitake H, Shellito P, Hodin R. Preoperative infliximab treatment in patients with ulcerative and indeterminate colitis does not increase rate of conversion to emergent and multistep abdominal surgery. Int. J. Colorectal Dis. Oct 2 [Epub ahead of print] (2009). *
Borg S, Persson U, Jess T, Thomsen OO, Ljung T, Riis L, Munkholm P. A maximum likelihood estimator of a Markov model for disease activity in Crohn's disease and ulcerative colitis for annually aggregated partial observations. Med. Decis. Making Jul 15 [Epub ahead of print] (2009).
Borgaonkar M, MacIntosh D, Fardy J, Simms L. Anti-tuberculous therapy for maintaining remission of Crohn's disease. Cochrane Database Syst. Rev. 2: CD000299 (2000). *
Borgaonkar MR, MacIntosh DG, Fardy JM. A meta-analysis of antimycobacterial therapy for Crohn's disease. Am. J. Gastroenterol. 95: 725-729 (2000). *
Borgaonkar MR, Townson G, Donnelly M, Irvine EJ. Providing disease-related information worsens health-related quality of life in inflammatory bowel disease. Inflamm. Bowel Dis. 8: 264-269 (2002). *
Borgiani P, Perricone C, Ciccacci C, Romano S, Novelli G, Biancone L, Petruzziello C, Pallone F. Interleukin-23R Arg381Gln is associated with susceptibility to Crohn's disease but not with phenotype in an Italian population. Gastroenterology 133: 1049-1051 (2007). *
Borgiani P, Vallo L, D'Apice MR, Giardina E, Pucci S, Capon F, Nistico S, Chimenti S, Pallone F, Novelli G. Exclusion of CARD15/NOD2 as a candidate susceptibility gene to psoriasis in the Italian population. Eur. J. Dermatol. 12: 540-542 (2002). *
Boriskin HS, Devito BS, Hines JJ, Scarmato VJ, Friedman B. CT enterography vs. capsule endoscopy. Abdom. Imaging 34: 149-155 (2009). *
Borley NR, Mortensen NJ, Jewell DP. MRI scanning in perianal Crohn's disease: an important diagnostic adjunct. Inflamm. Bowel Dis. 5: 231-233 (1999).
Borm ME, Bodegraven AA, Mulder CJ, Kraal G, Bouma G. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int. J. Immunogenet. 32: 401-405 (2005). *
Borm ME, van Bodegraven AA, Mulder CJ, Kraal G, Bouma G. The effect of NOD2 activation on TLR2-mediated cytokine responses is dependent on activation dose and NOD2 genotype. Genes Immun. 9: 274-278 (2008). *
Borody TJ, Bilkey S, Wettstein AR, Leis S, Pang G, Tye S. Anti-mycobacterial therapy in Crohn's disease heals mucosa with longitudinal scars. Dig. Liver Dis. 39: 438-444 (2007).
Borody TJ, Heifets LB. Severe recurrent Crohn's disease of ileocolonic anastomosis and antimicrobial (anti-mycobacterial) therapy. Gut 55: 1211 (2006). *
Borody TJ, Leis S, Warren EF, Surace R. Treatment of severe Crohn's disease using antimycobacterial triple therapy - approaching a cure? Dig. Liver Dis. 34: 29-38 (2002).
Borralho P, Vieira A, Freitas J, Chaves P, Soares J. Aberrant gastric apomucin expression in ulcerative colitis and associated neoplasia. Journal of Crohn's and Colitis 1: 35-40 (2007).
Borralho P, Vieira A, Loureiro R, Pereira PM, de Freitas J. Microcarcinoids associated with diversion colitis in a patient with Crohn's disease. Journal of Crohn's and Colitis 2: 246-249 (2008).
Borrelli O, Bascietto C, Viola F, Bueno de Mesquita M, Barbato M, Mancini V, Bosco S, Cucchiara S. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Dig. Liver Dis. 36: 342-347 (2004).
Borrelli O, Cordischi L, Cirulli M, Paganelli M, Labalestra V, Uccini S, Russo PM, Cucchiara S. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4: 744-753 (2006).
Borruel N, Carol M, Casellas F, Antolín M, de Lara F, Espín E, Naval J, Guarner F, Malagelada JR. Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 51: 659-664 (2002). *
Borthakur A, Bhattacharyya S, Dudeja PK, Tobacman JK. Carrageenan induces interleukin-8 production through distinct Bcl10 pathway in normal human colonic epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G829-G838 (2007). *
Bortoli A, Saibeni S, Tatarella M, Prada A, Beretta L, Rivolta R, Politi P, Ravelli P, Imperiali G, Colombo E, Pera A, Daperno M, Carnovali M, de Franchis R, Vecchi M; the Study Group for Inflammatory Bowel Diseases (GSMII). Pregnancy before and after the diagnosis of inflammatory bowel diseases: retrospective case-control study. J. Gastroenterol. Hepatol. 22: 542-549 (2007). *
Borum ML, Liu E. Crohn's disease mimicking bulimia nervosa. Prim. Care Companion J. Clin. Psychiatry 8: 311-312 (2006). *
Borzutzky A, Fried A, Chou J, Bonilla FA, Kim S, Dedeoglu F. NOD2-associated diseases: bridging innate immunity and autoinflammation. Clin. Immunol. May 23 [Epub ahead of print] (2009). *
Bos WE, Thio HB, Neumann HA, van der Fits L, Prens EP. The pathogenesis of inflammatory dermatoses, especially psoriasis. Ned. Tijdschr. Geneeskd. 150: 179-183 (2006).
Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics 3: 77-97 (2009). *
Bosca MM, Perez-Baylach CM, Solis MA, Anton R, Mayordomo E, Pons S, Minguez M, Benages A. Secondary amyloidosis in Crohn's disease: treatment with tumour necrosis factor inhibitor. Gut 55: 294-295 (2006). *
Bosch ME, Sanchez AJ, Rojas FS, Ojeda CB. Recent advances in analytical determination of thalidomide and its metabolites. J. Pharm. Biomed. Anal. 46: 9-17 (2008).
Bosch X. Hypercalcemia due to endogenous overproduction of 1,25-dihydroxyvitamin D in Crohn's disease. Gastroenterology 114: 1061-1065 (1998). *
Bosques-Padilla F, Galindo-Marines S, Yamamoto-Farusho J. Current concepts about the treatment of inflammatory bowel disease, biological therapy. Rev. Gastroenterol. Mex. 73: 217-230 (2008).
Bossuyt P, Verhaegen J, Van Assche G, Rutgeerts P, Vermeire S. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. Journal of Crohn's and Colitis 3: 4-7 (2009). *
Bossuyt X. Serologic markers in inflammatory bowel disease. Clin. Chem. 52: 171-181 (2006). *
Bosworth BP, Sanders A, Maltz C. Common variable immunodeficiency masquerading as Crohn's ileocolitis. Inflamm. Bowel Dis. 12: 151-152 (2006). *
Botoman VA, Bonner GF, Botoman DA. Management of inflammatory bowel disease. Am. Fam. Physician 57: 57-68, 71-72 (1998).
Botti F, Carrara A, Antonelli B, Quadri F, Maino M, Cesana B, Contessini-Avesani E. The minimal bowel resection in Crohn's disease: analysis of prognostic factors on the surgical recurrence. Ann. Ital. Chir. 74: 627-633 (2003).
Bottini N, Gloria-Bottini F, Amante A, Saccucci P, Bottini E. Genetic polymorphism and Th1/Th2 orientation. Int. Arch. Allergy Immunol. 138: 328-333 (2005).
Bottini N, Gloria-Bottini F, Lucarini N, Ronchetti PG, Fontana L. Inflammatory bowel disease: are there gender differences in the genetics of signal transduction? A preliminary study of cytosolic low molecular weight protein tyrosine phosphatase. Dis. Markers 16: 163-166 (2000).
Bottini N, Stefanini L, Lucarelli P, Bottini E. Adaptation to past malarial endemia and susceptibility to common diseases in modern populations: a study of adenosine deaminase and MN blood group genetic polymorphisms. Am. J. Phys. Anthropol. 128: 194-198 (2005). *
Bouali F, Berrah A, Si Ahmed-Bouali D, Harrieche F, Benhalima M, Hamladji RM, Arrada M. Immunological abnormalities in myelodysplastic syndromes. Prospective study (series of 40 patients). Rev. Med. Interne. 26: 777-783 (2005).
Boubaker J, Feki M, Hsairi M, Fekih M, Kaabachi N, Filali A, Mebazaa A. Osteoporosis and inflammatory bowel disease: prevalence and risk factors in Tunisian patients. Gastroenterol. Clin. Biol. 27: 901-907 (2003).
Boudiaf M, Jaff A, Soyer P, Bouhnik Y, Hamzi L, Rymer R. Small-bowel diseases: prospective evaluation of multi-detector row helical CT enteroclysis in 107 consecutive patients. Radiology 233: 338-344 (2004). *
Bougnoux ME, Diogo D, Francois N, Sendid B, Veirmeire S, Colombel JF, Bouchier C, Van Kruiningen H, d'Enfert C, Poulain D. Multilocus sequence typing reveals intrafamilial transmission and microevolutions of Candida albicans isolates from the human digestive tract. J. Clin. Microbiol. 44: 1810-1820 (2006). *
Bouguen G, Trouilloud I, Siproudhis L, Oussalah A, Bigard MA, Bretagne JF, Peyrin-Biroulet L. Long-term outcome of non-fistulizing (ulceration, stricture) perianal Crohn's disease in patients treated with infliximab. Aliment. Pharmacol. Ther. 30: 749-756 (2009). *
Bouhnik Y. Diagnostic tools in inflammatory bowel diseases. Rev. Prat. 55: 977-983 (2005).
Boulton-Jones JR, Pritchard K, Mahmoud AA. The use of 6-mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment. Pharmacol. Ther. 14: 1561-1565 (2000). *
Bouma G, Kaushiva A, Strober W. Experimental murine colitis is regulated by two genetic loci, including one on chromosome 11 that regulates IL-12 responses. Gastroenterology 123: 554-565 (2002). *
Bouma G, Neve S, van Grieken NC, Mulder CJ, Stoof TJ. A Crohn's disease patient with pustules and fever. Gut 58: 1537 (2009).
Bouma G, Oudkerk Pool M, Crusius JB, Schreuder GM, Hellemans HP, Meijer BU, Kostense PJ, Giphart MJ, Meuwissen SG, Pena AS. Evidence for genetic heterogeneity in inflammatory bowel disease (IBD); HLA genes in the predisposition to suffer from ulcerative colitis (UC) and Crohn's disease (CD). Clin. Exp. Immunol. 109: 175-179 (1997). *
Bouma G, Pena AS. Immunology in medical practice. XXVI. Immunogenetics of chronic inflammatory bowel diseases. Ned. Tijdschr. Geneeskd. 143: 2414-2420 (1999).
Bouma G, Poen AC, Garcia-Gonzalez MA, Schreuder GM, Felt-Bersma RJ, Meuwissen SG, Pena AS. HLA-DRB1*03, but not the TNFA -308 promoter gene polymorphism, confers protection against fistulising Crohn's disease. Immunogenetics 47: 451-455 (1998).
Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3: 521-533 (2003). *
Bouma G, Xia B, Crusius JB, Bioque G, Koutroubakis I, Von Blomberg BM, Meuwissen SG, Pena AS. Distribution of four polymorphisms in the tumour necrosis factor (TNF) genes in patients with inflammatory bowel disease (IBD). Clin. Exp. Immunol. 103: 391-396 (1996). *
Bourges O, Dorgeret S, Alberti C, Hugot JP, Sebag G, Cezard JP. Low bone mineral density in children with Crohn's disease. Arch. Pediatr. 11: 800-806 (2004).
Bourhis LL, Benko S, Girardin SE. Nod1 and Nod2 in innate immunity and human inflammatory disorders. Biochem. Soc. Trans. 35: 1479-1484 (2007). *
Bourikas LA, Kourbeti IS, Koutsopoulos AV, Koutroubakis IE. Disseminated tuberculosis in a Crohn's disease patient on anti-TNF alpha therapy despite chemoprophylaxis. Gut 57: 425 (2008).
Bourne PC, Terzyan SS, Cloud G, Landolfi NF, Vasquez M, Edmundson AB. Three-dimensional structures of a humanized anti-IFN-gamma Fab (HuZAF) in two crystal forms. Acta Crystallogr. D. Biol. Crystallogr. 60: 1761-1769 (2004). *
Bourne T, Fossati G, Nesbitt A. A PEGylated Fab' fragment against tumor necrosis factor for the treatment of Crohn disease: exploring a new mechanism of action. BioDrugs 22: 331-337 (2008).
Bourreille A, Doubremelle M, de la Bletiere DR, Segain JP, Toquet C, Buelow R, Galmiche JP. RDP58, a novel immunomodulatory peptide with anti-inflammatory effects. A pharmacological study in trinitrobenzene sulphonic acid colitis and Crohn disease. Scand. J. Gastroenterol. 38: 526-532 (2003). *
Bourreille A, Humbert B, Maugere P, Galmiche JP, Darmaun D. Glutamine metabolism in Crohn's disease: a stable isotope study. Clin. Nutr. 23: 1167-1175 (2004).
Bourreille A, Ignjatovic A, Aabakken L, Loftus EV Jr, Eliakim R, Pennazio M, Bouhnik Y, Seidman E, Keuchel M, Albert JG, Ardizzone S, Bar-Meir S, Bisschops R, Despott EJ, Fortun PF, Heuschkel R, Kammermeier J, Leighton JA, Mantzaris GJ, et al. Role of small-bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 41: 618-637 (2009).
Bourreille A, Jarry M, D'Halluin PN, Ben-Soussan E, Maunoury V, Bulois P, Sacher-Huvelin S, Vahedy K, Lerebours E, Heresbach D, Bretagne JF, Colombel JF, Galmiche JP. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of post-operative recurrence of Crohn's disease: a prospective study. Gut 55: 978-983 (2006). *
Bourrie B, Bribes E, Derocq JM, Vidal H, Casellas P. Sigma receptor ligands: applications in inflammation and oncology. Curr. Opin. Investig. Drugs 5: 1158-1163 (2004).
Bousvaros A. Mucosal healing in children with Crohn's disease: appropriate therapeutic goal or medical overkill? Inflamm. Bowel Dis. 10: 481-483 (2004). *
Bousvaros A, Guandalini S, Baldassano RN, Botelho C, Evans J, Ferry GD, Goldin B, Hartigan L, Kugathasan S, Levy J, Murray KF, Oliva-Hemker M, Rosh JR, Tolia V, Zholudev A, Vanderhoof JA, Hibberd PL. A randomized, double-blind trial of Lactobacillus GG versus placebo in addition to standard maintenance therapy for children with Crohn's disease. Inflamm. Bowel Dis. 11: 833-839 (2005). *
Bousvaros A, Sylvester F, Kugathasan S, Szigethy E, Fiocchi C, Colletti R, Otley A, Amre D, Ferry G, Czinn SJ, Splawski JB, Oliva-Hemker M, Hyams JS, Faubion WA, Kirschner BS, Dubinsky MC; and the Members of the Challenges in Pediatric IBD Study Groups. Challenges in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 12: 885-913 (2006). *
Bousvaros A, Zurakowski D, Duggan C, Law T, Rifai N, Goldberg NE, Leichtner AM. Vitamins A and E serum levels in children and young adults with inflammatory bowel disease: effect of disease activity. J. Pediatr. Gastroenterol. Nutr. 26: 129-135 (1998). *
Bouzaidi S, Ben Salem M, Mnif N, Ben Hammouda I, Ben Yedder J, Trabelsi S, Moussa A, Jemaa Y, Debbech R, Salem M, Najjar T, Hamza R. Bone mineral density in patients with Crohn's disease: about 53 cases. Tunis. Med. 82: 753-759 (2004).
Bovenschen HJ, Tjioe M, Vermaat H, Hoop D, Witteman BM, Janssens RW, Stoof TJ, Kerkhof PC. Induction of eruptive benign melanocytic naevi by immune suppressive agents, including biologicals. Br. J. Dermatol. 154: 880-884 (2006). *
Bower K, Begg DJ, Whittington RJ. Optimisation of culture of Mycobacterium avium subspecies paratuberculosis from blood samples. J. Microbiol. Methods Nov 20 [Epub ahead of print] (2009).
Boyanova L, Gergova G, Spassova Z, Koumanova R, Yaneva P, Mitov I, Derejian S, Krastev Z. Campylobacter infection in 682 Bulgarian patients with acute enterocolitis, inflammatory bowel disease, and other chronic intestinal diseases. Diagn. Microbiol. Infect. Dis. 49: 71-74 (2004).
Boye B, Jahnsen J, Mokleby K, Leganger S, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Wilhelmsen I, Sharpe M, Blomhoff S, Malt UF, Lundin KE. The INSPIRE study: are different personality traits related to disease-specific quality of life (IBDQ) in distressed patients with ulcerative colitis and Crohn's disease? Inflamm. Bowel Dis. 14: 680-686 (2008). *
Boye B, Lundin KE, Leganger S, Mokleby K, Jantschek G, Jantschek I, Kunzendorf S, Benninghoven D, Sharpe M, Wilhelmsen I, Blomhoff S, Malt UF, Jahnsen J. The INSPIRE study: do personality traits predict general quality of life (short form-36) in distressed patients with ulcerative colitis and Crohn's disease? Scand. J. Gastroenterol. 43: 1505-1513 (2008). *
Boyer L, Sidpra D, Jevon G, Buchan AM, Jacobson K. Differential responses of VIPergic and nitrergic neurons in paediatric patients with Crohn's disease. Auton. Neurosci. 134: 106-114 (2007).
Boyne MS, Dye KR. Crohn's colitis and idiopathic thrombocytopenic purpura. Postgrad. Med. J. 76: 299-300 (2000). *
Boysen T, Clausen MR. A case of acute liver failure caused by herpes simplex type 2. Scand. J. Infect. Dis. 36: 529-532 (2004).
Braat H, McGuirk P, Kate FT, Huibregtse I, Dunne P, Hommes D, Deventer S, Mills K. Prevention of experimental colitis by parenteral administration of a pathogen-derived immunomodulatory molecule. Gut 56: 351-357 (2007). *
Braat H, Peppelenbosch MP, Hommes DW. Immunology of Crohn's disease. Ann. N. Y. Acad. Sci. 1072: 135-154 (2006). *
Braat H, Peppelenbosch MP, Hommes DW. Interleukin-10-based therapy for inflammatory bowel disease. Expert Opin. Biol. Ther. 3: 725-731 (2003).
Braat H, Rottiers P, Hommes DW, Huyghebaert N, Remaut E, Remon JP, van Deventer SJ, Neirynck S, Peppelenbosch MP, Steidler L. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 754-759 (2006).
Braat H, Stokkers P, Hommes T, Cohn D, Vogels E, Pronk I, Spek A, van Kampen A, van Deventer S, Peppelenbosch M, Hommes D. Consequence of functional Nod2 and Tlr4 mutations on gene transcription in Crohn's disease patients. J. Mol. Med. 83: 601-609 (2005). *
Braat H, van den Brande J, van Tol E, Hommes D, Peppelenbosch M, van Deventer S. Lactobacillus rhamnosus induces peripheral hyporesponsiveness in stimulated CD4+ T cells via modulation of dendritic cell function. Am. J. Clin. Nutr. 80: 1618-1625 (2004). *
Brackmann S, Andersen SN, Aamodt G, Langmark F, Clausen OP, Aadland E, Fausa O, Rydning A, Vatn MH. Relationship between clinical parameters and the colitis-colorectal cancer interval in a cohort of patients with colorectal cancer in inflammatory bowel disease. Scand. J. Gastroenterol. 44: 46-55 (2009). *
Bradley PJ, Ferlito A, Devaney KO, Rinaldo A. Crohn's disease manifesting in the head and neck. Acta Otolaryngol. 124: 237-241 (2004).
Bradley RJ, Rosen MP. Subfertility and gastrointestinal disease: 'Unexplained' is often undiagnosed. Obstet. Gynecol. Surv. 59: 108-117 (2004).
Braegger CP, MacDonald TT. Immune mechanisms in chronic inflammatory bowel disease. Ann. Allergy 72: 135-141 (1994).
Bragagni G, Brogna R, Franceschetti P, Zoli G. Cardiac involvement in Crohn's disease: echocardiographic study. J. Gastroenterol. Hepatol. 22: 18-22 (2007). *
Brakenhoff LK, van der Heijde DM, Hommes DW, Huizinga TW, Fidder HH. The joint-gut axis in inflammatory bowel diseases. Journal of Crohn's and Colitis [In Press] (2009).
Branagan G, Thompson MR, Senapati A. Cleft closure for the treatment of unhealed perineal sinus. Colorectal Dis. 8: 314-317 (2006). *
Branco BC, Harpaz N, Sachar DB, Greenstein AJ, Tabrizian P, Bauer JJ, Greenstein AJ. Colorectal carcinoma in indeterminate colitis. Inflamm. Bowel Dis. 15: 1076-1081 (2009).
Brand S. Crohn’s disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn’s disease. Gut 58: 1152-1167 (2009).
Brand S, Beigel F, Olszak T, Zitzmann K, Eichhorst ST, Otte JM, Diepolder H, Marquardt A, Jagla W, Popp A, Leclair S, Herrmann K, Seiderer J, Ochsenkuhn T, Goke B, Auernhammer CJ, Dambacher J. IL-22 is increased in active Crohn's disease and promotes proinflammatory gene expression and intestinal epithelial cell migration. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G827-G838 (2006). *
Brand S, Crispin A. C-reactive protein polymorphism and Crohn's disease: authors' reply. Aliment. Pharmacol. Ther. 25: 520-521 (2007).
Brand S, Hofbauer K, Dambacher J, Schnitzler F, Staudinger T, Pfennig S, Seiderer J, Tillack C, Konrad A, Goke B, Ochsenkuhn T, Lohse P. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease phenotype. Am. J. Gastroenterol. 101: 99-106 (2006). *
Brand S, Olszak T, Beigel F, Diebold J, Otte JM, Eichhorst ST, Goke B, Dambacher J. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J. Cell. Biochem. 97: 709-723 (2006). *
Brand S, Staudinger T, Schnitzler F, Pfennig S, Hofbauer K, Dambacher J, Seiderer J, Tillack C, Konrad A, Crispin A, Goke B, Lohse P, Ochsenkuhn T. The role of Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms and CARD15/NOD2 mutations in the susceptibility and phenotype of Crohn's disease. Inflamm. Bowel Dis. 11: 645-652 (2005). *
Brandi MT, Ribeiro MS, Chebli LA, Franco MB, Pinto AL, Gaburri PD, Zanini A, Chebli JM. Psychological distress in Brazilian Crohn's disease patients: screening, prevalence, and risk factors. Med. Sci. Monit. 15: PH101-PH108 (2009).
Brandtzaeg P. The changing immunological paradigm in coeliac disease. Immunol. Lett. 105: 127-139 (2006).
Brandtzaeg P. Immunopathology of Crohn's disease. Ann. Gastroenterol. Hepatol. (Paris) 21: 202-220 (1985).
Brandtzaeg P. Inflammatory bowel disease: clinics and pathology. Do inflammatory bowel disease and periodontal disease have similar immunopathogeneses? Acta Odontol. Scand. 59: 235-243 (2001). *
Brandtzaeg P, Baklien K. Immunohistochemical studies of the immunoglobulin-producing cell systems of the human intestinal mucosa. Acta Histochem. Suppl. 21: 105-119 (1980).
Brandwein SL, McCabe RP, Cong Y, Waites KB, Ridwan BU, Dean PA, Ohkusa T, Birkenmeier EH, Sundberg JP, Elson CO. Spontaneously colitic C3H/HeJBir mice demonstrate selective antibody reactivity to antigens of the enteric bacterial flora. J. Immunol. 159: 44-52 (1997).
Brannigan AE, O'Connell PR, Hurley H, O'Neill A, Brady HR, Fitzpatrick JM, Watson RW. Neutrophil apoptosis is delayed in patients with inflammatory bowel disease. Shock 13: 361-366 (2000).
Brannigan AE, Watson RW, Beddy D, Hurley H, Fitzpatrick JM, O'Connell PR. Increased adhesion molecule expression in serosal fibroblasts isolated from patients with inflammatory bowel disease is secondary to inflammation. Ann. Surg. 235: 507-511 (2002). *
Brant SR. Exposed: the genetic underpinnings of ulcerative colitis relative to Crohn's disease. Gastroenterology 136: 396-399 (2009). *
Brant SR. IBD5: the second Crohn's disease gene? Inflamm. Bowel Dis. 8: 371-372 (2002). *
Brant SR, Fu Y, Fields CT, Baltazar R, Ravenhill G, Pickles MR, Rohal PM, Mann J, Kirschner BS, Jabs EW, Bayless TM, Hanauer SB, Cho JH. American families with Crohn's disease have strong evidence for linkage to chromosome 16 but not chromosome 12. Gastroenterology 115: 1056-1061 (1998). *
Brant SR, Nguyen GC. Is there a gender difference in the prevalence of Crohn's disease or ulcerative colitis? Inflamm. Bowel Dis. 14 Suppl. 2: S2-S3 (2008). *
Brant SR, Panhuysen CI, Bailey-Wilson JE, Rohal PM, Lee S, Mann J, Ravenhill G, Kirschner BS, Hanauer SB, Cho JH, Bayless TM. Linkage heterogeneity for the IBD1 locus in Crohn's disease pedigrees by disease onset and severity. Gastroenterology 119: 1483-1490 (2000). *
Brant SR, Panhuysen CI, Nicolae D, Reddy DM, Bonen DK, Karaliukas R, Zhang L, Swanson E, Datta LW, Moran T, Ravenhill G, Duerr RH, Achkar JP, Karban AS, Cho JH. MDR1 Ala893 polymorphism is associated with inflammatory bowel disease. Am. J. Hum. Genet.73: 1282-1292 (2003). *
Brant SR, Picco MF, Achkar JP, Bayless TM, Kane SV, Brzezinski A, Nouvet FJ, Bonen D, Karban A, Dassopoulos T, Karaliukas R, Beaty TH, Hanauer SB, Duerr RH, Cho JH. Defining complex contributions of NOD2/CARD15 gene mutations, age at onset, and tobacco use on Crohn's disease phenotypes. Inflamm. Bowel Dis. 9: 281-289 (2003). *
Brant SR, Shugart YY. Inflammatory bowel disease gene hunting by linkage analysis - rationale, methodology, and present status of the field. Inflamm. Bowel Dis. 10: 300-311 (2004). *
Brant SR, Wang MH, Rawsthorne P, Sargent M, Datta LW, Nouvet F, Shugart YY, Bernstein CN. A population-based case-control study of CARD15 and other risk factors in Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 102: 313-323 (2007). *
Bratcher JM, Korelitz BI. Toxicity of infliximab in the course of treatment of Crohn's disease. Expert Opin. Drug Saf. 5: 9-16 (2006).
Braun A, Treede I, Gotthardt D, Tietje A, Zahn A, Ruhwald R, Schoenfeld U, Welsch T, Kienle P, Erben G, Lehmann WD, Fuellekrug J, Stremmel W, Ehehalt R. Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflamm. Bowel Dis. 15: 1705-1720 (2009). *
Braun C, Zahn R, Martin K, Albert E, Folwaczny C. Polymorphisms of the ICAM-1 gene are associated with inflammatory bowel disease, regardless of the p-ANCA status. Clin. Immunol. 101: 357-360 (2001). *
Braun J. Primativism, siderophilic bacteria, and Crohn's disease. Inflamm. Bowel Dis. 10: 884-885 (2004). *
Braun J. In search of desire: mimicry, MAP, and Crohn's disease. Gastroenterology 131: 312-314 (2006). *
Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum. 57: 639-647 (2007). *
Braun J, de Keyser F, Brandt J, Mielants H, Sieper J, Veys E. New treatment options in spondyloarthropathies: increasing evidence for significant efficacy of anti-tumor necrosis factor therapy. Curr. Opin. Rheumatol. 13: 245-249 (2001).
Braun J, Sieper J. Overview of the use of the anti-TNF agent infliximab in chronic inflammatory diseases. Expert Opin. Biol. Ther. 3: 141-168 (2003).
Braun J, Targan SR. Multiparameter analysis of immunogenetic mechanisms in clinical diagnosis and management of inflammatory bowel disease. Adv. Exp. Med. Biol. 579: 209-218 (2006).
Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin. Immunol. 132: 1-9 (2009). *
Braveman JM, Schoetz DJ Jr, Marcello PW, Roberts PL, Coller JA, Murray JJ, Rusin LC. The fate of the ileal pouch in patients developing Crohn's disease. Dis. Colon Rectum 47: 1613-1619 (2004).
Breban M, Said-Nahal R, Hugot JP, Miceli-Richard C. Familial and genetic aspects of spondyloarthropathy. Rheum. Dis. Clin. North Am. 29: 575-594 (2003).
Brechmann T, Heyer C, Schmiegel W. Methotrexate-induced pneumonitis in a woman with Crohn's disease. Dtsch. Med. Wochenschr. 132: 1759-1762 (2007).
Breedveld FC. Tumour necrosis factor antagonists: infliximab, adalimumab and etanercept. Ned. Tijdschr. Geneeskd. 149: 2273-2277 (2005).
Breen EM, Ashley SW. Laparoscopic surgery for Crohn's disease? - a conditional yes. Inflamm. Bowel Dis. 6: 43-45 (2000). *
Breese E, Braegger CP, Corrigan CJ, Walker-Smith JA, MacDonald TT. Interleukin-2- and interferon-gamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology 78: 127-131 (1993). *
Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, Walker-Smith JA, MacDonald TT. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106: 1455-1466 (1994).
Bregenzer N, Hartmann A, Strauch U, Scholmerich J, Andus T, Bollheimer LC. Increased insulin resistance and beta cell activity in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 53-56 (2006). *
Bregenzer N, Schaffler A, Gelbmann CM, Steinkamp M, Reinshagen M, Scholmerich J, Andus T. Lack of correlation between the vitamin D receptor Fokl start codon polymorphism and bone mineral density in patients with Crohn's disease. Exp. Clin. Endocrinol. Diabetes 114: 1-5 (2006).
Bremner A, Roked S, Robinson R, Phillips I, Beattie M. Faecal calprotectin in children with chronic gastrointestinal symptoms. Acta Paediatr. 94: 1855-1858 (2005). *
Bremner AR, Beattie RM. Recent advances in the medical therapy of Crohn's disease in childhood. Expert Opin. Pharmacother. 8: 2553-2568 (2007).
Bremner AR, Griffiths M, Argent JD, Fairhurst JJ, Beattie RM. Sonographic evaluation of inflammatory bowel disease: a prospective, blinded, comparative study. Pediatr. Radiol. 36: 947-953 (2006). *
Bremner AR, Pridgeon J, Fairhurst J, Beattie RM. Ultrasound scanning may reduce the need for barium radiology in the assessment of small-bowel Crohn's disease. Acta Paediatr. 93: 479-481 (2004).
Brenmoehl J, Falk W, Goke M, Scholmerich J, Rogler G. Inflammation modulates fibronectin isoform expression in colonic lamina propria fibroblasts (CLPF). Int. J. Colorectal Dis. 23: 947-955 (2008). *
Brenmoehl J, Herfarth H, Gluck T, Audebert F, Barlage S, Schmitz G, Froehlich D, Schreiber S, Hampe J, Scholmerich J, Holler E, Rogler G. Genetic variants in the NOD2/CARD15 gene are associated with early mortality in sepsis patients. Intensive Care Med. 33: 1541-1548 (2007).
Brenmoehl J, Holler E, Rogler G. Polymorphisms within epithelial receptors: NOD2/CARD15. Methods Mol. Med. 134: 115-122 (2007).
Brenmoehl J, Lang M, Hausmann M, Leeb SN, Falk W, Scholmerich J, Goke M, Rogler G. Evidence for a differential expression of fibronectin splice forms ED-A and ED-B in Crohn's disease (CD) mucosa. Int. J. Colorectal Dis. 22: 611-623 (2007). *
Brenner DA. Gastrointestinal basic science 2002-2003: the year in review. Clin. Gastroenterol. Hepatol. 2: 9-13 (2004). *
Brenner DJ. Should computed tomography be the modality of choice for imaging Crohn's disease in children? The radiation risk perspective. Gut 57: 1489-1490 (2008).
Brentnall TA. Ursodiol: good drug makes good. Gastroenterology 124: 1139-1140 (2003). *
Brescianini S, Trinh T, Stoll M, Schreiber S, Rioux JD, Daly MJ. IBD5 is associated with an extensive complicated Crohn’s disease feature: implications from genotype-phenotype analysis. Gut 56: 149-150 (2007). *
Breslin NP, Nash C, Hilsden RJ, Hershfield NB, Price LM, Meddings JB, Sutherland LR. Intestinal permeability is increased in a proportion of spouses of patients with Crohn's disease. Am. J. Gastroenterol. 96: 2934-2938 (2001). *
Breslin NP, Todd A, Kilgallen C, O'Morain C. Monozygotic twins with Crohn's disease and ulcerative colitis: a unique case report. Gut 41: 557-560 (1997). *
Bressler B. The role of endoscopy in the management of postoperative patients with Crohn's disease. Can. J. Gastroenterol. 20: 631-632 (2006). *
Bressler B, Sands BE. Review article: medical therapy for fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 24: 1283-1293 (2006). *
Bresso F, Askling J, Astegiano M, Demarchi B, Sapone N, Rizzetto M, Gionchetti P, Lammers KM, de Leone A, Riegler G, Nimmo ER, Drummond H, Noble C, Torkvist L, Ekbom A, Zucchelli M, Lofberg R, Satsangi J, Pettersson S, D'Amato M. Potential role for the common cystic fibrosis DeltaF508 mutation in Crohn's disease. Inflamm. Bowel Dis. 13: 531-536 (2007). *
Bresson JL, Schmitz J. Malnutrition in Crohn's disease: substrate deficiency or misuse? Horm. Res. 38 Suppl. 1: 76-78 (1992).
Bret J, Lemaire O, Prat C, Zabraniecki L, Fournie B. Aseptic osteomyelitis responding to TNFalpha antagonist therapy in a patient with Crohn's disease. Joint Bone Spine 75: 489-491 (2008). *
Bretagnol F, Alves A, Panis Y. Laparoscopic ileocolectomy for Crohn's disease. J. Chir. (Paris) 144: 522-526 (2007).
Breynaert C, Vermeire S, Rutgeerts P, Van Assche G. Dysplasia and colorectal cancer in inflammatory bowel disease: a result of inflammation or an intrinsic risk? Acta Gastroenterol. Belg. 71: 367-372 (2008).
Breza TS Jr, Magro CM. Lichenoid and granulomatous dermatitis associated with atypical mycobacterium infections. J. Cutan. Pathol. 33: 512-515 (2006). *
Bridger S, Lee JC, Bjarnason I, Jones JE, Macpherson AJ. In siblings with similar genetic susceptibility for inflammatory bowel disease, smokers tend to develop Crohn's disease and non-smokers develop ulcerative colitis. Gut 51: 21-25 (2002). *
Briem-Richter A, Grabhorn E, Wenke K, Ganschow R. Hemorrhagic necrotizing pancreatitis with a huge pseudocyst in a child with Crohn's disease. Eur. J. Gastroenterol. Hepatol. Nov 30 [Epub ahead of print] (2009).
Brignola C, Belloli C, Ardizzone S, Astegiano M, Cottone M, Trallori G. The relationship between heritability and smoking habits in Crohn's disease. Italian Cooperative Study Group. Am. J. Gastroenterol. 95: 3171-3175 (2000). *
Brignola C, Belloli C, De Simone G, Varesco L, Walger P, Areni A, Calabrese C, Di Febo G, Barbara L. Familial adenomatous polyposis and inflammatory bowel disease associated in two kindreds. Dig. Dis. Sci. 40: 402-405 (1995).
Brihier H, Nion-Larmurier I, Afchain P, Tiret E, Beaugerie L, Gendre JP, Cosnes J. Intestinal perforation in Crohn's disease. Gastroenterol. Clin. Biol. 29: 1105-1111 (2005). *
Brimblecombe R. Mesalazine: a global safety evaluation. Scand. J. Gastroenterol. Suppl. 172: 66 (1990).
Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+ regulatory T cells in the lamina propria of patients with inflammatory bowel disease. J. Immunol. 174: 5814-5822 (2005). *
Brinar M, Hrstic I, Cukovic-Cavka S, Padovan RS, Zupancic-Salek S, Vucelic B. Chronic Budd-Chiari syndrome as a rare complication of Crohn's disease: a case report. Eur. J. Gastroenterol. Hepatol. Jun 18 [Epub ahead of print] (2009).
Brinckerhoff CE, Sporn MB. Retinoids and rexinoids for the 21st century: a brave new world for arthritis. J. Rheumatol. 30: 211-213 (2003).
Bringer MA, Barnich N, Glasser AL, Bardot O, Darfeuille-Michaud A. HtrA stress protein is involved in intramacrophagic replication of adherent and invasive Escherichia coli strain LF82 isolated from a patient with Crohn's disease. Infect. Immun. 73: 712-721 (2005). *
Bringer MA, Glasser AL, Tung CH, Meresse S, Darfeuille-Michaud A. The Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 replicates in mature phagolysosomes within J774 macrophages. Cell. Microbiol. 8: 471-484 (2006). *
Bringer MA, Rolhion N, Glasser AL, Darfeuille-Michaud A. The oxidoreductase DsbA plays a key role in the ability of the Crohn's disease-associated adherent-invasive Escherichia coli strain LF82 to resist macrophage killing. J. Bacteriol. 189: 4860-4871 (2007). *
Brinza D, He J, Zelikovsky A. Combinatorial search methods for multi-SNP disease association. Conf. Proc. IEEE Eng. Med. Biol. Soc. 1: 5802-5805 (2006).
Brinza D, Zelikovsky A. Design and validation of methods searching for risk factors in genotype case-control studies. J. Comput. Biol. 15: 81-90 (2008).
Briones T, Salvadalena G. An introduction to genetics and application to Crohn's disease. J. Wound Ostomy Continence Nurs. 34: 80-87 (2007).
Briskin M, Winsor-Hines D, Shyjan A, Cochran N, Bloom S, Wilson J, McEvoy LM, Butcher EC, Kassam N, Mackay CR, Newman W, Ringler DJ. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. 151: 97-110 (1997). *
Brito F, Barros FC, Zaltman C, Pugas Carvalho AT, de Vasconcellos Carneiro AJ, Fischer RG, Gustafsson A, de Silva Figueredo CM. Prevalence of periodontitis and DMFT index in patients with Crohn's disease and ulcerative colitis. J. Clin. Periodontol. 35: 555-560 (2008).
Brittenden J, Hosker HS, Healey C, Porter G. Oesophago-bronchial fistula causing cough and recurrent lower respiratory tract infections in a patient with Crohn's disease. Hosp. Med. 66: 310-311 (2005).
Broedl UC, Schachinger V, Lingenhel A, Lehrke M, Stark R, Seibold F, Goke B, Kronenberg F, Parhofer KG, Konrad-Zerna A. Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 13: 391-397 (2007). *
Broekroelofs J, Mulder AH, Nelis GF, Westerveld BD, Tervaert JW, Kallenberg CG. Anti-neutrophil cytoplasmic antibodies (ANCA) in sera from patients with inflammatory bowel disease (IBD). Relation to disease pattern and disease activity. Dig. Dis. Sci. 39: 545-549 (1994).
Brogan PA, Malik M, Shah N, Kilday JP, Ramsay A, Shah V, Murch SH, Thomson MA, Walker-Smith JA, Lindley KJ, Milla PJ, Dillon MJ. Systemic vasculitis: a cause of indeterminate intestinal inflammation. J. Pediatr. Gastroenterol. Nutr. 42: 405-415 (2006). *
Brogden RN, Sorkin EM. Mesalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in chronic inflammatory bowel disease. Drugs 38: 500-523 (1989).
Brohee P, Violon P, Mavroudakis N, Pirotte B, Brotchi J, Zegers de Beyl D, Hildebrand J. Central nervous system lesions associated with Crohn's disease. J. Neuroimaging 7: 195-198 (1997).
Bronner MP. Granulomatous appendicitis and the appendix in idiopathic inflammatory bowel disease. Semin. Diagn. Pathol. 21: 98-107 (2004).
Bronowski C, Smith SL, Yokota K, Corkill JE, Martin HM, Campbell BJ, Rhodes JM, Hart CA, Winstanley C. A subset of mucosa-associated Escherichia coli isolates from patients with colon cancer, but not Crohn's disease, share pathogenicity islands with urinary pathogenic E. coli. Microbiology 154: 571-583 (2008). *
Brookes MJ, Green JR. Maintenance of remission in Crohn's disease: current and emerging therapeutic options. Drugs 64: 1069-1089 (2004).
Brooklyn T, Probert C. A Crohn's repertoire: T cell receptor gammadelta. Inflamm. Bowel Dis. 9: 213-214 (2003). *
Brooks AJ, Begg EJ, Zhang M, Frampton CM, Barclay ML. Red blood cell methotrexate polyglutamate concentrations in inflammatory bowel disease. Ther. Drug Monit. 29: 619-625 (2007).
Brooks M. Crohn's disease, a functional deficiency of IgA? Lancet 1: 158 (1981).
Broom OJ, Widjaya B, Troelsen J, Olsen J, Nielsen OH. Mitogen activated protein kinases: a role in inflammatory bowel disease? Clin. Exp. Immunol. 158: 272-280 (2009). *
Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory bowel disease, and colon cancer. Semin. Liver Dis. 26: 31-41 (2006). *
Broome U, Glaumann H, Hellers G, Nilsson B, Sorstad J, Hultcrantz R. Liver disease in ulcerative colitis: an epidemiological and follow up study in the county of Stockholm. Gut 35: 84-89 (1994). *
Broome U, Lofberg R, Lundqvist K, Veress B. Subclinical time span of inflammatory bowel disease in patients with primary sclerosing cholangitis. Dis. Colon Rectum 38: 1301-1305 (1995).
Brosbol-Ravnborg A, Hvas CL, Agnholt J, Dahlerup JF, Vind I, Till A, Rosenstiel P, Hollsberg P. Clinical immunology review series: Toll-like receptor-induced granulocyte-macrophage colony-stimulating factor secretion is impaired in Crohn's disease by nucleotide oligomerization domain 2-dependent and -independent pathways. Clin. Exp. Immunol. 155: 487-495 (2009). *
Bross DA, Leichtner AM, Zurakowski D, Law T, Bousvaros A. Elevation of serum interleukin-6 but not serum-soluble interleukin-2 receptor in children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 23: 164-171 (1996). *
Brost S, Koschny R, Sykora J, Stremmel W, Lasitschka F, Walczak H, Ganten TM. Differential expression of the TRAIL/TRAIL-receptor system in patients with inflammatory bowel disease. Pathol. Res. Pract. Nov 30 [Epub ahead of print] (2009).
Brouquet A, Bretagnol F, Soprani A, Valleur P, Bouhnik Y, Panis Y. A laparoscopic approach to iterative ileocolonic resection for the recurrence of Crohn's disease. Surg. Endosc. Sep 3 [Epub ahead of print] (2009).
Browder LK, Sweet S, Kaiser AM. Modified Hanley procedure for management of complex horseshoe fistulae. Tech. Coloproctol. Oct 8 [Epub ahead of print] (2009). *
Brown AC, Valiere A. Probiotics and medical nutrition therapy. Nutr. Clin. Care 7: 56-68 (2004). *
Brown CJ, Jaffer H, Jaffer N, Burul C, McLeod RS. Spinal epidural abscess - a rare complication of inflammatory bowel disease. Can. J. Gastroenterol. 22: 177-180 (2008). *
Brown CJ, Maclean AR, Cohen Z, Macrae HM, O'Connor BI, McLeod RS. Crohn's disease and indeterminate colitis and the ileal pouch-anal anastomosis: outcomes and patterns of failure. Dis. Colon Rectum 48: 1542-1549 (2005). *
Brown MO. Inflammatory bowel disease. Prim. Care 26: 141-170 (1999).
Brown S, Applegate KE, Sandrasegaran K, Jennings SG, Garrett J, Skantharajah A, Maglinte DT. Fluoroscopic and CT enteroclysis in children: initial experience, technical feasibility, and utility. Pediatr. Radiol. 38: 497-510 (2008). *
Brown SJ, Abreu MT. Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr. Opin. Drug Discov. Devel. 8: 160-168 (2005).
Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am. J. Gastroenterol. 102: 2058-2069 (2007). *
Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum. 46: 3151-3158 (2002). *
Browning BL, Barclay ML, Bingham SA, Brand S, Buning C, Castro M, Cucchiara S, Dallapiccola B, Drummond H, Ferguson LR, Ferraris A, Fisher SA, Gearry RB, Glas J, Henckaerts L, Huebner C, Knafelz D, Lakatos L, Lakatos PL, Latiano A, Liu X, Mathew CG, et al. Gender-stratified analysis of DLG5 R30Q in 4707 Crohn's disease patients and 4973 controls from 12 Caucasian cohorts. J. Med. Genet. 45: 36-42 (2008).
Browning BL, Huebner C, Petermann I, Demmers P, McCulloch A, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Association of DLG5 variants with inflammatory bowel disease in the New Zealand Caucasian population and meta-analysis of the DLG5 R30Q variant. Inflamm. Bowel Dis. 13: 1069-1076 (2007). *
Browning BL, Huebner C, Petermann I, Gearry RB, Barclay ML, Shelling AN, Ferguson LR. Has Toll-like receptor 4 been prematurely dismissed as an inflammatory bowel disease gene? Association study combined with meta-analysis shows strong evidence for association. Am. J. Gastroenterol. 102: 2504-2512 (2007). *
Broxmeyer L. Is mad cow disease caused by a bacteria? Med. Hypotheses 63: 731-739 (2004).
Bruch HP. Crohn's disease: alternatives of preparation. Chirurg. 80: 734 (2009).
Bruckner HW, Hrehorovich VR, Sawhney HS, Meeus SI, Coopeman AM. Chemotherapeutic management of small bowel adenocarcinoma associated with Crohn's disease. J. Chemother. 18: 545-548 (2006).
Brugere-Picoux J. Crohn disease: uncertainty about the etiologic role of Mycobacterium paratuberculosis. Bull. Acad. Natl. Med. 182: 823-829 (1998).
Bruining DH Jr, Loftus EV Jr. Ultrasound-enteroclysis for Crohn's disease: the best of both worlds? Inflamm. Bowel Dis. 14: 290 (2008).
Bruining DH, Loftus EV. Evolving diagnostic strategies for inflammatory bowel disease. Curr. Gastroenterol. Rep. 8: 478-485 (2006).
Bruining DH, Loftus EV Jr. Crohn's disease clinical issues and treatment: what the radiologist needs to know and what the gastroenterologist wants to know. Abdom. Imaging 34: 297-302 (2009). *
Bruining DH, Siddiki HA, Fletcher JG, Tremaine WJ, Sandborn WJ, Loftus EV Jr. Prevalence of penetrating disease and extraintestinal manifestations of Crohn's disease detected with CT enterography. Inflamm. Bowel Dis. 14: 1701-1706 (2008). *
Brullet E, Bonfill X, Urrutia G, Ruiz Ochoa V, Cueto M, Clofent J, Martinez Salmeron JF, Riera J, Obrador A. Epidemiological study on the incidence of inflammatory bowel disease in 4 Spanish areas. Spanish Group on the Epidemiological Study of Inflammatory Bowel Disease. Med. Clin. (Barc.) 110: 651-656 (1998).
Brun V, Bastian H, Foussat A. Clinical grade production of IL-10 producing regulatory Tr1 lymphocytes for cell therapy of chronic inflammatory diseases. Int. Immunopharmacol. 9: 609-613 (2009).
Brunborg LA, Madland TM, Lind RA, Arslan G, Berstad A, Froyland L. Effects of short-term oral administration of dietary marine oils in patients with inflammatory bowel disease and joint pain: a pilot study comparing seal oil and cod liver oil. Clin. Nutr. 27: 614-622 (2008).
Brunello F, Pera A, Martini S, Marino L, Astegiano M, Barletti C, Gastaldi P, Verme G, Emanuelli G. Antibodies to Mycobacterium paratuberculosis in patients with Crohn's disease. Dig. Dis. Sci. 36: 1741-1745 (1991).
Brunner B, Hirschi C, Weimann R, Seibold F. Treatment-resistant lingual Crohn's disease disappears after infliximab. Scand. J. Gastroenterol. 40: 1255-1259 (2005). *
Brunner B, Scheurer U, Seibold F. Differences in yeast intolerance between patients with Crohn's disease and ulcerative colitis. Dis. Colon Rectum 50: 83-88 (2007). *
Brunner J, Sergi C, Muller T, Gassner I, Prufer F, Zimmerhackl LB. Juvenile sarcoidosis presenting as Crohn's disease. Eur. J. Pediatr. 165: 398-401 (2006). *
Bruno I, Martelossi S, Geatti O, Maggiore G, Guastalla P, Povolato M, Ventura A. Antigranulocyte monoclonal antibody immunoscintigraphy in inflammatory bowel disease in children and young adolescents. Acta Paediatr. 91: 1050-1055 (2002).
Brunser O, Gotteland M, Cruchet S. Functional fermented milk products. Nestle Nutr. Workshop Ser. Pediatr. Program 60: 235-250 (2007).
Brustolim D, Ribeiro-Dos-Santos R, Kast RE, Altschuler EL, Soares MB. A new chapter opens in anti-inflammatory treatments: the antidepressant bupropion lowers production of tumor necrosis factor-alpha and interferon-gamma in mice. Int. Immunopharmacol. 6: 903-907 (2006).
Bruzzese E, Canani RB, De Marco G, Guarino A. Microflora in inflammatory bowel diseases: a pediatric perspective. J. Clin. Gastroenterol. 38: S91-S93 (2004).
Bruzzese V. Diffused suberitrodermic psoriasis induced by infliximab. Reumatismo 59: 328-331 (2007).
Brynskov J, Feagan BG, Jewell D, McDonald JWD, Stange EF. Cyclosporine for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2: CD004377 (2004). *
Brynskov J, Nielsen OH, Ahnfelt-Ronne I, Bendtzen K. Cytokines (immunoinflammatory hormones) and their natural regulation in inflammatory bowel disease (Crohn's disease and ulcerative colitis): a review. Dig. Dis. 12: 290-304 (1994).
Brzezinski A, Rankin GB, Seidner DL, Lashner BA. Use of old and new oral 5-aminosalicylic acid formulations in inflammatory bowel disease. Cleve. Clin. J. Med. 62: 317-323 (1995).
Buccino GP, Corrente G, Visintini D. Crohn's disease and multiple sclerosis: a single case report. Ital. J. Neurol. Sci. 15: 303-306 (1994).
Buchanan E, Gaunt W, Cardigan T, Garrick V, McGrogan P, Russell R. The use of exclusive enteral nutrition (EEN) for induction of remission in children with Crohn's disease (CD) demonstrates that disease phenotype does not influence clinical remission. Aliment. Pharmacol. Ther. 30: 501-507 (2009). *
Buchanan GN, Owen HA, Torkington J, Lunniss PJ, Nicholls RJ, Cohen CR. Long-term outcome following loose-seton technique for external sphincter preservation in complex anal fistula. Br. J. Surg. 91: 476-480 (2004). *
Buchman AL. Bones and Crohn's: problems and solutions. Inflamm. Bowel Dis. 5: 212-227 (1999).
Buchman AL, Katz S, Fang JC, Bernstein CN, Abou-Assi SG; for the Teduglutide Study Group. Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease. Inflamm. Bowel Dis. Oct 9 [Epub ahead of print] (2009).
Buchman AL, Miller FH, Wallin A, Chowdhry AA, Ahn C. Videocapsule endoscopy versus barium contrast studies for the diagnosis of Crohn's disease recurrence involving the small intestine. Am. J. Gastroenterol. 99: 2171-2177 (2004). *
Buchman AL, Paine MF, Wallin A, Ludington SS. A higher dose requirement of tacrolimus in active Crohn's disease may be related to a high intestinal P-glycoprotein content. Dig. Dis. Sci. 50: 2312-2315 (2005). *
Buckland MS, Mylonaki M, Rampton D, Longhurst HJ. Serological markers (anti-Saccharomyces cerevisiae mannan antibodies and antineutrophil cytoplasmic antibodies) in inflammatory bowel disease: diagnostic utility and phenotypic correlation. Clin. Diagn. Lab. Immunol. 12: 1328-1330 (2005). *
Buckowitz A, Knaebel HP, Benner A, Blaker H, Gebert J, Kienle P, von Knebel Doeberitz M, Kloor M. Microsatellite instability in colorectal cancer is associated with local lymphocyte infiltration and low frequency of distant metastases. Br. J. Cancer 92: 1746-1753 (2005).
Buderus S, Boone J, Lyerly D, Lentze MJ. Fecal lactoferrin: a new parameter to monitor infliximab therapy. Dig. Dis. Sci. 49: 1036-1039 (2004). *
Bueno de Mesquita M, Ferrante M, Henckaerts L, Joossens M, Janssens V, Hlavaty T, Pierik M, Joossens S, Van Schuerbeek N, Van Assche G, Rutgeerts P, Vermeire S, Hoffman I. Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease. Eur. J. Pediatr. 168: 575-583 (2009). *
Buhner S, Buning C, Genschel J, Kling K, Herrmann D, Dignass A, Kuechler I, Krueger S, Schmidt HH, Lochs H. Genetic basis for increased intestinal permeability in families with Crohn’s disease: role of CARD15 3020insC mutation? Gut 55: 342-347 (2006). *
Buhner S, Nagel E, Korber J, Vogelsang H, Linn T, Pichlmayr R. Ileal and colonic fatty acid profiles in patients with active Crohn's disease. Gut 35: 1424-1428 (1994). *
Buisine MP, Desreumaux P, Debailleul V, Gambiez L, Geboes K, Ectors N, Delescaut MP, Degand P, Aubert JP, Colombel JF, Porchet N. Abnormalities in mucin gene expression in Crohn's disease. Inflamm. Bowel Dis. 5: 24-32 (1999). *
Buisine MP, Desreumaux P, Leteurtre E, Copin MC, Colombel JF, Porchet N, Aubert JP. Mucin gene expression in intestinal epithelial cells in Crohn's disease. Gut 49: 544-551 (2001). *
Bulian P, Gaidano G, Poeta GD, Gattei V. CD49d expression in chronic lymphocytic leukemia: a prognostic parameter and a therapeutic target. Future Oncol. 4: 355-358 (2008).
Bull TJ, McMinn EJ, Sidi-Boumedine K, Skull A, Durkin D, Neild P, Rhodes G,. Detection and verification of Mycobacterium avium subsp. paratuberculosis in fresh ileocolonic mucosal biopsy specimens from individuals with and without Crohn's disease. J. Clin. Microbiol. 41: 2915-2923 (2003). *
Bullen TF, Hershman MJ. Surgery for inflammatory bowel disease. Hosp. Med. 64: 719-723 (2003).
Buller HA. Problems in diagnosis of IBD in children. Neth. J. Med. 50: S8-S11 (1997).
Bulte M, Schonenbrucher H, Abdulmawjood A. From farm to fork - Mycobacterium avium ssp. paratuberculosis (MAP) as zoonotic agent? Berl. Munch. Tierarztl. Wochenschr. 118: 377-385 (2005).
Buning C, Durmus T, Molnar T, de Jong DJ, Drenth JP, Fiedler T, Gentz E, Todorov T, Haas V, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Landt O, Kage A, Buning H, Nickel R, Buttner J, Lochs H, Schmidt HH, Witt H. A study in three European IBD cohorts confirms that the ATG16L1 c.898A>G (p.Thr300Ala) variant is a susceptibility factor for Crohn’s disease. Journal of Crohn's and Colitis 1: 70-76 (2007).
Buning C, Geerdts L, Fiedler T, Gentz E, Pitre G, Reuter W, Luck W, Buhner S, Molnar T, Nagy F, Lonovics J, Dignass A, Landt O, Nickel R, Genschel J, Lochs H, Schmidt HH, Witt H. DLG5 variants in inflammatory bowel disease. Am. J. Gastroenterol. 101: 786-792 (2006). *
Buning C, Genschel J, Buhner S, Kruger S, Kling K, Dignass A, Baier P, Bochow B, Ockenga J, Schmidt HH, Lochs H. Mutations in the NOD2/CARD15 gene in Crohn's disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment. Pharmacol. Ther. 19: 1073-1078 (2004). *
Buning C, Genschel J, Weltrich R, Lochs H, Schmidt H. The interleukin-25 gene located in the inflammatory bowel disease (IBD) 4 region: no association with inflammatory bowel disease. Eur. J. Immunogenet. 30: 329-333 (2003). *
Buning C, Halangk J, Dignass A, Ockenga J, Deindl P, Nickel R, Genschel J, Landt O, Lochs H, Schmidt H, Witt H. Keratin 8 Y54H and G62C mutations are not associated with inflammatory bowel disease. Dig. Liver Dis. 36: 388-391 (2004).
Buning C, Lochs H. Conventional therapy for Crohn's disease. World J. Gastroenterol. 12: 4794-4806 (2006). *
Buning C, Molnar T, Nagy F, Lonovics J, Weltrich R, Bochow B, Genschel J, Schmidt H, Lochs H. NOD2/CARD15 gene polymorphism in patients with inflammatory bowel disease: is Hungary different? World J. Gastroenterol. 11: 407-411 (2005). *
Buning C, Ockenga J, Kruger S, Jurga J, Baier P, Dignass A, Vogel A, Strassburg C, Weltrich R, Genschel J, Lochs H, Schmidt H. The C/C(-13910) and G/G(-22018) genotypes for adult-type hypolactasia are not associated with inflammatory bowel disease. Scand. J. Gastroenterol. 38: 538-542 (2003). *
Buning C, Schmidt HH, Molnar T, DE Jong DJ, Fiedler T, Buhner S, Sturm A, Baumgart DC, Nagy F, Lonovics J, Drenth JP, Landt O, Nickel R, Buttner J, Lochs H, Witt H. Heterozygosity for IL23R p.Arg381Gln confers a protective effect not only against Crohn's disease but also ulcerative colitis. Aliment. Pharmacol. Ther. 26: 1025-1033 (2007). *
Buning C, Schmidt HH, Molnar T, Drenth JP, Fiedler T, Gentz E, Todorov T, Baumgart DC, Sturm A, Nagy F, Lonovics J, de Jong DJ, Landt O, Kage A, Nickel R, Buttner J, Lochs H, Witt H. No association of the CARD8 (TUCAN) c.30T>A (p.C10X) variant with Crohn's disease: a study in 3 independent European cohorts. Inflamm. Bowel Dis. 14: 332-337 (2008). *
Buning J, Homann N, von Smolinski D, Borcherding F, Noack F, Stolte M, Kohl M, Lehnert H, Ludwig D. Helminths as governors of inflammatory bowel disease. Gut 57: 1182-1183 (2008).
Buning J, Hundorfean G, Schmitz M, Zimmer KP, Strobel S, Gebert A, Ludwig D. Antigen targeting to MHC class II-enriched late endosomes in colonic epithelial cells: trafficking of luminal antigens studied in vivo in Crohn's colitis patients. FASEB J. 20: 359-361 (2006). *
Buning J, von Smolinski D, Tafazzoli K, Zimmer KP, Strobel S, Apostolaki M, Kollias G, Heath JK, Ludwig D, Gebert A. Multivesicular bodies in intestinal epithelial cells: responsible for MHC class II-restricted antigen processing and origin of exosomes. Immunology 125: 510-521 (2008). *
Bunni J, Monkhouse SJ, Armstrong CP. Colonic perforation following mild abdominal trauma in a patient with Crohn's disease: a case report. World J. Emerg. Surg. 3: 13 (2008). *
Burakoff R. Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis? Inflamm. Bowel Dis. 14 Suppl. 2: S202-S203 (2008). *
Burakoff R. Indeterminate colitis: clinical spectrum of disease. J. Clin. Gastroenterol. 38: S41-S43 (2004).
Burakoff R, Barish CF, Riff D, Pruitt R, Chey WY, Farraye FA, Shafran I, Katz S, Krone CL, Vander Vliet M, Stevens C, Sherman ML, Jacobson E, Bleday R. A phase 1/2A trial of STA 5326, an oral interleukin-12/23 inhibitor, in patients with active moderate to severe Crohn's disease. Inflamm. Bowel Dis. 12: 558-565 (2006). *
Burakoff R, Hande S, Ma J, Banks PA, Friedman S, Makrauer F, Liew CC. Differential regulation of peripheral leukocyte genes in patients with active Crohn's disease and Crohn's disease in remission. J. Clin. Gastroenterol. Oct 12 [Epub ahead of print] (2009).
Burczynski ME, Peterson RL, Twine NC, Zuberek KA, Brodeur BJ, Casciotti L, Maganti V, Reddy PS, Strahs A, Immermann F, Spinelli W, Schwertschlag U, Slager AM, Cotreau MM, Dorner AJ. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J. Mol. Diagn. 8: 51-61 (2006). *
Burgdorf F, Schreyogg J, Keller W, von Wietersheim J, Deter HC; und the German Study Group on Psychosocial Intervention in Crohn's Disease. Predictors of health-care utilization of patients with Crohn's disease. Results of a prospective randomized multicenter trial. Med. Klin. (Munich) 102: 881-887 (2007).
Burger DC, Florin TH. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med. J. Aust. 190: 341-342 (2009).
Burgmann T, Clara I, Graff L, Walker J, Lix L, Rawsthorne P, McPhail C, Rogala L, Miller N, Bernstein CN. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis - how much is irritable bowel syndrome? Clin. Gastroenterol. Hepatol. 4: 614-620 (2006).
Burgos-Vargas R. Spondyloarthropathies and psoriatic arthritis in children. Curr. Opin. Rheumatol. 5: 634-643 (1993).
Burgoyne CH, Field SL, Brown AK, Hensor EM, English A, Bingham SL, Verburg R, Fearon U, Lawson CA, Hamlin JP, Straszynski L, Veale D, Conaghan P, Hull MA, van Laar JM, Tennant A, Emery P, Isaacs JD, Ponchel F. Abnormal T-cell differentiation persists in rheumatoid arthritis patients in clinical remission and predicts relapse. Ann. Rheum. Dis. 67: 750-757 (2008).
Burke AP, Tavora F, Narula N, Tomaszewski JE, Virmani R. Aortitis and ascending aortic aneurysm: description of 52 cases and proposal of a histologic classification. Hum. Pathol. 39: 514-526 (2008).
Burke DA, Axon AT. Adhesive Escherichia coli in inflammatory bowel disease and infective diarrhoea. BMJ 297: 102-104 (1988). *
Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm. Bowel Dis. 14: 1197-1204 (2008). *
Burke JP, Kelleher B, Ramadan S, Quinlan M, Sugrue D, O'Donovan MA. Pericarditis as a complication of infliximab therapy in Crohn's disease. Inflamm. Bowel Dis. 14: 428-429 (2008). *
Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am. J. Gastroenterol. 102: 439-448 (2007). *
Burke ML, Jones MK, Gobert GN, Li YS, Ellis MK, McManus DP. Immunopathogenesis of human schistosomiasis. Parasite Immunol. 31: 163-176 (2009). *
Burke P, Meyer V, Kocoshis S, Orenstein D, Chandra R, Sauer J. Obsessive-compulsive symptoms in childhood inflammatory bowel disease and cystic fibrosis. J. Am. Acad. Child. Adolesc. Psychiatry 28: 525-527 (1989).
Burke P, Meyer V, Kocoshis S, Orenstein DM, Chandra R, Nord DJ, Sauer J, Cohen E. Depression and anxiety in pediatric inflammatory bowel disease and cystic fibrosis. J. Am. Acad. Child. Adolesc. Psychiatry 28: 948-951 (1989).
Burleson GR, Burleson FG. Testing human biologicals in animal host resistance models. J. Immunotoxicol. 5: 23-31 (2008).
Burmester GR, Mease PJ, Dijkmans BA, Gordon K, Lovell D, Panaccione R, Perez J, Pangan AL. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann. Rheum. Dis. 68: 1863-1869 (2009). *
Burnham JM, Shults J, Petit MA, Semeao E, Beck TJ, Zemel BS, Leonard MB. Alterations in proximal femur geometry in children treated with glucocorticoids for Crohn disease or nephrotic syndrome: impact of the underlying disease. J. Bone Miner. Res. 22: 551-559 (2007). *
Burnham JM, Shults J, Semeao E, Foster B, Zemel BS, Stallings VA, Leonard MB. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J. Bone Miner. Res. 19: 1961-1968 (2004).
Burnham JM, Shults J, Semeao E, Foster BJ, Zemel BS, Stallings VA, Leonard MB. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am. J. Clin. Nutr. 82: 413-420 (2005). *
Burnham WR, Lennard-Jones JE, Stanford JL, Bird RG. Mycobacteria as a possible cause of inflammatory bowel disease. Lancet 2: 693-696 (1978).
Burns DG. Smoking in inflammatory bowel disease and the irritable bowel syndrome. S. Afr. Med. J. 69: 232-233 (1986).
Burns KA, Martinon F. Inflammatory diseases: is ubiquitinated NEMO at the hub? Curr. Biol. 14: R1040-R1042 (2004). *
Burt RK, Traynor A, Oyama Y, Craig R. High-dose immune suppression and autologous hematopoietic stem cell transplantation in refractory Crohn disease. Blood 101: 2064-2066 (2003). *
Buscaglia JM, Giday SA, Kantsevoy SV, Clarke JO, Magno P, Yong E, Mullin GE. Performance characteristics of the suspected blood indicator feature in capsule endoscopy according to indication for study. Clin. Gastroenterol. Hepatol. 6: 298-301 (2008).
Bush M, Patel S, Lapinski R, Stone J. Perinatal outcomes in inflammatory bowel disease. J. Matern. Fetal. Neonatal. Med. 15: 237-241 (2004).
Buskila D, Odes LR, Neumann L, Odes HS. Fibromyalgia in inflammatory bowel disease. J. Rheumatol. 26: 1167-1171 (1999).
Busso N, Karababa M, Nobile M, Rolaz A, Van Gool F, Galli M, Leo O, So A, De Smedt T. Pharmacological inhibition of nicotinamide phosphoribosyltransferase/visfatin enzymatic activity identifies a new inflammatory pathway linked to NAD. PLoS ONE 3: e2267 (2008). *
Bustamante M, Devesa F, Pareja V, Ferrando MJ, Ortuno J, Borghol A. Development of inflammatory bowel disease in a husband and wife. Gastroenterol. Hepatol. 25: 244-246 (2002).
Butler M, Boyle JJ, Powell JJ, Playford RJ, Ghosh S. Dietary microparticles implicated in Crohn's disease can impair macrophage phagocytic activity and act as adjuvants in the presence of bacterial stimuli. Inflamm. Res. 56: 353-361 (2007). *
Butler M, Chaudhary R, van Heel DA, Playford RJ, Ghosh S. NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes - possible implications for NOD2-associated Crohn's disease. Journal of Crohn's and Colitis 1: 106-115 (2007).
Butt MT, Bener A, Al-Kaabi S, Yakoub R. Clinical characteristics of Crohn s disease in Qatar. Saudi Med. J. 26: 1796-1799 (2005).
Butterworth AD, Thomas AG, Akobeng AK. Probiotics for induction of remission in Crohn's disease. Cochrane Database Syst. Rev. 3: CD006634 (2008). *
Button LA, Roberts SE, Goldacre MJ, Akbari A, Rodgers SE, Williams JG. Hospitalized prevalence and 5-year mortality for IBD: record linkage study. World J. Gastroenterol. 16: 431-438 (2010). *
Buxton MJ, Lacey LA, Feagan BG, Niecko T, Miller DW, Townsend RJ. Mapping from disease-specific measures to utility: an analysis of the relationships between the inflammatory bowel disease questionnaire and Crohn's disease activity index in Crohn's disease and measures of utility. Value Health 10: 214-220 (2007).
Byrn JC, Wang JL, Divino CM, Nguyen SQ, Warner RR. Management of goblet cell carcinoid. J. Surg. Oncol. 94: 396-402 (2006).
Byrne CM, Solomon MJ, Young JM, Selby W, Harrison JD. Patient preferences between surgical and medical treatment in Crohn's disease. Dis. Colon Rectum 50: 586-597 (2007). *
Byrne FR, Viney JL. Mouse models of inflammatory bowel disease. Curr. Opin. Drug Discov. Devel. 9: 207-217 (2006).
Byun JR, Cho SH, Yang DH, Kim YK, Ju JK, Choi SK, Chung IJ. Ileovesical fistula caused by hepatocellular carcinoma. Korean J. Intern. Med. 20: 76-79 (2005).
Caballero T, Nogueras F, Medina MT, Caracuel MD, de Sola C, Martinez-Salmeron FJ, Rodrigo M, Garcia del Moral R. Intraepithelial and lamina propria leucocyte subsets in inflammatory bowel disease: an immunohistochemical study of colon and rectal biopsy specimens. J. Clin. Pathol. 48: 743-748 (1995). *
Cabral VL, Miszputen SJ, Catapani WR. Anti-neutrophil cytoplasmic antibodies in Brazilian patients with inflammatory bowel disease. Hepatogastroenterology 50: 412-415 (2003).
Cabre E, Gassull MA. Nutrition in inflammatory bowel disease: impact on disease and therapy. Curr. Opin. Gastroenterol. 17: 342-349 (2001).
Cabre E, Gassull MA. Probiotics for preventing relapse or recurrence in Crohn’s disease involving the ileum: are there reasons for failure? Journal of Crohn's and Colitis 1: 47-52 (2007).
Cabre E, Gassull MA. Nutritional and metabolic issues in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 6: 569-576 (2003).
Cabre Gelada E. Nutrition and inflammatory bowel disease. Nutr. Hosp. 22 Suppl. 2: 65-73 (2007).
Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch. Dis. Child. 89: 69-71 (2004). *
Cachia E, Calleja N, Aakeroy R, Degaetano J, Vassallo M. Incidence of inflammatory bowel disease in Malta between 1993 and 2005: a retrospective study. Inflamm. Bowel Dis. 14: 550-553 (2008). *
Cadwell K, Liu JY, Brown SL, Miyoshi H, Loh J, Lennerz JK, Kishi C, Kc W, Carrero JA, Hunt S, Stone CD, Brunt EM, Xavier RJ, Sleckman BP, Li E, Mizushima N, Stappenbeck TS, Virgin Iv HW. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456: 259-263 (2008). *
Cadwell K, Patel KK, Komatsu M, Virgin HW 4th, Stappenbeck TS. A common role for Atg16L1, Atg5 and Atg7 in small intestinal Paneth cells and Crohn disease. Autophagy 5: 250-252 (2009).
Cadwell K, Stappenbeck TS, Virgin HW. Role of autophagy and autophagy genes in inflammatory bowel disease. Curr. Top. Microbiol. Immunol. 335: 141-167 (2009).
Cagnard B, Tosoni-Verlingue D, Tribut O, Moizard C, Bridoux-Henno L, Delaperriere N, Bentue-Ferrer D, Dabadie A. Advantages of different dosages of active metabolites in the follow-up of azathioprine treatment for Crohn disease. Arch. Pediatr. 13 Suppl. 1: S67-S68 (2007).
Cai J, Li F, Zhou W, Luo HS. Ileocecal ulcer in Central China: case series. Dig. Dis. Sci. 52: 3169-3173 (2007). *
Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig. Dis. Sci. 54: 842-847 (2009). *
Cakal B, Gokmen A, Yalinkilic M, Cakal E, Ayaz S, Nadir I, Ozin Y, Dagli U, Ulker A. Natural anticoagulant protein levels in Turkish patients with inflammatory bowel disease. Blood Coagul. Fibrinolysis Dec 28 [Epub ahead of print] (2009).
Calabrese C, Gionchetti P, Rizzello F, Liguori G, Gabusi V, Tambasco R, Poggioli G, Pierangeli F, Campieri M, Di Febo G. Short-term treatment with infliximab in chronic refractory pouchitis and ileitis. Aliment. Pharmacol. Ther. 27: 759-764 (2008). *
Calabrese E, La Seta F, Buccellato A, Virdone R, Pallotta N, Corazziari E, Cottone M. Crohn's disease: a comparative prospective study of transabdominal ultrasonography, small intestine contrast ultrasonography, and small bowel enema. Inflamm. Bowel Dis. 11: 139-145 (2005). *
Calabrese E, Petruzziello C, Onali S, Condino G, Zorzi F, Pallone F, Biancone L. Severity of postoperative recurrence in Crohn's disease: correlation between endoscopic and sonographic findings. Inflamm. Bowel Dis. 15: 1635-1642 (2009).
Calabrese LH, Molloy ES. Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann. Rheum. Dis. 67 Suppl. 3: iii64-iii65 (2008).
Calder E. Radiological aspects of recoverable regional ileitis and its relationship to Crohn's disease. Glasgow Med. J. 30: 65-81 (1949).
Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn's disease and short stature: a pilot study. Inflamm. Bowel Dis. 11: 435-441 (2005). *
Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig. Dis. Sci. 34: 1841-1854 (1989).
Callen JP. Complications and adverse reactions in the use of newer biologic agents. Semin. Cutan. Med. Surg. 26: 6-14 (2007).
Calvet X, Gallardo O, Coronas R, Casellas F, Montserrat A, Torrejon A, Vergara M, Campo R, Brullet E. Remission on thiopurinic immunomodulators normalizes quality of life and psychological status in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 692-696 (2006). *
Calvet X, Motos J, Montserrat A, Gallardo O, Vergara M. Analysis of court criteria for awarding disability benefits to patients with Crohn's disease. Clin. Gastroenterol. Hepatol. 7: 1322-1327 (2009).
Calvino J, Romero R, Pintos E, Losada E, Novoa D, Guimil D, Mardaras J, Sanchez-Guisande D. Mesalazine-associated tubulo-interstitial nephritis in inflammatory bowel disease. Clin. Nephrol. 49: 265-267 (1998).
Cambridge G, Rampton DS, Stevens TR, McCarthy DA, Kamm M, Leaker B. Anti-neutrophil antibodies in inflammatory bowel disease: prevalence and diagnostic role. Gut 33: 668-674 (1992). *
Cameron CA, Sawatzky JA. Postoperative pain management: the challenges of the patient with Crohn's disease. Medsurg. Nurs. 17: 85-91 (2008).
Camilleri M. GIH clinical research 2003-2004: the year in review. Clin. Gastroenterol. Hepatol. 2: 1043-1047 (2004). *
Camilleri M. Anti-TNF antibodies for Crohn's disease. N. Engl. J. Med. 357: 1662 (2007).
Camilleri M, Nadeau A, Tremaine WJ, Lamsam J, Burton D, Odunsi S, Sweetser S, Singh R. Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry. Neurogastroenterol. Motil. 21: 734-e43 (2009).
Cammarota T, Sarno A, Robotti D, Bonenti G, Debani P, Versace K, Astegiano M, Pera A. US evaluation of patients affected by IBD: how to do it, methods and findings. Eur. J. Radiol. 69: 429-437 (2009).
Camoglio L, Te Velde AA, Tigges AJ, Das PK, Van Deventer SJ. Altered expression of interferon-gamma and interleukin-4 in inflammatory bowel disease. Inflamm. Bowel Dis. 4: 285-290 (1998). *
Campbell FC, Maxwell RJ. Rationale for cancer prevention strategies in high-risk ulcerative colitis. Surgeon 7: 96-100 (2009).
Campbell L, Augustin T, Cagir B. Nonconventional strictureplasties for Crohn's disease: a systematic review of outcomes. J. Surg. Res. 158: 236 (2010).
Campieri M. New steroids and new salicylates in inflammatory bowel disease: a critical appraisal. Gut 50 Suppl. 3: iii43-iii46 (2002). *
Campos FG, Waitzberg DL, Teixeira MG, Mucerino DR, Kiss DR, Habr-Gama A. Pharmacological nutrition in inflammatory bowel diseases. Nutr. Hosp. 18: 57-64 (2003).
Camus P, Piard F, Ashcroft T, Gal AA, Colby TV. The lung in inflammatory bowel disease. Medicine (Baltimore) 72: 151-183 (1993).
Canani RB, Romano MT, Greco L, Terrin G, Sferlazzas C, Barabino A, Fontana M, Roggero P, Guariso G, De Angelis G, Fecarotta S, Polito G, Cucchiara S. Effects of disease activity on anti-Saccharomyces cerevisiae antibodies - Implications for diagnosis and follow-up of children with Crohn's disease. Inflamm. Bowel Dis. 10: 234-239 (2004). *
Canavan C, Abrams KR, Hawthorne B, Drossman D, Mayberry JF. Long-term prognosis in Crohn's disease: factors that affect quality of life. Aliment. Pharmacol. Ther. 23: 377-385 (2006). *
Canavan C, Abrams KR, Hawthorne B, Mayberry JF. Long-term prognosis in Crohn's disease: an epidemiological study of patients diagnosed more than 20 years ago in Cardiff. Aliment. Pharmacol. Ther. 25: 59-65 (2007). *
Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn's disease. Aliment. Pharmacol. Ther. 23: 1097-1104 (2006). *
Canavan C, Abrams KR, Mayberry JF. Meta-analysis: mortality in Crohn's disease. Aliment. Pharmacol. Ther. 25: 861-870 (2007). *
Canbay A, Bechmann LP, Best J, Jochum C, Treichel U, Gerken G. Crohn's disease-induced non-alcoholic fatty liver disease (NAFLD) sensitizes for severe acute hepatitis B infection and liver failure. Z. Gastroenterol. 44: 245-248 (2006).
Candela G, Di Libero L, Varriale S, Manetta F, Giordano M, Lanza M, Nunziata A, Santini L. Anastomotic configuration as a risk factor in the recurring onset after intestinal resection for Crohn's disease: our point of view. Minerva Chir. 62: 61-67 (2007).
Candon S, Mosca A, Ruemmele F, Goulet O, Chatenoud L, Cezard JP. Clinical and biological consequences of immunization to infliximab in pediatric Crohn's disease. Clin. Immunol. 118: 11-19 (2006). *
Candy S, Wright J, Gerber M, Adams G, Gerig M, Goodman R. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 37: 674-678 (1995). *
Cane G, Moal VL, Pages G, Servin AL, Hofman P, Vouret-Craviari V. Up-regulation of intestinal vascular endothelial growth factor by Afa/Dr diffusely adhering Escherichia coli. PLoS ONE 2: e1359 (2007). *
Canedo J, Pinto RA, Regadas S, Regadas FS, Rosen L, Wexner SD. Laparoscopic surgery for inflammatory bowel disease: does weight matter? Surg. Endosc. Jan 1 [Epub ahead of print] (2010).
Cannioto Z, Berti I, Martelossi S, Bruno I, Giurici N, Crovella S, Ventura A. IBD and IBD mimicking enterocolitis in children younger than 2 years of age. Eur. J. Pediatr. 168: 149-155 (2009). *
Cannom RR, Kaiser AM, Ault GT, Beart RW Jr, Etzioni DA. Inflammatory bowel disease in the United States from 1998 to 2005: has infliximab affected surgical rates? Am. Surg. 75: 976-980 (2009).
Canto E, Moga E, Ricart E, Garcia-Bosch O, Garcia-Planella E, Juarez C, Vidal S. MDP-induced selective tolerance to TLR4 ligands: impairment in NOD2 mutant Crohn's disease patients. Inflamm. Bowel Dis. 15: 1686-1696 (2009). *
Canto E, Ricart E, Busquets D, Monfort D, Garcia-Planella E, Gonzalez D, Balanzo J, Rodriguez-Sanchez JL, Vidal S. Influence of a nucleotide oligomerization domain 1 (NOD1) polymorphism and NOD2 mutant alleles on Crohn's disease phenotype. World J. Gastroenterol. 13: 5446-5453 (2007). *
Canto E, Ricart E, Monfort D, Gonzalez-Juan D, Balanzo J, Rodriguez-Sanchez JL, Vidal S. TNFalpha production to TLR2 ligands in active IBD patients. Clin. Immunol. 119: 156-165 (2006). *
Cantor MJ, Nickerson P, Bernstein CN. The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease. Am. J. Gastroenterol. 100: 1134-1142 (2005). *
Cao J, Liu WJ, Xu XY, Zou XP. Endoscopic findings and clinicopathologic characteristics of colonic schistosomiasis: a report of 46 cases. World J. Gastroenterol. 16: 723-727 (2010). *
Cao Q, Si JM, Gao M, Zhou G, Hu WL, Li JH. Clinical presentation of inflammatory bowel disease: a hospital based retrospective study of 379 patients in eastern China. Chin. Med. J. (Engl.) 118: 747-752 (2005).
Cao Q, Zhu Q, Shang Y, Gao M, Si J. Thiopurine methyltransferase gene polymorphisms in Chinese patients with inflammatory bowel disease. Digestion 79: 58-63 (2009).
Caplan AI. Adult mesenchymal stem cells for tissue engineering versus regenerative medicine. J. Cell Physiol. 213: 341-347 (2007). *
Capon F, Di Meglio P, Szaub J, Prescott NJ, Dunster C, Baumber L, Timms K, Gutin A, Abkevic V, Burden AD, Lanchbury J, Barker JN, Trembath RC, Nestle FO. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum. Genet. 122: 201-206 (2007). *
Cappello M, Randazzo C, Rizzuto G, Bonura C, Di Vita G, Galia M. Splenic tuberculosis in a patient with Crohn's disease on infliximab: case report. Inflamm. Bowel Dis. 16: 368-370 (2010).
Caprilli R. Why does Crohn's disease usually occur in terminal ileum? Journal of Crohn's and Colitis 2: 352-356 (2008).
Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Dig. Liver Dis. 40: 709-716 (2008).
Caprilli R, Angelucci E, Cocco A. Early or late guided missile in the treatment of Crohn's disease? Dig. Liver Dis. 37: 973-979 (2005).
Caprilli R, Angelucci E, Cocco A, Viscido A, Annese V, Ardizzone S, Biancone L, Castiglione F, Cottone M, Meucci G, Paoluzi P, Papi C, Sturniolo GC, Vecchi M. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement. Dig. Liver Dis. 37: 407-417 (2005).
Caprilli R, Aratari A, Papi C. Infliximab and refractory ulcerative colitis. Journal of Crohn's and Colitis 3: 44 (2009).
Caprilli R, Cesarini M, Angelucci E, Frieri G. The long journey of salicylates in ulcerative colitis: the past and the future. Journal of Crohn's and Colitis 3: 149-156 (2009).
Caprilli R, Clemente V, Frieri G. Historical evolution of the management of severe ulcerative colitis. Journal of Crohn's and Colitis 2: 263-268 (2008).
Caprilli R, Cottone M, Tonelli F, Sturniolo G, Castiglione F, Annese V, Papi C, Viscido A, Camma C, Corrao G, Latella G. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment. Pharmacol. Ther. 17: 517-523 (2003). *
Caprilli R, Frieri G. The dyspeptic macrophage 30 years later: and update in the pathogenesis of Crohn's disease. Dig. Liver Dis. 41: 166-168 (2009).
Caprilli R, Gassull MA, Escher JC, Moser G, Munkholm P, Forbes A, Hommes DW, Lochs H, Angelucci E, Cocco A, Vucelic B, Hildebrand H, Kolacek S, Riis L, Lukas M, de Franchis R, Hamilton M, Jantschek G, Michetti P, O'Morain C, Anwar MM, Freitas JL, et al. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut 55 Suppl. 1: i36-i58 (2006). *
Caprilli R, Guagnozzi D. CARD 15 and Toll-like receptors: the link with Crohn's disease. Dig. Liver Dis. 35: 753-757 (2003).
Caprilli R, Viscido A, Guagnozzi D. Review article: biological agents in the treatment of Crohn's disease. Aliment. Pharmacol. Ther. 16: 1579-1590 (2002). *
Caprioli F, Losco A, Vigano C, Conte D, Biondetti P, Forzenigo LV, Basilisco G. Computer-assisted evaluation of perianal fistula activity by means of anal ultrasound in patients with Crohn's disease. Am. J. Gastroenterol. 101: 1551-1558 (2006). *
Caprioli F, Pallone F, Monteleone G. Th17 immune response in IBD: a new pathogenic mechanism. Journal of Crohn's and Colitis 2: 291-295 (2008).
Caprioli F, Sarra M, Caruso R, Stolfi C, Fina D, Sica G, Macdonald TT, Pallone F, Monteleone G. Autocrine regulation of IL-21 production in human T lymphocytes. J. Immunol. 180: 1800-1807 (2008). *
Caprioli F, Stolfi C, Caruso R, Fina D, Sica G, Biancone L, Pallone F, Monteleone G. Transcriptional and post-translational regulation of Flip, an inhibitor of Fas-mediated apoptosis, in human gut inflammation. Gut 57: 1674-1680 (2008).
Capristo E, Valentini G, Scarfone A, Addolorato G, Giancaterini A, Ghittoni G, Mingrone G, Greco AV, Gasbarrini G. Alterations of nutrional status in the main gastro-intestinal pathologies. Minerva Gastroenterol. Dietol. 45: 137-151 (1999).
Cara Terribas CJ, Gonzalez Guijarro L. Hypomethylation and multiple sclerosis, the susceptibility factor? Neurologia 17: 132-135 (2002).
Caradonna L, Amati L, Lella P, Jirillo E, Caccavo D. Phagocytosis, killing, lymphocyte-mediated antibacterial activity, serum autoantibodies, and plasma endotoxins in inflammatory bowel disease. Am. J. Gastroenterol. 95: 1495-1502 (2000). *
Caradonna L, Amati L, Magrone T, Pellegrino NM, Jirillo E, Caccavo D. Enteric bacteria, lipopolysaccharides and related cytokines in inflammatory bowel disease: biological and clinical significance. J. Endotoxin Res. 6: 205-214 (2000). *
Caramoy A, Lappas A, Fauser S, Kirchhof B. Central scotoma and blurred vision in a patient with Crohn's disease. Ophthalmologe 106: 836-838 (2009).
Carbone J, Gonzalez-Lara V, Sarmiento E, Chean C, Perez JL, Marin I, Rodriguez-Molina JJ, Gil J, Fernandez-Cruz E. Humoral and cellular monitoring to predict the development of infection in Crohn's disease patients beginning treatment with infliximab. Ann. N. Y. Acad. Sci. 1107: 346-355 (2007). *
Carbone J, Perez-Rojas J, Sarmiento E. Infectious pulmonary complications in patients treated with anti-TNF-alpha monoclonal antibodies and soluble TNF receptor. Curr. Infect. Dis. Rep. 11: 229-236 (2009).
Carbonnel F. Which place for methotrexate in treatment of luminal Crohn's disease? Gastroenterol. Clin. Biol. 33: 18-20 (2009).
Carbonnel F, Boutron MC. Ulcerative colitis: is it in the diet? Gut 58: 1577-1579 (2009). *
Carbonnel F, Jantchou P, Monnet E, Cosnes J. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroenterol. Clin. Biol. 33S3: S145-S157 (2009).
Carbonnel F, Macaigne G, Beaugerie L, Gendre JP, Cosnes J. Crohn's disease severity in familial and sporadic cases. Gut 44: 91-95 (1999). *
Card T, Hubbard R, Logan RF. Mortality in inflammatory bowel disease: a population-based cohort study. Gastroenterology 125: 1583-1590 (2003). *
Card T, Logan RF, Rodrigues LC, Wheeler JG. Antibiotic use and the development of Crohn's disease. Gut 53: 246-250 (2004). *
Card T, West J, Hubbard R, Logan RF. Hip fractures in patients with inflammatory bowel disease and their relationship to corticosteroid use: a population based cohort study. Gut 53: 251-255 (2004). *
Cardon LR. Genetics. Delivering new disease genes. Science 314: 1403-1405 (2006). *
Cardoso H, Nunes AC, Carneiro F, Veloso FT. Successful infliximab therapy for oral Crohn's disease. Inflamm. Bowel Dis. 12: 337-338 (2006). *
Carey R, Jurickova I, Ballard E, Bonkowski E, Han X, Xu H, Denson LA. Activation of an IL-6:STAT3-dependent transcriptome in pediatric-onset inflammatory bowel disease. Inflamm. Bowel Dis. 14: 446-457 (2008). *
Cariappa A, Sands B, Forcione D, Finkelstein D, Podolsky DK, Pillai S. Analysis of MHC class II DP, DQ and DR alleles in Crohn's disease. Gut 43: 210-215 (1998). *
Caricato M, Ausania F, Borzomati D, Valeri S, Coppola R, Verzi A, Tonini G. Large abdominal mass in Crohn's disease. Gut 53: 1493 (2004). *
Cario E, Golenbock DT, Visintin A, Runzi M, Gerken G, Podolsky DK. Trypsin-sensitive modulation of intestinal epithelial MD-2 as mechanism of lipopolysaccharide tolerance. J. Immunol. 176: 4258-4266 (2006). *
Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of Toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect. Immun. 68: 7010-7017 (2000). *
Carlo JT, Demarco D, Smith BA, Livingston S, Wiser K, Kuhn JA, Lamont JP. The utility of capsule endoscopy and its role for diagnosing pathology in the gastrointestinal tract. Am. J. Surg. 190: 886-890 (2006). *
Carlsen HS, Yamanaka T, Scott H, Rugtveit J, Brandtzaeg P. The proportion of CD40+ mucosal macrophages is increased in inflammatory bowel disease whereas CD40 ligand (CD154)+ T cells are relatively decreased, suggesting differential modulation of these costimulatory molecules in human gut lamina propria. Inflamm. Bowel Dis. 12: 1013-1024 (2006). *
Carlson GL. Surgical management of intestinal failure. Proc. Nutr. Soc. 62: 711-718 (2003). *
Carlson JA, Chen KR. Cutaneous vasculitis update: neutrophilic muscular vessel and eosinophilic, granulomatous, and lymphocytic vasculitis syndromes. Am. J. Dermatopathol. 29: 32-43 (2007).
Carlsson E, Bosaeus I, Nordgren S. What concerns subjects with inflammatory bowel disease and an ileostomy? Scand. J. Gastroenterol. 38: 978-984 (2003). *
Carneiro LA, Travassos LH, Girardin SE. Nod-like receptors in innate immunity and inflammatory diseases. Ann. Med. 39: 581-593 (2007).
Carol M, Borruel N, Antolin M, Llopis M, Casellas F, Guarner F, Malagelada JR. Modulation of apoptosis in intestinal lymphocytes by a probiotic bacteria in Crohn's disease. J. Leukoc. Biol. 79: 917-922 (2006). *
Carpenter E, Jackson MA, Friesen CA, Scarbrough M, Roberts CC. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab. J. Pediatr. 144: 541-544 (2004). *
Carpinteri R, Patelli I, Casanueva FF, Giustina A. Inflammatory and granulomatous expansive lesions of the pituitary. Best Pract. Res. Clin. Endocrinol. Metab. 23: 639-650 (2009).
Carranza DC, Young L. Successful treatment of metastatic Crohn's disease with cyclosporine. J. Drugs Dermatol. 7: 789-791 (2008).
Carrat Ugrave P, Dragonieri S, Nocerino MC, Trabucco SM, Lacedonia D, Parisi G, Resta O. A case of cryptogenic organizing pneumonia occurring in Crohn's disease. Can. Respir. J. 12: 437-439 (2005). *
Carriere V, Roussel L, Ortega N, Lacorre DA, Americh L, Aguilar L, Bouche G, Girard JP. IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc. Natl. Acad. Sci. U.S.A. 104: 282-287 (2007). *
Carrigan SO, Pink DB, Stadnyk AW. Neutrophil transepithelial migration in response to the chemoattractant fMLP but not C5a is phospholipase D-dependent and related to the use of CD11b/CD18. J. Leukoc. Biol. 82: 1575-1584 (2007). *
Carrion S, Marin I, Domenech E. Infliximab use in a patient with ulcerative colitis and alcoholic cirrhosis with portal hypertension. Journal of Crohn's and Colitis 2: 271-272 (2008).
Carroccio A, Di Prima L, Pirrone G, Ambrosiano G, Noto D, Cefalu AB. Anti-TNF (infliximab) treatment in Crohn disease: safety profile. Recenti Prog. Med. 97: 108-112 (2006).
Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, Bennett CL. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol. 10: 816-824 (2009).
Carter AB, Misyak SA, Hontecillas R, Bassaganya-Riera J. Dietary modulation of inflammation-induced colorectal cancer through PPARgamma. PPAR Res. 2009: 498352 (2009). *
Carter JD, Valeriano J, Vasey FB. Crohn disease worsened by anakinra administration. J. Clin. Rheumatol. 9: 276-277 (2003).
Carter MJ, Lobo AJ, Travis SP. Guidelines for the management of inflammatory bowel disease in adults. Gut 53 Suppl. 5: V1-V16 (2004). *
Carter PH, Zhao Q. Clinically validated approaches to the treatment of autoimmune diseases. Expert Opin. Investig. Drugs. Jan 6 [Epub ahead of print] (2010).
Carty E, MacEy M, Rampton DS. Inhibition of platelet activation by 5-aminosalicylic acid in inflammatory bowel disease. Aliment. Pharmacol. Ther. 14: 1169-1179 (2000). *
Caruso R, Sarra M, Stolfi C, Rizzo A, Fina D, Fantini MC, Pallone F, Macdonald TT, Monteleone G. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut. Gastroenterology 136: 2270-2279 (2009). *
Carvalho AT, Elia CC, de Souza HS, Elias PR, Pontes EL, Lukashok HP, de Freitas FC, Lapa e Silva JR. Immunohistochemical study of intestinal eosinophils in inflammatory bowel disease. J. Clin. Gastroenterol. 36: 120-125 (2003).
Carvalho FA, Barnich N, Sauvanet P, Darcha C, Gelot A, Darfeuille-Michaud A. Crohn's disease-associated Escherichia coli LF82 aggravates colitis in injured mouse colon via signaling by flagellin. Inflamm. Bowel Dis. 14: 1051-1060 (2008). *
Carvalho FA, Barnich N, Sivignon A, Darcha C, Chan CH, Stanners CP, Darfeuille-Michaud A. Crohn's disease adherent-invasive Escherichia coli colonize and induce strong gut inflammation in transgenic mice expressing human CEACAM. J. Exp. Med. 206: 2179-2189 (2009). *
Carvalho IA, Silva A Jr, Campos VE, Moreira MA. Short communication: detection of Mycobacterium avium subspecies paratuberculosis by polymerase chain reaction in bovine milk in Brazil. J. Dairy Sci. 92: 5408-5410 (2009).
Carvalho R, Dilworth P, Docimo S, Cuffari C. Crohn disease of the neovagina and augmented bladder in a child born with cloacal exstrophy. J. Pediatr. Gastroenterol. Nutr. 48: 106-109 (2009). *
Carvalho R, Hyams JS. Diagnosis and management of inflammatory bowel disease in children. Semin. Pediatr. Surg. 16: 164-171 (2007).
Carvalho RS, Abadom V, Dilworth HP, Thompson R, Oliva-Hemker M, Cuffari C. Indeterminate colitis: a significant subgroup of pediatric IBD. Inflamm. Bowel Dis. 12: 258-262 (2006). *
Casanelli JM, Keli E, N'Dri J, Bohoussou PE, Blegole C, Moussa B, N'guessan HA. Crohn's disease: first report in Cote-d'Ivoire. Med. Trop. (Mars.) 64: 384-386 (2004).
Casanova JL, Abel L. Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J. Exp. Med. 206: 1839-1843 (2009). *
Casati J, Toner BB, de Rooy EC, Drossman DA, Maunder RG. Concerns of patients with inflammatory bowel disease: a review of emerging themes. Dig. Dis. Sci. 45: 26-31 (2000). *
Casella G, D'Inca R, Oliva L, Daperno M, Saladino V, Zoli G, Annese V, Fries W, Cortellezzi C; the Italian Group - IBD. Prevalence of celiac disease in inflammatory bowel diseases: an IG-IBD multicentre study. Dig. Liver Dis. Sep 26 [Epub ahead of print] (2009).
Casella G, De Marco E, Antonelli E, Daperno M, Baldini V, Signorini S, Sannella F, Morelli A, Villanacci V, Bassotti G. The prevalence of hyper- and hypothyroidism in patients with ulcerative colitis Journal of Crohn's and Colitis 2: 327-330 (2008).
Casella G, De Marco E, Monti C, Baldini V. The therapeutic role of thalidomide in inflammatory bowel disease. Minerva Gastroenterol. Dietol. 52: 293-301 (2006).
Casellas F, Alcala MJ, Prieto L, Miro JR, Malagelada JR. Assessment of the influence of disease activity on the quality of life of patients with inflammatory bowel disease using a short questionnaire. Am. J. Gastroenterol. 99: 457-461 (2004). *
Casellas F, Arenas JI, Baudet JS, Fabregas S, Garcia N, Gelabert J, Medina C, Ochotorena I, Papo M, Rodrigo L, Malagelada JR. Impairment of health-related quality of life in patients with inflammatory bowel disease: a Spanish multicenter study. Inflamm. Bowel Dis. 11: 488-496 (2005). *
Casellas F, Borruel N, Antolin M, Varela E, Torrejon A, Armadans L, Guarner F, Malagelada JR. Fecal excretion of deoxyribonucleic acid in long-term follow-up of patients with inactive ulcerative colitis. Inflamm. Bowel Dis. 13: 386-390 (2007). *
Casellas F, Borruel N, Torrejon A, Varela E, Antolin M, Guarner F, Malagelada JR. Oral oligofructose-enriched inulin supplementation in acute ulcerative colitis is well tolerated and associated with lowered faecal calprotectin. Aliment. Pharmacol. Ther. 25: 1061-1067 (2007). *
Casellas F, Fontanet G, Borruel N, Malagelada J. The opinion of patients with inflammatory bowel disease on healthcare received. Rev. Esp. Enferm. Dig. 96: 174-184 (2004). *
Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Impact of surgery for Crohn's disease on health-related quality of life. Am. J. Gastroenterol. 95: 177-182 (2000). *
Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR. Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years. Inflamm. Bowel Dis. 13: 1395-1400 (2007). *
Casellas F, Vivancos JL, Sampedro M, Malagelada JR. Relevance of the phenotypic characteristics of Crohn's disease in patient perception of health-related quality of life. Am. J. Gastroenterol. 100: 2737-2742 (2005). *
Casellas Jorda F. TNF-alpha inhibitors in inflamatory bowel disease. Med. Clin. (Barc.) 123: 627-634 (2004).
Casellas Jorda F, Lopez Vivancos J. Evaluation of quality of life in digestive diseases. Gastroenterol. Hepatol. 27: 58-68 (2004).
Casillas S, Delaney CP. Laparoscopic surgery for inflammatory bowel disease. Dig. Surg. 22: 135-142 (2005).
Casillas S, Delaney CP, Senagore AJ, Brady K, Fazio VW. Does conversion of a laparoscopic colectomy adversely affect patient outcome? Dis. Colon Rectum 47: 1680-1685 (2004).
Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J. Immunol. 154: 2434-2440 (1995).
Caspersen S, Elkjaer M, Riis L, Pedersen N, Mortensen C, Jess T, Sarto P, Hansen TS, Wewer V, Bendtsen F, Moesgaard F, Munkholm P; on behalf of the Danish Crohn Colitis Database. Infliximab for inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up evaluation of malignancy and mortality. Clin. Gastroenterol. Hepatol. 6: 1212-1217 (2008).
Caspi O, Polliack A, Klar R, Ben-Yehuda D. The association of inflammatory bowel disease and leukemia - coincidence or not? Leuk. Lymphoma 17: 255-262 (1995).
Cassano N, Loconsole F, Coviello C, Vena GA. Infliximab in recalcitrant severe atopic eczema associated with contact allergy. Int. J. Immunopathol. Pharmacol. 19: 237-240 (2006).
Cassano R, Trombino S, Cilea A, Ferrarelli T, Muzzalupo R, Picci N. L-lysine pro-prodrug containing trans-ferulic acid for 5-amino salicylic acid colon delivery: synthesis, characterization and in vitro antioxidant activity evaluation. Chem. Pharm. Bull. (Tokyo) 58: 103-105 (2010). *
Cassater D, Gambaro G, Fabris A, Cena C, Calabria S, Capelluto S, Lupo A. Henoch-Schonlein purpura and Crohn's disease in a family. J. Nephrol. 19: 387-390 (2006).
Cassinotti A, Annaloro C, Ardizzone S, Onida F, Volpe AD, Clerici M, Usardi P, Greco S, Maconi G, Porro GB, Deliliers GL. Autologous haematopoietic stem cell transplantation without CD34+ cell selection in refractory Crohn's disease. Gut 57: 211-217 (2008).
Cassinotti A, Ardizzone S, Porro GB. Adalimumab for the treatment of Crohn's disease. Biologics 2: 763-777 (2008). *
Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohn's disease: a critical systematic review. Inflamm. Bowel Dis. 15: 1264-1275 (2009).
Casswall TH, Nemeth A, Nilsson I, Wadstrom T, Nilsson HO. Helicobacter species DNA in liver and gastric tissues in children and adolescents with chronic liver disease. Scand. J. Gastroenterol. 45: 160-167 (2010). *
Castellaneta SP, Afzal NA, Greenberg M, Deere H, Davies S, Murch SH, Walker-Smith JA, Thomson M. Diagnostic role of upper gastrointestinal endoscopy in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 39: 257-261 (2004). *
Castellanos E, Aranaz A, Gould KA, Linedale R, Stevenson K, Alvarez J, Dominguez L, de Juan L, Hinds J, Bull TJ. Discovery of stable and variable differences in the Mycobacterium avium subspecies paratuberculosis Types I, II and III genomes by pan-genome microarray analysis. Appl. Environ. Microbiol. 75: 676-686 (2009). *
Castellino F, Rosina F, Bansi DS, Bauducci M, Touscoz GA, Giorda L, Borghesio E, Bessone MP, Astegiano M, Musso A, et al. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease: do they recognize different subsets of a heterogeneous disease? Eur. J. Gastroenterol. Hepatol. 7: 859-864 (1995).
Castiglione F, Bucci L, Pesce G, De Palma GD, Camera L, Cipolletta F, Testa A, Diaferia M, Rispo A. Oral contrast-enhanced sonography for the diagnosis and grading of postsurgical recurrence of Crohn's disease. Inflamm. Bowel Dis. 14: 1240-1245 (2008). *
Castiglione F, De Sio I, Cozzolino A, Rispo A, Manguso F, Del Vecchio Blanco G, Di Girolamo E, Castellano L, Ciacci C, Mazzacca G. Bowel wall thickness at abdominal ultrasound and the one-year-risk of surgery in patients with Crohn's disease. Am. J. Gastroenterol. 99: 1977-1983 (2004). *
Castiglione F, Rispo A, Di Girolamo E, Cozzolino A, Manguso F, Grassia R, Mazzacca G. Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease. Aliment. Pharmacol. Ther. 18: 1107-1112 (2003). *
Castillo E, Thomassie LM, Whitlow CB, Margolin DA, Malcolm J, Beck DE. Continent ileostomy: current experience. Dis. Colon Rectum 48: 1263-1268 (2005). *
Castrellon A, Feldman PA, Suarez M, Spector S, Chua L, Byrnes J. Crohn's disease complicated by primary gastrointestinal Hodgkin's lymphoma presenting with small bowel perforation. J. Gastrointestin. Liver Dis. 18: 359-361 (2009). *
Castro M, Knafelz D, Rossi L, Ambrosini MI, Papadatou B, Mambrini G, Magnani M. Periodic treatment with autologous erythrocytes loaded with dexamethasone 21-phosphate for fistulizing pediatric Crohn's disease: case report. J. Pediatr. Gastroenterol. Nutr. 42: 313-315 (2006). *
Castro M, Papadatou B, Baldassare M, Balli F, Barabino A, Barbera C, Barca S, Barera G, Bascietto F, Berni Canani R, Calacoci M, Campanozzi A, Castellucci G, Catassi C, Colombo M, Covoni MR, Cucchiara S, D'Altilia MR, De Angelis GL, De Virgilis S, et al. Inflammatory bowel disease in children and adolescents in Italy: data from the pediatric national IBD register (1996-2003). Inflamm. Bowel Dis. 14: 1246-1252 (2008). *
Castro M, Rossi L, Papadatou B, Bracci F, Knafelz D, Ambrosini M, Calce A, Serafini S, Isacchi G, D'orio F, Mambrini G, Magnani M. Long-term treatment with autologous red blood cells loaded with dexamethasone 21-phosphate in pediatric patients affected by steroid-dependent Crohn disease. J. Pediatr. Gastroenterol. Nutr. 44: 423-426 (2007). *
Castro-Santos P, Mozo L, Gutierrez C, Suarez A. TNFalpha genotype influences development of IgA-ASCA antibodies in Crohn's disease patients with CARD15 wild type. Clin. Immunol. 121: 305-313 (2006). *
Castro-Santos P, Suarez A, Lopez-Rivas L, Mozo L, Gutierrez C. TNFalpha and IL-10 gene polymorphisms in inflammatory bowel disease. Association of -1082 AA low producer IL-10 genotype with steroid dependency. Am. J. Gastroenterol. 101: 1039-1047 (2006). *
Cat H, Sophani I, Lemann M, Modiglani R, Solue JC. Cyclosporin treatment of anal and perianal lesions associated with Crohn's disease. Turk. J. Gastroenterol. 14: 121-127 (2003). *
Catarzi S, Marcucci T, Papucci L, Favilli F, Donnini M, Tonelli F, Vincenzini MT, Iantomasi T. Apoptosis and Bax, Bcl-2, Mcl-1 expression in neutrophils of Crohn's disease patients. Inflamm. Bowel Dis. 14: 819-825 (2008). *
Catenacci MH, King KK. Images in emergency medicine. Crohn's disease. Ann. Emerg. Med. 46: 559, 564 (2005).
Caturelli E, Ghittoni G, Roselli P. Ultrasound assessment of vascularization of bowel wall in Crohn's disease. Eur. J. Radiol. 65: 242-243 (2008).
Caunedo Alvarez A, Herrerias Gutierrez JM. Role of endoscopic capsule in the diagnosis of digestive diseases. Med. Clin. (Barc.) 124: 427-433 (2005).
Cavaglieri CR, Nishiyama A, Fernandes LC, Curi R, Miles EA, Calder PC. Differential effects of short-chain fatty acids on proliferation and production of pro- and anti-inflammatory cytokines by cultured lymphocytes. Life Sci. 73: 1683-1690 (2003). *
Cavanaugh J. NOD2: ethnic and geographic differences. World J. Gastroenterol. 12: 3673-3677 (2006). *
Cavanaugh J; IBD International Genetics Consortium. International collaboration provides convincing linkage replication in complex disease through analysis of a large pooled data set: Crohn disease and chromosome 16. Am. J. Hum. Genet. 68: 1165-1171 (2001). *
Cavanaugh JA, Adams KE, Quak EJ, Bryce ME, O'Callaghan NJ, Rodgers HJ, Magarry GR, Butler WJ, Eaden JA, Roberts-Thomson IC, Pavli P, Wilson SR, Callen DF. CARD15/NOD2 risk alleles in the development of Crohn's disease in the Australian population. Ann. Hum. Genet. 67: 35-41 (2003). *
Cavanaugh JA, Callen DF, Wilson SR, Stanford PM, Sraml ME, Gorska M, Crawford J, Whitmore SA, Shlegel C, Foote S, Kohonen-Corish M, Pavli P. Analysis of Australian Crohn's disease pedigrees refines the localization for susceptibility to inflammatory bowel disease on chromosome 16. Ann. Hum. Genet. 62: 291-298 (1998). *
Cavanaugh JA, Pavli P. Ulcerative colitis: a genetic disease? Baillieres Clin. Gastroenterol. 11: 1-15 (1997).
Cave D. Capsule endoscopy and Crohn's disease. Gastrointest. Endosc. 61: 262-263 (2005). *
Cave NJ. Chronic inflammatory disorders of the gastrointestinal tract of companion animals. N. Z. Vet. J. 51: 262-274 (2003).
Caviglia R, Boskoski I, Cicala M. Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opin. Drug Saf. 7: 617-632 (2008).
Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 3: 39-49 (2009). *
Caviglia R, Ribolsi M, Rizzi M, Emerenziani S, Annunziata ML, Cicala M. Maintenance of remission with infliximab in inflammatory bowel disease: efficacy and safety long-term follow-up. World J. Gastroenterol. 13: 5238-5244 (2007). *
Caye-Thomasen P, Nielsen TR, Petri NE. Primary oral manifestation of Crohn disease. Ugeskr. Laeger. 164: 3363-3364 (2002).
Cazzato IA, Cammarota G, Nista EC, Cesaro P, Sparano L, Bonomo V, Gasbarrini GB, Gasbarrini A. Diagnostic and therapeutic impact of double-balloon enteroscopy (DBE) in a series of 100 patients with suspected small bowel diseases. Dig. Liver Dis. 39: 483-487 (2007).
Ceballos C. Growth and early onset inflammatory bowel disease. Gastroenterol. Nurs. 31: 101-104 (2008).
Celik Y, Dagli U, Yalin Kilic M, Toruner M, Ceren Ozen S, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, Mithat Bozdayi A. Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease. Scand. J. Gastroenterol. 41: 559-565 (2006). *
Cellier C, De Beenhouwer H, Berger A, Penna C, Carbonnel F, Parc R, Cugnenc PH, Le Quintrec Y, Gendre JP, Barbier JP, Portaels F. Mycobacterium paratuberculosis and Mycobacterium avium subsp. silvaticum DNA cannot be detected by PCR in Crohn's disease tissue. Gastroenterol. Clin. Biol. 22: 675-678 (1998).
Cellini C, Safar B, Fleshman J. Surgical management of pyogenic complications of Crohn's disease. Inflamm. Bowel Dis. 16: 512-517 (2010). *
Cenac N, Coelho AM, Nguyen C, Compton S, Andrade-Gordon P, MacNaughton WK, Wallace JL, Hollenberg MD, Bunnett NW, Garcia-Villar R, Bueno L, Vergnolle N. Induction of intestinal inflammation in mouse by activation of proteinase-activated receptor-2. Am. J. Pathol. 161: 1903-1915 (2002). *
Cepo J, Adams PC. Dietary advice and Crohn's disease - facts or folly? Can. J. Gastroenterol. 23: 747-748 (2009).
Cerezo Ruiz A, Gomez Camacho F, Garcia Sanchez V, Iglesias Flores E, Gallardo Valverde JM, DE Dios Vega JF. A young woman with Crohn's disease and portal gas. Gastroenterol. Hepatol. 31: 550-551 (2008).
Cerveny P, Bortlík M, Kubena A, Vlcek J, Lakatos PL, Lukas M. Nonadherence in inflammatory bowel disease: results of factor analysis. Inflamm. Bowel Dis. 13: 1244-1249 (2007). *
Cerveny P, Bortlik M, Vlcek J, Kubena A, Lukas M. Non-adherence to treatment in inflammatory bowel disease in Czech Republic? Journal of Crohn's and Colitis 1: 77-81 (2007).
Cesarini M, Angelucci E, Fiorino G, Crudeli A, Vernia P, Caprilli R. Postoperative recurrence of Crohn's disease and videocapsule endoscopy: it is necessary to leave no stone unturned. Inflamm. Bowel Dis. 14: 1165-1166 (2008). *
Cesarini M, Vernia P, Angelucci E. Acute lymphoid leukemia in a Crohn's disease patient during treatment with adalimumab after a prolonged treatment with azathioprine and steroids. Inflamm. Bowel Dis. 16: 371-372 (2010).
Cesaro A, Abakar-Mahamat A, Brest P, Lassalle S, Selva E, Filippi J, Hebuterne X, Hugot JP, Doglio A, Galland F, Naquet P, Vouret-Craviari V, Mograbi B, Hofman PM. Differential expression and regulation of ADAM17 and TIMP3 in acute inflamed intestinal epithelia. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1332-G1343 (2009). *
Ceyhan B. Pulmonary involvement in inflammatory bowel disease. Tuberk. Toraks. 54: 292-298 (2006).
Cezard JP, Munck A, Mouterde O, Morali A, Lenaerts C, Lachaux A, Turck D, Schmitz J, Maurage C, Girardet JP, Belli D, Lamireau T, Sarles J, Chouraqui JP, Descos B, Dabadi A, Meyer M, Olives JP, Mary JY. Prevention of relapse by mesalazine (pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial. Gastroenterol. Clin. Biol. 33: 31-40 (2009).
Cezard JP, Nouaili N, Talbotec C, Hugot JP, Gobert JG, Schmitz J, Mougenot JF, Alberti C, Goulet O. A prospective study of the efficacy and tolerance of a chimeric antibody to tumor necrosis factors (remicade) in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 36: 632-636 (2003). *
Cezard JP, Touati G, Alberti C, Hugot JP, Brinon C, Czernichow P. Growth in paediatric Crohn's disease. Horm. Res. 58 Suppl. 1: 11-15 (2002).
Chacon O, Bermudez LE, Barletta RG. Johne's disease, inflammatory bowel disease, and Mycobacterium paratuberculosis. Annu. Rev. Microbiol. 58: 329-363 (2004). *
Chakraborty A, Bremner AR, Moore I, Beattie RM. Coeliac disease and Crohn's disease: an association not to be forgotten. Hosp. Med. 64: 684-655 (2003).
Challis S, Surgenor S. Helping patients with Crohn's disease to stop smoking. Prof. Nurse 19: 386-389 (2004).
Chamaillard M, Girardin SE, Viala J, Philpott DJ. Nods, Nalps and Naip: intracellular regulators of bacterial-induced inflammation. Cell. Microbiol. 5: 581-592 (2003). *
Chamaillard M, Philpott D, Girardin SE, Zouali H, Lesage S, Chareyre F, Bui TH, Giovannini M, Zaehringer U, Penard-Lacronique V, Sansonetti PJ, Hugot JP, Thomas G. Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases. Proc. Natl. Acad. Sci. U.S.A. 100: 3455-3460 (2003). *
Chamberlin W. Importance of the Australian Crohn's disease antibiotic study. Gastroenterology 133: 1744-1745 (2007). *
Chamberlin W, Borody T, Naser S. MAP-associated Crohn's disease MAP, Koch's postulates, causality and Crohn's disease. Dig. Liver Dis. 39: 792-794 (2007).
Chamberlin W, Ghobrial G, Chehtane M, Naser SA. Successful treatment of a Crohn's disease patient infected with bacteremic Mycobacterium paratuberculosis. Am. J. Gastroenterol. 102: 689-691 (2007). *
Chamberlin W, Graham DY, Hulten K, El-Zimaity HM, Schwartz MR, Naser S, Shafran I, El-Zaatari FA. Review article: Mycobacterium avium subsp. paratuberculosis as one cause of Crohn's disease. Aliment. Pharmacol. Ther. 15: 337-346 (2001). *
Chamberlin W, Hulten K, Graham DY. Antibiotics as primary therapy for Crohn's disease. Drugs Today (Barc.) 36: 667-678 (2000).
Chamberlin W, Naser SA. Blood cultures of 19 Crohn's disease patients. Am. J. Gastroenterol. 103: 802-803 (2008). *
Chamberlin WM, Naser SA. Integrating theories of the etiology of Crohn's disease on the etiology of Crohn's disease: questioning the hypotheses. Med. Sci. Monit. 12: RA27-RA33 (2006). *
Chamberlin WM, Shafran I. Anti-mycobacterials and Crohn's disease. Aliment. Pharmacol. Ther. 28: 373-374 (2008). *
Chamberlin WM, Shafran I. Anti-mycobacterials and Crohn's disease. Aliment. Pharmacol. Ther. 28: 373-374 (2008). *
Chami G, Raza M, Bernstein CN. Usefulness and impact on management of positive and negative capsule endoscopy. Can. J. Gastroenterol. 21: 577-581 (2007). *
Chamouard P, Desprez D, Hugel B, Kunzelmann C, Gidon-Jeangirard C, Lessard M, Baumann R, Freyssinet JM, Grunebaum L. Circulating cell-derived microparticles in Crohn's disease. Dig. Dis. Sci. 50: 574-580 (2005). *
Chamouard P, Monneaux F, Richert Z, Voegeli AC, Lavaux T, Gaub MP, Baumann R, Oudet P, Muller S. Diminution of circulating CD4+CD25 high T cells in naive Crohn's disease. Dig. Dis. Sci. 54: 2084-2093 (2009). *
Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic value of C-reactive protein for predicting activity level of Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 882-887 (2006).
Champault A, Benoist S, Alves A, Panis Y. Surgical therapy for Crohn's disease of the colon and rectum. Gastroenterol. Clin. Biol. 28: 882-892 (2004).
Chan CY, Browning JC, Larsen F, Hsu S. Development of new-onset psoriasis in a patient receiving infliximab for treatment of rheumatoid arthritis. Dermatol. Online J. 14: 12 (2008). *
Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J. Drugs Dermatol. 3: 315-318 (2004).
Chan JW, Castellanos A. Infliximab and anterior optic neuropathy: case report and review of the literature. Graefes Arch. Clin. Exp. Ophthalmol. Nov 15 [Epub ahead of print] (2009). *
Chan RC, Katelaris PH, Stewart P, Lin BP. Small bowel adenocarcinoma with high levels of microsatellite instability in Crohn's disease. Hum. Pathol. 37: 631-634 (2006).
Chanda P, Sucheston L, Zhang A, Brazeau D, Freudenheim JL, Ambrosone C, Ramanathan M. AMBIENCE: a novel approach and efficient algorithm for identifying informative genetic and environment interactions associated with complex phenotypes. Genetics 180: 1191-1210 (2008). *
Chanda P, Sucheston L, Zhang A, Ramanathan M. The interaction index, a novel information-theoretic metric for prioritizing interacting genetic variations and environmental factors. Eur. J. Hum. Genet. 17: 1274-1286 (2009).
Chanda P, Zhang A, Brazeau D, Sucheston L, Freudenheim JL, Ambrosone C, Ramanathan M. Information-theoretic metrics for visualizing gene-environment interactions. Am. J. Hum. Genet. 81: 939-963 (2007). *
Chande N, Macdonald J, McDonald J. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. 4: CD006618 (2007). *
Chande N, Ponich T, Gregor J. A survey of Canadian gastroenterologists about the use of methotrexate in patients with Crohn's disease. Can. J. Gastroenterol. 19: 553-558 (2005). *
Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (I). Surgeon 1: 63-75 (2003).
Chandran P, Satthaporn S, Robins A, Eremin O. Inflammatory bowel disease: dysfunction of GALT and gut bacterial flora (II). Surgeon 1: 125-136 (2003).
Chang DK, Kim JJ, Choi H, Eun CS, Han DS, Byeon JS, Kim JO. Double balloon endoscopy in small intestinal Crohn's disease and other inflammatory diseases such as cryptogenic multifocal ulcerous stenosing enteritis (CMUSE). Gastrointest. Endosc. 66: S96-S98 (2007).
Chang H, Qin W, Li Y, Zhang J, Lin Z, Lv M, Sun Y, Feng J, Shen B. A novel human scFv fragment against TNF-alpha from de novo design method. Mol. Immunol. 44: 3789-3796 (2007). *
Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents - a guide for GPs. Aust. Fam. Physician 36: 1035-1038 (2007). *
Chang PK, Holt EG, De Villiers WJ, Boulanger BR. A new complication from a new technology: what a general surgeon should know about wireless capsule endoscopy. Am. Surg. 71: 455-458 (2005).
Chang SH, Tze-Chi Hsu, Su HC, Tung KY, Hsiao HT. Treatment of intractable enterocutaneous fistula with an island pedicled anterolateral thigh flap in Crohn's disease - case report. J. Plast. Reconstr. Aesthet. Surg. Dec 5 [Epub ahead of print] (2009).
Chao CC, Ng Jao YT, Mo LR. Capsule endoscopy for gastrointestinal bleeding with an obscure etiology. J. Formos. Med. Assoc. 104: 659-665 (2005).
Chao J, Mulani P. What is the rate of loss of response to infliximab therapy in Crohn's disease? Am. J. Gastroenterol. 104: 2353-2354 (2009). *
Chao JC, Lucha PA Jr. Enteritis cystica profunda: is trauma the etiology? Interval development in the previously normal ileum: a case report and literature review. Mil. Med. 173: 513-514 (2008).
Chaoui Z, Bernoussi A, Belmekki M, Berraho A. Uveitis and chronic intestinal inflammatory diseases: three case studies. J. Fr. Ophtalmol. 28: 854-856 (2005).
Chapman JM, Onnie CM, Prescott NJ, Fisher SA, Mansfield JC, Mathew CG, Lewis CM, Verzilli CJ, Whittaker JC. Searching for genotype-phenotype structure: using hierarchical log-linear models in Crohn disease. Am. J. Hum. Genet. 84: 178-187 (2009). *
Chapman RW, Arborgh BA, Rhodes JM, Summerfield JA, Dick R, Scheuer PJ, Sherlock S. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. Gut 21: 870-877 (1980). *
Chapman RW, Cottone M, Selby WS, Shepherd HA, Sherlock S, Jewell DP. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 27: 86-91 (1986). *
Chapman-Kiddell CA, Davies PS, Gillen L, Radford-Smith GL. Role of diet in the development of inflammatory bowel disease. Inflamm. Bowel Dis. 16: 137-151 (2010). *
Charach G, Grosskopf I, Weintraub M. Development of Crohn's disease in a patient with multiple sclerosis treated with copaxone. Digestion 77: 198-200 (2008). *
Charagundla SR, Levine MS, Torigian DA, Campbell MS, Furth EE, Rombeau J. Diffuse intestinal ganglioneuromatosis mimicking Crohn's disease. AJR Am. J. Roentgenol. 182: 1166-1168 (2004). *
Charpignon C, Beau P. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited? Gastroenterol. Clin. Biol. 32: 153-157 (2008). *
Charron M. Inflammatory bowel disease activity assessment with biologic markers and (99m)Tc-WBC scintigraphy: are there different trends in ileitis versus colitis? J. Nucl. Med. 44: 1586-1591 (2003). *
Charron M. Temporal correlation of the erythrocyte sedimentation rate with Tc-99m WBC uptake on children with inflammatory bowel diseases. Clin. Nucl. Med. 28: 905-907 (2003).
Charron M, Fernando del Rosario J, Kocoshis S. Distribution of acute bowel inflammation determined by technetium-labeled white blood cells in children with inflammatory bowel disease. Inflamm. Bowel Dis. 4: 84-88 (1998). *
Chatzicostas C, Koutroubakis IE, Tzardi M, Roussomoustakaki M, Prassopoulos P, Kouroumalis EA. Colonic tuberculosis mimicking Crohn's disease: case report. BMC Gastroenterol. 2: 10 (2002). *
Chatzicostas C, Roussomoustakaki M, Potamianos S, Paspatis G, Mouzas I, Romanos J, Mavrogeni H, Kouroumalis EA. Factors associated with disease evolution in Greek patients with inflammatory bowel disease. BMC Gastroenterol. 6: 21 (2006). *
Chaudhary R, Ghosh S. Prediction of response to infliximab in Crohn's disease. Dig. Liver Dis. 37: 559-563 (2005).
Chauveau E, Terrier F, Casassus-Buihle D, Moncoucy X, Oddes B. Macrophage activation syndrome after treatment with infliximab for fistulated Crohn's disease. Presse. Med. 34: 583-584 (2005).
Chavez-Lopez M, Delgado-Villafana J, Gallaga A, Huerta-Yanez G. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. Allergol. Immunopathol. (Madr.) 33: 291-292 (2005).
Chebli JM, Gaburri PD, De Souza AF, Pinto AL, Chebli LA, Felga GE, Forn CG, Pimentel CF. Long-term results with azathioprine therapy in patients with corticosteroid-dependent Crohn's disease: open-label prospective study. J. Gastroenterol. Hepatol. 22: 268-274 (2007). *
Check JH, Srivastava M, Brasile D, Amui J, Choe JK, Dix E. Successful pregnancy with frozen embryo transfer into a gestational carrier from eggs obtained from a woman in premature menopause. Clin. Exp. Obstet. Gynecol. 36: 154-157 (2009).
Cheema AA, McNeill AJ. Images in cardiology. Left main coronary artery stenosis associated with aortitis in a patient with Crohn's disease. Heart 92: 618 (2006). *
Cheifetz A, Itzkowitz S. The diagnosis and treatment of pouchitis in inflammatory bowel disease. J. Clin. Gastroenterol. 38: S44-S50 (2004).
Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, Plevy S. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98: 1315-1324 (2003). *
Cheifetz AS, Kornbluth AA, Legnani P, Schmelkin I, Brown A, Lichtiger S, Lewis BS. The risk of retention of the capsule endoscope in patients with known or suspected Crohn's disease. Am. J. Gastroenterol. 101: 2218-2222 (2006). *
Cheifetz AS, Lewis BS. Capsule endoscopy retention: is it a complication? J. Clin. Gastroenterol. 40: 688-691 (2006).
Cheikh I, Maamouri N, Chouaib S, Chaabouni H, Ouerghi H, Ben Ammar A. Association of celiac disease and Crohn's disease. A case report. Tunis. Med. 81: 969-971 (2003).
Chen AJ, Li F, DU J, Zhang Y, Gong EC, Shi XY. Expression of co-stimulatory molecule CD86 and its inducible co-stimulator in Crohn disease and their pathologic significance. Beijing Da Xue Xue Bao 41: 620-624 (2009).
Chen B, Zeng Z, Hou J, Chen M, Gao X, Hu P. Association of interleukin-17F 7488 single nucleotide polymorphism and inflammatory bowel disease in the Chinese population. Scand. J. Gastroenterol. 44: 720-726 (2009). *
Chen CC, Isomoto H, Narumi Y, Sato K, Oishi Y, Kobayashi T, Yanagihara K, Mizuta Y, Kohno S, Tsukamoto K. Haplotypes of PADI4 susceptible to rheumatoid arthritis are also associated with ulcerative colitis in the Japanese population. Clin. Immunol. 126: 165-171 (2008). *
Chen CM, Gong Y, Zhang M, Chen JJ. Reciprocal cross talk between Nod2 and TAK1 signaling pathways. J. Biol. Chem. 279: 25876-25882 (2004). *
Chen CS, Sullivan S, Anderson T, Tan AC, Alex PJ, Brant SR, Cuffari C, Bayless TM, Talor MV, Burek CL, Wang H, Li R, Datta LW, Wu Y, Winslow RL, Zhu H, Li X. Identification of novel serological biomarkers for inflammatory bowel disease using Escherichia coli proteome chip. Mol. Cell. Proteomics 8: 1765-1776 (2009). *
Chen DP, Weber SC, Constantinou PS, Ferris TA, Lowe HJ, Butte AJ. Clinical arrays of laboratory measures, or "clinarrays", built from an electronic health record enable disease subtyping by severity. AMIA Annu. Symp. Proc. 2007: 115-119 (2007).
Chen M, Peyrin-Biroulet L, Xia B, Rodriguez-Gueant RM, Bronowicki JP, Bigard MA, Gueant JL. Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China. BMC Med. Genet. 9: 78 (2008). *
Chen M, Xia B, Chen B, Guo Q, Li J, Ye M, Hu Z. N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. Can. J. Gastroenterol. 21: 155-158 (2007). *
Chen MC, Mudge CS, Klumpp D. Urothelial lesion formation is mediated by TNFR1 during neurogenic cystitis. Am. J. Physiol. Renal Physiol. 291: F741-F749 (2006). *
Chen S, Harisinghani MG, Wittenberg J. Small bowel CT fat density target sign in chronic radiation enteritis. Australas. Radiol. 47: 450-452 (2003).
Chen SC, Cummings OW, Hartley MP, Filomena CA, Cho WK. Hepatocellular carcinoma occurring in a patient with Crohn's disease treated with both azathioprine and infliximab. Dig. Dis. Sci. 51: 952-955 (2006). *
Chen W, Li D, Paulus B, Wilson I, Chadwick VS. High prevalence of Mycoplasma pneumoniae in intestinal mucosal biopsies from patients with inflammatory bowel disease and controls. Dig. Dis. Sci. 46: 2529-2535 (2001). *
Chen Y, Noble EG. Is exercise beneficial to the inflammatory bowel diseases? An implication of heat shock proteins. Med. Hypotheses 72: 84-86 (2009).
Cheng S, Vu P. Recurrent orbital myositis with radiological feature mimicking thyroid eye disease in a patient with Crohn's disease. Orbit. 28: 368-370 (2009).
Cheng Y, Desreumaux P. 5-Aminosalicylic acid is an attractive candidate agent for chemoprevention of colon cancer in patients with inflammatory bowel disease. World J. Gastroenterol. 11: 309-314 (2005). *
Cheon JH, Kim YS, Lee IS, Chang DK, Ryu JK, Lee KJ, Moon JS, Park CH, Kim JO, Shim KN, Choi CH, Cheung DY, Jang BI, Seo GS, Chun HJ, Choi MG; Korean Gut Image Study Group. Can we predict spontaneous capsule passage after retention? A nationwide study to evaluate the incidence and clinical outcomes of capsule retention. Endoscopy 39: 1046-1052 (2007).
Cheon JH, Shin SJ, Kim SW, Lee KM, Kim JS, Kim WH; IBD Study Group of the Korean Association of the Study of Intestinal Diseases. Diagnosis of intestinal Behcet's disease. Korean J. Gastroenterol. 53: 187-193 (2009).
Cheow HK, Voutnis DD, Evans JW, Szczepura KR, Swift EA, Bird NJ, Ruparelia P, Solanki CK, Ballinger JR, Chilvers ER, Middleton SJ, Peters AM. Quantification of disease activity in patients undergoing leucocyte scintigraphy for suspected inflammatory bowel disease. Eur. J. Nucl. Med. Mol. Imaging 32: 329-337 (2005). *
Cherian S, Singh P. Is routine ileoscopy useful? An observational study of procedure times, diagnostic yield, and learning curve. Am. J. Gastroenterol. 99: 2324-2329 (2004). *
Cherian V, Machnicki S. Posterior mediastinal masses in a patient with exacerbation of Crohn disease. Chest 131: 1963-1966 (2007). *
Chermesh I, Azriel A, Alter-Koltunoff M, Eliakim R, Karban A, Levi BZ. Crohn's disease and SLC11A1 promoter polymorphism. Dig. Dis. Sci. 52: 1632-1635 (2007). *
Chermesh I, Eliakim R. Capsule endoscopy in Crohn's disease - indications and reservations 2008. Journal of Crohn's and Colitis 2: 107-113 (2008).
Chermesh I, Tamir A, Lachter J, Eliakim R. Intravenous cyclosporine for inflammatory bowel disease - safe and effective. Hepatogastroenterology 54: 2003-2006 (2007).
Chermesh I, Tamir A, Reshef R, Chowers Y, Suissa A, Katz D, Gelber M, Halpern Z, Bengmark S, Eliakim R. Failure of synbiotic 2000 to prevent postoperative recurrence of Crohn's disease. Dig. Dis. Sci. 52: 385-389 (2007). *
Chermesh I, Tamir A, Suissa A, Eliakim R. Ferrus calcium citrate is absorbed better than iron bisglycinate in patients with Crohn's disease, but not in healthy controls. Dig. Dis. Sci. 51: 942-945 (2006). *
Cherry K. NOD2/CARD15 variants and Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 11 (2006). *
Chetty R, Hafezi S, Montgomery E. An incidental enterocolic lymphocytic phlebitis pattern is seen commonly in the rectal stump of patients with diversion colitis superimposed on inflammatory bowel disease. J. Clin. Pathol. 62: 464-467 (2009).
Cheung O, Regueiro MD. Inflammatory bowel disease emergencies. Gastroenterol. Clin. North Am. 32: 1269-1288 (2003).
Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L. Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France. Inflamm. Bowel Dis. Nov 2 [Epub ahead of print] (2009).
Chew MH, Goh MH, Ooi BS, Eu KW. Giant pseudopolyposis in Crohn's disease mimicking malignancy. Int. J. Colorectal Dis. 23: 823-824 (2008). *
Chew SS, Ngo TQ, Douglas PR, Newstead GL, Selby W, Solomon MJ. Cholecystectomy in patients with Crohn's ileitis. Dis. Colon Rectum 46: 1484-1488 (2003).
Chhor V, Sinaceur M, Journois D. Misleading abdominal pain following extracorporeal renal lithotripsy. Urol. Int. 83: 246-248 (2009).
Chiappini E, de Martino M, Mangiantini F, Lionetti P. Crohn disease and mycobacterial infection in children: an intriguing relationship. J. Pediatr. Gastroenterol. Nutr. 49: 550-558 (2009).
Chiarello PG, Penaforte FR, Japur CC, Souza CD, Vannucchi H, Troncon LE. Increased folate Intake with no changes in serum homocysteine and decreased levels of C-reactive protein in patients with inflammatory bowel diseases. Dig. Dis. Sci. 54: 627-633 (2009). *
Chiarenza L, Pignataro A, Lanza V. Refeeding syndrome in early pregnancy. Case report. Minerva Anestesiol. 71: 803-808 (2005).
Chiba M, Fukushima T, Horie Y, Iizuka M, Masamune O. No Mycobacterium paratuberculosis detected in intestinal tissue, including Peyer's patches and lymph follicles, of Crohn's disease. J. Gastroenterol. 33: 482-487 (1998).
Chiba M, Iizuka M, Horie Y, Igarashi K, Masamune O. HLA-DR antigen expression in macroscopically uninvolved areas of intestinal epithelia in Crohn's disease. Gastroenterol. Jpn. 24: 365-372 (1989).
Chiba M, Kono M, Hoshina S, Komatsu M, Kitagawa Y, Iizuka M, Watanabe S. Presence of bacterial 16S ribosomal RNA gene segments in human intestinal lymph follicles. Scand. J. Gastroenterol. 35: 824-831 (2000). *
Chiba M, Sugawara T, Tsuda H, Abe T, Tokairin T, Kashima Y. Esophageal ulcer of Crohn's disease: disappearance in 1 week with infliximab. Inflamm. Bowel Dis. 15: 1121-1122 (2009).
Chicharro M, Guarner L, Vilaseca J, Planas M, Malagelada J. Does cyclosporin A worsen liver function in patients with inflammatory bowel disease and total parenteral nutrition? Rev. Esp. Enferm. Dig. 92: 68-77 (2000).
Chiche L. A complicated case of Crohn's disease. J. Chir. (Paris) 142: 49-53 (2005).
Chin AC, Lee WY, Nusrat A, Vergnolle N, Parkos CA. Neutrophil-mediated activation of epithelial protease-activated receptors-1 and -2 regulates barrier function and transepithelial migration. J. Immunol. 181: 5702-5710 (2008). *
Chin AC, Parkos CA. Neutrophil transepithelial migration and epithelial barrier function in IBD: potential targets for inhibiting neutrophil trafficking. Ann. N. Y. Acad. Sci. 1072: 276-287 (2006). *
Chinen H, Matsuoka K, Sato T, Kamada N, Okamoto S, Hisamatsu T, Kobayashi T, Hasegawa H, Sugita A, Kinjo F, Fujita J, Hibi T. Lamina propria c-kit(+) immune precursors reside in human adult intestine and differentiate into natural killer cells. Gastroenterology 133: 559-573 (2007). *
Chiodini RJ. Crohn's disease and the mycobacterioses: a review and comparison of two disease entities. Clin. Microbiol. Rev. 2: 90-117 (1989). *
Chiodini RJ, Van Kruiningen HJ, Merkal RS, Thayer WR Jr, Coutu JA. Characteristics of an unclassified Mycobacterium species isolated from patients with Crohn's disease. J. Clin. Microbiol. 20: 966-971 (1984). *
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA. Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. J. Clin. Microbiol. 24: 357-363 (1986). *
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA, Merkal RS. In vitro antimicrobial susceptibility of a Mycobacterium sp. isolated from patients with Crohn's disease. Antimicrob. Agents Chemother. 26: 930-932 (1984). *
Chiodini RJ, Van Kruiningen HJ, Thayer WR, Merkal RS, Coutu JA. Possible role of mycobacteria in inflammatory bowel disease. I. An unclassified Mycobacterium species isolated from patients with Crohn's disease. Dig. Dis. Sci. 29: 1073-1079 (1984).
Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn's disease. Am. J. Gastroenterol. 102: 2541-2550 (2007). *
Cho HS, Byun TJ, Ahn SB, Kim TY, Eun CS, Jeon YC, Kim YS, Han DS. A case of familial Crohn's disease observed in a parent and his offspring. Korean J. Gastroenterol. 52: 247-250 (2008).
Cho J. Genetic aspects of inflammatory bowel disease: how far have we come, and where are we heading? Curr. Gastroenterol. Rep. 1: 491-495 (1999).
Cho J. Genetic advances in inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 9: 191-200 (2006).
Cho J. Update on inflammatory bowel disease genetics. Curr. Gastroenterol. Rep. 2: 434-439 (2000).
Cho JH. Advances in the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 6: 467-473 (2004).
Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat. Rev. Immunol. 8: 458-466 (2008). *
Cho JH. Inflammatory bowel disease: genetic and epidemiologic considerations. World J. Gastroenterol. 14: 338-347 (2008). *
Cho JH. Significant role of genetics in IBD: the NOD2 gene. Rev. Gastroenterol. Disord. 3 Suppl. 1: S18-S22 (2003). *
Cho JH. Update on the genetics of inflammatory bowel disease. Curr. Gastroenterol. Rep. 3: 458-463 (2001).
Cho JH. The Nod2 gene in Crohn's disease: implications for future research into the genetics and immunology of Crohn's disease. Inflamm. Bowel Dis. 7: 271-275 (2001). *
Cho JH, Abraham C. Inflammatory bowel disease genetics: Nod2. Annu. Rev. Med. 58: 401-416 (2007). *
Cho JH, Nicolae DL, Gold LH, Fields CT, LaBuda MC, Rohal PM, Pickles MR, Qin L, Fu Y, Mann JS, Kirschner BS, Jabs EW, Weber J, Hanauer SB, Bayless TM, Brant SR. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc. Natl. Acad. Sci. U.S.A. 95: 7502-7507 (1998). *
Cho JH, Nicolae DL, Ramos R, Fields CT, Rabenau K, Corradino S, Brant SR, Espinosa R, LeBeau M, Hanauer SB, Bodzin J, Bonen DK. Linkage and linkage disequilibrium in chromosome band 1p36 in American Chaldeans with inflammatory bowel disease. Hum. Mol. Genet. 9: 1425-1432 (2000). *
Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 133: 1327-1339 (2007). *
Cho SM, Cho SW, Regueiro M. Postoperative management of Crohn disease. Gastroenterol. Clin. North Am. 38: 753-762 (2009).
Cho SM, Cho SW, Regueiro M. Postoperative management of Crohn disease. Med. Clin. North Am. 94: 179-188 (2010).
Choi KD, Song HJ, Kim JS, Jung HC, Song IS. Efficacy and safety of treatment with infliximab in Crohn's disease - the experience of single center in Korea. Korean J. Gastroenterol. 46: 48-55 (2005).
Choi PM, Kim WH. Colon cancer surveillance. Gastroenterol. Clin. North Am. 24: 671-687 (1995).
Choi PM, Targan SR. Immunomodulator therapy in inflammatory bowel disease. Dig. Dis. Sci. 39: 1885-1892 (1994).
Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 35: 950-954 (1994). *
Chon H, Choi B, Lee E, Lee S, Jeong G. Immunomodulatory effects of specific bacterial components of Lactobacillus plantarum KFCC11389P on the murine macrophage cell line RAW 264.7. J. Appl. Microbiol. 107: 1588-1597 (2009). *
Chong AK, Taylor A, Miller A, Hennessy O, Connell W, Desmond P. Capsule endoscopy vs. push enteroscopy and enteroclysis in suspected small-bowel Crohn's disease. Gastrointest. Endosc. 61: 255-261 (2005). *
Chong SK, Grossman A, Walker-Smith JA, Rees LH. Endocrine dysfunction in children with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 3: 529-534 (1984).
Chopra A, Pardi DS, Loftus EV Jr, Tremaine WJ, Egan LJ, Faubion WA, Hanson KA, Johnson TA, Sandborn WJ. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm. Bowel Dis. 12: 29-32 (2006). *
Chopra P, Kanoje V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin. Investig. Drugs 17: 1411-1425 (2008).
Chorny A, Gonzalez-Rey E, Varela N, Robledo G, Delgado M. Signaling mechanisms of vasoactive intestinal peptide on inflammatory conditions. Regul. Pept. 137: 67-74 (2006).
Chosa M, Soeta S, Ichihara N, Nishita T, Asari M, Matsumoto S, Amasaki H. Pathomechanism of cellular infiltration in the perivascular region of several organs in SAMP1/Yit mouse. J. Vet. Med. Sci. 71: 1553-1560 (2009). *
Chow DK, Leong RW. The use of tacrolimus in the treatment of inflammatory bowel disease. Expert Opin. Drug Saf. 6: 479-485 (2007).
Chow DK, Leong RW, Lai LH, Wong GL, Leung WK, Chan FK, Sung JJ. Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm. Bowel Dis. 14: 536-541 (2008). *
Chow DK, Sung JJ, Wu JC, Tsoi KK, Leong RW, Chan FK. Upper gastrointestinal tract phenotype of Crohn's disease is associated with early surgery and further hospitalization. Inflamm. Bowel Dis. 15: 551-557 (2009).
Chow JY, Carlstrom K, Barrett KE. Growth hormone reduces chloride secretion in human colonic epithelial cells via EGF receptor and extracellular regulated kinase. Gastroenterology 125: 1114-1124 (2003). *
Chowers Y, Allez M. Efficacy of anti-TNF in Crohn's disease: how does it work? Curr. Drug Targets Nov 17 [Epub ahead of print] (2009).
Chowers Y, Odes S, Bujanover Y, Eliakim R, Bar Meir S, Avidan B. The month of birth is linked to the risk of Crohn's disease in the Israeli population. Am. J. Gastroenterol. 99: 1974-1976 (2004). *
Chowers Y, Sela BA, Holland R, Fidder H, Simoni FB, Bar-Meir S. Increased levels of homocysteine in patients with Crohn's disease are related to folate levels. Am. J. Gastroenterol. 95: 3498-3502 (2000). *
Choy MY, Walker-Smith JA, Williams CB, MacDonald TT. Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn's disease and ulcerative colitis. Gut 31: 1365-1370 (1990). *
Choy P, Bissett I, Docherty J, Parry B, Merrie A. Stapled versus handsewn methods for ileocolic anastomoses. Cochrane Database Syst. Rev. 3: CD004320 (2007). *
Chrissafidou A, Malek M, Musch E. Experimental study on the use of intravenous immunoglobulin (IVIg) in patients with steroid-resistant Crohn's disease. Z. Gastroenterol. 45: 605-608 (2007).
Christ AD, Stevens AC, Koeppen H, Walsh S, Omata F, Devergne O, Birkenbach M, Blumberg RS. An interleukin 12-related cytokine is up-regulated in ulcerative colitis but not in Crohn's disease. Gastroenterology 115: 307-313 (1998). *
Christerson U, Keita AV, Soderholm JD, Gustafson-Svard C. Increased expression of protease-activated receptor-2 in mucosal mast cells in Crohn's ileitis. Journal of Crohn's and Colitis 3: 100-108 (2009).
Christerson U, Keita AV, Soderholm JD, Gustafson-Svarda C. Potential role of protease-activated receptor-2-stimulated activation of cytosolic phospholipase A2 in intestinal myofibroblast proliferation: implications for stricture formation in Crohn's disease. Journal of Crohn's and Colitis 3: 15-24 (2009). *
Christianakis E, Pashalidis N, Kokkinou S, Pitiakoudis M, Mplevrakis E, Chorti M, Rizos S, Filippou D. Acute jejunoileal obstruction due to a pseudopolyp in a child with undiagnosed Crohn disease: a case report. J. Med. Case Reports 2: 54 (2008). *
Christodoulou DK, Katsanos KH, Kitsanou M, Stergiopoulou C, Hatzis J, Tsianos EV. Frequency of extraintestinal manifestations in patients with inflammatory bowel disease in Northwest Greece and review of the literature. Dig. Liver Dis. 34: 781-786 (2002).
Christophers E. Comorbidities in psoriasis. J. Eur. Acad. Dermatol. Venereol. 20 Suppl. 2: 52-55 (2006). *
Christophers E. Comorbidities in psoriasis. Clin. Dermatol. 25: 529-534 (2007).
Chua KH, Hilmi I, Ng CC, Eng TL, Palaniappan S, Lee WS, Goh KL. Identification of NOD2/CARD15 mutations in Malaysian patients with Crohn's disease. J. Dig. Dis. 10: 124-130 (2009). *
Chuah JH, Kim DS, Allen C, Hollis L. Metastatic Crohn's disease of the ear. Int. J. Otolaryngol. 2009: 871567 (2009).
Chun A, Chadi RM, Korelitz BI, Colonna T, Felder JB, Jackson MH, Morgenstern EH, Rubin SD, Sacknoff AG, Gleim GM. Intravenous corticotrophin vs. hydrocortisone in the treatment of hospitalized patients with Crohn's disease: a randomized double-blind study and follow-up. Inflamm. Bowel Dis. 4: 177-181 (1998). *
Chung CC, Tsang WW, Kwok SY, Li MK. Laparoscopy and its current role in the management of colorectal disease. Colorectal Dis. 5: 528-543 (2003). *
Chung KM, Kim HS, Park SY, Lim SR, Ryang DY, Jeong HK, Lee WS, Park CH, Lee JH, Choi SK, Rew JS. The changes in incidence of Crohn's disease and intestinal tuberculosis in Korea. Korean J. Gastroenterol. 52: 351-358 (2008).
Chung WJ, Sontheimer H. Sulfasalazine inhibits the growth of primary brain tumors independent of nuclear factor-kappaB. J. Neurochem. 110: 182-193 (2009).
Chung Y, Dong C. Don’t leave home without it: the IL-23 visa to TH-17 cells. Nat. Immunol. 10: 236-238 (2009). *
Chung-Faye G, Hayee B, Maestranzi S, Donaldson N, Forgacs I, Sherwood R. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation. Inflamm. Bowel Dis. 13: 1374-1378 (2007). *
Chutkan R. Video capsule endoscopy in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 54. May 7-8 (2004). *
Chutkan R, Sternthal M, Janowitz HD. A family with collagenous colitis, ulcerative colitis, and Crohn's disease. Am. J. Gastroenterol. 95: 3640-3641 (2000). *
Ciantar M, Adlam DM. Treatment with infliximab: implications in oral surgery? A case report. Br. J. Oral Maxillofac. Surg. 45: 507-510 (2007).
Ciccia F, Bombardieri M, Principato A, Giardina A, Tripodo C, Porcasi R, Peralta S, Franco V, Giardina E, Craxi A, Pitzalis C, Triolo G. Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis. Arthritis Rheum. 60: 955-965 (2009). *
Cichoz-Lach H. Esophageal Crohn disease. South. Med. J. 101: 886 (2008).
Cichoz-Lach H, Celinnski K. Modern methods of endoscopic diagnosis of gastrointestinal tract. J. Physiol. Pharmacol. 58 Suppl. 3: 21-31 (2007). *
Ciclitira PJ, Ellis HJ, Evans DJ. A solid-phase radioimmunoassay for measurement of circulating antibody titres to wheat gliadin and its subfractions in patients with adult coeliac disease. J. Immunol. Methods 62: 231-239 (1983).
Ciga M, Oteiza F, Marzo J, Armendariz P, De Miguel M, Ortiz H. Treatment of perianal Crohn's disease. An. Sist. Sanit. Navar. 29: 367-386 (2006).
Cima RR, Anderson KJ, Larson DW, Dozois EJ, Hassan I, Sandborn WJ, Loftus EV, Pemberton JH. Internet use by patients in an inflammatory bowel disease specialty clinic. Inflamm. Bowel Dis. 13: 1266-1270 (2007). *
Cinemre H, Bilir C, Gokosmanoglu F, Kadakal F. Anti-Saccharomyces cerevisiae antibodies in acute myocardial infarction. J. Investig. Med. 55: 444-449 (2007).
Cingoz O. Ustekinumab. MAbs. 1: 216-221 (2009).
Cioffi U, De Simone M, Ferrero S, Ciulla MM, Lemos A, Contessini Avesani E. Synchronous adenocarcinoma and carcinoid tumor of the terminal ileum in a Crohn's disease patient. BMC Cancer 5: 157 (2005). *
Ciorba MA, Prakash C. Wireless capsule endoscopy in the diagnosis of small bowel Crohn's disease. Inflamm. Bowel Dis. 9: 276 (2003). *
Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G. Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol. Res. 46: 1-6 (2002). *
Cirone K, Morsella C, Romano M, Paolicchi F. Mycobacterium avium subsp. paratuberculosis in food and its relationship with Crohn's disease. Rev. Argent Microbiol. 39: 57-68 (2007).
Ciulla A, Tomasello G, Urso G, Sanzo A, Maiorana A, Castronovo G, Damiani S. Abrikossoff's tumour: report of a rare case in anal perianal region. Ann. Ital. Chir. 75: 87-89 (2004).
Civitavecchia G, Renda MC, Ruggeri RF, Maggio A, Renna S, Orlando A, Cottone M. IL-23R determines susceptibility in Crohn's disease in a Mediterranean area. Inflamm. Bowel Dis. 15: 317-318 (2009). *
Claise C, Johanet C, Bouhnik Y, Kapel N, Homberg JC, Poupon R. Antineutrophil cytoplasmic autoantibodies in autoimmune liver and inflammatory bowel diseases. Liver 16: 28-34 (1996).
Clancy R, Ren Z, Turton J, Pang G, Wettstein A. Molecular evidence for Mycobacterium avium subspecies paratuberculosis (MAP) in Crohn's disease correlates with enhanced TNF-alpha secretion. Dig. Liver Dis. 39: 445-451 (2007).
Clara I, Lix LM, Walker JR, Graff LA, Miller N, Rogala L, Rawsthorne P, Bernstein CN. The Manitoba IBD index: evidence for a new and simple indicator of IBD activity. Am. J. Gastroenterol. 104: 1754-1763 (2009). *
Clare DF, Alexander FC, Mike S, Dan G, Allan F, Lisa W, Peter HJ. Accelerated infliximab infusions are safe and well tolerated in patients with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 71-75 (2009).
Claret L, Miquel S, Vieille N, Ryjenkov DA, Gomelsky M, Darfeuille Michaud A. The flagellar sigma factor Flia regulates adhesion and invasion of Crohn's disease-associated Escherichia coli via a c-di-GMP-dependent pathway. J. Biol. Chem. 282: 33275-33283 (2007). *
Clark CA, Mehta BH, Pruchnicki MC, Rodis JL. The pharmacist's role in teaching methotrexate injection for patients with Crohn's disease. Am. J. Health Syst. Pharm. 63: 1792-1794 (2006). *
Clark IA. How TNF was recognized as a key mechanism of disease. Cytokine Growth Factor Rev. 18: 335-343 (2007).
Clark MP, Benjamin E, Alusi G. A rare case of Crohn's disease in head and neck surgery. J. Laryngol. Otol. 117: 146-147 (2003).
Clark NM, Marinis JM, Cobb BA, Abbott DW. MEKK4 sequesters RIP2 to dictate NOD2 signal specificity. Curr. Biol. 18: 1402-1408 (2008).
Clarke AR, Meniel V. The intestinal stem cell niche studied through conditional transgenesis. Ernst Schering Found. Symp. Proc. 5: 99-108 (2006).
Clarke BW, Cassara JE, Morgan DR. Crohn's disease of the esophagus with esophagobronchial fistula formation: a case report and review of the literature. Gastrointest. Endosc. Oct 19 [Epub ahead of print] (2009).
Clarke JO, Giday SA, Magno P, Shin EJ, Buscaglia JM, Jagannath SB, Mullin GE. How good is capsule endoscopy for detection of periampullary lesions? Results of a tertiary-referral center. Gastrointest. Endosc. 68: 267-272 (2008).
Clarke K, Sagunarthy R, Kansal S. RDW as an additional marker in inflammatory bowel disease/undifferentiated colitis. Dig. Dis. Sci. 53: 2521-2523 (2008). *
Clarkston WK, Presti ME, Petersen PF, Zachary PE Jr, Fan WX, Leonardi CL, Vernava AM 3rd, Longo WE, Kreeger JM. Role of Mycobacterium paratuberculosis in Crohn's disease: a prospective, controlled study using polymerase chain reaction. Dis. Colon Rectum 41: 195-199 (1998).
Claus J, Pringot J, Ghijselings L, Landen S. Small bowel obstruction by abricot pit in Crohn's disease. JBR-BTR 89: 329 (2006).
Clavel T, Haller D. Bacteria- and host-derived mechanisms to control intestinal epithelial cell homeostasis: implications for chronic inflammation. Inflamm. Bowel Dis. 13: 1153-1164 (2007). *
Clayton EM, Rea MC, Shanahan F, Quigley EM, Kiely B, Hill C, Ross RP. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am. J. Gastroenterol. 104: 1162-1169 (2009).
Clemente G, Sarno G, De Rose AM, Mele C, Ranucci G, Nuzzo G. Unexpected diagnosis of Crohn's disease after the ingestion of a dental bridge. Inflamm. Bowel Dis. 15: 812-813 (2009).
Click RE, Van Kampen CL. Short communication: progression of Johne's disease curtailed by a probiotic. J. Dairy Sci. 92: 4846-4851 (2009). *
Cloney DL, Sutphen JL, Borowitz SM, Frierson H Jr. Crohn's disease complicating cystic fibrosis. South. Med. J. 87: 81-83 (1994).
Coban S, Ensari A, Kuzu MA, Yalcin S, Palabiyikoglu M, Ormeci N. Cytomegalovirus infection in a patient with Crohn's ileocolitis. Can. J. Gastroenterol. 19: 109-111 (2005). *
Cobden I, Rothwell J, Axon AT. Intestinal permeability and screening tests for coeliac disease. Gut 21: 512-518 (1980). *
Cobrin GM, Abreu MT. Defects in mucosal immunity leading to Crohn's disease. Immunol. Rev. 206: 277-295 (2005). *
Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. Dig. Dis. Sci. 51: 2045-2047 (2006). *
Coccia EM, Remoli ME, Di Giacinto C, Del Zotto B, Giacomini E, Monteleone G, Boirivant M. Cholera toxin subunit B inhibits IL-12 and IFN-gamma production and signalling in experimental colitis and Crohn's disease. Gut 54: 1558-1564 (2005). *
Coeffier M, Gloro R, Boukhettala N, Aziz M, Lecleire S, Vandaele N, Antonietti M, Savoye G, Bole-Feysot C, Dechelotte P, Reimund JM, Ducrotte P. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am. J. Gastroenterol. Dec 8 [Epub ahead of print] (2009). *
Coeffier M, Marion-Letellier R, Dechelotte P. Potential for amino acids supplementation during inflammatory bowel diseases. Inflamm. Bowel Dis. 16: 518-524 (2010).
Coelho J, Soyer P, Pautrat K, Boudiaf M, Vahedi K, Reignier S, Valleur P, Marteau P. Management of ileal stenosis in patients with Crohn's disease. Gastroenterol. Clin. Biol. 33: F75-F81 (2009).
Cohavy O, Harth G, Horwitz M, Eggena M, Landers C, Sutton C, Targan SR, Braun J. Identification of a novel mycobacterial histone H1 homologue (HupB) as an antigenic target of pANCA monoclonal antibody and serum immunoglobulin A from patients with Crohn's disease. Infect. Immun. 67: 6510-6517 (1999). *
Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn's disease. J. Eur. Acad. Dermatol. Venereol. 23: 561-565 (2009). *
Cohen HD, Das KM. The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent. J. Clin. Gastroenterol. 40 Suppl. 3: S150-S154 (2006).
Cohen JD, Bournerias I, Buffard V, Paufler A, Chevalier X, Bagot M, Claudepierre P. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J. Rheumatol. 34: 380-385 (2007).
Cohen LB. Re: Disappearance of Crohn's ulcers in the terminal ileum after thalidomide therapy. Can J Gastroenterol 2004; 18(2): 101-104. Can. J. Gastroenterol. 18: 419 (2004).
Cohen R, Robinson D Jr, Paramore C, Fraeman K, Renahan K, Bala M. Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002. Inflamm. Bowel Dis. 14: 738-743 (2008). *
Cohen RD. Mycobacterium in Crohn's: something to ruminate about? Gastroenterology 128: 2167-2168 (2005). *
Cohen RD. The cost of Crohn's disease: drugs or surgery? BioDrugs 14: 331-344 (2000).
Cohen RD. Infliximab as first-line therapy for severe Crohn's disease? Inflamm. Bowel Dis. 8: 58-59 (2002). *
Cohen RD. Efficacy and safety of repeated infliximab infusions for Crohn's disease: 1-year clinical experience. Inflamm. Bowel Dis. 7 Suppl. 1: S17-S22 (2001). *
Cohen RD. Evolving medical therapies for ulcerative colitis. Curr. Gastroenterol. Rep. 4: 497-505 (2002).
Cohen RD, Bowie WR, Enns R, Flint J, Fitzgerald JM. Pulmonary actinomycosis complicating infliximab therapy for Crohn's disease. Thorax 62: 1013-1014 (2007).
Cohen RD, Larson LR, Roth JM, Becker RV, Mummert LL. The cost of hospitalization in Crohn's disease. Am. J. Gastroenterol. 95: 524-530 (2000). *
Cohen RD, Tsang JF, Hanauer SB. Infliximab in Crohn's disease: first anniversary clinical experience. Am. J. Gastroenterol. 95: 3469-3477 (2000). *
Cohen RD, Waters HC, Tang B, Rahman MI. Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm. Bowel Dis. 14: 1707-1714 (2008). *
Cohen SA, Gralnek IM, Ephrath H, Saripkin L, Meyers W, Sherrod O, Napier A, Gobin T. Capsule endoscopy may reclassify pediatric inflammatory bowel disease: a historical analysis. J. Pediatr. Gastroenterol. Nutr. 47: 31-36 (2008). *
Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathioprine and infliximab for Crohn's disease. Inflamm. Bowel Dis. 13: 1453-1454 (2007). *
Colina M, Govoni M, Orzincolo C, Trotta F. Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects. Arthritis Rheum. 61: 813-821 (2009). *
Coll P, Guttormsen AB, Berstad A. Gastrointestinal disease with elevated plasma homocysteine level. Tidsskr. Nor. Laegeforen. 119: 3577-3579 (1999).
Colleran G, Cronin K, Hanaghan J, O'Dowd M, Bennani F, Waldron R. Concurrent diagnosis of Crohn's disease and colorectal carcinoma in a young man with abdominal pain. Journal of Crohn's and Colitis 2: 333-336 (2008).
Colletti RB, Baldassano RN, Milov DE, Margolis PA, Bousvaros A, Crandall WV, Crissinger KD, D'Amico MA, Day AS, Denson LA, Dubinsky M, Ebach DR, Hoffenberg EJ, Kader HA, Keljo DJ, Leibowitz IH, Mamula P, Pfefferkorn MD, Qureshi MA. Variation in care in pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 49: 297-303 (2009).
Colli MV, Amaro TA, Pinto AL, Gaburri PD, Chebli JM. Azathioprine toxicity in Crohn's disease: incidence, approach and course. Rev. Assoc. Med. Bras. 54: 415-421 (2008).
Collingwood S, Witherington J. Therapeutic approaches towards the treatment of gastroinstestinal disorders. Drug News Perspect. 20: 139-144 (2007).
Collins CB, Ho J, Wilson TE, Wermers JD, Tlaxca JL, Lawrence MB, Solga M, Lannigan J, Rivera-Nieves J. CD44 deficiency attenuates chronic murine ileitis. Gastroenterology 135: 1993-2002 (2008). *
Collins MT, Lisby G, Moser C, Chicks D, Christensen S, Reichelderfer M, Hoiby N, Harms BA, Thomsen OO, Skibsted U, Binder V. Results of multiple diagnostic tests for Mycobacterium avium subsp. paratuberculosis in patients with inflammatory bowel disease and in controls. J. Clin. Microbiol. 38: 4373-4381 (2000). *
Collins P, Mpofu C, Watson A, Rhodes J. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst. Rev. 2: CD000279 (2006). *
Collins S, Denou E, Verdu E, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. Dig. Liver Dis. 41: 850-853 (2009).
Colman RW. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des. 12: 2599-2607 (2006).
Colombel JF. Efficacy and safety of adalimumab for the treatment of Crohn's disease in adults. Expert Rev. Gastroenterol. Hepatol. 2: 163-176 (2008).
Colombel JF. The CARD15 (also known as NOD2) gene in Crohn's disease: are there implications for current clinical practice? Clin. Gastroenterol. Hepatol. 1: 5-9 (2003). *
Colombel JF, Gower-Rousseau C. Etiology of Crohn disease. Current data. Presse. Med. 23: 558-560 (1994).
Colombel JF, Guillemot F, Van Gossum A, Dufosse F, Cortot A, Dupont E, Paris JC. Familial Crohn's disease in multiple siblings: no linkage to the HLA system. Gastroenterol. Clin. Biol. 13: 676-678 (1989).
Colombel JF, Loftus EV Jr, Tremaine WJ, Egan LJ, Harmsen WS, Schleck CD, Zinsmeister AR, Sandborn WJ. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 126: 19-31 (2004). *
Colombel JF, Loftus EV Jr, Tremaine WJ, Pemberton JH, Wolff BG, Young-Fadok T, Harmsen WS, Schleck CD, Sandborn WJ. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am. J. Gastroenterol. 99: 878-883 (2004). *
Colombel JF, Reumaux D, Duthilleul P, Noel LH, Gower-Rousseau C, Paris JC, Cortot A. Antineutrophil cytoplasmic autoantibodies in inflammatory bowel diseases. Gastroenterol. Clin. Biol. 16: 656-660 (1992).
Colombel JF, Ricart E, Loftus EV, Tremaine WJ, Young-Fadok T, Dozois EJ, Wolff BG, Devine R, Pemberton JH, Sandborn WJ. Management of Crohn's disease of the ileoanal pouch with infliximab. Am. J. Gastroenterol. 98: 2239-2244 (2003). *
Colombel JF, Rutgeerts P, Malchow H, Jacyna M, Nielsen OH, Rask-Madsen J, Van Deventer S, Ferguson A, Desreumaux P, Forbes A, Geboes K, Melani L, Cohard M. Interleukin 10 (Tenovil) in the prevention of postoperative recurrence of Crohn's disease. Gut 49: 42-46 (2001). *
Colombel JF, Sandborn WJ. Development of fistulae in ileo-anal pouch does not necessarily indicate Crohn's disease: response. Am. J. Gastroenterol. 99: 2067 (2004). *
Colombel JF, Sandborn WJ, Panaccione R, Robinson AM, Lau W, Li J, Cardoso AT. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm. Bowel Dis. 15: 1308-1319 (2009). *
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 132: 52-65 (2007). *
Colombel JF, Sandborn WJ, Rutgeerts P, Kamm MA, Yu AP, Wu EQ, Pollack PF, Lomax KG, Chao J, Mulani PM. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am. J. Gastroenterol. 104: 1170-1179 (2009). *
Colombel JF, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts PJ, Enns RA, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. Gut 58: 940-948 (2009). *
Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by CT enterography: correlation with endoscopic severity and C-reactive protein. Gut 55: 1561-1567 (2006). *
Colombel JF, Watson AJ, Neurath MF. The 10 remaining mysteries of inflammatory bowel disease. Gut 57: 429-433 (2008). *
Colombo PL, Benedetti M, Tinozzi FP, Ticozzelli E, Maroni N, Di Sabatino A, Tinozzi S. Different approaches for medical or surgical management of Crohn's disease: the importance of the classification of Vienna. Ann. Ital. Chir. 77: 485-496 (2006).
Colpaert S, Vanstraelen K, Liu Z, Penninckx F, Geboes K, Rutgeerts P, Ceuppens J. Decreased lamina propria effector cell responsiveness to interleukin-10 in ileal Crohn's disease. Clin. Immunol. 102: 68-76 (2002). *
Colpaert S, Vastraelen K, Liu Z, Maerten P, Shen C, Penninckx F, Geboes K, Rutgeerts P, Ceuppens JL. In vitro analysis of interferon gamma (IFN-gamma) and interleukin-12 (IL-12) production and their effects in ileal Crohn's disease. Eur. Cytokine Netw. 13: 431-437 (2002).
Comabella M, Altet L, Peris F, Villoslada P, Sanchez A, Montalban X. Genetic analysis of SLC11A1 polymorphisms in multiple sclerosis patients. Mult. Scler. 10: 618-620 (2004). *
Comalada M, Peppelenbosch MP. Impaired innate immunity in Crohn's disease. Trends Mol. Med. 12: 397-399 (2006). *
Comelli EM, Lariani S, Zwahlen MC, Fotopoulos G, Holzwarth JA, Cherbut C, Dorta G, Corthesy-Theulaz I, Grigorov M. Biomarkers of human gastrointestinal tract regions. Mamm. Genome 20: 516-527 (2009). *
Comerford LW, Bickston SJ. Treatment of luminal and fistulizing Crohn's disease with infliximab. Gastroenterol. Clin. North Am. 33: 387-406 (2004).
Comes MC, Gower-Rousseau C, Colombel JF, Belaiche J, Van Kruiningen HJ, Nuttens MC, Cortot A. Inflammatory bowel disease in married couples: 10 cases in Nord Pas de Calais region of France and Liege county of Belgium. Gut 35: 1316-1318 (1994). *
Cominelli F. Cytokine-based therapies for Crohn's disease - new paradigms. N. Engl. J. Med. 351: 2045-2048 (2004). *
Cominelli F, Pizarro TT. Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment. Pharmacol. Ther. 10 Suppl. 2: 49-53 (1996).
Comite de nutrition de la Societe francaise de pediatrie. Nutritional treatment in childhood Crohn's disease. Arch. Pediatr. 12: 1255-1266 (2005).
Condino AA, Fidanza S, Hoffenberg EJ. A home infliximab infusion program. J. Pediatr. Gastroenterol. Nutr. 40: 67-69 (2005). *
Condino AA, Hoffenberg EJ, Accurso F, Penvari C, Anthony M, Gralla J, O'Connor JA. Frequency of ASCA seropositivity in children with cystic fibrosis. J. Pediatr. Gastroenterol. Nutr. 41: 23-26 (2005). *
Cong Y, Yang XG, Lv W, Xue Y. Prediction of novel and selective TNF-alpha converting enzyme (TACE) inhibitors and characterization of correlative molecular descriptors by machine learning approaches. J. Mol. Graph Model. 28: 236-244 (2009). *
Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 21: 311-323 (1999).
Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 34: 1081-1085 (1993). *
Connolly MP, Nielsen SK, Currie CJ, Poole CD, Travis SP. An economic evaluation comparing once daily with twice daily mesalazine for maintaining remission based on results from a randomised controlled clinical trial. Journal of Crohn's and Colitis 3: 32-37 (2009). *
Connor SJ, Paraskevopoulos N, Newman R, Cuan N, Hampartzoumian T, Lloyd AR, Grimm MC. CCR2 expressing CD4+ T lymphocytes are preferentially recruited to the ileum in Crohn's disease. Gut 53: 1287-1294 (2004). *
Conrad K, Schmechta H, Klafki A, Lobeck G, Uhlig HH, Gerdi S, Henker J. Serological differentiation of inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 14: 129-135 (2002).
Conscience I, Perceau G, Durlach A, Bernard P. Vulvar involvement in Crohn's disease: efficacy of metronidazole. Ann. Dermatol. Venereol. 133: 585-587 (2006).
Consigny Y, Modigliani R, Colombel JF, Dupas JL, Lemann M, Mary JY; Groupe d'Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). A simple biological score for predicting low risk of short-term relapse in Crohn's disease. Inflamm. Bowel Dis. 12: 551-557 (2006). *
Consolo P, Strangio G, Luigiano C, Giacobbe G, Pallio S, Familiari L. Optical coherence tomography in inflammatory bowel disease: prospective evaluation of 35 patients. Dis. Colon Rectum 51: 1374-1380 (2008). *
Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 55: 1760-1767 (2006). *
Contessini Avesani E, Vicentini L, Carrara A, Botti F, Reduzzi R, Dallera P. Surgical treatment of Crohn's disease. Indication and management in 20 patients. Minerva Gastroenterol. Dietol. 44: 17-21 (1998).
Conti F, Borrelli O, Anania C, Marocchi E, Romeo EF, Paganelli M, Valesini G, Cucchiara S. Chronic intestinal inflammation and seronegative spondyloarthropathy in children. Dig. Liver Dis. 37: 761-767 (2005).
Coogan PF, Rosenberg L. The use of folic acid antagonists and the risk of colorectal cancer. Pharmacoepidemiol. Drug Saf. 16: 1111-1119 (2007).
Cook L, Al-Hendawi E, Bates AW, Brennan M, Salvestrini C, Malik M, Torrente F, Ogunbiyi O, Lewis A, Heuschkel RB. Limited ileo-caecal resection for localised Crohn’s disease in childhood: clinical outcome and predictors of further surgery. Journal of Crohn's and Colitis 1: 82-86 (2007).
Cook LS. A causal role for Mycobacterium avium subspecies paratuberculosis in Crohn's disease? Can. J. Gastroenterol. 14: 479-480 (2000).
Cooke DM. Inflammatory bowel disease: primary health care management of ulcerative colitis and Crohn's disease. Nurse Pract. 16: 27-30, 35-36, 38-39 (1991).
Cooney R, Baker J, Brain O, Danis B, Pichulik T, Allan P, Ferguson DJ, Campbell BJ, Jewell D, Simmons A. NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation. Nat. Med. 16: 90-97 (2010). *
Cooney R, Cummings JR, Pathan S, Beckly J, Geremia A, Hancock L, Guo C, Morris A, Jewell DP. Association between genetic variants in myosin IXB and Crohn's disease. Inflamm. Bowel Dis. 15: 1014-1021 (2009). *
Cooney R, Jewell D. The genetic basis of inflammatory bowel disease. Dig. Dis. 27: 428-442 (2009).
Cooper JG, Purcell GP. Data mining for correlations between diet and Crohn's disease activity. AMIA Annu. Symp. Proc. 2006: 897 (2006). *
Cooper T, Savige J, Nassis L, Paspaliaris B, Neeson P, Neil J, Knight KR, Daskalakis M, Doery JC. Clinical associations and characterisation of antineutrophil cytoplasmic antibodies directed against bactericidal/permeability-increasing protein and azurocidin. Rheumatol. Int. 19: 129-136 (2000). *
Coppi LC, Thomazzi SM, Ayrizono MD, Coy CS, Fagundes JJ, Goes JR, Franchi GC Jr, Nowill AE, Montes CG, Antunes E, Ferraz JG. Comparative study of eosinophil chemotaxis, adhesion, and degranulation in vitro in ulcerative colitis and Crohn's disease. Inflamm. Bowel Dis. 13: 211-218 (2007). *
Corbaz A, ten Hove T, Herren S, Graber P, Schwartsburd B, Belzer I, Harrison J, Plitz T, Kosco-Vilbois MH, Kim SH, Dinarello CA, Novick D, van Deventer S, Chvatchko Y. IL-18-binding protein expression by endothelial cells and macrophages is up-regulated during active Crohn's disease. J. Immunol. 168: 3608-3616 (2002). *
Coremans G, Dockx S, Wyndaele J, Hendrickx A. Do anal fistulas in Crohn's disease behave differently and defy Goodsall's rule more frequently than fistulas that are cryptoglandular in origin? Am. J. Gastroenterol. 98: 2732-2735 (2003). *
Corleto VD, Pagnini C, Margagnoni G, Guagnozzi D, Torre MS, Martorelli M, Latiano A, Annese V, Caprilli R, Delle Fave G. IL-1beta-511 and IL-1RN*2 polymorphisms in inflammatory bowel disease: an Italian population study and meta-analysis of European studies. Dig. Liver Dis. Jul 28 [Epub ahead of print] (2009).
Cormier K, Mager D, Bannister L, Fortin M, Richards H, Jackson C, Pencharz P. Resting energy expenditure in the parenterally fed pediatric population with Crohn's disease. JPEN J. Parenter. Enteral Nutr. 29: 102-107 (2005). *
Cornelio Rde C, Pinto AL, Pace FH, Moraes JP, Chebli JM. Non-adherence to the therapy in Crohn's disease patients: prevalence and risk factors. Arq. Gastroenterol. 46: 183-189 (2009).
Cornelis S, Kersse K, Festjens N, Lamkanfi M, Vandenabeele P. Inflammatory caspases: targets for novel therapies. Curr. Pharm. Des. 13: 367-385 (2007).
Cornes JS, Stecher M. Primary Crohn's disease of the colon and rectum. Gut 2: 189-201 (1961). *
Cornillie F. Ten years of infliximab (Remicade(R)) in clinical practice: the story from bench to bedside. Eur. J. Pharmacol. Oct 15 [Epub ahead of print] (2009). *
Cornillie F, Shealy D, D'Haens G, Geboes K, Van Assche G, Ceuppens J, Wagner C, Schaible T, Plevy SE, Targan SR, Rutgeerts P. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment. Pharmacol. Ther. 15: 463-473 (2001). *
Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am. J. Gastroenterol. 103: 2394-2400 (2008). *
Cornish JA, Tan EK, Teare J, Teoh TG, Rai R, Clark SK, Tekkis PP. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut 56: 830-837 (2007). *
Corporaal S, Karrenbeld A, van der Linde K, Voskuil JH, Kleibeuker JH, Dijkstra G. Diffuse enteritis after colectomy for ulcerative colitis: two case reports and review of the literature. Eur. J. Gastroenterol. Hepatol. 21: 710-715 (2009).
Corrao G, Tragnone A, Caprilli R, Trallori G, Papi C, Andreoli A, Di Paolo M, Riegler G, Rigo GP, Ferrau O, Mansi C, Ingrosso M, Valpiani D. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: a nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int. J. Epidemiol. 27: 397-404 (1998). *
Correa I, Veny M, Esteller M, Pique JM, Yague J, Panes J, Salas A. Defective IL-10 production in severe phenotypes of Crohn's disease. J. Leukoc. Biol. 85: 896-903 (2009). *
Corti S, Stephan R. Detection of Mycobacterium avium subspecies paratuberculosis specific IS900 insertion sequences in bulk-tank milk samples obtained from different regions throughout Switzerland. BMC Microbiol. 2: 15 (2002). *
Coruzzi P, Castiglioni P, Parati G, Brambilla V, Brambilla L, Gualerzi M, Cademartiri F, Franze A, De Angelis G, Di Rienzo M, Di Mario F. Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn's disease. Eur. J. Clin. Invest. 37: 964-970 (2007). *
Cosnes J. Can we modulate the clinical course of inflammatory bowel diseases by our current treatment strategies? Dig. Dis. 27: 516-521 (2009).
Cosnes J. Understanding the opposite effects of smoking in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 48. May 7-8 (2004). *
Cosnes J. Tobacco and IBD: relevance in the understanding of disease mechanisms and clinical practice. Best Pract. Res. Clin. Gastroenterol. 18: 481-496 (2004).
Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre JP. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut 45: 218-222 (1999). *
Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn's disease. Inflamm. Bowel Dis. 8: 244-250 (2002). *
Cosnes J, Nion-Larmurier I, Afchain P, Beaugerie L, Gendre JP. Gender differences in the response of colitis to smoking. Clin. Gastroenterol. Hepatol. 2: 41-48 (2004). *
Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 54: 237-241 (2005). *
Cosnes J, Seksik P, Nion-Larmurier I, Beaugerie L, Gendre JP. Prior appendectomy and the phenotype and course of Crohn's disease. World J. Gastroenterol. 12: 1235-1242 (2006). *
Costa C, Incio J, Soares R. Angiogenesis and chronic inflammation: cause or consequence? Angiogenesis 10: 149-166 (2007). *
Costa F, Mumolo MG, Bellini M, Romano MR, Ceccarelli L, Arpe P, Sterpi C, Marchi S, Maltinti G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis. 35: 642-647 (2003).
Costa F, Mumolo MG, Ceccarelli L, Bellini M, Romano MR, Sterpi C, Ricchiuti A, Marchi S, Bottai M. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease. Gut 54: 364-368 (2005). *
Costa-Romero M, Coto-Segura P, Suarez-Saavedra S, Ramos-Polo E, Santos-Juanes J. Guttate psoriasis induced by infliximab in a child with Crohn's disease. Inflamm. Bowel Dis. 14: 1462-1463 (2008). *
Costas Armada P, Garcia-Mayor RV, Larranaga A, Seguin P, Perez Mendez LF. Rate of undernutrition and response to specific nutritional therapy in Crohn's disease. Nutr. Hosp. 24: 161-166 (2009).
Coste A, Dubuquoy L, Barnouin R, Annicotte JS, Magnier B, Notti M, Corazza N, Antal MC, Metzger D, Desreumaux P, Brunner T, Auwerx J, Schoonjans K. LRH-1-mediated glucocorticoid synthesis in enterocytes protects against inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 104: 13098-13103 (2007). *
Costello CM, Mah N, Hasler R, Rosenstiel P, Waetzig GH, Hahn A, Lu T, Gurbuz Y, Nikolaus S, Albrecht M, Hampe J, Lucius R, Kloppel G, Eickhoff H, Lehrach H, Lengauer T, Schreiber S. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med. 2: e199 (2005). *
Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease. Aliment. Pharmacol. Ther. 29: 1032-1041 (2009). *
Cottier H, Hassig A. Immunoglobulin in chronic inflammatory diseases. Vox. Sang. 51 Suppl. 2: 39-43 (1986).
Cottone M. Recurrent disease after resection for Crohn's disease: is it preventable? Inflamm. Bowel Dis. 12 Suppl. 3: S13-S14 (2006).
Cottone M, Cipolla C, Rosselli M. Epidemiology and pathogenesis of Crohn's disease. Chir. Ital. 47: 1-7 (1995).
Cottone M, Marrone C, Casa A, Oliva L, Orlando A, Calabrese E, Martorana G, Pagliaro L. Familial occurrence of inflammatory bowel disease in celiac disease. Inflamm. Bowel Dis. 9: 321-323 (2003). *
Cottone M, Martorana G, Di Mitri R, Camma C, Caprilli R. Epidemiology of inflammatory bowel disease in Italy. Ital. J. Gastroenterol. Hepatol. 31: 503-507 (1999).
Cottone M, Mocciaro F, Modesto I. Infliximab and ulcerative colitis. Expert Opin. Biol. Ther. 6: 401-408 (2006).
Cottone M, Mocciaro F, Orlando A. Infliximab prevents Crohn's disease recurrence after ileal resection. Expert Rev. Gastroenterol. Hepatol. 3: 231-234 (2009).
Cottone M, Mocciaro F, Scimeca D. Adalimumab induction for Crohn's disease. Gastroenterology 130: 1929 (2006). *
Cottone M, Orlando A, Modesto I. Postoperative maintenance therapy for inflammatory bowel disease. Curr. Opin. Gastroenterol. 22: 377-381 (2006).
Cottone M, Orlando A, Viscido A, Calabrese E, Camma C, Casa A. Review article: prevention of postsurgical relapse and recurrence in Crohn's disease. Aliment. Pharmacol. Ther. 17 Suppl. 2: 38-42 (2003). *
Cottone M, Renda MC, Mattaliano A, Oliva L, Fries W, Criscuoli V, Modesto I, Scimeca D, Maggio A, Casa A, Maisano S, Mocciaro F, Sferrazza A, Orlando A. Incidence of Crohn's disease and CARD15 mutation in a small township in Sicily. Eur. J. Epidemiol. 21: 887-892 (2006). *
Coulombe F, Behr MA. Crohn's disease as an immune deficiency? Lancet 374: 769-770 (2009). *
Courville EL, Siegel CA, Vay T, Wilcox AR, Suriawinata AA, Srivastava A. Isolated asymptomatic ileitis does not progress to overt Crohn disease on long-term follow-up despite features of chronicity in ileal biopsies. Am. J. Surg. Pathol. 33: 1341-1347 (2009).
Coury F, Annels N, Rivollier A, Olsson S, Santoro A, Speziani C, Azocar O, Flacher M, Djebali S, Tebib J, Brytting M, Egeler RM, Rabourdin-Combe C, Henter JI, Arico M, Delprat C. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat. Med. 14: 81-87 (2008). *
Coussens PM. Mycobacterium paratuberculosis and the bovine immune system. Anim. Health Res. Rev. 2: 141-161 (2001).
Cox DG, Crusius JB, Peeters PH, Bueno-de-Mesquita HB, Pena AS, Canzian F. Haplotype of prostaglandin synthase 2/cyclooxygenase 2 is involved in the susceptibility to inflammatory bowel disease. World J. Gastroenterol. 11: 6003-6008 (2005). *
Cox J. Inflammatory bowel disease: implications for the medical-surgical nurse. Medsurg. Nurs. 4: 427-434 (1995).
Cox KL, Cox KM. Oral vancomycin: treatment of primary sclerosing cholangitis in children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 27: 580-583 (1998). *
Coyne JD. Crohn's disease with inflammatory splenic granuloma. J. Clin. Pathol. 59: 889 (2006). *
Coyne K, Joshua-Gotlib S, Kimel M, Thompson C, Lewis A, Danilewitz M. Validation of the treatment satisfaction questionnaire for Crohn's disease (TSQ-C). Dig. Dis. Sci. 50: 252-258 (2005). *
Cozzi F, Podswiadek M, Cardinale G, Oliviero F, Dani L, Sfriso P, Punzi L. Mud-bath treatment in spondylitis associated with inflammatory bowel disease - a pilot randomised clinical trial. Joint Bone Spine 74: 436-439 (2007). *
Craggs A, Welfare M, Donaldson PT, Mansfield JC. The CC chemokine receptor 5 delta32 mutation is not associated with inflammatory bowel disease (IBD) in NE England. Genes Immun. 2: 114-116 (2001). *
Craggs A, West S, Curtis A, Welfare M, Hudson M, Donaldson P, Mansfield J. Absence of a genetic association between IL-1RN and IL-1B gene polymorphisms in ulcerative colitis and Crohn disease in multiple populations from northeast England. Scand. J. Gastroenterol. 36: 1173-1178 (2001). *
Craig D, Robins G, Howdle PD. Advances in celiac disease. Curr. Opin. Gastroenterol. 23: 142-148 (2007).
Craig RM, Traynor A, Oyama Y, Burt RK. Hematopoietic stem cell transplantation for severe Crohn's disease. Bone Marrow Transplant. 32 Suppl. 1: S57-S59 (2003). *
Crandall W, Hyams J, Kugathasan S, Griffiths A, Zrubek J, Olson A, Liu G, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano RN. Infliximab therapy in children with concurrent perianal Crohn disease: observations from REACH. J. Pediatr. Gastroenterol. Nutr. 49: 183-190 (2009).
Crane AM, Bradbury L, van Heel DA, McGovern DP, Brophy S, Rubin L, Siminovitch KA, Wordsworth BP, Calin A, Brown MA. Role of NOD2 variants in spondylarthritis. Arthritis Rheum. 46: 1629-1633 (2002). *
Cravo ML, Albuquerque CM, Salazar de Sousa L, Gloria LM, Chaves P, Dias Pereira A, Nobre Leitao C, Quina MG, Costa Mira F. Microsatellite instability in non-neoplastic mucosa of patients with ulcerative colitis: effect of folate supplementation. Am. J. Gastroenterol. 93: 2060-2064 (1998). *
Crawford NP, Colliver DW, Eichenberger MR, Funke AA, Kolodko V, Cobbs GA, Petras RE, Galandiuk S. CARD15 genotype-phenotype relationships in a small inflammatory bowel disease population with severe disease affection status. Dig. Dis. Sci. 52: 2716-2724 (2007). *
Crawford NP, Colliver DW, Funke AA, Young MN, Kelley S, Cobbs GA, Petras RE, Galandiuk S. Characterization of genotype-phenotype relationships and stratification by the CARD15 variant genotype for inflammatory bowel disease susceptibility loci using multiple short tandem repeat genetic markers. Hum. Mutat. 25: 156-166 (2005). *
Crawford NP, Eichenberger MR, Colliver DW, Lewis RK, Cobbs GA, Petras RE, Galandiuk S. Evaluation of Slc11a1 as an inflammatory bowel disease candidate gene. BMC Med. Genet. 6: 10 (2005). *
Crema MD, Richarme D, Azizi L, Hoeffel CC, Tubiana JM, Arrive L. Pouchography, CT, and MRI features of ileal J pouch-anal anastomosis. AJR Am. J. Roentgenol. 187: W594-W603 (2006). *
Cremon C, Pallotti F, Bacchilega M, Stanghellini V, Corinaldesi R, Barbara G. Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis. Expert Rev. Gastroenterol. Hepatol. 2: 735-740 (2008).
Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin. Nutr. 27: 328-339 (2008).
Cresti S, Ouaissi M, Sielezneff I, Chaix JB, Pirro N, Berthet B, Consentino B, Sastre B. Advantage of vacuum assisted closure on healing of wound associated with omentoplasty after abdominoperineal excision: a case report. World J. Surg. Oncol. 6: 136 (2008). *
Criscuoli V, Casa A, Orlando A, Pecoraro G, Oliva L, Traina M, Rizzo A, Cottone M. Severe acute colitis associated with CMV: a prevalence study. Dig. Liver Dis. 36: 818-820 (2004).
Crispino P, Pica R, Angelucci E, Consolazio A, Rivera M, Cassieri C, Paoluzi P. Hematological malignancies in chronic inflammatory bowel diseases: report of five cases and review of the literature. Int. J. Colorectal Dis. 22: 553-558 (2007). *
Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK. Analysis of families in the Multiple Autoimmune Disease Genetics Consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am. J. Hum. Genet. 76: 561-571 (2005). *
Croese J, Wood MJ, Melrose W, Speare R. Allergy controls the population density of Necator americanus in the small intestine. Gastroenterology 131: 402-409 (2006). *
Crohn BB. Psychic factors affecting the course of chronic ulcerative colitis. Gastroenterology 12: 325-327 (1949).
Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathologic and clinical entity. 1932. Mt. Sinai J. Med. 67: 263-268 (2000).
Crohn K, Birnbaum M. Environmental education evaluation: time to reflect, time for change. Eval. Program Plann. Aug 3 [Epub ahead of print] (2009).
Croitoru K, Zhou P. T-cell-induced mucosal damage in the intestine. Curr. Opin. Gastroenterol. 20: 581-586 (2004).
Crook DW, Knuesel PR, Froehlich JM, Eigenmann F, Unterweger M, Beer HJ, Kubik-Huch RA. Comparison of magnetic resonance enterography and video capsule endoscopy in evaluating small bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 54-65 (2009).
Cross R. Another anti-TNF therapy for patients with Crohn's disease. Inflamm. Bowel Dis. 14: 425-427 (2008). *
Cross RK, Binion DG. Narcotic use in patients with Crohn's disease: reply from Drs. Cross and Binion. Am. J. Gastroenterol. 101: 1397-1398 (2006). *
Cross RK, Jung C, Wasan S, Joshi G, Sawyer R, Roghmann MC. Racial differences in disease phenotypes in patients with Crohn's disease. Inflamm. Bowel Dis. 12: 192-198 (2006). *
Cross RK, Lapshin O, Finkelstein J. Patient subjective assessment of drug side effects in inflammatory bowel disease. J. Clin. Gastroenterol. 42: 244-251 (2008).
Cross RK, Wilson KT. Nitric oxide in inflammatory bowel disease. Inflamm. Bowel Dis. 9: 179-189 (2003). *
Cross RK, Wilson KT, Binion DG. Polypharmacy and Crohn's disease. Aliment. Pharmacol. Ther. 21: 1211-1216 (2005). *
Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am. J. Gastroenterol. 100: 2225-2259 (2005). *
Croucher PJ, Mascheretti S, Hampe J, Huse K, Frenzel H, Stoll M, Lu T, Nikolaus S, Yang SK, Krawczak M, Kim WH, Schreiber S. Haplotype structure and association to Crohn's disease of CARD15 mutations in two ethnically divergent populations. Eur. J. Hum. Genet. 11: 6-16 (2003). *
Crowson AN, Nuovo GJ, Mihm MC Jr, Magro C. Cutaneous manifestations of Crohn's disease, its spectrum, and its pathogenesis: intracellular consensus bacterial 16S rRNA is associated with the gastrointestinal but not the cutaneous manifestations of Crohn's disease. Hum. Pathol. 34: 1185-1192 (2003). *
Crumbock SC, Loeb SJ, Fick DM. Physical activity, stress, disease activity, and quality of life in adults with Crohn disease. Gastroenterol. Nurs. 32: 188-195 (2009).
Cruyssen BV, Peeters H, Hoffman IE, Laukens D, Coucke P, Marichal D, Cuvelier C, Remaut E, Veys EM, Mielants H, De Vos M, De Keyser F. CARD15 polymorphisms are associated with anti-Saccharomyces cerevisiae antibodies in Caucasian Crohn's disease patients. Clin. Exp. Immunol. 140: 354-359 (2005). *
Cserni T, Szekeres JP, Furka I, Nemeth N, Jozsa T, Miko I. Hydrostatic characteristics of the ileocolic valve and intussuscepted nipple valves: an animal model. J. Invest. Surg. 18: 185-191 (2005). *
Csernok E, Ai M, Gross WL, Wicklein D, Petersen A, Lindner B, Lamprecht P, Holle JU, Hellmich B. Wegener's autoantigen induces maturation of dendritic cells and licences them for TH1 priming via the protease-activated receptor-2 pathway. Blood 107: 4440-4448 (2006). *
Csillag C, Borup R, Olsen J, Nielsen FC, Nielsen OH. Treatment response and colonic gene expression in patients with Crohn's disease. Scand. J. Gastroenterol. 42: 834-840 (2007). *
Csillag C, Nielsen OH, Borup R, Nielsen FC. Microarrays and Crohn's disease: collecting reliable information. Scand. J. Gastroenterol. 40: 369-377 (2005). *
Csillag C, Nielsen OH, Borup R, Nielsen FC, Olsen J. Clinical phenotype and gene expression profile in Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G298-G304 (2007). *
Csillag C, Nielsen OH, Borup R, Olsen J, Bjerrum JT, Nielsen FC. CARD15 status and familial predisposition for Crohn's disease and colonic gene expression. Dig. Dis. Sci. 52: 1783-1789 (2007). *
Csillag C, Nielsen OH, Vainer B, Olsen J, Dieckgraefe BK, Hendel J, Vind I, Dupuy C, Nielsen FC, Borup R. Expression of the genes dual oxidase 2, lipocalin 2 and regenerating islet-derived 1 alpha in Crohn's disease. Scand. J. Gastroenterol. 42: 454-463 (2007). *
Csongei V, Jaromi L, Safrany E, Sipeky C, Magyari L, Farago B, Bene J, Polgar N, Lakner L, Sarlos P, Varga M, Melegh B. Interaction of the major inflammatory bowel disease susceptibility alleles in Crohn's disease patients. World J. Gastroenterol. 16: 176-183 (2010). *
Cuadrado E, Alonso M, de Juan MD, Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with adacolumn granulocytapheresis. World J. Gastroenterol. 14: 1521-1527 (2008). *
Cucchiara S, Escher JC, Hildebrand H, Amil-Dias J, Stronati L, Ruemmele FM. Pediatric inflammatory bowel diseases and the risk of lymphoma: should we revise our treatment strategies? J. Pediatr. Gastroenterol. Nutr. 48: 257-267 (2009).
Cucchiara S, Latiano A, Palmieri O, Canani RB, D'Inca R, Guariso G, Vieni G, De Venuto D, Riegler G, De'Angelis GL, Guagnozzi D, Bascietto C, Miele E, Valvano MR, Bossa F, Annese V; Italian Society of Pediatric Gastroenterology and Nutrition. Polymorphisms of tumor necrosis factor-alpha but not MDR1 influence response to medical therapy in pediatric-onset inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44: 171-179 (2007). *
Cucchiara S, Latiano A, Palmieri O, Staiano AM, D'Inca R, Guariso G, Vieni G, Rutigliano V, Borrelli O, Valvano MR, Annese V. Role of CARD15, DLG5 and OCTN genes polymorphisms in children with inflammatory bowel diseases. World J. Gastroenterol. 13: 1221-1229 (2007). *
Cucchiara S, Morley-Fletcher A. "New drugs: kids come first": children should be included in trials of new biological treatments. Inflamm. Bowel Dis. 13: 1165-1169 (2007). *
Cucchiara S, Romeo E, Viola F, Cottone M, Fontana M, Lombardi G, Rutigliano V, De'Angelis GL, Federici T. Infliximab for pediatric ulcerative colitis: a retrospective Italian multicenter study. Dig. Liver Dis. 40 Suppl. 2: S260-S264 (2008).
Cucino C, Sonnenberg A. The comorbid occurrence of other diagnoses in patients with ulcerative colitis and Crohn's disease. Am. J. Gastroenterol. 96: 2107-2112 (2001). *
Cucino C, Sonnenberg A. Cause of death in patients with inflammatory bowel disease. Inflamm. Bowel Dis. 7: 250-255 (2001). *
Cuenca F, Garcia Paredes J, Mendoza J, Cruz D, Herrero A, Diaz-Rubio M. Experience with granulocytapheresis in Crohn's disease. Rev. Esp. Enferm. Dig. 96: 501-506 (2004).
Cuffari C. Inflammatory bowel disease in children: a pediatrician's perspective. Minerva Pediatr. 58: 139-157 (2006).
Cuffari C. Anti-TNF therapy in Crohn's disease: a balance between a targeted therapeutic approach and drug-induced immunogenicity. Expert Rev. Gastroenterol. Hepatol. 1: 233-237 (2008).
Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 2: 410-417 (2004). *
Cuffari C, Dubinsky M, Darbari A, Sena L, Baldassano R. Crohn's jejunoileitis: the pediatrician's perspective on diagnosis and management. Inflamm. Bowel Dis. 11: 696-704 (2005). *
Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 48: 642-646 (2001). *
Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment. Pharmacol. Ther. 14: 1009-1014 (2000). *
Cuffari C, Li DY, Mahoney J, Barnes Y, Bayless TM. Peripheral blood mononuclear cell DNA 6-thioguanine metabolite levels correlate with decreased interferon-gamma production in patients with Crohn's disease on AZA therapy. Dig. Dis. Sci. 49: 133-137 (2004). *
Cui G, Olsen T, Christiansen I, Vonen B, Florholmen J, Goll R. Improvement of real-time polymerase chain reaction for quantifying TNF-alpha mRNA expression in inflamed colorectal mucosa: an approach to optimize procedures for clinical use. Scand. J. Clin. Lab. Invest. 66: 249-259 (2006). *
Cukovic-Cavka S. Diffuse jejunoileitis in an adolescent. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 69. May 7-8 (2004). *
Cukovic-Cavka S, Likic R, Francetic I, Rustemovic N, Opacic M, Vucelic B. Lactobacillus acidophilus as a cause of liver abscess in a NOD2/CARD15-positive patient with Crohn's disease. Digestion 73: 107-110 (2006). *
Cukovic-Cavka S, Vermeire S, Hrstic I, Claessens G, Kolacek S, Jakic-Razumovic J, Krznaric Z, Grubelic K, Radic D, Misak Z, Jadresin O, Rutgeerts P, Vucelic B. NOD2/CARD15 mutations in Croatian patients with Crohn's disease: prevalence and genotype-phenotype relationship. Eur. J. Gastroenterol. Hepatol. 18: 895-899 (2006).
Cullen G, O'Toole A, Keegan D, Sheahan K, Hyland JM, O'Donoghue DP. Long-term clinical results of ileocecal resection for Crohn's disease. Inflamm. Bowel Dis. 13: 1369-1373 (2007). *
Cullen G, Sands BE, Yajnik V. Babesiosis in a patient on infliximab for Crohn's disease. Inflamm. Bowel Dis. Nov 2 [Epub ahead of print] (2009).
Cullen S, Chapman R. Chapter 19. Sclerosing cholangitis: primary and secondary. In "Liver Immunology: Principles and Practice" (eds. Gershwin ME, Vierling JM, Manns MP), Humana Press Inc., Totowa, NJ, p. 249-261 (2007). *
Culliford A, Markowitz D, Rotterdam H, Green PHR. Scalloping of duodenal mucosa in Crohn's disease. Inflamm. Bowel Dis. 10: 270-273 (2004). *
Culligan B. Orbital myositis following streptococcal pharyngitis in a pediatric patient. Optometry 76: 250-258 (2005).
Culligan EP, Hill C, Sleator RD. Probiotics and gastrointestinal disease: successes, problems and future prospects. Gut Pathog. 1: 19 (2009). *
Culver EL, Salmon JF, Frith P, Travis SP. Recurrent posterior scleritis and orbital myositis as extra-intestinal manifestations of Crohn's disease: case report and systematic literature review. Journal of Crohn's and Colitis 2: 337-342 (2008).
Cummings JH, Kong SC. Probiotics, prebiotics and antibiotics in inflammatory bowel disease. Novartis Found. Symp. 263: 99-111 (2004).
Cummings JR, Cooney R, Pathan S, Anderson CA, Barrett JC, Beckly J, Geremia A, Hancock L, Guo C, Ahmad T, Cardon LR, Jewell DP. Confirmation of the role of ATG16l1 as a Crohn's disease susceptibility gene. Inflamm. Bowel Dis. 13: 941-946 (2007). *
Cummings JR, Jewell DP. Clinical implications of inflammatory bowel disease genetics on phenotype. Inflamm. Bowel Dis. 11: 56-61 (2005). *
Cummings JR, Keshav S, Travis SP. Medical management of Crohn's disease. BMJ 336: 1062-1066 (2008).
Cummings SA, Rubin DT. The complexity and challenges of genetic counseling and testing for inflammatory bowel disease. J. Genet. Couns. 15: 465-476 (2006). *
Cummins RE, Mullins D, Smith LJ, Ford MJ. Metastatic Crohn's disease: a case report. Pediatr. Dermatol. 13: 25-28 (1996).
Cunliffe RN. alpha-Defensins in the gastrointestinal tract. Mol. Immunol. 40: 463-467 (2003). *
Cunliffe RN, Kamal M, Rose FR, James PD, Mahida YR. Expression of antimicrobial neutrophil defensins in epithelial cells of active inflammatory bowel disease mucosa. J. Clin. Pathol. 55: 298-304 (2002). *
Cunliffe RN, Rose FR, Keyte J, Abberley L, Chan WC, Mahida YR. Human defensin 5 is stored in precursor form in normal Paneth cells and is expressed by some villous epithelial cells and by metaplastic Paneth cells in the colon in inflammatory bowel disease. Gut 48: 176-185 (2001). *
Cunnane SC, Manku MS, Horrobin DF. The pineal and regulation of fibrosis: pinealectomy as a model of primary biliary cirrhosis: roles of melatonin and prostaglandins in fibrosis and regulation of T lymphocytes. Med. Hypotheses 5: 403-414 (1979).
Cunninghame Graham DS. Genome-wide association studies in systemic lupus erythematosus: a perspective. Arthritis Res. Ther. 11: 119 (2009). *
Cuoco L, Vescovo G, Castaman R, Ravara B, Cammarota G, Angelini A, Salvagnini M, Dalla Libera L. Skeletal muscle wastage in Crohn's disease: a pathway shared with heart failure? Int. J. Cardiol. 127: 219-227 (2008).
Curione M, Barbato M, Amato S, Pannone V, Maiella G, Parlapiano C, Cucchiara S. Atrioventricular block associated with Crohn's relapsing colitis in a 12-year-old child. Inflamm. Bowel Dis. 16: 373-374 (2010).
Curova K, Kmetova M, Sabol M, Gombosova L, Lazurova I, Siegfried L. Enterovirulent E. coli in inflammatory and noninflammatory bowel diseases. Folia Microbiol. (Praha.) 54: 81-86 (2009).
Curran ME, Lau KF, Hampe J, Schreiber S, Bridger S, Macpherson AJ, Cardon LR, Sakul H, Harris TJ, Stokkers P, Van Deventer SJ, Mirza M, Raedler A, Kruis W, Meckler U, Theuer D, Herrmann T, Gionchetti P, Lee J, Mathew C, Lennard-Jones J. Genetic analysis of inflammatory bowel disease in a large European cohort supports linkage to chromosomes 12 and 16. Gastroenterology 115: 1066-1071 (1998). *
Currie CG, McCallum K, Poxton IR. Mucosal and systemic antibody responses to the lipopolysaccharide of Escherichia coli O157 in health and disease. J. Med. Microbiol. 50: 345-354 (2001). *
Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, Burgess M, Xie A, Braun MM. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. Rheumatology (Oxford) 46: 1688-1693 (2007). *
Cury DB, Moss AC. Ocular manifestations in a community-based cohort of patients with inflammatory bowel disease. Inflamm. Bowel Dis. Dec 8 [Epub ahead of print] (2009). *
Cury DB, Moss AC, Elias G, Nakao A. Adalimumab for cutaneous metastatic Crohn's disease. Inflamm. Bowel Dis. Sep 2 [Epub ahead of print] (2009).
Cury DH, Costa JE, Irika K, Mijji L, Garcez A, Buchiguel C, Silva I, Sipahi A. Protective effect of octreotide and infliximab in an experimental model of indomethacin-induced inflammatory bowel disease. Dig. Dis. Sci. 53: 2516-2520 (2008). *
Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br. J. Dermatol. 154: 726-729 (2006). *
Cuthbert AP, Fisher SA, Lewis CM, Mathew CG, Sanderson J, Forbes A. Genetic association between EPHX1 and Crohn's disease: population stratification, genotyping error, or random chance? Gut 53: 1386 (2004). *
Cuthbert AP, Fisher SA, Mirza MM, King K, Hampe J, Croucher PJ, Mascheretti S, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122: 867-874 (2002). *
Cuvelier C, Mielants H, De Vos M, Quatacker J, Veys E. Idiopathic inflammatory bowel diseases: immunological hypothesis. Acta Gastroenterol. Belg. 57: 292-299 (1994).
Cuzzocrea S. Emerging biotherapies for inflammatory bowel disease. Expert Opin. Emerg. Drugs 8: 339-347 (2003).
Czaja AJ, Shums Z, Donaldson PT, Norman GL. Frequency and significance of antibodies to Saccharomyces cerevisiae in autoimmune hepatitis. Dig. Dis. Sci. 49: 611-618 (2004). *
Czkwianianc E, Kolasa-Kicinska M, Trojanowska-Lipczyk J, Makosiej R, Malecka-Panas E. Analysis of frequency, clinical course and treatment of Crohn's disease based upon the own material and experience. Pol. Merkur. Lekarski. 26: 446-451 (2009).
Czub E, Herzig KH, Szaflarska-Poplawska A, Kiehne K, Socha P, Wos H, Kaminska B, Blaszczynski M, Cichy W, Bala G, Brodzicki J, Grzybowska-Chlebowczyk U, Walkowiak J. Fecal pyruvate kinase: a potential new marker for intestinal inflammation in children with inflammatory bowel disease. Scand. J. Gastroenterol. 42: 1147-1150 (2007). *
Czymek R, Limmer S, Kleemann M, Hildebrand P, Schmidt A, Jungbluth T, Roblick U, Kujath P, Bruch HP. Crohn's disease - a chameleon during pregnancy. Langenbecks Arch. Surg. 394: 517-527 (2009). *
D'Addabbo A, Latiano A, Palmieri O, Creanza MT, Maglietta R, Annese V, Ancona N. Association of genetic profiles to Crohn's disease by linear combinations of single nucleotide polymorphisms. Artif. Intell. Med. 46: 131-138 (2009).
D'Addabbo A, Latiano A, Palmieri O, Maglietta R, Annese V, Ancona N. Regularized least squares classifiers may predict Crohn's disease from profiles of single nucleotide polymorphisms. Ann. Hum. Genet. 71: 537-549 (2007). *
D'Aleo CM, Sabbi T, Gismondi P, Scattoni R, Ferrara P. Childhood Crohn's disease presenting as chronic constipation. Pediatr. Med. Chir. 31: 168-171 (2009).
D'Alessandria C, Malviya G, Viscido A, Aratari A, Maccioni F, Amato A, Scopinaro F, Caprilli R, Signore A. Use of a (99m)Tc labeled anti-TNFalpha monoclonal antibody in Crohn's disease: in vitro and in vivo studies. Q. J. Nucl. Med. Mol. Imaging 51: 334-342 (2007).
D'Amato M, Bruce S, Bresso F, Zucchelli M, Ezer S, Pulkkinen V, Lindgren C, Astegiano M, Rizzetto M, Gionchetti P, Riegler G, Sostegni R, Daperno M, D'Alfonso S, Momigliano-Richiardi P, Torkvist L, Puolakkainen P, Lappalainen M, Paavola-Sakki P, et al. Neuropeptide S receptor 1 gene polymorphism is associated with susceptibility to inflammatory bowel disease. Gastroenterology 133: 808-817 (2007). *
D'Argenio G, Biancone L, Cosenza V, Della Valle N, D'Armiento FP, Boirivant M, Pallone F, Mazzacca G. Transglutaminases in Crohn's disease. Gut 37: 690-695 (1995). *
D'Eredita G, Ferrarese F, Cecere V, Fabiano G. Factors affecting prognosis in patients with short bowel syndrome. G. Chir. 24: 302-304 (2003).
D'Haens G. Mucosal healing in pediatric Crohn's disease: the goal of medical treatment. Inflamm. Bowel Dis. 10: 479-480 (2004). *
D’Haens G. Pratical use of steroids in IBD. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 30 (2005). *
D'Haens G. Risks and benefits of biologic therapy for inflammatory bowel diseases. Gut 56: 725-732 (2007). *
D'Haens G. Medical management of major internal fistulae in Crohn's disease. Inflamm. Bowel Dis. 6: 244-245 (2000). *
D'Haens G. Anti-TNF-alpha treatment strategies: results and clinical perspectives. Gastroenterol. Clin. Biol. 33S3: S209-S216 (2009).
D'Haens G. Anti-TNF therapy for Crohn's disease. Curr. Pharm. Des. 9: 289-294 (2003).
D'Haens G. Optimizing the use of current drugs in IBD. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 65. May 7-8 (2004). *
D'Haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van de Mierop FJ, Coche JC, van der Woude J, Ochsenkuhn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 371: 660-667 (2008). *
D'Haens G, Daperno M. Advances in biologic therapy for ulcerative colitis and Crohn's disease. Curr. Gastroenterol. Rep. 8: 506-512 (2006).
D'Haens G, Daperno M. Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 4: 506-512 (2002).
D'Haens G, Feagan B, Stitt L. Early combined immunosuppression in Crohn's disease - authors' reply. Lancet 371: 1996-1997 (2008). *
D'Haens G, Hiele M, Rutgeerts P, Geboes K, Ceuppens JL. Depressed T cell reactivity to recall antigens in Crohn's disease before and after surgical resection. Gut 35: 1728-1733 (1994). *
D'Haens G, Hlavaty T. Advances in medical therapy for Crohn's disease. Curr. Gastroenterol. Rep. 6: 496-505 (2004).
D'Haens G, Rutgeerts P. Postoperative recurrence of Crohn's disease: pathophysiology and prevention. Inflamm. Bowel Dis. 5: 295-303 (1999). *
D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, Braakman T, Schaible T, Geboes K, Rutgeerts P. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 116: 1029-1034 (1999). *
D'Haens GR. Top-down therapy for Crohn's disease: rationale and evidence. Acta Clin. Belg. 64: 540-546 (2009).
D'Haens GR. Top-down therapy for IBD: rationale and requisite evidence. Nat. Rev. Gastroenterol. Hepatol. 7: 86-92 (2010).
D'Haens GR. Infliximab (Remicade), a new biological treatment for Crohn's disease. Ital. J. Gastroenterol. Hepatol. 31: 519-520 (1999).
D'Haens GR. Infliximab as disease-modifying therapy. Eur. J. Gastroenterol. Hepatol. 15: 233-237 (2003). *
D'Haens GR, Fedorak R, Lemann M, Feagan BG, Kamm MA, Cosnes J, Rutgeerts PJ, Marteau P, Travis S, Scholmerich J, Hanauer S, Sandborn WJ; the IOIBD Membership. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflamm. Bowel Dis. 15: 1599-1604 (2009).
D'Haens GR, Vermeire S, Van Assche G, Noman M, Aerden I, Van Olmen G, Rutgeerts P. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 135: 1123-1129 (2008). *
D'halluin PN, Tribut O, Branger B, Lebreton C, Bretagne JF, Bentue-Ferrer D, Heresbach D. RBC 6-TGN and hematological parameters in patients with Crohn's disease treated by azathioprine. Gastroenterol. Clin. Biol. 29: 1264-1269 (2005).
D'Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, Vettorato MG, Sturniolo GC. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease. Aliment. Pharmacol. Ther. 23: 1455-1461 (2006). *
D'Inca R, Dal Pont E, Di Leo V, Benazzato L, Martinato M, Lamboglia F, Oliva L, Sturniolo GC. Can calprotectin predict relapse risk in inflammatory bowel disease? Am. J. Gastroenterol. 103: 2007-2014 (2008).
D'Inca R, Dal Pont E, Di Leo V, Ferronato A, Fries W, Vettorato MG, Martines D, Sturniolo GC. Calprotectin and lactoferrin in the assessment of intestinal inflammation and organic disease. Int. J. Colorectal Dis. 22: 429-437 (2007). *
D'Inca R, Podswiadek M, Ferronato A, Punzi L, Salvagnini M, Sturniolo GC. Articular manifestations in inflammatory bowel disease patients: a prospective study. Dig. Liver Dis. 41: 565-569 (2009).
D'Odorico A, Bortolan S, Cardin R, D'Inca' R, Martines D, Ferronato A, Sturniolo GC. Reduced plasma antioxidant concentrations and increased oxidative DNA damage in inflammatory bowel disease. Scand. J. Gastroenterol. 36: 1289-1294 (2001).
D'Ovidio V, Aratari A, Viscido A, Pimpo MT, Caprilli R, Torchio P. Infliximab and quality of life in steroid-dependent Crohn's disease. Dig. Liver Dis. 36: 557-558 (2004).
D'Souza S, Levy E, Mack D, Israel D, Lambrette P, Ghadirian P, Deslandres C, Morgan K, Seidman EG, Amre DK. Dietary patterns and risk for Crohn's disease in children. Inflamm. Bowel Dis. 14: 367-373 (2008). *
da Fonseca LM, Castro FV, Celani MF, da Silva RG, Lacerda-Filho A. Ileo-uterine fistula during pregnancy in a patient with Crohn disease: an uncommon complication. ANZ J. Surg. 78: 1142-1143 (2008).
da Luz Moreira A, Stocchi L, Remzi FH, Geisler D, Hammel J, Fazio VW. Laparoscopic surgery for patients with Crohn's colitis: a case-matched study. J. Gastrointest. Surg. 11: 1529-1533 (2007). *
da Rosa Utiyama SR, da Silva Kotze LM, Nisihara RM, Carvalho RF, de Carvalho EG, de Sena MG, de Messias Reason IJ. Spectrum of autoantibodies in celiac patients and relatives. Dig. Dis. Sci. 46: 2624-2630 (2001). *
da Silva JG, De Brito T, Cintra Damiao AO, Laudanna AA, Sipahi AM. Histologic study of colonic mucosa in patients with chronic diarrhea and normal colonoscopic findings. J. Clin. Gastroenterol. 40: 44-48 (2006).
Da-Silva N, Arasaradnam RP, Getliffe KM, Sung EZ, Oo Y, Nwokolo CU. Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease. Dig. Liver Dis. Jan 8 [Epub ahead of print] (2010).
Dabrowska-Ufniarz E, Jarosz M, Jarosz O, Nekanda-Trepka A. A case of Lesniowski-Crohn disease preceded by Yersinia pseudotuberculosis infection. Wiad. Lek. 47: 784-787 (1994).
Dafnis G. Repeated coaxial colonic stenting in the palliative management of benign colonic obstruction. Eur. J. Gastroenterol. Hepatol. 19: 83-86 (2007).
Dagan E, Gershoni-Baruch R, Khatib I, Mori A, Brik R. MEFV, TNF1rA, CARD15 and NLRP3 mutation analysis in PFAPA. Rheumatol. Int. Jul 5 [Epub ahead of print] (2009). *
Dager WE, White RH. Low-molecular-weight heparin-induced thrombocytopenia in a child. Ann. Pharmacother. 38: 247-250 (2004).
Dagia C, Ditchfield M, Kean M, Catto-Smith T. Imaging for Crohn disease: use of 3-T MRI in a paediatric setting. J. Med. Imaging Radiat. Oncol. 52: 480-488 (2008).
Dahan S, Roda G, Pinn D, Roth-Walter F, Kamalu O, Martin AP, Mayer L. Epithelial:lamina propria lymphocyte interactions promote epithelial cell differentiation. Gastroenterology 134: 192-203 (2008). *
Dai H, Li Z, Zhang Y, Lv P, Gao X. Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus 18: 1087-1090 (2009). *
Dai J, Liu WZ, Zhao YP, Hu YB, Ge ZZ. Relationship between fecal lactoferrin and inflammatory bowel disease. Scand. J. Gastroenterol. 42: 1440-1444 (2007). *
Dai Z, Turtle CJ, Booth GC, Riddell SR, Gooley TA, Stevens AM, Spies T, Groh V. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J. Exp. Med. 206: 793-805 (2009). *
Daig R, Andus T, Aschenbrenner E, Falk W, Scholmerich J, Gross V. Increased interleukin 8 expression in the colon mucosa of patients with inflammatory bowel disease. Gut 38: 216-222 (1996). *
Daig R, Rogler G, Aschenbrenner E, Vogl D, Falk W, Gross V, Scholmerich J, Andus T. Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6. Gut 46: 350-358 (2000). *
Daiss W, Scheurlen M, Malchow H. Epidemiology of inflammatory bowel disease in the county of Tubingen (West Germany). Scand. J. Gastroenterol. Suppl. 170: 39-43 (1989).
Dajotoy T, Andersson P, Bjartell A, Lofdahl CG, Tapper H, Egesten A. Human eosinophils produce the T cell-attracting chemokines MIG and IP-10 upon stimulation with IFN-gamma. J. Leukoc. Biol. 76: 685-691 (2004). *
Dalal I, Karban A, Wine E, Eliakim R, Shirin H, Fridlender M, Shaoul R, Leshinsky-Silver E, Levine A. Polymorphisms in the TNF-alpha promoter and variability in the granulomatous response in patients with Crohn's disease. Pediatr. Res. 59: 825-828 (2006). *
Daley TD, Armstrong JE. Oral manifestations of gastrointestinal diseases. Can. J. Gastroenterol. 21: 241-244 (2007). *
Dalle IJ, Maes BD, Geboes KP, Lemahieu W, Geboes K. Crohn's-like changes in the colon due to mycophenolate? Colorectal Dis. 7: 27-34 (2005). *
Dalton S, Ghosh A, Zafar N, Riyad K, Dixon A. Competency in laparoscopic colorectal surgery is achievable with appropriate training but takes time: a comparison of 300 elective resections with anastomosis. Colorectal Dis. Jul 6 [Epub ahead of print] (2009). *
Dalton SJ, Ghosh A, Greenslade GL, Dixon AR. Laparoscopic colorectal surgery - why would you not want to have it and, more importantly, not be trained in it? A consecutive series of 500 elective resections with anastomoses. Colorectal Dis. Nov 2 [Epub ahead of print] (2009). *
Dalwadi H, Wei B, Kronenberg M, Sutton CL, Braun J. The Crohn's disease-associated bacterial protein I2 is a novel enteric T cell superantigen. Immunity 15: 149-158 (2001). *
Daly MJ, Pearce AV, Farwell L, Fisher SA, Latiano A, Prescott NJ, Forbes A, Mansfield J, Sanderson J, Langelier D, Cohen A, Bitton A, Wild G, Lewis CM, Annese V, Mathew CG, Rioux JD. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur. J. Hum. Genet. 13: 835-839 (2005). *
Daly MJ, Rioux JD. New approaches to gene hunting in IBD. Inflamm. Bowel Dis. 10: 312-317 (2004). *
Dalzell AM, Heaf DP, Carty H. Pathology mimicking distal intestinal obstruction syndrome in cystic fibrosis. Arch. Dis. Child. 65: 540-541 (1990).
Dambacher J, Beigel F, Seiderer J, Haller D, Goke B, Auernhammer CJ, Brand S. Interleukin-31 mediates MAP kinase and STAT1/3 activation in intestinal epithelial cells and its expression is up-regulated in inflammatory bowel disease. Gut 56: 1257-1265 (2007). *
Dambacher J, Beigel F, Zitzmann K, de Toni E, Goke B, Diepolder HM, Auernhammer CJ, Brand S. The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58: 1207-1217 (2009). *
Dambacher J, Staudinger T, Seiderer J, Sisic Z, Schnitzler F, Pfennig S, Hofbauer K, Konrad A, Tillack C, Otte JM, Diebold J, Goke B, Ochsenkuhn T, Lohse P, Brand S. Macrophage migration inhibitory factor (MIF) -173G/C promoter polymorphism influences upper gastrointestinal tract involvement and disease activity in patients with Crohn's disease. Inflamm. Bowel Dis. 13: 71-82 (2007). *
Damen GM, Hol J, de Ruiter L, Bouquet J, Sinaasappel M, van der Woude J, Laman JD, Hop WC, Buller HA, Escher JC, Nieuwenhuis EE. Chemokine production by buccal epithelium as a distinctive feature of pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 42: 142-149 (2006). *
Damergis JA, Chee K, Amitai A. Otogenic pneumococcal meningitis with pneumocephalus. J. Emerg. Med. Jun 30 [Epub ahead of print] (2008).
Dammeier J, Brauchle M, Falk W, Grotendorst GR, Werner S. Connective tissue growth factor: a novel regulator of mucosal repair and fibrosis in inflammatory bowel disease? Int. J. Biochem. Cell Biol. 30: 909-922 (1998). *
Danalioglu A. The frequency of sister chromatid exchanges in patients with Crohn's disease and the effect of therapy with "anti-tumor necrosis factor" on this frequency. Hepatogastroenterology 56: 729-733 (2009).
Danda D, Kurian G, Chacko A, Chandy G, Patra S, Mathew A, Thomas K. Crohn's disease in rheumatology clinic - an Indian experience. J. Postgrad. Med. 51: 269-272 (2005). *
Danelius M, Ost A, Lapidus AB. Inflammatory bowel disease-related lesions in the duodenal and gastric mucosa. Scand. J. Gastroenterol. 44: 441-445 (2009). *
Danelli P, Bartolucci C, Sampietro GM, Panizzo V, Sartani A, Maconi G, Parente E, Taschieri AM. Surgical options in the treatment of perianal Crohn's disease. Ann. Ital. Chir. 74: 635-640 (2003).
Danese S. Negative regulators of angiogenesis in inflammatory bowel disease: thrombospondin in the spotlight. Pathobiology 75: 22-24 (2008).
Danese S. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker. Dig. Liver Dis. 40 Suppl. 2: S225-S228 (2008).
Danese S, Angelucci E, Stefanelli T, Omodei P, Luigiano C, Finazzi S, Pagano N, Repici A, Vecchi M, Malesci A. Cytapheresis in inflammatory bowel diseases: current evidence and perspectives. Digestion 77: 96-107 (2008). *
Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases. World J. Gastroenterol. 12: 4807-4812 (2006). *
Danese S, Katz JA, Saibeni S, Papa A, Gasbarrini A, Vecchi M, Fiocchi C. Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients. Gut 52: 1435-1441 (2003). *
Danese S, Mocciaro F, Guidi L, Scribano ML, Comberlato M, Vito A, Elisabetta C, Tommaso S, Marzo M, Vangeli M, Pulitano' R, Manca A, Armuzzi A, Malesci A, Prantera C, Cottone M. Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use. Inflamm. Bowel Dis. 14: 1168-1170 (2008). *
Danese S, Motte Cd Cde L, Fiocchi C. Platelets in inflammatory bowel disease: clinical, pathogenic, and therapeutic implications. Am. J. Gastroenterol. 99: 938-945 (2004). *
Danese S, Pagano N, Angelucci E, Stefanelli T, Repici A, Omodei P, Daperno M, Malesci A. Tumor necrosis factor-alpha monoclonal antibodies for Crohn's disease: tipping the balance. Curr. Med. Chem. 14: 1489-1497 (2007).
Danese S, Papa A. PAI-1 and TAFI in inflammatory bowel disease: the yin and yang of the fibrinolytic system. Eur. J. Gastroenterol. Hepatol. 20: 826-828 (2008).
Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am. J. Gastroenterol. 102: 174-186 (2007). *
Danese S, Papa A, Scaldaferri F, Graziani C, Bonizzi M, Armuzzi A, Fedeli G, Gasbarrini G, Gasbarrini A. A novel pathogenic role for microvasculature in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 3-5 (2006).
Danese S, Peyrin-Biroulet L. Early combined immunosuppression in Crohn's disease. Lancet 371: 1996 (2008). *
Danese S, Sans M, de la Motte C, Graziani C, West G, Phillips MH, Pola R, Rutella S, Willis J, Gasbarrini A, Fiocchi C. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology 130: 2060-2073 (2006). *
Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. Autoimmun. Rev. 3: 394-400 (2004).
Danese S, Sans M, Scaldaferri F, Sgambato A, Rutella S, Cittadini A, Pique JM, Panes J, Katz JA, Gasbarrini A, Fiocchi C. TNF-alpha blockade down-regulates the CD40/CD40L pathway in the mucosal microcirculation: a novel anti-inflammatory mechanism of infliximab in Crohn's disease. J. Immunol. 176: 2617-2624 (2006). *
Danese S, Sans M, Spencer D, Beck I, Donate F, Plunkett M, de la Motte C, Redline R, Shaw D, Levine A, Mazar A, Fiocchi C. Angiogenesis blockade as a new therapeutic approach to experimental colitis. Gut 56: 855-862 (2007). *
Danese S, Scaldaferri F, Papa A, Pola R, Sans M, Gasbarrini G, Pola P, Gasbarrini A. Platelets: new players in the mucosal scenario of inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 8: 193-198 (2004).
Danese S, Semeraro S, Armuzzi A, Papa A, Gasbarrini A. Biological therapies for inflammatory bowel disease: research drives clinics. Mini. Rev. Med. Chem. 6: 771-784 (2006).
Danese S, Semeraro S, Marini M, Roberto I, Armuzzi A, Papa A, Gasbarrini A. Adhesion molecules in inflammatory bowel disease: therapeutic implications for gut inflammation. Dig. Liver Dis. 37: 811-818 (2005).
Danese S, Semeraro S, Papa A, Roberto I, Scaldaferri F, Fedeli G, Gasbarrini G, Gasbarrini A. Extraintestinal manifestations in inflammatory bowel disease. World J. Gastroenterol. 11: 7227-7236 (2005). *
Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M, Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular activation in inflammatory bowel disease. Am. J. Gastroenterol. 100: 886-895 (2005). *
Danese S, Stefanelli T, Omodei P, Zatelli S, Bonifacio C, Balzarini L, Repici A, Malesci A. Successful treatment of fistulizing Crohn's disease with certolizumab pegol. Inflamm. Bowel Dis. 14: 292-293 (2008). *
Daniels JA, Lederman HM, Maitra A, Montgomery EA. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am. J. Surg. Pathol. 31: 1800-1812 (2007).
Danik JS, Pare G, Chasman DI, Zee RY, Kwiatkowski DJ, Parker A, Miletich JP, Ridker PM. Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17,686 women: the Women’s Genome Health Study. Circ. Cardiovasc. Genet. 2: 134-141 (2009).
Danik JS, Pare G, Chasman DI, Zee RY, Kwiatkowski DJ, Parker A, Miletich JP, Ridker PM. Novel loci, including those related to Crohn disease, psoriasis, and inflammation, identified in a genome-wide association study of fibrinogen in 17,686 women: The Women's Genome Health Study. Circ. Cardiovasc. Genet. 2: 134-141 (2009).
Dann SM, Eckmann L. Innate immune defenses in the intestinal tract. Curr. Opin. Gastroenterol. 23: 115-120 (2007).
Danze PM, Colombel JF, Jacquot S, Loste MN, Heresbach D, Ategbo S, Khamassi S, Perichon B, Semana G, Charron D, Cezard JP. Association of HLA class II genes with susceptibility to Crohn's disease. Gut 39: 69-72 (1996). *
Danzi JT. Extraintestinal manifestations of idiopathic inflammatory bowel disease. Arch. Intern. Med. 148: 297-302 (1988).
Daoud L, El Euch D, Ben Tekaya N, Cherif F, Mokni M, Ben Osman A. Erythema nodosum: profile in a Tunisian teaching hospital. Tunis. Med. 85: 1020-1024 (2007).
Dapena Diaz JL, Diaz de Heredia Rubio C, Bastida Vila P, Llort Sales A, Elorza Alvarez I, Olive Oliveras T, Sanchez de Toledo Codina J. Haemophagocytic syndrome: a common pathogenic mechanism of various aetiologies. An. Pediatr. (Barc.) 71: 110-116 (2009).
Daperno M, D'haens G, Van Assche G, Baert F, Bulois P, Maunoury V, Sostegni R, Rocca R, Pera A, Gevers A, Mary JY, Colombel JF, Rutgeerts P. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointest. Endosc. 60: 505-512 (2004). *
Daperno M, Sostegni R, Lavagna A, Crocella L, Ercole E, Rigazio C, Rocca R, Pera A. The role of endoscopy in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 8: 209-214 (2004).
Darbari A, Kalloo AN, Cuffari C. Diagnostic yield, safety, and efficacy of push enteroscopy in pediatrics. Gastrointest. Endosc. 64: 224-228 (2006).
Darbari A, Sena L, Argani P, Oliva-Hemker JM, Thompson R, Cuffari C. Gadolinium-enhanced magnetic resonance imaging: a useful radiological tool in diagnosing pediatric IBD. Inflamm. Bowel Dis. 10: 67-72 (2004). *
Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, Bringer MA, Swidsinski A, Beaugerie L, Colombel JF. High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology 127: 412-421 (2004). *
Darfeuille-Michaud A, Colombel JF. Pathogenic Escherichia coli in inflammatory bowel diseases. Proceedings of the 1st International Meeting on E. coli and IBD, June 2007, Lille, France. Journal of Crohn's and Colitis 2: 255-262 (2008).
Darling A. Caring for the patient with Crohn's disease: practical do's and don'ts to improve patients' quality of life. Gastroenterol. Nurs. 31: S2-S4 (2008).
Daryani NE, Nayer Habibi A, Bashashati M, Keramati MR, Rafiee MJ, Ajdarkosh H, Azmi M. Takayasu's arteritis associated with Crohn's disease: a case report. J. Med. Case Reports 2: 87 (2008). *
Das K, Ghoshal UC, Dhali GK, Benjamin J, Ahuja V, Makharia GK. Crohn's disease in India: a multicenter study from a country where tuberculosis is endemic. Dig. Dis. Sci. 54: 1099-1107 (2009). *
Das KK, Nishino HT, Chan AT. Treatment-associated acute myeloid leukemia in a patient with Crohn's disease on 6-mercaptopurine. Inflamm. Bowel Dis. Feb 2 [Epub ahead of print] (2010). *
Das KM. "Is foe your friend?" Inflamm. Bowel Dis. 10: 693 (2004). *
Das KM. Immunopathogenesis of primary sclerosing cholangitis: possible role of a shared colonic and biliary epithelial antigen. J. Gastroenterol. Hepatol. 19: S290-S294 (2004). *
Das KM. Response: double blind trial in Crohn's disease of autologous colon extracted proteins (Am J Gastroenterol 2006;101:561-8). Am. J. Gastroenterol. 101: 2889-2890 (2006). *
Das KM. Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine. Postgrad. Med. 74: 141-148, 150-151 (1983).
Das KM, Bajpai M. Tropomyosins in human diseases: ulcerative colitis. Adv. Exp. Med. Biol. 644: 158-167 (2008).
Das KM, Dubin R. Clinical pharmacokinetics of sulphasalazine. Clin. Pharmacokinet. 1: 406-425 (1976).
Das KM, Eastwood MA. Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease. Clin. Pharmacol. Ther. 18: 514-520 (1975).
Dasari BV, Maxwell R, Gardiner KR. Assessment of complications following strictureplasty for small bowel Crohn's Disease. Ir. J. Med. Sci. Aug 28 [Epub ahead of print] (2009). *
Dasgupta A, Mandal A, Das KM. Circulating immunoglobulin G1 antibody in patients with ulcerative colitis against the colonic epithelial protein detected by a novel monoclonal antibody. Gut 35: 1712-1717 (1994). *
Dassopoulos T. Diagnostic methodologies: serology, endoscopy, and radiology. Curr. Gastroenterol. Rep. 3: 491-499 (2001).
Dassopoulos T, Frangakis C, Cruz-Correa M, Talor MV, Burek CL, Datta L, Nouvet F, Bayless TM, Brant SR. Antibodies to Saccharomyces cerevisiae in Crohn's disease: higher titers are associated with a greater frequency of mutant NOD2/CARD15 alleles and with a higher probability of complicated disease. Inflamm. Bowel Dis. 13: 143-151 (2007). *
Dassopoulos T, Nguyen GC, Bitton A, Bromfield GP, Schumm LP, Wu Y, Elkadri A, Regueiro M, Siemanowski B, Torres EA, Gregory FJ, Kane SV, Harrell LE, Franchimont D, Achkar JP, Griffiths A, Brant SR, Rioux JD, Taylor KD, Duerr RH, Silverberg MS, et al. Assessment of reliability and validity of IBD phenotyping within the National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) IBD Genetics Consortium (IBDGC). Inflamm. Bowel Dis. 13: 975-983 (2007). *
Dassopoulos T, Nguyen GC, Talor MV, Datta LW, Isaacs KL, Lewis JD, Gold MS, Valentine JF, Smoot DT, Harris ML, Oliva-Hemker M, Bayless TM; NIDDK IBD Genetics Consortium, Burek CL, Brant SR. NOD2 mutations and anti-Saccharomyces cerevisiae antibodies are risk factors for Crohn's disease in African Americans. Am. J. Gastroenterol. Oct 13 [Epub ahead of print] (2009). *
Dastidar SG, Rajagopal D, Ray A. Therapeutic benefit of PDE4 inhibitors in inflammatory diseases. Curr. Opin. Investig. Drugs 8: 364-372 (2007).
Dastych M, Dastych M Jr, Novotna H, Cihalova J. Lactulose/mannitol test and specificity, sensitivity, and area under curve of intestinal permeability parameters in patients with liver cirrhosis and Crohn's disease. Dig. Dis. Sci. 53: 2789-2792 (2008). *
Date RS, Panesar KJ, Neilly P. Infliximab as a therapy for non-Crohn's enterocutaneous fistulae. Int. J. Colorectal Dis. 19: 603-606 (2004). *
Datta I, Brar SS, Andrews CN, Dupre M, Ball CG, Buie WD, Beck PL. Microscopic colitis: a review for the surgical endoscopist. Can. J. Surg. 52: E167-E172 (2009).
Dave-Verma H, Moore S, Singh A, Martins N, Zawacki J. Computed tomographic enterography and enteroclysis: pearls and pitfalls. Curr. Probl. Diagn. Radiol. 37: 279-287 (2008).
Davidson RS, Marion G, White PC, Hutchings MR. Use of host population reduction to control wildlife infection: rabbits and paratuberculosis. Epidemiol. Infect. 137: 131-138 (2009).
Davies M, Harris D, Lohana P, Chandra Sekaran TV, Morgan AR, Beynon J, Carr ND. The surgical management of fistula-in-ano in a specialist colorectal unit. Int. J. Colorectal Dis. 23: 833-838 (2008). *
Davies RJ, Scott IS, Morris LS, Rushbrook SM, Bird K, Vowler SL, Arends M, Miller R, Coleman N. Increased expression of minichromosome maintenance protein 2 in active inflammatory bowel disease. Colorectal Dis. 6: 103-110 (2004).
Davies YK, Cox KM, Abdullah BA, Terry AB, Cox KL. Oral vancomycin: treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 37: 345-346 (2003). *
Davis MK, Andres JM, Jolley CD, Novak DA, Haafiz AB, Gonzalez-Peralta RP. Antibodies to Escherichia coli outer membrane porin C in the absence of anti-Saccharomyces cerevisiae antibodies and anti-neutrophil cytoplasmic antibodies are an unreliable marker of Crohn disease and ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 45: 409-413 (2007). *
Davis MK, Rufo PA, Polyak SF, Weinstein DA. Adalimumab for the treatment of Crohn-like colitis and enteritis in glycogen storage disease type Ib. J. Inherit. Metab. Dis. Jan 5 [Epub ahead of print] (2008). *
Davis RL, Bohlke K. Measles vaccination and inflammatory bowel disease: controversy laid to rest? Drug Saf. 24: 939-946 (2001).
Davis RL, Kramarz P, Bohlke K, Benson P, Thompson RS, Mullooly J, Black S, Shinefield H, Lewis E, Ward J, Marcy SM, Eriksen E, Destefano F, Chen R; Vaccine Safety Datalink Team. Measles-mumps-rubella and other measles-containing vaccines do not increase the risk for inflammatory bowel disease: a case-control study from the Vaccine Safety Datalink project. Arch. Pediatr. Adolesc. Med. 155: 354-359 (2001). *
Day AS, Stephenson T, Stewart M, Otley AR. Exclusive enteral nutrition for children with Crohn's disease: use in Australia and attitudes of Australian paediatric gastroenterologists. J. Paediatr. Child Health May 28 [Epub ahead of print] (2009).
Day AS, Whitten KE, Lemberg DA, Clarkson C, Vitug-Sales M, Jackson R, Bohane TD. Exclusive enteral feeding as primary therapy for Crohn's disease in Australian children and adolescents: a feasible and effective approach. J. Gastroenterol. Hepatol. 21: 1609-1614 (2006). *
Day AS, Whitten KE, Sidler M, Lemberg DA. Review article: nutritional therapy in paediatric Crohn's disease. Aliment. Pharmacol. Ther. 27: 293-307 (2008). *
Day MW. Fight back against inflammatory bowel disease. Nursing 38: 34-40 (2008).
Dayton MT. Preventing Crohn disease recurrence with drugs after ileocolectomy: an exercise in futility?: Comment on "Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease". Arch. Surg. 145: 47-48 (2010).
de Boer NK, Derijks LJ, Keizer-Garritsen JJ, Lambooy LH, Ruitenbeek W, Hooymans PM, van Bodegraven AA, de Jong DJ. Extended thiopurine metabolite assessment during 6-thioguanine therapy for immunomodulation in Crohn's disease. J. Clin. Pharmacol. 47: 187-191 (2007). *
de Boer NK, Jarbandhan SV, de Graaf P, Mulder CJ, van Elburg RM, van Bodegraven AA. Azathioprine use during pregnancy: unexpected intrauterine exposure to metabolites. Am. J. Gastroenterol. 101: 1390-1392 (2006). *
de Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth. J. Med. 63: 444-446 (2005). *
De Boer NK, Tuynman H, Bloemena E, Westerga J, Van Der Peet DL, Mulder CJ, Cuesta MA, Meuwissen SG, Van Nieuwkerk CM, Van Bodegraven AA. Histopathology of liver biopsies from a thiopurine-naive inflammatory bowel disease cohort: prevalence of nodular regenerative hyperplasia. Scand. J. Gastroenterol. 43: 604-608 (2008). *
de Boer NK, Van Elburg RM, Wilhelm AJ, Remmink AJ, Van Vugt JM, Mulder CJ, Van Bodegraven AA. 6-Thioguanine for Crohn's disease during pregnancy: thiopurine metabolite measurements in both mother and child. Scand. J. Gastroenterol. 40: 1374-1377 (2005). *
De Bona M, Bellumat A, Cian E, Valiante F, Moschini A, De Boni M. Capsule endoscopy findings in patients with suspected Crohn's disease and biochemical markers of inflammation. Dig. Liver Dis. 38: 331-335 (2006).
de Buhr MF, Hedrich HJ, Westendorf AM, Obermeier F, Hofmann C, Zschemisch NH, Buer J, Bumann D, Goyert SM, Bleich A. Analysis of Cd14 as a genetic modifier of experimental inflammatory bowel disease (IBD) in mice. Inflamm. Bowel Dis. 15: 1824-1836 (2009). *
De Diego C, Alcantara M, Valle J, Repiso A, Carrobles JM, Martinez-Castro P. Influence of smoking habits and CARD15 mutations on the onset of Crohn’s disease. Scand. J. Gastroenterol. 41: 1209-1211 (2006). *
de Dombal FT. Epidemiology of Crohn's disease of the colon. Ann. Gastroenterol. Hepatol. (Paris) 21: 191-200 (1985).
De Hertogh G, Aerssens J, de Hoogt R, Peeters P, Verhasselt P, Van Eyken P, Ectors N, Vermeire S, Rutgeerts P, Coulie B, Geboes K. Validation of 16S rDNA sequencing in microdissected bowel biopsies from Crohn's disease patients to assess bacterial flora diversity. J. Pathol. 209: 532-539 (2006). *
De Hertogh G, Aerssens J, Geboes KP, Geboes K. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J. Gastroenterol. 14: 845-852 (2008). *
De Hertogh G, Geboes K. Crohn's disease and infections: a complex relationship. MedGenMed. 6: 14 (2004). *
De Jager PL, Franchimont D, Waliszewska A, Bitton A, Cohen A, Langelier D, Belaiche J, Vermeire S, Farwell L, Goris A, Libioulle C, Jani N, Dassopoulos T, Bromfield GP, Dubois B, Cho JH, Brant SR, Duerr RH, Yang H, Rotter JI, Silverberg MS, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun. 8: 387-397 (2007). *
De Jager PL, Sawcer S, Waliszewska A, Farwell L, Wild G, Cohen A, Langelier D, Bitton A, Compston A, Hafler DA, Rioux JD. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. Eur. J. Hum. Genet. 14: 317-321 (2006). *
De Jesus LE, Marques AM, Rocha MS, Brom BR, Siqueira RR. Left colon stenosis caused by tuberculosis. J. Pediatr. Surg. 39: e5-e7 (2004).
De Jesus-Monge WE, Torres EA, Baez VM, De Jesus O, Rivera L, Gonzalez-Keelan C. Crohn's disease associated to chordoma: a case report. P. R. Health Sci. J. 23: 233-236 (2004).
de Jong DJ, Bac DJ, Tan G, de Boer SY, Grabowsky IL, Jansen JB, Greinwald R, Naber TH. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission. Neth. J. Med. 65: 339-345 (2007). *
de Jong DJ, Franke B, Naber AH, Willemen JJ, Heister AJ, Brunner HG, de Kovel CG, Hol FA. No evidence for involvement of IL-4R and CD11B from the IBD1 region and STAT6 in the IBD2 region in Crohn's disease. Eur. J. Hum. Genet. 11: 884-887 (2003). *
De Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 16: 207-212 (2004).
de Jong DJ, Nagengast FM. Tracing colorectal carcinoma in patients with inflammatory bowel disease. Ned. Tijdschr. Geneeskd. 151: 2758-2760 (2007).
de Jong DJ, Tielen J, Habraken CM, Wetzels JF, Naber AH. 5-Aminosalicylates and effects on renal function in patients with Crohn's disease. Inflamm. Bowel Dis. 11: 972-976 (2005). *
de Jong DJ, van der Logt EM, van Schaik A, Roelofs HM, Peters WH, Naber TH. Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase. Gut 52: 547-551 (2003). *
de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm. Bowel Dis. 12: 566-572 (2006). *
de Jong NS, Leach ST, Day AS. Polymeric formula has direct anti-inflammatory effects on enterocytes in an in vitro model of intestinal inflammation. Dig. Dis. Sci. 52: 2029-2036 (2007). *
De Keyser F. Gut inflammation in patients with spondyloarthropathy is prevalent and is linked to Crohn's disease. J. Postgrad. Med. 51: 272 (2005). *
De Keyser F, Baeten D, Van den Bosch F, De Vos M, Cuvelier C, Mielants H, Veys E. Gut inflammation and spondyloarthropathies. Curr. Rheumatol. Rep. 4: 525-532 (2002).
de la Fuente SG, Safford SD, Cantu E, Ludwig KA. Spinal abscess presenting as the initial symptom of Crohn's disease. Int. J. Colorectal Dis. 24: 601-602 (2009). *
De la Garza Gonzalez SJ, Garcia RG. Update in the endoscopic management of benign esophageal stenoses. Rev. Gastroenterol. Mex. 70 Suppl. 1: 20-24 (2007).
de la Morena Lopez F, Gisbert JP. Prevalence and characteristics of anemia in inflammatory bowel disease. Gastroenterol. Hepatol. 32: 591-599 (2009).
de la Quintana Jimenez P. Nurse involvement in clinical trials with cell therapy. Enferm. Clin. 19: 340-344 (2009).
De La Rue SA, Bickston SJ. Evidence-based medications for the treatment of the inflammatory bowel diseases. Curr. Opin. Gastroenterol. 22: 365-369 (2006).
de Lisle GW. Johne's disease in New Zealand: the past, present and a glimpse into the future. N. Z. Vet. J. 50: S53-S56 (2002).
De Matos V, Russo PA, Cohen AB, Mamula P, Baldassano RN, Piccoli DA. Frequency and clinical correlations of granulomas in children with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 46: 392-398 (2008). *
de Mesquita MB, Civitelli F, Levine A. Epidemiology, genes and inflammatory bowel diseases in childhood. Dig. Liver Dis. 40: 3-11 (2008).
de Oca J, Sanchez-Santos R, Rague JM, Biondo S, Pares D, Osorio A, del Rio C, Jaurrieta E. Long-term results of ileal pouch-anal anastomosis in Crohn's disease. Inflamm. Bowel Dis. 9: 171-175 (2003). *
de Oca J, Vilar L, Castellote J, Sanchez Santos R, Pares D, Biondo S, Osorio A, del Rio C, Jaurrieta E, Marti Rague J. Immunodulation with tacrolimus (FK506): results of a prospective, open-label, non-controlled trial in patients with inflammatory bowel disease. Rev. Esp. Enferm. Dig. 95: 465-470, 459-464 (2003).
De Palma GD, Rega M, Puzziello A, Aprea G, Ciacci C, Castiglione F, Ciamarra P, Persico M, Patrone F, Mastantuono L, Persico G. Capsule endoscopy is safe and effective after small-bowel resection. Gastrointest. Endosc. 60: 135-138 (2004). *
De Pascale A, Garofalo G, Perna M, Priola S, Fava C. Contrast-enhanced ultrasonography in Crohn's disease. Radiol. Med. (Torino) 111: 539-550 (2006). *
De Pascalis B, Bianchi A, Satta MA, Lupascu A, Mentella MC, Leo D, Fiore F, Fedeli P, Pontecorvi A, Pola P, Melina D, Gasbarrini A, De Marinis L, Armuzzi A. Growth hormone in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 10: 13-16 (2006).
De Quatrebarbes J, Cordel N, Bravard P, Lenormand B, Joly P. Miescher's cheilitis and lymphocytic clonal expansion: 2 cases. Ann. Dermatol. Venereol. 131: 55-57 (2004).
de Ridder L, Benninga MA, Taminiau JA, Hommes DW. Infliximab as first-line therapy in severe pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 43: 388-390 (2006). *
de Ridder L, Benninga MA, Taminiau JA, Hommes DW, van Deventer SJ. Infliximab use in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 45: 3-14 (2007). *
de Ridder L, Escher JC, Taminiau JA. Infliximab therapy in children and adolescents with refractory Crohn's disease in the Netherlands; experience with 23 patients. Ned. Tijdschr. Geneeskd. 146: 1879-1883 (2002).
de Ridder L, Rings EH, Damen GM, Kneepkens CM, Schweizer JJ, Kokke FT, Benninga MA, Norbruis OF, Hoekstra JH, Gijsbers CF, Escher JC. Infliximab dependency in pediatric Crohn's disease: long-term follow-up of an unselected cohort. Inflamm. Bowel Dis. 14: 353-358 (2008). *
de Ridder L, van Lingen AV, Taminiau JA, Benninga MA. Rectal bleeding in children: endoscopic evaluation revisited. Eur. J. Gastroenterol. Hepatol. 19: 317-320 (2007).
de Ridder L, Weersma RK, Dijkstra G, van der Steege G, Benninga MA, Nolte IM, Taminiau JA, Hommes DW, Stokkers PC. Genetic susceptibility has a more important role in pediatric-onset Crohn's disease than in adult-onset Crohn's disease. Inflamm. Bowel Dis. 13: 1083-1092 (2007). *
De Rosa FG, Shaz D, Campagna AC, Dellaripa PE, Khettry U, Craven DE. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? Infect. Control Hosp. Epidemiol. 24: 477-482 (2003). *
de Rossi TM, Krauss N, Voll RE, Nagel A, Weidenhiller M, Konturek PC, Hahn EG, Raithel M. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease. Digestion 78: 195-200 (2008). *
de Rossi TM, Krauss N, Wilken V, Giera B, Konturek PC, Kressel J, Hahn EG, Raithel M. Mast cell tryptase in sera of patients with Crohn's disease and mastocytosis. Eur. J. Gastroenterol. Hepatol. 21: 273-277 (2009).
De Sanctis JB, Garmendia JV, Moreno D, Larocca N, Mijares M, Di Giulio C, Salazar-Bookaman M, Wojewodka G, Radzioch D. Pharmacological modulation of Th17. Recent Pat. Inflamm. Allergy Drug Discov. 3: 149-156 (2009).
de Saussure P, Lavergne-Slove A, Mazeron MC, Alain S, Matuchansky C, Bouhnik Y. A prospective assessment of cytomegalovirus infection in active inflammatory bowel disease. Aliment. Pharmacol. Ther. 20: 1323-1327 (2004). *
de Saussure P, Soravia C. Images in clinical medicine. Crohn's disease. N. Engl. J. Med. 352: 2222 (2005). *
de Seny D, Fillet M, Meuwis MA, Geurts P, Lutteri L, Ribbens C, Bours V, Wehenkel L, Piette J, Malaise M, Merville MP. Discovery of new rheumatoid arthritis biomarkers using the surface-enhanced laser desorption/ionization time-of-flight mass spectrometry ProteinChip approach. Arthritis Rheum. 52: 3801-3812 (2005). *
de Silva AD, Tsironi E, Feakins RM, Rampton DS. Efficacy and tolerability of oral iron therapy in inflammatory bowel disease: a prospective, comparative trial. Aliment. Pharmacol. Ther. 22: 1097-1105 (2005). *
de Silva AP, Karunanayake AL, Dissanayaka TG, Dassanayake AS, Duminda HK, Pathmeswaran A, Wickramasinghe AR, de Silva HJ. Osteoporosis in adult Sri Lankan inflammatory bowel disease patients. World J. Gastroenterol. 15: 3528-3531 (2009). *
De Simone M, Cioffi U, Contessini-Avesani E, Oreggia B, Paliotti R, Pierini A, Bolla G, Oggiano E, Ferrero S, Magrini F, Ciulla MM. Elevated serum procollagen type III peptide in splanchnic and peripheral circulation of patients with inflammatory bowel disease submitted to surgery. BMC Gastroenterol. 4: 29 (2004). *
De Simone M, Cioffi U, Quatrini M, Lemos A, Ciulla M, Botti F, Carrara A, Marconato R, Contessini Avesani E. Crohn's disease and Takayasu's arteritis: is this association difficult to find out? Minerva Gastroenterol. Dietol. 52: 441-443 (2006).
De Simone M, Ciulla MM, Cioffi U, Poggi L, Oreggia B, Paliotti R, Botti F, Carrara A, Agosti F, Sartorio A, Contessini-Avesani E. Effects of surgery on peripheral N-terminal propeptide of type III procollagen in patients with Crohn's disease. J. Gastrointest. Surg. 11: 1361-1364 (2007). *
De Tena JG, Manzano L, Leal JC, Antonio ES, Sualdea V, Alvarez-Mon M. Active Crohn's disease patients show a distinctive expansion of circulating memory CD4(+)CD45RO(+)CD28(null) T cells. J. Clin. Immunol. 24: 185-196 (2004). *
de Villiers WJ. Crohn's disease and IL-10 therapy: promise regained. Inflamm. Bowel Dis. 9: 210-211 (2003). *
de Vlam K, Mielants H, Cuvelier C, De Keyser F, Veys EM, De Vos M. Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. J. Rheumatol. 27: 2860-2865 (2000).
De Vos M. Joint involvement in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 36-42 (2004). *
De Vos M. Intestines and joints: an entity? Verh. K. Acad. Geneeskd. Belg. 64: 85-99 (2002).
De Vos tot Nederveen Cappel WH, Langers AM, Hommes DW. First endoscopic appearance of ulcerative colitis. Journal of Crohn's and Colitis 3: 42-43 (2009).
de Vries HS, Plantinga TS, van Krieken JH, Stienstra R, van Bodegraven AA, Festen EA, Weersma RK, Crusius JB, Linskens RK, Joosten LA, Netea MG, de Jong DJ. Genetic association analysis of the functional c.714T>G polymorphism and mucosal expression of dectin-1 in inflammatory bowel disease. PLoS One 4: e7818 (2009). *
de Zoeten EF, Hancock WW. Strategies to cure experimental autoimmune colitis using antigen-specific Foxp3(+) regulatory T cells. Gastroenterology 134: 2171-2174 (2008). *
De' Angelis GL, Fornaroli F, De' Angelis N, Magiteri B, Bizzarri B. Wireless capsule endoscopy for pediatric small-bowel diseases. Am. J. Gastroenterol. 102: 1749-1757 (2007). *
Dear KL, Compston JE, Hunter JO. Treatments for Crohn's disease that minimise steroid doses are associated with a reduced risk of osteoporosis. Clin. Nutr. 20: 541-546 (2001).
Deban L, Correale C, Vetrano S, Malesci A, Danese S. Multiple pathogenic roles of microvasculature in inflammatory bowel disease: a Jack of all trades. Am. J. Pathol. 172: 1457-1466 (2008). *
Debler J, Schiemann U, Seybold U, Mussack T, Landauer N, Ladurner R, Gross M. Heat-shock protein HSP70-2 genotypes in patients with Crohn's disease: a more severe clinical course with intestinal complications in presence of the PstI-polymorphism. Eur. J. Med. Res. 8: 120-124 (2003).
Debniak T, Kurzawski G, Huzarski T, Byrski T, Gronwald J, Debniak B, Rozmiarek A, Dziuba I, Zlowocka E, Suchy J, Gorski B, Cybulski C, Mierzejewski M, Masojc B, Medrek K, Oszurek O, Lubinski J. NOD2 variants and the risk of malignant melanoma. Eur. J. Cancer Prev. 14: 143-146 (2005).
Dechairo B, Dimon C, van Heel D, Mackay I, Edwards M, Scambler P, Jewell D, Cardon L, Lench N, Carey A. Replication and extension studies of inflammatory bowel disease susceptibility regions confirm linkage to chromosome 6p (IBD3). Eur. J. Hum. Genet. 9: 627-633 (2001). *
Decker GA, Loftus EV Jr, Pasha TM, Tremaine WJ, Sandborn WJ. Crohn's disease of the esophagus: clinical features and outcomes. Inflamm. Bowel Dis. 7: 113-119 (2001). *
Decker P, Briand JP, de Murcia G, Pero RW, Isenberg DA, Muller S. Zinc is an essential cofactor for recognition of the DNA binding domain of poly(ADP-ribose) polymerase by antibodies in autoimmune rheumatic and bowel diseases. Arthritis Rheum. 41: 918-926 (1998). *
Declercq C, Gower-Rousseau C, Vernier-Massouille G, Salleron J, Balde M, Poirier G, Lerebours E, Dupas JL, Merle V, Marti R, Duhamel A, Cortot A, Salomez JL, Colombel JF. Mapping of inflammatory bowel disease in northern France: spatial variations and relation to affluence. Inflamm. Bowel Dis. Sep 22 [Epub ahead of print] (2009). *
Dedek P, Pozler O, Cihula J. Hepatobiliary disorders in chronic nonspecific intestinal inflammation. Cesk. Pediatr. 48: 590-594 (1993).
Dederichs F, Pinciu F, Gerhard H, Eveld K, Stallmach A. Listeria meningitis in a patient with Crohn's disease - a seldom, but clinically relevant adverse event of therapy with infliximab. Z. Gastroenterol. 44: 657-660 (2006).
Degagne E, Grbic DM, Dupuis AA, Lavoie EG, Langlois C, Jain N, Weisman GA, Sevigny J, Gendron FP. P2Y2 receptor transcription is increased by NF-kappaB and stimulates cyclooxygenase-2 expression and PGE2 released by intestinal epithelial cells. J. Immunol. 183: 4521-4529 (2009).
Dehmer C, Greinwald R, Loffler J, Grotz W, Wolf L, Hagmann HB, Schneider W, Kreisel W; German Salofalk Study Group. No dose-dependent tubulotoxicity of 5-aminosalicylic acid: a prospective study in patients with inflammatory bowel diseases. Int. J. Colorectal Dis. 18: 406-412 (2003). *
Dehni N, Remacle G, Dozois RR, Banchini F, Tiret E, Parc R. Salvage reoperation for complications after ileal pouch-anal anastomosis. Br. J. Surg. 92: 748-753 (2005). *
Deitch HR, Huppert J, Adams Hillard PJ. Unusual vulvar ulcerations in young adolescent females. J. Pediatr. Adolesc. Gynecol. 17: 13-16 (2004).
Dejaco C, Haas T, Kirchgatterer A, Miehsler W, Wenzl H, Knoflach P, Petritsch W, Vogelsang H, Reinisch W, Tilg H. Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases - consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH. Z. Gastroenterol. 44: 525-538 (2006).
Dejaco C, Harrer M, Waldhoer T, Miehsler W, Vogelsang H, Reinisch W. Antibiotics and azathioprine for the treatment of perianal fistulas in Crohn's disease. Aliment. Pharmacol. Ther. 18: 1113-1120 (2003). *
Dejica D. Serum soluble IL-2 receptor as a marker of lymphocyte activation in some autoimmune diseases. Effect of immunosuppressive therapy. Roum. Arch. Microbiol. Immunol. 60: 183-201 (2001).
Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM. Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis. Clin. Exp. Rheumatol. 22: 252-258 (2004).
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Agenant D, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. II. Prevalence of peripheral arthritis, sacroiliitis, and ankylosing spondylitis in patients suffering from inflammatory bowel disease. Ann. Rheum. Dis. 37: 33-35 (1978). *
Dekker-Saeys BJ, Meuwissen SG, Van Den Berg-Loonen EM, De Haas WH, Meijers KA, Tytgat GN. Ankylosing spondylitis and inflammatory bowel disease. III. Clinical characteristics and results of histocompatibility typing (HLA B27) in 50 patients with both ankylosing spondylitis and inflammatory bowel disease. Ann. Rheum. Dis. 37: 36-41 (1978). *
Del Vescovo R, Sansoni I, Caviglia R, Ribolsi M, Perrone G, Leoncini E, Grasso RF, Cicala M, Zobel BB. Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: differentiation of activity of Crohn's disease. Abdom. Imaging 33: 417-424 (2008). *
Del Zotto B, Mumolo G, Pronio AM, Montesani C, Tersigni R, Boirivant M. TGF-beta1 production in inflammatory bowel disease: differing production patterns in Crohn's disease and ulcerative colitis. Clin. Exp. Immunol. 134: 120-126 (2003). *
Delaini GG, Scaglia M, Lindholm E, Colucci G, Hulten L. Is an ileal pouch an alternative for patients requiring surgery for Crohn's proctocolitis? Tech. Coloproctol. 9: 222-224 (2005). *
Delaporte E. Immune-mediated inflammatory diseases and psoriasis. Ann. Dermatol. Venereol. 135 Suppl. 4: S269-S274 (2008).
Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 335-342 (2006).
Delboy H. Mode of action of sulfasalazine in chronic inflammatory enterocolonic diseases. Therapie 47: 157-159 (1992).
Delco F, Sonnenberg A. Commonalities in the time trends of Crohn's disease and ulcerative colitis. Am. J. Gastroenterol. 94: 2171-2176 (1999). *
DeLegge MH. Enteral feeding. Curr. Opin. Gastroenterol. 24: 184-189 (2008). *
Delgado F, Estrada-Chavez C, Romano M, Paolicchi F, Blanco-Viera F, Capellino F, Chavez-Gris G, Pereira-Suarez AL. Expression of NRAMP1 and iNOS in Mycobacterium avium subsp. paratuberculosis naturally infected cattle. Comp. Immunol. Microbiol. Infect. Dis. Apr 3 [Epub ahead of print] (2009). *
Delgado J, Delgado B, Sztarkier I, Cagnano E, Sperber AD, Fich A. Presentation of Crohn's disease as metastatic cutaneous non-caseating granulomatous lesions. Isr. Med. Assoc. J. 5: 897-898 (2003). *
Delgado M, Abad C, Martinez C, Juarranz MG, Arranz A, Gomariz RP, Leceta J. Vasoactive intestinal peptide in the immune system: potential therapeutic role in inflammatory and autoimmune diseases. J. Mol. Med. 80: 16-24 (2002). *
Delgado M, Abad C, Martinez C, Juarranz MG, Leceta J, Ganea D, Gomariz RP. PACAP in immunity and inflammation. Ann. N. Y. Acad. Sci. 992: 141-157 (2003). *
Delgado M, Singh S, De Haro S, Master S, Ponpuak M, Dinkins C, Ornatowski W, Vergne I, Deretic V. Autophagy and pattern recognition receptors in innate immunity. Immunol. Rev. 227: 189-202 (2009). *
Delikoukos S, Christodoulidis G, Zacharoulis D, Poultsidi A, Hatzitheofilou C. Multiple small bowel ruptures due to ischemic enteritis: a case report. World J. Gastroenterol. 12: 4262-4263 (2006). *
Dell'Isola B, Poyart C, Goulet O, Mougenot JF, Sadoun-Journo E, Brousse N, Schmitz J, Ricour C, Berche P. Detection of Mycobacterium paratuberculosis by polymerase chain reaction in children with Crohn's disease. J. Infect. Dis. 169: 449-451 (1994).
Delle Monache M, Salvio A, Fiocca F, Basoli A, Ricci GL. Primary sclerosing cholangitis: an analysis of 37 retrospective cases. Ital. J. Gastroenterol. 24: 485-488 (1992).
Delpre G, Kadish U, Gazit E, Joshua H, Zamir R. HLA antigens in ulcerative colitis and Crohn's disease in Israel. Gastroenterology 78: 1452-1457 (1980).
Deltenre P, Berson A, Marcellin P, Degott C, Biour M, Pessayre D. Mesalazine (5-aminosalicylic acid) induced chronic hepatitis. Gut 44: 886-888 (1999). *
Delvaux M, Ben Soussan E, Laurent V, Lerebours E, Gay G. Clinical evaluation of the use of the M2A patency capsule system before a capsule endoscopy procedure, in patients with known or suspected intestinal stenosis. Endoscopy 37: 801-807 (2005).
Delvaux M, Gay G. Capsule endoscopy: technique and indications. Best Pract. Res. Clin. Gastroenterol. 22: 813-837 (2008).
Delvaux M, Gerard Gay. Capsule endoscopy in 2005: facts and perspectives. Best Pract. Res. Clin. Gastroenterol. 20: 23-39 (2006).
Dema B, Fernandez-Arquero M, Maluenda C, Polanco I, Figueredo MA, de la Concha EG, Urcelay E, Nunez C. Lack of association of NKX2-3, IRGM and ATG16L1 inflammatory bowel diseases susceptibility variants with celiac disease. Hum. Immunol. 70: 946-949 (2009).
Demarchi B, Bresso F, Novero D, Palestro G, Sapone N, Pellicano R, Bonardi R, Smedile A, Rizzetto M, Astegiano M. Hepatocellular carcinoma complicating primary sclerosing cholangitis in Crohn's disease. A case report. Minerva Gastroenterol. Dietol. 53: 279-283 (2007).
DeMeo MT, Mutlu EA, Keshavarzian A, Tobin MC. Intestinal permeation and gastrointestinal disease. J. Clin. Gastroenterol. 34: 385-396 (2002). *
Demetter P, De Vos M, Van Huysse JA, Baeten D, Ferdinande L, Peeters H, Mielants H, Veys EM, De Keyser F, Cuvelier CA. Colon mucosa of both spondyloarthritis and Crohn's disease patients is enriched with macrophages expressing the scavenger receptor CD163. Ann. Rheum. Dis. 64: 321-324 (2005). *
Demicheli V, Jefferson T, Rivetti A, Price D, Demicheli V. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst. Rev. 4: CD004407 (2005). *
Demling L. Crohn disease caused by antibiotics? A medical hypothesis based on epidemiologic data. Fortschr. Med. 112: 195-196 (1994).
Demory D, Forel JM, Michel F, Guillin-Poujol A, Consentino B, Gainnier M, Papazian L, Sainty JM. Crohn disease and abdominal tuberculosis: complications related to a diagnostic error. Presse. Med. 35: 51-54 (2006).
Dendrinos KG, Becker JM, Stucchi AF, Saubermann LJ, Lamorte W, Farraye FA. Anti-Saccharomyces cerevisiae antibodies are associated with the development of postoperative fistulas following ileal pouch-anal anastomosis. J. Gastrointest. Surg. 10: 1060-1064 (2006).
Deng L, Ding W, Granstein RD. Thalidomide inhibits tumor necrosis factor-alpha production and antigen presentation by Langerhans cells. J. Invest. Dermatol. 121: 1060-1065 (2003). *
Denis MA, Reenaers C, Fontaine F, Belaiche J, Louis E. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm. Bowel Dis. 13: 1100-1105 (2007). *
Denizot Y, Chaussade S. Platelet activating factor and Crohn's disease. Gut 35: 141 (1994). *
Depoortere I. Motilin and motilin receptors: characterization and functional significance. Verh. K. Acad. Geneeskd. Belg. 63: 511-529 (2001).
Der G, Love T, Schreck J, Horn M. Primary sclerosing cholangitis: a case presentation. Gastroenterol. Nurs. 28: 13-16 (2005). *
Derakhshan F, Naderi N, Farnood A, Firouzi F, Habibi M, Rezvany MR, Javeri A, Bahari A, Balaii H, Rad MG, Aghazadeh R, Zali MR. Frequency of three common mutations of CARD15/NOD2 gene in Iranian IBD patients. Indian J. Gastroenterol. 27: 8-11 (2008). *
Derenne JL. Abrupt-onset obsessive-compulsive disorder (OCD) in a child with Crohn's disease. Psychosomatics 50: 425-426 (2009).
Deretic V. Multiple regulatory and effector roles of autophagy in immunity. Curr. Opin. Immunol. 21: 53-62 (2009).
Deretic V. Autophagy in infection. Curr. Opin. Cell Biol. Jan 28 [Epub ahead of print] (2010).
Deretic V. Links between autophagy, innate immunity, inflammation and Crohn's disease. Dig. Dis. 27: 246-251 (2009).
Deretic V, Master S, Singh S. Autophagy gives a nod and a wink to the inflammasome and Paneth cells in Crohn's disease. Dev. Cell 15: 641-642 (2008). *
Derijks LJ, Gilissen LP, Hooymans PM, Hommes DW. Review article: thiopurines in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24: 715-729 (2006). *
Desai HG, Gupte PA. Increasing incidence of Crohn's disease in India: is it related to improved sanitation? Indian J. Gastroenterol. 24: 23-24 (2005). *
Deschamps L, Bretagnol F, Couvelard A, Corcos O, Bedossa P, Panis Y. Inflammatory fibroid polyp in Crohn's disease revealed by ileoileal intussusception: case report and review of the literature. Inflamm. Bowel Dis. 14: 1317-1320 (2008). *
Descos L. Extra-intestinal manifestations. Rev. Prat. 41: 415-418 (1991).
Deshmukh H, Kim-Howard X, Nath SK. Replication of recently identified associated single-nucleotide polymorphisms from six autoimmune diseases in Genetic Analysis Workshop 16 rheumatoid arthritis data. BMC Proc. 3 Suppl. 7: S31 (2009). *
Deshpande AV, Lahei ER, Shun A, Martin HC, O'loughlin EV. Idiopathic fibrosing pancreatitis in children-a single-center experience. J. Pediatr. Surg. 41: 1987-1991 (2006).
Desilva S, Kaplan G, Panaccione R. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev. Gastroenterol. Disord. 8: 109-116 (2008).
Desir B, Amre DK, Lu SE, Ohman-Strickland P, Dubinsky M, Fisher R, Seidman EG. Utility of serum antibodies in determining clinical course in pediatric Crohn's disease. Clin. Gastroenterol. Hepatol. 2: 139-146 (2004). *
Desmet VJ, Geboes K. Liver lesions in inflammatory bowel disorders. J. Pathol. 151: 247-255 (1987).
Desmond AN, O'Regan K, Curran C, McWilliams S, Fitzgerald T, Maher MM, Shanahan F. Crohn's disease: factors associated with exposure to high levels of diagnostic radiation. Gut 57: 1524-1529 (2008).
Desplat-Jego S, Johanet C, Escande A, Goetz J, Fabien N, Olsson N, Ballot E, Sarles J, Baudon JJ, Grimaud JC, Veyrac M, Chamouard P, Humbel RL. Update on anti-Saccharomyces cerevisiae antibodies, anti-nuclear associated anti-neutrophil antibodies and antibodies to exocrine pancreas detected by indirect immunofluorescence as biomarkers in chronic inflammatory bowel diseases … World J. Gastroenterol. 13: 2312-2318 (2007). *
Despott EJ, Gupta A, Burling D, Tripoli E, Konieczko K, Hart A, Fraser C. Effective dilation of small-bowel strictures by double-balloon enteroscopy in patients with symptomatic Crohn's disease (with video). Gastrointest. Endosc. 70: 1030-1036 (2009).
Desreumaux P. Role of CARD15/Nod2 in the regulation of the host's response to pathogens in patients with Crohn's disease. Gastroenterol. Clin. Biol. 26: 1065-1066 (2002).
Desreumaux P, Colombel JF. Intestinal flora and Crohn's disease. Ann. Pharm. Fr. 61: 276-281 (2003).
Dessein R, Chamaillard M, Danese S. Innate immunity in Crohn's disease: the reverse side of the medal. J. Clin. Gastroenterol. 42 Suppl. 3 Pt. 1: S144-S147 (2008).
Deter HC, Keller W, von Wietersheim J, Jantschek G, Duchmann R, Zeitz M. Psychological treatment may reduce the need for healthcare in patients with Crohn's disease. Inflamm. Bowel Dis. 13: 745-752 (2007). *
Deter HC, von Wietersheim J, Jantschek G, Burgdorf F, Blum B, Keller W; the German Study Group on Psychosocial Intervention in Crohn's Disease. High-utilizing Crohn's disease patients under psychosomatic therapy. Biopsychosoc. Med. 2: 18 (2008). *
Detkova Z, Kupcova V, Prikazska M, Turecky L, Weissova S, Jahnova E. Different patterns of serum interleukin 10 response to treatment with anti-tumor necrosis factor alpha antibody (infliximab) in Crohn's disease. Physiol. Res. 52: 95-100 (2003). *
Dettinger M, Matzke M, McKay K, Sizer R, Thoreson M, Wrobleski D. Crohn's disease and ulcerative colitis. J. Contin. Educ. Nurs. 39: 151-152 (2008).
Deutschmann A, Mache CJ, Bodo K, Zebedin D, Ring E. Successful treatment of chronic recurrent multifocal osteomyelitis with tumor necrosis factor-alpha blockage. Pediatrics 116: 1231-1233 (2005). *
Devani M, Vecchi M, Ferrero S, Avesani EC, Arizzi C, Chao L, Colman RW, Cugno M. Kallikrein-kinin system in inflammatory bowel diseases: intestinal involvement and correlation with the degree of tissue inflammation. Dig. Liver Dis. 37: 665-673 (2005).
Devbhandari MP, Raco L, Hendrickse MT, Duncan AJ. Congenital bronchoesophageal fistula in a patient with Crohn's disease: a cautionary tale. Ann. Thorac. Surg. 79: 1776-1777 (2005).
Deveaux PG, Kimberling J, Galandiuk S. Crohn's disease: presentation and severity compared between black patients and white patients. Dis. Colon Rectum 48: 1404-1409 (2005). *
Devesa JM, Devesa M, Velasco GR, Vicente R, Garcia-Moreno F, Rey A, Lopez-Hervas P, Die J, Molina JM. Benign rectovaginal fistulas: management and results of a personal series. Tech. Coloproctol. 11: 128-134 (2007). *
Devlin SM, Hu B, Ippoliti A. Mucormycosis presenting as recurrent gastric perforation in a patient with Crohn's disease on glucocorticoid, 6-mercaptopurine, and infliximab therapy. Dig. Dis. Sci. 52: 2078-2081 (2007). *
Devlin SM, Panaccione R. Adalimumab for the treatment of Crohn's disease. Expert Opin. Biol. Ther. 8: 1011-1019 (2008).
Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med. Clin. North Am. 94: 1-18 (2010).
Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol. Clin. North Am. 38: 577-594 (2009).
Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, Abreu MT, Papadakis KA, Vasiliauskas EA, Melmed GY, Fleshner PR, Mei L, Rotter JI, Targan SR. NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology 132: 576-586 (2007). *
Devon KM, Brown CJ, Burnstein M, McLeod RS. Cancer of the anus complicating perianal Crohn's disease. Dis. Colon Rectum 52: 211-216 (2009).
Devroe H, Coene L, Mortelmans LJ, Jutten G. Colloid carcinoma arising in an anorectal fistula in Crohn's disease: a case report. Acta Chir. Belg. 105: 110-111 (2005).
Dewit O, Vanheuverzwyn R, Desager JP, Horsmans Y. Interaction between azathioprine and aminosalicylates: an in vivo study in patients with Crohn's disease. Aliment. Pharmacol. Ther. 16: 79-85 (2002). *
Dewulf Nde L, Monteiro RA, Passos AD, Vieira EM, Troncon LE. Compliance to drug therapy in inflammatory bowel diseases outpatients from an university hospital. Arq. Gastroenterol. 44: 289-296 (2007).
Dharancy S, Talbodec N, Asselah T, Hachulla E, Delaporte E, Cortot A, Colombel JF. The synovitis-acne-pustulosis-hyperostosis-osteitis (SAPHO) syndrome, a rare extra-digestive manifestation of Crohn's disease. Presentation of 1 case and review of the literature. Gastroenterol. Clin. Biol. 22: 240-243 (1998).
Dharmani P, Chadee K. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key. Curr. Mol. Pharmacol. 1: 195-212 (2008).
Dhawan SS, Finks AL, Wang BW. Mycobacterial coxitis masked by concomitant staphylococcal infection after infliximab for Crohn's disease. Joint Bone Spine 76: 107-108 (2009). *
Dhillon S, Loftus EV. Medical therapy of Crohn's disease. Curr. Treat. Options Gastroenterol. 8: 19-30 (2005).
Dhruva PK, Price PE, Torkington J. Current practice in management of Crohn's disease in Wales. Surgeon 6: 26-31 (2008).
Di Caro S, May A, Heine DG, Fini L, Landi B, Petruzziello L, Cellier C, Mulder CJ, Costamagna G, Ell C, Gasbarrini A; for the DBE-European Study Group. The European experience with double-balloon enteroscopy: indications, methodology, safety, and clinical impact. Gastrointest. Endosc. 62: 545-550 (2005).
Di Febo G, Calabrese C, Matassoni F. New trends in non-absorbable antibiotics in gastrointestinal disease. Ital. J. Gastroenterol. 24: S10-S13 (1992).
Di Fiore F, Lecleire S, Herve S, Savoye G, Lerebours E. Life-threatening bleeding revealing gastric involvement in a Crohn's disease patient. J. Clin. Gastroenterol. 38: 833-834 (2004).
Di Gangi M, Foti R, Leonardi R, Leonetti C, Castellino P. Recurrent new-onset uveitis in a patient with rheumatoid arthritis during anti-TNFalpha treatment. Reumatismo 59: 169-172 (2007).
Di L, Srivastava S, Zhdanova O, Ding Y, Li Z, Wulff H, Lafaille M, Skolnik EY. Inhibition of the K+ channel KCa3.1 ameliorates T cell-mediated colitis. Proc. Natl. Acad. Sci. U.S.A. Jan 14 [Epub ahead of print] (2010). *
Di Marco R, Mangano K, Quattrocchi C, Musumeci R, Speciale AM, Papaccio G, Buschard K, Bendtzen K, Nicoletti F. Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. Clin. Immunol. 109: 266-271 (2003). *
Di Mola FF, Di Sebastiano P, Gardini A, Innocenti P, Zimmermann A, Buchler MW, Friess H. Differential expression of connective tissue growth factor in inflammatory bowel disease. Digestion 69: 245-253 (2004).
Di Prima L, Sferrazza C, Avila D, Pirrone G, Cappello G, Di Lorenzo G, Carroccio A, Rini GB, Di Fede G. Osteoporotic risk in Crohn's disease. Recenti Prog. Med. 96: 254-260 (2005).
Di Sabatino A, Armellini E, Corazza GR. Doppler sonography in the diagnosis of inflammatory bowel disease. Dig. Dis. 22: 63-66 (2004).
Di Sabatino A, Carsetti R, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Tinozzi FP, Tinozzi S, Corazza GR. Immunoglobulin M memory B cell decrease in inflammatory bowel disease. Eur. Rev. Med. Pharmacol. Sci. 8: 199-203 (2004).
Di Sabatino A, Ciccocioppo R, Armellini E, Morera R, Ricevuti L, Cazzola P, Fulle I, Corazza GR. Serum bFGF and VEGF correlate respectively with bowel wall thickness and intramural blood flow in Crohn's disease. Inflamm. Bowel Dis. 10: 573-577 (2004). *
Di Sabatino A, Ciccocioppo R, Benazzato L, Sturniolo GC, Corazza GR. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients. Aliment. Pharmacol. Ther. 19: 1019-1024 (2004). *
Di Sabatino A, Ciccocioppo R, Cinque B, Millimaggi D, Morera R, Ricevuti L, Cifone MG, Corazza GR. Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn's disease. Gut 53: 70-77 (2004). *
Di Sabatino A, Ciccocioppo R, Luinetti O, Ricevuti L, Morera R, Cifone MG, Solcia E, Corazza GR. Increased enterocyte apoptosis in inflamed areas of Crohn's disease. Dis. Colon Rectum 46: 1498-1507 (2003).
Di Sabatino A, Corazza GR. Surviving too long in Crohn's disease. Gut 49: 6-8 (2001). *
Di Sabatino A, Fulle I, Ciccocioppo R, Ricevuti L, Tinozzi FP, Tinozzi S, Campani R, Corazza GR. Doppler enhancement after intravenous levovist injection in Crohn's disease. Inflamm. Bowel Dis. 8: 251-257 (2002). *
Di Sabatino A, Jackson C, Pickard K, Buckley M, Leakey N, Picariello L, Monteleone G, Tonelli F, Corazza GR, MacDonald TT, Pender S. Transforming growth factor-beta signalling and matrix metalloproteinases in the mucosa overlying Crohn’s disease strictures. Gut 58: 777-789 (2009).
Di Sabatino A, Morera R, Ciccocioppo R, Cazzola P, Gotti S, Tinozzi FP, Tinozzi S, Corazza GR. Oral butyrate for mildly to moderately active Crohn's disease. Aliment. Pharmacol. Ther. 22: 789-794 (2005). *
Di Sabatino A, Pender SL, Jackson CL, Prothero JD, Gordon JN, Picariello L, Rovedatti L, Docena G, Monteleone G, Rampton DS, Tonelli F, Corazza GR, Macdonald TT. Functional modulation of Crohn's disease myofibroblasts by anti-tumor necrosis factor antibodies. Gastroenterology 133: 137-149 (2007). *
Di Sabatino A, Rosado MM, Cazzola P, Biancheri P, Tinozzi FP, Laera MR, Cantoro L, Vanoli A, Carsetti R, Corazza GR. Splenic function and IgM-memory B cells in Crohn's disease patients treated with infliximab. Inflamm. Bowel Dis. 14: 591-596 (2008). *
Di Sabatino A, Rosado MM, Ciccocioppo R, Cazzola P, Morera R, Corazza GR, Carsetti R. Depletion of immunoglobulin M memory B cells is associated with splenic hypofunction in inflammatory bowel disease. Am. J. Gastroenterol. 100: 1788-1795 (2005). *
Di Sabatino A, Saarialho-Kere U, Buckley MG, Gordon JN, Biancheri P, Rovedatti L, Corazza GR, Macdonald TT, Pender SL. Stromelysin-1 and macrophage metalloelastase expression in the intestinal mucosa of Crohn's disease patients treated with infliximab. Eur. J. Gastroenterol. Hepatol. 21: 1049-1055 (2009).
Di Tola M, Sabbatella L, Anania MC, Viscido A, Caprilli R, Pica R, Paoluzi P, Picarelli A. Anti-tissue transglutaminase antibodies in inflammatory bowel disease: new evidence. Clin. Chem. Lab. Med. 42: 1092-1097 (2004).
Diaconescu MR, Costea I, Glod M, Ceobanu M, Bulimar V, Ciolpan C. Gastrocolic fistulas. Review of three cases. Rev. Med. Chir. Soc. Med. Nat. Iasi. 110: 899-904 (2006).
Dialynas DP, Rodgers VD. Anomalous leukopoiesis in two patients with Crohn's disease. J. Clin. Gastroenterol. 34: 64-71 (2002).
Diamanti A, Basso MS, Gambarara M, Papadatou B, Bracci F, Noto C, Castro M. Positive impact of blocking tumor necrosis factor alpha on the nutritional status in pediatric Crohn's disease patients. Int. J. Colorectal Dis. 24: 19-25 (2009). *
Diamanti A, Noto C, Basso MS, Papadatou B, Bracci F, Castro M. Efficacy and safety of intravenous neridronate in pediatric bone loss associated to Crohn's disease: a case report. Clin. Exp. Rheumatol. 27: 165 (2009).
Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Clinical outcome and safety of periodic infliximab therapy in children and adolescents with Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 39: 302-303 (2004). *
Diamanti A, Papadatou B, Knafelz D, Gambarara M, Ferretti F, Castro M. Complications of infliximab therapy in children and adolescents affected by Crohn's disease. Am. J. Gastroenterol. 98: 2812-2813 (2003). *
Dias VC, Lago P, Santos M. Ileouterine fistula: an unusual complication of Crohn's disease. Inflamm. Bowel Dis. 14: 1465-1466 (2008). *
Diaz Rodriguez C, Granja E, Vazquez Martul E, Sacristan F, Moreno Fernandez A, Gonzalez Rivero C, del Rio Romero D, Trinidad JC. Association between membranous glomerulonephritis and Crohn's disease. Nefrologia 24: 368-371 (2004).
Diaz Sibaja MA, Comeche Moreno MI, Mas Hesse B. Protocolized cognitive-behavioural group therapy for inflammatory bowel disease. Rev. Esp. Enferm. Dig. 99: 593-598 (2007).
Diaz-Gallo LM, Palomino-Morales RJ, Gomez-Garcia M, Cardena C, Rodrigo L, Nieto A, Alcain G, Cueto I, Lopez-Nevot MA, Martin J. The STAT4 gene influences genetic predisposition to ulcerative colitis but not Crohn's disease in the Spanish population: a replication study. Hum. Immunol. Feb 11 [Epub ahead of print] (2010).
Diaz-Valle D, Benitez del Castillo JM, Fernandez Acenero MJ, Pascual Allen D, Moriche Carretero M. Bilateral lid margin ulcers as the initial manifestation of Crohn disease. Am. J. Ophthalmol. 138: 292-294 (2004). *
Dibble JB, Sheridan P, Losowsky MS. A survey of vitamin D deficiency in gastrointestinal and liver disorders. Q. J. Med. 53: 119-134 (1984).
Dickinson AM, Middleton PG, Rocha V, Gluckman E, Holler E; Eurobank members. Genetic polymorphisms predicting the outcome of bone marrow transplants. Br. J. Haematol. 127: 479-490 (2004). *
Dickinson RJ, O'Connor HJ, Pinder I, Hamilton I, Johnston D, Axon AT. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut 26: 1380-1384 (1985). *
Dicksved J, Halfvarson J, Rosenquist M, Jarnerot G, Tysk C, Apajalahti J, Engstrand L, Jansson JK. Molecular analysis of the gut microbiota of identical twins with Crohn's disease. ISME J. 2: 716-727 (2008). *
Dideberg V, Kristjansdottir G, Milani L, Libioulle C, Sigurdsson S, Louis E, Wiman AC, Vermeire S, Rutgeerts P, Belaiche J, Franchimont D, Van Gossum A, Bours V, Syvanen AC. An insertion-deletion polymorphism in the interferon regulatory factor 5 (IRF5) gene confers risk of inflammatory bowel diseases. Hum. Mol. Genet. 16: 3008-3016 (2007). *
Dideberg V, Louis E, Farnir F, Bertoli S, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Belaiche J, Bours V. Lymphotoxin alpha gene in Crohn's disease patients: absence of implication in the response to infliximab in a large cohort study. Pharmacogenet. Genomics 16: 369-373 (2006).
Dideberg V, Theatre E, Farnir F, Vermeire S, Rutgeerts P, Vos MD, Belaiche J, Franchimont D, Gossum AV, Louis E, Bours V. The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet. Genomics 16: 727-734 (2006).
Dieckgraefe BK. What does football have in common with Crohn's disease? The best "defense-in" is a good offense. Inflamm. Bowel Dis. 11: 322-323 (2005). *
Dieckgraefe BK, Korzenik JR. Treatment of active Crohn's disease with recombinant human granulocyte-macrophage colony-stimulating factor. Lancet 360: 1478-1480 (2002). *
Dieckgraefe BK, Korzenik JR, Husain A, Dieruf L. Association of glycogen storage disease 1b and Crohn disease: results of a North American survey. Eur. J. Pediatr. 161 Suppl. 1: S88-S92 (2002).
Diedegraefe B. Giving the NOD to a new understanding of Crohn's disease: mother nature has finally started to show her CARDs. Inflamm. Bowel Dis. 10: 171-172 (2004). *
Diefenbach KA, Breuer CK. Pediatric inflammatory bowel disease. World J. Gastroenterol. 12: 3204-3212 (2006). *
Diego CD, Alcantara M, Valle J, Perez-Grueso MJ, Munoz-Rosas C, Carrobles JM, Martinez-Castro P. Frequency of CARD15 polymorphisms in patients with Crohn's disease from Toledo, Spain: genotype-phenotype correlation. Genet. Test. 10: 178-185 (2006).
Dieleman LA, Pena AS, Meuwissen SG, van Rees EP. Role of animal models for the pathogenesis and treatment of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. 223: 99-104 (1997).
Dietrich CF. Significance of abdominal ultrasound in inflammatory bowel disease. Dig. Dis. 27: 482-493 (2009).
Dietrich CF, Jedrzejczyk M, Ignee A. Sonographic assessment of splanchnic arteries and the bowel wall. Eur. J. Radiol. 64: 202-212 (2007).
Dietrich W, Erbguth F. Neurological complications of inflammatory intestinal diseases. Fortschr. Neurol. Psychiatr. 71: 406-414 (2003).
Difedele LM, He J, Bonkowski EL, Han X, Held MA, Bohan A, Menon RK, Denson LA. Tumor necrosis factor alpha blockade restores growth hormone signaling in murine colitis. Gastroenterology 128: 1278-1291 (2005). *
Dignass A, Marteau P. Mesalamine in the treatment of active Crohn's disease. Gastroenterology 128: 245-246 (2005). *
Dignass AU. Management of perianal fistulizing Crohn's disease: a conservative approach. Dtsch. Med. Wochenschr. 130: 1968 (2005).
Dignass AU, Baumgart DC, Sturm A. The aetiopathogenesis of inflammatory bowel disease - immunology and repair mechanisms. Aliment. Pharmacol. Ther. 20 Suppl. 4: 9-17 (2004). *
Dijkstra G, Hospers GA, Kleibeuker JH. Gene therapy with interleukin 10 in Crohn's disease: too early yet. Ned. Tijdschr. Geneeskd. 147: 2153-2156 (2003).
Dijkstra G, Moshage H, van Dullemen HM, de Jager-Krikken A, Tiebosch AT, Kleibeuker JH, Jansen PL, van Goor H. Expression of nitric oxide synthases and formation of nitrotyrosine and reactive oxygen species in inflammatory bowel disease. J. Pathol. 186: 416-421 (1998). *
Dilger K, Alberer M, Busch A, Enninger A, Behrens R, Koletzko S, Stern M, Beckmann C, Gleiter CH. Pharmacokinetics and pharmacodynamic action of budesonide in children with Crohn's disease. Aliment. Pharmacol. Ther. 23: 387-396 (2006). *
Dilger K, Fux R, Rock D, Morike K, Gleiter CH. Effect of high-dose metronidazole on pharmacokinetics of oral budesonide and vice versa: a double drug interaction study. J. Clin. Pharmacol. 47: 1532-1539 (2007). *
Dilger K, Schaeffeler E, Lukas M, Strauch U, Herfarth H, Muller R, Schwab M. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine. Ther. Drug Monit. 29: 1-5 (2007).
Dilger K, Schwab M, Fromm MF. Identification of budesonide and prednisone as substrates of the intestinal drug efflux pump P-glycoprotein. Inflamm. Bowel Dis. 10: 578-583 (2004). *
Dillman JR, Adler J, Zimmermann EM, Strouse PJ. CT enterography of pediatric Crohn disease. Pediatr. Radiol. Nov 20 [Epub ahead of print] (2009).
Dimakou K, Papaioannides D, Latsi P, Katsimboula S, Korantzopoulos P, Orphanidou D. Disseminated tuberculosis complicating anti-TNF-alpha treatment. Int. J. Clin. Pract. 58: 1052-1055 (2004). *
Dimberg J, Dienus O, Lofgren S, Hugander A, Wagsater D. Expression and gene polymorphisms of the chemokine CXCL5 in colorectal cancer patients. Int. J. Oncol. 31: 97-102 (2007). *
Dimitroulia E, Spanakis N, Konstantinidou AE, Legakis NJ, Tsakris A. Frequent detection of cytomegalovirus in the intestine of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 12: 879-884 (2006). *
Din S, Cochrane CJ, Noble CL, Satsangi J, Arnott ID. Combination therapy of infliximab and azathioprine reduces disease progression in Crohn's disease. Inflamm. Bowel Dis. 14: 143-145 (2008). *
Din S, Dahele A, Fennel J, Aitken S, Shand AG, Arnott ID, Satsangi J. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm. Bowel Dis. 14: 756-762 (2008). *
Dinarello CA. Interleukin-18 and the pathogenesis of inflammatory diseases. Semin. Nephrol. 27: 98-114 (2007).
Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine 21 Suppl. 2: S24-S34 (2003). *
Dinarello CA, Kim SH. IL-32, a novel cytokine with a possible role in disease. Ann. Rheum. Dis. 65 Suppl. 3: iii61-iii64 (2006). *
Dinca M, Fries W, Luisetto G, Peccolo F, Bottega F, Leone L, Naccarato R, Martin A. Evolution of osteopenia in inflammatory bowel disease. Am. J. Gastroenterol. 94: 1292-1297 (1999). *
Dinesen L, Travis S. Targeting nanomedicines in the treatment of Crohn's disease: focus on certolizumab pegol (CDP870). Int. J. Nanomedicine 2: 39-47 (2007).
Ding C, Jones G. Anti-interleukin-6 receptor antibody treatment in inflammatory autoimmune diseases. Rev. Recent Clin. Trials 1: 193-200 (2006).
Ding C, Xu J, Li J. ABT-874, a fully human monoclonal anti-IL-12/IL-23 antibody for the potential treatment of autoimmune diseases. Curr. Opin. Investig. Drugs 9: 515-522 (2008).
Dinter DJ, Chakraborty A, Brade J, Back W, Neff KW, Singer MV, Bocker U. Endoscopy and magnetic resonance imaging in patients with Crohn's disease: a retrospective single-centre comparative study. Scand. J. Gastroenterol. 43: 207-216 (2008). *
Dinulos JG, Darmstadt GL, Len MK, Rutledge JC, Murray KF. Infantile Crohn disease presenting with diarrhea and pyoderma gangrenosum. Pediatr. Dermatol. 23: 43-48 (2006). *
Dionisio PM, Gurudu SR, Leighton JA, Leontiadis GI, Fleischer DE, Hara AK, Heigh RI, Shiff AD, Sharma VK. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am. J. Gastroenterol. Dec 22 [Epub ahead of print] (2009). *
Dionne S, Hiscott J, D'Agata I, Duhaime A, Seidman EG. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig. Dis. Sci. 42: 1557-1566 (1997). *
Dippold W, Wittig B, Schwaeble W, Mayet W, Meyer zum Buschenfelde KH. Expression of intercellular adhesion molecule 1 (ICAM-1, CD54) in colonic epithelial cells. Gut 34: 1593-1597 (1993). *
Ditschkowski M, Einsele H, Schwerdtfeger R, Bunjes D, Trenschel R, Beelen DW, Elmaagacli AH. Improvement of inflammatory bowel disease after allogeneic stem-cell transplantation. Transplantation 75: 1745-1747 (2003).
Dixon A, Wurm P, Hart A, Robinson R. Distal adenomatous polyps are rare in patients with inflammatory bowel disease. Postgrad. Med. J. 82: 76-78 (2006). *
Djeddi D, Kongolo G, Goissen C, Mounard J, Ribeiro L, Cevallos R, Gottrand F, Pautard JC. Pulmonary involvement with Crohn's disease in an adolescent. Arch. Pediatr. 13: 202-203 (2006).
Dobbin CJ, Moriarty C, Bye PT. Granulomatous diseases in a patient with cystic fibrosis. J. Cyst. Fibros. 2: 35-37 (2003).
Doboseru R, Drug VL, Azoicai D, Mitrica D, Mihai C, Tarasi I, Popa I, Cijevschi-Prelipcean C, Stanciu C. The changing spectrum of lower gastrointestinal haemorrhages. Rev. Med. Chir. Soc. Med. Nat. Iasi. 108: 90-93 (2004).
Dobrowolska-Zachwieja A, Kaczmarek M, Hoppe-Golebiewska J, Kalak R, Slomski R, Linke K. Does smoking influence the course of Crohn's disease in patients with the presence of gene NOD2/CARD15 mutation? Pol. Merkuriusz. Lek. 18: 560-565 (2005).
Doerffel Y, Pavel M, Loening-Baucke V, Swidsinski A. Common biostructure of the fecal flora in celiac disease, Crohn's disease, and carcinoid tumors. Inflamm. Bowel Dis. 14: 1613-1614 (2008). *
Doering J, Begue B, Lentze MJ, Rieux-Laucat F, Goulet O, Schmitz J, Cerf-Bensussan N, Ruemmele FM. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn’s disease. Gut 53: 1632-1638 (2004). *
Doggrell SA. Inflammation, the key to much pathology. Highlights from the 7th World Congress on Inflammation, held August 20-24, 2005, in Melbourne, Australia. Timely Top. Med. Cardiovasc. Dis. 10: E4 (2006).
Doggrell SA. Inflammation, the key to much pathology. Drug News Perspect. 18: 531-539 (2005).
Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst. Rev. 4: CD006873 (2009).
Doherty G, Kalachand R, Patchett S. Adalimumab as therapy for fistulizing orofacial Crohn's disease. Inflamm. Bowel Dis. 16: 184-185 (2010).
Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. Aliment. Pharmacol. Ther. Jan 4 [Epub ahead of print] (2010). *
Doherty GA, Cheifetz AS. Targeting TNF in postoperative recurrence of Crohn's disease: can we extinguish the fire before it starts? Inflamm. Bowel Dis. 15: 1925-1926 (2009).
Doherty R. Is natalizumab effective as induction or maintenance therapy in Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 62-63 (2006). *
Dolan M, Lindberg G. The Inflammatory Bowel Disease Act: Congress considers landmark legislation focused exclusively on inflammatory bowel disease. Inflamm. Bowel Dis. 9: 59-60 (2003). *
Dolgin SE. Surgical management of upper gastrointestinal and small bowel Crohn's disease. Semin. Pediatr. Surg. 16: 172-177 (2007).
Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment. Pharmacol. Ther. 20: 615-621 (2004). *
Doman DB, Goldberg HJ, Golding MI. "Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by flora-Q probiotic maintenance therapy. Am. J. Gastroenterol. 103: 251-252 (2008). *
Domar U, Danielsson A, Hirano K, Stigbrand T. Alkaline phosphatase isozymes in non-malignant intestinal and hepatic diseases. Scand. J. Gastroenterol. 23: 793-800 (1988).
Domenech E. Inflammatory bowel disease: current therapeutic options. Digestion 73 Suppl. 1: 67-76 (2006). *
Domenech E, Hinojosa J, Esteve-Comas M, Gomollon F, Herrera JM, Bastida G, Obrador A, Ruiz R, Saro C, Gassull MA; for the Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). Granulocyteaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study. Aliment. Pharmacol. Ther. 20: 1347-1352 (2004). *
Domenech E, Hinojosa J, Nos P, Garcia-Planella E, Cabre E, Bernal I, Gassull MA. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Aliment. Pharmacol. Ther. 22: 1107-1113 (2005). *
Domenech E, Manosa M, Bernal I, Garcia-Planella E, Cabre E, Pinol M, Lorenzo-Zuniga V, Boix J, Gassull MA. Impact of azathioprine on the prevention of postoperative Crohn's disease recurrence: results of a prospective, observational, long-term follow-up study. Inflamm. Bowel Dis. 14: 508-513 (2008). *
Domenech E, Manosa M, Cabre E. Top-down therapy: is the evidence strong enough? Dig. Dis. 27: 306-311 (2009).
Domenech E, Manosa M, Masnou H, Navarro M, Garcia-Planella E, Bernal I, Gassull MA. Infliximab for the treatment of chronic anemia in Crohn's disease. Am. J. Gastroenterol. 100: 496 (2005). *
Domenech E, Manosa M, Navarro M, Masnou H, Garcia-Planella E, Zabana Y, Cabre E, Gassull MA. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J. Clin. Gastroenterol. 42: 395-399 (2008).
Domenech E, Nos P, Papo M, Lopez-San Roman A, Garcia-Planella E, Gassull MA. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine. Scand. J. Gastroenterol. 40: 52-55 (2005). *
Domenech E, Scala L, Bernal I, Garcia-Planella E, Casalots A, Pinol M, Esteve-Comas M, Cabre E, Boix J, Gassull MA. Azathioprine and mesalazine in the prevention of postsurgical recurrence of Crohn's disease: a retrospective study. Gastroenterol. Hepatol. 27: 563-567 (2004).
Domenech E, Zabana Y, Garcia-Planella E, Lopez San Roman A, Nos P, Ginard D, Gordillo J, Martinez-Silva F, Beltran B, Manosa M, Cabre E, Gassull MA. Clinical outcome of newly diagnosed Crohn's disease: a comparative, retrospective, study before and after infliximab availability. Aliment. Pharmacol. Ther. 31: 233-239 (2010). *
Dominguez J, Latorre I. Role of the T-cell interferon-gamma release assays in preventing reactivation of latent tuberculosis infection in immunosuppressed patients in treatment with anti-TNF agents. Journal of Crohn's and Colitis 2: 250-254 (2008).
Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency. Curr. Gastroenterol. Rep. 9: 116-122 (2007).
Dominitz JA, Young JC, Boyko EJ. Outcomes of infants born to mothers with inflammatory bowel disease: a population-based cohort study. Am. J. Gastroenterol. 97: 641-648 (2002). *
Donaldson P. HLA system and other genetic markers in PSC. Falk Symposium 136. XII FALK LIVER WEEK 2003 (Part I) In Honour of Hans Popper’s 100th Birthday. Cholestatic Liver Diseases: Therapeutical Options and Perspectives. Freiburg (Germany). p. 71-72. October 15-16 (2003). *
Donaldson PT. The role of genetics in immunopathogenesis. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, pp. 47-48 (2004). *
Donaldson PT. Basic concepts in PSC. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 73-75 (2005). *
Donlin LT, Danzl NM, Wanjalla C, Alexandropoulos K. Deficiency in expression of the signaling protein sin/efs leads to T-lymphocyte activation and mucosal inflammation. Mol. Cell. Biol. 25: 11035-11046 (2005). *
Donnelly BJ, Delaney PV, Healy TM. Evidence for a transmissible factor in Crohn's disease. Gut 18: 360-363 (1997). *
Donoghue HD, Holton J. Intestinal tuberculosis. Curr. Opin. Infect. Dis. 22: 490-496 (2009).
Dooley TP, Curto EV, Reddy SP, Davis RL, Lambert GW, Wilborn TW, Elson CO. Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. Inflamm. Bowel Dis. 10: 1-14 (2004). *
Dorer R, Odze RD. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease. Am. J. Surg. Pathol. 30: 871-877 (2006).
Dorman J, Steenkiste A, O'Leary L, McCarthy B, Lorenzen T, Foley T. Type 1 diabetes in offspring of parents with type 1 diabetes: the tip of an autoimmune iceberg? Pediatr. Diabetes 1: 17-22 (2000).
Dorn SD. Predictors of Crohn's disease. Gastroenterology 131: 334-335 (2006). *
Dorn SD, Abad JF, Panagopoulos G, Korelitz BI. Clinical characteristics of familial versus sporadic Crohn's disease using the Vienna classification. Inflamm. Bowel Dis. 10: 201-206 (2004). *
Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am. J. Gastroenterol. 102: 662-667 (2007). *
Dorner AJ, Goldman SJ, Keith Jr JC. Interleukin-11. BioDrugs 8: 418-429 (1997).
Dorrian A, Dempster M, Adair P. Adjustment to inflammatory bowel disease: the relative influence of illness perceptions and coping. Inflamm. Bowel Dis. 15: 47-55 (2009). *
Dos Reis SB, de Oliveira CC, Acedo SC, da Conceicao Miranda DD, Ribeiro ML, Pedrazzoli J Jr, Gambero A. Attenuation of colitis injury in rats using Garcinia cambogia extract. Phytother. Res. 23: 324-329 (2009).
Doss M, White MR, Tecle T, Hartshorn KL. Human defensins and LL-37 in mucosal immunity. J. Leukoc. Biol. Oct 6 [Epub ahead of print] (2009). *
Dossett LA, White LM, Welch DC, Herline AJ, Muldoon RL, Schwartz DA, Wise PE. Small bowel adenocarcinoma complicating Crohn's disease: case series and review of the literature. Am. Surg. 73: 1181-1187 (2007).
Dotan I. Disease behavior in adult patients: are there predictors for stricture or fistula formation? Dig. Dis. 27: 206-211 (2009).
Dotan I, Allez M, Nakazawa A, Brimnes J, Schulder-Katz M, Mayer LF. Intestinal epithelial cells from inflammatory bowel disease patients preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am. J. Physiol. Gastrointest. Liver Physiol. 292: G1630-G1640 (2007). *
Dotan I, Chowers Y, Rachmilewitz D, Chermesh I, Lavy A, Israeli E, Karban A, Schwaber MJ, Odes S, Eliakim R. Infliximab in inflammatory bowel diseases - conference summary and suggested guidelines. Harefuah. 145: 844-849, 860 (2006).
Dotan I, Fishman S, Dgani Y, Schwartz M, Karban A, Lerner A, Weishauss O, Spector L, Shtevi A, Altstock RT, Dotan N, Halpern Z. Antibodies against laminaribioside and chitobioside are novel serologic markers in Crohn's disease. Gastroenterology 131: 366-378 (2006). *
Dotan I, Mayer L. Immunopathogenesis of inflammatory bowel disease. Curr. Opin. Gastroenterol. 18: 421-427 (2002).
Dotan I, Werner L, Vigodman S, Weiss S, Brazowski E, Maharshak N, Chen O, Tulchinsky H, Halpern Z, Guzner-Gur H. CXCL12 is a constitutive and inflammatory chemokine in the intestinal immune system. Inflamm. Bowel Dis. Sep 22 [Epub ahead of print] (2009). *
Dotan N, Altstock RT, Schwarz M, Dukler A. Anti-glycan antibodies as biomarkers for diagnosis and prognosis. Lupus 15: 442-450 (2006).
Doubremelle M, Bourreille A, Zerbib F, Heresbach D, Metman EH, Beau P, Gournay J, Galmiche JP. Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study. Gastroenterol. Clin. Biol. 26: 973-979 (2002).
Douda T, Bures J, Rejchrt S, Kopacova M, Pecka M, Maly J. Mean platelet volume (MPV) in Crohn's disease patients. Cas. Lek. Cesk. 145: 870-873 (2006).
Dow CT. Paratuberculosis and type I diabetes. Is this the trigger? Med. Hypotheses 67: 782-785 (2006).
Draganov K, Dimitrova V, Ionkov A, Rusenov D, Tosheva E, Dimitrov K, Tonev S. Acquired entero-cutaneous fistulas - diagnostic and terapeutic approach. Khirurgiia (Sofiia) 2: 42-46 (2005).
Drai J, Borel P, Faure H, Galabert C, Le Moel G, Laromiguiere M, Fayol V. Fasting plasma carotenoids concentrations in Crohn's and pancreatic cancer patients compared to control subjects. Int. J. Vitam. Nutr. Res. 79: 87-94 (2009).
Drastich P. Capsule endoscopy - the past, presence, and future. Cas. Lek. Cesk. 145: 432-436 (2006).
Dray X, Marteau P. The use of enteral nutrition in the management of Crohn's disease in adults. JPEN J. Parenter. Enteral Nutr. 29: S166-S172 (2005). *
Dray X, Marteau P. Crohn's disease: nutrition should not be forgotten. Gastroenterol. Clin. Biol. 30: 215-216 (2006).
Dray X, Marteau P. Crohn's disease and ulcerative colitis. Rev. Prat. 57: 2305-2310 (2007).
Dray X, Sokol H, Vahedi K, Lavergne-Slove A, Marteau P. Pure ileal Crohn's disease without colonic involvement after a long ileo-colonic anastomosis (Lester Martin Procedure) for Hirschsprung's disease: an argument favoring a specific sensitivity of the ileum in a subset of patients with Crohn's disease. Inflamm. Bowel Dis. 13: 243-244 (2007). *
Dresner-Pollak R, Ackerman Z, Eliakim R, Karban A, Chowers Y, Fidder HH. The BsmI vitamin D receptor gene polymorphism is associated with ulcerative colitis in Jewish Ashkenazi patients. Genet. Test. 8: 417-420 (2004).
Dresner-Pollak R, Karmeli F, Eliakim R, Ackerman Z, Rachmilewitz D. Increased urinary N-telopeptide cross-linked type 1 collagen predicts bone loss in patients with inflammatory bowel disease. Am. J. Gastroenterol. 95: 699-704 (2000). *
Drews BH, Barth TF, Hanle MM, Akinli AS, Mason RA, Muche R, Thiel R, Pauls S, Klaus J, von Boyen G, Kratzer W. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn's disease. Eur. Radiol. 19: 1379-1386 (2009).
Drinda S, Franke S, Eidner T, Schmidt C, Ruster C, Bondeva T, Hein G, Wolf G. Decreased RAGE expression in peripheral blood mononuclear cells of patients with rheumatoid arthritis. Clin. Exp. Rheumatol. 27: 483-490 (2009).
Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PWN, O’Donoghue D, O’Sullivan M, O’Morain C, Mahmud N, Wikstrom AC, Kelleher D, McManus R. The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130: 341-348 (2006). *
Drini M, Prichard PJ, Brown GJ, Macrae FA. Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease. Med. J. Aust. 189: 464-465 (2008). *
Drosou A, Kirsner RS, Welsh E, Sullivan TP, Kerdel FA. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J. Cutan. Med. Surg. 7: 382-386 (2003). *
Drut R, Altamirano E. Small bowel gastric metaplasia. A report of three cases in children. J. Clin. Pathol. 61: 382-384 (2008).
Dryden GW. Overview of stem cell therapy for Crohn's disease. Expert Opin. Biol. Ther. 9: 841-847 (2009).
Dryden GW Jr. Overview of biologic therapy for Crohn's disease. Expert Opin. Biol. Ther. 9: 967-974 (2009).
Duarte AF, Nogueira A, Lisboa C, Azevedo F. Pioderma gangrenoso - abordagem clinica, laboratorial e terapeutica: revisao de 28 casos. Dermatol. Online J. 15: 3 (2009).
Dubcenco E, Jeejeebhoy KN, Petroniene R, Tang SJ, Zalev AH, Gardiner GW, Baker JP. Capsule endoscopy findings in patients with established and suspected small-bowel Crohn's disease: correlation with radiologic, endoscopic, and histologic findings. Gastrointest. Endosc. 62: 538-544 (2005).
Dubcenco E, Jeejeebhoy KN, Streutker CJ, Zalev AH, Garvey MB, Kim YI, Baker JP. A patient with anemia of obscure origin: Crohn's disease in disguise. Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 229-233 (2006). *
Dubcenco E, Jeejeebhoy KN, Tang SJ, Baker JP. The value of capsule endoscopy in the diagnosis and management of Crohn's disease: report of two cases. Gastrointest. Endosc. 59: 314-316 (2004). *
Dubcenco E, Ottaway CA, Chen DL, Baker JP. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur. J. Gastroenterol. Hepatol. 18: 565-566 (2006).
Dubinsky M. Evaluation and management of the patient with suspected recurrent Crohn's disease: the postoperative Crohn's disease patient. Am. J. Gastroenterol. 102 Suppl. 1: S38-S40 (2007). *
Dubinsky MC. New patients: should children be treated differently? Colorectal Dis. 8 Suppl. 1: 15-19 (2006).
Dubinsky MC. Diffuse jejunoileitis in adolescence. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 70. May 7-8 (2004). *
Dubinsky MC. Optimizing immunomodulator therapy for inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 506-511 (2003).
Dubinsky MC, Fleshner PP. Treatment of Crohn's disease of inflammatory, stenotic, and fistulizing phenotypes. Curr. Treat. Options Gastroenterol. 6: 183-200 (2003).
Dubinsky MC, Hassard PV, Seidman EG, Kam LY, Abreu MT, Targan SR, Vasiliauskas EA. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm. Bowel Dis. 7: 181-189 (2001). *
Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, Quiros A, Silber G, Wahbeh G, Katzir L, Vasiliauskas E, Bahar R, Otley A, Mack D, Evans J, Rosh J, Hemker MO, Leleiko N, Crandall W, Langton C, Landers C, Taylor KD, Targan SR, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin. Gastroenterol. Hepatol. 6: 1105-1111 (2008).
Dubinsky MC, Lin YC, Dutridge D, Picornell Y, Landers CJ, Farrior S, Wrobel I, Quiros A, Vasiliauskas EA, Grill B, Israel D, Bahar R, Christie D, Wahbeh G, Silber G, Dallazadeh S, Shah P, Thomas D, Kelts D, Hershberg RM, Elson CO, Targan SR, et al. Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am. J. Gastroenterol. 101: 360-367 (2006). *
Dubinsky MC, Mei L, Friedman M, Dhere T, Haritunians T, Hakonarson H, Kim C, Glessner J, Targan SR, McGovern DP, Taylor KD, Rotter JI. Genome wide association (GWA) predictors of anti-TNFalpha therapeutic responsiveness in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. Dec 14 [Epub ahead of print] (2009). *
Dubinsky MC, Reyes E, Ofman J, Chiou CF, Wade S, Sandborn WJ. A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Am. J. Gastroenterol. 100: 2239-2247 (2005). *
Dubinsky MC, Seidman EG. Diagnostic markers of inflammatory bowel disease. Curr. Opin. Gastroenterol. 16: 337-342 (2000).
Dubinsky MC, Wang D, Picornell Y, Wrobel I, Katzir L, Quiros A, Dutridge D, Wahbeh G, Silber G, Bahar R, Mengesha E, Targan SR, Taylor KD, Rotter JI. IL-23 receptor (IL-23R) gene protects against pediatric Crohn's disease. Inflamm. Bowel Dis. 13: 511-515 (2007). *
Dubner SE, Shults J, Baldassano RN, Zemel BS, Thayu M, Burnham JM, Herskovitz RM, Howard KM, Leonard MB. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 136: 123-130 (2009). *
Dubois PC, van Heel DA. New susceptibility genes for ulcerative colitis. Nat. Genet. 40: 686-688 (2008). *
Dubucquoi S. Physiological and pathological autoimmunity in neurological disease. Rev. Neurol. (Paris) 161: 1163-1176 (2005).
Dubucquoi S, Janin A, Klein O, Desreumaux P, Quandalle P, Cortot A, Capron M, Colombel JF. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 37: 242-246 (1995). *
Dubuquoy L, Jansson EA, Deeb S, Rakotobe S, Karoui M, Colombel JF, Auwerx J, Pettersson S, Desreumaux P. Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology 124: 1265-1276 (2003). *
Duburque C, Lelong J, Iacob R, Seddik M, Desreumaux P, Fournier C, Wallaert B, Cortot A, Colombel JF. Successful induction of tolerance to infliximab in patients with Crohn's disease and prior severe infusion reactions. Aliment. Pharmacol. Ther. 24: 851-858 (2006). *
Duchmann R, Schmitt E, Knolle P, Meyer zum Buschenfelde KH, Neurath M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. Eur. J. Immunol. 26: 934-938 (1996).
Duck LW, Walter MR, Novak J, Kelly D, Tomasi M, Cong Y, Elson CO. Isolation of flagellated bacteria implicated in Crohn's disease. Inflamm. Bowel Dis. 13: 1191-1201 (2007). *
Duclos B, Reimund JM, Lang JM, Coumaros G, Chamouard P, Lehr L, Baumann R, Koehl C, Weill JP. Mononuclear cell activation in Crohn's disease. Evaluation using serum assay of neopterin and interleukin-2 soluble receptors. Gastroenterol. Clin. Biol. 14: 22-27 (1990).
Dudley-Brown S, Nag A, Cullinan C, Ayers M, Hass S, Panjabi S. Health-related quality-of-life evaluation of Crohn disease patients after receiving natalizumab therapy. Gastroenterol. Nurs. 32: 327-339 (2009).
Duenas Pousa I, Mate Jimenez J, Salcedo Mora X, Abreu MT, Moreno Otero R, Gisber JP. Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study. Gastroenterol. Hepatol. 30: 518-525 (2007).
Duerksen DR, Fallows G, Bernstein CN. Vitamin B12 malabsorption in patients with limited ileal resection. Nutrition 22: 1210-1213 (2006). *
Duerr RH. Genome-wide association studies herald a new era of rapid discoveries in inflammatory bowel disease research. Gastroenterology 132: 2045-2049 (2007). *
Duerr RH. The genetics of inflammatory bowel disease. Gastroenterol. Clin. North Am. 31: 63-76 (2002).
Duerr RH. Update on the genetics of inflammatory bowel disease. J. Clin. Gastroenterol. 37: 358-367 (2003).
Duerr RH, Barmada MM, Zhang L, Achkar JP, Cho JH, Hanauer SB, Brant SR, Bayless TM, Baldassano RN, Weeks DE. Evidence for an inflammatory bowel disease locus on chromosome 3p26: linkage, transmission/disequilibrium and partitioning of linkage. Hum. Mol. Genet. 11: 2599-2606 (2002). *
Duerr RH, Barmada MM, Zhang L, Davis S, Preston RA, Chensny LJ, Brown JL, Ehrlich GD, Weeks DE, Aston CE. Linkage and association between inflammatory bowel disease and a locus on chromosome 12. Am. J. Hum. Genet. 63: 95-100 (1998). *
Duerr RH, Barmada MM, Zhang L, Pfutzer R, Weeks DE. High-density genome scan in Crohn disease shows confirmed linkage to chromosome 14q11-12. Am. J. Hum. Genet. 66: 1857-1862 (2000). *
Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee A, Gregersen PK, Barmada MM, Rotter JI, Nicolae DL, Cho JH. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 315: 1461-1463 (2006). *
Duffin KC, Krueger GG. Genetic variations in cytokines and cytokine receptors associated with psoriasis found by genome-wide association. J. Invest. Dermatol. 129: 827-833 (2009). *
Duffy MM, Regan MC, Ravichandran P, O'Keane C, Harrington MG, Fitzpatrick JM, O'Connell PR. Mucosal metabolism in ulcerative colitis and Crohn's disease. Dis. Colon Rectum 41: 1399-1405 (1998).
Duggan P, O'Brien M, Kiely M, McCarthy J, Shanahan F, Cashman KD. Vitamin K status in patients with Crohn's disease and relationship to bone turnover. Am. J. Gastroenterol. 99: 2178-2185 (2004). *
Dugoujon JM, Cambon-Thomsen A. Immunoglobulin allotypes (GM and KM) and their interactions with HLA antigens in autoimmune diseases: a review. Autoimmunity 22: 245-260 (1995).
Duijvestein M, van den Brink GR, Hommes DW. Stem cells as potential novel therapeutic strategy for inflammatory bowel disease. Journal of Crohn's and Colitis 2: 99-106 (2008).
Duley JA, Florin TH. Thiopurine therapies: problems, complexities, and progress with monitoring thioguanine nucleotides. Ther. Drug Monit. 27: 647-654 (2005).
Dumonceau JM, Adler M, Cremer M, Van Gossum A. The role of infectious agents in Crohn's disease. Acta Gastroenterol. Belg. 57: 301-305 (1994).
Dumonceau JM, Van Gossum A, Adler M, Fonteyne PA, Van Vooren JP, Deviere J, Portaels F. No Mycobacterium paratuberculosis found in Crohn's disease using polymerase chain reaction. Dig. Dis. Sci. 41: 421-426 (1996).
Dumonceau JM, Van Gossum A, Adler M, Van Vooren JP, Fonteyne PA, De Beenhouwer H, Portaels F. Detection of fastidious mycobacteria in human intestines by the polymerase chain reaction. Eur. J. Clin. Microbiol. Infect. Dis. 16: 358-363 (1997).
Dumortier J, Lapalus MG, Guillaud O, Poncet G, Gagnieu MC, Partensky C, Scoazec JY. Everolimus for refractory Crohn's disease: a case report. Inflamm. Bowel Dis. 14: 874-877 (2008). *
Duncan H, Swan C, Green J, Jones P, Brannigan K, Alldersea J, Fryer AA, Strange RC. Susceptibility to ulcerative colitis and Crohn's disease: interactions between glutathione S-transferase GSTM1 and GSTT1 genotypes. Clin. Chim. Acta 240: 53-61 (1995).
Dung NQ, Fusch G, Armbrust S, Jochum F, Fusch C. Use of bioelectrical impedance analysis and anthropometry to measure fat-free mass in children and adolescents with Crohn disease. J. Pediatr. Gastroenterol. Nutr. 44: 130-135 (2007). *
Dunn AC, Walmsley RS, Dedrick RL, Wakefield AJ, Lockwood CM. Anti-neutrophil cytoplasmic autoantibodies (ANCA) to bactericidal/permeability-increasing (BPI) protein recognize the carboxyl terminal domain. J. Infect. 39: 81-87 (1999).
Dunne C. Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm. Bowel Dis. 7: 136-145 (2001). *
Dupont B, Dupont C, Justum AM, Piquet MA, Reimund JM. Enteral nutrition in adult Crohn's disease: present status and perspectives. Mol. Nutr. Food Res. 52: 875-884 (2008). *
Duricova D, Pedersen N, Elkjaer M, Gamborg M, Munkholm P, Jess T. Overall and cause-specific mortality in Crohn's disease: a meta-analysis of population-based studies. Inflamm. Bowel Dis. 16: 347-353 (2010).
Duricova D, Pedersen N, Lenicek M, Hradsky O, Bronsky J, Adamcova M, Elkjaer M, Andersen PS, Vitek L, Larsen K, Lukas M, Nevoral J, Wewer V, Munkholm P. Infliximab dependency in children with Crohn's disease. Aliment. Pharmacol. Ther. 29: 792-799 (2009). *
Durusu M, Gurlek A, Simsek H, Balaban Y, Tatar G. Coincidence or causality: celiac and Crohn diseases in a case of Turner syndrome. Am. J. Med. Sci. 329: 214-216 (2005).
Dusatkova P, Hradsky O, Lenicek M, Bronsky J, Nevoral J, Kotalova R, Bajerova K, Vitek L, Lukas M, Cinek O. Association of IL23R p.381Gln and ATG16L1 p.197Ala with Crohn disease in the Czech population. J. Pediatr. Gastroenterol. Nutr. Jul 8 [Epub ahead of print] (2009).
Dwarakanath AD, Campbell BJ, Tsai HH, Sunderland D, Hart CA, Rhodes JM. Faecal mucinase activity assessed in inflammatory bowel disease using 14C threonine labelled mucin substrate. Gut 37: 58-62 (1995). *
Dwarakanath AD, Nash J, Rhodes JM. 'Conversion' from ulcerative colitis to Crohn's disease associated with corticosteroid treatment. Gut 35: 1141-1144 (1994). *
Dziechciarz P, Horvath A, Shamir R, Szajewska H. Meta-analysis: enteral nutrition in active Crohn's disease in children. Aliment. Pharmacol. Ther. 26: 795-806 (2007). *
Dzierzewicz Z, Cwalina B, Weglarz L, Wisniowska B, Szczerba J. Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products. Med. Sci. Monit. 10: BR185-BR190 (2004). *
Dziki A, Galbfach P. Crohn's disease - when to operate? Acta Chir. Iugosl. 51: 61-68 (2004).
Eade OE, Moulton C, MacPherson BR, Andre-Ukena SS, Albertini RJ, Beeken WL. Discordant HLA haplotype segregation in familial Crohn's disease. Gastroenterology 79: 271-275 (1980).
Eaden J. Colorectal carcinoma and inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 24-30 (2004). *
Eaden JA, Abrams K, Mayberry JF. The Crohn's and Colitis Knowledge Score: a test for measuring patient knowledge in inflammatory bowel disease. Am. J. Gastroenterol. 94: 3560-3566 (1999). *
Eaden JA, Abrams K, Mayberry JF. Does patient knowledge affect the colorectal cancer risk in ulcerative colitis? Postgrad. Med. J. 78: 615-618 (2002). *
Eames T, Landthaler M, Karrer S. Crohn's disease: an important differential diagnosis of granulomatous skin diseases. Eur. J. Dermatol. 19: 360-364 (2009).
East JE, Brooker JC, Rutter MD, Saunders BP. A pilot study of intrastricture steroid versus placebo injection after balloon dilatation of Crohn's strictures. Clin. Gastroenterol. Hepatol. 5: 1065-1069 (2007).
Eaves-Pyles T, Allen CA, Taormina J, Swidsinski A, Tutt CB, Eric Jezek G, Islas-Islas M, Torres AG. Escherichia coli isolated from a Crohn's disease patient adheres, invades, and induces inflammatory responses in polarized intestinal epithelial cells. Int. J. Med. Microbiol. 298: 397-409 (2008).
Ebach DR, Newberry R, Stenson WF. Differential role of tumor necrosis factor receptors in TNBS colitis. Inflamm. Bowel Dis. 11: 533-540 (2005). *
Eberhardson M, Lindberg K, Karlsson M, Karlen P, Winqvist O, Thorn M. The sentinel node technique is useful for studies of intestinal immunology in inflammatory bowel disease patients. Eur. J. Gastroenterol. Hepatol. 20: 985-988 (2008).
Ebert EC. Infliximab and the TNFalpha system. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G612-G620 (2009). *
Ebert EC, Bhatt BD, Liu S, Das KM. Induction of suppressor cells by Mycobacterium paratuberculosis antigen in inflammatory bowel disease. Clin. Exp. Immunol. 83: 320-325 (1991). *
Ebert EC, Geng X, Bajpai M, Pan Z, Tatar E, Das KM. Antibody to tropomyosin isoform 5 and complement induce the lysis of colonocytes in ulcerative colitis. Am. J. Gastroenterol. 104: 2996-3003 (2009). *
Ebert EC, Geng X, Lin J, Das KM. Autoantibodies against human tropomyosin isoform 5 in ulcerative colitis destroys colonic epithelial cells through antibody and complement-mediated lysis. Cell. Immunol. 244: 43-49 (2006). *
Ebert EC, Mehta V, Das KM. Activation antigens on colonic T cells in inflammatory bowel disease: effects of IL-10. Clin. Exp. Immunol. 140: 157-165 (2005). *
Ebert EC, Panja A, Das KM, Praveen R, Geng X, Rezac C, Bajpai M. Patients with inflammatory bowel disease may have a transforming growth factor-beta-, interleukin (IL)-2- or IL-10-deficient state induced by intrinsic neutralizing antibodies. Clin. Exp. Immunol. 155: 65-71 (2009). *
Ebinger M, Leidl R, Thomas S, Von Tirpitz C, Reinshagen M, Adler G, Konig HH. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J. Gastroenterol. Hepatol. 19: 192-199 (2004). *
Ebringer A, Rashid T, Tiwana H, Wilson C. A possible link between Crohn's disease and ankylosing spondylitis via Klebsiella infections. Clin. Rheumatol. 26: 289-297 (2007). *
Ebringer A, Wilson C. The use of a low starch diet in the treatment of patients suffering from ankylosing spondylitis. Clin. Rheumatol. 15 Suppl. 1: 62-66 (1996).
Echenique I, García Gonzralez JM, Echenique IA, Izquierdo NJ, Mella JR, Barasorda E, Mella MT, Figueroa-Boilo S. Hermansky Pudlak syndrome: an unusual form of procto-colitis. Bol. Asoc. Med. P. R. 100: 76-79 (2008).
Eckburg PB, Relman DA. The role of microbes in Crohn's disease. Clin. Infect. Dis. 44: 256-262 (2007). *
Ecker KW, Stallmach A, Loffler J, Greinwald R, Achenbach U. Long-term treatment of high intestinal output syndrome with budesonide in patients with Crohn's disease and ileostomy. Dis. Colon Rectum 48: 237-242 (2005). *
Eckmann L. Innate immunity and mucosal bacterial interactions in the intestine. Curr. Opin. Gastroenterol. 20: 82-88 (2004).
Eckmann L, Karin M. NOD2 and Crohn's disease: loss or gain of function? Immunity 22: 661-667 (2005). *
Eckstein TM, Chandrasekaran S, Mahapatra S, McNeil MR, Chatterjee D, Rithner CD, Ryan PW, Belisle JT, Inamine JM. A major cell wall lipopeptide of Mycobacterium avium subspecies paratuberculosis. J. Biol. Chem. 281: 5209-5215 (2006). *
Economou M, Filis G, Tsianou Z, Alamanos J, Kogevinas A, Masalas K, Petrou A, Tsianos EV. Crohn's disease incidence evolution in North-western Greece is not associated with alteration of NOD2/CARD15 variants. World J. Gastroenterol. 13: 5116-5120 (2007). *
Economou M, Pappas G. New global map of Crohn's disease: genetic, environmental, and socioeconomic correlations. Inflamm. Bowel Dis. 14: 709-720 (2008). *
Economou M, Trikalinos TA, Loizou KT, Tsianos EV, Ioannidis JP. Differential effects of NOD2 variants on Crohn's disease risk and phenotype in diverse populations: a metaanalysis. Am. J. Gastroenterol. 99: 2393-2404 (2004). *
Ectors N, Maillet B, Aerts R, Geboes K, Donner A, Borchard F, Lankisch P, Stolte M, Luttges J, Kremer B, Kloppel G. Non-alcoholic duct destructive chronic pancreatitis. Gut 41: 263-268 (1997). *
Edden Y, Ciardullo J, Sherafgan K, Harris MT, Bub DS, Gorfine SR, Bauer JJ. Laparoscopic-assisted ileocolic resection for Crohn's disease. JSLS 12: 139-142 (2008). *
Edden Y, Shussman N, Cohen M, Verstandig A, Pikarsky A. Endovascular treatment of ileocolic pseudoaneurysm after a laparoscopic-assisted bowel resection for Crohn disease. Vasc. Endovascular Surg. 42: 173-175 (2008).
Edelman LB, Toia G, Geman D, Zhang W, Price ND. Two-transcript gene expression classifiers in the diagnosis and prognosis of human diseases. BMC Genomics 10: 583 (2009). *
Eder P, Stawczyk-Eder K, Krela-Kazmierczak I, Linke K. Clinical utility of the assessment of fecal calprotectin in Lesniowski-Crohn's disease. Pol. Arch. Med. Wewn. 118: 622-626 (2008).
Edmiston N, Ooi C, Otton G, Boyle M. Vulval Crohn's disease. Sex Health 6: 87-89 (2009).
Edna TH, Bjerkeset T, Skreden K. Abdominal surgery for Crohn's disease during 30 years in Middle Norway. Hepatogastroenterology 51: 481-484 (2004).
Edouard A, Paillaud M, Merle S, Orhan C, Chenayer-Panelatti Dagger M, Cogeag EL. Incidence of inflammatory bowel disease in the French West Indies (1997-1999). Gastroenterol. Clin. Biol. 29: 779-783 (2005). *
Edsbacker S, Andersson T. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin. Pharmacokinet. 43: 803-821 (2004).
Edula RG, Picco MF. An evidence-based review of natalizumab therapy in the management of Crohn’s disease. Ther. Clin. Risk Manag. 5: 935-942 (2009). *
Edwards CJ. Immunological therapies for rheumatoid arthritis. Br. Med. Bull. 73-74: 71-82 (2005). *
Edwards CN, Griffith SG, Hennis AJ, Hambleton IR. Inflammatory bowel disease: incidence, prevalence, and disease characteristics in Barbados, West Indies. Inflamm. Bowel Dis. 14: 1419-1424 (2008). *
Efrat B, Iris G, Wang H, Eitan S, Yona K. A subgroup of first-degree relatives of Crohn's disease patients shows a profile of inflammatory markers in the blood which is more typical of Crohn's disease patients than of normal individuals. Mediators Inflamm. 2006: 74785 (2006). *
Efstratiadis G, Tsiaousis G, Leontsini M, Nikolaidis N, Dimitriadis C, Memmos D. Renal cancer in a patient with Crohn's disease and secondary amyloidosis. J. Nephrol. 19: 518-520 (2006).
Efthimiou P, Markenson JA. Role of biological agents in immune-mediated inflammatory diseases. South. Med. J. 98: 192-204 (2005).
Efthymiou A, Viazis N, Mantzaris G, Papadimitriou N, Tzourmakliotis D, Raptis S, Karamanolis DG. Does clinical response correlate with mucosal healing in patients with Crohn's disease of the small bowel? A prospective, case-series study using wireless capsule endoscopy. Inflamm. Bowel Dis. 14: 1542-1547 (2008). *
Efthymiou A, Viazis N, Vlachogiannakos J, Georgiadis D, Kalogeropoulos I, Mantzaris G, Karamanolis DG. Wireless capsule endoscopy versus enteroclysis in the diagnosis of small-bowel Crohn's disease. Eur. J. Gastroenterol. Hepatol. 21: 866-871 (2009).
Egan C, Craven M, Leng J, Mack M, Simpson K, Denkers E. CCR2-dependent intraepithelial lymphocytes mediate inflammatory gut pathology during Toxoplasma gondii infection. Mucosal Immunol. 2: 527-535 (2009).
Egan LJ. Mechanism of action of established drugs: cyclosporine, methotrexate and others. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 63-64. May 7-8 (2004). *
Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for Crohn's disease and ulcerative colitis. Curr. Gastroenterol. Rep. 7: 485-491 (2005).
Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin. Proc. 71: 69-80 (1996). *
Egan LJ, Sandborn WJ. Advances in the treatment of Crohn's disease. Gastroenterology 126: 1574-1581 (2004). *
Egan LJ, Sandborn WJ. Drug therapy of inflammatory bowel disease. Drugs Today (Barc.) 34: 431-446 (1998).
Egan LJ, Sandborn WJ, Mays DC, Tremaine WJ, Lipsky JJ. Plasma and rectal adenosine in inflammatory bowel disease: effect of methotrexate. Inflamm. Bowel Dis. 5: 167-173 (1999).
Egan LJ, Tremaine WJ, Mays DC, Lipsky JJ, Sandborn WJ. Clinical outcome and pharmacokinetics after addition of low-dose cyclosporine to methotrexate: a case study of five patients with treatment-resistant inflammatory bowel disease. Inflamm. Bowel Dis. 6: 286-289 (2000). *
Egana N, Paron L, Cuerda C, Breton I, Camblor M, Velasco C, Garcia-Peris P. Sea-blue histiocyte syndrome associated with home parenteral nutrition. Nutr. Hosp. 24: 361-363 (2009).
Egawa S, Hiwatashi N. Natural killer cell activity in patients with inflammatory bowel disease. J. Clin. Lab. Immunol. 20: 187-192 (1986).
Egetenmeier H, Lang GE. Papilledema in Crohn's disease. Klin. Monatsbl. Augenheilkd. 224: 943-944 (2007).
Ehehalt R, Wagenblast J, Erben G, Lehmann WD, Hinz U, Merle U, Stremmel W. Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray-tandem mass spectrometry. Scand. J. Gastroenterol. 39: 737-742 (2004). *
Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J. Rheumatol. Suppl. 74: 35-39 (2005).
Ehlin AG, Montgomery SM, Ekbom A, Pounder RE, Wakefield AJ. Prevalence of gastrointestinal diseases in two British national birth cohorts. Gut 52: 1117-1121 (2003). *
Ehmsen L, Marko C, Breidert M. Portal vein hypertension with azathioprine therapy in patients with Crohn's disease - is it a frequent phenomenon? Dtsch. Med. Wochenschr. 133: 950-953 (2008).
Ehrenpreis ED, Kane SV, Cohen LB, Cohen RD, Hanauer SB. Thalidomide therapy for patients with refractory Crohn's disease: an open-label trial. Gastroenterology 117: 1271-1277 (1999). *
Ehrhardt RO. New insights into the immunopathology of chronic inflammatory bowel disease. Semin. Gastrointest. Dis. 7: 144-150 (1996).
Ei-Matary W, Vandermeer B, Griffiths AM. Methotrexate for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. 3: CD007560 (2009). *
Eidelwein AP, Cuffari C, Abadom V, Oliva-Hemker M. Infliximab efficacy in pediatric ulcerative colitis. Inflamm. Bowel Dis. 11: 213-218 (2005). *
Eidelwein AP, Thompson R, Fiorino K, Abadom V, Oliva-Hemker M. Disease presentation and clinical course in black and white children with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 44: 555-560 (2007). *
Eike MC, Nordang GB, Karlsen TH, Boberg KM, Vatn MH; IBSEN study group, Dahl-Jorgensen K, Ronningen KS, Joner G, Flato B, Bergquist A, Thorsby E, Forre O, Kvien TK, Undlien DE, Lie BA. The FCRL3 -169T>C polymorphism is associated with rheumatoid arthritis and shows suggestive evidence of involvement with juvenile idiopathic arthritis in a Scandinavian panel of autoimmune diseases. Ann. Rheum. Dis. 67: 1287-1291 (2008).
Einarsdottir E, Koskinen LL, Dukes E, Kainu K, Suomela S, Lappalainen M, Ziberna F, Korponay-Szabo IR, Kurppa K, Kaukinen K, Adany R, Pocsai Z, Szeles G, Farkkila M, Turunen U, Halme L, Paavola-Sakki P, Not T, Vatta S, Ventura A, Lofberg R, et al. IL23R in the Swedish, Finnish, Hungarian and Italian populations: association with IBD and psoriasis, and linkage to celiac disease. BMC Med. Genet. 10: 8 (2009). *
Eisen GM. The economics of PillCam. Gastrointest. Endosc. Clin. N. Am. 16: 337-345 (2006).
Eitan A, Koliada M, Bickel A. The use of the loose seton technique as a definitive treatment for recurrent and persistent high trans-sphincteric anal fistulas: a long-term outcome. J. Gastrointest. Surg. 13: 1116-1119 (2009). *
Eivindson M, Gronbaek H, Flyvbjerg A, Frystyk J, Zimmermann-Nielsen E, Dahlerup JF. The insulin-like growth factor (IGF)-system in active ulcerative colitis and Crohn's disease: relations to disease activity and corticosteroid treatment. Growth Horm. IGF Res. 17: 33-40 (2007).
Eivindson M, Gronbaek H, Nielsen JN, Frystyk J, Flyvbjerg A, Jorgensen L, Vind I, Munkholm P, Jensen S, Brandslund I, Hey H. Insulin-like growth factors (IGFs) and IGF binding proteins in active Crohn's disease treated with omega-3 or omega-6 fatty acids and corticosteroids. Scand. J. Gastroenterol. 40: 1214-1221 (2005). *
Eivindson M, Gronbaek H, Skogstrand K, Thorsen P, Frystyk J, Flyvbjerg A, Dahlerup JF. The insulin-like growth factor (IGF) system and its relation to infliximab treatment in adult patients with Crohn's disease. Scand. J. Gastroenterol. 42: 464-470 (2007). *
Eivindson M, Nielsen JN, Gronbaek H, Flyvbjerg A, Hey H. The insulin-like growth factor system and markers of inflammation in adult patients with inflammatory bowel disease. Horm. Res. 64: 9-15 (2005).
Ekbom A. Can we predict the natural history of IBD? Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 29-30 (2006). *
Ekbom A. Paratuberculosis and Crohn's disease - possible linkage? Acta Vet. Scand. 44: 267-268 (2003).
Ekbom A, Brandt L, Granath F, Lofdahl CG, Egesten A. Increased risk of both ulcerative colitis and Crohn's disease in a population suffering from COPD. Lung 186: 167-172 (2008).
Ekbom A, Daszak P, Kraaz W, Wakefield AJ. Crohn's disease after in-utero measles virus exposure. Lancet 348: 515-517 (1996). *
Ekbom A, Helmick C, Zack M, Adami HO. The epidemiology of inflammatory bowel disease: a large, population-based study in Sweden. Gastroenterology 100: 350-358 (1991).
Ekbom A, Helmick C, Zack M, Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 67: 2015-2019 (1991).
Ekbom A, Montgomery SM. Environmental risk factors (excluding tobacco and microorganisms): critical analysis of old and new hypotheses. Best Pract. Res. Clin. Gastroenterol. 18: 497-508 (2004).
Ekbom A, Wakefield AJ, Zack M, Adami HO. Perinatal measles infection and subsequent Crohn's disease. Lancet 344: 508-510 (1994).
Ekkelenkamp MB, de Jong W, Hustinx W, Thijsent S. Streptomyces thermovulgaris bacteremia in Crohn's disease patient. Emerg. Infect. Dis. 10: 1883-1885 (2004).
Eksteen B, Liaskou E, Adams DH. Lymphocyte homing and its role in the pathogenesis of IBD. Inflamm. Bowel Dis. 14: 1298-1312 (2008). *
El Miedany Y, Youssef S, Ahmed I, El Gaafary M. The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases. Am. J. Gastroenterol. 101: 311-317 (2006). *
El Mokhtari NE, Ott SJ, Nebel A, Schaefer A, Rosenstiel P, Foerster M, Nothnagel M, Simon R, Schreiber S. Role of NOD2/CARD15 in coronary heart disease. BMC Genet. 8: 76 (2007). *
El Moutawakil B, Rafai MA, Gam I, Tahiri JM, Rhimou A, Slassi I. Crohn's disease presenting with reccurent acute polyradiculoneuropathy. Rev. Neurol. (Paris) 163: 244-246 (2007).
El Mouzan MI, Abdullah AM, Al Habbal MT. Epidemiology of juvenile-onset inflammatory bowel disease in Central Saudi Arabia. J. Trop. Pediatr. 52: 69-71 (2006).
El Otmani H, Moutaouakil F, Midafi N, Moudden M, Gam I, Hakim K, Fadel H, Rafai MA, El Moutawakkil B, Slassi I. Cobalamin deficiency: neurological aspects in 27 cases. Rev. Neurol. (Paris) 165: 263-267 (2009).
El Yafi F, Winkler R, Delvenne P, Boussif N, Belaiche J, Louis E. Altered expression of type I insulin-like growth factor receptor in Crohn's disease. Clin. Exp. Immunol. 139: 526-533 (2005). *
El-Gazzaz G, Zutshi M, Hull T. A retrospective review of chronic anal fistulaee treated by anal fistulae plug. Colorectal Dis. Feb 7 [Epub ahead of print] (2009). *
El-Hachem S, Regueiro M. Postoperative Crohn's disease: prevention and treatment. Expert Rev. Gastroenterol. Hepatol. 3: 249-256 (2009).
El-Hajj II, Abdul-Baki H, El-Zahabi LM, Barada KA. Primary coloduodenal fistula in a patient with Crohn's disease. Dig. Dis. Sci. 52: 59-63 (2007). *
El-Matary W. Enteral nutrition as a primary therapy of Crohn's disease: the pediatric perspective. Nutr. Clin. Pract. 24: 91-97 (2009). *
El-Matary W, Jaffray B, Scott J, Hodges S. Portal pyaemia as a presenting feature of paediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 43: 260-262 (2006). *
el-Omar E, Penman I, Cruikshank G, Dover S, Banerjee S, Williams C, McColl KE. Low prevalence of Helicobacter pylori in inflammatory bowel disease: association with sulphasalazine. Gut 35: 1385-1388 (1994). *
El-Tawil AM. Oestrogens and Crohn's disease: the missed link. Andrologia 40: 141-145 (2008).
El-Tawil AM. Effects of five different drinks on patients with Crohn's disease. Scand. J. Gastroenterol. 44: 764 (2009). *
El-Tawil AM. Zinc deficiency in men with Crohn's disease may contribute to poor sperm function and male infertility. Andrologia 35: 337-341 (2003).
El-Tawil AM. High incidence of Crohn's disease in pre-menopausal women: Escherichia coli may be contributing. Int. J. Colorectal Dis. 19: 498 (2004). *
El-Zaatari FA, Naser SA, Hulten K, Burch P, Graham DY. Characterization of Mycobacterium paratuberculosis p36 antigen and its seroreactivities in Crohn's disease. Curr. Microbiol. 39: 115-119 (1999). *
El-Zaatari FA, Osato MS, Graham DY. Etiology of Crohn's disease: the role of Mycobacterium avium paratuberculosis. Trends Mol. Med. 7: 247-252 (2001). *
Elbaz G, Fich A, Levy A, Holcberg G, Sheiner E. Inflammatory bowel disease and preterm delivery. Int. J. Gynaecol. Obstet. 90: 193-197 (2005).
Eleftheriadis N, Lambrecht G, D’Haens G, Baert F, Cabooter M, Louis E, Van Assche G, Schurmans P, Caenepeel P, Van Outryve M, Lammens P, Van Gossum A, De Vos M, on behalf of the Belgian IBD Research Group. Maintenance therapy for ulcerative colitis has no impact on changes in the extent of ulcerative colitis. Journal of Crohn's and Colitis 1: 21-27 (2007). *
Eleftherohorinou H, Wright V, Hoggart C, Hartikainen AL, Jarvelin MR, Balding D, Coin L, Levin M. Pathway analysis of GWAS provides new insights into genetic susceptibility to 3 inflammatory diseases. PLoS One 4: e8068 (2009). *
Elia PP, Fogaca HS, Barros RG, Zaltman C, Elia CS. Descriptive analysis of the social, clinical, laboratorial and anthropometric profiles of inflammatory bowel disease inwards patients from the "Clementino Fraga Filho" University Hospital, Rio de Janeiro, RJ, Brazil. Arq. Gastroenterol. 44: 332-339 (2007).
Eliakim AR. Video capsule endoscopy of the small bowel (PillCam SB). Curr. Opin. Gastroenterol. 22: 124-127 (2006).
Eliakim R. The impact of capsule endoscopy on Crohn's disease. Dig. Liver Dis. 39: 154-155 (2007).
Eliakim R. Video capsule endoscopy of the small bowel. Curr. Opin. Gastroenterol. 24: 159-163 (2008). *
Eliakim R. Video capsule endoscopy of the small bowel. Curr. Opin. Gastroenterol. Feb 8 [Epub ahead of print] (2010).
Eliakim R. Wireless capsule video endoscopy: three years of experience. World J. Gastroenterol. 10: 1238-1239 (2004). *
Eliakim R, Adler SN. Capsule video endoscopy in Crohn's disease-the European experience. Gastrointest. Endosc. Clin. N. Am. 14: 129-137 (2004).
Eliakim R, Fan QX, Babyatsky MW. Chronic nicotine administration differentially alters jejunal and colonic inflammation in interleukin-10 deficient mice. Eur. J. Gastroenterol. Hepatol. 14: 607-614 (2002).
Eliakim R, Suissa A, Yassin K, Katz D, Fischer D. Wireless capsule video endoscopy compared to barium follow-through and computerised tomography in patients with suspected Crohn's disease - final report. Dig. Liver Dis. 36: 519-522 (2004).
Elias E. Hepatology highlights. Hepatology 39: 1467-1468 (2004). *
Elices MJ. Antegren (Athena Neurosciences Inc). IDrugs 1: 221-227 (1998).
Elices MJ. Natalizumab. Elan/Biogen. Curr. Opin. Investig. Drugs 4: 1354-1362 (2003).
Elkayam O, Litinsky I, Levartovsky D, Caspi D. The changing face of spondyloarthropathies under TNF alpha blockade. Open Rheumatol. J. 2: 53-57 (2008). *
Elkjaer M, Dinesen L, Benazzato L, Rodriguez J, Logager V, Munkholm P. Efficacy of infliximab treatment in patients with severe fistulizing hidradenitis suppurativa. Journal of Crohn's and Colitis 2: 241-245 (2008).
Elkjaer M, Moser G, Reinisch W, Durovicova D, Lukas M, Vucelic B, Wewer V, Colombel JF, Shuhaibar M, O'Morain C, Politi P, Odes S, Bernklev T, Oresland T, Nikulina I, Belousova E, Van der Eijk I, Munkholm P. IBD patients need in health quality of care ECCO consensus. Journal of Crohn's and Colitis 2: 181-188 (2008).
Ellingson JL, Cheville JC, Brees D, Miller JM, Cheville NF. Absence of Mycobacterium avium subspecies paratuberculosis components from Crohn's disease intestinal biopsy tissues. Clin. Med. Res. 1: 217-226 (2003). *
Elliott DE, Li J, Blum A, Metwali A, Qadir K, Urban JF, Weinstock JV. Exposure to schistosome eggs protects mice from TNBS-induced colitis. Am. J. Physiol. Gastrointest. Liver Physiol. 284: G385-G391 (2003). *
Elliott DE, Summers RW, Weinstock JV. Helminths as governors of immune-mediated inflammation. Int. J. Parasitol. 37: 457-464 (2007). *
Elliott DE, Urban JF JR, Argo CK, Weinstock JV. Does the failure to acquire helminthic parasites predispose to Crohn's disease? FASEB J. 14: 1848-1855 (2000). *
Elliott DE, Weinstock JV. Helminthic therapy: using worms to treat immune-mediated disease. Adv. Exp. Med. Biol. 666: 157-166 (2009).
Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, Szapary P. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann. N. Y. Acad. Sci. 1182: 97-110 (2009). *
Elliott PR, Moore GT, Bell SJ, Connell WR. Severe recurrent Crohn's disease of the ileocolonic anastomosis disappearing completely with antibacterial therapy. Gut 54: 1818-1819 (2005). *
Ellis CN, Clark S. Fibrin glue as an adjunct to flap repair of anal fistulas: a randomized, controlled study. Dis. Colon Rectum 49: 1736-1740 (2006). *
Ellis RD, Goodlad JR, Limb GA, Powell JJ, Thompson RP, Punchard NA. Activation of nuclear factor kappa B in Crohn's disease. Inflamm. Res. 47: 440-445 (1998). *
Ellman MH, Hanauer S, Sitrin M, Cohen R. Crohn's disease arthritis treated with infliximab: an open trial in four patients. J. Clin. Rheumatol. 7: 67-71 (2001).
Elloumi H, Ben Abdelaziz A, Derbel F, Jmaa A, Lassoued Y, Arfaoui D, Ben Ali A, Letaief R, Hamida RB, Ghannem H, Ajmi S. Predictive factors of glucocorticosteroid treatment failure in severe acute idiopathic colitis. Acta Gastroenterol. Belg. 68: 226-229 (2005).
Elloumi H, Ben Abdelaziz A, Sfar S, Arfaoui D, Ben Slama A, Ghouma M, Ajmi S. Predictive factors of intestinal stenosis in Crohn's disease. Tunis. Med. 84: 711-713 (2006).
Elloumi H, Ben Slama A, Arfaoui D, Ghouma M, Sfar S, Ajmi S. Renal amyloidosis complicating Crohn's disease: report of two cases and review of literature. Tunis. Med. 84: 253-255 (2006).
Elloumi H, Sfar S, Ben Abdelaziz A, Arfaoui D, Mouna G, Ajmi S. Crohn's disease: influence of age at diagnosis on clinical type of disease. Tunis. Med. 85: 862-865 (2007).
Elmgreen J, Both H, Binder V. Familial occurrence of complement dysfunction in Crohn's disease: correlation with intestinal symptoms and hypercatabolism of complement. Gut 26: 151-157 (1985). *
Elmgreen J, Sorensen H, Berkowicz A. Polymorphism of complement C3 in chronic inflammatory bowel disease. Predominance of the C3F gene in Crohn's disease. Acta Med. Scand. 215: 375-378 (1984).
Eloy P, Leruth E, Goffart Y, Nollevaux MC, Fridman V, Dartevelle M, Melange M, Daele J, Bertrand B. Sinonasal involvement as a rare extraintestinal manifestation of Crohn's disease. Eur. Arch. Otorhinolaryngol. 264: 103-108 (2007). *
Elphick D, Liddell S, Mahida YR. Impaired luminal processing of human defensin-5 in Crohn's disease. persistence in a complex with chymotrypsinogen and trypsin. Am. J. Pathol. 172: 702-713 (2008). *
Elriz K, Savoye G, Tamion F, Dechelotte P, Lerebours E. Severe hypokaliemia and metabolic alkalosis in a Crohn's disease patient after budesonide treatment: evidence for intestinal secretion of potassium. Dig. Liver Dis. 40: 149-150 (2008).
Elsaghier A, Prantera C, Bothamley G, Wilkins E, Jindal S, Ivanyi J. Disease association of antibodies to human and mycobacterial hsp70 and hsp60 stress proteins. Clin. Exp. Immunol. 89: 305-309 (1992). *
Elsaghier A, Prantera C, Moreno C, Ivanyi J. Antibodies to Mycobacterium paratuberculosis-specific protein antigens in Crohn's disease. Clin. Exp. Immunol. 90: 503-508 (1992). *
Elsayed S, Zhang K. Isolation and 16S ribosomal RNA gene sequence-based identification of Clostridium scindens from an intra-abdominal abscess. Anaerobe 12: 13-16 (2006). *
Elsehety A, Bertorini TE. Neurologic and neuropsychiatric complications of Crohn's disease. South. Med. J. 90: 606-610 (1997).
Elseviers MM, D'Haens G, Lerebours E, Plane C, Stolear JC, Riegler G, Capasso G, Van Outryve M, Mishevska-Mukaetova P, Djuranovic S, Pelckmans P, De Broe ME; 5-ASA Study Group. Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy? Clin. Nephrol. 61: 83-89 (2004).
Elsing C, Placke J, Herrmann T. Alcohol binging causes peliosis hepatis during azathioprine therapy in Crohn's disease. World J. Gastroenterol. 13: 4646-4648 (2007). *
Elson CO. Commensal bacteria as targets in Crohn's disease. Gastroenterology 119: 254-257 (2000). *
Elson CO. Cyclosporine in Crohn's disease - low doses won't do it. Gastroenterology 98: 1383-1384 (1990).
Elson CO. Genes, microbes, and T cells - new therapeutic targets in Crohn's disease. N. Engl. J. Med. 346: 614-616 (2002). *
Elson CO. The basis of current and future therapy for inflammatory bowel disease. Am. J. Med. 100: 656-662 (1996). *
Elson CO, Cong Y, Qi F, Hershberg RM, Targan SR. Molecular approaches to the role of the microbiota in inflammatory bowel disease. Ann. N. Y. Acad. Sci. 1072: 39-51 (2006). *
Elson CO, Graeff AS, James SP, Strober W. Covert suppressor T cells in Crohn's disease. Gastroenterology 80: 1513-1521 (1981).
Elson CO, Machelski E, Weiserbs DB. T cell-B cell regulation in the intestinal lamina propria in Crohn's disease. Gastroenterology 89: 321-327 (1985).
Eltholth MM, Marsh VR, Van Winden S, Guitian FJ. Contamination of food products with Mycobacterium avium paratuberculosis: a systematic review. J. Appl. Microbiol. 107: 1061-1071 (2009). *
Emami MH, Gholamrezaei A, Daneshgar H. Hypnotherapy as an adjuvant for the management of inflammatory bowel disease: a case report. Am. J. Clin. Hypn. 51: 255-262 (2009).
Emanuel PO, Phelps RG. Metastatic Crohn's disease: a histopathologic study of 12 cases. J. Cutan. Pathol. 35: 457-461 (2008). *
Emerit J, Congy F, Loeper J. Recent data on the epidemiology and etiology of Crohn's disease. Nouv. Presse. Med. 11: 3195-3200 (1982).
Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin. Rev. Allergy Immunol. Jun 30 [Epub ahead of print] (2009). *
Emily M, Mailund T, Hein J, Schauser L, Schierup MH. Using biological networks to search for interacting loci in genome-wide association studies. Eur. J. Hum. Genet. 17: 1231-1240 (2009).
Emmert MY, Salzberg SP, Emmert LS, Behjati S, Plass A, Felix C, Falk V, Gruenenfelder J. Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease. Eur. J. Heart Fail. 11: 1106-1109 (2009).
Enc F, Yorulmaz E, Pehlivanoglu V, Tuncer I, Kiziltas S, Erbahceci A. Takayasu's arteritis in a case diagnosed as Crohn's disease. Turk. J. Gastroenterol. 18: 250-253 (2007). *
Enck P, Zimmermann K, Rusch K, Schwiertz A, Klosterhalfen S, Frick JS. The effects of ageing on the colonic bacterial microflora in adults. Z. Gastroenterol. 47: 653-658 (2009).
End C, Bikker F, Renner M, Bergmann G, Lyer S, Blaich S, Hudler M, Helmke B, Gassler N, Autschbach F, Ligtenberg AJ, Benner A, Holmskov U, Schirmacher P, Nieuw Amerongen AV, Rosenstiel P, Sina C, Franke A, Hafner M, Kioschis P, Schreiber S, et al. DMBT1 functions as pattern-recognition molecule for poly-sulfated and poly-phosphorylated ligands. Eur. J. Immunol. 39: 833-842 (2009). *
Endo K, Kinouchi Y, Kakuta Y, Ueki N, Takahashi S, Shimosegawa T. Involvement of NF-kappa B pathway in TL1A gene expression induced by lipopolysaccharide. Cytokine Oct 6 [Epub ahead of print] (2009).
Endo K, Shiga H, Kinouchi Y, Shimosegawa T. Inflammatory bowel disease: IBD. Rinsho Byori 57: 527-532 (2009).
Endres S, Lorenz R, Loeschke K. Lipid treatment of inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 2: 117-120 (1999).
Engel SH, Hullar TE, Adkins DR, Thorstad WL, Sunwoo JB. Temporal relationship between antitumor necrosis factor-alpha antibody therapy and recrudescence of head and neck squamous cell carcinoma. Laryngoscope 118: 450-452 (2008).
Engelhardt B, Briskin MJ. Therapeutic targeting of alpha4-integrins in chronic inflammatory diseases: tipping the scales of risk towards benefit? Eur. J. Immunol. 35: 2268-2273 (2005). *
Engelhardt B, Kappos L. Natalizumab: targeting alpha(4)-integrins in multiple sclerosis. Neurodegener. Dis. 5: 16-22 (2008).
Engin G. Computed tomography enteroclysis in the diagnosis of intestinal diseases. J. Comput. Assist. Tomogr. 32: 9-16 (2008).
Engin G, Balk E. Imaging findings of intestinal tuberculosis. J. Comput. Assist. Tomogr. 29: 37-41 (2005).
Engkilde K, Menne T, Johansen JD. Inflammatory bowel disease in relation to contact allergy: a patient-based study. Scand. J. Gastroenterol. 42: 572-576 (2007). *
English PL, Vender R. Occurrence of plantar pustular psoriasis during treatment with infliximab. J. Cutan. Med. Surg. 13: 40-42 (2009).
Engstrand L. Mycobacterium paratuberculosis and Crohn's disease. Scand. J. Infect. Dis. Suppl. 98: 27-29 (1995).
Engstrom JF, Arvanitakis C, Sagawa A, Abdou NI. Secretory immunoglobulin deficiency in a family with inflammatory bowel disease. Gastroenterology 74: 747-751 (1978).
Ennaifer R, Ouakaa-Kchaou A, Belhadj N, Elloumi H, Gargouri D, Kochlef A, Kilani A, Romani M, Kharrat J, Ghorbel A. Psoas abcess as the initial manifestation of Crohn's disease. Report of 3 cases. Tunis. Med. 87: 340-343 (2009).
Enomoto N, Takei Y, Kon K, Yamashina S, Suzuki S, Ikejima K, Sato N. Serine protease inhibitors prevent alcoholic liver injury. Nihon Arukoru Yakubutsu Igakkai Zasshi 40: 213-218 (2005).
Ensari C, Ensari A, Tumer N, Ertug E. Clinicopathological and epidemiological analysis of amyloidosis in Turkish patients. Nephrol. Dial. Transplant. 20: 1721-1725 (2005). *
Entrican JH, Busuttil A, Ferguson A. Are the focal microscopic jejunal lesions in Crohn's disease produced by a T-cell-mediated immune response? Scand. J. Gastroenterol. 22: 1071-1075 (1987).
Ephgrave K. Extra-intestinal manifestations of Crohn's disease. Surg. Clin. North Am. 87: 673-680 (2007).
Epifanio M, Baldisserotto M, Spolidoro JV, Gaiger A. Grey-scale and colour Doppler sonography in the evaluation of children with suspected bowel inflammation: correlation with colonoscopy and histological findings. Clin. Radiol. 63: 968-978 (2008).
Epple HJ. Therapy- and non-therapy-dependent infectious complications in inflammatory bowel disease. Dig. Dis. 27: 555-559 (2009).
Epstein D, Watermeyer G, Kirsch R. Review article: the diagnosis and management of Crohn's disease in populations with high-risk rates for tuberculosis. Aliment. Pharmacol. Ther. 25: 1373-1388 (2007). *
Epstein DJ. Cis-regulatory mutations in human disease. Brief. Funct. Genomic. Proteomic. 8: 310-316 (2009).
Epstein J, Docena G, Macdonald TT, Sanderson IR. Curcumin suppresses p38 mitogen-activated protein kinase activation, reduces IL-1beta and matrix metalloproteinase-3 and enhances IL-10 in the mucosa of children and adults with inflammatory bowel disease. Br. J. Nutr. Nov 2 [Epub ahead of print] (2009). *
Eradi B, Sandhu BK, Spray C, Cusick E. Highly destructive perianal Crohn disease. J. Pediatr. Gastroenterol. Nutr. 41: 667-669 (2005). *
Erasmus DL, Victor TC, van Eeden PJ, Falck V, van Helden P. Mycobacterium paratuberculosis and Crohn's disease. Gut 36: 942 (1995). *
Erber WF, Erber JA. Meta-analysis of the yield of capsule endoscopy in patients with Crohn's disease. Am. J. Gastroenterol. 101: 2669 (2006). *
Erdman SE, Poutahidis T, Tomczak M, Rogers AB, Cormier K, Plank B, Horwitz BH, Fox JG. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice. Am. J. Pathol. 162: 691-702 (2003). *
Ergas D, Eilat E, Mendlovic S, Sthoeger ZM. n-3 Fatty acids and the immune system in autoimmunity. Isr. Med. Assoc. J. 4: 34-38 (2002). *
Ergen FB, Arslan EB, Kerimoglu U, Akata D. Magnetic resonance fistulography for the demonstration of anovaginal fistula: an alternative imaging technique? J. Comput. Assist. Tomogr. 31: 243-246 (2007).
Ergin A, Adam T, Bussow K, Thiel A, Sieper J, Duchmann R. Identification of the predominant antigenic epitopes in intestinal flora in IBD. Mucosal Immunol. 1 Suppl. 1: S19-S23 (2008).
Eri R, Jonsson JR, Pandeya N, Purdie DM, Clouston AD, Martin N, Duffy D, Powell EE, Fawcett J, Florin TH, Radford-Smith GL. CCR5-Delta32 mutation is strongly associated with primary sclerosing cholangitis. Genes Immun. 5: 444-450 (2004). *
Eri R, Kodumudi KN, Summerlin DJ, Srinivasan M. Suppression of colon inflammation by CD80 blockade: evaluation in two murine models of inflammatory bowel disease. Inflamm. Bowel Dis. 14: 458-470 (2008). *
Erichsen K, Ulvik RJ, Nysaeter G, Johansen J, Ostborg J, Berstad A, Berge RK, Hausken T. Oral ferrous fumarate or intravenous iron sucrose for patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1058-1065 (2005). *
Eriksson A, Jennische E, Flach CF, Jorge A, Lange S. Real-time PCR quantification analysis of five mucosal transcripts in patients with Crohn's disease. Eur. J. Gastroenterol. Hepatol. 20: 290-296 (2008).
Eriksson A, Shafazand M, Jennische E, Lonnroth I, Lange S. Antisecretory factor-induced regression of Crohn's disease in a weak responder to conventional pharmacological treatment. Inflamm. Bowel Dis. 9: 398-400 (2003). *
Erkelens GW, Van Deventer SJ. Endoscopic treatment of strictures in Crohn's disease. Best Pract. Res. Clin. Gastroenterol. 18: 201-207 (2004).
Ernst A, Jacobsen B, Ostergaard M, Okkels H, Andersen V, Dagiliene E, Pedersen IS, Thorsgaard N, Drewes AM, Krarup HB. Mutations in CARD15 and smoking confer susceptibility to Crohn's disease in the Danish population. Scand. J. Gastroenterol. 42: 1445-1451 (2007). *
Ernst E. Frankincense: systematic review. BMJ 337: a2813 (2008).
Ersoy O, Harmanci O, Aydinli M, Sivri B, Bayraktar Y. Capability of capsule endoscopy in detecting small bowel ulcers. Dig. Dis. Sci. 54: 136-141 (2009). *
Ersoy O, Sivri B, Arslan S, Batman F, Bayraktar Y. How much helpful is the capsule endoscopy for the diagnosis of small bowel lesions? World J. Gastroenterol. 12: 3906-3910 (2006). *
Ertekin V, Selimoglu MA, Okcu N, Orbak Z, Gundogdu C. Intestinal tuberculosis mimicking Crohn's disease. J. Emerg. Med. 33: 421-423 (2007).
Ertugrul I, Tunc B, Yuksel I, Yolcu OF, Ulker A. PSOAS abscess: an atypical initial presentation of Crohn's disease. Dig. Liver Dis. 38: 357-358 (2006).
Erzin Y, Cosgun S, Dobrucali A, Tasyurekli M, Erdamar S, Tuncer M. Complicated granulomatous colitis in a patient with Hermansky-Pudlak syndrome, successfully treated with infliximab. Acta Gastroenterol. Belg. 69: 213-216 (2006).
Erzin Y, Uzun H, Karatas A, Celik AF. Serum YKL-40 as a marker of disease activity and stricture formation in patients with Crohn's disease. J. Gastroenterol. Hepatol. 23: e357-e362 (2008). *
Esaki M, Furuse M, Matsumoto T, Aoyagi K, Jo Y, Yamagata H, Nakano H, Fujishima M. Polymorphism of heat-shock protein gene HSP70-2 in Crohn disease: possible genetic marker for two forms of Crohn disease. Scand. J. Gastroenterol. 34: 703-707 (1999). *
Esaki M, Matsumoto T, Hizawa K, Nakamura S, Jo Y, Mibu R, Iida M. Preventive effect of nutritional therapy against postoperative recurrence of Crohn disease, with reference to findings determined by intra-operative enteroscopy. Scand. J. Gastroenterol. 40: 1431-1437 (2005). *
Esaki M, Matsumoto T, Nakamura S, Yada S, Fujisawa K, Jo Y, Iida M. Factors affecting recurrence in patients with Crohn's disease under nutritional therapy. Dis. Colon Rectum 49: S68-S74 (2006). *
Escher JC. Mucosal healing in pediatric Crohn's disease: pro/con balance. Inflamm. Bowel Dis. 10: 484 (2004). *
Escher JC. Nutritional therapy in paediatric Crohn's disease: more food for thought? Dig. Liver Dis. 38: 387-388 (2006).
Escher JC, Taminiau JA, Nieuwenhuis EE, Buller HA, Grand RJ. Treatment of inflammatory bowel disease in childhood: best available evidence. Inflamm. Bowel Dis. 9: 34-58 (2003). *
Escher JC, ten KF, Lichtenbelt K, Schornagel I, Buller H, Derkx B, Taminiau J. Value of rectosigmoidoscopy with biopsies for diagnosis of inflammatory bowel disease in children. Inflamm. Bowel Dis. 8: 16-22 (2002). *
Escher JC; European Collaborative Research Group on Budesonide in Paediatric IBD. Budesonide versus prednisolone for the treatment of active Crohn's disease in children: a randomized, double-blind, controlled, multicentre trial. Eur. J. Gastroenterol. Hepatol. 16: 47-54 (2004).
Escorsell A, Pares A, Rodes J, Solis-Herruzo JA, Miras M, de la Morena E. Epidemiology of primary sclerosing cholangitis in Spain. Spanish Association for the Study of the Liver. J. Hepatol. 21: 787-791 (1994).
Eshuis EJ, Bemelman WA, Stokkers PC. Infliximab for the treatment of ulcerative colitis. Expert Rev. Gastroenterol. Hepatol. 3: 219-229 (2009).
Eshuis EJ, Bemelman WA, van Bodegraven AA, Sprangers MA, Bossuyt PM, van Milligen de Wit AM, Crolla RM, Cahen DL, Oostenbrug LE, Sosef MN, Voorburg AM, Davids PH, van der Woude CJ, Lange J, Mallant RC, Boom MJ, Lieverse RJ, van der Zaag ES, et al. Laparoscopic ileocolic resection versus infliximab treatment of distal ileitis in Crohn's disease: a randomized multicenter trial (LIR!C-trial). BMC Surg. 8: 15 (2008). *
Eshuis EJ, Polle SW, Slors JF, Hommes DW, Sprangers MA, Gouma DJ, Bemelman WA. Long-term surgical recurrence, morbidity, quality of life, and body image of laparoscopic-assisted vs. open ileocolic resection for Crohn's disease: a comparative study. Dis. Colon Rectum 51: 858-867 (2008). *
Esrailian E, Spiegel BM, Targownik LE, Dubinsky MC, Targan SR, Gralnek IM. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment. Pharmacol. Ther. 26: 1005-1018 (2007). *
Essary B, Kim J, Anupindi S, Katz JA, Nimkin K. Pelvic MRI in children with Crohn disease and suspected perianal involvement. Pediatr. Radiol. 37: 201-208 (2007). *
Essers JB, Lee JJ, Kugathasan S, Stevens CR, Grand RJ, Daly MJ. Established genetic risk factors do not distinguish early and later onset Crohn's disease. Inflamm. Bowel Dis. 15: 1508-1514 (2009).
Esters N, Pierik M, van Steen K, Vermeire S, Claessens G, Joossens S, Vlietinck R, Rutgeerts P. Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease. Am. J. Gastroenterol. 99: 299-305 (2004). *
Esters N, Vermeire S, Joossens S, Noman M, Louis E, Belaiche J, De Vos M, Van Gossum A, Pescatore P, Fiasse R, Pelckmans P, Reynaert H, Poulain D, Bossuyt X, Rutgeerts P; Belgian Group of Infliximab Expanded Access Program in Crohn's Disease. Serological markers for prediction of response to anti-tumor necrosis factor treatment in Crohn's disease. Am. J. Gastroenterol. 97: 1458-1462 (2002). *
Esteve M, Loras C, Gonzalez-Huix F. Lamivudine resistance and exacerbation of hepatitis B in infliximab-treated Crohn's disease patient. Inflamm. Bowel Dis. 13: 1450-1451 (2007). *
Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM. Chronic hepatitis B reactivation following infliximab therapy in Crohn's disease patients: need for primary prophylaxis. Gut 53: 1363-1365 (2004). *
Esteve-Comas M, Nunez MC, Fernandez-Banares F, Abad-Lacruz A, Gil A, Cabre E, Gonzalez-Huix F, Bertran X, Gassull MA. Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease. Gut 34: 1370-1373 (1993). *
Estiarte R, Juan J, Colome E, Artes M, Jimenez FJ. Drug utilization study in patients with Crohn's disease in Spain. Eur. J. Gastroenterol. Hepatol. 15: 355-362 (2003).
Estrin HM, Hughes RW Jr. Oral manifestations in Crohn's disease: report of a case. Am. J. Gastroenterol. 80: 352-354 (1985).
Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J. Gastroenterol. 14: 5512-5518 (2008). *
Etchevers MJ, Jimenez IO. Smoking and Crohn's disease: cessation strategies. Gastroenterol. Hepatol. 32S2: 37-43 (2009).
Etchevers MJ, Ordas I, Ricart E. Optimizing the use of tumour necrosis factor inhibitors in Crohn's disease: a practical approach. Drugs 70: 109-120 (2010).
Etienney I, Bouhnik Y, Gendre JP, Lemann M, Cosnes J, Matuchansky C, Beaugerie L, Modigliani R, Rambaud JC. Crohn's disease over 20 years after diagnosis in a referral population. Gastroenterol. Clin. Biol. 28: 1233-1239 (2004). *
Ettorre GM, Pescatori M, Panis Y, Nemeth J, Crescenzi A, Valleur P. Mucosal changes in ileal pouches after restorative proctocolectomy for ulcerative and Crohn's colitis. Dis. Colon Rectum 43: 1743-1748 (2000).
Euler AR, Ament ME. Crohn's disease - a cause of arthritis, oxalate stones and fistulae in cystic fibrosis. West. J. Med. 125: 315-317 (1976).
Eun CS. Crohn's disease of the small bowel. Korean J. Gastroenterol. 45: 75-77 (2005).
EUROPEAN COMMISSION, DIRECTORATE-GENERAL HEALTH & CONSUMER PROTECTION, Directorate B - Scientific Health Opinions, Unit B3 - Management of scientific committees II. Possible links between Crohn’s disease and Paratuberculosis (http://europa.eu.int/comm/food/fs/sc/scah/out38_en.pdf). Report of the Scientific Committee on Animal Health and Animal Welfare Adopted 21 March 2000 (2000). *
Evans RC, Clarke L, Heath P, Stephens S, Morris AI, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNFalpha antibody CDP571. Aliment. Pharmacol. Ther. 11: 1031-1035 (1997).
Evers EA, Pfefferkorn MD, Steiner SJ. Factors predictive of Crohn disease following colectomy in medically refractory pediatric colitis. J. Pediatr. Gastroenterol. Nutr. 48: 283-286 (2009).
Evert M, Seiler C, Dombrowski F. Aberrant acinar cell CA 19-9 expression and peri-insular acinar cell alterations in an adult human pancreas. Virchows Arch. 446: 68-72 (2005). *
Ewaschuk JB, Dieleman LA. Probiotics and prebiotics in chronic inflammatory bowel diseases. World J. Gastroenterol. 12: 5941-5950 (2006). *
Ewaschuk JB, Tejpar QZ, Soo I, Madsen K, Fedorak RN. The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. Curr. Gastroenterol. Rep. 8: 486-498 (2006).
Ewe K. Crohn disease and ulcerative colitis - newer therapeutic approaches. Z. Gastroenterol. 31: 151-155 (1993).
Facchini S, Candusso M, Martelossi S, Liubich M, Panfili E, Ventura A. Efficacy of long-term treatment with thalidomide in children and young adults with Crohn disease: preliminary results. J. Pediatr. Gastroenterol. Nutr. 32: 178-181 (2001). *
Fagan C, Phelan D. Severe convulsant hypomagnesaemia and short bowel syndrome. Anaesth. Intensive Care 29: 281-283 (2001).
Fagerstam JP, Whiss PA, Strom M, Andersson RG. Expression of platelet P-selectin and detection of soluble P-selectin, NPY and RANTES in patients with inflammatory bowel disease. Inflamm. Res. 49: 466-472 (2000). *
Fagoonee S, De Luca L, De Angelis C, Castelli A, Rizzetto M, Pellicano R. Anti-Saccharomyces cerevisiae as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol. Dietol. 55: 37-40 (2009).
Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. beta-Defensin-3 and -4 in intestinal epithelial cells display increased mRNA expression in ulcerative colitis. Clin. Exp. Immunol. 137: 379-385 (2004). *
Fahlgren A, Hammarstrom S, Danielsson A, Hammarstrom ML. Increased expression of antimicrobial peptides and lysozyme in colonic epithelial cells of patients with ulcerative colitis. Clin. Exp. Immunol. 131: 90-101 (2003). *
Fahrlander H. Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid. Schweiz. Med. Wochenschr. 117: 1620-1623 (1987).
Faioni EM, Ferrero S, Fontana G, Gianelli U, Ciulla MM, Vecchi M, Saibeni S, Biguzzi E, Cordani N, Franchi F, Bosari S, Cattaneo M. Expression of endothelial protein C receptor and thrombomodulin in the intestinal tissue of patients with inflammatory bowel disease. Crit. Care Med. 32: S266-S270 (2004).
Fais S, Pallone F, Squarcia O, Biancone L, Ricci F, Paoluzi P, Boirivant M. HLA-DR antigens on colonic epithelial cells in inflammatory bowel disease: I. Relation to the state of activation of lamina propria lymphocytes and to the epithelial expression of other surface markers. Clin. Exp. Immunol. 68: 605-612 (1987). *
Faivre A, Franques J, De Paula AM, Gutierrez M, Bret S, Aubert S, Attarian S, Pouget J. Acute motor and sensory axonal neuropathy and concomitant encephalopathy during tumor necrosis factor-alpha antagonist therapy. J. Neurol. Sci. Jan 28 [Epub ahead of print] (2010).
Fakhoury M, Lecordier J, Medard Y, Peuchmaur M, Jacqz-Agrain E. Impact of inflammation on the duodenal mRNA expression of CYP3A and P-glycoprotein in children with Crohn's disease. Inflamm. Bowel Dis. 12: 745-749 (2006). *
Fallahi GH, Moazzami K, Tabatabaeiyan M, Zamani MM, Asgar-Shirazi M, Najafi M, Motamed F, Farahmand F, Khodad A, Khatami GR, Rezaei N. Clinical characteristics of Iranian pediatric patients with inflammatory bowel disease. Acta Gastroenterol. Belg. 72: 230-234 (2009).
Faller M, Gasser B, Massard G, Pauli G, Quoix E. Pulmonary migratory infiltrates and pachypleuritis in a patient with Crohn's disease. Respiration 67: 459-463 (2000). *
Fallon JC, Patchett S, Gulmann C, Murphy GM. Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab. Clin. Exp. Dermatol. 33: 43-45 (2008). *
Famularo G, Mosca L, Minisola G, Trinchieri V, De Simone C. Probiotic lactobacilli: a new perspective for the treatment of inflammatory bowel disease. Curr. Pharm. Des. 9: 1973-1980 (2003).
Fantini MC, Monteleone G, Macdonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1419-1423 (2007). *
Fantini MC, Monteleone G, MacDonald TT. IL-21 comes of age as a regulator of effector T cells in the gut. Mucosal Immunol. 1: 110-115 (2008).
Fantini MC, Pallone F. Cytokines: from gut inflammation to colorectal cancer. Curr. Drug Targets 9: 375-380 (2008).
Fantini MC, Pallone F, Monteleone G. Common immunologic mechanisms in inflammatory bowel disease and spondylarthropathies. World J. Gastroenterol. 15: 2472-2478 (2009). *
Farago B, Magyari L, Safrany E, Csongei V, Jaromi L, Horvatovich K, Sipeky C, Maasz A, Radics J, Gyetvai A, Szekanecz Z, Czirjak L, Melegh B. Functional variants of interleukin-23 receptor gene confer risk for rheumatoid arthritis but not for systemic sclerosis. Ann. Rheum. Dis. 67: 248-250 (2008).
Fardy J, MacIntosh D, Borgaonkar M, Gonsalves C. Antibiotics for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. 2: CD000295 (2004). *
Farhi D, Cosnes J, Zizi N, Chosidow O, Seksik P, Beaugerie L, Aractingi S, Khosrotehrani K. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients. Medicine (Baltimore) 87: 281-293 (2008).
Farhi D, Duriez P, Aractingi S, Cosnes J, Khosrotehrani K. Misleading pustular plaques of the lower limbs during Crohn's disease: two case reports. J. Med. Case Reports 1: 109 (2007). *
Farkas SA, Hornung M, Sattler C, Steinbauer M, Anthuber M, Obermeier F, Herfarth H, Schlitt HJ, Geissler EK. Preferential migration of CD62L cells into the appendix in mice with experimental chronic colitis. Eur. Surg. Res. 37: 115-122 (2005).
Farmer M, Hunt L, Eichenberger MR, Petras RE, Janosky JE, Galandiuk S. Association of susceptibility locus for inflammatory bowel disease on chromosome 16 with both ulcerative colitis and Crohn's disease. Dig. Dis. Sci. 46: 632-636 (2001). *
Farmer M, Petras RE, Hunt LE, Janosky JE, Galandiuk S. The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am. J. Gastroenterol. 95: 3184-3188 (2000). *
Farnbacher MJ, Reisch A, Lederer R, Schneider T. Cooperative use of video capsule endoscopy: effective and economic. Z. Gastroenterol. 42: 505-508 (2004).
Farrant MA, Mason JC, Wong NA, Longman RJ. Takayasu's arteritis following Crohn's disease in a young woman: any evidence for a common pathogenesis? World J. Gastroenterol. 14: 4087-4090 (2008). *
Farrell RJ. Crohn's disease: not all anti-TNFs are the same! Inflamm. Bowel Dis. 8: 232-233 (2002). *
Farrell RJ, Kelleher D. Glucocorticoid resistance in inflammatory bowel disease. J. Endocrinol. 178: 339-346 (2003). *
Farrell RJ, Murphy A, Long A, Donnelly S, Cherikuri A, O'Toole D, Mahmud N, Keeling PW, Weir DG, Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 118: 279-288 (2000). *
Farrell RJ, Shah SA, Lodhavia PJ, Alsahli M, Falchuk KR, Michetti P, Peppercorn MA. Clinical experience with infliximab therapy in 100 patients with Crohn's disease. Am. J. Gastroenterol. 95: 3490-3497 (2000). *
Farrokhyar F, Marshall JK, Easterbrook B, Irvine EJ. Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm. Bowel Dis. 12: 38-46 (2006). *
Farrokhyar F, Swarbrick ET, Grace RH, Hellier MD, Gent AE, Irvine EJ. Low mortality in ulcerative colitis and Crohn's disease in three regional centers in England. Am. J. Gastroenterol. 96: 501-507 (2001). *
Farrokhyar F, Swarbrick ET, Irvine EJ. A critical review of epidemiological studies in inflammatory bowel disease. Scand. J. Gastroenterol. 36: 2-15 (2001). *
Farthing MJ, Campbell CA, Walker-Smith J, Edwards CR, Rees LH, Dawson AM. Nocturnal growth hormone and gonadotrophin secretion in growth retarded children with Crohn's disease. Gut 22: 933-938 (1981). *
Fasano A. Surprises from celiac disease. Sci. Am. 301: 54-61 (2009).
Fatahzadeh M. Inflammatory bowel disease. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 108: e1-e10 (2009).
Fatahzadeh M, Schwartz RA, Kapila R, Rochford C. Orofacial Crohn's disease: an oral enigma. Acta Dermatovenerol. Croat. 17: 289-300 (2009).
Faubion WA Jr, Bousvaros A. Medical therapy for refractory pediatric Crohn's disease. Clin. Gastroenterol. Hepatol. 4: 1199-1213 (2006).
Faubion WA Jr, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology 121: 255-260 (2001). *
Faubion WA Jr, Loftus EV, Sandborn WJ, Freese DK, Perrault J. Pediatric "PSC-IBD": a descriptive report of associated inflammatory bowel disease among pediatric patients with PSC. J. Pediatr. Gastroenterol. Nutr. 33: 296-300 (2001). *
Faulds D, Goa KL, Benfield P. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 45: 953-1040 (1993).
Faure C, Giguere L. Functional gastrointestinal disorders and visceral hypersensitivity in children and adolescents suffering from Crohn's disease. Inflamm. Bowel Dis. 14: 1569-1574 (2008). *
Fausa O, Kolmannskog F, Ritland S. The pancreatic ducts in primary biliary cirrhosis and sclerosing cholangitis. Scand. J. Gastroenterol. Suppl. 107: 32-35 (1985).
Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory bowel disease and primary sclerosing cholangitis. Semin. Liver Dis. 11: 31-39 (1991).
Faust D, Menge F, Armbruster FP, Lembcke B, Stein J. Increased serum bone sialoprotein concentrations in patients with Crohn's disease. Z. Gastroenterol. 41: 243-247 (2003).
Faustini F, Zoli A, Ferraccioli GF. Immunologic and genetic links between spondylarthropathies and inflammatory bowel diseases. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 1-9 (2009).
Favalli EG, Varenna M, Sinigaglia L. Drug-induced agranulocytosis during treatment with infliximab in enteropathic spondyloarthropathy. Clin. Exp. Rheumatol. 23: 247-250 (2005).
Favila-Humara LC, Chavez-Gris GG, Carrillo-Casas EM, Hernandez-Castro R. Mycobacterium avium subsp. paratuberculosis detection in individual and bulk tank milk samples from bovine herds and caprine flocks. Foodborne Pathog. Dis. Nov 13 [Epub ahead of print] (2009).
Feagan BG. Endoscopic scoring system for Crohn's disease: viva the evolution! Gastrointest. Endosc. 60: 590-591 (2004). *
Feagan BG. Management of perianal and fistulizing disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, p. 37 (2005). *
Feagan BG. Methotrexate treatment for Crohn's disease. Inflamm. Bowel Dis. 4: 120-121 (1998). *
Feagan BG. Review article: economic issues in Crohn's disease - assessing the effects of new treatments on health-related quality of life. Aliment. Pharmacol. Ther. 13 Suppl. 4: 29-37 (1999). *
Feagan BG. Maintenance therapy for inflammatory bowel disease. Am. J. Gastroenterol. 98: S6-S17 (2003). *
Feagan BG. 5-ASA therapy for active Crohn's disease: old friends, old data, and a new conclusion. Clin. Gastroenterol. Hepatol. 2: 376-378 (2004). *
Feagan BG, Bala M, Yan S, Olson A, Hanauer S. Unemployment and disability in patients with moderately to severely active Crohn's disease. J. Clin. Gastroenterol. 39: 390-395 (2005).
Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn's disease. Am. J. Gastroenterol. 104: 1976-1983 (2009). *
Feagan BG, Enns R, Fedorak RN, Panaccione R, Pare P, Steinhart AH, Wild G. Infliximab for the treatment of Crohn's disease: efficacy, safety and pharmacoeconomics. Can. J. Clin. Pharmacol. 8: 188-198 (2001).
Feagan BG, Fedorak RN, Irvine EJ, Wild G, Sutherland L, Steinhart AH, Greenberg GR, Koval J, Wong CJ, Hopkins M, Hanauer SB, McDonald JW. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N. Engl. J. Med. 342: 1627-1632 (2000). *
Feagan BG, Greenberg GR, Wild G, Fedorak RN, Pare P, McDonald JW, Cohen A, Bitton A, Baker J, Dube R, Landau SB, Vandervoort MK, Parikh A. Treatment of active Crohn's disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin. Gastroenterol. Hepatol. 6: 1370-1377 (2008).
Feagan BG, McDonald JW, Koval JJ. Therapeutics and inflammatory bowel disease: a guide to the interpretation of randomized controlled trials. Gastroenterology 110: 275-283 (1996). *
Feagan BG, Panaccione R, Sandborn WJ, D'Haens GR, Schreiber S, Rutgeerts PJ, Loftus EV Jr, Lomax KG, Yu AP, Wu EQ, Chao J, Mulani P. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 135: 1493-1499 (2008). *
Feagan BG, Sandborn WJ. Initial therapy for mild to moderate Crohn's disease: mesalamine or budesonide? Rev. Gastroenterol. Disord. 2 Suppl. 2: S9-S15 (2002). *
Feagan BG, Sandborn WJ, Baker JP, Cominelli F, Sutherland LR, Elson CO, Salzberg BA, Archambault A, Bernstein CN, Lichtenstein GR, Heath PK, Cameron S, Hanauer SB. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease. Aliment. Pharmacol. Ther. 21: 373-384 (2005). *
Feagan BG, Sandborn WJ, Hass S, Niecko T, White J. Health-related quality of life during natalizumab maintenance therapy for Crohn's disease. Am. J. Gastroenterol. 102: 2737-2746 (2007). *
Feagan BG, Sandborn WJ, Lichtenstein G, Radford-Smith G, Patel J, Innes A. CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, for steroid-dependent Crohn's disease: a randomized, double-blind, placebo-controlled trial. Aliment. Pharmacol. Ther. 23: 617-628 (2006). *
Feagan BG, Sandborn WJ, Mittmann U, Bar-Meir S, D'Haens G, Bradette M, Cohen A, Dallaire C, Ponich TP, McDonald JW, Hebuterne X, Pare P, Klvana P, Niv Y, Ardizzone S, Alexeeva O, Rostom A, Kiudelis G, Spleiss J, Gilgen D, Vandervoort MK, Wong CJ, et al. Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials. JAMA 299: 1690-1697 (2008). *
Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn's disease: a payor perspective. Am. J. Gastroenterol. 95: 1955-1960 (2000). *
Feagans J, Victor D, Joshi V. Crohn disease of the esophagus: a review of the literature. South. Med. J. 101: 927-930 (2008).
Feagins LA, Cryer BL. Do non-steroidal anti-inflammatory drugs cause exacerbations of inflammatory bowel disease? Dig. Dis. Sci. Nov 19 [Epub ahead of print] (2009). *
Fearnhead NS, Chowdhury R, Box B, George BD, Jewell DP, Mortensen NJ. Long-term follow-up of strictureplasty for Crohn's disease. Br. J. Surg. 93: 475-482 (2006). *
Fedorak RN. Is it time to re-classify Crohn's disease? Best Pract. Res. Clin. Gastroenterol. 18 Suppl.: 99-106 (2004).
Fedorak RN, Bistritz L. Targeted delivery, safety, and efficacy of oral enteric-coated formulations of budesonide. Adv. Drug Deliv. Rev. 57: 303-316 (2005). *
Fedorak RN, Gangl A, Elson CO, Rutgeerts P, Schreiber S, Wild G, Hanauer SB, Kilian A, Cohard M, LeBeaut A, Feagan B. Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology 119: 1473-1482 (2000). *
Fedorak RN, Madsen KL. Probiotics and prebiotics in gastrointestinal disorders. Curr. Opin. Gastroenterol. 20: 146-155 (2004).
Fedorak RN, Madsen KL. Probiotics and the management of inflammatory bowel disease. Inflamm. Bowel Dis. 10: 286-299 (2004). *
Fedorak RN; Canadian Association of Gastroenterology. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can. J. Gastroenterol. 15: 367-370 (2001). *
Feeney M, Ciegg A, Winwood P, Snook J. A case-control study of measles vaccination and inflammatory bowel disease. The East Dorset Gastroenterology Group. Lancet 350: 764-766 (1997). *
Feeney MA, Murphy F, Clegg AJ, Trebble TM, Sharer NM, Snook JA. A case-control study of childhood environmental risk factors for the development of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 14: 529-534 (2002).
Fefferman DS, Farrell RJ. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clin. Gastroenterol. Hepatol. 3: 11-24 (2005). *
Fefferman DS, Lodhavia PJ, Alsahli M, Falchuk KR, Peppercorn MA, Shah SA, Farrell RJ. Smoking and immunomodulators do not influence the response or duration of response to infliximab in Crohn's disease. Inflamm. Bowel Dis. 10: 346-351 (2004). *
Feher J, Lengyel G. The effectivity and safety of the biological therapy with adalimumab. Orv. Hetil. 150: 1215-1222 (2009).
Feillet H, Bach JF. Increased incidence of inflammatory bowel disease: the price of the decline of infectious burden? Curr. Opin. Gastroenterol. 20: 560-564 (2004).
Fekih M, Ben Hlima S, Zitouni M, Matri S, Boubaker J, Makni S, Azza F. Interest of serologic markers in inflammatory bowel disease. About 105 cases. Tunis. Med. 85: 821-828 (2007).
Fekih M, Hefaiedh R, Matri S, Djebbi S, Boubaker J, Filali A. An unexplicated inflammatory syndrome could be due to renal amyloidis associated to Crohn's disease. Tunis. Med. 86: 1022-1023 (2008).
Felaco P, Castellani ML, De Lutiis MA, Felaco M, Pandolfi F, Salini V, De Amicis D, Vecchiet J, Tete S, Ciampoli C, Conti F, Cerulli G, Caraffa A, Antinolfi P, Cuccurullo C, Perrella A, Theoharides TC, Conti P, Toniato E, Kempuraj D, Shaik YB. IL-32: a newly-discovered proinflammatory cytokine. J. Biol. Regul. Homeost. Agents 23: 141-147 (2009).
Feld J, Heathcote E. Epidemiology of autoimmune liver disease. J. Gastroenterol. Hepatol. 18: 1118-1128 (2003). *
Felder JB, Korelitz BI, Rajapakse R, Schwarz S, Horatagis AP, Gleim G. Effects of nonsteroidal antiinflammatory drugs on inflammatory bowel disease: a case-control study. Am. J. Gastroenterol. 95: 1949-1954 (2000). *
Feldmann M, Brennan FM, Paleolog E, Cope A, Taylor P, Williams R, Woody J, Maini RN. Anti-TNFalpha therapy of rheumatoid arthritis: what can we learn about chronic disease? Novartis Found. Symp. 256: 53-69 (2004).
Feldmann M, Pusey CD. Is there a role for TNF-alpha in anti-neutrophil cytoplasmic antibody-associated vasculitis? Lessons from other chronic inflammatory diseases. J. Am. Soc. Nephrol. 17: 1243-1252 (2006). *
Feldstein RC, Sood S, Katz S. Small bowel adenocarcinoma in Crohn's disease. Inflamm. Bowel Dis. 14: 1154-1157 (2008). *
Felekis T, Katsanos K, Kitsanou M, Trakos N, Theopistos V, Christodoulou D, Asproudis I, Tsianos EV. Spectrum and frequency of ophthalmologic manifestations in patients with inflammatory bowel disease: a prospective single-center study. Inflamm. Bowel Dis. 15: 29-34 (2009). *
Feliciani C, De Simone C, Amerio P. Dermatological signs during inflammatory bowel diseases. Eur. Rev. Med. Pharmacol. Sci. 13 Suppl. 1: 15-21 (2009).
Felizardo M, Gomes A, Sousa M, Teixeira A, Freitas J, Tavares A, Vaz Patto J, Gomes M. Immunosuppression and tuberculosis. Rev. Port. Pneumol. 13: S23-S24 (2007).
Fell JM. Control of systemic and local inflammation with transforming growth factor beta containing formulas. JPEN J. Parenter. Enteral Nutr. 29: S126-S133 (2005). *
Fell JM, Walker-Smith JA, Spencer J, MacDonald TT. The distribution of dividing T cells throughout the intestinal wall in inflammatory bowel disease (IBD). Clin. Exp. Immunol. 104: 280-285 (1996). *
Feller AC, Lohler J, Reimann J, Merz H. Pathogenetic models ulcerative colitis and Crohn disease. Verh. Dtsch. Ges. Pathol. 80: 104-108 (1996).
Feller M, Huwiler K, Egger M. Mycobacterium avium subspecies paratuberculosis and Crohn's disease - authors' reply. Lancet Infect. Dis. 8: 345-346 (2008).
Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect. Dis. Jan 12 [Epub ahead of print] (2010). *
Feller M, Huwiler K, Stephan R, Altpeter E, Shang A, Furrer H, Pfyffer GE, Jemmi T, Baumgartner A, Egger M. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7: 607-613 (2007).
Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, Reinisch W, Teml A, Schwab M, Lichter P, Radlwimmer B, Stange EF. A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. Am. J. Hum. Genet. 79: 439-448 (2006). *
Fellermann K, Stange EF. How effective is natalizumab induction therapy in patients with Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 78-79 (2008). *
Fellermann K, Wehkamp J, Herrlinger KR, Stange EF. Crohn's disease: a defensin deficiency syndrome? Eur. J. Gastroenterol. Hepatol. 15: 627-634 (2003). *
Felley C, Guyot J, Hess J, Mottet C, Delarive J, Michetti P. Main therapeutic advance. Rev. Med. Suisse. 2: 191-1944, 196-198, 201-203 (2006).
Felley C, Mottet C, Hess J, Maillard MH, Delarive J, Michetti P. Main therapeutic advances in IBD in 2008. Rev. Med. Suisse. 5: 185-186, 188-190, 192-194 (2009).
Felley C, Mottet C, Juillerat P, Froehlich F, Burnand B, Vader JP, Michetti P, Gonvers JJ. Fistulizing Crohn's disease. Digestion 71: 26-28 (2005).
Felley C, Mottet C, Juillerat P, Pittet V, Froehlich F, Vader JP, Michetti P, Gonvers JJ. Fistulizing Crohn's disease. Digestion 76: 109-112 (2007). *
Felt-Bersma RJ. Endoanal ultrasound in perianal fistulas and abscesses. Dig. Liver Dis. 38: 537-543 (2006).
Felt-Bersma RJ, Bartelsman JF. Haemorrhoids, rectal prolapse, anal fissure, peri-anal fistulae and sexually transmitted diseases. Best Pract. Res. Clin. Gastroenterol. 23: 575-592 (2009).
Felt-Bersma RJ, Cazemier M. Endosonography in anorectal disease: an overview. Scand. J. Gastroenterol. Suppl. 243: 165-174 (2006). *
Femiano F, Lanza A, Buonaiuto C, Perillo L, Dell'ermo A, Cirillo N. Pyostomatitis vegetans: a review of the literature. Med. Oral Patol. Oral Cir. Bucal. 14: E114-E117 (2009).
Feng Y, Zheng P, Zhao H, Wu K. SLC22A4 and SLC22A5 gene polymorphisms and Crohn's disease in the Chinese Han population. J. Dig. Dis. 10: 181-187 (2009). *
Ferguson A, Sedgwick DM, Drummond J. Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut 35: 665-668 (1994). *
Ferguson GG, Lee EW, Hunt SR, Ridley CH, Brandes SB. Management of the bladder during surgical treatment of enterovesical fistulas from benign bowel disease. J. Am. Coll. Surg. 207: 569-572 (2008).
Ferguson LR, Browning BL, Huebner C, Petermann I, Shelling AN, Demmers P, McCulloch A, Gearry RB, Barclay ML, Philpott M. Single nucleotide polymorphisms in human Paneth cell defensin A5 may confer susceptibility to inflammatory bowel disease in a New Zealand Caucasian population. Dig. Liver Dis. 40: 723-730 (2008).
Ferguson LR, Han DY, Fraser AG, Huebner C, Lam WJ, Morgan AR, Duan H, Karunasinghe N. Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn's disease in a New Zealand population. Mutat. Res. Jan 25 [Epub ahead of print] (2010).
Ferguson LR, Han DY, Huebner C, Petermann I, Barclay ML, Gearry RB, McCulloch A, Demmers PS. Tumor necrosis factor receptor superfamily, member 1B haplotypes increase or decrease the risk of inflammatory bowel diseases in a New Zealand Caucasian population. Gastroenterol. Res. Pract. 2009:591704 (2009).
Ferguson LR, Huebner C, Petermann I, Gearry RB, Barclay ML, Demmers P, McCulloch A, Han DY. Single nucleotide polymorphism in the tumor necrosis factor-alpha gene affects inflammatory bowel diseases risk. World J. Gastroenterol. 14: 4652-4661 (2008). *
Ferguson LR, Philpott M, Dryland P. Nutrigenomics in the whole-genome scanning era: Crohn's disease as example. Cell. Mol. Life Sci. 64: 3105-3118 (2007). *
Ferguson MM, MacFadyen EE. Orofacial granulomatosis - a 10 year review. Ann. Acad. Med. Singapore 15: 370-377 (1986).
Ferkolj I, Hocevar A, Golouh R, Dolenc Voljc M. Infliximab for treatment of resistant pyoderma gangrenosum associated with Crohn's disease. Acta Dermatovenerol. Alp. Panonica Adriat. 15: 173-177 (2006).
Ferkolj I, Ihan A, Markovic S. CD19+ in intestinal mucosa predict the response to infliximab in Crohn's disease. Hepatogastroenterology 52: 1128-1133 (2005).
Ferkolj I, Ihan A, Markovic S, Veceric Z, Pohar M. Infliximab reduces the number of activated mucosal lymphocytes in patients with Crohn's disease. J. Gastrointestin. Liver Dis. 15: 231-235 (2006). *
Ferlitsch A, Reinisch W, Puspok A, Dejaco C, Schillinger M, Schofl R, Potzi R, Gangl A, Vogelsang H. Safety and efficacy of endoscopic balloon dilation for treatment of Crohn's disease strictures. Endoscopy 38: 483-487 (2006).
Fernandez A, Tabuenca O, Peteiro A. A "false positive" octreoscan in ileal Crohn's disease. World J. Gastroenterol. 14: 5349-5352 (2008). *
Fernandez JP, Llana B, Dominguez L, Roiz C, Zeidan N, Garcia L. False-positive Tc-99m HMPAO leukocyte scan secondary to adenocarcinoma of the Ileum. Clin. Nucl. Med. 29: 63-64 (2004).
Fernandez L, Martinez A, Mendoza JL, Urcelay E, Fernandez-Arquero M, Garcia-Paredes J, Diaz-Rubio M, de la Concha EG. Interleukin-10 polymorphisms in Spanish patients with IBD. Inflamm. Bowel Dis. 11: 739-743 (2005). *
Fernandez L, Mendoza JL, Martinez A, Urcelay E, Fernandez-Arquero M, Garcia-Paredes J, Pena AS, Diaz-Rubio M, de la Concha EG. IBD1 and IBD3 determine location of Crohn's disease in the Spanish population. Inflamm. Bowel Dis. 10: 715-722 (2004). *
Fernandez Perez FJ, Rodriguez F, De Sola C, Fernandez Moreno N, Vera F, Rivera R, Sanchez Cantos A. Granulocytapheresis in inflammatory bowel disease. Efficacy of an induction plus maintenance sessions protocol at 32 weeks. Rev. Esp. Enferm. Dig. 99: 628-635 (2007). *
Fernandez Rivero JM, Rocha Ramirez JL, Villanueva Saenz E, Sierra Montenegro E, Rojas Illanes M. Anorectal tuberculosis. Case report. Rev. Gastroenterol. Mex. 72: 40-42 (2007).
Fernandez-Banares F, Abad-Lacruz A, Xiol X, Gine JJ, Dolz C, Cabre E, Esteve M, Gonzalez-Huix F, Gassull MA. Vitamin status in patients with inflammatory bowel disease. Am. J. Gastroenterol. 84: 744-748 (1989).
Fernandez-Banares F, Cabre E, Gonzalez-Huix F, Gassull MA. Enteral nutrition as primary therapy in Crohn's disease. Gut 35: S55-S59 (1994). *
Fernandez-Banares F, Esteve-Comas M, Mane J, Navarro E, Bertran X, Cabre E, Bartoli R, Boix J, Pastor C, Gassull MA. Changes in mucosal fatty acid profile in inflammatorybowel disease and in experimental colitis: a common response to bowel inflammation. Clin. Nutr. 16: 177-183 (1997).
Fernandez-Banares F, Mingorance MD, Esteve M, Cabre E, Lachica M, Abad-Lacruz A, Gil A, Humbert P, Boix J, Gassull MA. Serum zinc, copper, and selenium levels in inflammatory bowel disease: effect of total enteral nutrition on trace element status. Am. J. Gastroenterol. 85: 1584-1589 (1990).
Fernandez-Banares F, Salas A, Esteve M. Pitfalls and errors in the diagnosis of collagenous and lymphocytic colitis. Journal of Crohn's and Colitis 2: 343-347 (2008).
Fernandez-Flores A, Dajil S. Enterobiasis mimicking Crohn's disease. Indian J. Gastroenterol. 23: 149-150 (2004). *
Fernandez-Nebro A, Urena I, Irigoyen MV, Garcia-Vicuna R, Konno S, Iizuka M, Horie Y, Itou H, Shindo K, Watanabe S. Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease * author's reply. Gut 55: 1666-1667 (2006). *
Fernandez-Rodriguez E, Camarero-Gonzalez E. Patient with Crohn's disease and seizures due to hypomagnesemia. Nutr. Hosp. 22: 720-722 (2007).
Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, Rioux JD. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genet. 4: e1000024 (2008). *
Ferraccioli GF, Gremese E. Biological therapies in autoimmune chronic inflammatory diseases (ACIDs). Eur. Rev. Med. Pharmacol. Sci. 10: 37-40 (2006).
Ferrandiz-Pulido C, Bartralot R, Fuente MJ, Heras C, Bassas P, Aparicio G, Bodet D, Mollet J, Tortola MT, Garcia-Patos V. Postoperative pyoderma gangrenosum: diagnostic value of 16s ribosomal RNA sequencing and review of the literature. Clin. Exp. Dermatol. 34: 598-602 (2009). *
Ferrante M, D'Haens G, Dewit O, Baert F, Holvoet J, Geboes K, De Hertogh G, Van Assche G, Vermeire S, Rutgeerts P; on behalf of the Belgian IBD Research Group. Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series. Inflamm. Bowel Dis. 16: 243-249 (2010).
Ferrante M, D'Haens G, Rutgeerts P, Vermeire S, Van Assche G. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease). Curr. Gastroenterol. Rep. 11: 504-508 (2009).
Ferrante M, de Hertogh G, Hlavaty T, D'Haens G, Penninckx F, D'Hoore A, Vermeire S, Rutgeerts P, Geboes K, van Assche G. The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence. Gastroenterology 130: 1595-1606 (2006). *
Ferrante M, De Hertogh G, Penninckx F, Van Assche G. Protein-losing enteropathy in Crohn's disease. Clin. Gastroenterol. Hepatol. 3: A25 (2005). *
Ferrante M, Declerck S, Coopmans T, De Hertogh G, Van Assche G, Penninckx F, Rutgeerts P, Geboes K, D'Hoore A, Vermeire S. Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: a role for serological markers and microbial pattern recognition receptor genes? Journal of Crohn's and Colitis 2: 142-151 (2008).
Ferrante M, Henckaerts L, Joossens M, Pierik M, Joossens S, Dotan N, Norman G, Altstock R, Van Steen K, Rutgeerts P, Van Assche G, Vermeire S. New serological markers in inflammatory bowel disease are associated with complicated disease behaviour. Gut 56: 1394-1403 (2007). *
Ferrante M, Penninckx F, De Hertogh G, Geboes K, D'Hoore A, Noman M, Vermeire S, Rutgeerts P, Van Assche G. Protein-losing enteropathy in Crohn's disease. Acta Gastroenterol. Belg. 69: 384-389 (2006).
Ferrante M, Pierik M, Henckaerts L, Joossens M, Claes K, Van Schuerbeek N, Vlietinck R, Rutgeerts P, Van Assche G, Vermeire S. The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. Inflamm. Bowel Dis. 12: 870-878 (2006). *
Ferrante M, Vermeire S, Fidder H, Schnitzler F, Noman M, Van Assche G, De Hertogh G, Hoffman I, D'Hoore A, Van Steen K, Geboes K, Penninckx F, Rutgeerts P. Long-term outcome after infliximab for refractory ulcerative colitis. Journal of Crohn's and Colitis 2: 219-225 (2008).
Ferrarese F, Cecere V, Fabiano G. Extensive small bowel resections. Chir. Ital. 57: 631-634 (2005).
Ferraris A, Torres B, Knafelz D, Barabino A, Lionetti P, de Angelis GL, Iacono G, Papadatou B, D'Amato G, Di Ciommo V, Dallapiccola B, Castro M. Relationship between CARD15, SLC22A4/5, and DLG5 polymorphisms and early-onset inflammatory bowel diseases: an Italian multicentric study. Inflamm. Bowel Dis. 12: 355-361 (2006).
Ferraris L, Karmeli F, Eliakim R, Klein J, Fiocchi C, Rachmilewitz D. Intestinal epithelial cells contribute to the enhanced generation of platelet activating factor in ulcerative colitis. Gut 34: 665-668 (1993). *
Ferreira AC, Almeida S, Tavares M, Canedo P, Pereira F, Regalo G, Figueiredo C, Trindade E, Seruca R, Carneiro F, Amil J, Machado JC, Tavarela-Veloso F. NOD2/CARD15 and TNFA, but not IL1B and IL1RN, are associated with Crohn's disease. Inflamm. Bowel Dis. 11: 331-339 (2005). *
Ferreira AC, Gomes L, Maximo V, Amil J, Carneiro F, Machado JC, Tavarela-Veloso F. GRIM-19 mutations are not associated with Crohn's disease. Inflamm. Bowel Dis. 14: 434-435 (2008). *
Ferreiros-Vidal I, Amarelo J, Barros F, Carracedo A, Gomez-Reino JJ, Gonzalez A. Lack of association of ankylosing spondylitis with the most common NOD2 susceptibility alleles to Crohn's disease. J. Rheumatol. 30: 102-104 (2003).
Ferreiros-Vidal I, Barros F, Pablos JL, Carracedo A, Gomez-Reino JJ, Gonzalez A. CARD15/NOD2 analysis in rheumatoid arthritis susceptibility. Rheumatology (Oxford) 42: 1380-1382 (2003). *
Ferreiros-Vidal I, Garcia-Meijide J, Carreira P, Barros F, Carracedo A, Gomez-Reino JJ, Gonzalez A. The three most common CARD15 mutations associated with Crohn's disease and the chromosome 16 susceptibility locus for systemic lupus erythematosus. Rheumatology (Oxford) 42: 570-574 (2003). *
Ferrero S, Ragni N. Inflammatory bowel disease: management issues during pregnancy. Arch. Gynecol. Obstet. 270: 79-85 (2004).
Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1beta generation. Clin. Exp. Immunol. 147: 227-235 (2007). *
Ferstl FJ, Obert R. Computed tomography (CT) of acute diverticulitis of the cecum and ascending colon. Rofo. 176: 1257-1264 (2004).
Ferwerda G, Kramer M, de Jong D, Piccini A, Joosten LA, Devesaginer I, Girardin SE, Adema GJ, van der Meer JW, Kullberg BJ, Rubartelli A, Netea MG. Engagement of NOD2 has a dual effect on proIL-1beta mRNA transcription and secretion of bioactive IL-1beta. Eur. J. Immunol. 38: 184-191 (2008). *
Ferwerda G, Kullberg BJ, de Jong DJ, Girardin SE, Langenberg DM, van Crevel R, Ottenhoff TH, Van der Meer JW, Netea MG. Mycobacterium paratuberculosis is recognized by Toll-like receptors and NOD2. J. Leukoc. Biol. 82: 1011-1018 (2007). *
Festen EA, Goyette P, Scott R, Annese V, Zhernakova A, Brant SR, Cho JH, Silverberg MS, Taylor KD, de Jong DJ, Stokkers PC, McGovern D, Palmieri O, Achkar JP, Xavier RJ, Duerr RH, Daly MJ, Wijmenga C, Weersma RK, Rioux JD. Genetic variants in the region harbouring IL2/IL21 associated to ulcerative colitis. Gut 58: 799-804 (2009). *
Festen EA, Szperl AM, Weersma RK, Wijmenga C, Wapenaar MC. Inflammatory bowel disease and celiac disease: overlaps in the pathology and genetics, and their potential drug targets. Endocr. Metab. Immune Disord. Drug Targets 9: 199-218 (2009).
Feuchtenberger M, Kneitz C, Tony HP. Treatment of rheumatoid arthritis (RA) with anticytokines. MMW Fortschr. Med. 148: 44-45, 47 (2006).
Feuerlein S, Pauls S, Juchems MS, Stuber T, Hoffmann MH, Brambs HJ, Ernst AS. Pitfalls in abdominal diffusion-weighted imaging: how predictive is restricted water diffusion for malignancy. AJR Am. J. Roentgenol. 193: 1070-1076 (2009).
Fiasse R, Latinne D. Intestinal helminths: a clue explaining the low incidence of inflammatory bowel diseases in Subsaharan Africa? Potential benefits and hazards of helminth therapy. Acta Gastroenterol. Belg. 69: 418-422 (2006).
Ficari F, Fazi M, Garcea A, Nesi G, Tonelli F. Anal carcinoma occurring in Crohn's disease patients with chronic anal fistula. Suppl. Tumori. 4: S31 (2005).
Fichera A. Crohn's disease: how modern is the management of fistulizing disease? Nat. Rev. Gastroenterol. Hepatol. 6: 511-512 (2009).
Fichera A, Lovadina S, Rubin M, Cimino F, Hurst RD, Michelassi F. Patterns and operative treatment of recurrent Crohn's disease: a prospective longitudinal study. Surgery 140: 649-654 (2006). *
Fichera A, McCormack R, Rubin MA, Hurst RD, Michelassi F. Long-term outcome of surgically treated Crohn's colitis: a prospective study. Dis. Colon Rectum 48: 963-969 (2005). *
Fichera A, Peng SL, Elisseou NM, Rubin MA, Hurst RD. Laparoscopy or conventional open surgery for patients with ileocolonic Crohn's disease? A prospective study. Surgery 142: 566-571 (2007).
Fickert P, Hinterleitner TA, Wenzl HH, Aichbichler BW, Petritsch W. Mycophenolate mofetil in patients with Crohn's disease. Am. J. Gastroenterol. 93: 2529-2532 (1998). *
Ficsor L, Varga VS, Tagscherer A, Tulassay Z, Molnar B. Automated classification of inflammation in colon histological sections based on digital microscopy and advanced image analysis. Cytometry A. 73: 230-237 (2008).
Fidder H, Chowers Y, Ackerman Z, Pollak RD, Crusius JB, Livneh A, Bar-Meir S, Avidan B, Shinhar Y. The familial Mediterranean fever (MEVF) gene as a modifier of Crohn's disease. Am. J. Gastroenterol. 100: 338-343 (2005). *
Fidder HH, Heijmans R, Chowers Y, Bar-Meir S, Avidan B, Pena AS, Crusius JB. TNF-857 polymorphism in Israeli Jewish patients with inflammatory bowel disease. Int. J. Immunogenet. 33: 81-85 (2006). *
Fidder HH, Hommes DW. Anti-TNF and Crohn's disease: when should we start? Curr. Drug Targets Nov 17 [Epub ahead of print] (2009).
Fidder HH, Nadler M, Lahat A, Lahav M, Bardan E, Avidan B, Bar-Meir S. The utility of capsule endoscopy in the diagnosis of Crohn's disease based on patient's symptoms. J. Clin. Gastroenterol. 41: 384-387 (2007).
Fidder HH, Olschwang S, Avidan B, Zouali H, Lang A, Bardan E, Picard O, Bar-Meir S, Colombel JF, Chowers Y. Association between mutations in the CARD15 (NOD2) gene and Crohn's disease in Israeli Jewish patients. Am. J. Med. Genet. 121A: 240-244 (2003). *
Fidler HM, Thurrell W, Johnson NM, Rook GA, McFadden JJ. Specific detection of Mycobacterium paratuberculosis DNA associated with granulomatous tissue in Crohn's disease. Gut 35: 506-510 (1994). *
Fidler JL, Guimaraes L, Einstein DM. MR imaging of the small bowel. Radiographics 29: 1811-1825 (2009).
Fiedler T, Buning C, Reuter W, Pitre G, Gentz E, Schmidt H, Buttner J, Ockenga J, Gerloff T, Meisel C, Lochs H, Roots I, Kopke K, Johne A. Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn's disease. Eur. J. Clin. Pharmacol. 63: 917-925 (2007). *
Field FJ, Watt K, Mathur SN. TNF-alpha decreases ABCA1 expression and attenuates HDL cholesterol efflux in the human intestinal cell line, Caco-2. J. Lipid Res. Jan 26 [Epub ahead of print] (2010). *
Fielding JF. The relative risk of inflammatory bowel disease among parents and siblings of Crohn's disease patients. J. Clin. Gastroenterol. 8: 655-657 (1986).
Fields S, Rosainz L, Korelitz BI, Panagopoulos G, Schneider J. Rectal strictures in Crohn's disease and coexisting perirectal complications. Inflamm. Bowel Dis. 14: 29-31 (2008). *
Fieschi C, Allez M, Casanova JL. High risk of infectious disease caused by salmonellae and mycobacteria infections in patients with Crohn disease treated with anti-interleukin-12 antibody. Clin. Infect. Dis. 40: 1381 (2005). *
Figler M, Gasztonyi B, Cseh J, Horvath G, Kisbenedek AG, Bokor S, Decsi T. Association of n-3 and n-6 long-chain polyunsaturated fatty acids in plasma lipid classes with inflammatory bowel diseases. Br. J. Nutr. 97: 1154-1161 (2007). *
Figueroa C, Peralta A, Herrera L, Castro P, Gutierrez A, Valenzuela J, Aguillon JC, Quera R, Hermoso MA. NOD2/CARD15 and Toll-like 4 receptor gene polymorphism in Chilean patients with inflammatory bowel disease. Eur. Cytokine Netw. 17: 125-130 (2006).
Figueroa CC, Quera PR, Valenzuela EJ, Jensen BC. Inflammatory bowel disease: experience of two Chilean centers. Rev. Med. Chil. 133: 1295-1304 (2005).
Filik L. Recombinant factor VIIa for severe gastrointestinal hemorrhage associated with Crohn disease. South. Med. J. 100: 559 (2007).
Filik L, Dagli U, Ulker A. C-reactive protein and monitoring the activity of Crohn's disease. Adv. Ther. 23: 655-662 (2006).
Filik L, Ulker A, Tunc B, Disibeyaz S, Dagli U. Liver abscess: a rare but an important complication that must be considered in Crohn's disease. Acta Gastroenterol. Belg. 67: 303-305 (2004).
Filippi J, Al-Jaouni R, Wiroth JB, Hebuterne X, Schneider SM. Nutritional deficiencies in patients with Crohn's disease in remission. Inflamm. Bowel Dis. 12: 185-191 (2006). *
Filippi J, Eyraud E, Al-Jaouni R, Schneider SM, Hebuterne X. Food intake and micronutrient status in patients with Crohn's disease. Clin. Nutr. 22: S34 (2003). *
Filippi J, Mambrini P, Arab K, Schneider SM, Hebuterne X. Treatment of oesophageal Crohn's disease by infliximab. Gastroenterol. Clin. Biol. 29: 84-85 (2005).
Filippi L, Biancone L, Petruzziello C, Schillaci O. Tc-99m HMPAO-labeled leukocyte scintigraphy with hybrid SPECT/CT detects perianal fistulas in Crohn disease. Clin. Nucl. Med. 31: 541-542 (2006).
Filippone A, Cianci R, Milano A, Valeriano S, Di Mizio V, Storto ML. Obscure gastrointestinal bleeding and small bowel pathology: comparison between wireless capsule endoscopy and multidetector-row CT enteroclysis. Abdom. Imaging 33: 398-406 (2008). *
Fina D, Caruso R, Pallone F, Monteleone G. Interleukin-21 (IL-21) controls inflammatory pathways in the gut. Endocr. Metab. Immune Disord. Drug Targets 7: 288-291 (2007).
Finlay DG, Basu D, Sellin JH. Effect of race and ethnicity on perceptions of inflammatory bowel disease. Inflamm. Bowel Dis. 12: 503-507 (2006). *
Finnie IA, Shields R, Sutton R, Donnelly R, Morris AI. Crohn's disease and myasthenia gravis: a possible role for thymectomy. Gut 35: 278-279 (1994). *
Fiocchi C. Inflammatory bowel disease. Current concepts of pathogenesis and implications for therapy. Minerva Gastroenterol. Dietol. 48: 215-226 (2002).
Fiocchi C. The multifactorial pathogenesis of IBD. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, pp. 21-22 (2006). *
Fiocchi C. Susceptibility genes and overall pathogenesis of inflammatory bowel disease: where do we stand? Dig. Dis. 27: 226-235 (2009).
Fiocchi C. Closing fistulas in Crohn's disease - should the accent be on maintenance or safety? N. Engl. J. Med. 350: 934-936 (2004). *
Fiocchi C, Battisto JR, Farmer RG. Studies on isolated gut mucosal lymphocytes in inflammatory bowel disease. Detection of activated T cells and enhanced proliferation to Staphylococcus aureus and lipopolysaccharides. Dig. Dis. Sci. 26: 728-736 (1981).
Fiorino G, Rovida S, Correale C, Danese S. Emerging biologics in the treatment of inflammatory bowel disease: what is around the corner? Curr. Drug Targets Nov 17 [Epub ahead of print] (2009).
Fireman E, Masarwy F, Groisman G, Shtark M, Kopelman Y, Kivity S, Fireman Z. Induced sputum eosinophilia in ulcerative colitis patients: the lung as a mirror image of intestine? Respir. Med. 103: 1025-1032 (2009).
Fireman Z, Eliakim R, Adler S, Scapa E. Capsule endoscopy in real life: a four-centre experience of 160 consecutive patients in Israel. Eur. J. Gastroenterol. Hepatol. 16: 927-931 (2004).
Fireman Z, Kopelman Y. Small bowel capsule endoscopy: have we conquered the last frontier? Isr. Med. Assoc. J. 10: 298-301 (2008). *
Fireman Z, Kopelman Y, Fish L, Sternberg A, Scapa E, Mahaina E. Effect of oral purgatives on gastric and small bowel transit time in capsule endoscopy. Isr. Med. Assoc. J. 6: 521-523 (2004). *
Fireman Z, Kopelman Y, Friedman S, Ephrath H, Choman E, Debby H, Eliakim R. Age and indication for referral to capsule endoscopy significantly affect small bowel transit times: the Given database. Dig. Dis. Sci. 52: 2884-2887 (2007). *
Fireman Z, Zachlka R, Abu Mouch S, Kopelman Y. The role of endoscopy in the evaluation of iron deficiency anemia in premenopausal women. Isr. Med. Assoc. J. 8: 88-90 (2006). *
Firouzi F, Bahari A, Aghazadeh R, Zali MR. Appendectomy, tonsillectomy, and risk of inflammatory bowel disease: a case control study in Iran. Int. J. Colorectal Dis. 21: 155-159 (2006). *
Firouzi F, Rashidi M, Hashemi S, Kangavari M, Bahari A, Daryani NE, Emam MM, Naderi N, Shalmani HM, Farnood A, Zali M. A decision tree-based approach for determining low bone mineral density in inflammatory bowel disease using WEKA software. Eur. J. Gastroenterol. Hepatol. 19: 1075-1081 (2007).
Fischer C, Maier K, Stumpf E, von Gaisberg U, Klotz U. Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. Eur. J. Clin. Pharmacol. 25: 511-515 (1983).
Fischer F, Bruch HP, Roblick U, Schwandner O, Schiedeck T. Early results of laparoscopic surgical procedures in Crohn's disease. Zentralbl. Chir. 129: 200-204 (2004).
Fischer S, Lakatos PL, Group TH, Lakatos L, Kovacs A, Molnar T, Altorjay I, Papp M, Szilvasi A, Tulassay Z, Osztovits J, Papp J, Demeter P, Schwab R, Tordai A, Andrikovics H. ATP-binding cassette transporter ABCG2 (BCRP) and ABCB1 (MDR1) variants are not associated with disease susceptibility, disease phenotype response to medical therapy or need for surgery in Hungarian patients with inflammatory bowel diseases. Scand. J. Gastroenterol. 42: 726-733 (2007). *
Fischler B, Johansson M, Gjertsen H, Ericzon BG, Bergquist A, Broome U, Nemeth A. Living-related liver transplantation in children - a single center evaluation of the outcome of donor candidates and recipients. Pediatr. Transplant. 12: 531-535 (2008). *
Fishbein T, Novitskiy G, Mishra L, Matsumoto C, Kaufman S, Goyal S, Shetty K, Johnson L, Lu A, Wang A, Hu F, Kallakury B, Lough D, Zasloff M. NOD2-expressing bone marrow-derived cells appear to regulate epithelial innate immunity of the transplanted human small intestine. Gut 57: 323-330 (2008). *
Fisher NC, Yee L, Nightingale P, McEwan R, Gibson JA. Measles virus serology in Crohn's disease. Gut 41: 66-69 (1997). *
Fisher SA, Hampe J, Macpherson AJ, Forbes A, Lennard-Jones JE, Schreiber S, Curran ME, Mathew CG, Lewis CM. Sex stratification of an inflammatory bowel disease genome search shows male-specific linkage to the HLA region of chromosome 6. Eur. J. Hum. Genet. 10: 259-265 (2002). *
Fisher SA, Hampe J, Onnie CM, Daly MJ, Curley C, Purcell S, Sanderson J, Mansfield J, Annese V, Forbes A, Lewis CM, Schreiber S, Rioux JD, Mathew CG. Direct or indirect association in a complex disease: the role of SLC22A4 and SLC22A5 functional variants in Crohn disease. Hum. Mutat. 27: 778-785 (2006).
Fisher SA, Moody A, Mirza MM, Cuthbert AP, Hampe J, Macpherson A, Sanderson J, Forbes A, Mansfield J, Schreiber S, Lewis CM, Mathew CG. Genetic variation at the chromosome 16 chemokine gene cluster: development of a strategy for association studies in complex disease. Ann. Hum. Genet. 67: 377-390 (2003). *
Fisher SA, Tremelling M, Anderson CA, Gwilliam R, Bumpstead S, Prescott NJ, Nimmo ER, Massey D, Berzuini C, Johnson C, Barrett JC, Cummings FR, Drummond H, Lees CW, Onnie CM, Hanson CE, Blaszczyk K, Inouye M, et al. Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. Nat. Genet. 40: 710-712 (2008). *
Fishman SJ, Feins NR, D' Amato RJ, Folkman J. Long-term remission of Crohn's disease treated with thalidomide: a seminal case report. Angiogenesis 3: 201-204 (1999). *
Fitzpatrick E, Bourke B, Drumm B, Rowland M. The incidence of cyclic vomiting syndrome in children: population-based study. Am. J. Gastroenterol. 103: 991-995 (2008). *
Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis. Colon Rectum 50: 337-348 (2007). *
Fiume I, Napolitano V, del Genio G, Rossetti G, Del Genio A. A mesenteric window to approach a posterior side leak after laparoscopic assisted stapled strictureplasty for Crohn's disease. Ann. Ital. Chir. 77: 259-262 (2006).
Fix OK, Soto JA, Andrews CW, Farraye FA. Gastroduodenal Crohn's disease. Gastrointest. Endosc. 60: 985 (2004). *
Flamant M, Bourreille A. Biologic therapies in inflammatory bowel disease. Rev. Med. Interne. 28: 852-861 (2007).
Flamant M, Trang C, Bourreille A. Wireless capsule in inflammatory bowel disease. Gastroenterol. Clin. Biol. 33S3: S183-S189 (2009).
Flasar MH, Johnson T, Roghmann MC, Cross RK. Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: a retrospective cohort study. Inflamm. Bowel Dis. 14: 13-19 (2008). *
Flatt PR, Bailey CJ, Green BD. Dipeptidyl peptidase IV (DPP IV) and related molecules in type 2 diabetes. Front. Biosci. 13: 3648-3660 (2008).
Flavell RA. Molecular immunologic approaches to the study of inflammatory bowel diseases. Falk Symposium 142: GASTROENTEROLOGY WEEK FREIBURG 2004 (Part I) AUTOIMMUNE LIVER DISEASE, Freiburg (Germany), October 12 - 13, 2004, p. 19 (2004). *
Fleshman JW. Pyogenic complications of Crohn's disease, evaluation, and management. J. Gastrointest. Surg. 12: 2160-2163 (2008). *
Fletcher JG. CT enterography technique: theme and variations. Abdom. Imaging 34: 283-288 (2009). *
Fletcher PC, Schneider MA. Is there any food I can eat?: living with inflammatory bowel disease and/or irritable bowel syndrome. Clin. Nurse Spec. 20: 241-247 (2006).
Fletcher PC, Schneider MA, VAN Ravenswaay V, Leon Z. I am doing the best that I can!: living with inflammatory bowel disease and/or irritable bowel syndrome (part II). Clin. Nurse. Spec. 22: 278-285 (2008).
Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: structured review of the literature. J. Rheumatol. 33: 2124-2131 (2006).
Floch MH. Probiotics, irritable bowel syndrome, and inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 283-288 (2003).
Floch MH, Madsen KK, Jenkins DJ, Guandalini S, Katz JA, Onderdonk A, Walker WA, Fedorak RN, Camilleri M. Recommendations for probiotic use. J. Clin. Gastroenterol. 40: 275-278 (2006).
Floer M, Binion DG, Nelson VM, Manley S, Wellner M, Sadeghi S, Behmaram B, Sewell C, Otterson MF, Kucharzik T, Rafiee P. Role of MutS homologue 2 (MSH2) in intestinal myofibroblast proliferation during Crohn's disease stricture formation. Am. J. Physiol. Gastrointest. Liver Physiol. 295: G581-G590 (2008). *
Flood L, Innal E, Lofberg R, Wikstrom AC. Patients with ulcerative colitis responding to steroid treatment up-regulate glucocorticoid receptor levels in colorectal mucosa. Journal of Crohn's and Colitis 2: 123-130 (2008).
Flores-Barragan JM, Hernandez-Gonzalez A, Gallardo-Alcaniz MJ, Del Real-Francia MA, Vaamonde-Gamo J. Clinical and therapeutic heterogeneity of cerebral venous thrombosis: a description of a series of 20 cases. Rev. Neurol. 49: 573-576 (2009).
Florie J, Horsthuis K, Hommes DW, Nio CY, Reitsma JB, van Deventer SJ, Stoker J. Magnetic resonance imaging compared with ileocolonoscopy in evaluating disease severity in Crohn's disease. Clin. Gastroenterol. Hepatol. 3: 1221-1228 (2005).
Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand. J. Gastroenterol. 41: 306-311 (2006). *
Florin TH, Woods HJ. Inhibition of methanogenesis by human bile. Gut 37: 418-421 (1995). *
Flourie B, Moussata D, Nancey S, Bonvoisin S, Benahmed M, Descos L. Cancer and inflammatory bowel diseases. Gastroenterol. Clin. Biol. 27: S104-S111 (2003).
Flynn RS, Murthy KS, Grider JR, Kellum JM, Kuemmerle JF. Endogenous IGF-I and alphaVbeta3 integrin ligands regulate the increased smooth muscle hyperplasia of stricturing Crohn's disease. Gastroenterology 138: 285-293 (2010). *
Focosi D, Maggi F, Ceccherini-Nelli L, Marchi S, Petrine M. Progressive multifocal leukoencephalopathy in autoimmune disorders. Gut 58: 605 (2009).
Foell D, Kucharzik T, Kraft M, Vogl T, Sorg C, Domschke W, Roth J. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut 52: 847-853 (2003). *
Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, Ehrchen J, Heidemann J, Borody T, Roth J, Clancy R. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J. Pathol. 216: 183-192 (2008). *
Folch-Puy E, Granell S, Dagorn JC, Iovanna JL, Closa D. Pancreatitis-associated protein I suppresses NF-kappaB activation through a JAK/STAT-mediated mechanism in epithelial cells. J. Immunol. 176: 3774-3779 (2006). *
Folsch UR, Grebe J, Schreiber S. Competence network "inflammatory bowel diseases". Internist (Berl.) 45: 402-408 (2004).
Folwaczny C. Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications. Z. Gastroenterol. 40: 991-998 (2002).
Folwaczny C, Glas J, Folwaczny M, Torok HP. Autologous hematopoietic stem cell transplantation in refractory Crohn's disease: a feasible therapeutic approach? Gastroenterology 128: 2180 (2005). *
Folwaczny C, Glas J, Mussack T, Torok HP. Adoptive transfer of genetic susceptibility to Crohn's disease. Gut 53: 473 (2004). *
Folwaczny C, Glas J, Torok HP. Crohn's disease: an immunodeficiency? Eur. J. Gastroenterol. Hepatol. 15: 621-626 (2003). *
Folwaczny C, Loeschke K, Schnettler D, Jager G, Wiebecke B, Hoelscher M, Sauer T, Konig A, Endres SP, Fricke H. Endothelial cell autoantibodies are a marker of disease susceptibility in inflammatory bowel disease but apparently not linked to persistent measles virus infection. Clin. Immunol. 95: 197-202 (2000). *
Folwaczny C, Noehl N, Endres SP, Heldwein W, Loeschke K, Fricke H. Antinuclear autoantibodies in patients with inflammatory bowel disease. High prevalence in first-degree relatives. Dig. Dis. Sci. 42: 1593-1597 (1997). *
Folwaczny C, Noehl N, Endres SP, Loeschke K, Fricke H. Antineutrophil and pancreatic autoantibodies in first-degree relatives of patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33: 523-528 (1998). *
Folwaczny C, Urban S, Schroder M, Hofmann B, Noehl N, Konig A, Loeschke K, Fricke H. Alpha1-antitrypsin alleles and phenotypes in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33: 78-81 (1998). *
Folwaczny M, Glas J, Torok HP, Mauermann D, Folwaczny C. The 3020insC mutation of the NOD2/CARD15 gene in patients with periodontal disease. Eur. J. Oral Sci. 112: 316-319 (2004).
Fomin VV, Popova EN, Burnevich EZ, Kuznetsova AV. Hippocratic fingers: clinical importance and differential diagnosis. Klin. Med. (Mosk.) 85: 64-68 (2007).
Fonager K, Sorensen HT, Mellemkjaer L, Olsen JH, Olsen J. Risk of colorectal cancer in relatives of patients with inflammatory bowel disease (Denmark). Cancer Causes Control 9: 389-392 (1998). *
Fonseca Chebli JM, Gaburri PD, Ferreira Pinto JR. Enterovesical fistula in Crohn's disease. Lancet 364: 68 (2004). *
Fontanet G, Casellas F, Malagelada JR. The Crohn-Colitis Care Unit: analysis of the first 3 years of activity. Gac. Sanit. 18: 483-485 (2004).
Foong KS, Patel R, Forbes A, Day RM. Anti-TNF-alpha-loaded microspheres as a prospective novel treatment for Crohn's disease fistulae. Tissue Eng. Part C Methods Nov 3 [Epub ahead of print] (2009).
Forabosco P, Collins A, Latiano A, Annese V, Clementi M, Andriulli A, Fortina P, Devoto M, Morton NE. Combined segregation and linkage analysis of inflammatory bowel disease in the IBD1 region using severity to characterise Crohn's disease and ulcerative colitis. On behalf of the GISC. Eur. J. Hum. Genet. 8: 846-852 (2000). *
Forbes A. Crohn's or abdominal tuberculosis? Gut 54: 1156 (2005). *
Forbes A. Parenteral nutrition: new advances and observations. Curr. Opin. Gastroenterol. 20: 114-118 (2004).
Forbes A. Is there a role for multidrug therapy in active Crohn's disease? Inflamm. Bowel Dis. 14 Suppl. 2: S257-S258 (2008). *
Forbes A. Review article: Crohn's disease - the role of nutritional therapy. Aliment. Pharmacol. Ther. 16 Suppl. 4: 48-52 (2002). *
Forbes A, Kalantzis T. Crohn's disease: the cold chain hypothesis. Int. J. Colorectal Dis. 21: 399-401 (2006). *
Forbes SS, O'Connor BI, Victor JC, Cohen Z, McLeod RS. Sepsis is a major predictor of failure after ileal pouch-anal anastomosis. Dis. Colon Rectum 52: 1975-1981 (2009).
Forchielli ML, Walker WA. The role of gut-associated lymphoid tissues and mucosal defence. Br. J. Nutr. 93 Suppl. 1: S41-S48 (2005). *
Forcione DG, Rosen MJ, Kisiel JB, Sands BE. Anti-Saccharomyces cerevisiae antibody (ASCA) positivity is associated with increased risk for early surgery in Crohn's disease. Gut 53: 1117-1122 (2004). *
Forcione DG, Sands B, Isselbacher KJ, Rustgi A, Podolsky DK, Pillai S. An increased risk of Crohn's disease in individuals who inherit the HLA class II DRB3*0301 allele. Proc. Natl. Acad. Sci. U.S.A. 93: 5094-5098 (1996). *
Forde AM, Feighery C, Jackson J. Characterisation of anti-neutrophil cytoplasmic antibody target antigens using electrophoresis and western blotting techniques. Br. J. Biomed. Sci. 55: 247-252 (1998).
Forde AM, Feighery C, Jackson J. Anti-monocyte cytoplasmic antibodies in granulomatous disease. Clin. Immunol. Immunopathol. 81: 88-95 (1996). *
Fornaciari G, Salvarani C, Beltrami M, Macchioni P, Stockbrugger RW, Russel MG. Muscoloskeletal manifestations in inflammatory bowel disease. Can. J. Gastroenterol. 15: 399-403 (2001). *
Fornaro R, Frascio M, Denegri A, Stabilini C, Impenatore M, Mandolfino F, Lazzara F, Gianetta E. Crohn's disease and cancer. Ann. Ital. Chir. 80: 119-125 (2009).
Forrest EH, Oien KA, Dickson S, Galloway D, Mills PR. Improvement in cholestasis associated with total parenteral nutrition after treatment with an antibody against tumour necrosis factor alpha. Liver 22: 317-320 (2002).
Forrester B, Pawade J, Horner P. The potential role of serology in diagnosing chronic lymphogranuloma venereum (LGV): a case of LGV mimicking Crohn's disease. Sex. Transm. Infect. 82: 139-140 (2006).
Forshaw MJ, Guirguis O, Hennigan TW. IgA nephropathy in association with Crohn's disease. Int. J. Colorectal Dis. 20: 463-465 (2005). *
Fortea Ormaechea JI, Gisbert JP, Marin-Jimenez I. Role of Mycobacterium avium paratuberculosis in the etiopathogenesis of Crohn's disease. Gastroenterol. Hepatol. 32: 353-363 (2009).
Fortin G, Yurchenko K, Collette C, Rubio M, Villani AC, Bitton A, Sarfati M, Franchimont D. L-Carnitine, a diet component and organic cation transporter OCTN ligand, displays immunosuppressive properties and abrogates intestinal inflammation. Clin. Exp. Immunol. 156: 161-171 (2009). *
Foster EN, Nguyen KK, Sheikh RA, Prindiville TP. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. Clin. Dev. Immunol. 12: 145-149 (2005). *
Foster EN, Quiros JA, Prindiville TP. Long-term follow-up of the endoscopic treatment of strictures in pediatric and adult patients with inflammatory bowel disease. J. Clin. Gastroenterol. 42: 880-885 (2008).
Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Bacquet-Deschryver H, Kozyreff-Meurice M, Menard JF, Muraine M, Savoye G, Loet XL, Tharasse C, Vittecoq O. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. Rheumatology (Oxford) 48: 761-764 (2009).
Fournier MR, Klein J, Minuk GY, Bernstein CN. Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am. J. Gastroenterol. Feb 16 [Epub ahead of print] (2010). *
Fow J, Grossman S. A comprehensive guide to patient-focused management strategies for Crohn disease. Gastroenterol. Nurs. 30: 93-98 (2007).
Fowler EV, Doecke J, Simms LA, Zhao ZZ, Webb PM, Hayward NK, Whiteman DC, Florin TH, Montgomery GW, Cavanaugh JA, Radford-Smith GL. ATG16L1 T300A shows strong associations with disease subgroups in a large Australian IBD population: further support for significant disease heterogeneity. Am. J. Gastroenterol. 103: 2519-2526 (2008). *
Fowler EV, Eri R, Hume G, Johnstone S, Pandeya N, Lincoln D, Templeton D, Radford-Smith GL. TNFalpha and IL10 SNPs act together to predict disease behaviour in Crohn's disease. J. Med. Genet. 42: 523-528 (2005). *
Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig. Dis. Sci. 36: 179-184 (1991).
Fox LP, Pasternack FR, Geyer AS, Grossman ME. Perineal squamous cell cancer in a patient with fistulizing and ulcerating Crohn's disease. Clin. Exp. Dermatol. 30: 718-719 (2005). *
Fraga XF, Vergara M, Medina C, Casellas F, Bermejo B, Malagelada JR. Effects of smoking on the presentation and clinical course of inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 9: 683-687 (1997).
Franchimont D. C-reactive protein: informative or misleading marker of Crohn's disease? Inflamm. Bowel Dis. 13: 501-502 (2007). *
Franchimont D, Roland S, Gustot T, Quertinmont E, Toubouti Y, Gervy MC, Deviere J, Van Gossum A. Impact of infliximab on serum leptin levels in patients with Crohn's disease. J. Clin. Endocrinol. Metab. 90: 3510-3516 (2005). *
Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, Abramowicz M, Van Gossum A, Deviere J, Rutgeerts P. Deficient host-bacteria interactions in inflammatory bowel disease? The Toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis. Gut 53: 987-992 (2004). *
Franchimont N, Putzeys V, Collette J, Vermeire S, Rutgeerts P, De Vos M, Van Gossum A, Franchimont D, Fiasse R, Pelckmans P, Malaise M, Belaiche J, Louis E. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment. Pharmacol. Ther. 20: 607-614 (2004). *
Franchimont N, Reenaers C, Lambert C, Belaiche J, Bours V, Malaise M, Delvenne P, Louis E. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients. Clin. Exp. Immunol. 138: 491-498 (2004). *
Franchimont N, Reenaers C, Louis E. Infliximab and the bone in Crohn's disease. Aliment. Pharmacol. Ther. 21: 918-919 (2005). *
Francis G, Duggan A. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance. Gastroenterology 135: 2156-2157 (2008). *
Francoeur C, Bouatrouss Y, Seltana A, Pinchuk IV, Vachon PH, Powell DW, Sawan B, Seidman EG, Beaulieu JF. Degeneration of the pericryptal myofibroblast sheath by proinflammatory cytokines in inflammatory bowel diseases. Gastroenterology 136: 268-277.e3 (2009). *
Francoeur C, Escaffit F, Vachon PH, Beaulieu JF. Pro-inflammatory cytokines TNFalpha and IFNgamma alter laminin expression under an apoptosis-independent mechanism in human intestinal epithelial cells. Am. J. Physiol. Gastrointest. Liver Physiol. 287: G592-G598 (2004). *
Francolla KA, Altman A, Sylvester FA. Hemophagocytic syndrome in an adolescent with Crohn disease receiving azathioprine and infliximab. J. Pediatr. Gastroenterol. Nutr. 47: 193-195 (2008). *
Frank DN. Mycobacterium avium subspecies paratuberculosis and Crohn's disease. Lancet Infect. Dis. 8: 345 (2008).
Frank DN, Pace NR. Gastrointestinal microbiology enters the metagenomics era. Curr. Opin. Gastroenterol. 24: 4-10 (2008). *
Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U.S.A. 104: 13780-13785 (2007). *
Frank TS, Cook SM. Analysis of paraffin sections of Crohn's disease for Mycobacterium paratuberculosis using polymerase chain reaction. Mod. Pathol. 9: 32-35 (1996).
Franke A, Balschun T, Karlsen TH, Hedderich J, May S, Lu T, Schuldt D, Nikolaus S, Rosenstiel P, Krawczak M, Schreiber S. Replication of signals from recent studies of Crohn's disease identifies previously unknown disease loci for ulcerative colitis. Nat. Genet. 40: 713-715 (2008). *
Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, et al. Sequence variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. Nat. Genet. 40: 1319-1323 (2008). *
Franke A, Fischer A, Nothnagel M, Becker C, Grabe N, Till A, Lu T, Muller Quernheim J, Wittig M, Hermann A, Balschun T, Hofmann S, Niemiec R, Schulz S, Hampe J, Nikolaus S, Nurnberg P, Krawczak M, Schurmann M, Rosenstiel P, Nebel A, Schreiber S. Genome-wide association analysis in sarcoidosis and Crohn disease unravels a common susceptibility locus on 10p12.2. Gastroenterology 135: 1207-1215 (2008). *
Franke A, Hampe J, Rosenstiel P, Becker C, Wagner F, Hasler R, Little RD, Huse K, Ruether A, Balschun T, Wittig M, Elsharawy A, Mayr G, Albrecht M, Prescott NJ, Onnie CM, Fournier H, Keith T, Radelof U, Platzer M, Mathew CG, Stoll M, Krawczak M, et al. Systematic association mapping identifies NELL1 as a novel IBD disease gene. PLoS ONE. 2: e691 (2007). *
Fraquelli M, Colli A, Casazza G, Paggi S, Colucci A, Massironi S, Duca P, Conte D. Role of US in detection of Crohn disease: meta-analysis. Radiology 236: 95-101 (2005). *
Fraquelli M, Sarno A, Girelli C, Laudi C, Buscarini E, Villa C, Robotti D, Porta P, Cammarota T, Ercole E, Rigazio C, Senore C, Pera A, Malacrida V, Gallo C, Maconi G. Reproducibility of bowel ultrasonography in the evaluation of Crohn's disease. Dig. Liver Dis. 40: 860-866 (2008).
Fraser Cummings JR, Ahmad T, Geremia A, Beckly J, Cooney R, Hancock L, Pathan S, Guo C, Cardon LR, Jewell DP. Contribution of the novel inflammatory bowel disease gene IL23R to disease susceptibility and phenotype. Inflamm. Bowel Dis. 13: 1063-1068 (2007). *
Fraser JK, Wulur I, Alfonso Z, Hedrick MH. Fat tissue: an underappreciated source of stem cells for biotechnology. Trends Biotechnol. 24: 150-154 (2006). *
Freeman H, Noble M. Lack of evidence for Mycobacterium avium subspecies paratuberculosis in Crohn's disease. Inflamm. Bowel Dis. 11: 782-783 (2005). *
Freeman H, Roeck B, Devine D, Carter C. Prospective evaluation of neutrophil autoantibodies in 500 consecutive patients with inflammatory bowel disease. Can. J. Gastroenterol. 11: 203-207 (1997). *
Freeman HJ. Long-term prognosis of early-onset Crohn's disease diagnosed in childhood or adolescence. Can. J. Gastroenterol. 18: 661-665 (2004). *
Freeman HJ. Crohn's disease defined in three elderly sisters. Can. J. Gastroenterol. 19: 251-252 (2005). *
Freeman HJ. Comparison of longstanding pediatric-onset and adult-onset Crohn's disease. J. Pediatr. Gastroenterol. Nutr. 39: 183-186 (2004). *
Freeman HJ. Atypical perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease. Can. J. Gastroenterol. 11: 689-693 (1997). *
Freeman HJ. Age-dependent phenotypic clinical expression of Crohn's disease. J. Clin. Gastroenterol. 39: 774-777 (2005).
Freeman HJ. Erythema nodosum and pyoderma gangrenosum in 50 patients with Crohn's disease. Can. J. Gastroenterol. 19: 603-606 (2005). *
Freeman HJ. Long-term clinical behavior of jejunoileal involvement in Crohn's disease. Can. J. Gastroenterol. 19: 575-578 (2005). *
Freeman HJ. Osteomyelitis and osteonecrosis in inflammatory bowel disease. Can. J. Gastroenterol. 11: 601-606 (1997). *
Freeman HJ. Crohn's disease initially diagnosed after age 60 years. Age Ageing 36: 587-589 (2007).
Freeman HJ. Granuloma-positive Crohn's disease. Can. J. Gastroenterol. 21: 583-587 (2007). *
Freeman HJ. Complications of collagenous colitis. World J. Gastroenterol. 14: 1643-1645 (2008). *
Freeman HJ. Colorectal cancer risk in Crohn's disease. World J. Gastroenterol. 14: 1810-1811 (2008). *
Freeman HJ. Use of the Crohn's disease activity index in clinical trials of biological agents. World J. Gastroenterol. 14: 4127-4130 (2008). *
Freeman HJ. Recent developments on the role of Clostridium difficile in inflammatory bowel disease. World J. Gastroenterol. 14: 2794-2796 (2008). *
Freeman HJ. What is the cancer risk in Crohn's disease? Inflamm. Bowel Dis. 14 Suppl. 2: S63-S64 (2008). *
Freeman HJ. Refractory celiac disease and sprue-like intestinal disease. World J. Gastroenterol. 14: 828-830 (2008). *
Freeman HJ. Inflammatory bowel diseases in Indo-Canadians with and without antineutrophil cytoplasmic autoantibodies. Can. J. Gastroenterol. 14: 21-26 (2000). *
Freeman HJ. Multifocal stenosing ulceration of the small intestine. World J. Gastroenterol. 15: 4883-4885 (2009). *
Freeman HJ. Long-term natural history of Crohn's disease. World J. Gastroenterol. 15: 1315-1318 (2009). *
Freeman HJ. Familial Crohn's disease in single or multiple first-degree relatives. J. Clin. Gastroenterol. 35: 9-13 (2002).
Freeman HJ. Temporal and geographic evolution of longstanding Crohn's disease over more than 50 years. Can. J. Gastroenterol. 17: 696-700 (2003). *
Freeman HJ. Inflammatory bowel disease with cytoplasmic-staining antineutrophil cytoplasmic antibody and extensive colitis. Can. J. Gastroenterol. 12: 279-282 (1998). *
Freeman HJ. Colorectal cancer complicating Crohn's disease. Can. J. Gastroenterol. 15: 231-236 (2001). *
Freeman HJ. Natural history and clinical behavior of Crohn's disease extending beyond two decades. J. Clin. Gastroenterol. 37: 216-219 (2003).
Freeman HJ, Davis JE, Prest ME, Lawson EJ. Granulomatous bronchiolitis with necrobiotic pulmonary nodules in Crohn's disease. Can. J. Gastroenterol. 18: 687-690 (2004). *
Freeman HJ, Flak B. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can. J. Gastroenterol. 19: 313-316 (2005). *
Freeman HJ, Freeman KJ. Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascular necrosis) in Crohn's disease. Can. J. Gastroenterol. 14: 138-143 (2000). *
Freeman HJ, Roeck B, Devine DV, Carter CJ. Atypical perinuclear antineutrophil cytoplasmic antibodies after colectomy in inflammatory bowel disease. Can. J. Gastroenterol. 11: 305-310 (1997). *
Freeman ML, Hawes RH, Vakil N, Camilleri M, Hanauer SB. Best of DDW 2001. Highlights from the 2001 Digestive Disease Week. May 20-23, 2001, Atlanta, GA. Rev. Gastroenterol. Disord. 1: 100-110 (2001). *
Frei P, Fried M, Hungerbuhler V, Rammert C, Rousson V, Kullak-Ublick GA. Analysis of risk factors for low bone mineral density in inflammatory bowel disease. Digestion 73: 40-46 (2006). *
Freilinger T, Riedel E, Holtmannspotter M, Dichgans M, Peters N. Ischemic stroke and peripheral arterial thromboembolism in a patient with Crohn's disease: a case presentation. J. Neurol. Sci. 266: 177-179 (2008).
Frenz MB, Dunckley P, Camporota L, Jewell DP, Travis SP. Comparison between prospective and retrospective evaluation of Crohn's disease activity index. Am. J. Gastroenterol. 100: 1117-1120 (2005). *
Frenzer A, Fierz W, Rundler E, Hammer B, Binek J. Atypical, cytoplasmic and perinuclear anti-neutrophil cytoplasmic antibodies in patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 13: 950-954 (1998). *
Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V, Yazici H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behcet's syndrome. Clin. Exp. Rheumatol. 23: S67-S70 (2005).
Freudenberg F, Carey MC. Hepatobiliary manifestations in inflammatory bowel disease. Falk Symposium 146: GUT-LIVER INTERACTIONS: BASIC AND CLINICAL CONCEPTS, Innsbruck (Austria), March 11-12, 2005, pp. 56-57 (2005). *
Frey MR, Edelblum KL, Mullane MT, Liang D, Polk DB. The ErbB4 growth factor receptor is required for colon epithelial cell survival in the presence of TNF. Gastroenterology 136: 217-226 (2009). *
Freysdottir J, Zhang S, Tilakaratne WM, Fortune F. Oral biopsies from patients with orofacial granulomatosis with histology resembling Crohn's disease have a prominent Th1 environment. Inflamm. Bowel Dis. 13: 439-445 (2007). *
Frezza EE. Laparoscopic vertical sleeve gastrectomy for morbid obesity. The future procedure of choice? Surg. Today 37: 275-281 (2007).
Friberg C, Bjorck K, Nilsson S, Inerot A, Wahlstrom J, Samuelsson L. Analysis of chromosome 5q31-32 and psoriasis: confirmation of a susceptibility locus but no association with SNPs within SLC22A4 and SLC22A5. J. Invest. Dermatol. 126: 998-1002 (2006). *
Friedman DJ, Kunzli BM, A-Rahim YI, Sevigny J, Berberat PO, Enjyoji K, Csizmadia E, Friess H, Robson SC. CD39 deletion exacerbates experimental murine colitis and human polymorphisms increase susceptibility to inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 106: 16788-16793 (2009). *
Friedman S. Cancer in Crohn's disease. Gastroenterol. Clin. North Am. 35: 621-639 (2006).
Friedman S. Management of inflammatory bowel disease during pregnancy and nursing. Semin. Gastrointest. Dis. 12: 245-252 (2001).
Friedman S. Medical therapy and birth outcomes in women with Crohn's disease: what should we tell our patients? Am. J. Gastroenterol. 102: 1414-1416 (2007). *
Friedman S, Marion JF, Scherl E, Rubin PH, Present DH. Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm. Bowel Dis. 7: 1-7 (2001). *
Friedman S, Rubin PH, Bodian C, Harpaz N, Present DH. Screening and surveillance colonoscopy in chronic Crohn's colitis: results of a surveillance program spanning 25 years. Clin. Gastroenterol. Hepatol. 6: 993-998 (2008).
Friedrichs F, Brescianini S, Annese V, Latiano A, Berger K, Kugathasan S, Broeckel U, Nikolaus S, Daly MJ, Schreiber S, Rioux JD, Stoll M. Evidence of transmission ratio distortion of DLG5 R30Q variant in general and implication of an association with Crohn disease in men. Hum. Genet. 119: 305-311 (2006). *
Friedrichs F, Henckaerts L, Vermeire S, Kucharzik T, Seehafer T, Moller-Krull M, Bornberg-Bauer E, Stoll M, Weiner J 3rd. The Crohn's disease susceptibility gene DLG5 as a member of the CARD interaction network. J. Mol. Med. 86: 423-432 (2008). *
Friedrichs F, Stoll M. Role of discs large homolog 5. World J. Gastroenterol. 12: 3651-3656 (2006). *
Fries W, Muja C, Crisafulli C, Costantino G, Longo G, Cuzzocrea S, Mazzon E. Infliximab and etanercept are equally effective in reducing enterocyte apoptosis in experimental colitis. Int. J. Med. Sci. 5: 169-180 (2008). *
Fries W, Muja C, Crisafulli C, Cuzzocrea S, Mazzon E. Dynamics of enterocyte tight junctions - effect of experimental colitis and two different anti-TNF strategies. Am. J. Physiol. Gastrointest. Liver Physiol. 294: G938-G947 (2008). *
Fries W, Renda MC, Lo Presti MA, Raso A, Orlando A, Oliva L, Giofre MR, Maggio A, Mattaliano A, Macaluso A, Cottone M. Intestinal permeability and genetic determinants in patients, first-degree relatives, and controls in a high-incidence area of Crohn's disease in Southern Italy. Am. J. Gastroenterol. 100: 2730-2736 (2005). *
Friesen CA, Calabro C, Christenson K, Carpenter E, Welchert E, Daniel JF, Haslag S, Roberts CC. Safety of infliximab treatment in pediatric patients with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 39: 265-269 (2004). *
Fritscher-Ravens A, Scherbakov P, Bufler P, Torroni F, Ruuska T, Nuutinen H, Thomson M, Tabbers M, Milla P. The feasibility of wireless capsule endoscopy in detecting small intestinal pathology in children under the age of 8 years - a multicentre European study. Gut 58: 1467-1472 (2009).
Frizelle FA, Ing A, Gearry RB, Whitehead M, Faragher IG, Dobbs B. Immunomodulation does not alter histology in resected Crohn's disease. Tech. Coloproctol. Sep 23 [Epub ahead of print] (2009).
Froehlich F, Fried M, Gonvers JJ, Saraga E, Thorens J, Pecoud A. Association of Crohn's disease and Cogan's syndrome. Dig. Dis. Sci. 39: 1134-1137 (1994).
Froehlich F, Juillerat P, Felley C, Mottet C, Vader JP, Burnand B, Michetti P, Gonvers JJ. Treatment of postoperative Crohn's disease. Digestion 71: 49-53 (2005).
Froehlich F, Juillerat P, Mottet C, Felley C, Vader JP, Burnand B, Gonvers JJ, Michetti P. Obstructive fibrostenotic Crohn's disease. Digestion 71: 29-30 (2005).
Froehlich F, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Gonvers JJ, Michetti P. Fibrostenotic Crohn's disease. Digestion 76: 113-115 (2007). *
Froehlich F, Juillerat P, Pittet V, Felley C, Mottet C, Vader JP, Michetti P, Gonvers JJ. Maintenance of surgically induced remission of Crohn's disease. Digestion 76: 130-135 (2007). *
Froilan Torres C, Castro Carbajo P, Pajares Villarroya R, Plaza Santos R, Gomez Senent S, Martin Arranz MD, Adan Merino L, Martin Arranz E, Mancenido Marcos N, Peces R, Benito Lopez D. Acute spontaneous tumor lysis syndrome in a patient with Crohn s disease taking immunosuppressants. Rev. Esp. Enferm. Dig. 101: 288-294 (2009).
Frokjaer JB, Larsen E, Steffensen E, Nielsen AH, Drewes AM. Magnetic resonance imaging of the small bowel in Crohn's disease. Scand. J. Gastroenterol. 40: 832-842 (2005). *
Frol'ova L, Smetana K Jr, Borovska D, Kitanovicova A, Klimesova K, Janatkova I, Malíckova K, Lukas M, Drastich P, Benes Z, Tuckova L, Manning JC, Andre S, Gabius HJ, Tlaskalova-Hogenova H. Detection of galectin-3 in patients with inflammatory bowel diseases: new serum marker of active forms of IBD? Inflamm. Res. 58: 503-512 (2009). *
Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J. Histochem. Cytochem. 56: 267-274 (2008). *
Fromm M, Krug SM, Zeissig S, Richter JF, Rosenthal R, Schulzke JD, Gunzel D. High-resolution analysis of barrier function. Ann. N. Y. Acad. Sci. 1165: 74-81 (2009). *
Fromont A, De Seze J, Fleury MC, Maillefert JF, Moreau T. Inflammatory demyelinating events following treatment with anti-tumor necrosis factor. Cytokine 45: 55-57 (2009).
Frontela C, Canali R, Virgili F. Use of dietary phenols to modulate inflammatory bowel response. Gastroenterol. Hepatol. Nov 17 [Epub ahead of print] (2009).
Froslie KF, Jahnsen J, Moum BA, Vatn MH; IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 133: 412-422 (2007). *
Fry LC, Bellutti M, Neumann H, Malfertheiner P, Monkemuller K. Incidence of bleeding lesions within reach of conventional upper and lower endoscopes in patients undergoing double balloon enteroscopy for obscure gastrointestinal bleeding. Aliment. Pharmacol. Ther. 29: 342-349 (2009). *
Fry LC, Bellutti M, Neumann H, Malfertheiner P, Monkemuller K. Utility of double-balloon enteroscopy for the evaluation of malabsorption. Dig. Dis. 26: 134-139 (2008).
Fry LC, Carey EJ, Shiff AD, Heigh RI, Sharma VK, Post JK, Hentz JG, Fleischer DE, Leighton JA. The yield of capsule endoscopy in patients with abdominal pain or diarrhea. Endoscopy 38: 498-502 (2006).
Fry LC, Rickes S, Monkemuller K, Malfertheiner P. Crohn's disease associated with Takayasu's arteritis. Acta Gastroenterol. Latinoam. 35: 238-242 (2005).
Fugate SE, Ramsey AM. Resistance to oral vitamin K for reversal of overanticoagulation during Crohn's disease relapse. J. Thromb. Thrombolysis 17: 219-223 (2004). *
Fujii T, Shiba M, Takatera H. A case of ammonium urate urolithiasis with Crohn's disease. Hinyokika. Kiyo. 49: 615-617 (2003).
Fujii T, Takada-Takatori Y, Kawashima K. Basic and clinical aspects of non-neuronal acetylcholine: expression of an independent, non-neuronal cholinergic system in lymphocytes and its clinical significance in immunotherapy. J. Pharmacol. Sci. 106: 186-192 (2008). *
Fujimori S, Tatsuguchi A, Gudis K, Kishida T, Mitsui K, Ehara A, Kobayashi T, Sekita Y, Seo T, Sakamoto C. High dose probiotic and prebiotic cotherapy for remission induction of active Crohn's disease. J. Gastroenterol. Hepatol. 22: 1199-1204 (2007). *
Fujino K, Takami Y, G de la Fuente S, Ludwig KA, Mantyh CR. Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J. Gastrointest. Surg. 8: 842-848 (2004).
Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52: 65-70 (2003). *
Fujioka M, Yoshida S, Kitamura R, Matsuoka Y. Iliopsoas muscle abscess secondary to sacral pressure ulcer treated with computed tomography-guided aspiration and continuous irrigation: a case report. Ostomy Wound Manage. 54: 44-48 (2008).
Fujisawa M, Kiyosue M, Hori M, Ozaki H. Identification of Card15/Nod2 mRNA in intestinal tissue of experimentally induced colitis in rats. J. Vet. Med. Sci. 68: 701-708 (2006). *
Fujisawa T, Kimura A, Ushijima K, Nakashima E, Inoue T, Yamashita Y, Kato H. Intestinal absorption of ursodeoxycholic acid in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 26: 279-285 (1998). *
Fujise T, Iwakiri R, Tsunada S, Morita H, Kikkawa A, Ootani A, Sakata H, Fujimoto K. A case of Crohn's disease successfully treated with infliximab without steroid. Nippon Shokakibyo Gakkai Zasshi 103: 295-300 (2006).
Fujita H, Eishi Y, Ishige I, Saitoh K, Takizawa T, Arima T, Koike M. Quantitative analysis of bacterial DNA from Mycobacteria spp., Bacteroides vulgatus, and Escherichia coli in tissue samples from patients with inflammatory bowel diseases. J. Gastroenterol. 37: 509-516 (2002). *
Fujita K, Naito S, Okabe N, Yao T. Immunological studies in Crohn's disease. I. Association with HLA systems in the Japanese. J. Clin. Lab. Immunol. 14: 99-102 (1984).
Fujita N, Saitoh T, Kageyama S, Akira S, Noda T, Yoshimori T. Differential involvement of ATG16L1 in Crohn's disease and canonical autophagy: analysis of the organization of the ATG16L1 complex in fibroblasts. J. Biol. Chem. 284: 32602-32609 (2009). *
Fujita T. Is Crohn's disease associated with appendectomy or appendicitis? Am. J. Gastroenterol. 104: 1324 (2009). *
Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease. Biochem. Soc. Trans. 35: 1473-1478 (2007). *
Fukuda A, Nakase H, Seno H, Nabeshima M, Sawada M, Chiba T. Refractory enterovesical and duodenocolic fistulas in Crohn's disease successfully managed with tacrolimus. J. Gastroenterol. 40: 433-435 (2005). *
Fukuda Y, Matsui T, Suzuki Y, Kanke K, Matsumoto T, Takazoe M, Matsumoto T, Motoya S, Honma T, Sawada K, Yao T, Shimoyama T, Hibi T. Adsorptive granulocyte and monocyte apheresis for refractory Crohn's disease: an open multicenter prospective study. J. Gastroenterol. 39: 1158-1164 (2004). *
Fukuda Y, Takazoe M, Sugita A, Kosaka T, Kinjo F, Otani Y, Fujii H, Koganei K, Makiyama K, Nakamura T, Suda T, Yamamoto S, Ashida T, Majima A, Morita N, Murakami K, Oshitani N, Takahama K, Tochihara M, Tsujikawa T, Watanabe M. Oral spherical adsorptive carbon for the treatment of intractable anal fistulas in Crohn's disease: a multicenter, randomized, double-blind, placebo-controlled trial. Am. J. Gastroenterol. 103: 1721-1729 (2008). *
Fukumoto A, Tanaka S, Yamamoto H, Yao T, Matsui T, Iida M, Goto H, Sakamoto C, Chiba T, Sugano K. Diagnosis and treatment of small-bowel stricture by double balloon endoscopy. Gastrointest. Endosc. 66: S108-S112 (2007).
Fukunaga K, Miwa H, Matsumoto T. Role of leukocytapheresis in the management of inflammatory bowel disease. Trop. Gastroenterol. 28: 11-15 (2007).
Fukushima K, Fiocchi C. Paradoxical decrease of mitochondrial DNA deletions in epithelial cells of active ulcerative colitis patients. Am. J. Physiol. Gastrointest. Liver Physiol. 286: G804-G813 (2004). *
Fukushima K, Fujii H, Yamamura T, Sugita A, Kameoka S, Nagawa H, Futami K, Watanabe T, Hatakeyama K, Sawada T, Yoshioka K, Kusunoki M, Konishi F, Watanabe M, Takahashi K, Ogawa H, Funayama Y, Hibi T, Sasaki I. Pouchitis atlas for objective endoscopic diagnosis. J. Gastroenterol. 42: 799-806 (2007). *
Fukushima K, Funayama Y, Shibata C, Takahashi K, Ogawa H, Kinouchi Y, Noguchi M, Kato E, Sasaki I. Familial adenomatous polyposis complicated with Crohn's disease. Int. J. Colorectal Dis. 21: 730-731 (2006). *
Fukushima K, Yonezawa H, Fiocchi C. Inflammatory bowel disease-associated gene expression in intestinal epithelial cells by differential cDNA screening and mRNA display. Inflamm. Bowel Dis. 9: 290-301 (2003). *
Fuller-Thomson E, Sulman J. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm. Bowel Dis. 12: 697-707 (2006). *
Funakoshi K, Sugimura K, Anezaki K, Bannai H, Ishizuka K, Asakura H. Spectrum of cytokine gene expression in intestinal mucosal lesions of Crohn's disease and ulcerative colitis. Digestion 59: 73-78 (1998).
Funayama Y, Kumagai E, Takahashi KI, Fukushima K, Sasaki I. Early diagnosis and early corticosteroid administration improves healing of peristomal pyoderma gangrenosum in inflammatory bowel disease. Dis. Colon Rectum 52: 311-314 (2009).
Fung E, Smyth DJ, Howson JM, Cooper JD, Walker NM, Stevens H, Wicker LS, Todd JA. Analysis of 17 autoimmune disease-associated variants in type 1 diabetes identifies 6q23/TNFAIP3 as a susceptibility locus. Genes Immun. 10: 188-191 (2009). *
Funke B, Autschbach F, Kim S, Lasitschka F, Strauch U, Rogler G, Gdynia G, Li L, Gretz N, Macher-Goeppinger S, Sido B, Schirmacher P, Meuer SC, Roth W. Functional characterization of decoy receptor 3 in Crohn's disease. Gut 58: 483-491 (2009).
Furlano RI, Anthony A, Day R, Brown A, McGarvey L, Thomson MA, Davies SE, Berelowitz M, Forbes A, Wakefield AJ, Walker-Smith JA, Murch SH. Colonic CD8 and gamma delta T-cell infiltration with epithelial damage in children with autism. J. Pediatr. 138: 366-372 (2001). *
Furness JB, Kearney K, Robbins HL, Hunne B, Selmer IS, Neylon CB, Chen MX, Tjandra JJ. Intermediate conductance potassium (IK) channels occur in human enteric neurons. Auton. Neurosci. 112: 93-97 (2004). *
Furrie E. A molecular revolution in the study of intestinal microflora. Gut 55: 141-143 (2006). *
Furrie E, Macfarlane S, Cummings JH, Macfarlane GT. Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut 53: 91-98 (2004). *
Furst A, Schmidbauer C, Swol-Ben J, Iesalnieks I, Schwandner O, Agha A. Gracilis transposition for repair of recurrent anovaginal and rectovaginal fistulas in Crohn's disease. Int. J. Colorectal Dis. 23: 349-353 (2008). *
Furukawa A, Saotome T, Yamasaki M, Maeda K, Nitta N, Takahashi M, Tsujikawa T, Fujiyama Y, Murata K, Sakamoto T. Cross-sectional imaging in Crohn disease. Radiographics 24: 689-702 (2004). *
Furuta R, Ina K, Kataoka T. Coloduodenal fistula in Crohn's disease. Clin. Gastroenterol. Hepatol. 6: e20-e21 (2008).
Furuya D, Yagihashi A, Komatsu M, Masashi N, Tsuji N, Kobayashi D, Watanabe N. Serum interleukin-18 concentrations in patients with inflammatory bowel disease. J. Immunother. 25 Suppl. 1: S65-S67 (2002).
Furuya Y, Ozeki T, Takayanagi R, Yokoyama H, Okuyama K, Yamada Y. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease. Drug Metab. Pharmacokinet. 22: 20-25 (2007). *
Fuss IJ. Cytokine network in inflammatory bowel disease. Curr. Drug Targets Inflamm. Allergy 2: 101-112 (2003).
Fuss IJ, Becker C, Yang Z, Groden C, Hornung RL, Heller F, Neurath MF, Strober W, Mannon PJ. Both IL-12p70 and IL-23 are synthesized during active Crohn's disease and are down-regulated by treatment with anti-IL-12 p40 monoclonal antibody. Inflamm. Bowel Dis. 12: 9-15 (2006). *
Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, Yang Z, Exley M, Kitani A, Blumberg RS, Mannon P, Strober W. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J. Clin. Invest. 113: 1490-1497 (2004). *
Fuss IJ, Neurath M, Boirivant M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157: 1261-1270 (1996).
Fuss IJ, Strober W. The role of IL-13 and NK T cells in experimental and human ulcerative colitis. Mucosal Immunol. 1 Suppl. 1: S31-S33 (2008).
Futami K, Arima S. Role of strictureplasty in surgical treatment of Crohn's disease. J. Gastroenterol. 40 Suppl. 16: 35-39 (2005).
Fyderek K, Strus M, Kowalska-Duplaga K, Gosiewski T, Wedrychowicz A, Jedynak-Wasowicz U, Sladek M, Pieczarkowski S, Adamski P, Kochan P, Heczko PB. Mucosal bacterial microflora and mucus layer thickness in adolescents with inflammatory bowel disease. World J. Gastroenterol. 15: 5287-5294 (2009). *
Gabalec L, Bures J, Sedova M, Valenta Z. Quality of life of Crohn's disease patients. Cas. Lek. Cesk. 148: 201-205 (2009).
Gaca AM, Jaffe TA, Delaney S, Yoshizumi T, Toncheva G, Nguyen G, Frush DP. Radiation doses from small-bowel follow-through and abdomen/pelvis MDCT in pediatric Crohn disease. Pediatr. Radiol. 38: 285-291 (2008). *
Gadowska-Cicha A, Latos W, Niepsuj KJ, Sieron A. The therapy of Lesniowski-Crohn disease of the upper part of the gastrointestinal tract. Wiad. Lek. 58: 307-312 (2005).
Gaertner WB, Decanini A, Mellgren A, Lowry AC, Goldberg SM, Madoff RD, Spencer MP. Does infliximab infusion impact results of operative treatment for Crohn's perianal fistulas? Dis. Colon Rectum 50: 1754-1760 (2007). *
Gaertner WB, Hagerman GF, Finne CO, Alavi K, Jessurun J, Rothenberger DA, Madoff RD. Fistula-associated anal adenocarcinoma: good results with aggressive therapy. Dis. Colon Rectum 51: 1061-1067 (2008). *
Gaia E, Cavalot F, De Giuli P, Emanuelli G. Primary sclerosing cholangitis associated with colonic Crohn disease and marked eosinophilia. Description of a case. Minerva Gastroenterol. Dietol. 37: 59-63 (1991).
Gaia E, Pais P, Salacone P, Morello C. Preliminary results obtained with cefoperazone plus corticosteroids in the treatment of active Crohn's disease. Inflamm. Bowel Dis. 15: 1123-1124 (2009).
Gaj F, Trecca A, Crispino P, Silano V. Role of wireless capsule endoscopy in the study of intestinal diseases. Critical analysis and observation of the first 50 cases. Chir. Ital. 59: 69-73 (2007).
Gaj P, Habior A, Mikula M, Ostrowski J. Lack of evidence for association of primary sclerosing cholangitis and primary biliary cirrhosis with risk alleles for Crohn's disease in Polish patients. BMC Med. Genet. 9: 81 (2008). *
Gal E, Geller A, Fraser G, Levi Z, Niv Y. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI). Dig. Dis. Sci. 53: 1933-1937 (2008). *
Galamb O, Gyorffy B, Sipos F, Spisak S, Nemeth AM, Miheller P, Tulassay Z, Dinya E, Molnar B. Inflammation, adenoma and cancer: objective classification of colon biopsy specimens with gene expression signature. Dis. Markers 25: 1-16 (2008).
Galandi D, Allgaier HP. Diet therapy in chronic inflammatory bowel disease: results from meta-analysis and randomized controlled trials. Schweiz. Rundsch. Med. Prax. 91: 2041-2049 (2002).
Galandiuk S, Davis BR. Infliximab-induced disseminated histoplasmosis in a patient with Crohn's disease. Nat. Clin. Pract. Gastroenterol Hepatol. 5: 283-287 (2008).
Galandiuk S, Kimberling J, Al-Mishlab TG, Stromberg AJ. Perianal Crohn disease: predictors of need for permanent diversion. Ann. Surg. 241: 796-802 (2005). *
Galati V, Grilli E, Busi Rizzi E, Prantera C, Petrosillo N. Cerebral tubercular lesions in a patient treated with infliximab for Crohn's disease. J. Neurol. 255: 1981-1982 (2008).
Galbraith SS, Drolet BA, Kugathasan S, Paller AS, Esterly NB. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings. Pediatrics 116: e439-e444 (2005). *
Galeazzi M, Gasbarrini G, Ghirardello A, Grandemange S, Hoffman HM, Manna R, Podswiadek M, Punzi L, Sebastiani GD, Touitou I, Doria A. Autoinflammatory syndromes. Clin. Exp. Rheumatol. 24: S79-S85 (2006).
Gallahan WC, Case D, Bloomfeld RS. An analysis of the placebo effect in Crohn's disease over time. Aliment. Pharmacol. Ther. 31: 102-107 (2010). *
Gallardo GL, Moya MP, Rey MD, Arroyo MJ, Davila FM, Sanchez-Covisa MA. Amyloid goiter secondary to Crohn's disease. Endocrinol. Nutr. 56: 384-386 (2009).
Gallucci F, Russo R, Buono R, Acampora R, Madrid E, Uomo G. Indications and results of videocapillaroscopy in clinical practice. Adv. Med. Sci. 53: 149-157 (2008).
Galluzzi L, Kepp O, Zitvogel L, Kroemer G. Bacterial invasion: linking autophagy and innate immunity. Curr. Biol. 20: R106-R108 (2010). *
Galmarini CM. OSI-461 (OSI). Curr. Opin. Investig. Drugs 5: 648-656 (2004).
Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol. Nutr. Food Res. 49: 601-608 (2005). *
Gamarra RM, McGraw SD, Drelichman VS, Maas LC. Serum sickness-like reactions in patients receiving intravenous infliximab. J. Emerg. Med. 30: 41-44 (2006).
Gambero A, Marostica M, Abdalla Saad MJ, Pedrazzoli J. Mesenteric adipose tissue alterations resulting from experimental reactivated colitis. Inflamm. Bowel Dis. 13: 1357-1364 (2007). *
Game X, Malavaud B, Alric L, Mouzin M, Sarramon JP, Rischmann P. Infliximab treatment of Crohn disease ileovesical fistula. Scand. J. Gastroenterol. 38: 1097-1098 (2003). *
Gan H, Ouyang Q, Bu H. Mycobacterium paratuberculosis in the intestine of patients with Crohn's disease. Zhonghua Nei Ke Za Zhi 36: 228-230 (1997).
Gan SI, Urbanski S, Coderre SP, Panaccione R. Isolated visceral small artery fibromuscular hyperplasia-induced ischemic colitis mimicking inflammatory bowel disease. Am. J. Gastroenterol. 99: 2058-2062 (2004). *
Ganesan S, Travis SP, Ahmad T, Jazrawi R. Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr. Opin. Investig. Drugs 3: 1301-1306 (2002).
Ganesan S, Travis SP, Ahmad T, Jazrawi R. Role of tumor necrosis factor in Crohn's disease. Curr. Opin. Investig. Drugs 3: 1297-1300 (2002).
Ganesh R, Suresh N, Ezhilarasi S, Rajajee S, Sathiyasekaran M. Crohn's disease presenting as palatal ulcer. Indian J. Pediatr. 73: 229-231 (2006). *
Ganguli SC, Kamath MV, Redmond K, Chen Y, Irvine EJ, Collins SM, Tougas G. A comparison of autonomic function in patients with inflammatory bowel disease and in healthy controls. Neurogastroenterol. Motil. 19: 961-967 (2007).
Gao A, Mutharia L, Chen S, Rahn K, Odumeru J. Effect of pasteurization on survival of Mycobacterium paratuberculosis in milk. J. Dairy Sci. 85: 3198-3205 (2002). *
Gao A, Odumeru J, Raymond M, Hendrick S, Duffield T, Mutharia L. Comparison of milk culture, direct and nested polymerase chain reaction (PCR) with fecal culture based on samples from dairy herds infected with Mycobacterium avium subsp. paratuberculosis. Can. J. Vet. Res. 73: 58-64 (2009). *
Gao M, Cao Q, Luo LH, Wu ML, Hu WL, Si JM. NOD2/CARD15 gene polymorphisms and susceptibility to Crohn's disease in Chinese Han population. Zhonghua Nei Ke Za Zhi 44: 210-212 (2005).
Gao Q, Hogezand RA, Lamers CB, Verspaget HW. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease. Aliment. Pharmacol. Ther. 20: 585-592 (2004). *
Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, van den Berg M, van Hogezand RA, Lamers CB, Verspaget HW. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig. Liver Dis. 37: 584-592 (2005).
Gao Q, Meijer MJ, Schluter UG, van Hogezand RA, van der Zon JM, van den Berg M, van Duijn W, Lamers CB, Verspaget HW. Infliximab treatment influences the serological expression of matrix metalloproteinase (MMP)-2 and -9 in Crohn's disease. Inflamm. Bowel Dis. 13: 693-702 (2007). *
Gao X, Hu PJ, He Y, Liao SY, Peng S, Chen MH. Diagnostic role of anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Zhonghua Nei Ke Za Zhi 44: 428-430 (2005).
Garajova B, Hanke I, Prochazka V. Our experience with treatment of postoperative pain in Crohn's disease. Rozhl. Chir. 86: 233-235 (2007).
Garcea G, Majid I, Sutton CD, Pattenden CJ, Thomas WM. Diagnosis and management of colovesical fistulae; six-year experience of 90 consecutive cases. Colorectal Dis. 8: 347-352 (2006). *
Garcia Herola A, Nos P, Hinijosa J, Hoyos M, Moles J, Carmona E, Puig N, Sanchez-Cuenca J, Ponce J, Berenguer J. HLA antigens and anti-neutrophil cytoplasmic antibodies (ANCA) in inflammatory bowel disease. Rev. Esp. Enferm. Dig. 95: 755-759 (2003).
Garcia Lopez S. Inflammatory bowel disease. If a patient with Crohn's disease remains in remission for 4 years with azathioprine (or mercaptopurine), should the drug be withdrawn? Gastroenterol. Hepatol. 31: 704-705 (2008).
Garcia Rodriguez LA, Gonzalez-Perez A, Johansson S, Wallander MA. Risk factors for inflammatory bowel disease in the general population. Aliment. Pharmacol. Ther. 22: 309-315 (2005). *
Garcia Rodriguez LA, Ruigomez A, Panes J. Acute gastroenteritis is followed by an increased risk of inflammatory bowel disease. Gastroenterology 130: 1588-1594 (2006). *
Garcia Vilela E, De Lourdes De Abreu Ferrari M, Oswaldo Da Gama Torres H, Guerra Pinto A, Carolina Carneiro Aguirre A, Paiva Martins F, Marcos Andrade Goulart E, Sales Da Cunha A. Influence of Saccharomyces boulardii on the intestinal permeability of patients with Crohn's disease in remission. Scand. J. Gastroenterol. 43: 842-848 (2008). *
Garcia-Diaz M, Nevado L, Berenguer A, Bureo JC, Bureo P, Saenz de Santamaria J. Acute renal failure associated with 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterol. Hepatol. 18: 18-21 (1995).
Garcia-Gonzalez MA, Pena AS. Nitric oxide and inflammatory bowel disease. Rev. Esp. Enferm. Dig. 90: 870-876 (1998).
Garcia-Herola A, Nos P, Hoyos M, Hinojosa J, Moles JR, Pascual S, Bustamante M, Sanchez Cuenca JM, Carmona E, Ponce J, Berenguer J. Significance of the determination of antineutrophil cytoplasmic antibodies (ANCA) in ulcerative colitis and Crohn's disease. Gastroenterol. Hepatol. 21: 169-173 (1998).
Garcia-Olmo D, Garcia-Arranz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin. Biol. Ther. 8: 1417-1423 (2008).
Garcia-Olmo D, Garcia-Arranz M, Herreros D, Pascual I, Peiro C, Rodriguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis. Colon Rectum 48: 1416-1423 (2005). *
Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis. Colon Rectum 52: 79-86 (2009).
Garcia-Olmo D, Herreros D, Pascual M, Pascual I, De-La-Quintana P, Trebol J, Garcia-Arranz M. Treatment of enterocutaneous fistula in Crohn's disease with adipose-derived stem cells: a comparison of protocols with and without cell expansion. Int. J. Colorectal Dis. 24: 27-30 (2009). *
Garcia-Salces I, Baldellou R, Horndler C, Zubiri M. Subcorneal pustular dermatosis with pathergy phenomenon in a patient with Crohn's disease. J. Eur. Acad. Dermatol. Venereol. 23: 349-350 (2009).
Garcia-Sanchez M, Poyato-Gonzalez A, Giraldez-Jimenez M, Gomez-Camacho F, Espigares Del Aguila A, Dios-Vega J. MALT lymphoma in a patient with Crohns disease. A causal or incidental association? Gastroenterol. Hepatol. 29: 74-76 (2006).
Garcia-Sanchez Mdel V, Gomez-Camacho F, Poyato-Gonzalez A, Iglesias-Flores EM, de Dios-Vega JF, Sancho-Zapatero R. Infliximab therapy in a patient with Crohn's disease and chronic hepatitis B virus infection. Inflamm. Bowel Dis. 10: 701-702 (2004). *
Garcia-Vega E, Fernandez-Rodriguez C. A stress management programme for Crohn's disease. Behav. Res. Ther. 42: 367-383 (2004). *
Gardiner KR, Anderson NH, McCaigue MD, Erwin PJ, Halliday MI, Rowlands BJ. Adsorbents as antiendotoxin agents in experimental colitis. Gut 34: 51-55 (1993). *
Gardiner KR, Crockard AD, Halliday MI, Rowlands BJ. Class II major histocompatibility complex antigen expression on peripheral blood monocytes in patients with inflammatory bowel disease. Gut 35: 511-516 (1994). *
Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, Rowlands BJ. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 36: 897-901 (1995). *
Gardner MS, Rowland MD, Siu AY, Bundy JL, Wagener DK, Stephenson JL. Comprehensive defensin assay for saliva. Anal. Chem. 81: 557-566 (2009). *
Garg S, Garg K, Altaf M, Magaldi JA. Refractory vertebral sarcoidosis responding to infliximab. J. Clin. Rheumatol. 14: 238-240 (2008).
Garnett WR, Yunker N. Treatment of Crohn's disease with infliximab. Am. J. Health Syst. Pharm. 58: 307-316 (2001).
Garolla A, D'Inca R, Checchin D, Biagioli A, De Toni L, Nicoletti V, Scarpa M, Bolzonello E, Sturniolo GC, Foresta C. Reduced endothelial progenitor cell number and function in inflammatory bowel disease: a possible link to the pathogenesis. Am. J. Gastroenterol. 104: 2500-2507 (2009). *
Garrett KA, Remzi FH, Kirat HT, Fazio VW, Shen B, Kiran RP. Outcome of salvage surgery for ileal pouches referred with a diagnosis of Crohn's disease. Dis. Colon Rectum 52: 1967-1974 (2009).
Garrett-Sinha LA, John S, Gaffen SL. IL-17 and the Th17 lineage in systemic lupus erythematosus. Curr. Opin. Rheumatol. 20: 519-525 (2008).
Garrick V, Atwal P, Barclay AR, McGrogan P, Russell RK. Successful implementation of a nurse-led teaching programme to administer methotrexate in the community setting to children with Crohn's disease. Aliment. Pharmacol. Ther. 29: 90-96 (2009). *
Garrido A, Martinez M, Ortega J, Lobato A, Rodriguez M, Guerrero F. Epidemiology of chronic inflammatory bowel disease in the Northern area of Huelva. Rev. Esp. Enferm. Dig. 96: 687-694 (2004).
Garrido E, Sanroman AL, Rodriguez-Gandia MA, Rivero M, Royuela A, Moreira V, Milicua JM. Optimized protocol for diagnosis of acute ileitis. Clin. Gastroenterol. Hepatol. 7: 1183-1188 (2009).
Garrity JA, Coleman AW, Matteson EL, Eggenberger ER, Waitzman DM. Treatment of recalcitrant idiopathic orbital inflammation (chronic orbital myositis) with infliximab. Am. J. Ophthalmol. 138: 925-930 (2004).
Gasche C, Alizadeh BZ, Pena AS. Genotype-phenotype correlations: how many disorders constitute inflammatory bowel disease? Eur. J. Gastroenterol. Hepatol. 15: 599-606 (2003). *
Gasche C, Bakos S, Dejaco C, Tillinger W, Zakeri S, Reinisch W. IL-10 secretion and sensitivity in normal human intestine and inflammatory bowel disease. J. Clin. Immunol. 20: 362-370 (2000). *
Gasche C, Grundtner P. Genotypes and phenotypes in Crohn’s disease: do they help in clinical management? Gut 54: 162-167 (2005). *
Gasche C, Nemeth M, Grundtner P, Willheim-Polli C, Ferenci P, Schwarzenbacher R. Evolution of Crohn's disease-associated Nod2 mutations. Immunogenetics 60: 115-120 (2008). *
Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, Jewell DP, Rachmilewitz D, Sachar DB, Sandborn WJ, Sutherland LR. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm. Bowel Dis. 6: 8-15 (2000). *
Gassler N, Kopitz J, Tehrani A, Ottenwalder B, Schnolzer M, Kartenbeck J, Lyer S, Autschbach F, Poustka A, Otto HF, Mollenhauer J. Expression of acyl-CoA synthetase 5 reflects the state of villus architecture in human small intestine. J. Pathol. 202: 188-196 (2004). *
Gassull MA. The role of nutrition in the treatment of inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 79-83 (2004). *
Gassull MA. Review article: the intestinal lumen as a therapeutic target in inflammatory bowel disease. Aliment. Pharmacol. Ther. 24 Suppl. 3: 90-95 (2006). *
Gassull MA. Can nutritional therapy replace pharmacologic therapy in pediatric Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 6: 80-81 (2009).
Gassull MA. Nutrition and inflammatory bowel disease: its relation to pathophysiology, outcome and therapy. Dig. Dis. 21: 220-227 (2003).
Gassull MA, Cabre E. Nutrition in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 4: 561-569 (2001).
Gatzka M, Simon M, Schuler G, Luftl M. Rosacea fulminans, pyostomatitis and pyovulvitis in Crohn's disease. Dapsone as key factor in combination therapy? Hautarzt. 57: 898-902 (2006).
Gaujoux S, Couchard AC, Al Youssef J, Paquet JC. Ureteral obstruction and Crohn's disease. Gastroenterol. Clin. Biol. 31: 611-613 (2007).
Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with Crohn's disease treated with enteral nutrition as primary therapy. J. Hum. Nutr. Diet. 18: 337-342 (2005). *
Gay G, Delvaux M. Double balloon enteroscopy in Crohn's disease and related disorders: our experience. Gastrointest. Endosc. 66: S82-S90 (2007).
Gay G, Delvaux M, Fassler I. Outcome of capsule endoscopy in determining indication and route for push-and-pull enteroscopy. Endoscopy 38: 49-58 (2006).
Gay G, Delvaux M, Laurent V, Reibel N, Regent D, Grosdidier G, Roche JF. Temporary intestinal occlusion induced by a "patency capsule" in a patient with Crohn's disease. Endoscopy 37: 174-177 (2005).
Gay G, Delvaux M, Rey JF. The role of video capsule endoscopy in the diagnosis of digestive diseases: a review of current possibilities. Endoscopy 36: 913-920 (2004).
Gay J, Kokkotou E, O'Brien M, Pothoulakis C, Karalis KP. Interleukin-6 genetic ablation protects from trinitrobenzene sulfonic acid-induced colitis in mice. Putative effect of antiinflammatory cytokines. Neuroimmunomodulation 13: 114-121 (2006).
Gaya DR, Black RA, MacKenzie JF. Crohn's disease and MAP. Lancet 364: 2179 (2004). *
Gaya DR, Lyon TD, Duncan A, Neilly JB, Han S, Howell J, Liddell C, Stanley AJ, Morris AJ, Mackenzie JF. Faecal calprotectin in the assessment of Crohn's disease activity. QJM 98: 435-441 (2005). *
Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet 367: 1271-1284 (2006). *
Gazouli M, Atsaves V, Mantzaris G, Economou M, Nasioulas G, Evangelou K, Archimandritis AJ, Anagnou NP. Role of functional polymorphisms of NRAMP1 gene for the development of Crohn's disease. Inflamm. Bowel Dis. 14: 1323-1330 (2008). *
Gazouli M, Koundourakis A, Ikonomopoulos J, Gialafos EJ, Rapti A, Gorgoulis VG, Kittas C. CARD15/NOD2, CD14, and Toll-like receptor 4 gene polymorphisms in Greek patients with sarcoidosis. Sarcoidosis Vasc. Diffuse Lung Dis. 23: 23-29 (2006).
Gazouli M, Mantzaris G, Archimandritis AJ, Nasioulas G, Anagnou NP. Single nucleotide polymorphisms of OCTN1, OCTN2, and DLG5 genes in Greek patients with Crohn's disease. World J. Gastroenterol. 11: 7525-7530 (2005). *
Gazouli M, Mantzaris G, Kotsinas A, Zacharatos P, Papalambros E, Archimandritis A, Ikonomopoulos J, Gorgoulis VG. Association between polymorphisms in the Toll-like receptor 4, CD14, and CARD15/NOD2 and inflammatory bowel disease in the Greek population. World J. Gastroenterol. 11: 681-685 (2005). *
Gazouli M, Zacharatos P, Mantzaris GJ, Barbatis C, Ikonomopoulos I, Archimandritis AJ, Lukas JC, Papalambros E, Gorgoulis V. Association of NOD2/CARD15 variants with Crohn's disease in a Greek population. Eur. J. Gastroenterol. Hepatol. 16: 1177-1182 (2004).
Ge ZZ, Chen HY, Gao YJ, Gu JL, Hu YB, Xiao SD. Clinical application of wireless capsule endoscopy in pediatric patients for suspected small bowel diseases. Eur. J. Pediatr. 166: 825-829 (2007). *
Ge ZZ, Chen HY, Gao YJ, Gu JL, Hu YB, Xiao SD. Clinical application of wireless capsule endoscopy in pediatric and adolescent patients. Zhonghua Er Ke Za Zhi 44: 676-679 (2006).
Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy and push enteroscopy in the diagnosis of obscure gastrointestinal bleeding. Chin. Med. J. (Engl.) 117: 1045-1049 (2004).
Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy in diagnosis of small bowel Crohn's disease. World J. Gastroenterol. 10: 1349-1352 (2004). *
Gearry RB, Aitken J, Roberts R, Ismail S, Keenan J, Barclay M. Mycobacterium avium paratuberculosis and Crohn's disease. J. Gastroenterol. Hepatol. 20: 1943 (2005). *
Gearry RB, Ajlouni Y, Nandurkar S, Iser JH, Gibson PR. 5-Aminosalicylic acid (mesalazine) use in Crohn's disease: a survey of the opinions and practice of Australian gastroenterologists. Inflamm. Bowel Dis. 13: 1009-1015 (2007). *
Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed short-chain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease - a pilot study. Journal of Crohn's and Colitis 3: 8-14 (2009). *
Gearry RB, Lea RA, Roberts RL, Chambers GK, Barclay ML, Kennedy MA. CARD15 allele frequency differences in New Zealand Maori: ancestry specific susceptibility to Crohn’s disease in New Zealand? Gut 55: 580 (2006). *
Gearry RB, Richardson A, Frampton CM, Collett JA, Burt MJ, Chapman BA, Barclay ML. High incidence of Crohn's disease in Canterbury, New Zealand: results of an epidemiologic study. Inflamm. Bowel Dis. 12: 936-943 (2006). *
Gearry RB, Richardson AK, Frampton CM, Dodgshun AJ, Barclay ML. Population-based cases control study of inflammatory bowel disease risk factors. J. Gastroenterol. Hepatol. Jan 14 [Epub ahead of print] (2010). *
Gearry RB, Roberts RL, Burt MJ, Frampton CM, Chapman BA, Collett JA, Shirley P, Allington MD, Kennedy MA, Barclay ML. Effect of inflammatory bowel disease classification changes on NOD2 genotype-phenotype associations in a population-based cohort. Inflamm. Bowel Dis. 13: 1220-1227 (2007). *
Gearry RB, Wakeman CJ, Barclay ML, Chapman BA, Collett JA, Burt MJ, Frizelle FA. Surveillance for dysplasia in patients with inflammatory bowel disease: a national survey of colonoscopic practice in new zealand. Dis. Colon Rectum 47: 314-322 (2004). *
Gebhardt T, Lorentz A, Detmer F, Trautwein C, Bektas H, Manns MP, Bischoff SC. Growth, phenotype, and function of human intestinal mast cells are tightly regulated by transforming growth factor beta1. Gut 54: 928-934 (2005). *
Geboes K. Is histology useful for the assessment of the efficacy of immunosuppressive agents in IBD and if so, how should it be applied ? Acta Gastroenterol. Belg. 67: 285-289 (2004).
Geboes K. Biological therapies in IBD: an international course. IDrugs 4: 265-267 (2001).
Geboes K. From inflammation to lesion. Acta Gastroenterol. Belg. 57: 273-284 (1994).
Geboes K. What histologic features best differentiate Crohn's disease from ulcerative colitis? Inflamm. Bowel Dis. 14 Suppl. 2: S168-S169 (2008). *
Geboes K, Colombel JF, Greenstein A, Jewell DP, Sandborn WJ, Vatn MH, Warren B, Riddell RH; The Pathology Task Force of the International Organization of Inflammatory Bowel Diseases (IOIBD; K G., D.P.J, B.W., R.H.R.). Indeterminate colitis: a review of the concept - what's in a name? Inflamm. Bowel Dis. 14: 850-857 (2008). *
Geboes K, Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 50 Suppl. 3: III37-III42 (2002). *
Geboes K, De Hertogh G. Indeterminate colitis. Inflamm. Bowel Dis. 9: 324-331 (2003). *
Geboes K, Rutgeerts P, Opdenakker G, Olson A, Patel K, Wagner CL, Marano CW. Endoscopic and histologic evidence of persistent mucosal healing and correlation with clinical improvement following sustained infliximab treatment for Crohn's disease. Curr. Med. Res. Opin. 21: 1741-1754 (2005).
Geboes K, Rutgeerts P, Penninckx F, Desmet V, Vantrappen G. Changes in small intestinal epithelial expression of MHC class II antigen after terminal ileal resection for Crohn's disease. Int. J. Colorectal Dis. 3: 102-108 (1988).
Geddes K, Philpott DJ. A new role for intestinal alkaline phosphatase in gut barrier maintenance. Gastroenterology 135: 8-12 (2008). *
Gee MI, Grace MG, Wensel RH, Sherbaniuk RW, Thomson AB. Nutritional status of gastroenterology outpatients: comparison of inflammatory bowel disease with functional disorders. J. Am. Diet. Assoc. 85: 1591-1599 (1985).
Geerling BJ, Badart-Smook A, Stockbrugger RW, Brummer RJ. Comprehensive nutritional status in patients with long-standing Crohn disease currently in remission. Am. J. Clin. Nutr. 67: 919-926 (1998). *
Geerling BJ, Badart-Smook A, van Deursen C, van Houwelingen AC, Russel MG, Stockbrugger RW, Brummer RJ. Nutritional supplementation with n-3 fatty acids and antioxidants in patients with Crohn's disease in remission: effects on antioxidant status and fatty acid profile. Inflamm. Bowel Dis. 6: 77-84 (2000). *
Gehlert T, Devergne O, Niedobitek G. Epstein-Barr virus (EBV) infection and expression of the interleukin-12 family member EBV-induced gene 3 (EBI3) in chronic inflammatory bowel disease. J. Med. Virol. 73: 432-438 (2004). *
Gehrig KA, Dinulos JG. Acrodermatitis due to nutritional deficiency. Curr. Opin. Pediatr. Dec 3 [Epub ahead of print] (2009).
Geier DL, Miner PB Jr. New therapeutic agents in the treatment of inflammatory bowel disease. Am. J. Med. 93: 199-208 (1992).
Geiger AJ. Crohn's disease: infectious and osteopathic aspects. J. Am. Osteopath. Assoc. 87: 456-457 (1987).
Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease - do we have reliable markers? Inflamm. Bowel Dis. 6: 123-131 (2000). *
Gelfenbeyn M, Goodkin R, Kliot M. Sterile recurrent spinal epidural abscess in a patient with Crohn's disease: a case report. Surg. Neurol. 65: 178-184 (2006).
Gellona VJ, Zarraonandia AA, Zuniga DA, Palma CR, Contreras PJ, Silva ChJ, Gonzalez DR, Quintana VC. Infliximab in the treatment of patients with Crohn's disease: preliminary report. Rev. Med. Chil. 134: 320-325 (2006).
Gemignani F. A further cause of secondary restless legs syndrome: Crohn's disease. Inflamm. Bowel Dis. 16: 280-281 (2010).
Generini S, Giacomelli R, Fedi R, Fulminis A, Pignone A, Frieri G, Del Rosso A, Viscido A, Galletti B, Fazzi M, Tonelli F, Matucci Cerinic M. Infliximab in spondyloarthropathy associated with Crohn's disease: an open study on the efficacy in inducing and maintaining remission of musculoskeletal and gut manifestations. Ann. Rheum. Dis. 63: 1664-1669 (2004). *
Geng X, Biancone L, Dai HH, Lin JJ, Yoshizaki N, Dasgupta A, Pallone F, Das KM. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology 114: 912-922 (1998). *
Gentilucci UV, Caviglia R, Picardi A, Carotti S, Ribolsi M, Galati G, Petitti T, Afeltra A, Cicala M. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment. Pharmacol. Ther. 21: 1063-1071 (2005). *
Georges RN, Lipman S, Silvestri F, Sussman B, Dardik H. Endovascular treatment of mycotic hepatic artery aneurysm in the hostile abdomen - a case report. Vasc. Surg. 35: 477-481 (2001).
Georgios K, Helias A, Athanassios K, Eleni M, Konstantinos A. Craniofacial surgical management of a patient with systematic juvenile idiopathic arthritis and Crohn's disease. J. Craniofac. Surg. 20: 948-950 (2009).
Gerber NL, Steinberg AD. Clinical use of immunosuppressive drugs: part II. Drugs 11: 90-112 (1976).
Gergely P, Fekete B. New possibilities of treating patients with autoimmune disorders. Orv. Hetil. 148: S58-S62 (2007).
Gerhardt T, Wolff M, Fischer HP, Sauerbruch T, Reichel C. Pitfalls in the diagnosis of intestinal tuberculosis: a case report. Scand. J. Gastroenterol. 40: 240-243 (2005). *
Gerloni V, Pontikaki I, Gattinara M, Fantini F. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. Ann. Rheum. Dis. 67: 1145-1152 (2008).
Germanidis G, Lazaraki G, Gintikas S, Karayannis D, Mikoudi K, Sion M. Refractory Crohn-associated acute immune thrombocytopenic purpura treated with infliximab. A proposed pathogenetic mechanism. Eur. J. Intern. Med. 18: 344-346 (2007).
Gersemann M, Becker S, Kubler I, Koslowski M, Wang G, Herrlinger KR, Griger J, Fritz P, Fellermann K, Schwab M, Wehkamp J, Stange EF. Differences in goblet cell differentiation between Crohn's disease and ulcerative colitis. Differentiation 77: 84-94 (2009). *
Gersemann M, Wehkamp J, Fellermann K, Stange EF. Crohn's disease - defect in innate defence. World J. Gastroenterol. 14: 5499-5503 (2008). *
Gertsch J. Anti-inflammatory cannabinoids in diet: towards a better understanding of CB(2) receptor action? Commun. Integr. Biol. 1: 26-28 (2008).
Getliffe KM, Al Dulaimi D, Martin-Ruiz C, Holder RL, von Zglinicki T, Morris A, Nwokolo CU. Lymphocyte telomere dynamics and telomerase activity in inflammatory bowel disease: effect of drugs and smoking. Aliment. Pharmacol. Ther. 21: 121-131 (2005). *
Gewirtz AT. Flag in the crossroads: flagellin modulates innate and adaptive immunity. Curr. Opin. Gastroenterol. 22: 8-12 (2006).
Gewirtz AT. TLRs in the gut. III. Immune responses to flagellin in Crohn's disease: good, bad, or irrelevant? Am. J. Physiol. Gastrointest. Liver Physiol. 292: G706-G710 (2007). *
Gewirtz AT, Vijay-Kumar M, Brant SR, Duerr RH, Nicolae DL, Cho JH. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am. J. Physiol. Gastrointest. Liver Physiol. 290: G1157-G1163 (2006). *
Ghadiali AH, Strother M, Naser SA, Manning EJ, Sreevatsan S. Mycobacterium avium subsp. paratuberculosis strains isolated from Crohn's disease patients and animal species exhibit similar polymorphic locus patterns. J. Clin. Microbiol. 42: 5345-5348 (2004). *
Ghanchi FD, Rembacken BJ. Inflammatory bowel disease and the eye. Surv. Ophthalmol. 48: 663-676 (2003). *
Ghandil P, Chelala C, Dubois-Laforgue D, Senee V, Caillat-Zucman S, Kockum I, Luthman H, Nerup J, Pociot F, Timsit J, Julier C. Crohn's disease associated CARD15 (NOD2) variants are not involved in the susceptibility to type 1 diabetes. Mol. Genet. Metab. 86: 379-383 (2005). *
Ghandour K, Issa M. Oral Crohn's disease with late intestinal manifestations. Oral Surg. Oral Med. Oral Pathol. 72: 565-567 (1991).
Gheorghe C, Iacob R, Bancila I. Olympus capsule endoscopy for small bowel examination. J. Gastrointestin. Liver Dis. 16: 309-313 (2007). *
Gheorghe C, Pascu O, Gheorghe L, Iacob R, Dumitru E, Tantau M, Vadan R, Goldis A, Balan G, Iacob S, Dobru D, Saftoiu A. Epidemiology of inflammatory bowel disease in adults who refer to gastroenterology care in Romania: a multicentre study. Eur. J. Gastroenterol. Hepatol. 16: 1153-1159 (2004).
Gheorghe L, Gheorghe C, Badea M, Vadan R, Parvulescu I, Toader C, Tugui L, Papuc O, Ionescu R, Preda C, Calin I, Diculescu M. Infliximab for Crohn's disease in clinical practice: the experience of a single center in Romania. Rom. J. Gastroenterol. 12: 7-13 (2003).
Ghezzi A, Zaffaroni M. Neurological manifestations of gastrointestinal disorders, with particular reference to the differential diagnosis of multiple sclerosis. Neurol. Sci. 22 Suppl. 2: S117-S122 (2001).
Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Mol. Biotechnol. 31: 239-244 (2005).
Ghezzi P, Cerami A. Tumor necrosis factor as a pharmacological target. Methods Mol. Med. 98: 1-8 (2004).
Ghidirim G, Ignatenco S, Misin I, Gagauz I, Tiple I, Cutitari I, Zastavnitchi G. Recurrent Crohn's disease in the ileocolonic anastomosis complicated with duodenal fistula. Chirurgia (Bucur) 102: 607-610 (2007).
Ghosh N, Chaki R, Mandal V, Lin GD, Mandal SC. Mechanisms and efficacy of immunobiologic therapies for inflammatory bowel diseases. Int. Rev. Immunol. 29: 4-37 (2010). *
Ghosh S. Maintenance therapy versus episodic therapy with infliximab for Crohn’s disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 80-81 (2004). *
Ghosh S. Anti-TNF therapy in Crohn's disease. Novartis Found. Symp. 263: 193-205 (2004).
Ghosh S. How effective is adalimumab for inducing remission in patients with moderate-to-severe Crohn's disease? Nat. Clin. Pract. Gastroenterol. Hepatol. 3: 540-541 (2006). *
Ghosh S. Therapeutic value of alpha-4 integrin blockade in inflammatory bowel disease:the role of natalizumab. Expert Opin. Biol. Ther. 3: 995-1000 (2003).
Ghosh S. The challenges of medication non-adherence in ulcerative colitis: practical suggestions to help patients. Journal of Crohn's and Colitis 2: 97-98 (2008).
Ghosh S, Armitage E, Wilson D, Minor PD, Afzal MA. Detection of persistent measles virus infection in Crohn's disease: current status of experimental work. Gut 48: 748-752 (2001). *
Ghosh S, Chaudhary R, Carpani M, Playford R. Interfering with interferons in inflammatory bowel disease. Gut 55: 1071-1073 (2006). *
Ghosh S, Chaudhary R, Carpani M, Playford RJ. Is thiopurine therapy in ulcerative colitis as effective as in Crohn's disease? Gut 55: 6-8 (2006). *
Ghosh S, Goldin E, Gordon FH, Malchow HA, Rask-Madsen J, Rutgeerts P, Vyhnalek P, Zadorova Z, Palmer T, Donoghue S; Natalizumab Pan-European Study Group. Natalizumab for active Crohn's disease. N. Engl. J. Med. 348: 24-32 (2003). *
Ghosh S, Mitchell R. Impact of inflammatory bowel disease on quality of life: results of the European Federation of Crohn’s and Ulcerative Colitis Associations (EFCCA) patient survey. Journal of Crohn's and Colitis 1: 10-20 (2007).
Ghoshal UC, Ghoshal U, Singh H, Tiwari S. Anti-Saccharomyces cerevisiae antibody is not useful to differentiate between Crohn's disease and intestinal tuberculosis in India. J. Postgrad. Med. 53: 166-170 (2007). *
Ghoshal UC, Shukla A. Malnutrition in inflammatory bowel disease patients in northern India: frequency and factors influencing its development. Trop. Gastroenterol. 29: 95-97 (2008).
Giachino D, Van Duist MM, Regazzoni S, Gregori D, Bardessono M, Salacone P, Scaglione N, Sostegni R, Sapone N, Bresso F, Sambataro A, Gaia E, Pera A, Astegiano M, De Marchi M. Analysis of the CARD15 variants R702W, G908R and L1007fs in Italian IBD patients. Eur. J. Hum. Genet. 12: 206-212 (2004). *
Giachino DF, Regazzoni S, Bardessono M, Marchi MD, Gregori D, Study TP. Modeling the role of genetic factors in characterizing extraintestinal manifestations in Crohns disease patients: does this improve outcome predictions? Curr. Med. Res. Opin. 23: 1657-1665 (2007).
Giacomelli R, Passacantando A, Frieri G, Parzanese I, D'Alo S, Vernia P, Pimpo MT, Petrucci C, Caprilli R, Cifone MG, Tonietti G. Circulating soluble factor-inhibiting natural killer (NK) activity of fresh peripheral blood mononuclear cells (PBMC) from inflammatory bowel disease (IBD) patients. Clin. Exp. Immunol. 115: 72-77 (1999). *
Giaffer MH, Holdsworth CD, Duerden BI. Virulence properties of Escherichia coli strains isolated from patients with inflammatory bowel disease. Gut 33: 646-650 (1992). *
Giallourakis C, Stoll M, Miller K, Hampe J, Lander ES, Daly MJ, Schreiber S, Rioux JD. IBD5 is a general risk factor for inflammatory bowel disease: replication of association with Crohn disease and identification of a novel association with ulcerative colitis. Am. J. Hum. Genet. 73: 205-211 (2003). *
Giampaolo B, Giuseppe P, Michele B, Alessandro M, Fabrizio S, Alfonso C. Treatment of active steroid-refractory inflammatory bowel diseases with granulocytapheresis: our experience with a prospective study. World J. Gastroenterol. 12: 2201-2204 (2006). *
Giannini S, Martes C. Anemia in inflammatory bowel disease. Minerva Gastroenterol. Dietol. 52: 275-291 (2006).
Giardiello FM, Lazenby AJ, Yardley JH, Bias WB, Johnson J, Alianiello RG, Bedine MS, Bayless TM. Increased HLA A1 and diminished HLA A3 in lymphocytic colitis compared to controls and patients with collagenous colitis. Dig. Dis. Sci. 37: 496-499 (1992).
Giardina E, Novelli G, Costanzo A, Nistico S, Bulli C, Sinibaldi C, Sorgi ML, Chimenti S, Pallone F, Taccari E, Borgiani P. Psoriatic arthritis and CARD15 gene polymorphisms: no evidence for association in the Italian population. J. Invest. Dermatol. 122: 1106-1107 (2004). *
Giaslakiotis K, Baird A, Warren BF. Submucosal fat deposition in a patient with Crohn's disease: the fat halo sign. Histopathology 53: 611-612 (2008). *
Gibson J, Collins A, Morton N. Individual disease risk and multimetric analysis of Crohn disease. Proc. Natl. Acad. Sci. U.S.A. 105: 15843-15847 (2008). *
Gibson J, Wray D, Bagg J. Oral staphylococcal mucositis: a new clinical entity in orofacial granulomatosis and Crohn's disease. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 89: 171-176 (2000).
Gibson P, Rosella O. Interleukin 8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. Gut 37: 536-543 (1995). *
Gibson P, Rosella O, Nov R, Young G. Colonic epithelium is diffusely abnormal in ulcerative colitis and colorectal cancer. Gut 36: 857-863 (1995). *
Gibson PR. Overview of inflammatory bowel disease in Australia in the last 50 years. J. Gastroenterol. Hepatol. 24 Suppl. 3: S63-S68 (2009). *
Gibson PR. Increased gut permeability in Crohn's disease: is TNF the link? Gut 53: 1724-1725 (2004). *
Gibson PR, Anderson RP. Inflammatory bowel disease. Med. J. Aust. 169: 387-394 (1998).
Gibson PR, Iser J. Flammatory bowel disease. Aust. Fam. Physician 34: 233-237 (2005).
Gibson PR, Jewell DP. Local immune mechanisms in inflammatory bowel disease and colorectal carcinoma. Natural killer cells and their activity. Gastroenterology 90: 12-19 (1986).
Gibson PR, Shepherd SJ. Personal view: food for thought - western lifestyle and susceptibility to Crohn's disease. The FODMAP hypothesis. Aliment. Pharmacol. Ther. 21: 1399-1409 (2005). *
Gibson PR, Weston AR, Shann A, Florin TH, Lawrance IC, Macrae FA, Radford-Smith G. Relationship between disease severity, quality of life and health-care resource use in a cross-section of Australian patients with Crohn's disease. J. Gastroenterol. Hepatol. 22: 1306-1312 (2007). *
Gibson TB, Ng E, Ozminkowski RJ, Wang S, Burton WN, Goetzel RZ, Maclean R. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J. Occup. Environ. Med. 50: 1261-1272 (2008).
Gidwani AL, Blake G. Four pathologies in one. Ir. J. Med. Sci. 177: 77-78 (2008). *
Gierthmuhlen M, Laiffer G, Viehl CT, Savic S, Bremerich J, Mueller C, Christ M. No ordinary anal fistula... Internist (Berl.) 49: 490-494 (2008).
Gigase P, De Clerck LS, Van Cotthem KA, Bridts CH, Stevens WJ, Van Outryve M, Pelckmans PA. Anti-neutrophil cytoplasmic antibodies in inflammatory bowel disease with special attention for IgA-class antibodies. Dig. Dis. Sci. 42: 2171-2174 (1997). *
Gijsbers K, Van Assche G, Joossens S, Struyf S, Proost P, Rutgeerts P, Geboes K, Van Damme J. CXCR1-binding chemokines in inflammatory bowel diseases: down-regulated IL-8/CXCL8 production by leukocytes in Crohn's disease and selective GCP-2/CXCL6 expression in inflamed intestinal tissue. Eur. J. Immunol. 34: 1992-2000 (2004). *
Gil J, Jalocha L, Wojtun S. Imaging methods in inflammatory bowel disease. Pol. Merkur. Lekarski. 22: 442-445 (2007).
Gil J, Wojtun S, Stec-Michalska K, Chojnacki C. Inflammatory bowel diseases - imaging diagnostics. Pol. Merkuriusz. Lek. 17 Suppl. 1: 27-31 (2004).
Gil-Simon P, Barrio Andres J, Atienza Sanchez R, Julian Gomez L, Lopez Represa C, Caro-Paton A. Bronchiolitis obliterans organizing pneumonia and Crohn s disease. Rev. Esp. Enferm. Dig. 100: 175-177 (2008).
Gil-Simon P, Barrio J, Saracibar E, Perez-Miranda M, Julian L, Antonio Gil Ruiz J, Caro-Paton A. Esophageal Crohn's disease. Gastroenterol. Hepatol. 31: 108-109 (2008).
Gilad J. Antimycobacterial therapy for Crohn's disease. Am. J. Gastroenterol. 95: 2985-2986 (2000). *
Gilat T, Hacohen D, Lilos P, Langman MJ. Childhood factors in ulcerative colitis and Crohn's disease. An international cooperative study. Scand. J. Gastroenterol. 22: 1009-1024 (1987).
Gilat T, Rozen P. Epidemiology of Crohn's disease and ulcerative colitis: etiologic implications. Isr. J. Med. Sci. 15: 305-308 (1979).
Gilbert D, O'Malley S, Selby W. Are repeat upper gastrointestinal endoscopy and colonoscopy necessary within six months of capsule endoscopy in patients with obscure gastrointestinal bleeding? J. Gastroenterol. Hepatol. 23: 1806-1809 (2008). *
Gilbert-Barness E, Fox T, Morrow G, Luquette M, Pomerance H. Williams syndrome associated with Crohn disease, multiple infections, and chronic granulomatous disease. Pediatr. Pathol. Mol. Med. 23: 29-37 (2004).
Gilberts EC, Greenstein AJ, Katsel P, Harpaz N, Greenstein RJ. Molecular evidence for two forms of Crohn disease. Proc. Natl. Acad. Sci. U.S.A. 91: 12721-12724 (1994). *
Giles JT, Bathon JM. Serious infections associated with anticytokine therapies in the rheumatic diseases. J. Intensive Care Med. 19: 320-334 (2004). *
Gilger MA, Gann ME, Opekun AR, Gleason WA Jr. Efficacy of ursodeoxycholic acid in the treatment of primary sclerosing cholangitis in children. J. Pediatr. Gastroenterol. Nutr. 31: 136-141 (2000). *
Gilissen LP, Derijks LJ, Bos LP, Bus PJ, Hooymans PM, Engels LG. Therapeutic drug monitoring in patients with inflammatory bowel disease and established azathioprine therapy. Clin. Drug Investig. 24: 479-486 (2004).
Gilissen LP, Derijks LJ, Verhoeven HM, Bierau J, Hooymans PM, Hommes DW, Engels LG. Pancytopenia due to high 6-methylmercaptopurine levels in a 6-mercaptopurine treated patient with Crohn's disease. Dig. Liver Dis. 39: 182-186 (2007).
Gill H, Prasad J. Probiotics, immunomodulation, and health benefits. Adv. Exp. Med. Biol. 606: 423-454 (2008).
Gill KR, Mahadevan U. Infliximab for the treatment of metastatic hepatic and pulmonary Crohn's disease. Inflamm. Bowel Dis. 11: 210-212 (2005). *
Gill KR, Stark ME. Hookworm infestation masquerading as Crohn's disease: diagnosis by double-balloon enteroscopy. Am. J. Gastroenterol. 104: 795-796 (2009). *
Gillberg R, Dotevall G, Ahren C. Chronic inflammatory bowel disease in patients with coeliac disease. Scand. J. Gastroenterol. 17: 491-496 (1982).
Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 35: 651-655 (1994). *
Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 35: 1590-1592 (1994). *
Giller JP, Vinciguerra M, Heller A, Kunken FR, Kahn E. Treatment of gingival Crohn's disease with laser therapy. N. Y. State Dent. J. 63: 32-35 (1997).
Gilman J, Shanahan F, Cashman KD. Altered levels of biochemical indices of bone turnover and bone-related vitamins in patients with Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 23: 1007-1016 (2006). *
Gilman J, Shanahan F, Cashman KD. Determinants of vitamin D status in adult Crohn's disease patients, with particular emphasis on supplemental vitamin D use. Eur. J. Clin. Nutr. 60: 889-896 (2006). *
Ginsburg CH, Dambrauskas JT, Ault KA, Falchuk ZM. Impaired natural killer cell activity in patients with inflammatory bowel disease: evidence for a qualitative defect. Gastroenterology 85: 846-851 (1983).
Ginsburg PM, Dassopoulos T, Ehrenpreis ED. Thalidomide treatment for refractory Crohn's disease: a review of the history, pharmacological mechanisms and clinical literature. Ann. Med. 33: 516-525 (2001).
Gionchetti P, Rizzello F. CBP-1011 (InKine Pharmaceutical Co). IDrugs 4: 935-938 (2001).
Gionchetti P, Rizzello F, Campieri M. Probiotics in gastroenterology. Curr. Opin. Gastroenterol. 18: 235-239 (2002).
Gionchetti P, Rizzello F, Campieri M. Probiotics and antibiotics in inflammatory bowel disease. Curr. Opin. Gastroenterol. 17: 331-335 (2001).
Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, Tambasco R, Calabrese C, Campieri M. Antibiotics and probiotics in treatment of inflammatory bowel disease. World J. Gastroenterol. 12: 3306-3313 (2006). *
Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M. Antimicrobials in the management of inflammatory bowel disease. Digestion 73 Suppl. 1: 77-85 (2006). *
Gionchetti P, Rizzello F, Morselli C, Romagnoli R, Campieri M. Management of inflammatory bowel disease: does rifaximin offer any promise? Chemotherapy 51 Suppl. 1: 96-102 (2005).
Girardin M, Waschke KA, Seidman EG. A case of acute loss of vision as the presenting symptom of Crohn's disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 4: 695-698 (2007). *
Girardin SE, Boneca IG, Viala J, Chamaillard M, Labigne A, Thomas G, Philpott DJ, Sansonetti PJ. Nod2 is a general sensor of peptidoglycan through muramyl dipeptide (MDP) detection. J. Biol. Chem. 278: 8869-8872 (2003). *
Girardin SE, Hugot JP, Sansonetti PJ. Lessons from Nod2 studies: towards a link between Crohn's disease and bacterial sensing. Trends Immunol. 24: 652-658 (2003). *
Girardin SE, Philpott DJ. Mini-review: the role of peptidoglycan recognition in innate immunity. Eur. J. Immunol. 34: 1777-1782 (2004). *
Girelli CM, Porta P, Malacrida V, Barzaghi F, Rocca F. Clinical outcome of patients examined by capsule endoscopy for suspected small bowel Crohn's disease. Dig. Liver Dis. 39: 148-154 (2007).
Girlich C, Jung EM, Iesalnieks I, Schreyer AG, Zorger N, Strauch U, Schacherer D. Quantitative assessment of bowel wall vascularisation in Crohn's disease with contrast-enhanced ultrasound and perfusion analysis. Clin. Hemorheol. Microcirc. 43: 141-148 (2009).
Girometti R, Zuiani C, Toso F, Brondani G, Sorrentino D, Avellini C, Bazzocchi M. MRI scoring system including dynamic motility evaluation in assessing the activity of Crohn's disease of the terminal ileum. Acad. Radiol. 15: 153-164 (2008).
Girona E, Borras-Blasco J, Conesa-Garcia V, Navarro-Ruiz A, Solis J, Garcia-Sepulcre MF, Oliver-Garcia I. Successful treatment of severe gastrointestinal bleeding secondary to Crohn disease with recombinant factor VIIa. South. Med. J. 100: 601-604 (2007).
Gironella M, Iovanna JL, Sans M, Gil F, Penalva M, Closa D, Miquel R, Pique JM, Panes J. Anti-inflammatory effects of pancreatitis associated protein in inflammatory bowel disease. Gut 54: 1244-1253 (2005). *
Girschick HJ, Zimmer C, Klaus G, Darge K, Dick A, Morbach H. Chronic recurrent multifocal osteomyelitis: what is it and how should it be treated? Nat. Clin. Pract. Rheumatol. 3: 733-738 (2007). *
Girszyn N, Leport J, Arnaud L, Kahn JE, Piette AM, Bletry O. Crohn's disease affecting only vulvoperineal area. Presse. Med. 36: 1762-1765 (2007).
Gisbert JP, Bermejo F, Pajares R, Perez-Calle JL, Rodriguez M, Algaba A, Mancenido N, de la Morena F, Carneros JA, McNicholl AG, Gonzalez-Lama Y, Mate J. Oral and intravenous iron treatment in inflammatory bowel disease: hematological response and quality of life improvement. Inflamm. Bowel Dis. 15: 1485-1491 (2009).
Gisbert JP, Bermejo F, Perez-Calle JL, Taxonera C, Vera I, McNicholl AG, Algaba A, Lopez P, Lopez-Palacios N, Calvo M, Gonzalez-Lama Y, Carneros JA, Velasco M, Mate J. Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse. Inflamm. Bowel Dis. 15: 1190-1198 (2009).
Gisbert JP, Gomollon F, Cara C, Luna M, Gonzalez-Lama Y, Pajares JM, Mate J, Guijarro LG. Thiopurine methyltransferase activity in the inflammatory bowel disease. A study on 7046 Spanish patients. Med. Clin. (Barc.) 125: 281-285 (2005).
Gisbert JP, Gonzalez-Lama Y, Mate J. Role of biological markers in inflammatory bowel disease. Gastroenterol. Hepatol. 30: 117-129 (2007).
Gisbert JP, Luna M, Gonzalez-Lama Y, Pousa ID, Velasco M, Moreno-Otero R, Mate J. Effect of 5-aminosalicylates on renal function in patients with inflammatory bowel disease: 4-year follow-up study. Gastroenterol. Hepatol. 31: 477-484 (2008).
Gisbert JP, Luna M, Legido J, Hermida C, Mate J, Pajares JM. Anti-neutrophil cytoplasmic antibodies in the diagnosis of ulcerative colitis and Crohn's disease. Med. Clin. (Barc.) 122: 134-135 (2004).
Gisbert JP, Luna M, Mate J, Gonzalez-Guijarro L, Cara C, Pajares JM. Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study. Hepatogastroenterology 53: 399-404 (2006).
Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig. Liver Dis. 41: 56-66 (2009).
Gisbert JP, McNicholl AG, Gomollon F. Questions and answers on the role of fecal lactoferrin as a biological marker in inflammatory bowel disease. Inflamm. Bowel Dis. 15: 1746-1754 (2009).
Gisbert JP, Nino P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study on 394 patients. Aliment. Pharmacol. Ther. 28: 228-238 (2008). *
Gisbert JP, Nino P, Rodrigo L, Cara C, Guijarro LG. Thiopurine methyltransferase (TPMT) activity and adverse effects of azathioprine in inflammatory bowel disease: long-term follow-up study of 394 patients. Am. J. Gastroenterol. 101: 2769-2776 (2006). *
Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am. J. Gastroenterol. 104: 760-767 (2009).
Gitlin L, Biesecker J. Australian Crohn's antibiotic study opens new horizons. Gastroenterology 133: 1743-1744 (2007). *
Gitnick G. Current views of the etiology of inflammatory bowel disease. Semin. Pediatr. Surg. 3: 2-7 (1994).
Gitnick G. Etiology of inflammatory bowel diseases: where have we been? Where are we going? Scand. J. Gastroenterol. Suppl. 175: 93-96 (1990).
Gjone E, Orning OM, Myren J. Crohn's disease in Norway 1956-63. Gut 7: 372-374 (1966). *
Gjurow D, Grzelewski T, Sobocinska A, Stelmach I. Tumor necrosis factor inhibitors in pediatric asthma. Recent Pat. Inflamm. Allergy Drug Discov. 3: 143-148 (2009).
Glanemann B, Schonenbrucher H, Bridger N, Abdulmawjood A, Neiger R, Bulte M. Detection of Mycobacterium avium subspecies paratuberculosis-specific DNA by PCR in intestinal biopsies of dogs. J. Vet. Intern. Med. 22: 1090-1094 (2008).
Glas J, Folwaczny M, Folwaczny C. Crohn's disease recurrence in small bowel transplant. Am. J. Gastroenterol. 99: 2067 (2004). *
Glas J, Konrad A, Schmechel S, Dambacher J, Seiderer J, Schroff F, Wetzke M, Roeske D, Torok HP, Tonenchi L, Pfennig S, Haller D, Griga T, Klein W, Epplen JT, Folwaczny C, Lohse P, Goke B, Ochsenkuhn T, Mussack T, Folwaczny M, Muller-Myhsok B, Brand S. The ATG16L1 gene variants rs2241879 and rs2241880 (T300A) are strongly associated with susceptibility to Crohn's disease in the German population. Am. J. Gastroenterol. 103: 682-691 (2008). *
Glas J, Martin K, Brunnler G, Kopp R, Folwaczny C, Weiss EH, Albert ED. MICA, MICB and C1_4_1 polymorphism in Crohn's disease and ulcerative colitis. Tissue Antigens 58: 243-249 (2001). *
Glas J, Seiderer J, Pasciuto G, Tillack C, Diegelmann J, Pfennig S, Konrad A, Schmechel S, Wetzke M, Torok HP, Stallhofer J, Jurgens M, Griga T, Klein W, Epplen JT, Schiemann U, Mussack T, Lohse P, Goke B, Ochsenkuhn T, et al. rs224136 on chromosome 10q21.1 and variants in PHOX2B, NCF4, and FAM92B are not major genetic risk factors for susceptibility to Crohn's disease in the German population. Am. J. Gastroenterol. 104: 665-672 (2009). *
Glas J, Seiderer J, Wetzke M, Konrad A, Torok HP, Schmechel S, Tonenchi L, Grassl C, Dambacher J, Pfennig S, Maier K, Griga T, Klein W, Epplen JT, Schiemann U, Folwaczny C, Lohse P, Goke B, Ochsenkuhn T, Muller-Myhsok B, Folwaczny M, Mussack T, Brand S. rs1004819 is the main disease-associated IL23R variant in German Crohn's disease patients: combined analysis of IL23R, CARD15, and OCTN1/2 variants. PLoS ONE 2: e819 (2007). *
Glas J, Stallhofer J, Ripke S, Wetzke M, Pfennig S, Klein W, Epplen JT, Griga T, Schiemann U, Lacher M, Koletzko S, Folwaczny M, Lohse P, Goke B, Ochsenkuhn T, Muller-Myhsok B, Brand S. Novel genetic risk markers for ulcerative colitis in the IL2/IL21 region are in epistasis with IL23R and suggest a common genetic background for ulcerative colitis and celiac disease. Am. J. Gastroenterol. 104: 1737-1744 (2009). *
Glas J, Torok HP, Daczo J, Tonenchi L, Folwaczny M, Folwaczny C. The leukocyte count predicts the efficacy of treatment with azathioprine in inflammatory bowel disease. Eur. J. Med. Res. 10: 535-538 (2005).
Glas J, Torok HP, Tonenchi L, Kapser J, Schiemann U, Muller-Myhsok B, Folwaczny M, Folwaczny C. Association of polymorphisms in the interleukin-18 gene in patients with Crohn's disease depending on the CARD15/NOD2 genotype. Inflamm. Bowel Dis. 11: 1031-1037 (2005). *
Glas J, Torok HP, Tonenchi L, Muller-Myhsok B, Mussack T, Wetzke M, Klein W, Epplen JT, Griga T, Schiemann U, Lohse P, Seiderer J, Schnitzler F, Brand S, Ochsenkuhn T, Folwaczny M, Folwaczny C. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARD15/NOD2, IKBL, and IL-1RN genes. Inflamm. Bowel Dis. 12: 606-611 (2006). *
Glas J, Torok HP, Tonenchi L, Wetzke M, Beynon V, Teshome MY, Cotofana S, Schiemann U, Griga T, Klein W, Epplen JT, Folwaczny C, Folwaczny M, Mussack T, Weiss EH. The 14-bp deletion polymorphism in the HLA-G gene displays significant differences between ulcerative colitis and Crohn's disease and is associated with ileocecal resection in Crohn's disease. Int. Immunol. 19: 621-626 (2007). *
Glas J, Torok HP, Unterhuber H, Radlmayr M, Folwaczny C. The -295T-to-C promoter polymorphism of the IL-16 gene is associated with Crohn's disease. Clin. Immunol. 106: 197-200 (2003). *
Glasser AL, Darfeuille-Michaud A. Abnormalities in the handling of intracellular bacteria in Crohn's disease: a link between infectious etiology and host genetic susceptibility. Arch. Immunol. Ther. Exp. (Warsz.) 56: 237-244 (2008).
Glassman MS, Newman LJ, Berezin S, Gryboski JD. Cow's milk protein sensitivity during infancy in patients with inflammatory bowel disease. Am. J. Gastroenterol. 85: 838-840 (1990).
Glazier KD, Palance AL, Griffel LH, Das KM. The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease. J. Clin. Gastroenterol. 39: 21-26 (2005).
Gleeson F, Clarke E, Kelly S, Hargadan G, Kenny E, Macmathuna P, Lennon J. Diagnosis by EUS trucut biopsy of extrapulmonary tuberculosis in a patient with Crohn's disease treated with infliximab. Gastrointest. Endosc. 61: 489-492 (2005). *
Glehen O, Mithieux F, Traverse-Glehen A, Isaac S, Bienvenu J, Francois Y, Chung R, Gilly FN. Enteral immunotherapy in the treatment of chronic enterocolitis in interleukin-10-deficient mice. Hepatogastroenterology 50: 670-675 (2003).
Glinskii AB, Ma J, Ma S, Grant D, Lim CU, Sell S, Glinsky GV. Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders. Cell Cycle 8: 3925-3942 (2009).
Glinsky GV. Disease phenocode analysis identifies SNP-guided microRNA maps (MirMaps) associated with human "master" disease genes. Cell Cycle 7: 3680-3694 (2008). *
Glinsky GV. SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways. Cell Cycle 7: 3564-3576 (2008). *
Glinsky GV. An SNP-guided microRNA map of fifteen common human disorders identifies a consensus disease phenocode aiming at principal components of the nuclear import pathway. Cell Cycle 7: 2570-2583 (2008). *
Glintborg B. Pancreatitis in a patient with Crohn disease treated with mesalazine and azathioprine. Ugeskr. Laeger. 162: 4553-4554 (2000).
Gloria-Bottini F, Bottini N, Renzetti G, Bottini E. ACP1 and Th class of immunological disease: evidence of interaction with gender. Int. Arch. Allergy Immunol. 143: 170-176 (2007).
Gnewuch C, Liebisch G, Langmann T, Dieplinger B, Mueller T, Haltmayer M, Dieplinger H, Zahn A, Stremmel W, Rogler G, Schmitz G. Serum bile acid profiling reflects enterohepatic detoxification state and intestinal barrier function in inflammatory bowel disease. World J. Gastroenterol. 15: 3134-3141 (2009). *
Gobbato N, Rachid M, Perdigon G. Anti-inflammatory effect of yoghurt in an experimental inflammatory bowel disease in mouse. J. Dairy Res. 75: 497-504 (2008). *
Gobron C, Kaci R, Sokol H, Vahedi K, Lejoyeux P, Guillaud C, Wechsler B, Gray F, Bousser MG. Unilateral carotid granulomatous arteritis and Crohn's disease. Rev. Neurol. (Paris) Nov 26 [Epub ahead of print] (2009).
Gockel HR, Lugering A, Heidemann J, Schmidt M, Domschke W, Kucharzik T, Lugering N. Thalidomide induces apoptosis in human monocytes by using a cytochrome c-dependent pathway. J. Immunol. 172: 5103-5109 (2004). *
Godefroy C, Pilleul F, Dugougeat F, Yzebe D, Lachaux A, Pracros J, Valette P. Value of contrast-enhanced MR enterography in pediatric Crohn's disease: preliminary study. J. Radiol. 86: 1685-1692 (2005).
Godet PG, May GR, Sutherland LR. Meta-analysis of the role of oral contraceptive agents in inflammatory bowel disease. Gut 37: 668-673 (1995). *
Godfrey KM, James MP. Treatment of severe acne with isotretinoin in patients with inflammatory bowel disease. Br. J. Dermatol. 123: 653-655 (1990).
Goertz RS, Konturek PC, Naegel A, Janka R, Amann K, Maennlein G, Wein A, Hahn EG, Boxberger F. Experiences with a long-term treatment of a massive gluteal acne inversa with infliximab in Crohn's disease. Med. Sci. Monit. 15: CS14-CS18 (2009). *
Goggins MG, Goh J, O'Connell MA, Weir DG, Kelleher D, Mahmud N. Soluble adhesion molecules in inflammatory bowel disease. Ir. J. Med. Sci. 170: 107-111 (2001).
Goh J, O'Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment. Pharmacol. Ther. 17: 307-320 (2003). *
Goh K, Xiao SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J. Dig. Dis. 10: 1-6 (2009). *
Goic-Barisic I, Ledina D, Tonkic M, Luksic B, Barisic I. Lymphoid form of intestinal tuberculosis with miliary dissemination: case report. Acta Med. Croatica 60: 505-508 (2006).
Goischke HK, Ochsendorf FR. Acne inversa in Crohn's disease. Z. Gastroenterol. 39: 965-969 (2001).
Goke M, Hoffmann JC, Evers J, Kruger H, Manns MP. Elevated serum concentrations of soluble selectin and immunoglobulin type adhesion molecules in patients with inflammatory bowel disease. J. Gastroenterol. 32: 480-486 (1997).
Gold BD. Epidemiology and management of gastro-oesophageal reflux in children. Aliment. Pharmacol. Ther. 19 Suppl. 1: 22-27 (2004).
Gold N, Issenman R, Roberts J, Watt S. Well-adjusted children: an alternate view of children with inflammatory bowel disease and functional gastrointestinal complaints. Inflamm. Bowel Dis. 6: 1-7 (2000). *
Gold R, Jawad A, Miller DH, Henderson DC, Fassas A, Fierz W, Hartung HP. Expert opinion: guidelines for the use of natalizumab in multiple sclerosis patients previously treated with immunomodulating therapies. J. Neuroimmunol. 187: 156-158 (2007).
Goldacre MJ, Duncan M, Cook-Mozaffari P, Griffith M, Travis S. Inflammatory bowel disease, peptic ulcer and diverticular disease as certified causes of death in an English population 1979-2003. Eur. J. Gastroenterol. Hepatol. 20: 96-103 (2008).
Goldacre MJ, Wotton CJ, Yeates D, Seagroatt V, Jewell D. Cancer in patients with ulcerative colitis, Crohn's disease and coeliac disease: record linkage study. Eur. J. Gastroenterol. Hepatol. 20: 297-304 (2008).
Golder SK, Schreyer AG, Endlicher E, Feuerbach S, Scholmerich J, Kullmann F, Seitz J, Rogler G, Herfarth H. Comparison of capsule endoscopy and magnetic resonance (MR) enteroclysis in suspected small bowel disease. Int. J. Colorectal Dis. 21: 97-104 (2006). *
Golder WA. The "creeping fat sign" - really diagnostic for Crohn's disease? Int. J. Colorectal Dis. 24: 1-4 (2009). *
Goldfarb NI, Pizzi LT, Fuhr JP, Salvador C, Sikirica V, Kornbluth A, Lewis B. Diagnosing Crohn's disease: an economic analysis comparing wireless capsule endoscopy with traditional diagnostic procedures. Dis. Manag. 7: 292-304 (2004).
Goldman AS. The immune system in human milk and the developing infant. Breastfeed. Med. 2: 195-204 (2007).
Goldshmid O, Dovorish Z, Zehavi T, Eisen A, Bar-Dayan Y, Amital H. Coexistent pyoderma gangrenosum and tibialis anterior myositis as presenting manifestations of Crohn's disease: case report and review of the literature. Rheumatol. Int. Oct 22 [Epub ahead of print] (2009). *
Goldstein ES, Marion JF, Present DH. 6-Mercaptopurine is effective in Crohn's disease without concomitant steroids. Inflamm. Bowel Dis. 10: 79-84 (2004). *
Goldstein ES, Rubin PH. Endoscopic therapy for inflammatory bowel disease. Curr. Treat. Options Gastroenterol. 6: 237-243 (2003).
Goldstein F. Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects. J. Clin. Gastroenterol. 9: 654-658 (1987).
Goldstein F, Farquhar S, Thornton JJ, Abramson J. Favorable effects of sulfasalazine on small bowel Crohn's disease: a long-term study. Am. J. Gastroenterol. 82: 848-853 (1987).
Goldstein F, Menduke H, Thornton JJ 3rd, Abramson J. Anti-inflammatory drug treatment of Crohn's disease: a prospective evaluation of 100 consecutively treated patients. J. Clin. Gastroenterol. 2: 77-85 (1980).
Goldstein N, Dulai M. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am. J. Clin. Pathol. 126: 1-12 (2006). *
Goldstein NS. Isolated ileal erosions in patients with mildly altered bowel habits. A follow-up study of 28 patients. Am. J. Clin. Pathol. 125: 838-846 (2006).
Goldstein NS, Sanford WW, Bodzin JH. Crohn's-like complications in patients with ulcerative colitis after total proctocolectomy and ileal pouch-anal anastomosis. Am. J. Surg. Pathol. 21: 1343-1353 (1997).
Golfieri R, Cappelli A, Giampalma E, Rizzello F, Gionchetti P, Laureti S, Poggioli G, Campieri M. CT-guided percutaneous pelvic abscess drainage in Crohn's disease. Tech. Coloproctol. 10: 99-105 (2006). *
Golofeevsky VY. Histological evaluation of activity of the ulcerative colitis in its initial stage of development. Falk Symposium 154: INFLAMMATORY BOWEL DISEASE - DIAGNOSTIC AND THERAPEUTIC STRATEGIES, Moscow (Russia), June 9 - 10, 2006, p. 42 (2006). *
Golpe R, Mateos A, Perez-Valcarcel J, Lapena JA, Garcia-Figueiras R, Blanco J. Multiple pulmonary nodules in a patient with Crohn's disease. Respiration 70: 306-309 (2003). *
Gomard-Mennesson E, Fabien N, Cordier JF, Ninet J, Tebib J, Rousset H. Clinical significance of anti-histidyl-tRNA synthetase (Jo1) autoantibodies. Ann. N. Y. Acad. Sci. 1109: 414-420 (2007). *
Gomariz RP, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F, Garcia-Gomez M, Leceta J, Juarranz Y. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J. Leukoc. Biol. 78: 491-502 (2005). *
Gomariz RP, Juarranz Y, Abad C, Arranz A, Leceta J, Martinez C. VIP-PACAP system in immunity: new insights for multitarget therapy. Ann. N. Y. Acad. Sci. 1070: 51-74 (2006). *
Gomes CM, Giraldo PC, Gomes Fde A, Amaral R, Passos MR, Goncalves AK. Genital ulcers in women: clinical, microbiologic and histopathologic characteristics. Braz. J. Infect. Dis. 11: 254-260 (2007).
Gomez de la Concha E. Inflammatory bowel disease: genotype-fenotype relationship. An. R. Acad. Nac. Med. (Madr.) 123: 307-317 (2006).
Gomez EG, San Roman AL, San Jose FB. Idiopathic pancreatitis in inflammatory bowel disease. Journal of Crohn's and Colitis 2: 237-240 (2008).
Gomez-Zavala A, Garcia-Leiva J, Perez-Aguilar R. Intermittent intestinal sub-occlusion secondary to Crohn's disease. Rev. Gastroenterol. Mex. 74: 238-239 (2009).
Gomollon F. Inflammatory bowel disease. Gastroenterol. Hepatol. 31 Suppl. 4: 42-46 (2008).
Gomollon F, Gisbert JP. Must immunomodulators be added to biological treatment in inflammatory bowel disease? Gastroenterol. Hepatol. Jul 17 [Epub ahead of print] (2009).
Gomollon F, Gisbert JP, Gassull MA. Crohnology: a tale of time and times and inflammatory bowel diseases. World J. Gastroenterol. 14: 5489-5490 (2008). *
Gomollon F, Lopez SG. Treatment with anti-TNFalpha agents in Crohn's disease: what drug we have to use and when? Acta Gastroenterol. Latinoam. 38: 133-145 (2008).
Goncalves DU, de Castro MM, Galvao CP, Brandao AZ, de Castro MC, Lambertucci JR. Cheilitis granulomatosa associated with Melkersson-Rosenthal syndrome. Rev. Bras. Otorrinolaringol. (Engl. Ed.) 73: 132-133 (2007). *
Goncalves NS, Ghaem-Maghami M, Monteleone G, Frankel G, Dougan G, Lewis DJ, Simmons CP, MacDonald TT. Critical role for tumor necrosis factor alpha in controlling the number of lumenal pathogenic bacteria and immunopathology in infectious colitis. Infect. Immun. 69: 6651-6659 (2001). *
Gondim FA, Brannagan TH 3rd, Sander HW, Chin RL, Latov N. Peripheral neuropathy in patients with inflammatory bowel disease. Brain 128: 867-879 (2005). *
Gong JF, Niu LY, Wei XW, Zhu WM, Li N, Li JS. Therapeutic effects of combined enteral nutrition with Tripterygium Wilfordii Polyglycosidium in remission induction of active adult Crohn's disease. Zhonghua Wai Ke Za Zhi 47: 1213-1217 (2009).
Gonlusen G, Akgun H, Ertan A, Olivero J, Truong LD. Renal failure and nephrocalcinosis associated with oral sodium phosphate bowel cleansing: clinical patterns and renal biopsy findings. Arch. Pathol. Lab. Med. 130: 101-106 (2006).
Gonvers JJ, Juillerat P, Mottet C, Felley C, Burnand B, Vader JP, Michetti P, Froehlich F. Maintenance of remission in Crohn's disease. Digestion 71: 41-48 (2005).
Gonvers JJ, Juillerat P, Mottet C, Pittet V, Felley C, Vader JP, Michetti P, Froehlich F. Maintenance of medically induced remission of Crohn's disease. Digestion 76: 116-129 (2007). *
Gonzaga JE, Ananthakrishnan AN, Issa M, Beaulieu DB, Skaros S, Zadvornova Y, Johnson K, Otterson MF, Binion DG. Durability of infliximab in Crohn's disease: a single-center experience. Inflamm. Bowel Dis. 15: 1837-1843 (2009).
Gonzalez Carro P, Perez Roldan F, Roncero Garcia Escribano O, Lafuente R, Legaz Huidobro ML, Amigo Echenagusia A. Case report: combination therapy with granulocyte apheresis and infliximab for refractory Crohn's disease. J. Clin. Apher. 21: 249-251 (2006).
Gonzalez M, Collaud S, Gervaz P, Frossard JL, Morel P. Surgical treatment of duodenal stenosis in Crohn's disease. Ann. Chir. 131: 636-638 (2006).
Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M. Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136: 978-989 (2009). *
Gonzalez S, Rodrigo L, Martinez-Borra J, Lopez-Vazquez A, Fuentes D, Nino P, Cadahia V, Saro C, Dieguez MA, Lopez-Larrea C. TNF-alpha -308A promoter polymorphism is associated with enhanced TNF-alpha production and inflammatory activity in Crohn's patients with fistulizing disease. Am. J. Gastroenterol. 98: 1101-1016 (2003). *
Gonzalez-Huezo M, Ruiz-Mejia R, Rosales-Solís A, Carrillo-Ponce C. Primary sclerosing cholangitis of small ducts, associated with eosinophilic gastroenteritis. Case report and literature review. Rev. Gastroenterol. Mex. 73: 242-246 (2008).
Gonzalez-Lama Y, Abreu L, Vera MI, Pastrana M, Tabernero S, Revilla J, Duran JG, Escartin P. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm. Bowel Dis. 11: 8-15 (2005). *
Gonzalez-Lama Y, Gisbert JP, Mate J. The role of tacrolimus in inflammatory bowel disease: a systematic review. Dig. Dis. Sci. 51: 1833-1840 (2006). *
Gonzalez-Lama Y, Lopez-San Roman A, Marin-Jimenez I, Casis B, Vera I, Bermejo F, Perez-Calle JL, Taxonera C, Martinez-Silva F, Menchen L, Martinez-Montiel P, Calvo M, Carneros JA, Lopez P, Mendoza JL, Milicua JM, Huerta A, Sanchez F, Abreu L, et al. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterol. Hepatol. 31: 421-426 (2008).
Gonzalez-Lara V, Carneros JA, Nunez-Martinez O, Rodriguez C, Escudero M, Alvarez R. The prolonged administration of intravenous immunoglobulins as a treatment for refractory fistulous Crohn's diseases. Gastroenterol. Hepatol. 23: 12-13 (2000).
Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 131: 1799-1811 (2006). *
Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic effect of urocortin and adrenomedullin in a murine model of Crohn's disease. Gut 55: 824-832 (2006). *
Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Delgado M. Therapeutic action of Ghrelin in a mouse model of colitis. Gastroenterology 130: 1707-1720 (2006). *
Gonzalez-Rey E, Varela N, Chorny A, Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des. 13: 1113-1139 (2007).
Gonzalez-Rey E, Varela N, Sheibanie AF, Chorny A, Ganea D, Delgado M. Cortistatin, an antiinflammatory peptide with therapeutic action in inflammatory bowel disease. Proc. Natl. Acad. Sci. U.S.A. 103: 4228-4233 (2006). *
Goode T, O'Connell J, Anton P, Wong H, Reeve J, O'Sullivan GC, Collins JK, Shanahan F. Neurokinin-1 receptor expression in inflammatory bowel disease: molecular quantitation and localisation. Gut 47: 387-396 (2000). *
Goodgame RW, Kimball K, Akram S, Ike E, Ou CN, Sutton F, Graham D. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn's disease. Aliment. Pharmacol. Ther. 15: 1861-1866 (2001). *
Goodhand J, Dawson R, Hefferon M, Tshuma N, Swanson G, Wahed M, Croft NM, Lindsay JO. Inflammatory bowel disease in young people: the case for transitional clinics. Inflamm. Bowel Dis. Oct 15 [Epub ahead of print] (2009).
Goossens D, Jonkers D, Stobberingh E, van den Bogaard A, Russel M, Stockbrugger R. Probiotics in gastroenterology: indications and future perspectives. Scand. J. Gastroenterol. Suppl. 239: 15-23 (2003). *
Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ. Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J. Clin. Microbiol. 44: 4136-4141 (2006). *
Gorard DA, Hunt JB, Payne-James JJ, Palmer KR, Rees RG, Clark ML, Farthing MJ, Misiewicz JJ, Silk DB. Initial response and subsequent course of Crohn's disease treated with elemental diet or prednisolone. Gut 34: 1198-1202 (1993). *
Gordon CM. Bone loss in children with Crohn disease: evidence of "osteoimmune" alterations. J. Pediatr. 148: 429-432 (2006). *
Gordon CM. Boning up: exploring bone structure and strength in children with Crohn's disease. Gastroenterology 136: 35-39 (2009). *
Gordon FH, Lai CW, Hamilton MI, Allison MC, Srivastava ED, Fouweather MG, Donoghue S, Greenlees C, Subhani J, Amlot PL, Pounder RE. A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 121: 268-274 (2001). *
Gordon JN, Macdonald TT. Osteopontin: a new addition to the constellation of cytokines which drive T helper cell type 1 responses in Crohn's disease. Gut 54: 1213-1215 (2005). *
Gordon JN, MacDonald TT. Biological therapy in Crohn's disease. Hosp. Med. 64: 708-712 (2003).
Gordon JN, Pickard KM, Di Sabatino A, Prothero JD, Pender SL, Goggin PM, Macdonald TT. Matrix metalloproteinase-3 production by gut IgG plasma cells in chronic inflammatory bowel disease. Inflamm. Bowel Dis. 14: 195-203 (2008). *
Gordon JN, Sabatino AD, Macdonald TT. The pathophysiologic rationale for biological therapies in inflammatory bowel disease. Curr. Opin. Gastroenterol. 21: 431-437 (2005).
Gorecki W, Krysta M, Bysiek A, Wojciechowski P, Wyrobek L. Gastrografin challenge test for the management of subileus in children. Przegl. Lek. 64 Suppl. 3: 53-55 (2007).
Goritsas C, Papadopoulos N, Trigidou R, Tzathas H. Primary sclerosing cholangitis lesions in a patient with Crohn's disease and HCV infection. J. Gastrointestin. Liver Dis. 16: 222-223 (2007). *
Gosk-Bierska I, McBane RD, Waszczuk E, Paradowski L, Wysokinski WE. Prevalence of lower extremity venous disease in inflammatory bowel disease. Int. Angiol. 26: 67-71 (2007).
Gosselink MP, Schouten WR, Van Lieshout LM, Hop WC, Laman JD, Ruseler-Van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain Lactobacillus rhamnosus GG. Dis. Colon Rectum 47: 876-884 (2004). *
Gotteland M, Saenz R, Lopez M, Altshiller H, Llorens P, Brunser O. Interleukin-6 and interferon-gamma release from blood mononuclear cells and colonic mucosa from patients with ulcerative colitis. Rev. Med. Chil. 126: 1043-1048 (1998).
Goupille P. What are the risks of not intensively treating a chronic inflammatory disease? Ann. Dermatol. Venereol. 135 Suppl. 5: S290-S294 (2008).
Gourtsoyianni S, Papanikolaou N, Amanakis E, Bourikas L, Roussomoustakaki M, Grammatikakis J, Gourtsoyiannis N. Crohn's disease lymphadenopathy: MR imaging findings. Eur. J. Radiol. 69: 425-428 (2009).
Gourtsoyiannis N, Papanikolaou N, Grammatikakis J, Papamastorakis G, Prassopoulos P, Roussomoustakaki M. Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur. Radiol. 14: 1017-1024 (2004). *
Gourtsoyiannis NC, Grammatikakis J, Papamastorakis G, Koutroumbakis J, Prassopoulos P, Rousomoustakaki M, Papanikolaou N. Imaging of small intestinal Crohn's disease: comparison between MR enteroclysis and conventional enteroclysis. Eur. Radiol. 16: 1915-1925 (2006). *
Gourtsoyiannis NC, Papanikolaou N. Magnetic resonance enteroclysis. Semin. Ultrasound CT MR 26: 237-246 (2005).
Gourtsoyiannis NC, Papanikolaou N, Karantanas A. Magnetic resonance imaging evaluation of small intestinal Crohn's disease. Best Pract. Res. Clin. Gastroenterol. 20: 137-156 (2006).
Gower-Rousseau C, Salomez JL, Dupas JL, Marti R, Nuttens MC, Votte A, Lemahieu M, Lemaire B, Colombel JF, Cortot A. Incidence of inflammatory bowel disease in northern France (1988-1990). Gut 35: 1433-1438 (1994). *
Goyal A, Mansel RE, Young HL, Douglas-Jones A. Metastatic cutaneous Crohn's disease of the nipple: report of a case. Dis. Colon Rectum 49: 132-134 (2006). *
Goyal A, Srivastava A. Gallstone ileus following endoscopic retrograde cholangiopancreatography and sphincterotomy: a case report. J. Med. Case Reports 2: 342 (2008). *
Goyer P, Alves A, Bretagnol F, Bouhnik Y, Valleur P, Panis Y. Impact of complex Crohn's disease on the outcome of laparoscopic ileocecal resection: a comparative clinical study in 124 patients. Dis. Colon Rectum 52: 205-210 (2009).
Goyette P, Labbe C, Trinh TT, Xavier RJ, Rioux JD. Molecular pathogenesis of inflammatory bowel disease: genotypes, phenotypes and personalized medicine. Ann. Med. 39: 177-199 (2007).
Goyette P, Lefebvre C, Ng A, Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Latiano A, Aumais G, Deslandres C, Jobin G, Annese V, Daly MJ, Xavier RJ, Rioux JD. Gene-centric association mapping of chromosome 3p implicates MST1 in IBD pathogenesis. Mucosal Immunol. 1: 131-138 (2008). *
Grabig A, Veltzke-Schlieker W, Sturm A. Acute pancreatitis and duodenobiliary fistula - a rare complication of Crohn's disease. Dtsch. Med. Wochenschr. 132: 1264-1267 (2007).
Gradel KO, Nielsen HL, Schonheyder HC, Ejlertsen T, Kristensen B, Nielsen H. Increased short and long term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology 137: 495-501 (2009). *
Graff LA, Walker JR, Clara I, Lix L, Miller N, Rogala L, Rawsthorne P, Bernstein CN. Stress coping, distress, and health perceptions in inflammatory bowel disease and community controls. Am. J. Gastroenterol. 104: 2959-2969 (2009). *
Graff LA, Walker JR, Lix L, Clara I, Rawsthorne P, Rogala L, Miller N, Jakul L, McPhail C, Ediger J, Bernstein CN. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin. Gastroenterol. Hepatol. 4: 1491-1501.e1 (2006).
Graham DB, Jager DL, Borum ML. Metastatic Crohn's disease of the face. Dig. Dis. Sci. 51: 2062-2063 (2006). *
Graham DB, Tishon JR, Borum ML. An evaluation of vaginal symptoms in women with Crohn's disease. Dig. Dis. Sci. 53: 765-766 (2008). *
Graham DY, Markesich DC, Yoshimura HH. Mycobacteria and inflammatory bowel disease. Results of culture. Gastroenterology 92: 436-442 (1987).
Graham MF, Diegelmann RF, Elson CO, Lindblad WJ, Gotschalk N, Gay S, Gay R. Collagen content and types in the intestinal strictures of Crohn's disease. Gastroenterology 94: 257-265 (1988).
Grahnquist L, Chapman SC, Hvidsten S, Murphy MS. Evaluation of 99mTc-HMPAO leukocyte scintigraphy in the investigation of pediatric inflammatory bowel disease. J. Pediatr. 143: 48-53 (2003). *
Grainge MJ, West J, Card TR. Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet Feb 8 [Epub ahead of print] (2010). *
Gramlich T, Petras RE. Pathology of inflammatory bowel disease. Semin. Pediatr. Surg. 16: 154-163 (2007).
Gran JT, Husby G. Joint manifestations in gastrointestinal diseases. 1. Pathophysiological aspects, ulcerative colitis and Crohn's disease. Dig. Dis. 10: 274-294 (1992).
Grand RJ. Section editor's commentary. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease. Inflamm. Bowel Dis. 7: 345-346 (2001). *
Grandbois L, Lomasney LM, Demos TC, Tehrani R. Radiologic case study. Seronegative spondyloarthropathy associated with Crohn's disease. Orthopedics 28: 1296, 1375-1379 (2005).
Granito A, Muratori L, Muratori P, Guidi M, Lenzi M, Bianchi FB, Volta U. Anti-Saccharomyces cerevisiae antibodies (ASCA) in coeliac disease. Gut 55: 296 (2006). *
Granito A, Zauli D, Muratori P, Muratori L, Grassi A, Bortolotti R, Petrolini N, Veronesi L, Gionchetti P, Bianchi FB, Volta U. Anti-Saccharomyces cerevisiae and perinuclear anti-neutrophil cytoplasmic antibodies in coeliac disease before and after gluten-free diet. Aliment. Pharmacol. Ther. 21: 881-887 (2005). *
Grant SF, Baldassano RN, Hakonarson H. Classification of genetic profiles of Crohn's disease: a focus on the ATG16L1 gene. Expert Rev. Mol. Diagn. 8: 199-207 (2008).
Granzotto M, Fabbro E, Maschio M, Martelossi S, Quaglia S, Tommasini A, Presani G, Ventura A. Heterozygous nucleotide-binding oligomerization domain-2 mutations affect monocyte maturation in Crohn's disease. World J. Gastroenterol. 13: 6191-6196 (2007). *
Grassia R, Bodini P, Dizioli P, Staiano T, Iiritano E, Bianchi G, Buffoli F. Neuroendocrine carcinomas arising in ulcerative colitis: coincidences or possible correlations? World J. Gastroenterol. 15: 4193-4195 (2009). *
Grassia R, Staiano T, Buffoli F, Paolo B. Severe esophageal Crohn's disease: healing of lesions after 1 week therapy with infliximab. Journal of Crohn's and Colitis 3: 138-139 (2009).
Grassl GA, Valdez Y, Bergstrom KS, Vallance BA, Finlay BB. Chronic enteric Salmonella infection in mice leads to severe and persistent intestinal fibrosis. Gastroenterology 134: 768-780.e2 (2008). *
Gravallese EM, Kantrowitz FG. Arthritic manifestations of inflammatory bowel disease. Am. J. Gastroenterol. 83: 703-709 (1988).
Grave B, McCullough M, Wiesenfeld D. Orofacial granulomatosis - a 20-year review. Oral Dis. 15: 46-51 (2009).
Gray BK, Lockhartmummery HE, Morson BC. Crohn's disease of the anal region. Gut 6: 515-524 (1965). *
Greaves ML, Pochapin M. Asymptomatic ileitis: past, present, and future. J. Clin. Gastroenterol. 40: 281-285 (2006).
Greaves WO, Wang LJ. Malakoplakia of the spleen: a case report. Int. J. Surg. Pathol. May 28 [Epub ahead of print] (2008).
Green C, Elliott L, Beaudoin C, Bernstein CN. A population-based ecologic study of inflammatory bowel disease: searching for etiologic clues. Am. J. Epidemiol. 164: 615-623 (2006). *
Green CJ, Mountford V, Hamilton H, Kettlewell MG, Travis SP. A 15-year audit of home parenteral nutrition provision at the John Radcliffe Hospital, Oxford. QJM 101: 365-369 (2008).
Green FH, Fox H. The distribution of mucosal antibodies in the bowel of patients with Crohn's disease. Gut 16: 125-131 (1975). *
Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm. Bowel Dis. 10: 318-320 (2004). *
Greenberg GR. Infliximab as first-line therapy for Crohn's disease is premature. Inflamm. Bowel Dis. 8: 60-62 (2002). *
Greenberg GR, Feagan BG, Martin F, Sutherland LR, Thomson AB, Williams CN, Nilsson LG, Persson T. Oral budesonide as maintenance treatment for Crohn's disease: a placebo-controlled, dose-ranging study. Canadian Inflammatory Bowel Disease Study Group. Gastroenterology 110: 45-51 (1996). *
Greenbloom SL, Steinhart AH, Greenberg GR. Combination ciprofloxacin and metronidazole for active Crohn's disease. Can. J. Gastroenterol. 12: 53-56 (1998). *
Greenlee J. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications. Int. M.S. J. 13: 100-107 (2006). *
Greenson JK. Dysplasia in inflammatory bowel disease. Semin. Diagn. Pathol. 19: 31-37 (2002).
Greenson JK, Huang SC, Herron C, Moreno V, Bonner JD, Tomsho LP, Ben-Izhak O, Cohen HI, Trougouboff P, Bejhar J, Sova Y, Pinchev M, Rennert G, Gruber SB. Pathologic predictors of microsatellite instability in colorectal cancer. Am. J. Surg. Pathol. 33: 126-133 (2009).
Greenstein AJ, Janowitz HD, Sachar DB. The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients. Medicine (Baltimore) 55: 401-412 (1976).
Greenstein AJ, Lachman P, Sachar DB, Springhorn J, Heimann T, Janowitz HD, Aufses AH Jr. Perforating and non-perforating indications for repeated operations in Crohn's disease: evidence for two clinical forms. Gut 29: 588-592 (1988). *
Greenstein AJ, Zhang LP, Miller AT, Yung E, Branco BC, Sachar DB, Greenstein AJ. Relationship of the number of Crohn's strictures and strictureplasties to postoperative recurrence. J. Am. Coll. Surg. 208: 1065-1070 (2009). *
Greenstein RJ. Is Crohn's disease caused by a Mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect. Dis. 3: 507-514 (2003).
Greenstein RJ, Greenstein AJ. Is there clinical, epidemiological and molecular evidence for two forms of Crohn's disease? Mol. Med. Today. 1: 343-348 (1995).
Greenwood M, Meechan JG. General medicine and surgery for dental practitioners. Part 3: gastrointestinal system. Br. Dent. J. 194: 659-663 (2003).
Grehan M, Danon S, Lee A, Daskalopoulos G, Mitchell H. Absence of mucosa-associated colonic Helicobacters in an Australian urban population. J. Clin. Microbiol. 42: 874-876 (2004). *
Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J. Leukoc. Biol. 83: 493-498 (2008). *
Grieshaber MC, Mozaffarieh M, Flammer J. What is the link between vascular dysregulation and glaucoma? Surv. Ophthalmol. 52: S144-S154 (2007).
Griffin IJ, Kim SC, Hicks PD, Liang LK, Abrams SA. Zinc metabolism in adolescents with Crohn's disease. Pediatr. Res. 56: 235-239 (2004). *
Griffiths AM. Use of 6-mercapturine/azathioprine as the immunomodulator of choice for moderately active Crohn's disease: con. Inflamm. Bowel Dis. 11: 200-202 (2005). *
Griffiths AM. Enteral nutrition in the management of Crohn's disease. JPEN J. Parenter. Enteral Nutr. 29: S108-S117 (2005). *
Griffiths AM. Enteral feeding in inflammatory bowel disease. Curr. Opin. Clin. Nutr. Metab. Care 9: 314-318 (2006).
Griffiths AM. Anti-TNF therapies have eliminated the need for steroids in pediatric Crohn's disease: con. Why use a drug with an unknown long-term safety profile if more established therapies will be effective? Inflamm. Bowel Dis. 7: 342-344 (2001). *
Griffiths AM. Growth retardation in early-onset inflammatory bowel disease: should we monitor and treat these patients differently? Dig. Dis. 27: 404-411 (2009).
Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract. Res. Clin. Gastroenterol. 18: 509-523 (2004).
Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn's disease. Gut 34: 939-943 (1993). *
Griffiths AM, Otley AR, Hyams J, Quiros AR, Grand RJ, Bousvaros A, Feagan BG, Ferry GR. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm. Bowel Dis. 11: 185-196 (2005). *
Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, Doria A. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. Clin. Exp. Rheumatol. 24: S72-S78 (2006).
Griga T, Klein W, Epplen JT, Hebler U, Stachon A, May B. CD14 expression on monocytes and soluble CD14 plasma levels in correlation to the promotor polymorphism of the endotoxin receptor CD14 gene in patients with inactive Crohn's disease. Hepatogastroenterology 52: 808-811 (2005).
Griga T, May B, Pfisterer O, Muller KM, Brasch F. Immunohistochemical localization of vascular endothelial growth factor in colonic mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 49: 116-123 (2002).
Griga T, Tromm A, Muller KM, May B. Overlap syndrome between autoimmune hepatitis and primary sclerosing cholangitis in two cases. Eur. J. Gastroenterol. Hepatol. 12: 559-564 (2000).
Griga T, Tromm A, Spranger J, May B. Increased serum levels of vascular endothelial growth factor in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 33: 504-508 (1998). *
Griga T, Voigt E, Gretzer B, Brasch F, May B. Increased production of vascular endothelial growth factor by intestinal mucosa of patients with inflammatory bowel disease. Hepatogastroenterology 46: 920-923 (1999).
Griga T, Werner S, Koller M, Tromm A, May B. Vascular endothelial growth factor (VEGF) in Crohn's disease: increased production by peripheral blood mononuclear cells and decreased VEGF165 labeling of peripheral CD14+ monocytes. Dig. Dis. Sci. 44: 1196-1201 (1999). *
Griga T, Wilkens C, Schmiegel W, Folwaczny C, Hagedorn M, Duerig N, Epplen J, Klein W. Association between the promoter polymorphism T/C at position -159 of the CD14 gene and anti-inflammatory therapy in patients with inflammatory bowel disease. Eur. J. Med. Res. 10: 183-186 (2005).
Griga T, Wilkens C, Wirkus N, Epplen J, Schmiegel W, Klein W. A polymorphism in the macrophage migration inhibitory factor gene is involved in the genetic predisposition of Crohn's disease and associated with cumulative steroid doses. Hepatogastroenterology 54: 784-786 (2007).
Griggs L, Schwartz DA. Medical options for treating perianal Crohn's disease. Dig. Liver Dis. 39: 979-987 (2007).
Griggs LR, Schwartz DA. Successful paternity of a healthy child while taking methotrexate for Crohn's disease. Am. J. Gastroenterol. 101: 2893-2894 (2006). *
Grigor'eva GA, Meshalkina Niu. Algorithm of diagnosis and treatment of complicated forms of nonspecific ulcerative colitis and Crohn's disease. Ter. Arkh. 77: 48-55 (2005).
Grimaldi C. Methotrexate: the best choice for second-line maintenance treatment in active Crohn's disease? Gastroenterol. Clin. Biol. 33: 21-22 (2009).
Grimaud JC, Bourliere M. Contraception and hepatogastroenterology. Fertil. Contracept. Sex 17: 407-413 (1989).
Grimble RF. Immunonutrition. Curr. Opin. Gastroenterol. 21: 216-222 (2005).
Grimes DS. Mycobacterium avium subspecies paratuberculosis as a cause of Crohn's disease. Gut 52: 155 (2003). *
Grimm MC, Pavli P. NOD2 mutations and Crohn’s disease: are Paneth cells and their antimicrobial peptides the link? Gut 53: 1558-1560 (2004). *
Grimm MC, Pavli P, Van de Pol E, Doe WF. Evidence for a CD14+ population of monocytes in inflammatory bowel disease mucosa - implications for pathogenesis. Clin. Exp. Immunol. 100: 291-297 (1995). *
Grimm MC, Pullman WE, Bennett GM, Sullivan PJ, Pavli P, Doe WF. Direct evidence of monocyte recruitment to inflammatory bowel disease mucosa. J. Gastroenterol. Hepatol. 10: 387-395 (1995).
Grip O, Bredberg A, Lindgren S, Henriksson G. Increased subpopulations of CD16(+) and CD56(+) blood monocytes in patients with active Crohn's disease. Inflamm. Bowel Dis. 13: 566-572 (2007). *
Grip O, Janciauskiene S. Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease. PLoS ONE 4: e5263 (2009). *
Grip O, Janciauskiene S, Bredberg A. Use of atorvastatin as an anti-inflammatory treatment in Crohn's disease. Br. J. Pharmacol. 155: 1085-1092 (2008). *
Grip O, Janciauskiene S, Lindgren S. Circulating monocytes and plasma inflammatory biomarkers in active Crohn's disease: elevated oxidized low-density lipoprotein and the anti-inflammatory effect of atorvastatin. Inflamm. Bowel Dis. 10: 193-200 (2004). *
Grip O, Janciauskiene S, Lindgren S. Macrophages in inflammatory bowel disease. Curr. Drug Targets Inflamm. Allergy 2: 155-160 (2003).
Grivceva Stardelova K, Misevska P, Zdravkovska M, Trajkov D, Serafimoski V. Total parenteral nutrition in treatment of patients with inflammatory bowel disease. Prilozi. 29: 21-43 (2008).
Groenendaal H, Zagmutt FJ. Scenario analysis of changes in consumption of dairy products caused by a hypothetical causal link between Mycobacterium avium subspecies paratuberculosis and Crohn's disease. J. Dairy Sci. 91: 3245-3258 (2008).
Gronbaek H, Vestergaard EM, Hey H, Nielsen JN, Nexo E. Serum trefoil factors in patients with inflammatory bowel disease. Digestion 74: 33-39 (2006). *
Gronhagen-Riska C, Fyhrquist F, Hortling L, Koskimies S. Familial occurrence of sarcoidosis and Crohn's disease. Lancet 1: 1287-1288 (1983).
Grool TA, Kuipers EJ. Inflammatory bowel disease in three elderly patients; an unexpected diagnosis in long-standing abdominal complaints. Ned. Tijdschr. Geneeskd. 148: 1849-1852 (2004).
Grootenhuis MA, Maurice-Stam H, Derkx BH, Last BF. Evaluation of a psychoeducational intervention for adolescents with inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 21: 430-435 (2009).
Grose RH, Thompson FM, Baxter AG, Pellicci DG, Cummins AG. Deficiency of invariant NK T cells in Crohn's disease and ulcerative colitis. Dig. Dis. Sci. 52: 1415-1422 (2007). *
Groselj D, Grabec I, Seme K, Ihan A, Ferkolj I. Prediction of clinical response to anti-TNF treatment by oral parameters in Crohn's disease. Hepatogastroenterology 55: 112-119 (2008).
Grosjean OV. The resistible growth of health care costs. Acta Chir. Belg. 108: 4-14 (2008).
Gross K, Karagiannides I, Thomou T, Koon HW, Bowe C, Kim H, Giorgadze N, Tchkonia T, Pirtskhalava T, Kirkland JL, Pothoulakis C. Substance P promotes expansion of human mesenteric preadipocytes through proliferative and anti-apoptotic pathways. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G1012-G1019 (2009). *
Gross KJ, Pothoulakis C. Role of neuropeptides in inflammatory bowel disease. Inflamm. Bowel Dis. 13: 918-932 (2007). *
Gross V. Oral pH-modified release budesonide for treatment of inflammatory bowel disease, collagenous and lymphocytic colitis. Expert Opin. Pharmacother. 9: 1257-1265 (2008).
Gross V, Andus T, Leser HG, Roth M, Scholmerich J. Inflammatory mediators in chronic inflammatory bowel diseases. Klin. Wochenschr. 69: 981-987 (1991).
Grossman AB, Baldassano RN. Specific considerations in the treatment of pediatric inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol. 2: 105-124 (2008).
Grossman AB, Mamula P. What is the optimal management approach for pediatric patients with severe ulcerative colitis? Nat. Clin. Pract. Gastroenterol. Hepatol. 5: 542-543 (2008).
Grossman CJ, Hydo LJ, Wang JC, Pochapin M, Barie PS. Devastating presentations of regional enteritis (Crohn's disease): two reports of survival following severe multiple organ dysfunction syndrome. Surg. Infect. (Larchmt.) 5: 301-307 (2004).
Grottrup-Wolfers E, Moeller J, Karbach U, Muller-Lissner S, Endres S. Elevated cell-associated levels of interleukin 1beta and interleukin 6 in inflamed mucosa of inflammatory bowel disease. Eur. J. Clin. Invest. 26: 115-122 (1996).
Grucela A, Steinhagen RM. Current surgical management of ulcerative colitis. Mt. Sinai J. Med. 76: 606-612 (2009). *
Grucela AL, Bauer JJ, Gorfine SR, Chessin DB. Outcome and long-term function of restorative proctocolectomy for Crohn's disease: comparison to patients with ulcerative colitis. Colorectal Dis. Dec 14 [Epub ahead of print] (2009). *
Grucela AL, Patel P, Goldstein E, Palmon R, Sachar DB, Steinhagen RM. Granulomatous enterocolitis associated with Hermansky-Pudlak syndrome. Am. J. Gastroenterol. 101: 2090-2095 (2006). *
Grundemann D, Harlfinger S, Golz S, Geerts A, Lazar A, Berkels R, Jung N, Rubbert A, Schomig E. Discovery of the ergothioneine transporter. Proc. Natl. Acad. Sci. U.S.A. 102: 5256-5261 (2005). *
Grundmann S, Hoefer IE, Ulusans S, van Royen N, Schirmer SH, Ozaki CK, Bode C, Piek JJ, Buschmann IR. Anti-tumor necrosis factor-alpha therapies attenuate adaptive arteriogenesis in the rabbit. Am. J. Physiol. Heart Circ. Physiol. 289: H1497-H1505 (2005). *
Grungreiff K, Abicht K, Kluge M, Presser HJ, Franke D, Kleine FD, Klauck S, Diete U. Clinical studies on zinc in chronic liver diseases. Z. Gastroenterol. 26: 409-415 (1988).
Gryboski JD. Ulcerative colitis in children 10 years old or younger. J. Pediatr. Gastroenterol. Nutr. 17: 24-31 (1993).
Gryboski JD. Crohn's disease in children 10 years old and younger: comparison with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 18: 174-182 (1994).
Gu Q, Ouyang Q, Zhang WY, Li GD. A comparison of clinical and pathologic characteristics between Crohn's disease and intestinal tuberculosis. Zhonghua Nei Ke Za Zhi 48: 291-294 (2009).
Guagnozzi D, Caprilli R. Natalizumab in the treatment of Crohn's disease. Biologics 2: 275-284 (2008). *
Guagnozzi D, Cossu A, Viscido A, Corleto V, Annese V, Latiano A, Delle Fave G, Caprilli R. Acute intestinal obstruction and NOD2/CARD15 mutations among Italian Crohn's disease patients. Eur. Rev. Med. Pharmacol. Sci. 8: 179-185 (2004).
Guan Q, Ma Y, Hillman CL, Ma A, Zhou G, Qing G, Peng Z. Development of recombinant vaccines against IL-12/IL-23 p40 and in vivo evaluation of their effects in the downregulation of intestinal inflammation in murine colitis. Vaccine 27: 7096-7104 (2009). *
Guandalini S. Probiotics for children: use in diarrhea. J. Clin. Gastroenterol. 40: 244-248 (2006).
Guandalini S. Use of Lactobacillus-GG in paediatric Crohn's disease. Dig. Liver Dis. 34 Suppl. 2: S63-S65 (2002).
Guarner F. Inulin and oligofructose: impact on intestinal diseases and disorders. Br. J. Nutr. 93 Suppl. 1: S61-S65 (2005).
Guarner F. Prebiotics in inflammatory bowel diseases. Br. J. Nutr. 98 Suppl. 1: S85-S89 (2007). *
Guarner F. Prebiotics, probiotics and helminths: the 'natural' solution? Dig. Dis. 27: 412-417 (2009).
Guassora AD, Kruuse C, Thomsen OO, Binder V. Quality of life study in a regional group of patients with Crohn disease. A structured interview study. Scand. J. Gastroenterol. 35: 1068-1074 (2000). *
Guenther L, Gulliver W. Psoriasis comorbidities. J. Cutan. Med. Surg. 13 Suppl. 2: S77-S87 (2009).
Guerre-Schmidt AR, Pelletier F, Carbonnel F, Humbert P, Aubin F. Dermatosis-arthritis syndrome associated with Crohn's disease in a teenager. Rev. Med. Interne. 27: 874-877 (2006).
Guerreiro CS, Ferreira P, Tavares L, Santos PM, Neves M, Brito M, Cravo M. Fatty acids, IL6, and TNFalpha polymorphisms: an example of nutrigenetics in Crohn's disease. Am. J. Gastroenterol. 104: 2241-2249 (2009). *
Guessous I, Juillerat P, Pittet V, Froehlich F, Burnand B, Mottet C, Felley C, Michetti P, Vader JP. Evaluating appropriateness of treatment for Crohn's disease: feasibility of an explicit approach. Digestion 75: 46-52 (2007). *
Guex-Crosier Y, Zografos L. New therapies in ophthalmology: inhibitors of TNF-alpha. Rev. Med. Suisse. 1: 140-141 (2005).
Gui GP, Thomas PR, Tizard ML, Lake J, Sanderson JD, Hermon-Taylor J. Two-year-outcomes analysis of Crohn's disease treated with rifabutin and macrolide antibiotics. J. Antimicrob. Chemother. 39: 393-400 (1997). *
Guidat A, Fleyfel M, Vallet B, Desreumaux P, Levron JC, Gambiez L, Colombel JF, Scherpereel P. Inflammation increases sufentanil requirements during surgery for inflammatory bowel diseases. Eur. J. Anaesthesiol. 20: 957-962 (2003).
Guidi L, Costanzo M, Ciarniello M, De Vitis I, Pioli C, Gatta L, Pace L, Tricerri A, Bartoloni C, Coppola L, Balistreri P, Doria G, Fedeli G, Gasbarrini GB. Increased levels of NF-kB inhibitors (IeBalpha and IeBgamma) in the intestinal mucosa of Crohn's disease patients during infliximab treatment. Int. J. Immunopathol. Pharmacol. 18: 155-164 (2005).
Guidi L, De Franco A, De Vitis I, Armuzzi A, Semeraro S, Roberto I, Papa A, Bock E, Gasbarrini G, Fedeli G. Contrast-enhanced ultrasonography with SonoVue after infliximab therapy in Crohn's disease. Eur. Rev. Med. Pharmacol. Sci. 10: 23-26 (2006).
Guidi L, Minordi LM, Semeraro S, De Vitis I, Roberto I, Ennas S, Guglielmo S, Di Candia L, Papa A, Urgesi R, Grillo A, Brizi MG, Vecchioli A, Fedeli G. Clinical correlations of small bowel CT and contrast radiology findings in Crohn's disease. Eur. Rev. Med. Pharmacol. Sci. 8: 215-217 (2004).
Guidi L, Mocci G, Marzo M, Rutella S. Treatment of Crohn's disease with colony-stimulating factors: an overview. Ther. Clin. Risk Manag. 4: 927-934 (2008). *
Guidi L, Ratto C, Semeraro S, Roberto I, De Vitis I, Papa A, Marzo M, Parello A, Foglietto G, Doglietto GB, Gasbarrini GB, Fedeli G. Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: a single-centre experience. Tech. Coloproctol. 12: 111-117 (2008). *
Guilford WJ, Parkinson JF. Second-generation beta-oxidation resistant 3-oxa-lipoxin A(4) analogs. Prostaglandins Leukot. Essent. Fatty Acids 73: 245-250 (2005). *
Guilhon de Araujo Sant'anna AM, Dubois J, Miron MC, Seidman EG. Wireless capsule endoscopy for obscure small-bowel disorders: final results of the first pediatric controlled trial. Clin. Gastroenterol. Hepatol. 3: 264-270 (2005). *
Guimaraes LS, Fidler JL, Fletcher JG, Bruining DH, Huprich JE, Siddiki H, Sandborn WJ, Loftus EV Jr, Pardi DS, McCollough CH. Assessment of appropriateness of indications for CT enterography in younger patients. Inflamm. Bowel Dis. 16: 226-232 (2010).
Guimbaud R, Bertrand V, Chauvelot-Moachon L, Quartier G, Vidon N, Giroud JP, Couturier D, Chaussade S. Network of inflammatory cytokines and correlation with disease activity in ulcerative colitis. Am. J. Gastroenterol. 93: 2397-2404 (1998). *
Guindi M, Riddell RH. Indeterminate colitis. J. Clin. Pathol. 57: 1233-1244 (2004). *
Gulec B, Yasar M, Yildiz S, Oter S, Akay C, Deveci S, Sen D. Effect of hyperbaric oxygen on experimental acute distal colitis. Physiol. Res. 53: 493-500 (2004). *
Gullberg E, Soderholm JD. Peyer's patches and M cells as potential sites of the inflammatory onset in Crohn's disease. Ann. N. Y. Acad. Sci. 1072: 218-232 (2006). *
Gulwani-Akolkar B, Akolkar PN, Lin XY, Heresbach D, Manji R, Katz S, Yang SY, Silver J. HLA class II alleles associated with susceptibility and resistance to Crohn's disease in the Jewish population. Inflamm. Bowel Dis. 6: 71-76 (2000). *
Gumber S, Taylor DL, Marsh IB, Whittington RJ. Growth pattern and partial proteome of Mycobacterium avium subsp. paratuberculosis during the stress response to hypoxia and nutrient starvation. Vet. Microbiol. 133: 344-357 (2009). *
Gumber S, Whittington RJ. Analysis of the growth pattern, survival and proteome of Mycobacterium avium subsp. paratuberculosis following exposure to heat. Vet. Microbiol. 136: 82-90 (2009). *
Gunesh S, Thomas GA, Williams GT, Roberts A, Hawthorne AB. The incidence of Crohn's disease in Cardiff over the last 75 years: an update for 1996-2005. Aliment. Pharmacol. Ther. 27: 211-219 (2008). *
Gunthert AR, Hinney B, Nesselhut K, Hanf V, Emons G. Vulvitis granulomatosa and unilateral hypertrophy of the vulva related to Crohn's disease: a case report. Am. J. Obstet. Gynecol. 191: 1719-1720 (2004).
Guo QS, Xia B, Jiang Y, Qu Y, Li J. NOD2 3020insC frameshift mutation is not associated with inflammatory bowel disease in Chinese patients of Han nationality. World J. Gastroenterol. 10: 1069-1071 (2004). *
Gupta A, Derbes C, Sellin J. Clinical indications of the use of antineutrophil cytoplasmic antibodies and anti-Saccharomyces cerevisiae antibodies in the evaluation of inflammatory bowel disease at an academic medical center. Inflamm. Bowel Dis. 11: 898-902 (2005). *
Gupta A, Paski S, Issenman R, Webber C. Lumbar spine bone mineral density at diagnosis and during follow-up in children with IBD. J. Clin. Densitom. 7: 290-295 (2004).
Gupta A, Street AC, Macrae FA. Tumour necrosis factor alpha inhibitors: screening for tuberculosis infection in inflammatory bowel disease. Med. J. Aust. 188: 168-170 (2008).
Gupta AK, Skinner AR. A review of the use of infliximab to manage cutaneous dermatoses. J. Cutan. Med. Surg. 8: 77-89 (2004). *
Gupta G, Gelfand JM, Lewis JD. Increased risk of demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129: 819-826 (2005). *
Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 4: 1483-1490 (2006).
Gupta N, Bostrom AG, Kirschner BS, Cohen SA, Abramson O, Ferry GD, Gold BD, Winter HS, Baldassano RN, Smith T, Heyman MB. Presentation and disease course in early- compared to later-onset pediatric Crohn's disease. Am. J. Gastroenterol. 103: 2092-2098 (2008). *
Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Gold BD, Cohen SA, Winter HS, Baldassano RN, Abramson O, Smith T, Heyman MB. Incidence of stricturing and penetrating complications of Crohn's disease diagnosed in pediatric patients. Inflamm. Bowel Dis. Sep 16 [Epub ahead of print] (2009). *
Gupta N, Bostrom AG, Kirschner BS, Ferry GD, Winter HS, Baldassano RN, Gold BD, Abramson O, Smith T, Cohen SA, Heyman MB. Gender differences in presentation and course of disease in pediatric patients with Crohn disease. Pediatrics 120: e1418-e1425 (2007). *
Gupta N, Cohen SA, Bostrom AG, Kirschner BS, Baldassano RN, Winter HS, Ferry GD, Smith T, Abramson O, Gold BD, Heyman MB. Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology 130: 1069-1077 (2006). *
Gupta N, Khera S, Vempati RP, Sharma R, Bijlani RL. Effect of yoga based lifestyle intervention on state and trait anxiety. Indian J. Physiol. Pharmacol. 50: 41-47 (2006).
Gupta SK, Fitzgerald JF, Croffie JM, Pfefferkorn MD, Molleston JP, Corkins MR. Comparison of serological markers of inflammatory bowel disease with clinical diagnosis in children. Inflamm. Bowel Dis. 10: 240-244 (2004). *
Gur C, Karussis D, Golden E, Doron S, Ilan Y, Safadi R. Amelioration of experimental colitis by Copaxone is associated with class-II-restricted CD4 immune blocking. Clin. Immunol. 118: 307-316 (2006). *
Gurbindo C, Sabbah S, Menezes J, Justinich C, Marchand R, Seidman EG. Interleukin-2 production in pediatric inflammatory bowel disease: evidence for dissimilar mononuclear cell function in Crohn's disease and ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 17: 247-254 (1993).
Gurudu S, Fiocchi C, Katz JA. Inflammatory bowel disease. Best Pract. Res. Clin. Gastroenterol. 16: 77-90 (2002).
Gurudu SR, Leighton JA. Assessment and validation of the new capsule endoscopy Crohn's disease activity index (CECDAI): what difference does it make? Inflamm. Bowel Dis. 15: 1607-1608 (2009).
Gurudu SR, Vargas HE, Leighton JA. New frontiers in small-bowel imaging: the expanding technology of capsule endoscopy and its impact in clinical gastroenterology. Rev. Gastroenterol. Disord. 8: 1-14 (2008).
Guslandi M. Antibiotics for inflammatory bowel disease: do they work? Eur. J. Gastroenterol. Hepatol. 17: 145-147 (2005).
Guslandi M. Probiotics in Crohn's disease. Gut 49: 873-874 (2001). *
Guslandi M. Probiotics for Crohn's disease: are they all alike? Inflamm. Bowel Dis. 13: 1314 (2007). *
Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur. J. Gastroenterol. Hepatol. 15: 697-698 (2003).
Guslandi M, Zhang L, Man SM, Day AS, Leach ST, Lemberg DA, Dutt S, Stormon M, Otley A, O'Loughlin EV, Magoffin A, Ng PH, Mitchell H. Campylobacter concisus: a new character in the Crohn's disease story? J. Clin. Microbiol. 47: 1614-1615 (2009). *
Gustofson RL, Kim N, Liu S, Stratton P. Endometriosis and the appendix: a case series and comprehensive review of the literature. Fertil. Steril. 86: 298-303 (2006). *
Gustot T, Lemmers A, Louis E, Nicaise C, Quertinmont E, Belaiche J, Roland S, Van Gossum A, Deviere J, Franchimont D. Profile of soluble cytokine receptors in Crohn's disease. Gut 54: 488-495 (2005). *
Gutierrez A, Frances R, Amoros A, Zapater P, Garmendia M, Ndongo M, Cano R, Jover R, Such J, Perez-Mateo M. Cytokine association with bacterial DNA in serum of patients with inflammatory bowel disease. Inflamm. Bowel Dis. 15: 508-514 (2009).
Gutierrez A, Lee H, Sands BE. Outcome of surgical versus percutaneous drainage of abdominal and pelvic abscesses in Crohn's disease. Am. J. Gastroenterol. 101: 2283-2289 (2006). *
Gutierrez LS. The role of thrombospondin 1 on intestinal inflammation and carcinogenesis. Biomark. Insights 2008: 171-178 (2008).
Gutierrez O, Pipaon C, Inohara N, Fontalba A, Ogura Y, Prosper F, Nunez G, Fernandez-Luna JL. Induction of Nod2 in myelomonocytic and intestinal epithelial cells via nuclear factor-kappa B activation. J. Biol. Chem. 277: 41701-41705 (2002). *
Gutkowski K, Bilkiewicz T. Experimental methods in the treatment of Lesniowski-Crohn disease. Pol. Merkuriusz. Lek. 20: 457-461 (2006).
Gutkowski K, Hartleb M. Inflammatory bowel diseases in pregnancy. Ginekol. Pol. 80: 379-382 (2009).
Guven K, Acunas B. Multidetector computed tomography angiography of the abdomen. Eur. J. Radiol. 52: 44-55 (2004).
Guyot A, Begon E, Abramowitz L, Landry J, Marinho E, Descamps V, Crickx B. A case of acute and necrotizing cutaneous Mycobacterium marinum infection in a patient treated with infliximab for Crohn's disease. Ann. Dermatol. Venereol. 136: 806-810 (2009).
Ha C, Magowan S, Accortt NA, Chen J, Stone CD. Risk of arterial thrombotic events in inflammatory bowel disease. Am. J. Gastroenterol. 104: 1445-1451 (2009).
Ha NR, Lee HL, Lee OY, Yoon BC, Choi HS, Hahm JS, Lee DH, Lee MH. A case of Crohn's disease presenting with free perforation and portal venous gas. Korean J. Gastroenterol. 50: 319-323 (2007).
Haag K, Scholmerich J. Prerequisites for therapy of inflammatory bowel diseases. Pathophysiology - symptomatology - diagnosis. Fortschr. Med. 109: 232-237 (1991).
Haapamaki J, Turunen U, Roine RP, Farkkila MA, Arkkila PE. Finnish patients with inflammatory bowel disease have fewer symptoms and are more satisfied with their treatment than patients in the previous European survey. Scand. J. Gastroenterol. 43: 821-830 (2008). *
Haapamaki J, Turunen U, Roine RP, Farkkila MA, Arkkila PE. Impact of demographic factors, medication and symptoms on disease-specific quality of life in inflammatory bowel disease. Qual. Life Res. 18: 961-969 (2009). *
Haapamaki MM, Gronroos J, Nurmi H, Irjala K, Peuravuori H, Nevalainen TJ. Value of blood tests including serum group IIA phospholipase A2 and bactericidal/permeability-increasing protein in Crohn's disease. Scand. J. Clin. Lab. Invest. 66: 585-594 (2006). *
Haas SL, Abbatista M, Brade J, Singer MV, Bocker U. Interleukin-18 serum levels in inflammatory bowel diseases: correlation with disease activity and inflammatory markers. Swiss Med. Wkly. 139: 140-145 (2009). *
Haas SL, Andreas Koch W, Schreiber S, Reinhard I, Koyama N, Singer MV, Bocker U. -137 (G/C) IL-18 promoter polymorphism in patients with inflammatory bowel disease. Scand. J. Gastroenterol. 40: 1438-1443 (2005). *
Haas SL, Ruether A, Singer MV, Schreiber S, Bocker U. Functional P2X(7) receptor polymorphisms (His155Tyr, Arg307Gln, Glu496Ala) in patients with Crohn's disease. Scand. J. Immunol. 65: 166-170 (2007). *
Habal FM, Hui G, Greenberg GR. Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. Gastroenterology 105: 1057-1060 (1993).
Habib Z, Arnaud B, Pascal de L, Caroline F, Yves A, Jean-Pierre C, Michel P, Jean-Pierre H, Dominique B. CARD15/NOD2 is not a predisposing factor for necrotizing enterocolitis. Dig. Dis. Sci. 50: 1684-1687 (2005). *
Habtezion A, Silverberg MS, Parkes R, Mikolainis S, Steinhart AH. Risk factors for low bone density in Crohn's disease. Inflamm. Bowel Dis. 8: 87-92 (2002). *
Hachisu Y, Okamura S, Tanaka H, Tanaka Y, Morita K, Kudo T, Iida T, Kawamura O, Kusano M, Mori M. Crohn's disease complicating psoas abscess treated by drainage and infliximab administration. Nippon Shokakibyo Gakkai Zasshi 106: 1364-1369 (2009).
Hacker UT, Bidlingmaier C, Gomolka M, Keller E, Eigler A, Hartmann G, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S. Inflammatory bowel disease: no association between allele combinations of the interleukin (IL) I beta and IL-I receptor antagonist gene polymorphisms. Eur. J. Clin. Invest. 28: 214-219 (1998).
Hacker UT, Gomolka M, Keller E, Eigler A, Folwaczny C, Fricke H, Albert E, Loeschke K, Endres S. Lack of association between an interleukin-1 receptor antagonist gene polymorphism and ulcerative colitis. Gut 40: 623-627 (1997). *
Hacsek G, Arato A, Savilahti E, Paszti I. Characteristics of HLA II antigen expression in the rectal mucosa of children suffering from ulcerative colitis and Crohn disease. Orv. Hetil. 136: 2279-2282 (1995).
Haderslev KV, Jeppesen PB, Sorensen HA, Mortensen PB, Staun M. Vitamin D status and measurements of markers of bone metabolism in patients with small intestinal resection. Gut 52: 653-658 (2003). *
Haderslev KV, Tjellesen L, Haderslev PH, Staun M. Assessment of the longitudinal changes in bone mineral density in patients receiving home parenteral nutrition. JPEN J. Parenter. Enteral Nutr. 28: 289-294 (2004). *
Hadithi M, Cazemier M, Meijer GA, Bloemena E, Felt-Bersma RJ, Mulder CJ, Meuwissen SG, Pena AS, van Bodegraven AA. Retrospective analysis of old-age colitis in the Dutch inflammatory bowel disease population. World J. Gastroenterol. 14: 3183-3187 (2008). *
Hadrich I, Vandewalle P, Cheikhrouhou F, Makni F, Krichen MS, Sendid B, Standaert-Vitse A, Ayadi A, Poulain D. Ethnic and socio-cultural specificities in Tunisia have no impact on the prevalence of anti-Saccharomyces cerevisiae antibodies in Crohn's disease patients, their relatives or associated clinical factors. Scand. J. Gastroenterol. 42: 717-725 (2007). *
Hadziselimovic F. Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 46: 208-211 (2008). *
Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 37: 260-263 (1995). *
Hafeez N, Mesleh G, Treitman A, Berkelhammer C. Sterile seroma after surgical drainage of purulent psoas abscess in Crohn's disease. Inflamm. Bowel Dis. Jul 1 [Epub ahead of print] (2009).
Hafer A, Kramer S, Duncker S, Kruger M, Manns MP, Bischoff SC. Effect of oral lactulose on clinical and immunohistochemical parameters in patients with inflammatory bowel disease: a pilot study. BMC Gastroenterol. 7: 36 (2007). *
Hafner C, Meyer S, Langmann T, Schmitz G, Bataille F, Hagen I, Becker B, Roesch A, Rogler G, Landthaler M, Vogt T. Ephrin-B2 is differentially expressed in the intestinal epithelium in Crohn's disease and contributes to accelerated epithelial wound healing in vitro. World J. Gastroenterol. 11: 4024-4031 (2005). *
Hafner S, Timmer A, Herfarth H, Rogler G, Scholmerich J, Schaffler A, Ehrenstein B, Jilg W, Ott C, Strauch UG, Obermeier F. The role of domestic hygiene in inflammatory bowel diseases: hepatitis A and worm infestations. Eur. J. Gastroenterol. Hepatol. 20: 561-566 (2008).
Hager E, Isenberg G, Gonsalves C, Moudgill N, Dong S, Dimuzio P. A new anatomic variant of the aorta: a case report. J. Vasc. Surg. 48: 213-215 (2008).
Hages M, Pietrzik K. Assessment of the folate supply in children with regard to cobalamin and iron maintenance. 3: Modification of the supply status by various diseases. Int. J. Vitam. Nutr. Res. 55: 287-294 (1985).
Haggett PJ, Moore NR, Shearman JD, Travis SP, Jewell DP, Mortensen NJ. Pelvic and perineal complications of Crohn's disease: assessment using magnetic resonance imaging. Gut 36: 407-410 (1995). *
Hagiu C, Badea R. Applicability of abdominal ultrasonography in inflammatory bowel diseases. J. Gastrointestin. Liver Dis. 16: 205-209 (2007). *
Hagymasi K, Molnar B, Tulassay Z. Stem cell transplantation in the treatment of gastrointestinal diseases. Orv. Hetil. 149: 1449-1455 (2008).
Hagymasi K, Tulassay Z. Inflammatory bowel disease and colorectal cancer. Orv. Hetil. 147: 1977-1982 (2006).
Hagymasi K, Tulassay Z. Genotype-phenotype associations in inflammatory bowel disease. Orv. Hetil. 146: 1767-1773 (2005).
Hahn HP, Hornick JL. Immunoreactivity for CD25 in gastrointestinal mucosal mast cells is specific for systemic mastocytosis. Am. J. Surg. Pathol. 31: 1669-1676 (2007).
Hahnloser D, Pemberton JH, Wolff BG, Larson DR, Crownhart BS, Dozois RR. Results at up to 20 years after ileal pouch-anal anastomosis for chronic ulcerative colitis. Br. J. Surg. 94: 333-340 (2007). *
Haider AS, Cardinale IR, Whynot JA, Krueger JG. Effects of etanercept are distinct from infliximab in modulating proinflammatory genes in activated human leukocytes. J. Investig. Dermatol. Symp. Proc. 12: 9-15 (2007). *
Haider D, Dhawahir-Scala FE, Strouthidis NG, Davies N. Acute panuveitis with hypopyon in Crohn's disease secondary to medical therapy; a case report. J. Med. Case Reports. 1: 42 (2007). *
Haile LA, Wasielewski RV, Gamrekelashvili J, Kruger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 135: 871-881.e5 (2008). *
Hait EJ, Barendse RM, Arnold JH, Valim C, Sands BE, Korzenik JR, Fishman LN. Transition of adolescents with inflammatory bowel disease from pediatric to adult care: a survey of adult gastroenterologists. J. Pediatr. Gastroenterol. Nutr. 48: 61-65 (2009). *
Hait EJ, Bousvaros A, Schuman M, Shamberger RC, Lillehei CW. Pouch outcomes among children with ulcerative colitis treated with calcineurin inhibitors before ileal pouch anal anastomosis surgery. J. Pediatr. Surg. 42: 31-34 (2007).
Hait L, Bousvaros A, Grand R. Pediatric inflammatory bowel disease: what children can teach adults. Inflamm. Bowel Dis. 11: 519-527 (2005). *
Halbwachs-Mecarelli L, Nusbaum P, Noel LH, Reumaux D, Erlinger S, Grunfeld JP, Lesavre P. Antineutrophil cytoplasmic antibodies (ANCA) directed against cathepsin G in ulcerative colitis, Crohn's disease and primary sclerosing cholangitis. Clin. Exp. Immunol. 90: 79-84 (1992). *
Hale S, Lightman S. Anti-TNF therapies in the management of acute and chronic uveitis. Cytokine 33: 231-237 (2006).
Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology 124: 1767-1773 (2003). *
Halfvarson J, Bresso F, D'Amato M, Jarnerot G, Pettersson S, Tysk C. CARD15/NOD2 polymorphisms do not explain concordance of Crohn's disease in Swedish monozygotic twins. Dig. Liver Dis. 37: 768-772 (2005).
Halfvarson J, Jess T, Bodin L, Jarnerot G, Munkholm P, Binder V, Tysk C. Longitudinal concordance for clinical characteristics in a Swedish-Danish twin population with inflammatory bowel disease. Inflamm. Bowel Dis. 13: 1536-1544 (2007). *
Halfvarson J, Jess T, Magnuson A, Montgomery SM, Orholm M, Tysk C, Binder V, Jarnerot G. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm. Bowel Dis. 12: 925-933 (2006). *
Halfvarson J, Standaert-Vitse A, Jarnerot G, Sendid B, Jouault T, Bodin L, Duhamel A, Colombel JF, Tysk C, Poulain D. ASCA in twins with inflammatory bowel disease. Gut 54: 1237-1243 (2005). *
Halim MA, Al-Otaibi T, Elsisi A, El-Sayed A, Nair P, Said T, Balaha MA, Nampoory M. De novo post renal transplantation inflammatory bowel disease. Saudi J. Kidney Dis. Transpl. 19: 624-626 (2008). *
Halim MA, Said T, Nair P, Schmidt I, Hassan A, Johny KV, Al-Muzairai I, Samhan M, Nampoory MR, Al-Mousawi M. De novo Crohn's disease in a renal transplant recipient. Transplant. Proc. 39: 1278-1279 (2007). *
Haller C, Kemmler G, Judmair G, Rathner G, Kinzl H, Richter R, Gunther V. Social network and social support in patients with chronic inflammatory bowel disease. Z. Psychosom. Med. Psychother. 49: 36-48 (2003).
Haller CA, Markowitz J. IBD in children: lessons for adults. Curr. Gastroenterol. Rep. 9: 528-532 (2007).
Haller D, Antoine JM, Bengmark S, Enck P, Rijkers GT, Lenoir-Wijnkoop I. Guidance for substantiating the evidence for beneficial effects of probiotics: probiotics in chronic inflammatory bowel disease and the functional disorder irritable bowel syndrome. J. Nutr. Jan 27 [Epub ahead of print] (2010).
Haller D, Holt L, Parlesak A, Zanga J, Bauerlein A, Sartor RB, Jobin C. Differential effect of immune cells on non-pathogenic Gram-negative bacteria-induced nuclear factor-kappaB activation and pro-inflammatory gene expression in intestinal epithelial cells. Immunology 112: 310-320 (2004). *
Hallgren R, Colombel JF, Dahl R, Fredens K, Kruse A, Jacobsen NO, Venge P, Rambaud JC. Neutrophil and eosinophil involvement of the small bowel in patients with celiac disease and Crohn's disease: studies on the secretion rate and immunohistochemical localization of granulocyte granule constituents. Am. J. Med. 86: 56-64 (1989).
Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J. Gastroenterol. 12: 3668-3672 (2006). *
Halme L, Turunen U, Helio T, Paavola P, Walle T, Miettinen A, Jarvinen H, Kontula K, Farkkila M. Familial and sporadic inflammatory bowel disease: comparison of clinical features and serological markers in a genetically homogeneous population. Scand. J. Gastroenterol. 37: 692-698 (2002). *
Halme L, Turunen U, Paavola-Sakki P, Helio T, Lappalainen M, Farkkila M, Kontula K, Repo H. CARD15 frameshift mutation in patients with CROHN disease is associated with immune dysregulation. Scand. J. Gastroenterol. 39: 1243-1249 (2004). *
Halstensen TS, Das KM, Brandtzaeg P. Epithelial deposits of immunoglobulin G1 and activated complement colocalise with the M(r) 40 kD putative autoantigen in ulcerative colitis. Gut 34: 650-657 (1993). *
Halverson A. Timing for surgery in intestinal Crohn's disease. Am. J. Gastroenterol. 102 Suppl. 1: S79-S80 (2007). *
Halverson A. The management of perianal Crohn's disease. Am. J. Gastroenterol. 102 Suppl. 1: S85-S87 (2007). *
Hamdan-Khalil R, Gala JL, Allorge D, Lo-Guidice JM, Horsmans Y, Houdret N, Broly F. Identification and functional analysis of two rare allelic variants of the thiopurine S-methyltransferase gene, TPMT*16 and TPMT*19. Biochem. Pharmacol. 69: 525-529 (2005). *
Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D. Inhibition of anti-tuberculosis T lymphocyte function with tumor necrosis factor antagonists. Arthritis Res. Ther. 8: R114 (2006). *
Hamilton MI, Bradley NJ, Srai SK, Thrasivoulou C, Pounder RE, Wakefield AJ. Autoimmunity in ulcerative colitis: tropomyosin is not the major antigenic determinant of the Das monoclonal antibody, 7E12H12. Clin. Exp. Immunol. 99: 404-411 (1995). *
Hamilton SR. Colorectal carcinoma in patients with Crohn's disease. Gastroenterology 89: 398-407 (1985).
Hamling J, Raedler A, Helmchen U, Schreiber S. 5-Aminosalicylic acid-associated renal tubular acidosis with decreased renal function in Crohn's disease. Digestion 58: 304-307 (1997).
Hamm CM, Reimers MA, McCullough CK, Gorbe EB, Lu J, Gu CC, Li E, Dieckgraefe BK, Gong Q, Stappenbeck TS, Stone CD, Dietz DW, Hunt SR. NOD2 status and human ileal gene expression. Inflamm. Bowel Dis. Feb 12 [Epub ahead of print] (2010). *
Hampe J, Cuthbert A, Croucher PJ, Mirza MM, Mascheretti S, Fisher S, Frenzel H, King K, Hasselmeyer A, MacPherson AJ, Bridger S, van Deventer S, Forbes A, Nikolaus S, Lennard-Jones JE, Foelsch UR, Krawczak M, Lewis C, Schreiber S, Mathew CG. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 357: 1925-1928 (2001). *
Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, Albrecht M, Mayr G, De La Vega FM, Briggs J, Gunther S, Prescott NJ, Onnie CM, Hasler R, Sipos B, Folsch UR, Lengauer T, Platzer M, Mathew CG, Krawczak M, Schreiber S. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39: 207-211 (2007). *
Hampe J, Grebe J, Nikolaus S, Solberg C, Croucher PJ, Mascheretti S, Jahnsen J, Moum B, Klump B, Krawczak M, Mirza MM, Foelsch UR, Vatn M, Schreiber S. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: a cohort study. Lancet 359: 1661-1665 (2002). *
Hampe J, Hermann B, Bridger S, MacPherson AJ, Mathew CG, Schreiber S. The interferon-gamma gene as a positional and functional candidate gene for inflammatory bowel disease. Int. J. Colorectal Dis. 13: 260-263 (1998). *
Hampe J, Lynch NJ, Daniels S, Bridger S, Macpherson AJ, Stokkers P, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME, Schreiber S. Fine mapping of the chromosome 3p susceptibility locus in inflammatory bowel disease. Gut 48: 191-197 (2001). *
Hampe J, Schreiber S, Shaw SH, Lau KF, Bridger S, Macpherson AJ, Cardon LR, Sakul H, Harris TJ, Buckler A, Hall J, Stokkers P, van Deventer SJ, Nurnberg P, Mirza MM, Lee JC, Lennard-Jones JE, Mathew CG, Curran ME. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am. J. Hum. Genet. 64: 808-816 (1999). *
Hampe J, Shaw SH, Saiz R, Leysens N, Lantermann A, Mascheretti S, Lynch NJ, MacPherson AJ, Bridger S, van Deventer S, Stokkers P, Morin P, Mirza MM, Forbes A, Lennard-Jones JE, Mathew CG, Curran ME, Schreiber S. Linkage of inflammatory bowel disease to human chromosome 6p. Am. J. Hum. Genet. 65: 1647-1655 (1999). *
Hampson SJ, Parker MC, Saverymuttu SH, Joseph AE, McFadden JJ, Hermon-Taylor J. Quadruple antimycobacterial chemotherapy in Crohn's disease: results at 9 months of a pilot study in 20 patients. Aliment. Pharmacol. Ther. 3: 343-352 (1989).
Han DY, Fraser AG, Dryland P, Ferguson LR. Environmental factors in the development of chronic inflammation: a case-control study on risk factors for Crohn's disease within New Zealand. Mutat. Res. Sep 11 [Epub ahead of print] (2009).
Han PD, Cohen RD. Managing immunogenic responses to infliximab: treatment implications for patients with Crohn's disease. Drugs 64: 1767-1777 (2004).
Han S, Wang G, Qiu S, de la Motte C, Wang HQ, Gomez G, Englander EW, Greeley GH Jr. Increased colonic apelin production in rodents with experimental colitis and in humans with IBD. Regul. Pept. 142: 131-137 (2007).
Han SH, Lee OY, Yang SY, Jun DW, Lee HL, Jeon YC, Han DS, Sohn JH, Yoon BC, Choi HS, Hahm JS, Lee MH, Lee DH, Kee CS. A case of optic neuritis associated with Crohn's disease. Korean J. Gastroenterol. 48: 42-45 (2006).
Han SW, Gregory W, Nylander D, Tanner A, Trewby P, Barton R, Welfare M. The SIBDQ: further validation in ulcerative colitis patients. Am. J. Gastroenterol. 95: 145-151 (2000). *
Han X, Benight N, Osuntokun B, Loesch K, Frank S, Denson L. Tumour necrosis factor alpha blockade induces an anti- inflammatory growth hormone signalling pathway in experimental colitis. Gut 56: 73-81 (2007). *
Han X, Osuntokun B, Benight N, Loesch K, Frank SJ, Denson LA. Signal transducer and activator of transcription 5b promotes mucosal tolerance in pediatric Crohn's disease and murine colitis. Am. J. Pathol. 169: 1999-2013 (2006). *
Han X, Sosnowska D, Bonkowski EL, Denson LA. Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology 129: 185-203 (2005). *
Han X, Uchida K, Jurickova I, Koch D, Willson T, Samson C, Bonkowski E, Trauernicht A, Kim MO, Tomer G, Dubinsky M, Plevy S, Kugathsan S, Trapnell BC, Denson LA. Granulocyte-macrophage colony-stimulating factor autoantibodies in murine ileitis and progressive ileal Crohn's disease. Gastroenterology 136: 1261-1271.e3 (2009). *
Hanai H. Positions of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J. Gastroenterol. 12: 7568-7577 (2006). *
Hanai H. Leucocytapheresis for inflammatory bowel disease in the era of biologic therapy. Eur. J. Gastroenterol. Hepatol. 20: 596-600 (2008).
Hanai H, Iida T, Takeuchi K, Watanabe F, Yamada M, Kikuyama M, Maruyama Y, Iwaoka Y, Hirayama K, Nagata S, Takai K. Adsorptive depletion of elevated proinflammatory CD14(+)CD16(+)DR(++) monocytes in patients with inflammatory bowel disease. Am. J. Gastroenterol. 103: 1210-1216 (2008). *
Hanauer S, Lukas M, Macintosh D, Rutgeerts P, Sandborn W, Pollack P. A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology 127: 332 (2004). *
Hanauer S, Sandborn WJ, Persson A, Persson T. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial. Aliment. Pharmacol. Ther. 21: 363-371 (2005). *
Hanauer SB. A BALANCING VIEW: lifetime channeling of infliximab for Crohn's disease. Am. J. Gastroenterol. 100: 1438-1439 (2005). *
Hanauer SB. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 26-31 (2004). *
Hanauer SB. Aminosalicylates in inflammatory bowel disease. Aliment. Pharmacol. Ther. 20 Suppl. 4: 60-65 (2004). *
Hanauer SB. The case for using 5-aminosalicyclates in Crohn's disease: pro. Inflamm. Bowel Dis. 11: 609-612 (2005). *
Hanauer SB. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: overview of randomized clinical studies. Rev. Gastroenterol. Disord. 4 Suppl. 3: S18-S24 (2004). *
Hanauer SB. New biologicals for inflammatory bowel disease. Gastroenterology & Hepatology Annual Review Vol. 1, June 2006, p. 67-71 (2006). *
Hanauer SB. Medical therapy for ulcerative colitis. Curr. Opin. Gastroenterol. 16: 324-328 (2000).
Hanauer SB. Medical therapy for Crohn's disease. Curr. Opin. Gastroenterol. 15: 308-314 (1999).
Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm. Bowel Dis. 12 Suppl. 1: S3-S9 (2006). *
Hanauer SB. Turning traditional treatment strategies on their heads: current evidence for "step-up" versus "top-down". Rev. Gastroenterol. Disord. 7 Suppl. 2: S17-S22 (2007).
Hanauer SB. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk? Gut 56: 1181-1183 (2007). *
Hanauer SB. Early aggressive therapy for Crohn's disease. Curr. Gastroenterol. Rep. 10: 566-567 (2008).
Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment. Pharmacol. Ther. 13 Suppl. 4: 16-22 (1999). *
Hanauer SB. Immunosuppressive therapy in the formation of antibodies to infliximab in Crohn's disease. Curr. Gastroenterol. Rep. 9: 487-488 (2008).
Hanauer SB. Medical management of Crohn's disease: treatment algorithms 2009. Dig. Dis. 27: 536-541 (2009).
Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm. Bowel Dis. 15: 1570-1582 (2009).
Hanauer SB. Crohn's disease therapy: step up or top down therapy. Acta Gastroenterol. Belg. 64: 189-190 (2001).
Hanauer SB. Optimal approach to perianal Crohn's disease. Falk Symposium 140. Inflammatory Bowel Disease: Translation from Basic Research to Clinical Practice. Dubrovnik (Croatia). p. 75. May 7-8 (2004). *
Hanauer SB. Assessing the risk of lymphomas in inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 50-51 (2003). *
Hanauer SB. Crohn's disease: step up or top down therapy. Best Pract. Res. Clin. Gastroenterol. 17: 131-137 (2003). *
Hanauer SB. Factoring in growth factors for treatment of inflammatory bowel disease. Curr. Gastroenterol. Rep. 5: 485 (2003).
Hanauer SB. Biologics in peri-operative management of Crohn's disease. Acta Gastroenterol. Belg. 64: 191-192 (2001).
Hanauer SB, Cohen RD, Becker RV 3rd, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin. Ther. 20: 1009-1028 (1998). *
Hanauer SB, Dassopoulos T. Evolving treatment strategies for inflammatory bowel disease. Annu. Rev. Med. 52: 299-318 (2001). *
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P; ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549 (2002). *
Hanauer SB, Korelitz BI, Rutgeerts P, Peppercorn MA, Thisted RA, Cohen RD, Present DH. Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 127: 723-729 (2004). *
Hanauer SB, Krawitt EL, Robinson M, Rick GG, Safdi MA. Long-term management of Crohn's disease with mesalamine capsules (Pentasa). Pentasa Crohn's Disease Compassionate Use Study Group. Am. J. Gastroenterol. 88: 1343-1351 (1993).
Hanauer SB, Meyers S. Management of Crohn's disease in adults. Am. J. Gastroenterol. 92: 559-566 (1997). *
Hanauer SB, Present DH. The state of the art in the management of inflammatory bowel disease. Rev. Gastroenterol. Disord. 3: 81-92 (2003). *
Hanauer SB, Present DH, Wolf JL, Jones WK, Marts SA. The state of the art in the management of inflammatory bowel disease. Based on the proceedings of a roundtable held December 12-13, 2001. Clinician 20: 1-31 (2002). *
Hanauer SB, Sandborn W; Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am. J. Gastroenterol. 96: 635-643 (2001). *
Hanauer SB, Sandborn WJ. European evidence-based consensus on the diagnosis and management of Crohn's disease. Gut 56: 161-163 (2007). *
Hanauer SB, Sandborn WJ. Refining the role of TNF antagonists for Crohn's disease. Rev. Gastroenterol. Disord. 7 Suppl. 1: S1-S2 (2007).
Hanauer SB, Sandborn WJ, Davis GL, Keeffe EB, Vakil N, Katz PO, Talley NJ, Rex DK, Guda NM, Freeman ML, Hawes RH. Highlights from the 2004 digestive disease week. Rev. Gastroenterol. Disord. 4: 129-161 (2004). *
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (Adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130: 323-333 (2006). *
Hanauer SB, Sandborn WJ, Vakil N, Katz PO, Talley NJ, Rex DK, Hawes RH, Guda NM, Freeman ML, Keeffe EB, Balart LA. Best of DDW 2006. Rev. Gastroenterol. Disord. 6: 153-189 (2006).
Hanauer SB, Sparrow M. Therapy of ulcerative colitis. Curr. Opin. Gastroenterol. 20: 345-350 (2004).
Hanauer SB, Stromberg U. Oral pentasa in the treatment of active Crohn's disease: a meta-analysis of double-blind, placebo-controlled trials. Clin. Gastroenterol. Hepatol. 2: 379-388 (2004). *
Hanauer SB, Thisted RA. Treatment of Crohn's disease: the "long" of it. Gastroenterology 128: 2164-2166 (2005). *
Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin. Gastroenterol. Hepatol. 2: 542-553 (2004). *
Hancock L, Beckly J, Geremia A, Cooney R, Cummings F, Pathan S, Guo C, Warren BF, Mortensen N, Ahmad T, Jewell D. Clinical and molecular characteristics of isolated colonic Crohn's disease. Inflamm. Bowel Dis. 14: 1667-1677 (2008). *
Hancock L, Windsor AC, Mortensen NJ. Inflammatory bowel disease: the view of the surgeon. Colorectal Dis. 8 Suppl. 1: 10-14 (2006).
Hande S, Wilson-Rich N, Bousvaros A, Zholudev A, Maurer R, Banks P, Makrauer F, Reddy S, Burakoff R, Friedman S. 5-Aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm. Bowel Dis. 12: 251-257 (2006). *
Hannaway CD, Hull TL. Current considerations in the management of rectovaginal fistula from Crohn's disease. Colorectal Dis. 10: 747-755 (2008). *
Hannon TS, Dimeglio LA, Pfefferkorn MD, Denne SC. Acute effects of enteral nutrition on protein turnover in adolescents with Crohn disease. Pediatr. Res. 61: 356-360 (2007). *
Hansen R, Thomson JM, El-Omar EM, Hold GL. The role of infection in the aetiology of inflammatory bowel disease. J. Gastroenterol. Jan 15 [Epub ahead of print] (2010). *
Hanson K. Urinary stones and Crohn's disease. Urol. Nurs. 25: 466-468 (2005).
Hansson M, Gao Y, Rosen H, Tapper H, Olsson I. Hematopoietic secretory granules as vehicles for the local delivery of cytokines and soluble cytokine receptors at sites of inflammation. Eur. Cytokine Netw. 15: 167-176 (2004).
Hara AK, Alam S, Heigh RI, Gurudu SR, Hentz JG, Leighton JA. Using CT enterography to monitor Crohn's disease activity: a preliminary study. AJR Am. J. Roentgenol. 190: 1512-1516 (2008). *
Hara AK, Leighton JA, Heigh RI, Sharma VK, Silva AC, De Petris G, Hentz JG, Fleischer DE. Crohn disease of the small bowel: preliminary comparison among CT enterography, capsule endoscopy, small-bowel follow-through, and ileoscopy. Radiology 238: 128-134 (2006). *
Hara AK, Swartz PG. CT enterography of Crohn's disease. Abdom. Imaging 34: 289-295 (2009). *
Hara J, Ohtani H, Matsumoto T, Nakamura S, Kitano A, Arakawa T, Nagura H, Kobayashi K. Expression of costimulatory molecules B7-1 and B7-2 in macrophages and granulomas of Crohn's disease: demonstration of cell-to-cell contact with T lymphocytes. Lab. Invest. 77: 175-184 (1997).
Haram K, Gjelland K. Foetal growth restriction. Tidsskr. Nor. Laegeforen. 127: 2665-2669 (2007).
Haraoui B. Differentiating the efficacy of the tumor necrosis factor inhibitors. Semin. Arthritis Rheum. 34: 7-11 (2005). *
Haraoui B. Differentiating the efficacy of tumor necrosis factor inhibitors. J. Rheumatol. Suppl. 74: 3-7 (2005).
Haraoui B, Krelenbaum M. Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action. Semin. Arthritis Rheum. 39: 176-181 (2009). *
Harbord MW, Marks DJ, Forbes A, Bloom SL, Day RM, Segal AW. Impaired neutrophil chemotaxis in Crohn's disease relates to reduced production of chemokines and can be augmented by granulocyte-colony stimulating factor. Aliment. Pharmacol. Ther. 24: 651-660 (2006). *
Hardarson S, Labrecque DR, Mitros FA, Neil GA, Goeken JA. Antineutrophil cytoplasmic antibody in inflammatory bowel and hepatobiliary diseases. High prevalence in ulcerative colitis, primary sclerosing cholangitis, and autoimmune hepatitis. Am. J. Clin. Pathol. 99: 277-281 (1993).
Harder J, Glaser R, Schroder JM. The role and potential therapeutical applications of antimicrobial proteins in infectious and inflammatory diseases. Endocr. Metab. Immune Disord. Drug Targets 7: 75-82 (2007).
Hardin JA, Wallace LE, Wong JF, O'Loughlin EV, Urbanski SJ, Gall DG, MacNaughton WK, Beck PL. Aquaporin expression is downregulated in a murine model of colitis and in patients with ulcerative colitis, Crohn's disease and infectious colitis. Cell Tissue Res. 318: 313-323 (2004). *
Hardy JG, Healey JN, Reynolds JR. Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease. Aliment. Pharmacol. Ther. 1: 273-280 (1987).
Harewood GC, Loftus EV Jr, Tefferi A, Tremaine WJ, Sandborn WJ. Concurrent inflammatory bowel disease and myelodysplastic syndromes. Inflamm. Bowel Dis. 5: 98-103 (1999). *
Harewood GC, Mattek NC, Holub JL, Peters D, Lieberman DA. Variation in practice of ileal intubation among diverse endoscopy settings: results from a national endoscopic database. Aliment. Pharmacol. Ther. 22: 571-578 (2005). *
Harinarayan CV. Crohn's disease & osteoimmunology - is vitamin D the cross-talk co-ordinator? Indian J. Med. Res. 130: 108-111 (2009). *
Harms B, Bremner AR, Mulligan J, Fairhurst J, Griffiths DM, Salmon T, Beattie RM. Crohn's disease post-cardiac transplantation presenting with severe growth failure and delayed onset of puberty. Pediatr. Allergy Immunol. 15: 186-189 (2004). *
Harpavat M, Greenspan SL, O'Brien C, Chang CC, Bowen A, Keljo DJ. Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J. Pediatr. Gastroenterol. Nutr. 40: 295-300 (2005). *
Harpavat M, Keljo DJ, Regueiro MD. Metabolic bone disease in inflammatory bowel disease. J. Clin. Gastroenterol. 38: 218-224 (2004).
Harpaz N, Schiano T, Ruf AE, Shukla D, Tao Y, Fishbein TM, Sauter BV, Gondolesi GE. Early and frequent histological recurrence of Crohn's disease in small intestinal allografts. Transplantation 80: 1667-1670 (2005).
Harpaz N, Talbot IC. Colorectal cancer in idiopathic inflammatory bowel disease. Semin. Diagn. Pathol. 13: 339-357 (1996).
Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol. Clin. North Am. 33: 303-317 (2004).
Harrell LE, Rubin DT, Hanauer SB. Fever and right upper quadrant pain in a pregnant woman at 30 weeks' gestation. Nat. Clin. Pract. Gastroenterol. Hepatol. 1: 113-116 (2004). *
Harrer M, Reinisch W, Dejaco C, Kratzer V, Gmeiner M, Miehsler W, Norman GL, Gangl A, Vogelsang H. Do high serum levels of anti-Saccharomyces cerevisiae antibodies result from a leakiness of the gut barrier in Crohn's disease? Eur. J. Gastroenterol. Hepatol. 15: 1281-1285 (2003).
Harries AD, Brown R, Heatley RV, Williams LA, Woodhead S, Rhodes J. Vitamin D status in Crohn's disease: association with nutrition and disease activity. Gut 26: 1197-1203 (1985). *
Harrington S, Mohamed S, Bloch R. Small bowel obstruction by a primary phytobezoar in Crohn's disease. Am. Surg. 75: 93-94 (2009).
Harris D. Left middle cerebral artery infarct in a young man with Crohn's disease. J. R. Soc. Med. 102: 443-444 (2009).
Harris JE, Lammerding AM. Crohn's disease and Mycobacterium avium subsp. paratuberculosis: current issues. J. Food Prot. 64: 2103-2110 (2001).
Harris MD, Richards R. First case report of adalimumab-induced psoriasis in Crohn's disease. Am. J. Gastroenterol. 104: 792-793 (2009).
Harris NR, Whatley JR, Carter PR, Morgan GA, Grisham MB. Altered microvascular hemodynamics during the induction and perpetuation of chronic gut inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. 296: G750-G754 (2009). *
Harrison J, Hanauer SB. Medical treatment of Crohn's disease. Gastroenterol. Clin. North Am. 31: 167-184, x (2002).
Harsha WT, Kalandarova E, McNutt P, Irwin R, Noel J. Nutritional supplementation with transforming growth factor-beta, glutamine, and short chain fatty acids minimizes methotrexate-induced injury. J. Pediatr. Gastroenterol. Nutr. 42: 53-58 (2006). *
Hart AL, Al-Hassi HO, Rigby RJ, Bell SJ, Emmanuel AV, Knight SC, Kamm MA, Stagg AJ. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129: 50-65 (2005). *
Hart AL, Kamm MA, Knight SC, Stagg AJ. Quantitative and functional characteristics of intestinal-homing memory T cells: analysis of Crohn's disease patients and healthy controls. Clin. Exp. Immunol. 135: 137-145 (2004). *
Hart AL, Plamondon S, Kamm MA. Topical tacrolimus in the treatment of perianal Crohn's disease: exploratory randomized controlled trial. Inflamm. Bowel Dis. 13: 245-253 (2007). *
Hart JW, Bremner AR, Wootton SA, Beattie RM. Measured versus predicted energy expenditure in children with inactive Crohn's disease. Clin. Nutr. 24: 1047-1055 (2005).
Hartley JE, Fazio VW, Remzi FH, Lavery IC, Church JM, Strong SA, Hull TL, Senagore AJ, Delaney CP. Analysis of the outcome of ileal pouch-anal anastomosis in patients w